0001636422-24-00015210-Q Health Catalyst, Inc. 20241106202411061802511802521802520252 0 0001636422-24-000152 10-Q 103 20240930 20241107 20241106 Health Catalyst, Inc. 0001636422 7370 453337483 DE 1231 10-Q 34 001-38993 241432477 10897 SOUTH RIVER FRONT PARKWAY, #300 SOUTH JORDAN UT 84095 801-708-6800 10897 SOUTH RIVER FRONT PARKWAY, #300 SOUTH JORDAN UT 84095 HQC Holdings, Inc. 20150312 10-Q 1 hcat-20240930.htm 10-Q hcat-20240930000163642212/312024Q3falseP3YP1Y0.03267970P3Yxbrli:sharesiso4217:USDiso4217:USDxbrli:shareshcat:segmentxbrli:pureutr:Diso4217:USDhcat:instrumenthcat:vote000163642220-01-012024-09-300001636422202411-01000163642202409-30000163642220231-2-310001636422hcat:TechnologyMember2024-07-012024-09-300001636422hcat:TechnologyMember2023-07-012023-09-300001636422hcat:TechnologyMember2024-01-012024-09-300001636422hcat:TechnologyMember2023-01-012023-09-300001636422hcat:ProfessionalServicesMember2024-07-012024-09-300001636422hcat:ProfessionalServicesMember2023-07-012023-09-300001636422hcat:ProfessionalServicesMember2024-01-012024-09-300001636422hcat:ProfessionalServicesMember2023-01-012023-09-300001636422hcat:ProfessionalServicesMember2023-07-012024-09-300001636422hcat:ProfessionalServicesMember2023-07-012023-09-300001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-06-300001636422us-gaap:RetainedEarningsMember2024-06-300001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-07-012024-09-300001636422us-gaap:RetainedEarningsMember2024-07-012024-09-300001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-09-300001636422us-gaap:RetainedEarningsMember2024-09-300001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-06-300001636422us-gaap:RetainedEarningsMember2023-06-300001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001636422222023-06-300001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-07-012023-09-300001636422us-gaap:RetainedEarningsMember2023-07-012023-09-300001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-09-300001636422us-gaap:RetainedEarningsMember2023-09-300001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001636422222023-09-300001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-12-310001636422us-gaap:RetainedEarningsMember2023-12-310001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-01-012024-09-300001636422us-gaap:RetainedEarningsMember2024-01-012024-09-300001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-12-310001636422us-gaap:RetainedEarningsMember2022-12-310001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-3100016364222022-12-310001636422us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-01-012023-09-300001636422us-gaap:RetainedEarningsMember2023-01-012023-09-300001636422us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001636422hcat:TechnologyAndProfessionalServicesMembersrt:MinimumMember2024-01-012024-09-300001636422hcat:TechnologyAndProfessionalServicesMembersrt:MaximumMember2024-01-012024-09-300001636422hcat:TechnologyAndProfessionalServicesMember2024-01-012024-09-300001636422srt:MinimumMemberus-gaap:ComputerEquipmentMember2024-09-300001636422srt:MaximumMemberus-gaap:ComputerEquipmentMember2024-09-300001636422srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2024-09-300001636422srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2024-09-300001636422srt:MinimumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-09-300001636422srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-09-300001636422srt:MinimumMemberus-gaap:SoftwareDevelopmentMember2024-09-300001636422srt:MaximumMemberus-gaap:SoftwareDevelopmentMember2024-09-300001636422us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2024-09-300001636422hcat:ClientRelationshipsAndContractsMembersrt:MinimumMember2024-09-300001636422hcat:ClientRelationshipsAndContractsMembersrt:MaximumMember2024-09-300001636422us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MinimumMember2024-09-300001636422us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MaximumMember2024-09-300001636422us-gaap:TrademarksMembersrt:MinimumMember2024-09-300001636422us-gaap:TrademarksMembersrt:MaximumMember2024-09-300001636422hcat:LumeonLtd.Member2024-08-012024-08-010001636422hcat:LumeonLtd.Member2024-08-010001636422hcat:LumeonLtd.Memberus-gaap:CustomerRelationshipsMember2024-08-010001636422hcat:LumeonLtd.Memberus-gaap:DevelopedTechnologyRightsMember2024-08-010001636422hcat:LumeonLtd.Memberus-gaap:TrademarksMember2024-08-010001636422hcat:LumeonLtd.Member2024-01-012024-09-300001636422hcat:CareviveSystemsInc.Member2024-05-242024-05-240001636422hcat:CareviveSystemsInc.Member2024-05-240001636422hcat:CareviveSystemsInc.Memberus-gaap:CustomerRelationshipsMember2024-05-240001636422hcat:CareviveSystemsInc.Memberus-gaap:DevelopedTechnologyRightsMember2024-05-240001636422hcat:CareviveSystemsInc.Memberus-gaap:TrademarksMember2024-05-240001636422hcat:CareviveSystemsInc.Member2024-01-012024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMember2024-07-012024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMember2023-07-012023-09-300001636422hcat:CareviveAndLumeonAcquisitionsMember2024-01-012024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMember2023-01-012023-09-300001636422hcat:AmortizationOfAcquiredIntangibleAssetsMember2024-07-012024-09-300001636422hcat:AmortizationOfAcquiredIntangibleAssetsMember2023-07-012023-09-300001636422hcat:AmortizationOfAcquiredIntangibleAssetsMember2024-01-012024-09-300001636422hcat:AmortizationOfAcquiredIntangibleAssetsMember2023-01-012023-09-300001636422us-gaap:AcquisitionRelatedCostsMember2024-07-012024-09-300001636422us-gaap:AcquisitionRelatedCostsMember2023-07-012023-09-300001636422us-gaap:AcquisitionRelatedCostsMember2024-01-012024-09-300001636422us-gaap:AcquisitionRelatedCostsMember2023-01-012023-09-300001636422hcat:TotalProFormaAdjustmentsMember2024-07-012024-09-300001636422hcat:TotalProFormaAdjustmentsMember2023-07-012023-09-300001636422hcat:TotalProFormaAdjustmentsMember2024-01-012024-09-300001636422hcat:TotalProFormaAdjustmentsMember2023-01-012023-09-300001636422hcat:ERSCorporationMember2023-10-022023-10-020001636422hcat:ERSCorporationMember2023-10-020001636422us-gaap:RestrictedStockMemberhcat:ERSCorporationMember2023-10-022023-10-020001636422hcat:ERSCorporationMemberus-gaap:CustomerRelationshipsMember2023-10-020001636422hcat:ERSCorporationMemberus-gaap:DevelopedTechnologyRightsMember2023-10-020001636422hcat:ERSCorporationMemberus-gaap:TrademarksMember2023-10-020001636422hcat:RecurringTechnologyMember2024-07-012024-09-300001636422hcat:RecurringTechnologyMember2023-07-012023-09-300001636422hcat:RecurringTechnologyMember2024-01-012024-09-300001636422hcat:RecurringTechnologyMember2023-01-012023-09-300001636422hcat:OneTimeTechnologyMember2024-07-012024-09-300001636422hcat:OneTimeTechnologyMember2023-07-012023-09-300001636422hcat:OneTimeTechnologyMember2024-01-012024-09-300001636422hcat:OneTimeTechnologyMember2023-01-012023-09-300001636422country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300001636422country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300001636422country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300001636422country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300001636422hcat:TechnologyMember2024-09-300001636422hcat:TechnologyMember2023-12-310001636422hcat:ProfessionalServicesMember2024-09-300001636422hcat:ProfessionalServicesMember2023-12-310001636422us-gaap:DevelopedTechnologyRightsMember2024-09-300001636422hcat:ClientRelationshipsAndContractsMember2024-09-300001636422us-gaap:ComputerSoftwareIntangibleAssetMember2024-09-300001636422us-gaap:TrademarksMember2024-09-300001636422us-gaap:DevelopedTechnologyRightsMember2023-12-310001636422hcat:ClientRelationshipsAndContractsMember2023-12-310001636422us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310001636422us-gaap:TrademarksMember2023-12-310001636422us-gaap:ComputerEquipmentMember2024-09-300001636422us-gaap:ComputerEquipmentMember2023-12-310001636422us-gaap:LeaseholdImprovementsMember2024-09-300001636422us-gaap:LeaseholdImprovementsMember2023-12-310001636422us-gaap:FurnitureAndFixturesMember2024-09-300001636422us-gaap:FurnitureAndFixturesMember2023-12-310001636422us-gaap:SoftwareDevelopmentMember2024-09-300001636422us-gaap:SoftwareDevelopmentMember2023-12-310001636422us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-09-300001636422us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001636422hcat:LeaseholdImprovementsAndFurnitureAndFixturesMember2023-01-012023-09-300001636422hcat:LeaseholdImprovementsAndFurnitureAndFixturesMember2024-01-012024-09-300001636422us-gaap:MoneyMarketFundsMember2024-09-300001636422us-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMember2024-09-300001636422us-gaap:USTreasurySecuritiesMember2024-09-300001636422us-gaap:CashEquivalentsMemberus-gaap:USTreasurySecuritiesMember2024-09-300001636422hcat:ShortTermMarketableSecurityMemberus-gaap:USTreasurySecuritiesMember2024-09-300001636422us-gaap:CommercialPaperMember2024-09-300001636422us-gaap:CashEquivalentsMemberus-gaap:CommercialPaperMember2024-09-300001636422us-gaap:CorporateBondSecuritiesMember2024-09-300001636422us-gaap:CashEquivalentsMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001636422hcat:ShortTermMarketableSecurityMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001636422us-gaap:CashEquivalentsMember2024-09-300001636422hcat:ShortTermMarketableSecurityMember2024-09-300001636422us-gaap:MoneyMarketFundsMember2023-12-310001636422us-gaap:CashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-12-310001636422hcat:ShortTermMarketableSecurityMemberus-gaap:MoneyMarketFundsMember2023-12-310001636422us-gaap:USTreasurySecuritiesMember2023-12-310001636422us-gaap:CashEquivalentsMemberus-gaap:USTreasurySecuritiesMember2023-12-310001636422hcat:ShortTermMarketableSecurityMemberus-gaap:USTreasurySecuritiesMember2023-12-310001636422us-gaap:CommercialPaperMember2023-12-310001636422us-gaap:CashEquivalentsMemberus-gaap:CommercialPaperMember2023-12-310001636422hcat:ShortTermMarketableSecurityMemberus-gaap:CommercialPaperMember2023-12-310001636422us-gaap:CashEquivalentsMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001636422us-gaap:CashEquivalentsMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001636422hcat:ShortTermMarketableSecurityMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001636422us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001636422hcat:ShortTermMarketableSecurityMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001636422us-gaap:CashEquivalentsMember2023-12-310001636422hcat:ShortTermMarketableSecurityMember2023-12-310001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001636422us-gaap:FairValueMeasurementsRecurringMember2024-09-300001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2023-12-310001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001636422us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001636422us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001636422us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001636422us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001636422us-gaap:FairValueMeasurementsRecurringMember2023-12-310001636422hcat:SeniorNotesDue2025Memberus-gaap:ConvertibleNotesPayableMember2024-09-300001636422hcat:SeniorNotesDue2025Memberus-gaap:ConvertibleNotesPayableMember2023-12-

310001636422hcat:RightOfUseAssetsLeaseholdImprovementsAndFurnitureAndFixturesMember2024-01-012024-09-300001636422hcat:RightOfUseAssetsLeaseholdImprovementsAndFurnitureAndFixturesMember2023-01-012023-09-300001636422hcat:LumeonLtd.Member2024-09-300001636422hcat:CareviveSystemsInc.Member2024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMember2024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputQuotedPriceMemberhcat:ValuationBlackScholesMember2024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberhcat:ValuationBlackScholesMember2024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMemberhcat:ValuationBlackScholesMember2024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberhcat:ValuationBlackScholesMember2024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMemberus-gaap:FairValueInputsLevel3Memberhcat:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001636422hcat:CareviveAndLumeonAcquisitionsMemberus-gaap:FairValueInputsLevel3Memberhcat:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-09-300001636422hcat:CareviveAndLumeonAcquisitionsMemberus-gaap:FairValueInputsLevel3Memberhcat:ContingentConsiderationLiabilityMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001636422srt:MinimumMember2024-09-300001636422srt:MaximumMember2024-09-300001636422hcat:RightOfUseAssetMember2024-01-012024-09-300001636422hcat:RightOfUseAssetMember2023-01-012023-09-300001636422hcat:SeniorNotesDue2025Memberus-gaap:ConvertibleNotesPayableMember2020-04-140001636422hcat:InterestRateTermLoanMember2024-09-300001636422hcat:InterestRateTermLoanMember2023-12-310001636422us-gaap:ConvertibleNotesPayableMember2024-07-012024-09-300001636422us-gaap:ConvertibleNotesPayableMember2023-07-012023-09-300001636422us-gaap:ConvertibleNotesPayableMember2024-01-012024-09-300001636422us-gaap:ConvertibleNotesPayableMember2023-01-012023-09-300001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMember2024-07-160001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMember2024-07-160001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMemberhcat:TermLoanMember2024-07-160001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:DelayedDrawTermLoanMember2024-07-160001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:DelayedDrawTermLoanMembersrt:MinimumMember2024-07-162024-07-160001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:DelayedDrawTermLoanMember2024-07-162024-07-160001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:DelayedDrawTermLoanMembersrt:MaximumMember2024-07-162024-07-160001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMembersrt:MinimumMember2024-07-162024-07-160001636422hcat:CreditAgreementMemberus-gaap:LineOfCreditMembersrt:MaximumMember2024-07-162024-07-160001636422hcat:SeniorNotesDue2025Memberus-gaap:ConvertibleNotesPayableMember2020-04-142020-04-140001636422020-04-140001636422hcat:SeniorNotesDue2025Memberus-gaap:ConvertibleNotesPayableMemberhcat:DebtInstrumentConvertibleSalePriceOfStockThresholdMember2020-04-142020-04-140001636422hcat:CappedCallMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-04-092020-04-090001636422hcat:CappedCallMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-04-080001636422hcat:SeniorNotesDue2025Memberus-gaap:ConvertibleNotesPayableMember2024-01-012024-09-300001636422hcat:AbleHealthInc Memberhcat:VitalwareLLCMember2024-09-300001636422hcat:AbleHealthInc Memberhcat:VitalwareLLCMember2023-12-310001636422hcat:ShareRepurchasePlanMember2022-09-300001636422hcat:ShareRepurchasePlanMember2024-07-012024-09-300001636422hcat:ShareRepurchasePlanMember2023-01-012023-03-310001636422hcat:ShareRepurchasePlanMember2022-07-012022-09-300001636422hcat:ShareRepurchasePlanMember2024-09-300001636422us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001636422us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001636422us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001636422us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001636422us-gaap:PhantomShareUnitsPSUsMember2023-01-012023-09-300001636422us-gaap:SeniorNotesMember2024-01-012024-09-300001636422us-gaap:SeniorNotesMember2023-01-012023-09-300001636422us-gaap:EmployeeStockMember2024-01-012024-09-300001636422us-gaap:EmployeeStockMember2023-01-012023-09-300001636422us-gaap:RestrictedStockMember2024-01-012024-09-300001636422us-gaap:RestrictedStockMember2023-01-012023-09-300001636422hcat:CappedCallMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300001636422hcat:StockIncentivePlan2011Member2024-09-300001636422hcat:StockIncentivePlan2019Member2024-09-300001636422hcat:StockIncentivePlan2011Member2024-01-012024-09-300001636422hcat:StockIncentivePlan2019Member2024-01-010001636422hcat:StockIncentivePlanMember2024-09-300001636422hcat:StockIncentivePlanMember2023-12-310001636422us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001636422us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001636422us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001636422us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001636422us-gaap:PhantomShareUnitsPSUsMember2024-07-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMember2023-07-012023-09-300001636422us-gaap:PhantomShareUnitsPSUsMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMember2023-01-012023-09-300001636422us-gaap:EmployeeStockMember2024-07-012024-09-300001636422us-gaap:EmployeeStockMember2023-07-012023-09-300001636422us-gaap:EmployeeStockMember2024-01-012024-09-300001636422us-gaap:EmployeeStockMember2023-01-012023-09-300001636422us-gaap:RestrictedStockMember2024-07-012024-09-300001636422us-gaap:RestrictedStockMember2023-07-012023-09-300001636422us-gaap:RestrictedStockMember2024-01-012024-09-300001636422us-gaap:RestrictedStockMember2023-01-012023-09-300001636422us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001636422us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001636422us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001636422us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001636422us-gaap:CostOfSalesMember2024-07-012024-09-300001636422us-gaap:CostOfSalesMember2023-07-012023-09-300001636422us-gaap:CostOfSalesMember2024-01-012024-09-300001636422us-gaap:CostOfSalesMember2023-01-012023-09-300001636422us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300001636422us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300001636422us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300001636422us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300001636422us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001636422us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001636422us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001636422us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001636422us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001636422us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001636422us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001636422us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001636422us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001636422us-gaap:RestrictedStockUnitsRSUMember2023-12-310001636422us-gaap:RestrictedStockUnitsRSUMember2024-09-300001636422us-gaap:PhantomShareUnitsPSUsMemberhcat:MeasurementInputTotalShareholderReturnMembersrt:WeightedAverageMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMemberus-gaap:MeasurementInputRevenueMultipleMembersrt:WeightedAverageMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMemberus-gaap:MeasurementInputEbitdaMultipleMembersrt:WeightedAverageMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMembersrt:MinimumMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMembersrt:MaximumMember2024-01-012024-09-300001636422us-gaap:PhantomShareUnitsPSUsMembersrt:MinimumMember2023-01-012023-09-300001636422us-gaap:PhantomShareUnitsPSUsMembersrt:MaximumMember2023-01-012023-09-300001636422us-gaap:PhantomShareUnitsPSUsMember2023-12-310001636422us-gaap:PhantomShareUnitsPSUsMember2024-09-300001636422us-gaap:EmployeeStockMember2019-07-310001636422us-gaap:EmployeeStockMember2019-07-012019-07-310001636422us-gaap:EmployeeStockMember2024-01-010001636422us-gaap:EmployeeStockMember2024-09-300001636422us-gaap:EmployeeStockMembersrt:MinimumMember2024-01-012024-09-300001636422us-gaap:EmployeeStockMembersrt:MaximumMember2024-01-012024-09-300001636422us-gaap:EmployeeStockMembersrt:MinimumMember2023-01-012023-09-300001636422us-gaap:EmployeeStockMembersrt:MaximumMember2023-01-012023-09-300001636422us-gaap:RestrictedStockMemberhcat:KPINinjaMember2022-02-242022-02-240001636422us-gaap:RestrictedStockMemberhcat:ARMUSCorporationMember2022-04-292022-04-290001636422us-gaap:RestrictedStockMemberhcat:ARMUSCorporationMember2023-10-022023-10-020001636422us-gaap:SettledLitigationMember2023-06-152023-06-150001636422us-gaap:SettledLitigationMember2023-01-012023-09-300001636422us-gaap:SettledLitigationMember2023-07-012023-09-300001636422us-gaap:SettledLitigationMember2024-07-012024-09-300001636422us-gaap:SettledLitigationMember2024-01-012024-09-300001636422222024-10-012024-09-300001636422026-10-012024-09-300001636422us-gaap:RelatedPartyMember2024-07-012024-09-300001636422us-gaap:RelatedPartyMember2024-01-012024-09-300001636422us-gaap:RelatedPartyMember2023-07-012023-09-300001636422us-gaap:RelatedPartyMember2024-09-300001636422us-gaap:RelatedPartyMember2023-12-310001636422hcat:TechnologyMember2024-07-012024-09-300001636422hcat:TechnologyMember2023-07-012023-09-300001636422hcat:TechnologyMember2024-01-012024-09-300001636422hcat:TechnologyMember2023-01-012023-09-300001636422hcat:ProfessionalServicesMember2024-07-012024-09-300001636422hcat:ProfessionalServicesMember2023-07-012023-09-300001636422hcat:ProfessionalServicesMember2024-01-012024-09-300001636422hcat:ProfessionalServicesMember2023-01-012023-09-300001636422us-gaap:OperatingSegmentsMemberhcat:TechnologyMember2024-07-012024-09-300001636422us-gaap:OperatingSegmentsMemberhcat:TechnologyMember2023-07-012023-09-300001636422us-gaap:OperatingSegmentsMemberhcat:TechnologyMember2024-01-012024-09-300001636422us-gaap:OperatingSegmentsMemberhcat:TechnologyMember2023-01-012023-09-300001636422us-gaap:OperatingSegmentsMemberhcat:ProfessionalServicesMember2024-07-012024-09-300001636422us-gaap:OperatingSegmentsMemberhcat:ProfessionalServicesMember2023-07-012023-09-300001636422us-gaap:OperatingSegmentsMemberhcat:ProfessionalServicesMember2024-01-012024-09-300001636422us-gaap:OperatingSegmentsMember2024-07-012024-09-300001636422us-gaap:OperatingSegmentsMember2023-07-012023-09-300001636422us-gaap:OperatingSegmentsMember2024-01-012024-09-300001636422us-gaap:OperatingSegmentsMember2023-01-012023-09-300001636422us-gaap:MaterialReconcilingItemsMember2024-07-012024-09-300001636422us-gaap:MaterialReconcilingItemsMember2023-07-012023-09-300001636422us-gaap:MaterialReconcilingItemsMember2024-01-012024-09-300001636422us-gaap:MaterialReconcilingItemsMember2023-01-012023-09-300001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2023RestructuringPlanMember2024-07-012024-09-300001636422hcat:TechnologyMemberhcat:A2023RestructuringPlanMember2024-01-012024-09-300001636422hcat:ProfessionalServicesMemberhcat:A2023RestructuringPlanMember2024-01-012024-09-300001636422us-gaap:SellingAndMarketingExpenseMemberhcat:A2023RestructuringPlanMember2024-01-012024-09-300001636422us-gaap:ResearchAndDevelopmentExpenseMemberhcat:A2023RestructuringPlanMember2024-01-012024-09-300001636422us-gaap:GeneralAndAdministrativeExpenseMemberhcat:A2023RestructuringPlanMember2024-01-012024-09-300001636422hcat:A2023RestructuringPlanMember2024-01-012024-09-300001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2023RestructuringPlanMember2024-01-012024-09-300001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2023RestructuringPlanMember2023-12-310001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2023RestructuringPlanMember2024-01-012024-03-310001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2023RestructuringPlanMember2024-03-310001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2023RestructuringPlanMember2024-04-012024-06-300001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2023RestructuringPlanMember2024-06-300001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2023RestructuringPlanMember2024-09-300001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2022RestructuringPlanMember2023-07-012023-09-300001636422hcat:TechnologyMemberhcat:A2022RestructuringPlanMember2023-01-012023-09-300001636422hcat:ProfessionalServicesMemberhcat:A2022RestructuringPlanMember2023-01-012023-09-300001636422us-gaap:SellingAndMarketingExpenseMemberhcat:A2022RestructuringPlanMember2023-01-012023-09-300001636422us-gaap:ResearchAndDevelopmentExpenseMemberhcat:A2022RestructuringPlanMember2023-01-012023-09-300001636422us-gaap:GeneralAndAdministrativeExpenseMemberhcat:A2022RestructuringPlanMember2023-01-012023-09-300001636422hcat:A2022RestructuringPlanMember2023-01-012023-09-300001636422hcat:SeveranceAndOtherTeamMemberCostsMemberhcat:A2022RestructuringPlanMember2023-01-012023-09-30Â Â Â Â .UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_____FORM 10-Q _____(Mark One)â˜Â Â Â QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedÂ SeptemberÂ 30, 2024 Orâ˜ Â Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____Commission File Number: 001-38993 HEALTH CATALYST, INC. (Exact name of registrant as specified in its charter)_____Delaware45-3337483(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification Number)10897 South River Front Parkway #300 South Jordan UT 84095 (Address of principal executive offices, including zip code) (801) 708-6800 (Registrantâ€™s telephone number, including area code)_____Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of exchange on which registeredCommon Stock, par value $0.001 per shareHCATThe Nasdaq Global Select MarketIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Large accelerated filerâ˜’Accelerated Filerâ˜Emerging growthÂ companyâ˜Non-accelerated Filerâ˜Smaller reporting companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’As of NovemberÂ 1, 2024, the Registrant had 60,847,658 shares of common stock outstanding.HEALTH CATALYST, INC.Table of ContentsPagePart I. Financial InformationItem 1.Financial Statements4Condensed Consolidated Balance Sheets as of SeptemberÂ 30, 2024 (unaudited) and DecemberÂ 31, 20234Condensed Consolidated Statements of Operations for the Three and Nine Months Ended SeptemberÂ 30, 2024 and 2023 (unaudited)6Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months

Ended SeptemberÂ 30, 2024 and 2023 (unaudited)7Condensed Consolidated Statements of Stockholdersâ€™ Equity for the Three and Nine Months Ended SeptemberÂ 30, 2024 and 2023 (unaudited)8Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 (unaudited)10Notes to the Condensed Consolidated Financial Statements (unaudited)12Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations46Item 3.Quantitative and Qualitative Disclosures about Market Risk71Item 4.Controls and Procedures72Part II. Other InformationItem 1.Legal Proceedings74Item 1A.Risk Factors74Item 2.Unregistered Sales of Equity Securities and Use of Proceeds112Item 5.Other Information112Item 6.Exhibits113SignaturesSpecial Note Regarding Forward-looking StatementsAs used in this Quarterly Report on Form 10-Q, unless expressly indicated or the context otherwise requires, references to â€œHealth Catalyst,â€ â€œwe,â€ â€œus,â€ â€œour,â€ â€œthe Company,â€ and similar references refer to Health Catalyst, Inc. and its consolidated subsidiaries. This Quarterly Report on Form 10-Q, including the section titled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Forward-looking statements are only predictions based on our managementâ€™s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts are â€œforward-looking statementsâ€ for purposes of these provisions, including those relating to future events or our future financial performance and financial guidance. These forward-looking statements, which are subject to a number of risks, uncertainties, and assumptions, generally relate to future events or our future financial or operating performance. In some cases, you can identify these statements by forward-looking words such as â€œbelieve,â€ â€œmay,â€ â€œwill,â€ â€œestimate,â€ â€œcontinue,â€ â€œanticipate,â€ â€œdesign,â€ â€œintend,â€ â€œexpect,â€ â€œcould,â€ â€œplan,â€ â€œpotential,â€ â€œpredict,â€ â€œseek,â€ â€œshould,â€ â€œwould,â€ â€œtarget,â€ â€œproject,â€ or â€œcontemplate,â€ the negative of terms like these or other comparable terminology, and other words or terms of similar meaning in connection with any discussion of expectations, projections, plans, strategy, intentions, or future results of operations or financial performance. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about our:Â â€¢ability to attract new clients and retain and expand our relationships with existing clients;â€¢ability to expand our service offerings, develop new platform features, and rollout and migrate existing DOS Subscription Clients to our new platform, Health Catalyst Ignite;1â€¢future financial performance, including trends in revenue, costs of revenue, gross margin, and operating expenses;â€¢ability to compete successfully in competitive markets;â€¢ability to respond to rapid technological changes;â€¢expectations and management of future growth;â€¢ability to enter new markets and manage our expansion efforts, particularly internationally;â€¢ability to attract and retain highly-qualified employees, whom we refer to as team members;â€¢ability to effectively and efficiently protect our brand;â€¢ability to timely scale and adapt our infrastructure;â€¢ability to maintain, protect, and enhance our intellectual property and not infringe upon othersâ€™ intellectual property; â€¢ability to successfully identify, acquire, and integrate companies and assets; â€¢expectations regarding our key financial metrics; andâ€¢expectations regarding the impact of any macroeconomic challenges (including high inflationary and/or high interest rate environments or market volatility and measures taken in response thereto) and any new public health crisis, on our business and results of operations.These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the section titled â€œRisk Factorsâ€ in this Quarterly Report on Form 10-Q and other documents that may be filed by us from time to time with the Securities and Exchange Commission (the SEC). Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements and you should not place undue reliance on our forward-looking statements.The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law.You should read this Quarterly Report on Form 10-Q in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended DecemberÂ 31, 2023, included in our Annual Report on Form 10-K.Summary of Risk Factorsâ€¢We operate in a highly competitive industry, and if we are not able to compete effectively, our business and results of operations will be harmed.â€¢We may be unable to successfully execute on our growth initiatives, business strategies, or operating plans as well as cost reduction and restructuring initiatives.â€¢If we fail to effectively manage our growth and organizational change, our business and results of operations could be harmed.2â€¢Macroeconomic challenges (including high inflationary and/or high interest rate environments, or market volatility and measures taken in response thereto) and any new public health crisis could harm our business, results of operations, and financial condition.â€¢If we do not continue to innovate and provide services that are useful to clients and users, we may not remain competitive, and our revenue and results of operations could suffer.â€¢Our business could be adversely affected if our clients are not satisfied with our cloud-based data platform, software analytics applications, and professional services expertise (our Solution).â€¢If our existing clients do not continue or renew their contracts with us, renew at lower fee levels, or decline to purchase additional technology and services from us, it could have a material adverse effect on our business, financial condition, and results of operations.â€¢Our business and operations may suffer in the event of information technology system failures, cyberattacks, or deficiencies in our cybersecurity.â€¢Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.â€¢Our Solution is dependent on our ability to source data from third parties, and such third parties could take steps to block our access to data, or increase fees or impose fees for such access, which could impair our ability to provide our Solution, limit the effectiveness of our Solution, or adversely affect our financial condition and results of operations.â€¢Our results of operations have in the past fluctuated and may continue to fluctuate significantly, and if we fail to meet the expectations of securities analysts or investors, our stock price and the value of an investment in our common stock could decline substantially. â€¢Our term loan facility exposes us to interest rate risks, contains covenants and other provisions that restrict our ability to take certain actions, and may limit our ability to operate or grow our business in the future.â€¢Our pricing may change over time and our ability to efficiently price our Solution will affect our results of operations and our ability to attract or retain clients.â€¢If our Solution fails to provide accurate and timely information, or if our content or any other element of our Solution is associated with faulty clinical decisions or treatment, we could be exposed to litigation, investigations or have liability to clients, clinicians, patients, or others, which could adversely affect our results of operations.â€¢We rely on third-party providers, including Microsoft Azure, for computing infrastructure, network connectivity, and other technology-related services needed to deliver our Solution. Any disruption in the services provided by such third-party providers could adversely affect our business and subject us to liability.â€¢We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties, and our own systems for providing our Solution to our users, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation, potentially require us to issue credits to our clients, and negatively impact our relationships with users or clients, adversely affecting our brand and our business.â€¢Failure by our clients to obtain proper permissions and waivers may result in claims against us or may limit or prevent our use of data, which could harm our business.3Part I. Financial InformationItem 1.Â Financial StatementsHEALTH CATALYST, INC.Condensed Consolidated Balance Sheets(in thousands, except share and per share data)As ofSeptember 30,As ofDecember 31,20242023(unaudited)AssetsCurrent assets:Cash and cash equivalents$328,327Â $106,276Â Short-term investments58,929Â 211,452Â Accounts receivable, net(1)51,648Â 60,290Â Prepaid expenses and other assets18,510Â 15,379Â Total current assets457,414Â 393,397Â Property and equipment, net27,908Â 25,712Â Intangible assets, net76,463Â 73,384Â Operating lease right-of-use assets11,222Â 13,927Â Goodwill234,387Â 190,652Â Other assets5,656Â 4,742Â Total assets$813,050Â $701,814Â Liabilities and stockholdersâ€™ equityCurrent liabilities:Accounts payable$14,278Â $6,641Â Accrued liabilities23,548Â 23,282Â Deferred revenue(1)52,202Â 55,753Â Operating lease liabilities3,329Â 3,358Â Current portion of long-term debt230,423Â â€”Â Total current liabilities323,780Â 89,034Â Long-term debt, net of current portion114,611Â 228,034Â Deferred revenue, net of current portion258Â 77Â Operating lease liabilities, net of current portion15,969Â 17,676Â Other liabilities3,395Â 74Â Total liabilities458,013Â 334,895Â Commitments and contingencies (Note 15)Stockholdersâ€™ equity:Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023â€”Â â€”Â 4Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; 60,847,658 and 58,295,491 shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively1,521,146Â 1,484,056Â Accumulated deficit(1,165,999)(1,117,170)Accumulated other comprehensive income (loss)(110)33Â Total stockholdersâ€™ equity355,037Â 366,919Â Total liabilities and stockholdersâ€™ equity$813,050Â $701,814Â _____(1)Â Â Â Â Includes amounts attributable to related party transactions. See Note 17 for further details.The accompanying notes are an integral part of these condensed consolidated financial statements.5HEALTH CATALYST, INC.Condensed Consolidated Statements of Operations(in thousands, except per share data)(unaudited)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Revenue(1):Technology$48,653Â $45,973Â $143,254Â $140,483Â Professional services27,700Â 27,800Â 83,724Â 80,371Â Total revenue76,353Â 73,773Â 226,978Â 220,854Â Cost of revenue, excluding depreciation and amortization:Technology17,609Â 15,169Â 48,991Â 45,755Â Professional services24,704Â 26,618Â 71,899Â 73,774Â Total cost of revenue, excluding depreciation and amortization42,313Â 41,787Â 120,890Â 119,529Â Operating expenses:Sales and marketing11,342Â 15,084Â 43,145Â 50,050Â Research and development14,193Â 17,667Â 42,948Â 52,339Â General and administrative12,209Â 13,625Â 41,136Â 61,129Â Depreciation and amortization9,983Â 10,190Â 31,165Â 31,919Â Total operating expenses47,727Â 56,566Â 158,394Â 195,437Â Loss from operations(13,687)(24,580)(52,306)(94,112)Interest and other income (expense), net(1,514)2,607Â 3,185Â 6,490Â Loss before income taxes(15,201)(21,973)(49,121)(87,622)Income tax provision (benefit)(475)59Â (292)213Â Net loss$(14,726)$(22,032)$(48,829)$(87,835)Net loss per share, basic and diluted(0.24)(0.39)(0.82)(1.57)Weighted-average shares outstanding used in calculating net loss per share, basic and diluted60,441Â 56,711Â 59,449Â 56,062Â _____(1)Â Â Â Â Includes amounts attributable to related party transactions. See Note 17 for further details.The accompanying notes are an integral part of these condensed consolidated financial statements.6HEALTH CATALYST, INC.Condensed Consolidated Statements of Comprehensive Loss(in thousands)(unaudited)Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Net loss$(14,726)$(22,032)$(48,829)$(87,835)Other comprehensive income (loss):Change in net unrealized gains (losses) on available for sale investments105Â 35Â (63)490Â Change in foreign currency translation adjustment(53)(1)(80)(12)Comprehensive loss$(14,674)$(21,998)$(48,972)$(87,357)The accompanying notes are an integral part of these condensed consolidated financial statements.7HEALTH CATALYST, INC.Condensed Consolidated Statements of Stockholdersâ€™ Equity(in thousands, except share data)(unaudited)Three Months Ended September 30, 2024Common Stock and Additional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Total Stockholdersâ€™ EquitySharesAmountBalance as of June 30, 202460,075,178Â $1,508,437Â $(1,151,273)$(162)$357,002Â Vesting of restricted stock units379,584Â â€”Â â€”Â â€”Â â€”Â Exercise of stock options5,904Â 39Â â€”Â â€”Â 39Â Stock-based compensationâ€”Â 9,818Â â€”Â â€”Â 9,818Â Issuance of common stock related to acquisitions386,992Â 2,852Â â€”Â â€”Â 2,852Â Net lossâ€”Â â€”Â (14,726)â€”Â (14,726)Other comprehensive incomeâ€”Â â€”Â â€”Â 52Â 52Â Balance as of September 30, 202460,847,658Â $1,521,146Â $(1,165,999)$(110)$355,037Â Three Months Ended September 30, 2023Common Stock and Additional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Total Stockholdersâ€™ EquitySharesAmountBalance as of June 30, 202356,541,641Â $1,454,897Â $(1,064,826)$(204)$389,867Â Vesting of restricted stock units and restricted shares497,789Â â€”Â â€”Â â€”Â â€”Â Exercise of stock options4,682Â 40Â â€”Â â€”Â 40Â Stock-based compensationâ€”Â 14,485Â â€”Â â€”Â 14,485Â Net lossâ€”Â â€”Â (22,032)â€”Â (22,032)Other comprehensive incomeâ€”Â â€”Â â€”Â 34Â 34Â Balance as of September 30, 202357,044,112Â $1,469,422Â $(1,086,858)$(170)$382,394Â The accompanying notes are an integral part of these condensed consolidated financial statements.8HEALTH CATALYST, INC.Condensed Consolidated Statements of Stockholdersâ€™ Equity(in thousands, except share data)(unaudited)Nine Months Ended September 30, 2024Common Stock and Additional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Total Stockholdersâ€™ EquitySharesAmountBalance as of December 31, 202358,295,491Â $1,484,056Â $(1,117,170)$33Â $366,919Â Vesting of restricted stock units and restricted shares1,486,435Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock under employee stock purchase plan263,482Â 1,431Â â€”Â â€”Â 1,431Â Exercise of stock options26,668Â 169Â â€”Â â€”Â 169Â Stock-based compensationâ€”Â 30,054Â â€”Â â€”Â 30,054Â Issuance of common stock related to acquisitions775,582Â 5,436Â â€”Â â€”Â 5,436Â Net lossâ€”Â â€”Â (48,829)â€”Â (48,829)Other comprehensive lossâ€”Â â€”Â â€”Â (143)(143)Balance as of September 30, 202460,847,658Â $1,521,146Â $(1,165,999)$(110)$355,037Â Nine Months Ended September 30, 2023Common Stock and Additional Paid-in CapitalAccumulated DeficitAccumulated Other Comprehensive Income (Loss)Total Stockholdersâ€™ EquitySharesAmountBalance as of December 31, 202255,261,922Â $1,424,681Â $(999,023)$(648)$425,010Â Vesting of restricted stock units and restricted shares1,554,641Â â€”Â â€”Â â€”Â â€”Â Issuance of common stock under employee stock purchase plan244,133Â 2,206Â â€”Â â€”Â 2,206Â Exercise of stock options128,443Â 937Â â€”Â â€”Â 937Â Stock-based compensationâ€”Â 43,406Â â€”Â â€”Â 43,406Â Repurchase of common stock(145,027)(1,808)â€”Â â€”Â (1,808)Net lossâ€”Â â€”Â (87,835)â€”Â (87,835)Other comprehensive incomeâ€”Â â€”Â â€”Â 478Â 478Â Balance as of September 30, 202357,044,112Â $1,469,422Â $(1,086,858)$(170)$382,394Â The accompanying notes are an integral part of these condensed consolidated financial statements.9HEALTH CATALYST, INC.Condensed Consolidated Statements of Cash Flows(in thousands)(unaudited)Nine Months EndedSeptember 30,20242023Cash flows from operating activitiesNet loss$(48,829)$(87,835)Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Stock-based compensation expense29,316Â 42,745Â Depreciation and amortization31,165Â 31,919Â Impairment of long-lived assets2,200Â 2,681Â Non-cash operating lease expense1,981Â 2,272Â Amortization of debt discount, issuance costs, and deferred financing costs2,078Â 1,132Â Investment discount and premium accretion(3,899)(6,816)Provision for expected credit losses3,433Â 1,626Â Deferred tax provision (benefit)(517)6Â Change in fair value of contingent consideration liabilities(1,642)â€”Â Other87Â 101Â Change in operating assets and liabilities:Accounts receivable, net6,304Â 259Â Prepaid expenses and other assets(617)385Â Accounts payable, accrued liabilities, and other liabilities4,810Â 1,847Â Deferred revenue(5,259)(1,688)Operating lease liabilities(2,525)(2,673)Net cash provided by (used in) operating activities18,086Â (14,039)Cash flows from investing activitiesProceeds from the sale and maturity of short-term investments206,488Â 256,101Â Purchase of short-term investments(50,197)(254,448)Acquisition of businesses, net of cash acquired(54,889)â€”Â Capitalization of internal-use software(9,858)(9,331)Purchases of intangible assets(504)(986)Purchases of property and equipment(1,203)(981)Proceeds from the sale of property and equipment10Â 21Â Net cash provided by (used in) investing activities89,847Â (9,624)Cash flows from financing activitiesProceeds from issuance of long-term debt, net of issuance costs115,472Â â€”Â Payment of deferred financing costs(3,000)â€”Â Proceeds from employee stock purchase plan2,061Â 3,206Â Proceeds from exercise of stock options169Â 937Â Repurchase of common stockâ€”Â (1,808)Repayment of seller-financed debt(646)â€”Â 10Net cash provided by financing activities114,056Â 2,335Â Effect of exchange rate changes on cash and cash equivalents62Â (13)Net increase (decrease) in cash and cash equivalents222,051Â (21,341)Cash and cash equivalents at beginning of period106,276Â 116,312Â Cash and cash equivalents at end of period$328,327Â $94,971Â Supplemental disclosures of non-cash investing and financing informationCommon stock issued in connection with acquisitions$5,436Â $â€”Â Stock-based compensation capitalized as internal-use software738Â 622Â Purchase of property and equipment included in accounts payable and accrued liabilities310Â 21Â Capitalized internal-use software included in accounts payable and accrued liabilities(322)88Â Operating lease right-of-use assets obtained in exchange for operating lease obligationsâ€”Â 2,033Â Purchase of intangible assets included in accounts payable and accrued liabilitiesâ€”Â 1,310Â The accompanying notes are an integral part of these condensed consolidated financial statements.11HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)1. Description of Business and Summary of Significant Accounting PoliciesNature of operationsHealth Catalyst, Inc. (Health Catalyst) was incorporated under the laws of Delaware in September 2011. We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data platform, software analytics applications, and professional services expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S.

generally accepted accounting principles (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended DecemberÂ 31, 2023 included in our Annual Report on Form 10-K.Interim unaudited condensed consolidated financial statementsThe accompanying interim condensed consolidated balance sheet as ofÂ SeptemberÂ 30, 2024, the interim condensed consolidated statements of operations for theÂ three and nine months ended SeptemberÂ 30, 2024Â andÂ 2023, our interim condensed consolidated statements of stockholdersâ€™ equity for theÂ three and nine months ended SeptemberÂ 30, 2024 and 2023, and our interim condensed consolidated statements of cash flows for theÂ nine months ended SeptemberÂ 30, 2024Â andÂ 2023Â are unaudited. Our condensed consolidated balance sheet as ofÂ DecemberÂ 31, 2023Â was derived from audited financial statements, but does not include all disclosures required by GAAP. Our interim unaudited condensed consolidated financial statements have been prepared on a basis consistent with our annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Companyâ€™s financial position, its operations and cash flows for the periods presented. The historical results are not necessarily indicative of future results, and the results of operations for theÂ three and nine months ended SeptemberÂ 30, 2024Â are not necessarily indicative of the results to be expected for the full year or any other period.Principles of consolidationThe condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.Use of estimatesThe preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, reserves for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software, impairment assessments of goodwill, intangible assets, and other long-lived assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ significantly from those estimates.12HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Segment reportingOperating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit.Net loss per shareBasic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period, when dilutive. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as the effect is anti-dilutive.Revenue recognitionWe derive our revenue primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: â€¢Identification of the contract, or contracts, with a client;â€¢Identification of the performance obligations in the contract;â€¢Determination of the transaction price;â€¢Allocation of the transaction price to the performance obligations in the contract; andâ€¢Recognition of revenue when, or as, we satisfy the performance obligation.We recognize revenue net of any taxes collected from clients and subsequently remitted to governmental authorities.Technology revenueTechnology revenue primarily consists of subscription fees charged to clients for access to use our technology. We provide clients access to our technology through either an all-access or limited-access, modular subscription. The majority of our subscription arrangements are cloud-based and do not provide clients the right to take possession of the technology or contain a significant penalty if the client were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the client. Our subscription contracts generally have a three- or five-year term, of which many are terminable after one year upon 90 daysâ€™ notice.Subscriptions that allow the client to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the client. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the client.13HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Professional services revenueProfessional services revenue primarily includes data and analytics services, domain expertise services, Tech-enabled Managed Services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our clients on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our clients. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the â€œright to invoiceâ€ practical expedient. Contracts with multiple performance obligationsMany of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include client demographics and the types of users. Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we generally use the residual method due to a limited number of standalone transactions and/or prices that are highly variable.Variable considerationWe have also entered into at-risk and shared savings arrangements with certain clients whereby we receive variable consideration based on the achievement of measurable improvements that may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. Contract balancesContract assets resulting from services performed prior to invoicing clients are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $8.3 million and $4.7 million, respectively. We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the client. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.5 million and $55.8 million, respectively.Deferred costsWe capitalize sales commissions and associated fringe costs, such as benefits and payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with clients, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the client contract. 14HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, $2.2Â million and $2.2 million, respectively, of deferred contract acquisition costs are expected to be amortized within the next 12 months and are included in prepaid expenses and other assets on the condensed consolidated balance sheets. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the remaining $2.9Â million and $3.3 million, respectively, of deferred contract acquisition costs are included in non-current other assets.Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average client life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average client life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs was $0.7Â million and $0.6Â million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $2.0Â million and $1.6 for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively, and is included within sales and marketing expense in the condensed consolidated statements of operations.We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.Cost of revenue, excluding depreciation and amortizationCost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, license and revenue share fees, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue in the interim condensed consolidated statements of operations excludes costs related to depreciation and amortization.Cash and cash equivalentsWe consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.Short-term investmentsOur investment policy limits investments to highly-rated instruments. We classify and account for our short-term investments as available for sale securities as we may sell these securities at any time for use in our current operations or for other purposes, even prior to maturity. As a result, we classify our short-term investments, including securities with contractual maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. 15HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Accounts receivableAccounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, client payment patterns, the establishment of specific reserves for clients in an adverse financial condition, and our expectations of changes in macroeconomic conditions, including high interest rates and high inflation, that may impact the collectability of outstanding receivables. We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)Allowance for credit losses at the beginning of period$6,600Â $3,800Â $4,105Â $2,300Â Provision for expected credit losses(5)112Â 3,433Â 1,626Â Less: Write-offs, net of recoveries5Â (12)(938)(26)Allowance for credit losses at the end of period$6,600Â $3,900Â $6,600Â $3,900Â LeasesWe determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our lease contracts do not have a readily determinable implicit rate, we use our incremental borrowing rate based on the information available at the commencement date to determine the present value of lease payments. The incremental borrowing rate is the estimated rate incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable costs related to our leased office space, such as maintenance and utilities based on actual usage, are not included in the measurement of right-of-use assets and lease liabilities, but are expensed as incurred.Property and equipmentProperty and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows:Computer equipment2-3 yearsFurniture and fixtures3-5 yearsLeasehold improvementsLesser of lease term or estimated useful life16HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Computer software2-5 yearsCapitalized internal-use software costs2-5 yearsWhen there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset, plus any terminal value, in the asset group. If the carrying amount of the asset group exceeds those estimated future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets.Intangible assetsIntangible assets include developed technologies, client relationships, client contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assetsâ€™ estimated useful lives. The estimated useful life of each asset category is as follows:Developed technologies3-10 yearsClient relationships and contract backlog2-7 yearsComputer software licenses1-5 yearsTrademarks1-5 yearsGoodwillWe record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, client relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually on October 31 or more frequently if indicators of impairment are present or circumstances suggest that impairment may exist. Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Judgment in the assessment of qualitative factors of impairment may include changes in business climate, market conditions, or other events impacting the reporting unit. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. Performing a quantitative goodwill impairment test includes the determination of the fair value of a reporting unit, which requires management to use significant judgment and estimation. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of the reporting units, as well as the sensitivity of the respective fair values to the underlying significant assumptions. Typical methods to derive the fair value of reporting units include using the income or market approaches. The significant assumptions used to form the basis of the estimates include, among others, the selection of valuation methodologies, estimates of expected revenue, including revenue growth rates, and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, and the selection of appropriate market comparable companies. Many of these significant assumptions are forward-looking and could be affected by future economic and market conditions. If a quantitative analysis is necessary, we typically engage the assistance of a valuation specialist in concluding on fair value measurements in connection with determining the fair values of our reporting units. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unitâ€™s fair value. There was no

impairment of goodwill for the three and nine months ended SeptemberÂ 30, 2024 and 2023.Â 17HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Business combinationsThe results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of the acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration transferred over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill.We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the client-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for client relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of material assets acquired and liabilities assumed in a business combination. For the three and nine months ended SeptemberÂ 30, 2024, we expensed $1.7 million and $4.2Â million, respectively, of transaction costs associated with business combinations. For the three and nine months ended SeptemberÂ 30, 2023, we expensed $1.6 million of transaction costs associated with business combinations. The costs were expensed as incurred and are included in general and administrative expense in our condensed consolidated statements of operations.Contingent consideration liabilitiesOur acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements.We generally value the expected contingent consideration and the corresponding liabilities using the Monte Carlo method or Black-Scholes model based on estimates of potential payment scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period.As applicable, the portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes in the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations.18HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Advertising costsAll advertising costs are expensed as incurred. For each of theÂ three months ended SeptemberÂ 30, 2024Â andÂ 2023, we incurredÂ $0.4 million of advertising costs, and $4.1 million and $1.6 million for the nine months ended September 30, 2024 and 2023, respectively.Development costs and internal-use softwareFor technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our clients on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life with amortization included in depreciation and amortization expense in our condensed consolidated statements of operations. Stock-based compensationStock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date or, when applicable, the modification date. The grant date fair value of our stock-based awards is typically determined using the market closing price of our common stock on the date of grant; however, we also consider whether any adjustments are required when the market closing price does not reflect certain material non-public information that we know but is unavailable to marketplace participants on the date of grant. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. For awards subject to market conditions, we estimate the fair value as of the grant date using a Monte Carlo simulation valuation model which requires the use of various assumptions, including historic stock price volatility and risk-free interest rates as of the valuation date corresponding to the length of time remaining in the performance period. Stock-based compensation expense for awards with market conditions is recognized over the requisite service period using the accelerated attribution method and is not reversed if the market condition is not met.Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period.The measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.19HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Restructuring costsWe define restructuring costs as expenses directly associated with restructuring activities. Such costs include severance and related tax and benefit expenses from workforce reductions, impairment of discontinued capitalized software projects, and other miscellaneous charges. We record team member-related severance costs when there is a substantive plan in place and the related costs are probable and estimable. For one-time termination benefits for team members (i.e., no substantive plan or future service requirement), the cost is recorded when the terms of the one-time termination benefits are communicated to the impacted team members and the amount can be reasonably estimated. Income taxesDeferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and tax credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not currently accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because the impact would be immaterial due to our net operating losses and tax credit carryforwards. Significant judgment is required to evaluate uncertain tax positions.Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations.Fair value of financial instrumentsThe carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. The carrying value of operating lease liabilities and convertible senior notes approximate fair value based on interest rates available for debt with similar terms at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. Money market funds and short-term investments are measured at fair value on a recurring basis. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:â€¢LevelÂ 1- Quoted prices in active markets for identical assets or liabilities.20HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)â€¢LevelÂ 2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.â€¢LevelÂ 3- Inputs that are generally unobservable and typically reflect managementâ€™s estimate of assumptions that market participants would use in pricing the asset or liability.All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios.Foreign currencyThe functional currency of our international subsidiaries is generally their local currency. We translate these subsidiariesâ€™ financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholdersâ€™ equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented.Recent accounting pronouncements not yet adoptedIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segmentâ€™s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segmentâ€™s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. We expect that the disclosure changes that result from the adoption of this ASU will not have a material impact on our consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entityâ€™s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2025.In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the provision of this ASU to determine the impact it may have on our consolidated financial statements and related disclosures, and we expect additional disclosures upon adoption.21HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)2. Business CombinationsThe business acquisitions discussed below are included in our results of operations from the date of acquisition.2024 AcquisitionsLumeon Ltd.On August 1, 2024, we acquired Lumeon Ltd. (Lumeon), a digital health company dedicated to helping provider organizations mend broken care coordination processes through automated care orchestration. We accounted for the acquisition of Lumeon as a business combination. The acquisition consideration transferred was $39.8 million and was comprised of estimated net cash consideration of $36.2 million, Health Catalyst common shares with a fair value of $2.9 million, and contingent consideration based on certain earn-out performance targets for Lumeon during an earn-out period ending on June 30, 2025, with an acquisition-date fair value of $0.7 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Lumeon. The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Lumeon (in thousands):Assets acquired:Accounts receivable, net$967Â Prepaid expenses and other assets795Â Property and equipment, net165Â Client relationships3,700Â Developed technology11,400Â Trademarks1,300Â Total assets acquired18,327Â Less liabilities assumed:Accrued and other current liabilities1,151Â Deferred revenue1,759Â Net deferred tax liabilities3,679Â Total liabilities assumed6,589Â Total assets acquired, net11,738Â Goodwill28,092Â Total consideration transferred, net of cash acquired$39,830Â The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and five years, respectively. The resulting goodwill from the Lumeon acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. The preliminary allocation of the consideration transferred is subject to potential adjustments. Balances subject to adjustment are primarily tax-related matters, including the tax basis of assets acquired and liabilities assumed. During the measurement period, we may record adjustments to the provisional amounts recognized in our initial accounting for the acquisition. We expect the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). There were no measurement period adjustments recorded during the three months ended September 30, 2024. 22HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)The amount of revenue attributable to the acquired business of Lumeon was not material to our condensed consolidated statement of operations for the three and nine months ended September 30, 2024. Income (loss) information for Lumeon after the acquisition date through SeptemberÂ 30, 2024 is not presented as the Lumeon business was integrated into our operations immediately following the acquisition and is impracticable to quantify.In addition to the purchase price, we agreed to make cash retention payments in an aggregate amount of up to $5.0 million to continuing Lumeon team members, a portion of which is variable based upon the achievement of earn-out performance targets. The retention payments are generally subject to vesting based upon continued employment over a required service period. Such amounts are recorded as post-combination compensation expense and recognized on a straight-line basis over the relevant vesting terms. During the nine months ended September 30, 2024, we recognized compensation expense of $1.1 million related to these retention payments.Carevive Systems, Inc.On May 24, 2024, we acquired Carevive Systems, Inc. (Carevive), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. We accounted for the acquisition of Carevive as a business combination. Oncology providers and life science researchers use Careviveâ€™s flagship platform and/or Carevive data in routine clinical practice for treatment care planning, clinical trial screening, care coordination, remote patient monitoring, and/or post-treatment care. The acquisition consideration transferred was $22.1 million and was comprised of estimated net cash consideration of $18.6 million, Health Catalyst common shares with a fair value of $2.6 million, and contingent consideration based on certain earn-out performance targets for Carevive during an earn-out period ending on June 30, 2025, with an acquisition-date fair value of $0.9 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Carevive. The following table

summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Carevive (in thousands):Assets acquired:Accounts receivable, net$96Â Prepaid expenses and other assets64Â Client relationships2,700Â Developed technology4,800Â Trademarks300Â Total assets acquired7,960Â Less liabilities assumed:Accrued and other current liabilities1,389Â Deferred revenue76Â Total liabilities assumed1,465Â Total assets acquired, net6,495Â Goodwill15,643Â Total consideration transferred, net of cash acquired$22,138Â The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and three years, respectively. The resulting goodwill from the Carevive acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. 23HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)The preliminary allocation of the consideration transferred is subject to potential adjustments. Balances subject to adjustment are primarily tax-related matters, including the tax basis of assets acquired and liabilities assumed. During the measurement period, we may record adjustments to the provisional amounts recognized in our initial accounting for the acquisition. We expect the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). There were no measurement period adjustments recorded during the three and nine months ended September 30, 2024. The amount of revenue attributable to the acquired business of Carevive was not material to our consolidated statement of operations for the three and nine months ended September 30, 2024. Income (loss) information for Carevive after the acquisition date through SeptemberÂ 30, 2024 is not presented as the Carevive business was integrated into our operations immediately following the acquisition and is impracticable to quantify.In addition to the purchase price, we agreed to make cash retention payments in an aggregate amount of up to $1.8 million to continuing Carevive team members, a portion of which is variable based upon the achievement of earn-out performance targets. The retention payments are generally subject to vesting based upon continued employment over a required service period. Such amounts are recorded as post-combination compensation expense and recognized on a straight-line basis over the relevant vesting terms. During the nine months ended September 30, 2024, we recognized compensation expense of $0.8 million related to these retention payments.Unaudited Pro Forma Financial Information The following table reflects our unaudited pro forma combined results of operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023 as if the acquisitions of Carevive and Lumeon had taken place on JanuaryÂ 1, 2023 (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Pro forma net loss$(14,818)$(27,407)$(56,182)$(107,898)The unaudited pro forma information is presented for informational purposes only and is not intended to present actual results that would have been attained had the acquisition been completed as of JanuaryÂ 1, 2023 or to project potential results as of any future date or for any future periods. The unaudited pro forma information, including adjustments, are based upon available information and certain assumptions that we believe are reasonable. Pro forma revenue has not been presented for these 2024 acquisitions as the impact to our condensed consolidated financial statements was not material. The nature and amount of material, nonrecurring pro forma adjustments directly attributable to these acquisitions which are included in the pro forma net loss, as applicable, are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Amortization of acquired intangible assets(303)(1,331)$(2,788)$(3,993)Acquisition-related costs, net1,487Â â€”Â 5,731Â (1,534)Total pro forma adjustments$1,184Â $(1,331)$2,943Â $(5,527)24HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)2023 Acquisition of Electronic Registry Systems, Inc.On October 2, 2023, we acquired Electronic Registry Systems, Inc. (ERS), a cloud-based provider of clinical registry development and data management software based in Cincinnati, Ohio. We accounted for the acquisition of ERS as a business combination. ERS provides cancer registry compliance and informatics services to enable customers to achieve their cancer center clinical and business objectives with a goal of improving cancer care for every patient, including through its CRStar platform. The acquisition consideration transferred comprised of net cash consideration of $11.4Â million. The purchase resulted in Health Catalyst acquiring 100% ownership in ERS.An additional 175,901 shares of our common stock subject to a restriction agreement (restricted shares) were issued pursuant to the terms of the acquisition agreement. The vesting of these restricted shares was originally subject to eighteen months of continued employment with cliff vesting upon the eighteen-month anniversary of the acquisition close date. The value of these restricted shares was originally scheduled to be recognized as post-combination stock-based compensation expense on a straight-line basis over the vesting term, but due to workforce reductions made as part of the 2023 Restructuring Plan (as defined below), the ERS restricted shares fully vested in February 2024, resulting in an acceleration of the related stock-based compensation expense. Refer to Note 13-Stock-Based Compensation for additional details related to our stock-based compensation.The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of ERS (in thousands):Assets acquired:Accounts receivable$478Â Prepaid expenses and other assets73Â Client relationships5,300Â Developed technology3,100Â Trademarks100Â Total assets acquired9,051Â Less liabilities assumed:Accrued and other current liabilities78Â Deferred revenue2,251Â Total liabilities assumed2,329Â Total assets acquired, net6,722Â Goodwill4,670Â Total consideration transferred, net of cash acquired$11,392Â The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and two years, respectively. The resulting goodwill from the ERS acquisition was fully allocated to the technology reporting unit and is deductible for income tax purposes. 25HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)3. RevenueDisaggregation of RevenueThe following table represents Health Catalystâ€™s revenue disaggregated by type of arrangement (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Recurring technology$48,653Â $45,973Â $143,254Â $140,126Â One-time technology (i.e., perpetual license)â€”Â â€”Â â€”Â 357Â Professional services27,700Â 27,800Â 83,724Â 80,371Â Total revenue$76,353Â $73,773Â $226,978Â $220,854Â Revenue related to contracts with clients located in the United States was 96.9% and 98.5% for the three months ended September 30, 2024 and 2023, respectively, and 97.6% and 98.3% for the nine months ended September 30, 2024 and 2023, respectively.4. Goodwill and Intangible AssetsWe operate our business in two operating segments that also represent our reporting units. Our reporting units are organized based on our technology and professional services. We have not incurred any goodwill impairment charges.Goodwill by reporting unit is as follows (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Technology$233,605Â $189,870Â Professional services782Â 782Â Total goodwill$234,387Â $190,652Â As of SeptemberÂ 30, 2024, intangible assets consisted of the following (in thousands):CostAccumulated AmortizationNet(unaudited)Developed technologies$120,129Â $(90,573)$29,556Â Client relationships and contracts96,464Â (53,735)42,729Â Computer software licenses11,144Â (9,084)2,060Â Trademarks4,420Â (2,302)2,118Â Total intangible assets$232,157Â $(155,694)$76,463Â Amortization expense of acquired intangible assets was $6.8 million and $7.1 million for the three months ended SeptemberÂ 30, 2024 andÂ 2023, respectively, and $21.6 million and $22.4 million for the nine months ended September 30, 2024 and 2023, respectively. Amortization expense for intangible assets is included in depreciation and amortization in our condensed consolidated statements of operations. We have not incurred any intangible asset impairment charges for the three and nine months ended SeptemberÂ 30, 2024 and 2023.26HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)As of DecemberÂ 31, 2023, intangible assets consisted of the following (in thousands):CostAccumulated AmortizationNetDeveloped technologies$103,929Â $(79,057)$24,872Â Client relationships and contracts90,064Â (45,230)44,834Â Computer software licenses10,680Â (7,933)2,747Â Trademarks2,820Â (1,889)931Â Total intangible assets$207,493Â $(134,109)$73,384Â 5. Property and EquipmentProperty and equipment consisted of the following (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Computer equipment$10,532Â $9,638Â Leasehold improvements8,429Â 8,814Â Furniture and fixtures3,748Â 3,735Â Capitalized internal-use software costs41,526Â 30,771Â Computer software111Â 111Â Total property and equipment64,346Â 53,069Â Less: accumulated depreciation(36,438)(27,357)Property and equipment, net$27,908Â $25,712Â Our long-lived assets are located in the United States. Depreciation expense totaled $3.1 million for each of the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $9.5 million for each of the nine months ended September 30, 2024 and 2023, respectively. Depreciation expense includes the amortization of capitalized internal-use software costs. During each of the nine months ended SeptemberÂ 30, 2024 and 2023, we impaired $0.7 million of leasehold improvements related to our corporate office space designated for subleasing. Refer to Note 9 for additional details. We capitalized $4.4 million and $3.0 million of internal-use software costs for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $10.8 million and $9.6 million for the nine months ended September 30, 2024 and 2023, respectively. We incurred $2.5 million and $2.1 million of capitalized internal-use software cost amortization expense for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $7.2 million and $6.4 million for the nine months ended September 30, 2024 and 2023, respectively.6. Short-term InvestmentsWe classify our short-term investments as available for sale. Available-for-sale securities are recorded on our condensed consolidated balance sheets at fair market value and any unrealized gains or losses are reported as part of other comprehensive loss on the condensed consolidated statements of comprehensive loss. We determine realized gains or losses on the sales of investments through the specific identification method and record such gains or losses as part of interest and other expense, net on the condensed consolidated statements of operations. We did not have any material realized gains or losses on investments during the three and nine months ended SeptemberÂ 30, 2024 and 2023. We measure the fair value of investments on a recurring basis. 27HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of SeptemberÂ 30, 2024 (in thousands):Amortized CostUnrealized GainsUnrealized LossesFair ValueCash equivalentsShort-term Investments(unaudited)Money market funds$322,989Â $â€”Â $â€”Â $322,989Â $322,989Â $â€”Â U.S. treasury notes19,397Â 9Â â€”Â 19,406Â â€”Â 19,406Â Commercial paper12,092Â 7Â â€”Â 12,099Â â€”Â 12,099Â Corporate bonds27,416Â 8Â â€”Â 27,424Â â€”Â 27,424Â Total$381,894Â $24Â $â€”Â $381,918Â $322,989Â $58,929Â The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of DecemberÂ 31, 2023 (in thousands):Amortized CostUnrealized GainsUnrealized LossesFair ValueCash equivalentsShort-term InvestmentsMoney market funds$99,779Â $â€”Â $â€”Â $99,779Â $99,779Â $â€”Â U.S. treasury notes65,856Â 68Â â€”Â 65,924Â â€”Â 65,924Â Commercial paper85,358Â â€”Â (18)85,340Â â€”Â 85,340Â Corporate bonds43,746Â 49Â â€”Â 43,795Â â€”Â 43,795Â U.S. agency securities16,405Â â€”Â (12)16,393Â â€”Â 16,393Â Total$311,144Â $117Â (30)311,231Â $99,779Â $211,452Â The following table presents the contractual maturities of our short-term investments as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 (in thousands):As of September 30, 2024As of December 31, 2023Amortized CostFair ValueAmortized CostFair Value(unaudited)Due within one year$58,905Â $58,929Â $211,365Â $211,452Â Total$58,905Â $58,929Â $211,365Â $211,452Â Accrued interest receivables related to our available-for-sale securities of $1.4 million and $0.9 million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively, were included within prepaid expenses and other assets on our condensed consolidated balance sheets. On a quarterly basis we evaluate unrealized losses on our available-for-sale debt securities and the related accrued interest receivables to determine whether a decline in the fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors. We do not intend to sell investments that are in an unrealized loss position and it is not likely that we will be required to sell any investments before recovery of their amortized cost basis. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, there were no material unrealized losses due to expected credit loss-related factors.28HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)7. Fair Value of Financial InstrumentsAssets and liabilities measured at fair value on a recurring basis as of SeptemberÂ 30, 2024 were as follows (in thousands):September 30, 2024Level 1Level 2Level 3Total(unaudited)Money market funds$322,989Â $â€”Â $â€”Â $322,989Â U.S. Treasury notes19,406Â â€”Â â€”Â 19,406Â Commercial paperâ€”Â 12,099Â â€”Â 12,099Â Corporate bondsâ€”Â 27,424Â â€”Â 27,424Â Contingent consideration liabilitiesâ€”Â â€”Â â€”Â â€”Â Total$342,395Â $39,523Â $â€”Â $381,918Â Assets measured at fair value on a recurring basis as of DecemberÂ 31, 2023 were as follows (in thousands):December 31, 2023Level 1Level 2Level 3TotalMoney market funds$99,779Â $â€”Â $â€”Â $99,779Â U.S. Treasury notes65,924Â â€”Â â€”Â 65,924Â Commercial paperâ€”Â 85,339Â â€”Â 85,339Â Corporate bondsâ€”Â 43,796Â â€”Â 43,796Â U.S. agency securitiesâ€”Â 16,393Â â€”Â 16,393Â Total$165,703Â $145,528Â $â€”Â $311,231Â There were no transfers between Level 1 and Level 2 of the fair value measurement hierarchy during the three and nine months ended SeptemberÂ 30, 2024 and 2023.Convertible senior notesAs ofÂ SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the estimated fair value of our convertible senior notes, with aggregate principal totalingÂ $230.0Â million,Â wasÂ $227.9 million and $218.7 million, respectively. We estimate the fair value based on quoted market prices in an inactive market on the last trading day of the reporting period (Level 2). These convertible senior notes are recorded at face value less unamortized debt discount and transaction costs on our condensed consolidated balance sheets. Refer toÂ Note 10â€”Debt for further information.Nonrecurring fair value measurementsWe recorded impairment charges of $2.2 million and $2.7 million related to the impairment of ROU assets and leasehold improvements associated with office space designated for subleasing during the nine months ended September 30, 2024 and 2023. These impairment charges were derived from the difference between the carrying value and the fair value of the relevant asset groups. The fair value of these asset groups was estimated using a discounted cash flow analysis of the office space designated for subleasing and included certain unobservable (Level 3) inputs, including the anticipated future sublease terms and rates.29HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Level 3 fair value measurementsThe Lumeon acquisition consideration included an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Lumeon during an earn-out period that ends on June 30, 2025. The Lumeon contingent consideration is capped at $25.0 million and will be paid in cash to the extent achieved. We value Lumeonâ€™s expected contingent consideration and the corresponding liability using the Black-Scholes valuation method based on estimates of potential pay-out scenarios. The Carevive acquisition consideration included an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Carevive during an earn-out period that ends on June 30, 2025. The Carevive contingent consideration is capped at $10.0 million and will be paid in cash to the extent achieved. We value Careviveâ€™s expected contingent consideration and the corresponding liability using the Black-Scholes valuation method based on estimates of potential pay-out scenarios. The outstanding contingent consideration liabilities are categorized as Level 3 fair value measurements and are remeasured as of each reporting period. The aggregate intrinsic value of the revenue-based earn-out contingent consideration liabilities is zeroÂ based on a point estimate of our internal forecasting of the ultimate earn-outs that will be earned as of SeptemberÂ 30, 2024. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs used during the three months ended SeptemberÂ 30, 2024:Valuation MethodMarket Price of Revenue RiskRevenue VolatilityExpected Term (years)Risk-free interest rate(unaudited)Revenue-based earn-out liabilitiesBlack-Scholes8.4%20%1.25.0%The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):Fair Value Measurements Using Significant Unobservable Inputs (Level 3)(unaudited)Balance as of JanuaryÂ 1, 2024$â€”Â Acquisition-date contingent consideration liabilities from acquisitions (see Note 2)1,642Â Change in fair value of contingent consideration liabilities(1,642)Balance as of SeptemberÂ 30, 2024$â€”Â 30HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)8. Accrued LiabilitiesAs of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, accrued liabilities consisted of the following (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Accrued compensation and benefit expenses$9,838Â $11,680Â Restructuring liabilities(1)7Â 2,355Â Other accrued liabilities13,703Â 9,247Â Total accrued liabilities$23,548Â $23,282Â _____(1)Restructuring liabilities include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in these condensed consolidated financial statements.9. LeasesWe lease office space under operating leases that expire between 2024 and 2031. The terms of the leases provide for rental payments on a graduated scale, options to renew the leases (one to five years), landlord incentives or allowances, and periods of free rent. We subleased portions of our corporate headquarters to various sublessees with subleases commencing at various dates between 2021 and 2024.Components of lease expense (income) are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Operating lease expense$692Â $760Â $1,986Â $2,334Â Short-term lease expense50Â 9Â 114Â 51Â Sublease income(414)(308)(1,068)(935)Total$328Â $461Â $1,032Â $1,450Â We also incur immaterial variable costs related to our leased office space, such as maintenance and utilities based on actual usage, which are not included in the measurement of right-of-use assets and lease liabilities, but are expensed as incurred.During the nine months ended SeptemberÂ 30, 2024 and 2023, we identified asset impairment indicators for multiple of our corporate office spaces designated for subleasing. We performed a recoverability test of the

relevant asset group, comprised of operating lease ROU and other related assets, and determined that the carrying value of this asset group was not fully recoverable. As a result, we measured and recognized total impairment charges of $2.2 million and $2.7 million during the nine months ended September 30, 2024 and 2023, respectively, representing the amount by which the carrying value exceeded the estimated fair value of this asset group. The impairment charges were recorded as part of general and administrative expense in our condensed consolidated statements of operations. During the nine months ended September 30, 2024, $1.5 million of the impairment charge was allocated to ROU assets and the remaining $0.7 million was allocated to leasehold improvements, while during the nine months ended September 30, 2023, $2.0 million of the impairment charge was allocated to ROU assets and the remaining $0.7 million was allocated to leasehold improvements.31HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)10. DebtDebt consisted of the following as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 (in thousands):September 30, 2024December 31, 2023(unaudited)2.50% convertible senior notes due 2025$230,000Â $230,000Â Variable interest rate term loan maturing 2029125,000Â â€”Â Total Principal Outstanding355,000Â 230,000Â Less: Unamortized discount and issuance costs(9,966)(1,966)Net carrying amount345,034Â 228,034Â Less: Current portion of long-term debt(230,423)â€”Â Long-term debt, net of current portion$114,611Â $228,034Â Components of interest expense are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Contractual interest expense$4,541Â $1,445Â $7,444Â $4,329Â Amortization of debt discount and issuance costs769Â 378Â 1,529Â 1,132Â Amortization of deferred financing costs816Â â€”Â 816Â â€”Â Total$6,126Â $1,823Â $9,789Â $5,461Â Maturity of DebtAs of SeptemberÂ 30, 2024, we are subject to required principal payments and debt maturity as follows (in thousands):Contractual MaturityFiscal year:(unaudited)2024$313Â 2025231,250Â 20261,250Â 20271,250Â 20281,250Â 2029119,687Â Total debt maturities355,000Â Less: Unamortized debt discount and issuance costs(9,966)Net carrying amount$345,034Â Credit AgreementOn July 16, 2024 (the Closing Date), we entered into a credit agreement with Silver Point Finance, LLC, as administrative agent and collateral agent, and the lenders from time-to-time party thereto (the Credit Agreement). The Credit Agreement provides a five-year term loan facility in an aggregate principal amount of up to $225.0Â million, consisting of an initial term loan of $125.0Â million, which was funded in full on the Closing Date, and a delayed draw term loan facility in an aggregate principal amount of up to $100.0Â million, which was undrawn as of the Closing Date. 32HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)We have the option to draw up to $40.0Â million under the delayed draw facility within six months after the Closing Date and up to an additional $60.0Â million under the delayed draw facility within eighteen months after the Closing Date, in each case, subject to satisfaction of certain conditions, including a minimum liquidity threshold and a maximum recurring revenue/leverage ratio. We are required to pay a commitment fee on the unutilized commitments under the delayed draw term loan facility ranging from 1.5% to 2.5% per year depending on the year and the amount of the unutilized delayed draw term loan. The deferred financing costs related to the delayed draw facility, including the directly attributable debt discount, have been capitalized to other assets on our condensed consolidated balance sheets, and amortized to interest expense in the condensed consolidated statement of operations, in each case over the respective terms.Borrowings under the initial term loan bear interest at a rate per annum equal to the secured overnight financing rate (SOFR) plus 6.5%. Commencing with the quarter ending on December 31, 2024, we are required to make quarterly principal payments in an amount equal to 0.25% of the aggregate original principal amount. The final maturity date of the term loans is July 16, 2029.We expect to use the net proceeds from the initial term loan, together with cash on hand, (i) to repurchase, repay, and/or pay amounts of cash due upon conversion of any or all of the Notes at any time on or prior to the maturity thereof and (ii) for working capital and general corporate purposes. We expect to use the proceeds from the delayed draw term loan facility, if any, to fund our inorganic growth strategy through permitted acquisitions (including deferred purchase price or similar arrangements related thereto) and to pay fees, costs, and expenses in connection therewith.We are required to prepay the term loans upon the occurrence of certain events, and we may voluntarily prepay the term loans, in whole or in part, at any time, subject to certain notice requirements and prepayment amounts. Prior to July 16, 2028, such mandatory prepayments or voluntary prepayments are subject to a prepayment premium ranging from 1.0% to 3.0% plus a make whole amount depending on the year of such prepayment. Our obligations under the Credit Agreement and the other loan documents are required to be guaranteed by all of our present and future domestic and foreign subsidiaries, subject to certain exceptions (Guarantors). All obligations under the Credit Agreement and the other loan documents are secured by a first priority perfected lien on, and security interest in, substantially all of our and our Guarantorâ€™s present and future assets, subject to certain exceptions.The Credit Agreement contains various representations and warranties, affirmative covenants, and negative covenants, including covenants that restrict our and our subsidiariesâ€™ ability to take certain actions including, among other things and subject to certain exceptions, the incurrence of debt, the granting of liens, engaging in mergers and other fundamental changes, the making of investments, entering into transactions with affiliates, the payment of dividends and other restricted payments, the prepayment of other indebtedness and the sale of assets. We are also required to comply with a minimum liquidity threshold, a maximum recurring revenue-based leverage ratio, and a maximum EBITDA-based leverage ratio. The Credit Agreement also includes various events of default, including, among others: non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations or warranties, cross-default to other material indebtedness, bankruptcy and insolvency events, invalidity or impairment of security interests or invalidity of loan documents, certain ERISA events, unsatisfied or unstayed judgments and change of control. Upon the occurrence of an event of default, the administrative agent and the lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Credit Agreement and the related loan documents, including proceeding against the collateral securing such borrowings. As of SeptemberÂ 30, 2024, we were in compliance with all covenants under the Credit Agreement.33HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Convertible senior notesOn AprilÂ 14, 2020, we issued $230.0Â million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025 (Notes), in a private placement to qualified institutional buyers exempt from registration under the Securities Act (Note Offering). The net proceeds from the issuance of the Notes were approximately $222.5Â million, after deducting the initial purchasersâ€™ discounts and offering expenses payable by us.The Notes are governed by an indenture (the Indenture) between us, as the issuer, and U.S. Bank National Association, as trustee. The Notes are our senior, unsecured obligations and accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Indenture does not contain any financial or operating covenants or restrictions on the payments of dividends, the incurrence of indebtedness, or the issuance or repurchase of securities by us or any of our subsidiaries. On or after April 20, 2023, we may redeem, for cash, all or a portion of the Notes, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.The Notes have an initial conversion rate of 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock). Following certain corporate events that occur prior to the maturity date, we will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event. Additionally, upon the occurrence of a corporate event that constitutes a â€œfundamental changeâ€ per the Indenture, holders of the Notes may require the Company to repurchase for cash all or a portion of their Notes at a purchase price equal to 100% of the principal amount of the Notes plus accrued and unpaid interest.Holders of the Notes were able to convert all or any portion of their Notes at any time prior to the close of business on October 14, 2024, in integral multiples of $1,000 principal amount, only under the following circumstances:â€¢During any calendar quarter commencing after the calendar quarter ended on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;â€¢During the five business day period after any five consecutive trading day period (the measurement period) in which the trading price as defined in the Indenture per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; â€¢If we call such notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; orâ€¢Upon the occurrence of specified corporate events described in the Indenture.On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time irrespective of the foregoing circumstances. Upon conversion, holders will receive cash, shares of our common stock or a combination of cash and shares of common stock, at our election.34HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)As of SeptemberÂ 30, 2024, the conditions allowing holders of the Notes to convert were not met and, therefore, the Notes were not convertible as of such date. However, due to the April 2025 maturity date now being within twelve months, the Notes are classified as a current liability on our condensed consolidated balance sheet. Based on the closing price of our common stock of $8.14 per share on the last trading day of the period ended SeptemberÂ 30, 2024, the if-converted value of the Notes was less than their respective principal amounts.Capped callsOn April 8, 2020, concurrently with the pricing of the Notes, we entered into privately negotiated capped call transactions (Base Capped Calls) with certain option counterparties. In addition, in connection with the initial purchasersâ€™ exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. We used approximately $21.7 million of the net proceeds from the Note Offering to pay the cost of the Capped Calls and allocated issuance costs. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price. The Capped Calls are separate transactions that we entered into with the option counterparties, and are not part of the terms of the Notes. As the Capped Call transactions are considered indexed to our own stock and are considered equity classified, they were recorded in stockholdersâ€™ equity and are not accounted for as derivatives. The cost incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital on our condensed consolidated balance sheets.11. Stockholdersâ€™ EquityPreferred stockOur board of directors has the authority, without further action by our stockholders, to issue up to 25,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, and privileges thereof, including voting rights. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, no shares of this preferred stock were issued and outstanding.Common stockWe had 500,000,000 shares of common stock, par value $0.001 per share, authorized, of which 60,847,658 and 58,530,880 shares were legally issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. The shares legally issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 included zero shares and 235,389 shares, respectively, issued pursuant to acquisition agreements, which were subject to a restriction agreement and were unvested, and as such, for accounting purposes they were not considered to be outstanding common stock shares. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on our common stock through SeptemberÂ 30, 2024.Share repurchase planDuring the third quarter of 2022, our board of directors authorized a share repurchase program to repurchase up to $40.0Â million of our outstanding shares of common stock (Share Repurchase Plan). There were no share repurchases during the first, second or third quarter of 2024. During the first quarter of 2023, we repurchased and retired 145,027 shares of our common stock for $1.8Â million at an average purchase price of $12.45 per share. 35HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)This is in addition to the 709,139 shares of common stock we repurchased and retired for $8.4Â million at an average purchase price of $11.81 per share during the third quarter of 2022. The total remaining authorization for future shares of common stock repurchases under our Share Repurchase Plan is $29.8Â million as of SeptemberÂ 30, 2024.12. Net Loss Per ShareThe following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Net loss per share, basic and dilutedNumerator:Net loss$(14,726)$(22,032)$(48,829)$(87,835)Denominator:Weighted-average shares outstanding used in calculating net loss per share, basic and diluted60,440,694Â 56,710,602Â 59,448,966Â 56,061,925Â Net loss per share, basic and diluted(0.24)(0.39)(0.82)(1.57)During the three and nine months ended SeptemberÂ 30, 2024 and 2023, we incurred net losses and, therefore, the effect of our stock options, restricted stock units, performance-based restricted stock units, convertible senior notes, employee stock purchase plan, and restricted shares were not included in the calculation of diluted net loss per share as the effect would be anti-dilutive.The calculation of diluted net loss per share does not include the effect of the following potentially outstanding shares of common stock. The effects of these potentially outstanding shares were not included in the calculation of diluted net loss per share when the effect would have been anti-dilutive:As of September 30,20242023(unaudited)Common stock options1,071,509Â 1,404,287Â Restricted stock units4,160,419Â 4,196,967Â Performance-based restricted stock units524,994Â 211,548Â Shares related to convertible senior notes7,516,331Â 7,516,331Â Employee stock purchase plan207,388Â 184,908Â Restricted sharesâ€”Â 324,562Â Total potentially dilutive securities13,480,641Â 13,838,603Â In connection with the offering of our convertible senior notes, we entered into Capped Calls with initial caps on the conversion price of $42.00 per share, which are excluded from the calculation of diluted earnings per share, as they would be anti-dilutive.36HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)13. Stock-Based Compensation In 2011, our board of directors adopted the Health Catalyst, Inc. 2011 Stock Incentive Plan (2011 Plan), which provided for the direct award, sale of shares, and granting of RSUs and options for our common stock to our directors, team members, or consultants. In connection with our initial public offering (IPO), our board of directors adopted the 2019 Stock Option and Incentive Plan (2019 Plan). The 2019 Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce, including the grant of incentive and non-statutory stock options, restricted and unrestricted stock, RSUs, and stock appreciation rights to our directors, team members, or consultants.We initially reserved 2,756,607 shares of our common stock (2,500,000 under the 2019 Plan and 256,607 shares under the 2011 Plan) that were available immediately prior to the IPO registration date. The 2019 Plan provides that the number of shares reserved available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee. As of JanuaryÂ 1, 2024, there were an additional 2,926,544 shares reserved for issuance under the 2019 Plan. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, there were 23,644,211 and 20,717,667 shares authorized for grant, respectively, and 4,420,022 and 3,831,444 shares available for grant under the 2019 Plan, respectively. The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our condensed consolidated statements of operations (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Restricted stock units$8,655Â $11,591Â $25,065Â $34,531Â Performance-based restricted stock units673Â 406Â 1,523Â 1,117Â Employee stock purchase plan184Â 357Â 746Â 1,464Â Restricted sharesâ€”Â 1,878Â 1,969Â 5,573Â Optionsâ€”Â â€”Â 13Â 60Â Total stock-based compensation$9,512Â $14,232Â $29,316Â $42,745Â Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Cost of revenue$2,051Â $2,424Â $5,488Â $7,090Â Sales and marketing2,555Â 5,149Â 8,997Â 16,049Â Research and development1,871Â 2,927Â 5,391Â 8,677Â General and administrative3,035Â 3,732Â 9,440Â 10,929Â Total stock-based compensation$9,512Â $14,232Â $29,316Â $42,745Â 37HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Stock optionsThere were no stock options granted during the nine months ended September 30, 2024 or 2023. A summary of the share option activity under the 2019 Plan for the nine months ended September 30, 2024, is as follows:Time-Based Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Life in YearsAggregate Intrinsic Value(unaudited)Outstanding at JanuaryÂ 1, 20241,396,452Â $11.70Â Options exercised(26,668)6.35Â Options cancelled/forfeited(298,275)11.23Â Outstanding at SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â Vested and expected to vest as of SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â Vested and exercisable as of SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â The aggregate intrinsic value of stock options exercised was less than $0.1 million for the nine months ended SeptemberÂ 30, 2024. The aggregate intrinsic value of stock options exercised was $0.7 million for the nine months ended September 30, 2023. The total grant date fair value of stock options vested during the nine months ended September 30, 2024 and 2023 was zero and $0.4 million, respectively. All of our outstanding stock options are fully

vested and there is no longer any related unrecognized compensation expense.Restricted stock units (RSUs)The service-based condition for restricted stock units (RSUs) is generally satisfied overÂ four years with a cliff vesting period of one year and quarterly vesting thereafter. The following table sets forth the outstanding RSUs and related activity for theÂ nine months ended SeptemberÂ 30, 2024:Restricted Stock UnitsWeighted Average Grant Date Fair Value(unaudited)Unvested and outstanding at JanuaryÂ 1, 20243,111,584Â $19.16Â RSUs granted2,616,356Â 8.55Â RSUs vested(1,207,994)21.64Â RSUs forfeited(359,527)15.49Â Unvested and outstanding at SeptemberÂ 30, 20244,160,419Â $12.09Â During the nine months ended September 30, 2024 and 2023, we granted RSUs with a weighted-average grant date fair value of $8.55 and $11.99, respectively, which represents the weighted-average closing price of our common stock on the grant date. The total grant date fair value of RSUs vested during the nine months ended September 30, 2024 and 2023 was $26.1 million and $35.2 million, respectively. As of SeptemberÂ 30, 2024, we had $43.0 million of unrecognized stock-based compensation expense related to outstanding RSUs expected to be recognized over a weighted-average period of 1.9 years.Performance-based restricted stock units (PRSUs)2024 Executive PRSUsDuring the nine months ended September 30, 2024, certain named executive officers and other leadership team members were granted executive PRSUs with a three-year measurement period that include service conditions, performance conditions, and market conditions. 38HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)The vesting of these PRSUs will be determined based on market-based targets for total shareholder return (TSR) achievement (weighted 25%) and financial performance targets for revenue growth rate achievement (weighted 25%) and Adjusted EBITDA margin achievement (weighted 50%). These PRSUs may vest in an amount up to the amount granted, subject to satisfaction of the pre-established targets. The number of PRSUs that will vest for the 2024, 2025, and 2026 vesting periods will be calculated as follows: (i) the market/performance achievement for the applicable vesting period, multiplied by (ii) approximately 33.33% of the PRSUs for each of the 2024, 2025, and 2026 vesting periods, each rounded to the nearest whole share.2023 Executive PRSUsDuring the nine months ended September 30, 2023, certain named executive officers and other leadership team members were granted executive PRSUs with a three-year measurement period that include service conditions, performance conditions, and market conditions. The vesting of these PRSUs will be determined based on market-based targets for total shareholder return (TSR) achievement and financial performance targets for revenue growth rate achievement and Adjusted EBITDA margin achievement. Each of the three market and performance targets are weighted equally and these PRSUs may vest in an amount up to the amount granted, subject to satisfaction of the pre-established targets. The number of PRSUs that will vest in 2023, 2024, and 2025 will be calculated as follows: (i) the market/performance achievement for the applicable vesting period, multiplied by (ii) approximately 33.33% of the PRSUs for each of the 2023, 2024, and 2025 vesting periods, each rounded to the nearest whole share.The fair value of the market-based tranches included in the executive PRSUs were estimated on the date of grants using the Monte Carlo simulation valuation model with the following assumptions for the nine months ended September 30, 2024 and 2023:Nine Months EndedSeptember 30, 2024Nine Months EndedSeptember 30, 2023(unaudited)Expected volatility65.5%61.7%Expected term (in years)1-31-3Risk-free interest rate4.33% - 4.91%4.38% - 5.01%Expected dividendsâ€”â€”The following table sets forth the outstanding PRSUs, including executive PRSUs with market-based tranches, and related activity for theÂ nine months ended SeptemberÂ 30, 2024:Performance-based Restricted Stock UnitsWeighted Average Grant Date Fair Value(unaudited)Unvested and outstanding at JanuaryÂ 1, 2024188,533Â $12.99Â PRSUs granted445,000Â 9.45Â PRSUs vested(43,052)13.89Â PRSUs forfeited(65,487)12.77Â Unvested and outstanding at SeptemberÂ 30, 2024524,994Â $9.94Â During the nine months ended September 30, 2024 and 2023, we granted PRSUs with a weighted-average grant date fair value of $9.45 and $12.62, respectively, which represents the weighted-average closing price of our common stock on the grant date for performance-based tranches and the estimated grant date fair value using a Monte Carlo simulation valuation model for market-based tranches. The total grant date fair value of PRSUs vested during the nine months ended September 30, 2024 and 2023 was $0.6 million and $4.8 million, respectively. As of SeptemberÂ 30, 2024, we had $2.7 million of unrecognized stock-based compensation expense related to outstanding PRSUs expected to be recognized over a remaining weighted-average period of 1.6 years.39HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Employee stock purchase planIn connection with our IPO in July 2019, our board of directors adopted the ESPP and a total of 750,000 shares of common stock were initially reserved for issuance under the ESPP. The number of shares of common stock available for issuance under the ESPP will be increased on the first day of each calendar year beginning January 1, 2020 and each year thereafter until the ESPP terminates. The number of shares of common stock reserved and available for issuance under the ESPP shall be cumulatively increased by the least of (i) 750,000 shares, (ii) one percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of common stock as determined by the ESPP Administrator. As of JanuaryÂ 1, 2024, the number of shares of common stock available for issuance under the ESPP increased by 585,308 shares. The ESPP generally provides for six-month offering periods. The offering periods generally start on the first trading day after June 30 and December 31 of each year. The ESPP permits participants to elect to purchase shares of common stock through fixed percentage contributions from eligible compensation during each offering period, not to exceed 15% of the eligible compensation a participant receives during an offering period or accrue at a rate which exceeds $25,000 of the fair value of the stock (determined on the option grant date(s)) for each calendar year. A participant may purchase the lowest of (i) a number of shares of common stock determined by dividing such participantâ€™s accumulated payroll deductions on the exercise date by the option price, (ii) 2,500 shares, or (iii) such other lesser maximum number of shares as shall have been established by the ESPP Administrator in advance of the offering period. Amounts deducted and accumulated by the participant will be used to purchase shares of common stock at the end of each offering period. The purchase price of the shares will be 85% of the lower of the fair value of common stock on the first trading day of each offering period or on the purchase date. Participants may end their participation at any time during an offering period and will be paid their accumulated contributions that have not been used to purchase shares of common stock. Participation ends automatically upon termination of employment.The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended SeptemberÂ 30, 2024 and 2023:Nine Months Ended September 30,20242023(unaudited)Expected volatility55.5% - 56.8%54.3% - 99.4%Expected term (in months)66Risk-free interest rate5.24% - 5.37%4.77% - 5.53%Expected dividendsâ€”â€”During the nine months ended SeptemberÂ 30, 2024, we issued 263,482 shares under the ESPP, with a weighted-average purchase price of $5.43. Total cash proceeds from the purchase of shares under the ESPP during the nine months ended September 30, 2024 were $2.1 million. As of September 30, 2024, a total of 207,388 shares were issuable to employees based on ESPP contribution elections and unrecognized ESPP compensation cost was $0.2 million, which is expected to be recognized over the remaining portion of the current offering period during the three months ending December 31, 2024. As of SeptemberÂ 30, 2024, 1,791,984 shares were available for future issuance under the ESPP.40HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)Restricted shares issued in connection with business combinationsAs part of the KPI Ninja acquisition that closed on February 24, 2022, 356,919 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was subject to continuous service with 25% vesting upon each six-month anniversary of the acquisition close date, with the final vesting date as of February 24, 2024. As part of the ARMUS acquisition that closed on April 29, 2022, 235,330 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was subject to eighteen months of continuous service with cliff vesting upon the eighteen-month anniversary of the acquisition close date, or October 29, 2023. As part of the ERS acquisition that closed on October 2, 2023, 175,901 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was originally subject to eighteen months of continuous service with cliff vesting . However, due to workforce reductions made as part of the 2023 Restructuring Plan, the ERS restricted shares were fully vested in February 2024, resulting in an acceleration of the related stock-based compensation expense.As of SeptemberÂ 30, 2024, all of our previously issued shares of restricted stock are fully vested and there is no longer any related unrecognized compensation expense.14. Income TaxesThe tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, we update our estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, we make a cumulative adjustment in such period. The quarterly tax provision and the estimate of our annual effective tax rate are subject to variation due to several factors, including variability in our loss before income taxes, the mix of jurisdictions to which such income or loss relates, changes in how we conduct business, and tax law developments. For the nine months ended September 30, 2024 and 2023, our estimated effective tax rate was 3.1% and (0.2)%, respectively. The variations between our estimated effective tax rate and the U.S. statutory rate areÂ primarily due to our full valuation allowance. We consider all available evidence to evaluate the recovery of deferred tax assets, including historical levels of income, legislative developments, and risks associated with estimates of future taxable income. We have provided a full valuation allowance for our net deferred tax assets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, due to the uncertainty surrounding the future realization of such assets and the cumulative losses we have generated.We recognize tax benefits from uncertain tax positions when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We believe that we have provided adequate reserves for income tax uncertainties in all open tax years. We do not anticipate material changes in the total amount of our unrecognized tax benefits within 12 months of the reporting date.15. Commitments and ContingenciesLitigationLiabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.41HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)We are involved in legal proceedings from time to time that arise in the normal course of business. In the opinion of management, such routine claims and lawsuits are not significant, and we do not expect them to have a material adverse effect on our business, financial condition, results of operations, or liquidity, except as noted below. We were party to the proceedings set forth below.On December 21, 2020, Pascal Metrics, Inc. (Pascal Metrics) filed a complaint against the Company in the Delaware Chancery Court (as amended, the Complaint) alleging that the Company misappropriated alleged trade secrets of Pascal Metrics and seeking monetary damages. The Complaint focused upon Patient Safety Monitor. On June 15, 2023, we entered into a settlement and mutual release agreement (Settlement Agreement) with Pascal Metrics and agreed to pay $18.8Â million without admission of any wrongdoing, resolving the litigation amongst the parties. The Settlement Agreement provided us with a broad intellectual property license of the alleged trade secrets that were the subject matter of the Complaint. The Complaint was dismissed with prejudice on June 20, 2023 and the settlement amount was paid on June 27, 2023. During the nine months ended September 30, 2023, we recorded $21.3 million, of litigation charges related to the Complaint that were recorded as part of general and administrative expense in our condensed consolidated statements of operations, of which less than $0.1Â million was recorded during the three months ended September 30, 2023. There were no similar litigation charges recorded during the three and nine months ended SeptemberÂ 30, 2024.16. Deferred Revenue and Performance ObligationsDeferred revenue includes advance client payments and billings in excess of revenue recognized.Â For the three months ended SeptemberÂ 30, 2024 and 2023, 43% and 45%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period. For the nine months ended SeptemberÂ 30, 2024 and 2023, 22% and 23%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period.Most of our technology and professional services contracts have a three- or five-year term, of which many are terminable after one year upon 90 daysâ€™ notice. For arrangements that do not allow the client to cancel within one year or less, we expect to recognize $290.5 million of revenue on unsatisfied performance obligations as of SeptemberÂ 30, 2024. We expect to recognize approximately 65% of the remaining performance obligations over the next 24 months, with the balance recognized thereafter. 17. Related PartiesWe have entered into arrangements with a client, Carle Health, and a member of the clientâ€™s executive leadership team began serving on our board of directors effective July 1, 2023 and currently serves on our board of directors. We recognized revenue from this related party of $4.2 million and $12.4 million for the three and nine months ended SeptemberÂ 30, 2024, respectively. For the three months ended September 30, 2023, we recognized $4.1 million of revenue from this related party. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, we had receivables from this related party of $1.3 million and $1.9 million, respectively, and deferred revenue with this related party of $0.3 million and $0.1 million, respectively.We have revenue arrangements with clients that are also our investors. None of these clients hold a significant amount of ownership in our equity interests.18. SegmentsWe operate our business in two operating segments that also represent our reportable segments. Our business is organized based on our technology offerings and professional services. Accordingly, our segments are:â€¢Technology â€“ Our technology segment (Technology) includes our data platform, analytics applications, and support services and generates revenue primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; and42HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)â€¢Professional Services â€“ Our professional services segment (Professional Services) is generally the combination of analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to our clients to more fully configure and utilize the benefits of our Technology offerings.Revenue and cost of revenue generally are directly attributed to our segments. All segment revenue is from our external clients. Asset and other balance sheet information at the segment level is not reported to our Chief Operating Decision Maker.Segment revenue and Adjusted Gross Profit for the three and nine months ended SeptemberÂ 30, 2024 and 2023 were as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)RevenueTechnology$48,653Â $45,973Â $143,254Â $140,483Â Professional Services27,700Â 27,800Â 83,724Â 80,371Â Total$76,353Â $73,773Â $226,978Â $220,854Â Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)Adjusted Gross ProfitTechnology$31,571Â $31,367Â $95,794Â $96,356Â Professional Services4,718Â 3,205Â 16,618Â 13,011Â Total reportable segments Adjusted Gross Profit36,289Â 34,572Â 112,412Â 109,367Â Less Adjusted Gross Profit reconciling items:Stock-based compensation(2,051)(2,424)(5,488)(7,090)Acquisition-related costs, net(1)(198)(162)(576)(506)Restructuring costsâ€”Â â€”Â (260)(446)Less other reconciling items:Sales and marketing(11,342)(15,084)(43,145)(50,050)Research and development(14,193)(17,667)(42,948)(52,339)General and administrative(12,209)(13,625)(41,136)(61,129)Depreciation and amortization(9,983)(10,190)(31,165)(31,919)Interest and other income (expense), net(1,514)2,607Â 3,185Â 6,490Â Loss before income taxes $(15,201)$(21,973)$(49,121)$(87,622)_____(1)Acquisition-related costs, net include deferred retention expenses attributable to the Lumeon, Carevive, ARMUS, and KPI Ninja acquisitions.19. Restructuring Costs 2023 Restructuring PlanDuring the quarter and year ended December 31, 2023, our board of directors authorized a reduction of our global workforce as part of a restructuring plan intended to optimize our cost structure and focus our investment of resources in key priority areas to align with strategic changes (2023 Restructuring Plan). 43HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)As part of the 2023 Restructuring Plan, we significantly reduced headcount throughout both our professional services and technology segments, including among our senior leadership team. The restructuring costs primarily related to severance and other team member costs from workforce reductions and impairment of a discontinued capitalized internal-use software project.The following table summarizes our 2023 Restructuring Plan costs by financial statement line item for the nine months ended SeptemberÂ 30, 2024 (in thousands). We had no restructuring costs for the three months ended SeptemberÂ 30, 2024.Nine Months Ended September 30, 2024Severance and Other Team Member CostsImpairment Charges(1)Total(unaudited)Cost of revenue, excluding depreciation and amortization:Technology$79Â $â€”Â $79Â Professional services181Â â€”Â 181Â Sales and marketing449Â â€”Â 449Â Research and development443Â â€”Â 443Â General and administrative936Â â€”Â 936Â Total $2,088Â $â€”Â $2,088Â 2023 Restructuring Plan final cumulative charges incurred$8,240Â $615Â $8,855Â _____(1)Consists of impairment of a discontinued internal-use software project as part of the 2023 Restructuring Plan.Restructuring liabilities related to the 2023 Restructuring Plan are included as a component of accrued liabilities on our condensed consolidated balance sheets. The following table summarizes our current year restructuring-related activities, including costs incurred, cash payments, and the resulting liability balances (in thousands):Restructuring Liabilities(unaudited)Balance as of December 31, 2023$2,355Â Severance and other restructuring costs1,813Â Cash payments(3,157)Balance as of March 31, 2024$1,011Â Severance and other restructuring costs275Â Cash payments(941)Balance as of June 30, 2024$345Â Severance and other restructuring costsâ€”Â Cash payments(338)Balance as of September 30, 2024$7Â Our restructuring activities as part of the 2023 Restructuring Plan are substantially complete with no additional restructuring costs expected during the remainder of 2024. 44HEALTH CATALYST, INC.Notes to the Condensed Consolidated Financial Statements(unaudited)2022 Restructuring PlanDuring the third quarter of 2022, we initiated a restructuring plan (2022 Restructuring Plan) to optimize our cost structure and focus our investment of resources in key priority areas to align with strategic changes. As part of the 2022 Restructuring Plan, we significantly reduced investment in our life sciences business unit, which is generally part of the technology segment, and also reduced headcount throughout the Company, including among our senior leadership team. The restructuring costs primarily related to severance and other team member costs from workforce

reductions, impairment of discontinued capitalized internal-use software projects, and other miscellaneous charges. We substantially completed all actions under the 2022 Restructuring Plan in early 2023 and, as of December 31, 2023, the related restructuring liabilities were completely settled through cash outlays made to impacted team members. The following table summarizes our 2022 Restructuring Plan costs by financial statement line item for the nine months ended SeptemberÂ 30, 2023 (in thousands). We had no restructuring costs for the three months ended SeptemberÂ 30, 2023.Nine Months Ended SeptemberÂ 30, 2023(unaudited)Severance and Other Team Member CostsImpairment Charges(1)Other(2)TotalCost of revenue, excluding depreciation and amortization:Technology$12Â $â€”Â $â€”Â $12Â Professional services434Â â€”Â â€”Â 434Â Sales and marketing1,190Â â€”Â 15Â 1,205Â Research and development286Â â€”Â â€”Â 286Â General and administrative94Â â€”Â 24Â 118Â Total $2,016Â $â€”Â $39Â $2,055Â 2022 Restructuring Plan final, cumulative charges incurred through December 31, 2023$8,071Â $1,225Â $1,184Â $10,480Â _____(1)Consists of impairment of a discontinued internal-use software project as part of the 2022 Restructuring Plan. (2)Includes other minor miscellaneous charges associated with the restructuring plan.45Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements, the accompanying notes, and other financial information included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results could differ materially from those forward-looking statements below. Factors that could cause or contribute to those differences include, but are not limited to, those identified below and those discussed in the sections titled â€œRisk Factorsâ€ and â€œSpecial Note Regarding Forward-looking Statements.â€OverviewWe are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data platforms, software analytics applications, and professional services expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. We envision a future where all healthcare decisions are data informed.Highlights from the three and nine months ended SeptemberÂ 30, 2024 included:â€¢We recognized total revenue of $76.4 million and $73.8 million for the three months ended September 30, 2024 and 2023, respectively, and $227.0 million and $220.9 million for the nine months ended September 30, 2024, and 2023, respectively. The growth in revenue was primarily due to revenue from new clients and revenue expansion from existing clients. â€¢We incurred net losses of $14.7 million and $22.0 million for the three months ended September 30, 2024 and 2023, respectively, and $48.8 million and $87.8 million for the nine months ended September 30, 2024, and 2023, respectively.â€¢Our Adjusted EBITDA was $7.3 million and $2.0 million for the three months ended September 30, 2024 and 2023, respectively, and $18.2 million and $9.7 million for the nine months ended September 30, 2024, and 2023, respectively. See the section titled â€œKey Financial Metricsâ€”Reconciliation of Non-GAAP Financial Measuresâ€ below for more information about Adjusted EBITDA, including the limitations of such measure and a reconciliation to net loss, the most directly comparable measure calculated in accordance with GAAP.See the section titled â€œKey Factors Affecting Our Performanceâ€ for more information about important opportunities and challenges related to our business.Macroeconomic Environment and Strategic Operating PlanRecent macroeconomic challenges (including high levels of inflation and high interest rates) and the tight labor market continue to adversely affect workforces, organizations, governments, clients, economies, and financial markets globally. These factors have disrupted the normal operations of many businesses, including our business. These factors have also placed the national healthcare system under significant operational and budgetary strain.The health system end market, in particular, has experienced meaningful financial strain over the last couple of years, in which it has realized significant increases in labor and supply costs without a commensurate increase in revenue, leading to a deterioration in operating margins across many of our clients and prospective clients. We saw a decrease in pipeline demand in 2023 relative to the period prior due to the onset of these macroeconomic factors in 2022, as well as some elevated realized and anticipated down-sell and churn levels, primarily for the parts of our Solution that do not offer near-term, financial return on investment (ROI), such as our clinically-focused technology offerings and our more traditional consulting Professional Services. 46In recent quarters, we have been encouraged to have seen incremental improvements, including in the nine month period ending SeptemberÂ 30, 2024, and we are encouraged to see improving and stabilizing operating margins for clients and prospective clients in our health system end market. With respect to other near-term implications of the macroeconomic environment, we anticipate improvement in our 2024 bookings metrics relative to 2022 and 2023 for both net new DOS Subscription Client additions and Dollar-based Retention Rate. As it relates to Dollar-based Retention Rate, we expect execution on bookings in the fourth quarter of 2024, including Tech-enabled Managed Services (TEMS) bookings, to have a meaningful impact on our Dollar-based Retention Rate for the 2024 year. We also anticipate that a higher proportion of our net bookings will occur in the fourth quarter of 2024 as compared to our historical average.Through SeptemberÂ 30, 2024, our year-to-date net new DOS Subscription Client additions had a lower average starting annual recurring revenue (ARR) as compared to historical levels. We currently expect our aggregated average subscription revenue and non-recurring revenue for all net new DOS Subscription Clients signed in the year ended December 31, 2024 (net new 2024 DOS Subscription Clients) will be between $400,000 and $1,000,000, driven primarily by momentum in modular additions from Health Catalyst Ignite, such as Healthcare.AI and Ninja Universe, Health Catalyst Igniteâ€™s interoperability platform, which has resulted in subscription revenue that is significantly lower than subscription revenue derived from a contract that includes access to all of the DOS platform components and analytic applications. Our modular pricing, which can be lower than our historical averages, has enabled a higher volume of opportunities. This average dollar range is comprised of net new 2024 DOS Subscription Clients with (i) average revenue in the expected average range or significantly above the expected average range noted above, driven by the size of the client organization and the bundle of technology and services included in their subscription and (ii) average revenue meaningfully below the low-end of the expected range noted above, driven by sales of stand-alone Health Catalyst Ignite module components, which provided greater deal certainty in a more challenging macroeconomic environment, and which we believe will provide an opportunity to expand our relationship with these DOS Subscription Clients in the future, including through cross-selling efforts.We have introduced Health Catalyst Ignite, our next-generation data and analytics platform, which benefits from significant scalability and modularity. We expect to migrate existing DOS Subscription Clients to this new platform over the next approximately two years. Over the medium-term, we expect the migration to Health Catalyst Ignite to result in a technology gross margin tailwind; however, we expect a near-term headwind as clients are being migrated. We anticipate new DOS Subscription Clients in 2024 and beyond will be deployed directly onto Health Catalyst Ignite. Furthermore, given the modularity of Health Catalyst Ignite and migrations to its platform, we now primarily refer to DOS Subscription Clients as Platform Subscription Clients. Our Health Catalyst Ignite platform provides advantages related to elastic compute and modularity and allows us to offer a flexible menu of options for clients to benefit from these improved efficiencies. These options include expanding their relationship and spend by purchasing additional applications and features; immediate savings while maintaining the same functionality through a price reduction as part of the migration; or maintaining existing spend and realizing improvement in operations and functionality from the enhanced capabilities of Health Catalyst Ignite.We benefit from a highly recurring revenue model, in which greater than 90% of our revenue is recurring in nature, and a high level of technology revenue predictability, especially within our Platform Subscription Clients whose contracts, when sold as a bundle with our analytics applications, often have annual built-in, contractual technology revenue escalators. As previously described, within our professional services segment, a subset of clients have reduced their spend, while in the technology segment, a subset of modular clients and smaller platform clients have reduced their application and analytics spend. However, we anticipate our aggregate churn levels in 2024 to improve compared to 2023. Given the improved bookings performance of our TEMS offering in recent years, a higher proportion of our bookings in 2023 came from our professional services offering relative to 2022, as health systems looked for solutions to effectively address their near-term expense challenges. While this change in bookings mix will lead to lower professional services gross margin and Adjusted Professional Services Gross Margin and Total Adjusted Gross Margin in future years, we expect that we will achieve improvements in net loss and Adjusted EBITDA as a result of the minimal incremental operating expense required to support our TEMS growth. We continue to anticipate that our adjusted operating expenses as a percentage of revenue will trend lower, largely due to our restructuring efforts and meaningful continued operating leverage.47We continue to proactively respond to the macroeconomic environment with a strategic operating plan that emphasizes our offerings and go-to-market approach in the areas where we have the most competitive differentiation and where clients are most likely to achieve measurable financial and operational ROI both in the near term and over time. We believe this focus will enable us to move forward in a position of continued competitive and financial strength. We will continue to refine this strategic operating plan and are continuing to make several investments in research and development, primarily in enhancing the capabilities within Health Catalyst Ignite, in order to maintain our position as a market-leading data platform over the long term.Key Financial MetricsWe regularly review a number of metrics, including the following key financial metrics, to manage our business and evaluate our operating performance compared to that of other companies in our industry:Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023GAAP Financial Measures:(in thousands, except percentages)(in thousands, except percentages)Total revenue$76,353Â $73,773Â $226,978Â $220,854Â Gross profit$27,758Â $25,339Â $85,885Â $80,100Â Gross margin36Â %34Â %38Â %36Â %Net loss$(14,726)$(22,032)$(48,829)$(87,835)Non-GAAP Financial Measures:Adjusted Gross Profit$36,289Â $34,572Â $112,412Â $109,367Â Adjusted Gross Margin48Â %47Â %50Â %50Â %Adjusted EBITDA$7,295Â $1,992Â $18,194Â $9,669Â We monitor the key metrics set forth in the preceding table to help us evaluate trends, establish budgets, measure the effectiveness and efficiency of our operations, and determine team member incentives. We discuss Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted EBITDA in more detail below.Reconciliation of non-GAAPÂ financial measuresIn addition to our results determined in accordance with GAAP, we believe certain non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted EBITDA, are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.48AdjustedÂ Gross Profit andÂ AdjustedÂ Gross MarginGross profit is a GAAP financial measure that is calculated as revenue less cost of revenue, including depreciation and amortization of capitalized software development costs and acquired technology. We calculate gross margin as gross profit divided by our revenue. AdjustedÂ Gross Profit is aÂ non-GAAPÂ financial measure that we define as gross profit, adjusted for (i) depreciation and amortization, (ii) stock-based compensation, (iii) acquisition-related costs, net, and (iv) restructuring costs, as applicable. We defineÂ AdjustedÂ Gross Margin as ourÂ AdjustedÂ Gross Profit divided by our revenue. We believeÂ AdjustedÂ Gross Profit andÂ AdjustedÂ Gross Margin are useful to investors as they eliminate the impact of certainÂ non-cashÂ expenses and allow a direct comparison of these measures between periods without the impact ofÂ non-cashÂ expenses, as well as certain other non-recurring operating expenses, and certain other non-recurring operating expenses. We present both of these measures for our technology and professional services business. We believe theseÂ non-GAAPÂ measures are useful in evaluating our operating performance compared to that of other companies in our industry, as these metrics generally eliminate the effects of certain items that may vary from company to company for reasons unrelated to overall profitability.The following is a calculation of our gross profit and gross margin and a reconciliation of gross profit and gross margin to our Adjusted Gross Profit and Adjusted Gross Margin in total and for technology and professional services for the three months ended September 30, 2024 and 2023.Three Months Ended September 30, 2024(in thousands, except percentages)TechnologyProfessional ServicesTotalRevenue$48,653Â $27,700Â $76,353Â Cost of revenue, excluding depreciation and amortization(17,609)(24,704)(42,313)Amortization of intangible assets, cost of revenue(3,741)â€”Â (3,741)Depreciation of property and equipment, cost of revenue(2,541)â€”Â (2,541)Gross profit24,762Â 2,996Â 27,758Â Gross margin51Â %11Â %36Â %Add:Amortization of intangible assets, cost of revenue3,741Â â€”Â 3,741Â Depreciation of property and equipment, cost of revenue2,541Â â€”Â 2,541Â Stock-based compensation450Â 1,601Â 2,051Â Acquisition-related costs, net(1)77Â 121Â 198Â Adjusted Gross Profit$31,571Â $4,718Â $36,289Â Adjusted Gross Margin65Â %17Â %48Â %_____(1)Acquisition-related costs, net include deferred retention expenses attributable to the Lumeon, Carevive, ARMUS, and KPI Ninja acquisitions.49Three Months Ended September 30, 2023(in thousands, except percentages)TechnologyProfessional ServicesTotalRevenue$45,973Â $27,800Â $73,773Â Cost of revenue, excluding depreciation and amortization(15,169)(26,618)(41,787)Amortization of intangible assets, cost of revenue(4,390)â€”Â (4,390)Depreciation of property and equipment, cost of revenue(2,257)â€”Â (2,257)Gross profit24,157Â 1,182Â 25,339Â Gross margin53Â %4Â %34Â %Add:Amortization of intangible assets, cost of revenue4,390Â â€”Â 4,390Â Depreciation of property and equipment, cost of revenue2,257Â â€”Â 2,257Â Stock-based compensation497Â 1,927Â 2,424Â Acquisition-related costs, net(1)66Â 96Â 162Â Adjusted Gross Profit$31,367Â $3,205Â $34,572Â Adjusted Gross Margin68Â %12Â %47Â %_____(1)Acquisition-related costs, net include deferred retention expenses attributable to the ARMUS and KPI Ninja acquisitions.Technology gross margin decreased from 53% for the three months ended September 30, 2023 to 51% for the three months ended September 30, 2024. Adjusted Technology Gross Margin decreased from 68% for the three months ended September 30, 2023 to 65% for the three months ended September 30, 2024. This year-over-year result was mainly driven by continued costs associated with transitioning a portion of our client base to Azure-hosted environments as well as from costs associated with migrating a subset of Platform Subscription Clients to Health Catalyst Ignite, partially offset by existing clients paying higher technology access fees from contractual, built-in escalators, without a corresponding increase in hosting costs. We expect Adjusted Technology Gross Margin to fluctuate and potentially decline in the near term, primarily due to additional costs associated with the migration of clients to Health Catalyst Ignite and Ninja Universe deployment costs incurred prior to the commencement of revenue recognition. The potential decline is also attributable to a small subset of modular clients reducing their subscriptions to our software analytic applications, which tend to be higher margin offerings.Professional services gross margin increased from 4% for the three months ended September 30, 2023 to 11% for the three months ended September 30, 2024. Adjusted Professional Services Gross Margin increased from 12% for the three months ended September 30, 2023 to 17% for the three months ended September 30, 2024, primarily due to higher utilization rates and cost management efforts, driven in large part by the reduction in force that primarily occurred late in the fourth quarter of 2023 and early 2024. Our professional services are comprised of data and analytics services, domain expertise services, TEMS, and implementation services. The majority of our professional services revenue is generated from data and analytic services and domain expertise services, which are the highest gross margin professional services we provide. The delivery mix among all of our services in a given period can lead to fluctuations in our Adjusted Professional Services Gross Margin.Total gross margin increased from 34% for the three months ended September 30, 2023 to 36% for the three months ended September 30, 2024. Total Adjusted Gross Margin increased from 47% for the three months ended September 30, 2023 to 48% for the three months ended September 30, 2024. We expect total Adjusted Gross Margin to fluctuate and decline in the near term, primarily due to anticipated growth in professional services, including TEMS.50The following is a calculation of our gross profit and gross margin and a reconciliation of gross profit and gross margin to our Adjusted Gross Profit and Adjusted Gross Margin in total and for technology and professional services for the nine months ended September 30, 2024 and 2023.Nine Months Ended September 30, 2024(in thousands, except percentages)TechnologyProfessional ServicesTotalRevenue$143,254Â $83,724Â $226,978Â Cost of revenue, excluding depreciation and amortization(48,991)(71,899)(120,890)Amortization of intangible assets, cost of revenue(12,695)â€”Â (12,695)Depreciation of property and equipment, cost of revenue(7,508)â€”Â (7,508)Gross profit74,060Â 11,825Â 85,885Â Gross margin52Â %14Â %38Â %Add:Amortization of intangible assets, cost of revenue12,695Â â€”Â 12,695Â Depreciation of property and equipment, cost of revenue7,508Â â€”Â 7,508Â Stock-based compensation1,206Â 4,282Â 5,488Â Acquisition-related costs, net(1)246Â 330Â 576Â Restructuring costs(2)79Â 181Â 260Â Adjusted Gross Profit$95,794Â $16,618Â $112,412Â Adjusted Gross Margin67Â %20Â %50Â %_____(1)Acquisition-related costs, net include deferred retention expenses attributable to the Lumeon, Carevive, ARMUS, and KPI Ninja acquisitions.(2)Restructuring costs include severance and other team member costs from workforce reductions. Nine Months Ended September 30,

2023(in thousands, except percentages)TechnologyProfessional ServicesTotalRevenue$140,483Â $80,371Â $220,854Â Cost of revenue, excluding depreciation and amortization(45,755)(73,774)(119,529)Amortization of intangible assets, cost of revenue(14,372)â€”Â (14,372)Depreciation of property and equipment, cost of revenue(6,853)â€”Â (6,853)Gross profit73,503Â 6,597Â 80,100Â Gross margin52Â %8Â %36Â %Add:Amortization of intangible assets, cost of revenue14,372Â â€”Â 14,372Â Depreciation of property and equipment, cost of revenue6,853Â â€”Â 6,853Â Stock-based compensation1,408Â 5,682Â 7,090Â Acquisition-related costs, net(1)208Â 298Â 506Â Restructuring costs(2)12Â 434Â 446Â Adjusted Gross Profit$96,356Â $13,011Â $109,367Â Adjusted Gross Margin69Â %16Â %50Â %_____(1)Acquisition-related costs, net include deferred retention expenses attributable to the ARMUS and KPI Ninja acquisitions.(2)Restructuring costs include severance and other team member costs from workforce reductions. 51Technology gross margin remained consistent at 52% for each of the nine months ended September 30, 2024 and 2023. Adjusted Technology Gross Margin decreased from 69% for the nine months ended September 30, 2023 to 67% for the nine months ended September 30, 2024. This year-over-year result was mainly driven by continued costs associated with transitioning a portion of our client base to Azure-hosted environments as well as from costs associated with migrating a subset of Platform Subscription Clients to Health Catalyst Ignite, partially offset by existing clients paying higher technology access fees from contractual, built-in escalators, without a corresponding increase in hosting costs. We expect Adjusted Technology Gross Margin to fluctuate and potentially decline in the near term, primarily due to additional costs associated with the migration of clients to Health Catalyst Ignite, also due to costs associated with Ninja Universe deployments prior to revenue recognition. The potential decline is also attributable to a small subset of modular clients reducing their subscriptions to our software analytic applications, which tend to be higher margin offerings.Professional services gross margin increased from 8% for the nine months ended September 30, 2023 to 14% for the nine months ended September 30, 2024. Adjusted Professional Services Gross Margin increased from 16% for the nine months ended September 30, 2023 to 20% for the nine months ended September 30, 2024, primarily due to higher utilization rates and cost management efforts, driven in large part by the reduction in force that primarily occurred late in the fourth quarter of 2023 and early 2024. Our professional services are comprised of data and analytics services, domain expertise services, TEMS, and implementation services. The majority of our professional services revenue is generated from data and analytic services and domain expertise services, which are the highest gross margin professional services we provide. The delivery mix among all of our services in a given period can lead to fluctuations in our Adjusted Professional Services Gross Margin.In the fourth quarter of 2023, our board of directors approved workforce reductions as part of a restructuring plan intended to optimize our cost structure and focus our investment of resources in key priority areas to align with strategic changes (2023 Restructuring Plan). These reductions enabled significant improvement in our Adjusted Professional Services Gross Margin in the first three quarters of 2024 compared to the fourth quarter of 2023. However we still expect Adjusted Professional Services Gross Margin to fluctuate on a quarterly basis due to changes in the mix of services we provide, the amount of operational overhead required to deliver our services, and clients delaying or reducing services due to a potentially uncertain and challenging macroeconomic environment.Specifically, in the near term, we expect our mix of services to include more TEMS, which have minimal initial services gross margins that gradually increase over time as we drive efficiencies in service delivery through the use of our technology. As part of our TEMS contracts, we often re-badge existing health system team members within the applicable functional area as Health Catalyst team members. We often provide a client with a near-term discount relative to their existing costs for the scope of the TEMS opportunity, and we drive incremental gross margin over time by leveraging our technology and know-how to make processes more efficient and reduce the clientâ€™s labor costs. While there will be a headwind to gross margin from these TEMS in the near term, we believe this model will benefit our mid and long-term Adjusted EBITDA and profitability targets due to improved direct margin on these services over time, our ability to drive operating leverage with lower relative incremental operating expense investment required, and the fact that these contracts typically result in long-term technology subscription contract renewals or expansions. Total gross margin increased from 36% for the nine months ended September 30, 2023 to 38% for the nine months ended September 30, 2024. Total Adjusted Gross Margin remained constant at 50% for the nine months ended September 30, 2023 and 2024. We expect total Adjusted Gross Margin to fluctuate and decline in the near term, primarily due to anticipated growth in professional services, including TEMS.52Adjusted EBITDAAdjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for (i) interest and other (income) expense, net, (ii) income tax provision (benefit), (iii) depreciation and amortization, (iv) stock-based compensation, (v) acquisition-related costs, net, (vi) litigation costs, (vii) restructuring costs, and (viii) non-recurring lease-related charges. We view acquisition-related expenses when applicable, such as transaction costs and changes in the fair value of contingent consideration liabilities that are directly related to business combinations, as costs that are unpredictable, dependent upon factors outside of our control, and are not necessarily reflective of operational performance during a period. We believe that excluding restructuring costs, litigation costs, and non-recurring lease-related charges allows for more meaningful comparisons between operating results from period to period as these are separate from the core activities that arise in the ordinary course of our business and are not part of our ongoing operations. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and a comparison with our past financial performance, and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. Our Adjusted EBITDA improved year-over-year as a result of our revenue growth and cost reduction initiatives as well as the timing of some non-headcount expenses. We generally expect annual Adjusted EBITDA to continue to improve going forward, although it may fluctuate from quarter to quarter as a result of the timing of non-recurring revenue and the seasonality of certain operating costs.The following is a reconciliation of our Adjusted EBITDA to net loss, the most directly comparable financial measure calculated in accordance with GAAP, for the three and nine months ended SeptemberÂ 30, 2024 and 2023.Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(in thousands)(in thousands)Net loss$(14,726)$(22,032)$(48,829)$(87,835)Add:Interest and other (income) expense, net1,514Â (2,607)(3,185)(6,490)Income tax provision (benefit)(475)59Â (292)213Â Depreciation and amortization9,983Â 10,190Â 31,165Â 31,919Â Stock-based compensation9,512Â 14,232Â 29,316Â 42,745Â Acquisition-related costs, net(1)1,487Â 2,126Â 5,731Â 3,102Â Litigation costs(2)â€”Â 24Â â€”Â 21,279Â Restructuring costs(3)â€”Â â€”Â 2,088Â 2,055Â Non-recurring lease-related charges(4)â€”Â â€”Â 2,200Â 2,681Â Adjusted EBITDA$7,295Â $1,992Â $18,194Â $9,669Â _____(1)Acquisition-related costs, net include third-party fees associated with due diligence and deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments.(2)Litigation costs include costs related to litigation that are outside the ordinary course of our business. For additional details, refer to Note 15 in our condensed consolidated financial statements.(3)Restructuring costs include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in our condensed consolidated financial statements.(4)Non-recurring lease-related charges includes the lease-related impairment charge related to our corporate office space designated for subleasing. For additional details, refer to Note 9 in our condensed consolidated financial statements.53Key Factors Affecting Our PerformanceWe believe that our future growth, success, and performance are dependent on many factors, including those set forth below. While these factors present significant opportunities for us, they also represent the challenges that we must successfully address in order to grow our business and improve our results of operations.â€¢Impact of challenging macroeconomic environment, including high inflation and high interest rates, and the tight labor market. Recent macroeconomic challenges (including the high levels of inflation and high interest rates) and the tight labor market continue to adversely affect workforces, organizations, governments, clients, economies, and financial markets globally, leading to an economic downturn and increased market volatility. They have also disrupted the normal operations of many businesses, including ours. Our health system end market is currently experiencing meaningful financial strain from significant inflation. In particular, they are experiencing increases in labor and supply costs without a commensurate increase in revenue, leading to significant margin pressure. This margin pressure could continue to decrease healthcare industry spending, adversely affect demand for our technology and services, cause one or more of our clients to file for bankruptcy protection or go out of business, cause one or more of our clients to fail to renew, terminate, or renegotiate their contracts, impact expected spending from new clients, negatively impact collections of accounts receivable, and harm our business, results of operations, and financial condition. It is not possible for us to predict the duration or magnitude of the adverse results of the challenging macroeconomic environment and its effects on our business, results of operations, or financial condition at this time.â€¢Add new clients. We believe our ability to increase our client base will enable us to drive growth. Our potential client base is generally in the early stages of data and analytics adoption and maturity. We expect to further penetrate the market over time as potential clients invest in commercial data and analytics solutions. As one of the first data platform and analytics vendors focused specifically on healthcare organizations, we have an early-mover advantage and strong brand awareness. Our clients are large, complex organizations who typically have long procurement cycles, which, as a result, may lead to declines relative to our historic pace of our new client additions, which included small clients.â€¢Leverage recent product and services offerings to drive expansion. We believe that our ability to expand within our client base will enable us to drive growth. Over the last few years, we have developed and deployed several new analytics applications, including PowerCosting (formerly known as CORUS), PowerLabor, Touchstone, Patient Safety Monitor, Pop Analyzer (formerly known as Population Builder), Value Optimizer, and others. Because we are in the early stages of certain of our applicationsâ€™ lifecycles and maturity, we do not have enough information to know the impact on revenue growth by upselling these applications and associated services to current and new clients.â€¢Impact of acquisitions. We have acquired multiple companies over the last few years, including Medicity in June 2018, Able Health in February 2020, Healthfinch in July 2020, Vitalware in September 2020, Twistle in July 2021, KPI Ninja in February 2022, ARMUS in April 2022, ERS in October 2023, Carevive in May 2024, and Lumeon in August 2024. The historical and go-forward revenue growth profiles of these businesses may vary from our core DOS Subscription Clients, which can positively or negatively impact our overall growth rate. For example, Medicity clients have generated a lower dollar-based retention rate than DOS Subscription Clients and we expect declining revenue from Medicity clients in the foreseeable future. As we integrate the teams acquired via our recent acquisitions, we have also incurred integration-related costs and duplicative costs that could impact our operating cost profile in the near term.â€¢Changing revenue mix. Our technology and professional services offerings have materially different gross margin profiles. While our professional services offerings help our clients achieve measurable improvements and make them stickier, they have lower gross margins than our technology revenue. For the nine months ended September 30, 2024, our technology revenue and professional services revenue represented 63% and 37% of total revenue, respectively. Changes in our percentage of revenue attributable to Technology and Professional Services would impact future gross margin and Adjusted Gross Margin. 54Furthermore, changes within the types of professional services we offer over time can have a material impact on our professional services margin and Adjusted Professional Services Gross Margin, impacting our future gross margin and Total Adjusted Gross Margin. See the section titled â€œKey Financial Metrics â€“ Reconciliation of Non-GAAP Financial Measuresâ€ above for more information.â€¢Transitions to Microsoft Azure and migration to Health Catalyst Ignite. We incur hosting fees related to providing DOS through a cloud-based environment hosted by Microsoft Azure. We maintain a small number of clients that have deployed DOS on-premise. We are in the process of migrating clients who deployed DOS on-premise to Azure-hosted environments. The Azure cloud provides clients with more advanced DOS product functionality and a more seamless client experience; however, hosting clients in Azure is more costly than on-premise deployments on a per-client basis. We have also started migrating certain clients to Health Catalyst Ignite. These transitions have and will continue to result in higher cost of technology revenue and a reduced Adjusted Technology Gross Margin.Recent AcquisitionsLumeon Acquisition On August 1, 2024, we acquired Lumeon Ltd. (Lumeon), a digital health company dedicated to helping provider organizations mend broken care coordination processes through automated care orchestration. We accounted for the acquisition of Lumeon as a business combination. The acquisition consideration transferred was $39.8 million and was comprised of estimated net cash consideration of $36.2 million, Health Catalyst common shares with a fair value of $2.9 million, and contingent consideration based on certain earn-out performance targets for Lumeon during an earn-out period ending on June 30, 2025, with an acquisition-date fair value of $0.7 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Lumeon. Carevive AcquisitionOn May 24, 2024, we acquired Carevive Systems, Inc. (Carevive), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. We accounted for the acquisition of Carevive as a business combination. Oncology providers and life science researchers use Careviveâ€™s flagship platform and/or Carevive data in routine clinical practice for treatment care planning, clinical trial screening, care coordination, remote patient monitoring, and/or post-treatment care. The acquisition consideration transferred was $22.1 million and was comprised of net cash consideration of $18.6 million, shares of our common stock with a fair value of $2.6 million, and contingent consideration based on certain earn-out performance targets for Carevive during an earn-out period ending on June 30, 2025, with an acquisition-date fair value of $0.9 million. The purchase resulted in us acquiring 100% ownership in Carevive. ERS Corporation AcquisitionOn OctoberÂ 2, 2023, we acquired Electronic Registry Systems, Inc. (ERS), a cloud-based provider of clinical registry development and data management software focused on oncology with advanced data analytics expertise, for preliminary consideration of approximately $11.5 million in cash and 175,901 shares of our common stock that was originally subject to revesting over a period of 18 months.Components of Our Results of OperationsRevenueWe derive our revenue from sales of technology and professional services. For the three months ended September 30, 2024 and 2023, technology revenue represented 64% and 62% of total revenue, respectively, and professional services represented 36% and 38% of total revenue, respectively. For the nine months ended September 30, 2024 and 2023, technology revenue represented 63% and 64% of total revenue, respectively, and professional services represented 37% and 36% of total revenue, respectively.55Technology revenue.Â Â Â Â Technology revenue primarily consists of subscription fees charged to clients for access to use our data platform and analytics applications. We provide clients access to our technology through either an all-access or limited-access, modular subscription. Most of our subscription contracts are cloud-based and generally have a three- or five-year term, of which many are terminable after one year upon 90 daysâ€™ notice. The majority of our DOS subscription contracts have built-in annual escalators for technology access fees. Also included in technology revenue is the maintenance and support we provide, which generally includes updates and support services.Professional services revenue.Â Â Â Â Professional services revenue primarily includes analytics services, domain expertise services, Tech-enabled Managed Services, and implementation services. Professional services arrangements typically include a fee for making FTE services available to our clients on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our clients. From a revenue mix perspective, we anticipate that full-year 2024 professional services year-over-year revenue growth will slightly outpace technology year-over-year growth, driven by the heavier weighting of our Tech-enabled Managed Services bookings in the second half of 2022 and 2023, as well as the anticipated elevated churn levels, primarily for offerings that do not provide a near-term measurable financial ROI, such as some of our clinically-focused technology offerings and our traditional consulting professional services.Deferred revenueDeferred revenue consists of client billings in advance of revenue being recognized from our technology and professional services arrangements. We primarily invoice our clients for technology arrangements annually or quarterly in advance. Amounts anticipated to be recognized within one year of the balance sheet date are recorded as deferred revenue and the remaining portion is recorded as deferred revenue, net of current portion on our condensed consolidated balance sheets.Cost of revenue, excluding depreciation and amortizationCost of technology revenue.Â Â Â Â Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, license and revenue share fees, contractor costs, and salary and related personnel costs for our cloud services and support teams.Although we expect cost of technology revenue to increase in absolute dollars as we increase headcount, cloud computing, and hosting costs to accommodate growth, and as we continue to transition clients to third-party hosted data centers with Microsoft Azure and migrate clients to Health Catalyst Ignite, our next generation data platform, we anticipate cost of technology revenue as a percentage of technology revenue will generally decrease over the long term. We expect cost of technology revenue as a percentage of technology revenue to fluctuate and potentially increase in the near term, primarily due to additional costs associated with transitioning a small number of clients from on-premise deployments to Microsoft Azure-hosted environments and migrating clients to Health Catalyst Ignite, our next generation data platform.Cost of professional services revenue.Â Â Â Cost of professional services revenue consists primarily of costs related to delivering our teamâ€™s expertise in analytics, strategic advisory, improvement, and implementation services. These costs primarily include salary and related personnel costs, travel-related costs, and outside contractor costs. We expect the 2023 Restructuring Plan to reduce future, ongoing cost of professional services revenue. We further expect that the future savings from the reduced headcount will be offset by continued growth in our professional services, including TEMS.56Operating expenseSales and marketing. Sales and marketing expenses primarily include salary and related personnel costs for our sales, marketing, and account management teams, lead generation, marketing events, including our Healthcare Analytics Summit, marketing programs, and outside contractor costs associated with the sale and marketing of our offerings. We plan to continue to invest in sales and marketing to grow our client base, expand in new markets, and

increase our brand awareness. The trend and timing of sales and marketing expenses will depend in part on the timing of our expansion into new markets and marketing campaigns. Our sales and marketing expenses may fluctuate as a percentage of our revenue from period to period due to the timing and extent of these expenses.Research and development. Research and development expenses primarily include salary and related personnel costs for our data platform and analytics applications teams, subscriptions, and outside contractor costs associated with the development of products. We have developed an open, flexible, and scalable data platform. We plan to continue to invest in research and development to develop new solutions and enhance our applications library. The 2023 Restructuring Plan increased our research and development expenses in the first quarter of 2024 due to severance costs, but we expect that the reduction in headcount will reduce future, ongoing research and development expenses. Our research and development expenses may fluctuate as a percentage of our revenue from period to period due to the nature, timing, and extent of these expenses.General and administrative. General and administrative expenses primarily include salary and related personnel costs for our legal, finance, people operations, IT, and other administrative teams, including certain executives. General and administrative expenses also include facilities, subscriptions, corporate insurance, accounting, directorsâ€™ fees, litigation costs, and the change in fair value of contingent consideration liabilities. Our general and administrative expenses may fluctuate as a percentage of our revenue from period to period due to the timing and extent of these expenses.Depreciation and amortization.Â Depreciation and amortization expenses are primarily attributable to our capital investment and consist of fixed asset depreciation, amortization of intangibles considered to have definite lives, and amortization of capitalized internal-use software costs.Interest and other income (expense), netInterest and other income (expense), net primarily consists of income from our investment holdings partially offset by interest expense. Interest expense is primarily attributable to the Notes. It also includes the amortization of discounts on debt and amortization of deferred financing costs related to our debt arrangements.Income tax provision (benefit)Income tax provision (benefit) consists of U.S. federal, state, and foreign income taxes. Because of the uncertainty of the realization of the deferred tax assets, we have a full valuation allowance for our net deferred tax assets, including net operating loss carryforwards (NOLs) and tax credits related primarily to research and development.As of DecemberÂ 31, 2023, we had federal and state NOLs of $602.6 million and $505.5 million, respectively, which will begin to expire for federal and state tax purposes in 2032 and 2023, respectively. Our existing NOLs may be subject to limitations arising from ownership changes and, if we undergo an ownership change in the future, our ability to utilize our NOLs and tax credits could be further limited by SectionsÂ 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code). Future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under SectionsÂ 382 and 383 of the Code. Our NOLs and tax credits may also be limited under similar provisions of state law.On August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was enacted and signed into U.S. law. The IRA includes provisions imposing a 1% excise tax on share repurchases in excess of the fair value of stock issuances, including compensatory stock issuances, that occur after December 31, 2022 and introduces a 15% corporate alternative minimum tax on adjusted financial statement income. We do not expect the tax provisions of the IRA to have a material impact on our condensed consolidated financial statements.57Results of OperationsThe following tables set forth our condensed consolidated results of operations data and such data as a percentage of total revenue for each of the periods indicated:Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(in thousands)(in thousands)Revenue:Technology$48,653Â $45,973Â $143,254Â $140,483Â Professional services27,700Â 27,800Â 83,724Â 80,371Â Total revenue76,353Â 73,773Â 226,978Â 220,854Â Cost of revenue, excluding depreciation and amortization shown below:Technology(1)(2)(3)17,609Â 15,169Â 48,991Â 45,755Â Professional services(1)(2)(3)24,704Â 26,618Â 71,899Â 73,774Â Total cost of revenue, excluding depreciation and amortization42,313Â 41,787Â 120,890Â 119,529Â Operating expenses:Sales and marketing(1)(2)(3)11,342Â 15,084Â 43,145Â 50,050Â Research and development(1)(2)(3)14,193Â 17,667Â 42,948Â 52,339Â General and administrative(1)(2)(3)(4)(5)12,209Â 13,625Â 41,136Â 61,129Â Depreciation and amortization9,983Â 10,190Â 31,165Â 31,919Â Total operating expenses47,727Â 56,566Â 158,394Â 195,437Â Loss from operations(13,687)(24,580)(52,306)(94,112)Interest and other income (expense), net(1,514)2,607Â 3,185Â 6,490Â Loss before income taxes(15,201)(21,973)(49,121)(87,622)Income tax provision (benefit)(475)59Â (292)213Â Net loss$(14,726)$(22,032)$(48,829)$(87,835)(1)Includes stock-based compensation expense, as follows:Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023Stock-Based Compensation Expense:(in thousands)(in thousands)Cost of revenue, excluding depreciation and amortization:Technology$450Â $497Â $1,206Â $1,408Â Professional services1,601Â 1,927Â 4,282Â 5,682Â Sales and marketing2,555Â 5,149Â 8,997Â 16,049Â Research and development1,871Â 2,927Â 5,391Â 8,677Â General and administrative3,035Â 3,732Â 9,440Â 10,929Â Total$9,512Â $14,232Â $29,316Â $42,745Â 58(2)Includes acquisition-related costs (benefit), net, as follows:Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023Acquisition-related costs (benefit), net:(in thousands)(in thousands)Cost of revenue, excluding depreciation and amortization:Technology$77Â $66Â $246Â $208Â Professional services121Â 96Â 330Â 298Â Sales and marketing151Â 102Â 738Â 304Â Research and development183Â 198Â 612Â 587Â General and administrative955Â 1,664Â 3,805Â 1,705Â Total$1,487Â $2,126Â $5,731Â $3,102Â (3)Includes restructuring costs, as follows:Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023Restructuring costs:(in thousands)(in thousands)Cost of revenue, excluding depreciation and amortization:Technology$â€”Â $â€”Â $79Â $12Â Professional servicesâ€”Â â€”Â 181Â 434Â Sales and marketingâ€”Â â€”Â 449Â 1,205Â Research and developmentâ€”Â â€”Â 443Â 286Â General and administrativeâ€”Â â€”Â 936Â 118Â Total$â€”Â $â€”Â $2,088Â $2,055Â (4)Includes litigation costs, as follows:Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023Litigation costs:(in thousands)(in thousands)General and administrative$â€”Â $24Â $â€”Â $21,279Â Total$â€”Â $24Â $â€”Â $21,279Â (5)Includes non-recurring lease-related charges, as follows:Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023Non-recurring lease-related charges:(in thousands)(in thousands)General and administrative$â€”Â $â€”Â $2,200Â $2,681Â Total$â€”Â $â€”Â $2,200Â $2,681Â 59Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023Revenue:Technology64Â %62Â %63Â %64Â %Professional services36Â 38Â 37Â 36Â Total revenue100Â 100Â 100Â 100Â Cost of revenue, excluding depreciation and amortization shown below:Technology23Â 21Â 22Â 21Â Professional service32Â 36Â 32Â 33Â Total cost of revenue, excluding depreciation and amortization55Â 57Â 54Â 54Â Operating expensesSales and marketing15Â 20Â 19Â 23Â Research and development19Â 24Â 19Â 24Â General and administrative16Â 18Â 18Â 28Â Depreciation and amortization13Â 14Â 14Â 14Â Total operating expenses63Â 76Â 70Â 89Â Loss from operations(18)(33)(24)(43)Interest and other income (expense), net(2)4Â 1Â 3Â Loss before income taxes(20)(29)(23)(40)Income tax provision (benefit)(1)â€”Â â€”Â â€”Â Net loss(19)%(29)%(23)%(40)%Discussion of the Three Months Ended September 30, 2024 and 2023 RevenueThree Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Revenue:Technology$48,653Â $45,973Â $2,680Â 6Â %Professional services27,700Â 27,800Â (100)â€”Â %Total revenue$76,353Â $73,773Â $2,580Â 3Â %Percentage of revenue:Technology64Â %62Â %Professional services36Â 38Â Total100Â %100Â %Total revenue was $76.4 million for the three months ended September 30, 2024, compared to $73.8 million for the three months ended September 30, 2023, an increase of $2.6 million, or 3%. 60Technology revenue was $48.7 million, or 64% of total revenue, for the three months ended September 30, 2024, compared to $46.0 million, or 62% of total revenue, for the three months ended September 30, 2023. The technology revenue increase was primarily from growth from new Platform Subscription Clients, revenue from existing clients paying higher technology access fees from contractual, annual escalators, and new offerings of expanded support services, partially offset by elevated churn levels.Professional services revenue was essentially flat for the three months ended September 30, 2024 and 2023, and represented 36% and 38% of total revenue, respectively.Cost of revenue, excluding depreciation and amortizationThree Months Ended September 30,20242023$Â Change%Â Change(inÂ thousands, except percentages)Cost of revenue, excluding depreciation and amortization:Technology$17,609Â $15,169Â $2,440Â 16Â %Professional services24,704Â 26,618Â (1,914)(7)%Total cost of revenue, excluding depreciation and amortization$42,313Â $41,787Â $526Â 1Â %Percentage of total revenue55Â %57Â %Cost of technology revenue, excluding depreciation and amortization, was $17.6 million for the three months ended September 30, 2024, compared to $15.2 million for the three months ended September 30, 2023, an increase of $2.4 million, or 16%. The increase was primarily due to a $1.6 million increase in cloud computing and hosting costs largely from the expanded use of Microsoft Azure to serve existing and new clients, a $0.4 million increase in license and revenue share fees, and a $0.2 million increase in salary and related personnel costs, including stock-based compensation.Cost of professional services revenue was $24.7 million for the three months ended September 30, 2024, compared to $26.6 million for the three months ended September 30, 2023, a decrease of $1.9 million, or 7%. This decrease was primarily due to a $1.2 million decrease in salary and related personnel cost related to the 2023 Restructuring Plan, a $0.3 million decrease in contractor and outside service provider fees and a $0.3 million decrease in stock-based compensation.Operating expensesSales and marketingThree Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Sales and marketing$11,342Â $15,084Â $(3,742)(25)%Percentage of total revenue15Â %20Â %Sales and marketing expenses were $11.3 million for the three months ended September 30, 2024, compared to $15.1 million for the three months ended September 30, 2023, a decrease of $3.7 million, or 25%. The decrease was primarily due to a $2.6 million decrease in stock-based compensation, a $0.8 million decrease in salary and related personnel costs, and a $0.2 million decrease in decrease in contractor and outside service provider fees.Sales and marketing expense as a percentage of total revenue decreased from 20% in the three months ended September 30, 2023 to 15% in the three months ended September 30, 2024. 61Research and developmentThree Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Research and development$14,193Â $17,667Â $(3,474)(20)%Percentage of total revenue19Â %24Â %Research and development expenses were $14.2 million for the three months ended September 30, 2024, compared to $17.7 million for the three months ended September 30, 2023, a decrease of $3.5 million, or 20%. The decrease was primarily due to a $2.7 million decrease in salary and related personnel costs, a $1.1 million decrease in stock-based compensation, partially offset by a $0.4 million increase contractor and outside service provider fees.Research and development expense as a percentage of revenue decreased from 24% in the three months ended September 30, 2023 to 19% in the three months ended September 30, 2024. General and administrativeThree Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)General and administrative$12,209Â $13,625Â $(1,416)(10)%Percentage of total revenue16Â %18Â %General and administrative expenses were $12.2 million for the three months ended September 30, 2024, compared to $13.6 million for the three months ended September 30, 2023, a decrease of $1.4 million, orÂ 10%. The decrease was primarily due to a $1.6 million decrease in the fair value of contingent consideration liabilities and a $0.7 million decrease in stock-based compensation. These decreases were partially offset by a $0.8 million increase in salary and related personnel costs and a $0.2 million increase in contractor and outside service provider fees.General and administrative expense as a percentage of revenue decreased from 18% in the three months ended September 30, 2023 to 16% in the three months ended September 30, 2024.Depreciation and amortizationThree Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Depreciation and amortization$9,983Â $10,190Â $(207)(2)%Percentage of total revenue13Â %14Â %Depreciation and amortization expenses were consistent year over year with $10.0 million for the three months ended September 30, 2024, compared to $10.2 million for the three months ended September 30, 2023.Depreciation and amortization expense as a percentage of revenue decreased from 14% in the three months ended September 30, 2023 to 13% in the three months ended September 30, 2024.62Interest and other income (expense), netThree Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Interest income$4,735Â 4,458Â $277Â 6Â %Interest expense(6,126)(1,823)(4,303)236Â %Other expense(123)(28)(95)339Â %Total interest and other income (expense), net$(1,514)$2,607Â $(4,121)(158)%Interest and other income (expense), net decreased $4.1 million, or 158%, for the three months ended September 30, 2024, compared to the three months ended September 30, 2023. This change is primarily due to a $4.3 million increase in interest expense related to our new credit agreement with Silver Point Finance.Income tax provision (benefit)Three Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Income tax provision (benefit)(475)59Â $(534)(905)%Our income tax provision consists of current and deferred taxes for U.S. federal, state, and foreign income taxes. As we have a full valuation allowance on our net deferred tax assets, our income tax provision typically consists primarily of minimal state and foreign income taxes, which is the case for the three months ended September 30, 2023. The income tax benefit for the three months ended September 30, 2024 is primarily due to a foreign deferred income tax benefit offset by minimal current state and foreign income taxes.Discussion of the Nine Months Ended September 30, 2024 and 2023 RevenueNine Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Revenue:Technology$143,254Â $140,483Â $2,771Â 2Â %Professional services83,724Â 80,371Â 3,353Â 4Â %Total revenue$226,978Â $220,854Â $6,124Â 3Â %Percentage of revenue:Technology63Â %64Â %Professional services37Â %36Â %Total100Â %100Â %Total revenue was $227.0 million for the nine months ended September 30, 2024, compared to $220.9 million for the nine months ended September 30, 2023, an increase of $6.1 million, or 3%. Technology revenue was $143.3 million, or 63% of total revenue, for the nine months ended September 30, 2024, compared to $140.5 million, or 64% of total revenue, for the nine months ended September 30, 2023. The technology revenue increase was primarily due to growth from new Platform Subscription Clients, revenue from existing clients paying higher technology access fees from contractual, annual escalators, and new offerings of expanded support services, partially offset by elevated churn levels.63Professional services revenue was $83.7 million, orÂ 37% of total revenue, for the nine months ended September 30, 2024, compared to $80.4 million, or 36% of total revenue, for the nine months ended September 30, 2023. The professional services revenue growth is primarily due to implementation, analytics, and other improvement services being provided to Platform Subscription Clients, which includes Tech-enabled Managed Services.Cost of revenue, excluding depreciation and amortizationNine Months Ended September 30,20242023$Â Change%Â Change(inÂ thousands, except percentages)Cost of revenue, excluding depreciation and amortization:Technology$48,991Â $45,755Â $3,236Â 7Â %Professional services71,899Â 73,774Â (1,875)(3)%Total cost of revenue, excluding depreciation and amortization$120,890Â $119,529Â $1,361Â 1Â %Percentage of total revenue54Â %54Â %Cost of technology revenue, excluding depreciation and amortization, was $49.0 million for the nine months ended September 30, 2024, compared to $45.8 million for the nine months ended September 30, 2023, an increase of $3.2 million, or 7%. The increase was primarily due to a $3.7 million increase in cloud computing and hosting costs largely from the expanded use of Microsoft Azure to serve existing and new clients, partially offset by a $0.3 million decrease in salary and related personnel costs, including stock-based compensation, and a $0.2 million decrease in license and revenue share fees.Cost of professional services revenue was $71.9 million for the nine months ended September 30, 2024, compared to $73.8 million for the nine months ended September 30, 2023, an decrease of $1.9 million, or 3%. Notable changes in the cost of professional services revenue for the period include a $1.4 million decrease in stock-based compensation, a $1.3 million decrease in contractor and outside service provider fees, and a $0.3 million decrease in restructuring charges, partially offset by a $1.1 million increase in in salary and related personnel cost.Operating expensesSales and marketingNine Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Sales and marketing$43,145Â $50,050Â $(6,905)(14)%Percentage of total revenue19Â %23Â %Sales and marketing expenses were $43.1 million for the nine months ended September 30, 2024, compared to $50.1 million for the nine months ended September 30, 2023, a decrease of $6.9 million, or 14%. The decrease was primarily due to a $7.1 million decrease in stock-based compensation, a $3.0 million decrease in salary and related personnel costs, and a $0.3 million decrease in restructuring charges. These decreases were partially offset by a $1.8 million increase in our provision for expected credit losses and a $1.5 million increase in contractor and outside service provider fees.Sales and marketing expense as a percentage of total revenue decreased from 23% in the nine months ended September 30, 2023 to 19% in the nine months ended September 30, 2024. 64Research and developmentNine Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Research and development$42,948Â $52,339Â $(9,391)(18)%Percentage of total revenue19Â %24Â %Research and development expenses were $42.9 million for the nine months ended September 30, 2024, compared to $52.3 million for the nine months ended September 30, 2023, a decrease of $9.4 million, or 18%. The decrease was primarily due to a $4.3 million decrease in salary and related personnel costs, a $3.3 million decrease in stock-based compensation, and a $1.7 million decrease in contractor and outside service provider fees.Research and development expense as a percentage of revenue decreased from 24% in the nine months ended September 30, 2023 to 19% in the nine months ended September 30, 2024. General and administrativeNine Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)General and administrative$41,136Â $61,129Â $(19,993)(33)%Percentage of total revenue18Â %28Â %General and administrative expenses were $41.1 million for the nine months ended September 30, 2024, compared to $61.1 million for the nine months ended September 30, 2023, a decrease of $20.0 million, orÂ 33%. The decrease was primarily due to a $21.3 million decrease in litigation costs compared to those that occurred in the prior-year period and are out of the ordinary course of business, a $1.5 million decrease in stock-based compensation, and a $0.5 million decrease in lease-related impairment charges. These decreases were partially offset by a $2.4 increase in salary and related personnel costs and a $0.9 million net increase in acquisition-related

costs.General and administrative expense as a percentage of revenue decreased from 28% in the nine months ended September 30, 2023 to 18% in the nine months ended September 30, 2024.Depreciation and amortizationNine Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Depreciation and amortization$31,165Â $31,919Â $(754)(2)%Percentage of total revenue14Â %14Â %Depreciation and amortization expenses were $31.2 million for the nine months ended September 30, 2024, compared to $31.9 million for the nine months ended September 30, 2023, a decrease of $0.8 million, orÂ 2%. This decrease was primarily due to certain acquired intangible assets from our business combinations becoming fully amortized.Depreciation and amortization expense as a percentage of revenue remained constant at 14% for the nine months ended September 30, 2024, and 2023 .65Interest and other income (expense), netNine Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Interest income$13,135Â 11,968Â $1,167Â 10Â %Interest expense(9,789)(5,461)(4,328)79Â %Other expense(161)(17)(144)847Â %Total interest and other income (expense), net$3,185Â $6,490Â $(3,305)(51)%Interest and other income (expense), net decreased $3.3 million, or 51%, for the nine months ended September 30, 2024, compared to the nine months ended September 30, 2023. This change is primarily due to a $4.5 million increase in interest expense related to our new credit agreement with Silver Point Finance, partially offset by a $1.2 increase in interest income on our short-term investments, primarily due to higher market interest rates.Income tax provision (benefit)Nine Months Ended September 30,20242023$Â Change%Â Change(in thousands, except percentages)Income tax provision (benefit)(292)213Â $(505)(237)%Our income tax provision consists of current and deferred taxes for U.S. federal, state, and foreign income taxes. As we have a full valuation allowance on our net deferred tax assets, our income tax provision typically consists primarily of minimal state and foreign income taxes, which is the case for the nine months ended September 30, 2023. The income tax benefit for the three months ended September 30, 2024 is due to a foreign deferred income tax benefit offset by minimal current state and foreign income taxes.66Liquidity and Capital ResourcesAs of SeptemberÂ 30, 2024, we had cash, cash equivalents, and short-term investments of $387.3 million, which were held for working capital and other general corporate purposes, which may include acquisitions and strategic transactions. Our cash equivalents and short-term investments are comprised primarily of money market funds, U.S. treasury notes, commercial paper, corporate bonds, and U.S. agency securities. Since inception, we have financed our operations primarily from the proceeds we received through private sales of equity securities, payments received from clients under technology and professional services arrangements, borrowings under our loan and security agreements (including our Credit Agreement described below), our IPO, the Note Offering, and the Secondary Public Equity Offering. Our future capital requirements will depend on many factors, including our pace of new client growth and expanded client relationships, technology and professional services renewal activity, and the timing and extent of spend to support the expansion of sales, marketing, development, share repurchases, and acquisition-related activities. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us, or at all. If we are unable to raise additional capital when desired, our business, results of operations, and financial condition would be adversely affected.We believe our existing cash, cash equivalents, and marketable securities will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months, though we may require additional capital resources in the future. Credit AgreementOn July 16, 2024 (the Closing Date), we entered into a credit agreement with Silver Point Finance, LLC as administrative agent and collateral agent, and the lenders from time to time party thereto (Credit Agreement). The Credit Agreement provides a five-year term loan facility in an aggregate principal amount of up to $225 million, consisting of an initial term loan in the aggregate principal amount of $125 million, which was funded on the Closing Date, and a delayed draw term loan facility in the aggregate principal amount of $100 million, which was undrawn on the Closing Date. We have the option to draw up to $40 million under the delayed draw facility within six months after the Closing Date and up to an additional $60 million under the delayed draw facility within eighteen months after the Closing Date, in each case, subject to satisfaction of certain conditions, including a minimum liquidity threshold and a maximum recurring revenue ratio. Borrowings under the Credit Agreement are expected to bear interest at a rate per annum equal to the secured overnight financing rate (SOFR) plus 6.5%. Commencing with the quarter ending on December 31, 2024, we are required to make quarterly principal payments in an amount equal to 0.25% of the aggregate original principal amount. The final maturity date of the term loans is July 16, 2029.We expect the net proceeds from the initial term loan to be used, together with cash on hand, (i) to repurchase, repay and/or pay amounts of cash due upon conversion of any or all of our Notes at any time on or prior to the maturity of the Notes and (ii) for working capital and general corporate purposes. The proceeds from the delayed draw term loan facility, if any, will be used to fund our inorganic growth strategy through permitted acquisitions (including deferred purchase price or similar arrangements related thereto) and to pay fees, costs, and expenses in connection therewith. Refer to â€œNote 10â€”Debtâ€ to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional details regarding the Credit Agreement. Share repurchase planDuring the third quarter of 2022, our board of directors authorized a share repurchase program to repurchase up to $40.0Â million of our outstanding shares of common stock (Share Repurchase Plan). During the nine months ended September 30, 2024, there were no shares repurchased. During the nine months ended September 30, 2024, we repurchased and retired 145,027 shares of our common stock for $1.8Â million at an average purchase price of $12.45 per share. The total remaining authorization for future shares of common stock repurchases under our Share Repurchase Plan is $29.8Â million as of SeptemberÂ 30, 2024.67Convertible senior notesOn April 14, 2020, we issued $230.0Â million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025, pursuant to an Indenture dated April 14, 2020, with U.S. Bank National Association, as trustee, in a private offering to qualified institutional buyers. We received net proceeds from the sale of the Notes of $222.5Â million, after deducting the initial purchasersâ€™ discounts and offering expenses payable by us. The Notes are senior, unsecured obligations and will accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Notes are convertible into cash, shares of our common stock, or a combination of cash and shares of our common stock, with the form of consideration determined at our election. The conversion rate is initially 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock).Capped callsOn April 8, 2020, concurrently with the pricing of the Notes, we entered into privately negotiated capped call transactions (Base Capped Calls) with certain financial institutions, or option counterparties. In addition, in connection with the initial purchasersâ€™ exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (Additional Capped Calls, and, together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. We used approximately $21.6 million of the net proceeds from the Note Offering to pay the option premium cost of the Capped Calls. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price.Refer to â€œNote 10â€”Debtâ€ to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional details regarding the private offering of the Notes and the Capped Calls.Cash flowsThe following table summarizes our cash flows for the nine months ended September 30, 2024 and 2023:Nine Months Ended September 30,20242023(in thousands)Net cash provided by (used in) operating activities$18,086Â $(14,039)Net cash provided by (used in) investing activities89,847Â (9,624)Net cash provided by financing activities114,056Â 2,335Â Effect of exchange rate changes62Â (13)Net increase (decrease) in cash and cash equivalents$222,051Â $(21,341)Operating activitiesOur largest source of operating cash flows is cash collections from our clients for technology and professional services arrangements. Our primary uses of cash from operating activities are for employee-related expenses, marketing expenses, and technology costs.For the nine months ended September 30, 2024, net cash provided by operating activities was $18.1 million, which included a net loss of $48.8 million. Non-cash adjustments primarily consisted of $31.2 million in depreciation and amortization, $29.3 million in stock-based compensation, $3.4 million from the provision for expected credit losses, and $2.2 million from lease-related impairment charges, offset by $3.9 million in net interest income from the accretion of discounts on our short-term investments. 68For the nine months ended September 30, 2023, net cash used in operating activities was $14.0 million, which included a net loss of $87.8 million. Non-cash adjustments primarily consisted of $31.9 million in depreciation and amortization, $42.7 million in stock-based compensation, and $2.7 million from lease-related impairment charges, offset by $6.8 million in net interest income from the accretion of discounts on our short-term investments.Investing activitiesNet cash provided by investing activities for the nine months ended September 30, 2024 of $89.8 million was primarily due to $206.5 million provided from the sale and maturity of short-term investments, reduced by $50.2 million in purchases of short-term investments, $54.9 million used in the acquisition of businesses, and $9.9 million of capitalized internal-use software development costs.Net cash provided by investing activities for the nine months ended September 30, 2023 of $9.6 million was primarily due to $256.1 million provided from the sale and maturity of short-term investments, reduced by $254.4 million in purchases of short-term investments, and $9.3 million of capitalized internal-use software development costs.Financing activitiesNet cash provided by financing activities for the nine months ended September 30, 2024 of $114.1 million was primarily the result of $115.5 million of proceeds from the issuance of our Credit Agreement, net of issuance costs and $2.1 million in proceeds from our ESPP, reduced by $3.0 million for the deferred financing costs. Net cash provided by financing activities for the nine months ended September 30, 2023 of $2.3 million was primarily the result of $3.2 million in proceeds from our ESPP and $0.9 million in stock option exercise proceeds, reduced by $1.8 million in repurchases of common stock.Contractual Obligations and CommitmentsThere have been no material changes to the contractual obligations as disclosed in our Annual Report on Form 10-K, filed with the SEC on February 22, 2024 other than the new Credit Agreement entered into on July 16, 2024, as described in the Liquidity and Capital Resources section above and â€œNote 10â€”Debt.â€Refer to â€œNote 10â€”Debtâ€, and â€œNote 15â€”Commitments and Contingenciesâ€ to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information regarding our commitments and contractual obligations.Off-BalanceÂ Sheet ArrangementsAs of SeptemberÂ 30, 2024, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitatingÂ off-balanceÂ sheet arrangements or other contractually narrow or limited purposes.Critical Accounting Policies and EstimatesOur managementâ€™s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and related disclosures. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances, and we evaluate these estimates on an ongoing basis. 69Critical accounting policies and estimates are those that we consider critical to understanding our historical and future performance, as these policies relate to the more significant areas involving managementâ€™s judgments and estimates.Due to the high level of inflation, rising interest rates, and market volatility, amongst other factors, there has been uncertainty and disruption in the global economy and financial markets. We are not aware of any specific event or circumstance that would require updates to our estimates or judgments or require us to revise the carrying value of our assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. We will continue to actively monitor the impact of the recent inflationary pressures, market volatility caused by bank failures, the challenging macroeconomic environment in general, and other factors on our estimates, including our expected credit losses, goodwill impairment assessments, and the fair value and/or recoverability of other assets.There have been no material changes to our critical accounting policies and estimates as previously disclosed in our Annual Report on Form 10-K, filed with the SEC on February 22, 2024. See â€œNote 1â€”Description of Business and Summary of Significant Accounting Policiesâ€ to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information regarding the Companyâ€™s significant accounting policies.Recent Accounting PronouncementsSee â€œNote 1â€”Description of Business and Summary of Significant Accounting Policiesâ€ to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for more information regarding recently issued accounting pronouncements.70Item 3.Â Quantitative and Qualitative Disclosures about Market RiskÂ We are exposed to certain market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates but may include foreign currency exchange risk and inflation in the future.Interest rate riskWe had cash, cash equivalents, and short-term investments of $387.3 million as of SeptemberÂ 30, 2024, which are held primarily for working capital purposes. We do not make investments for trading or speculative purposes. Our cash equivalents and short-term investments are subject to market risk due to changes in interest rates. Fixed-rate securities may have their market value adversely affected due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fluctuate due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates. However, because we classify our investments as â€œavailable for sale,â€ no gains or losses are recognized due to changes in interest rates unless such securities are sold prior to maturity or declines in fair value are determined to be other-than-temporary.As of SeptemberÂ 30, 2024, a hypothetical 100 basis point change in interest rates would not have had a material impact on the value of our cash equivalents or investment portfolio. Fluctuations in the value of our cash equivalents and investment portfolio caused by a change in interest rates (gains or losses on the carrying value) are recorded in other comprehensive income and are realized only if we sell the underlying securities prior to maturity.On April 14, 2020, we issued $230.0 million in aggregate principal amount Convertible Senior Notes due 2025 (Notes), in a private placement to qualified institutional buyers exempt from registration under the Securities Act (Note Offering). The Notes have a fixed annual interest rate of 2.50%, and, therefore, we do not have economic interest rate exposure on the Notes. However, the values of the Notes are exposed to interest rate risk. Generally, the fair value of our fixed interest rate Notes will increase as interest rates fall and decrease as interest rates rise. We carry the Notes at face value less unamortized discount on our condensed consolidated balance sheets, and we present the fair value for required disclosure purposes only. On July 16, 2024, we entered into the Credit Agreement consisting of a $125 million funded term loan and a delayed draw term loan facility in the aggregate principal amount of $100 million, which was undrawn as of the Closing Date. The maturity date of the term loans is July 16, 2029. The interest that accrues on outstanding principal of the term loans is payable in cash on a quarterly basis, which portion accrues at a floating rate equal to SOFR plus 6.5% per year. In the event that SOFR is unavailable, interest will accrue at a floating rate equal to the alternate base rate (as described in the Credit Agreement) plus 5.5% per year. Commencing with the quarter ending on December 31, 2024, we are required to make quarterly principal payments in an amount equal to 0.25% of the aggregate original principal amount, and the final maturity date of the term loans is July 16, 2029.In addition to the floating interest rate, we are required to pay a commitment fee on the unutilized commitments under the delayed draw facility ranging from 1.5% to 2.5% per year depending upon the year and the unutilized delayed draw term loan.Interest rate risk also reflects our exposure to movements in interest rates associated with our borrowings. As of the time of this filing a hypothetical change in interest rates of 100 basis points would not have a material impact on the fair value of our outstanding debt.71Foreign currency exchange riskOur reporting currency is the U.S. dollar, and the functional currency of our international subsidiaries is typically their local currency. Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, particularly changes in the British Pound, Indian Rupee, and Singapore Dollar. Due to the relatively small size of our international operations to date, our foreign currency exposure has been fairly limited and not material to our business. Accordingly, we have not instituted a hedging program. We are considering the costs and benefits of initiating such a program and may in the future hedge balances and transactions denominated in currencies other than the U.S. dollar as we expand our international operations.Today, our international sales contracts are generally denominated in U.S. dollars, while our international operating expenses are often denominated in local currencies. In the future, an increasing portion of our international sales contracts may be denominated in local currencies. Additionally, as we expand our international operations a larger portion of our operating expenses will be denominated in local currencies. Therefore, fluctuations in the value of the U.S. dollar and foreign currencies may affect our results of operations when translated into U.S. dollars.Inflation riskThe recent high inflationary environment has adversely affected workforces, organizations, governments, clients, economies, and financial markets globally, leading to an economic downturn and increased market volatility. It has also disrupted the normal operations of many businesses, including ours. Our health system end market is currently experiencing meaningful financial strain from significant inflation with increases in labor and supply costs without a commensurate increase in revenue, leading to significant margin pressure. Although we are unable to determine the exact impact of inflation on our clients and on our business, we continue to monitor and assess the impact of inflationary pressures on our business operations. If our costs, including labor costs, were to become subject to significant inflationary pressures on an ongoing basis, we may not be able to fully

offset such higher costs by increasing fees for our Solution. Our inability or failure to do so could harm our business, results of operations, or financial condition.Item 4.Â Controls and ProceduresEvaluation of disclosure controls and proceduresWe maintain â€œdisclosure controls and procedures,â€ as defined in Rule 13aâ€“15(e) and Rule 15dâ€“15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as ofÂ SeptemberÂ 30, 2024. Based on the evaluation of our disclosure controls and procedures as ofÂ SeptemberÂ 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.Changes in internal control over financial reportingThere was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 72Inherent limitations on effectiveness of controlsOur management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.73Part II. Other InformationItem 1.Â Legal ProceedingsWe are, and from time to time may be, party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of these matters could materially affect our future results of operations, cash flows, or financial position. We are not presently party to any other legal proceedings that in the opinion of management, if determined to adversely affect us, may individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows.For information regarding a legal proceeding that was dismissed with prejudice on June 20, 2023, refer to â€œNote 15â€“Commitments and Contingenciesâ€ to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.Item 1A. Risk FactorsYou should carefully consider the following risk factors, in addition to the other information contained in this Quarterly Report on Form 10-Q, including the section of this report titled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ and our financial statements and related notes. If any of the events described in the following risk factors and the risks described elsewhere in this report occurs, our business, operating results and financial condition could be seriously harmed. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report.Risks Related to Our Business and IndustryWe operate in a highly competitive industry, and if we are not able to compete effectively, our business and results of operations will be harmed.The market for healthcare solutions is intensely competitive. We compete across various segments within the healthcare market, including with respect to data analytics and technology platforms, healthcare consulting, care management and coordination, population health management, and health information exchange. Competition in our market involves rapidly changing technologies, evolving regulatory requirements and industry expectations, frequent new product introductions, and changes in client requirements. If we are unable to keep pace with the evolving needs of our clients and continue to develop and introduce new applications and services in a timely and efficient manner, demand for our Solution may be reduced and our business and results of operations will be adversely affected.We face competition from industry-agnostic analytics companies, electronic health record (EHR) companies, such as Epic Systems and Cerner, point solution vendors, and healthcare organizations that perform their own analytics. These competitors include large, well-financed, and technologically sophisticated entities. Some of our current large competitors, such as Optum Analytics and IBM, have greater name recognition, longer operating histories, significantly greater resources than we do, and/or more established distribution networks and relationships with healthcare providers. As a result, our current and potential competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or client requirements. In addition, current and potential competitors have established, and may in the future establish, cooperative relationships with vendors of complementary products or services to increase the availability of their products or services to the marketplace. Current or future competitors may consolidate to improve the breadth of their products, directly competing with our Solution. Accordingly, new competitors may emerge that have greater market share, larger client bases, greater breadth and volume of data, more widely adopted proprietary technologies, broader offerings, greater marketing expertise, greater financial resources, and larger sales forces than we have, which could put us at a competitive disadvantage. 74Further, in light of these advantages, even if our Solution is more effective than the product or service offerings of our competitors, current or potential clients might select competitive products and services in lieu of purchasing our Solution. We face competition from niche vendors, who offer stand-alone products and services, and from existing enterprise vendors, including those currently focused on software products, which have information systems in place with clients in our target markets. These existing enterprise vendors may now, or in the future, offer or promise products or services with less functionality than our Solution, but offer ease of integration with existing systems and that leverage existing vendor relationships. Increased competition is likely to result in pricing pressures, which could negatively impact our sales, profitability, or market share.Our patient engagement, population health, and care coordination services face competition from a wide variety of market participants. For example, certain health systems have developed their own population health and care coordination systems. If we fail to distinguish our offerings from the other options available to healthcare providers, the demand for and market share of those offerings may decrease.Changes in the healthcare industry could affect the demand for our Solution, cause our existing contracts to be terminated, and negatively impact the process of negotiating future contracts.As the healthcare industry evolves, changes in our client and vendor bases may reduce the demand for our Solution, result in the termination of existing contracts or certain services provided under existing contracts, and make it more difficult to negotiate new contracts on terms that are acceptable to us. For example, the increasing market share of EHR companies in data analytic services at hospital systems may cause our existing clients to terminate contracts with us in order to engage EHR companies to provide these services. Similarly, client and vendor consolidation results in fewer, larger entities with increased bargaining power and the ability to demand terms that are unfavorable to us. If these trends continue, we cannot assure you that we will be able to continue to maintain or expand our client base, negotiate contracts with acceptable terms, or maintain our current pricing structure, and our revenue may decrease.General reductions in expenditures by healthcare organizations, or reductions in such expenditures within market segments that we serve, could have similar impacts with regard to our Solution. Such reductions may result from, among other things, reduced governmental funding for healthcare; a decrease in the number of, or the market exclusivity available to, new drugs coming to market; or adverse changes in business or economic conditions affecting healthcare payors or providers, the pharmaceutical industry, or other healthcare companies that purchase our services (e.g., changes in the design of health plans). In addition, changes in government regulation of the healthcare industry could potentially negatively impact our existing and future contracts. Any of these changes could reduce the purchase of our Solution by such clients, reducing our revenue and possibly requiring us to materially revise our offerings. In addition, our clientsâ€™ expectations regarding pending or potential industry developments may also affect their budgeting processes and spending plans with respect to our Solution.Macroeconomic challenges (including high inflationary and/or high interest rate environments, or market volatility caused by bank failures and measures taken in response thereto), the tight labor market, and any new public health crisis could harm our business, results of operations, and financial condition.Recent macroeconomic challenges (including high inflationary and/or high interest rate environments), and the tight labor market continue to adversely affect workforces, organizations, governments, clients, economies, and financial markets globally and have disrupted the normal operations of many businesses, including our business. These factors have and could further decrease healthcare industry spending, adversely affect demand for our Solution, cause one or more of our clients to file for bankruptcy protection or go out of business, cause one or more of our clients to fail to renew, terminate, or renegotiate their contracts, impact expected spending from new clients, negatively impact collections of accounts receivable, and harm our business, results of operations, and financial condition. Further, the sales cycle for a new DOS Subscription Client, which we estimate to typically be approximately one year, could lengthen, as we experienced in 2022 and 2023, resulting in a potentially longer delay between increasing operating expenses and the generation of corresponding revenue, if any. 75We cannot predict with any certainty whether and to what degree the disruption caused by any new public health crisis, the high inflationary environment, rising interest rates, market volatility caused by bank failures and measures taken in response thereto, and reactions to any of the foregoing will continue and expect to face difficulty accurately predicting our internal financial forecasts. Further, it is not possible for us to predict the duration or magnitude of the adverse results of public health crises, and macroeconomic challenges (including the high inflationary and/or high interest rate environments), and their effects on our business, results of operations, or financial condition at this time. Further, market volatility as a result of future failures of financial institutions, similar to the failures of Silicon Valley Bank and Signature Bank, could lead to market-wide liquidity shortages, impair the ability of companies to access near-term working capital needs and create additional market and economic uncertainty. In the event of a failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.We may be unable to successfully execute on our growth initiatives, business strategies, or operating plans, as well as cost reduction and restructuring initiatives.We are continually executing a number of growth initiatives, strategies, and operating plans designed to enhance our business, as well as some cost reduction and restructuring initiatives. We may not be able to successfully complete these growth initiatives, strategies, operating plans, and cost reduction and restructuring initiatives, and realize all of the benefits, including growth targets and cost savings, that we expect to achieve or it may be more costly to do so than we anticipate. For example, the migration of existing DOS Subscription Clients to Health Catalyst Ignite involves risk and may cause disruptions to our Solution, difficulties as clients acclimate to a new platform, or other challenges that could impair our clientsâ€™ use of our technology, any of which could lead to client dissatisfaction and non-renewals. Further, costs associated with the transition to Health Catalyst Ignite have and may continue to result in higher cost of technology revenue, which may not decrease over timeA variety of factors could cause us not to realize some or all of the expected benefits of our growth initiatives, strategies, operating plans or cost reduction and restructuring initiatives. These factors include, among others, delays in the anticipated timing of activities related to such growth initiatives, strategies, operating plans, and cost reduction and restructuring initiatives, increased difficulty and cost in implementing these efforts, including difficulties in complying with new regulatory requirements and the incurrence of other unexpected costs associated with operating the business. For example, on October 31, 2023, our board of directors authorized the 2023 Restructuring Plan as part of a restructuring plan intended to optimize our cost structure and focus our investment of resources in key priority areas to align with strategic changes. The 2023 Restructuring Plan reduced our global workforce by approximately 10% during the fourth quarter of 2023 and the first quarter of 2024. We may incur additional expenses not currently contemplated due to events associated with the 2023 Restructuring, such as costs in connection with attrition beyond our intended reduction in force, the loss of institutional knowledge and expertise, or other unforeseen difficulties, delays, or other impacts on other areas of our liabilities and obligations, in each case which could result in losses in future periods or which could otherwise prevent us from realizing, in full or in part, the anticipated benefits and savings from the 2023 Restructuring Plan.Our continued implementation of the 2023 Restructuring Plan or any other programs may disrupt our operations and performance. As a result, we cannot assure you that we will realize these benefits. If, for any reason, the benefits we realize are less than our estimates or the implementation of these growth initiatives, strategies, operating plans, and cost reduction and restructuring initiatives adversely affect our operations or cost more or take longer to effectuate than we expect, or if our assumptions prove inaccurate, our business, financial condition, and results of operations may be materially adversely affected.76If we fail to provide effective professional services and high-quality client support, our business and reputation would suffer.Our professional services and high-quality, ongoing client support are important to the successful marketing and sale of our products and services and for the renewal of existing client agreements. Providing these services and support requires that our professional services and support personnel have healthcare, technical, and other knowledge and expertise, making it difficult for us to hire qualified personnel and scale our professional services and support operations. The demand on our client support organization will increase as we expand our business and pursue new clients, and such increased support could require us to devote significant development services and support personnel, which could strain our team and infrastructure and reduce our profit margins. If we do not help our clients quickly resolve any post-implementation issues and provide effective ongoing client support, our ability to sell additional products and services to existing and future clients could suffer and our reputation would be harmed.Our sales cycles can be long and unpredictable, and our sales efforts require a considerable investment of time and expense. If our sales cycle lengthens or we invest substantial resources pursuing unsuccessful sales opportunities, our results of operations and growth would be harmed.Our sales process entails planning discussions with prospective clients, analyzing their existing solutions, and identifying how these potential clients can use and benefit from our Solution. The sales cycle for a new DOS Subscription Client, from the time of prospect qualification to the completion of the first sale, we estimate to typically be approximately one year and in some cases has exceeded two years. We spend substantial time, effort, and money in our sales efforts without any assurance that our efforts will result in the sale of our Solution. In addition, our sales cycle and timing of sales can vary substantially from client to client because of various factors, including the discretionary nature of potential clientsâ€™ purchasing and budget decisions, the announcement or planned introduction of new analytics applications or services by us or our competitors, and the purchasing approval processes of potential clients. Further, the sales cycles of certain Solutions with a more limited operating history, such as TEMS, can be more difficult to predict and, at times, longer than our typical sales cycle. If our sales cycle lengthens, as we experienced in 2022 and 2023, or we invest substantial resources pursuing unsuccessful sales opportunities, our results of operations and growth would be harmed.Our Solution may not operate properly, which could damage our reputation, give rise to claims against us, or divert application of our resources from other purposes, any of which could harm our business and results of operations.Proprietary software development is time-consuming, expensive, and complex. Unforeseen difficulties can arise. We may encounter technical obstacles, and it is possible that we will discover additional problems that prevent our applications from operating properly. If our systems do not function reliably or fail to meet user or client expectations in terms of performance, clients could assert liability claims against us or attempt to cancel their contracts with us, and users of our software could choose to cease their use of our Solution. This could damage our reputation and impair our ability to attract or retain clients.Information services as complex as those we offer have, in the past, contained, and may in the future develop or contain, undetected defects, vulnerabilities, or errors. We cannot be assured that material performance problems or defects in our software or software provided by our vendors will not arise in the future. Errors may result from sources beyond our control, including the receipt, entry, or interpretation of patient information; the interface of our software with legacy systems or vendor systems that we did not develop; or errors in data provided by third parties. Despite testing, defects or errors may arise in our existing or new software or service processes following introduction to the market.Clients rely on our Solution to collect, manage, and report clinical, financial, and operational data, and to provide timely and accurate information regarding medical treatment and care delivery patterns. They may have a greater sensitivity to service errors and security vulnerabilities than clients of software products in general. Clinicians may also refer to our predictive models for care delivery prioritization, and to inform treatment protocols. 77Limitations of liability and disclaimers that purport to limit our liability for damages related to defects in our software or content which we may include in our subscription and services agreements may not be enforced by a court or other tribunal or otherwise effectively protect us from related

claims. In most cases, we maintain liability insurance coverage, including coverage for errors and omissions. However, it is possible that claims could exceed the amount of our applicable insurance coverage or that this coverage may not continue to be available on acceptable terms or in sufficient amounts.In light of this, defects, vulnerabilities, and errors and any failure by us to identify and address them could result in loss of revenue or market share; liability to clients, clinicians, their patients, or others; failure to achieve market acceptance or expansion; diversion of development and management resources; delays in the introduction of new services; injury to our reputation; and increased service and maintenance costs. Defects, vulnerabilities, or errors in our software and service processes might discourage existing or potential clients from purchasing services from us. Correction of defects, vulnerabilities, or errors could prove to be impossible or impractical. The costs incurred in correcting any defects, vulnerabilities, or errors or in responding to resulting claims or liability may be substantial and could adversely affect our results of operations.If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing clients and to our ability to attract new clients. The promotion of our brands may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly difficult and expensive. Our marketing activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our results of operations could be harmed. In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our clients, or any adverse publicity surrounding one of our investors or clients, could make it substantially more difficult for us to attract new clients. If we do not successfully maintain and enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with clients, which would harm our business, results of operations, and financial condition.If we do not continue to innovate and provide services that are useful to clients and users, we may not remain competitive, and our revenue and results of operations could suffer.The market for healthcare in the United States is in the early stages of structural change and is rapidly evolving, including towards a more value-based care model. Our success depends on our ability to keep pace with technological developments, satisfy increasingly sophisticated client and user requirements, and sustain market acceptance. Our future financial performance will depend in part on growth in this market and on our ability to adapt to emerging demands of this market, including adapting to the ways our clients or users access and use our Solution. Although we have built several new software analytics applications in the last few years, we may not be able to sustain this rate of innovation and/or the new software analytics applications may not meet the evolving needs of our clients. Our competitors are constantly developing products and services that may become more efficient or appealing to our clients or users. As a result, we must continue to invest significant resources in research and development in order to enhance our existing services and applications, and introduce new high-quality services and applications that clients will want, while offering our Solution at competitive prices. If we are unable to predict user preferences or industry changes, or if we are unable to maintain and improve our Solution on a timely or cost-effective basis, we may lose clients and users. Our results of operations would also suffer if our innovations are not responsive to the needs of our clients, are not appropriately timed with market opportunity, or are not effectively brought to market, including as the result of delayed releases or releases that are ineffective or have errors or defects. As technology continues to develop, our competitors may be able to offer results that are, or that are perceived to be, substantially similar to, or better than, those generated by our Solution. This may force us to compete on additional service attributes and to expend significant resources in order to remain competitive.78Our business could be adversely affected if our clients are not satisfied with our Solution.We depend on client satisfaction to succeed with respect to our Solution. Our sales organization is dependent on the quality of our offerings, our business reputation, and the strong recommendations from existing clients. If our Solution does not function reliably or fails to meet client expectations in terms of performance and availability, clients could assert claims against us, terminate their contracts with us or publish negative feedback. This could damage our reputation and impair our ability to attract or retain clients. Furthermore, we provide professional services to clients to support their use of our Solution and to achieve measurable clinical, financial, and operational improvements. Any failure to maintain high-quality professional services, or a market perception that we do not maintain high-quality professional services, could harm our reputation, adversely affect our ability to sell our Solution to existing and prospective clients, and harm our business, results of operations, and financial condition.If our existing clients do not continue or renew their contracts with us, renew at lower fee levels, or decline to purchase additional technology and services from us, it could have a material adverse effect on our business, financial condition, and results of operations.We expect to derive a significant portion of our revenue from the renewal of existing client contracts and sales of additional technology and services to existing clients. As part of our growth strategy, for instance, we have recently focused on expanding our Solution among current clients, including Solutions with a more limited operating history, such as TEMS. As a result, selling additional technology and services is critical to our future business, revenue growth, and results of operations. Factors that may affect our ability to sell additional technology and services include, but are not limited to, the following:â€¢the price, performance, and functionality of our Solution;â€¢the availability, price, performance, and functionality of competing solutions;â€¢our ability to develop and sell complementary technology and services;â€¢the stability, performance, and security of our hosting infrastructure and hosting services;â€¢our ability to continuously deliver measurable improvements;â€¢health systemsâ€™ demand for professional services to augment their internal data analytics function;â€¢changes in healthcare laws, regulations, or trends; â€¢the business environment of our clients and, in particular, our clientsâ€™ financial performance and headcount reductions by our clients; andâ€¢the impact of macroeconomic challenges, including the impact of high inflationary and/or high interest rate environments, market volatility caused by bank failures and measures taken in response thereto, the tight labor market, and the impact of any natural disasters or public health emergencies, such as the COVID-19 pandemic, upon our clients.We generally enter into subscription contracts with our clients for access to our Solution. Many of these contracts have initial terms of one to three years. Most of our clients have no obligation to renew their subscriptions for our Solution after the initial term expires. Although we have long-term contracts with many clients, these contracts may be terminated by the client (generally, subject to providing us with prior notice before their term expires) for convenience or for certain specified reasons, including changes in the regulatory landscape, loss of certain third-party licenses, breach of our contractual obligations, including poor performance by us in areas that include repeated failures by us to provide specified levels of service over certain performance periods, or dissatisfaction with changes in our Solution, such as the deployment of Health Catalyst Ignite and the migration of existing DOS Subscription Clients thereto. 79We expect that future contracts will contain similar provisions. If any of our contracts with our clients are terminated, we may not be able to recover all fees due under the terminated contract and we will lose future revenue from that client, which may adversely affect our results of operations. In addition, our clients may negotiate terms less advantageous to us upon renewal, which may reduce our revenue from these clients. Our future results of operations also depend, in part, on our ability to upgrade and enhance our Solution. If our clients fail to renew their contracts, renew their contracts upon less favorable terms, or at lower fee levels or fail to purchase new technology and services from us, our revenue may decline or our future revenue growth may be constrained.Our results of operations have in the past fluctuated and may continue to fluctuate significantly, and if we fail to meet the expectations of securities analysts or investors, our stock price and the value of an investment in our common stock could decline substantially.Our results of operations are likely to fluctuate, and if we fail to meet or exceed the expectations of securities analysts or investors, the trading price of our common stock could decline. Moreover, our stock price may be based on expectations of our future performance that may be unrealistic or that may not be met. Some of the factors that could cause our financial performance and results of operations to fluctuate from quarter to quarter include:â€¢the extent to which our Solution achieves or maintains market acceptance;â€¢our ability to introduce new applications, updates, and enhancements to our existing applications on a timely basis;â€¢new competitors and the introduction of enhanced products and services from new or existing competitors;â€¢the length of our contracting and implementation cycles and our fulfillment periods for our Solution;â€¢the mix of revenue generated from professional services as compared to technology subscriptions;â€¢clients reducing or eliminating their spend with us in response to macroeconomic factors or otherwise;â€¢the financial condition of our current and future clients;â€¢changes in client budgets and procurement policies;â€¢changes in regulations or marketing strategies;â€¢the impact of macroeconomic challenges, including the high inflationary and/or high interest rate environments, market volatility caused by bank failures and measures taken in response thereto, and public health crises, such as the COVID-19 pandemic, on our clients, partners, and business;â€¢the amount and timing of our investment in research and development activities;â€¢the amount and timing of our investment in sales and marketing activities;â€¢technical difficulties or interruptions to our Solution, including related to updates to our technology or technology migrations, in particular, those related to our migration of existing DOS Subscription Clients to Health Catalyst Ignite;â€¢our ability to hire and retain qualified personnel;â€¢changes in the regulatory environment related to healthcare;â€¢regulatory compliance costs;80â€¢the timing, size, and integration success of potential future acquisitions; â€¢unforeseen legal expenses, including litigation and settlement costs; andâ€¢buying patterns of our clients and the related seasonality impacts on our business.Many of these factors are not within our control, and the occurrence of one or more of them might cause our results of operations to vary widely. For example, we have experienced, and expect that we will continue to experience, seasonality in the number of new clients that subscribe to our Solution; specifically, new clients (DOS Subscription Clients in particular) tend to subscribe to our Solution at higher rates in the second and fourth quarters of the year. Seasonality in our business may cause period-to-period fluctuations in certain of our operating results and financial metrics, and thus limit our ability to predict our future results. As such, we believe that quarter-to-quarter comparisons of our revenue and results of operations may not be meaningful and should not be relied upon as an indication of future performance.A significant portion of our operating expense is relatively fixed in nature in the short term, and planned expenditures are based in part on expectations regarding future revenue and profitability. Accordingly, unexpected revenue shortfalls, lower-than-expected revenue increases as a result of planned expenditures, and longer-than-expected impact on profitability and margins as a result of planned expenditures may decrease our gross margins and profitability and could cause significant changes in our results of operations from quarter to quarter. In addition, our future quarterly results of operations may fluctuate and may not meet the expectations of securities analysts or investors. If this occurs, the trading price of our common stock could fall substantially, either suddenly or over time.Our pricing may change over time and our ability to efficiently price our Solution will affect our results of operations and our ability to attract or retain clients.In the past, we have adjusted our prices as a result of offering new applications and services and client demand. For example, in the fourth quarter of 2018, we began to introduce new pricing for our Solution to new clients and, in 2015, we introduced our subscription model, in each case, the full effect of which we expected would be realized in future years. While we determine our prices based on prior experience, feedback from clients, and other factors and information, our assessments may not be accurate and we could be underpricing or overpricing our Solution, which may require us to continue to adjust our pricing model. Furthermore, as our applications and services change, then we may need to, or choose to, revise our pricing as our prior experience in those areas will be limited. Such changes to our pricing model or our inability to efficiently price our Solution could harm our business, results of operations, and financial condition and impact our ability to predict our future performance.If our Solution fails to provide accurate and timely information, or if our content or any other element of our Solution is associated with faulty clinical decisions or treatment, we could have liability to clients, clinicians, patients, or others, which could adversely affect our results of operations.Our Solution may be used by clients to support clinical decision-making by providers and interpret information about patient medical histories, treatment plans, medical conditions, and the use of particular medications. If our Solution is associated with faulty clinical decisions or treatment, then clients or their patients could assert claims against us that could result in substantial costs to us, harm our reputation in the industry, and cause demand for our Solution to decline. In addition, our analytics services may be used by our clients to inform clinical decision-making, provide access to patient medical histories, and assist in creating patient treatment plans. Therefore, if data analyses are presented incorrectly in our Solution or they are incomplete, or if we make mistakes in the capture or input of these data, adverse consequences, including death, may occur and give rise to product liability, medical malpractice liability, and other claims against us by clients, clinicians, patients, or others. We often have little control over data accuracy, yet a court or government agency may take the position that our storage and display of health information exposes us to personal injury liability or other liability for wrongful delivery or handling of healthcare services or erroneous health information.81Our clinical guidelines, algorithms, and protocols may be viewed as providing healthcare professionals with guidance on care management, care coordination, or treatment decisions. If our content, or content we obtain from third parties, contains inaccuracies, or we introduce inaccuracies in the process of implementing third-party content, it is possible that patients, clinicians, consumers, the providers of the third-party content, or others may sue us if they are harmed as a result of such inaccuracies. We cannot assure you that our software development, editorial, and other quality control procedures will be sufficient to ensure that there are no errors or omissions in any particular content or our software or algorithms.The assertion of such claims and ensuing litigation, regardless of its outcome, could result in substantial cost to us, divert managementâ€™s attention from operations, damage our reputation, and decrease market acceptance of our Solution. We attempt to limit by contract our liability for damages, have our clients assume responsibility for clinical treatment, diagnoses, medical oversight, and dosing decisions, and require that our clients assume responsibility for medical care and approve key algorithms, clinical guidelines, clinical protocols, content, and data. Despite these precautions, the allocations of responsibility and limitations of liability set forth in our contracts may not be enforceable, be binding upon patients, or otherwise protect us from liability for damages. Furthermore, general liability and errors and omissions insurance coverage and medical malpractice liability coverage may not continue to be available on acceptable terms or may not be available in sufficient amounts to cover one or more large claims against us. In addition, the insurer might disclaim coverage as to any future claim. One or more large claims could exceed our available insurance coverage. If any of these events occur, they could materially adversely affect our business, financial condition, or results of operations.Although we carry insurance covering medical malpractice claims in amounts that we believe are appropriate in light of the risks attendant to our business, successful medical liability claims could result in substantial damage awards that exceed the limits of our insurance coverage. In addition, professional liability insurance is expensive and insurance premiums may increase significantly in the future, particularly as we expand our Solution. As a result, adequate professional liability insurance may not be available to our providers or to us in the future at acceptable costs or at all.Any claims made against us that are not fully covered by insurance could be costly to defend against, result in substantial damage awards against us, and divert the attention of our management and our providers from our operations, which could have a material adverse effect on our business, financial condition, and results of operations. In addition, any claims may adversely affect our business or reputation.Future litigation against us could be costly and time-consuming to defend and could result in additional liabilities.We may from time to time be subject to legal proceedings and claims that arise in the ordinary course of business, such as claims brought by our clients or vendors in connection with commercial disputes, litigation related to intellectual property, and employment claims made by our current or former employees. Claims may also be asserted by or on behalf of a variety of other parties, including government agencies, patients or vendors of our clients, or stockholders. Any litigation involving us may result in substantial costs, operationally restrict our business, and may divert managementâ€™s attention and resources, which may seriously harm our business, overall financial condition, and results of operations. Insurance may not cover existing or future claims, be sufficient to fully compensate us for one or more of such claims, or continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, thereby reducing our results of operations and resulting in a reduction in the trading price of our stock.82We derive a significant portion of our revenue from our largest clients. The loss, termination, or renegotiation of any contract could negatively impact our results.Historically, we have relied on a limited number of clients for a significant portion of our total revenue and accounts receivable. Our three largest clients during 2023 comprised 5.5%, 3.6%, and 3.5% of our revenue, or 12.6% in the aggregate. Our three largest clients during 2022 comprised 4.1%, 3.7%, and 3.4% of our revenue, or 11.2% in the aggregate. The sudden loss of any of our largest clients or the renegotiation of any of our largest client contracts could adversely affect our results of operations. In the ordinary course of business, we engage in active discussions and renegotiations with our clients in respect of our Solution and the terms of our client agreements, including our fees. As our clientsâ€™ businesses respond to market dynamics and financial pressures, and as our clients make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, we expect that certain of our clients will, from time to time, seek to restructure their agreements with us. In the ordinary course, we renegotiate the terms of our agreements with our clients in connection with renewals or extensions of these agreements. These discussions and future discussions could result in reductions to the fees and changes to the scope of services contemplated by our original client contracts and consequently could negatively impact our revenue, business, and prospects.Because we rely on a limited number of clients for a significant portion of our revenue, we depend on the creditworthiness of these clients. Our clients are subject to a number of risks including reductions in payment rates from governmental payors, higher than expected healthcare costs, and lack of predictability of financial results when entering new lines of business. If the financial condition of our clients declines, our credit risk could increase. Should one or more of our significant clients declare bankruptcy, be declared insolvent, or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this

could adversely affect our ongoing revenue, the collectability of our accounts receivable, our bad debt reserves and net income.Because we generally recognize technology and professional services revenue ratably over the term of the contract for our services, a significant downturn in our business may not be reflected immediately in our results of operations, which increases the difficulty of evaluating our future financial performance.We generally recognize technology and professional services revenue ratably over the term of a contract. As a result, a substantial portion of our revenue is generated from contracts entered into during prior periods. Consequently, a decline in new contracts in any quarter may not affect our results of operations in that quarter but could reduce our revenue in future quarters. Additionally, the timing of renewals or non-renewals of a contract during any quarter may only affect our financial performance in future quarters. For example, the non-renewal of a subscription agreement late in a quarter will have minimal impact on revenue for that quarter but will reduce our revenue in future quarters. Accordingly, the effect of significant declines in sales may not be reflected in our short-term results of operations, which would make these reported results less indicative of our future financial results. By contrast, a non-renewal occurring early in a quarter may have a significant negative impact on revenue for that quarter and we may not be able to offset a decline in revenue due to non-renewal with revenue from new contracts entered into in the same quarter. In addition, we may be unable to quickly adjust our costs in response to reduced revenue.If we are unable to implement and maintain effective internal controls over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected.As a public company, we are required to maintain internal controls over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal controls over financial reporting. We are also required to provide an annual management report on the effectiveness of our internal control over financial reporting. Many of the internal controls we have implemented pursuant to the Sarbanes-Oxley Act are process controls with respect to which a material weakness may be found whether or not any error has been identified in our reported financial statements. This may be confusing to investors and result in damage to our 83reputation, which may harm our business. Additionally, the proper design and assessment of internal controls over financial reporting are subject to varying interpretations, and, as a result, application in practice may evolve over time as new guidance is provided by regulatory and governing bodies and as common practices evolve. This could result in continuing uncertainty regarding the proper design and assessment of internal controls over financial reporting and higher costs necessitated by ongoing revisions to internal controls. We must continue to monitor and assess our internal control over financial reporting. If in the future we have any material weaknesses, we may not detect errors on a timely basis and our financial statements may be materially misstated. Additionally, if we are unable to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, are unable to assert that our internal controls over financial reporting are effective, identify material weaknesses in our internal controls over financial reporting, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal controls over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of our common stock could be adversely affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.We may acquire other companies or technologies, which could divert our managementâ€™s attention, result in dilution to our stockholders, and otherwise disrupt our operations and we may have difficulty integrating any such acquisitions successfully or realizing the anticipated benefits therefrom, any of which could have an adverse effect on our business, financial condition, and results of operations.We may seek to acquire or invest in businesses, applications, services, or technologies that we believe could complement or expand our Solution, enhance our technical capabilities, or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. We have in the past and may in the future have difficulty integrating acquired businesses. During 2020 we acquired Able Health, Healthfinch, and Vitalware, during 2021 we acquired Twistle, during 2022 we acquired ARMUS and KPI Ninja, during 2023 we acquired ERS, and during 2024 we acquired Carevive and Lumeon. We may have difficulty cross-selling our Solution to acquired clients, and we may have difficulty integrating, or incur integration-related costs associated with, newly acquired team members.We have limited experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations, and technologies successfully, or effectively manage the combined business following the acquisition. We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including, but not limited to:â€¢inability to integrate or benefit from acquired technologies or services in a profitable manner;â€¢unanticipated costs or liabilities associated with the acquisition;â€¢difficulty integrating the accounting systems, operations, and personnel of the acquired business;â€¢difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;â€¢difficulty converting the clients of the acquired business onto our DOS platform and contract terms, including disparities in the revenue, licensing, support, or professional services model of the acquired business;â€¢diversion of managementâ€™s attention from other business concerns;â€¢adverse effects on our existing business relationships with business partners and clients as a result of the acquisition;â€¢the potential loss of key employees;84â€¢use of resources that are needed in other parts of our business; andâ€¢use of substantial portions of our available cash to consummate the acquisition.In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. If our acquisitions do not yield expected returns or fair value estimates deteriorate, we may be required to take charges to our results of operations based on this impairment assessment process, which could adversely affect our results of operations. Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our results of operations. In addition, if an acquired business fails to meet our expectations, our business, financial condition, and results of operations may suffer. Also, the anticipated benefit of any acquisition may not materialize or may be prohibited by contractual obligations we may enter into in the future with lenders or other third parties. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities, or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing, or size of future acquisitions, or the effect that any such transactions might have on our results of operations.Because competition for our target employees is intense, we may not be able to attract and retain the highly skilled employees we need to support our continued growth.To continue to execute on our growth and operating plan, we must attract and retain highly qualified personnel, and we may modify our compensation program and practices for our team members. Competition for such personnel is intense, especially for senior sales executives and software engineers with high levels of experience in designing and developing applications and consulting and analytics services. We may not be successful in attracting and retaining qualified personnel, including due to changes to our compensation program or practices. We have from time to time in the past experienced, and we expect to continue to experience in the future, difficulty in hiring and retaining highly skilled employees with appropriate qualifications. For example, the 2023 Restructuring Plan and other restructurings may result in attrition beyond our intended reduction in force or may adversely impact our ability to recruit and hire qualified personnel in the future. In addition, our search for replacements for departed employees may cause uncertainty regarding the future of our business, impact employee hiring and retention, and adversely impact our revenue, results of operations, and financial condition. Many of the companies with which we compete for experienced personnel have greater resources than we have. In addition, in making employment decisions, particularly in the Internet and high-technology industries, job candidates often consider the value of the equity awards they may receive in connection with their employment. Volatility in the price of our stock or failure to obtain stockholder approval for increases in the number of shares available for grant under our equity plans may, therefore, adversely affect our ability to attract or retain key employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.We depend on our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.Our success depends largely upon the continued services of our key executive officers and recruitment of additional highly skilled employees. From time to time, there may be changes in our senior management team resulting from the hiring or departure of executives, which could disrupt our business. Several of our senior leaders are active members of the Church of Jesus Christ of Latter-Day Saints. There is a risk that in the future, one or more of these individuals could receive a call to serve in a full-time capacity for the church, which has already occurred, including with our former Chief Operating Officer, Paul Horstmeier, who stepped down from his role of Chief Operating Officer effective March 31, 2023. Hiring executives with needed skills or the replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives. In addition, competition for qualified management in our industry is intense. Many of the companies with which we compete for management personnel have greater financial and other resources than we do. We have not entered into term-based employment agreements with our executive officers. All of our employees are â€œat-willâ€ employees, and their employment can be terminated by us or them at any time, for any reason. The departure of key personnel 85could adversely affect the conduct of our business. In such event, we would be required to hire other personnel to manage and operate our business, and there can be no assurance that we would be able to employ a suitable replacement for the departing individual, or that a replacement could be hired on terms that are favorable to us. In addition, volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart. If we are not able to retain any of our key management personnel, our business could be harmed.Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity, and teamwork fostered by our culture, which could harm our business.We believe that our corporate culture has been an important contributor to our success, which we believe fosters innovation, teamwork, and passion for providing high levels of client satisfaction. As we continue to grow, we must effectively integrate, develop, and motivate a growing number of new employees. As a result, we may find it difficult to maintain our corporate culture, which could limit our ability to innovate and operate effectively. Any failure to preserve our culture could also negatively affect our ability to retain and recruit personnel, maintain our performance, or execute on our business strategy.If we fail to effectively manage our growth and organizational change, our business and results of operations could be harmed.We have experienced, and may continue to experience, rapid growth and organizational change, which has placed, and may continue to place, significant demands on our management, operational, and financial resources. In addition, if we fail to successfully integrate new team members or fail to effectively manage organizational changes, it could harm our culture, business, financial condition and results of operations. For example, the expense reduction measures taken in connection with the 2023 Restructuring Plan may result in unintended consequences and costs, including costs associated with attrition beyond our intended reduction in force, a decrease in morale among team members following the completion of the 2023 Restructuring Plan, adverse impacts in our ability to recruit and hire qualified personnel in the future, and the loss of institutional knowledge and expertise, which could result in losses in future periods or otherwise prevent us from realizing, in full or in part, the anticipated benefits and savings from the 2023 Restructuring Plan. In addition, we must continue to maintain, and may need to enhance, our information technology infrastructure and financial and accounting systems and controls, as well as manage expanded operations in geographically distributed locations, which may include offshore and near shore, which will place additional demands on our resources and operations. We also must attract, train, and retain a significant number of qualified sales and marketing personnel, professional services personnel, software engineers, technical personnel, service offering personnel, and management personnel. At times, this will require us to invest in and commit significant financial, operational, and management resources to grow and change in these areas without undermining the corporate culture that has been critical to our growth so far. If we do not achieve the benefits anticipated from these investments or organizational changes, or if the realization of these benefits is delayed, our results of operations may be adversely affected. If we fail to provide effective client training on our Solution and high-quality client support, our business and reputation could suffer. Failure to effectively manage our growth or organizational changes could lead us to over-invest or under-invest in technology and operations; result in weaknesses in our infrastructure, systems, or controls; give rise to operational mistakes, losses, or loss of productivity or business opportunities; reduce client or user satisfaction; limit our ability to respond to competitive pressures; and result in loss of team members and reduced productivity of remaining team members. Our growth or organizational changes could require significant capital expenditures and may divert financial resources and management attention from other projects, such as the development of new or enhanced services or the acquisition of suitable businesses or technologies. If our management is unable to effectively manage our growth or organizational changes, our expenses may increase more than expected, cost savings may not be realized, our revenue could decline or may grow more slowly than expected, and we may be unable to implement our business strategy, and may adversely affect our business, financial condition and results of operations.We may not grow at the rates we historically have achieved or at all, even if our key metrics may indicate growth.86We have experienced periods of significant growth, including in the last five years. At times, our growth has moderated. Future revenue may not grow at the same rates experienced during times of significant growth or may decline. Further, larger revenue opportunities that include portions of our Solution with less operating history could cause our growth to become less predictable and/or choppier relative to prior periods. Our future growth will depend, in part, on our ability to grow our revenue from existing clients, to complete sales to potential future clients, to expand our client and member bases, to prevent churn of existing clients, and to develop new solutions. Our future growth may also be driven by expansion into adjacent markets and/or international expansion. We can provide no assurances that we will be successful in executing on these growth strategies or that we will continue to grow our revenue or to generate net income. Our historical results may not be indicative of future performance. Our ability to execute on our existing sales pipeline, create additional sales pipelines, and expand our client base depends on, among other things, the attractiveness of our Solution relative to those offered by our competitors, our ability to demonstrate the value of our existing and future services, and our ability to attract and retain a sufficient number of qualified sales and marketing leadership and support personnel. In addition, our existing clients may be slower to adopt our Solution than we currently anticipate, which could adversely affect our results of operations and growth prospects.Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. The estimates and forecasts relating to the size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and growth forecasts, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.Risks Related to Data and Intellectual PropertyFailure by our clients to obtain proper permissions and waivers may result in claims against us or may limit or prevent our use of data, which could harm our business.We require our clients to provide necessary notices and to obtain necessary permissions and waivers for use and disclosure of the information that we receive, and we require contractual assurances from them that they have done so and will do so. If they do not obtain necessary permissions and waivers, then our use and disclosure of information that we receive from them or on their behalf may be restricted or prohibited by state, federal, or international privacy or data protection laws, or other related privacy and data protection laws. This could impair our functions, processes, and databases that reflect, contain, or are based upon such data and may prevent the use of such data, including our ability to provide such data to third parties that are incorporated into our service offerings. Furthermore, this may cause us to breach obligations to third parties to whom we may provide such data, such as third-party service or technology providers that are incorporated into our service offerings. In addition, this could interfere with or prevent data sourcing, data analyses, or limit other data-driven activities that benefit us. Moreover, we may be subject to claims, civil and/or criminal liability or government or state attorneys general investigations for use or disclosure of information by reason of lack of valid notice, permission, or waiver. These claims, liabilities or government or state attorneys general investigations could subject us to unexpected costs and adversely affect our financial condition and results of operations.87Our business and operations may suffer in the event of information technology system failures, cyberattacks, or deficiencies in our cybersecurity.Our Solution involves the storage and transmission of our clientsâ€™ proprietary information, including personal or identifying information regarding patients and their protected health information (PHI). Despite the implementation of security measures, our information technology systems and those of our clients, contractors, consultants, and collaborators are vulnerable to attack, damage and interruption from cyberattacks, â€œphishingâ€ attacks, computer viruses and malware (e.g., ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication, and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Further,

political and international uncertainty, competition and disputes, including the war involving Russia and Ukraine, could create tension that results in cyber-attacks or cybersecurity incidents that could either directly or indirectly impact our operations. Because the techniques used to obtain unauthorized access or sabotage systems change frequently and generally are not identified until they are launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Moreover, the detection, prevention, and remediation of known or unknown security vulnerabilities, including those arising from third-party hardware or software, may result in additional direct or indirect costs and management time. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. As a result, unauthorized access or security breaches as a result of third-party action, employee error, malfeasance, or otherwise could result in the loss or inappropriate use of information, litigation, indemnity obligations, damage to our reputation, and other liability such as government or state Attorney General investigations. We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could adversely affect our ability to attract new clients, cause existing clients to elect to not renew their subscriptions, result in reputational damage, or subject us to third-party lawsuits, regulatory fines, mandatory disclosures, or other action or liability, which could adversely affect our results of operations. Our general liability insurance may not be adequate to cover all potential claims to which we are exposed and may not be adequate to indemnify us for liability that may be imposed or the losses associated with such events, and in any case, such insurance may not cover all of the specific costs, expenses, and losses we could incur in responding to and remediating a security breach. A security breach of another significant provider of cloud-based solutions may also negatively impact the demand for our Solution.Our Solution is dependent on our ability to source data from third parties, and such third parties could take steps to block our access to data, or increase fees or impose fees for such access, which could impair our ability to provide our Solution, limit the effectiveness of our Solution or adversely affect our financial condition and results of operations.Our data platform requires us to source data from multiple clinical, financial, and operational data sources, which sources are also typically third-party vendors of our clients. The functioning of our analytics applications and our ability to perform analytics services is predicated on our ability to establish interfaces that download the relevant data from these source systems on a repeated basis and in a reliable manner. We may encounter vendors that engage in information blocking practices that may inhibit our ability to access the relevant data on behalf of clients or impose new or additional costs. 88In 2020, the U.S. Department of Health and Human Servicesâ€™ Office of the National Coordinator for Health Information Technology (ONC) and the Centers for Medicare and Medicaid Services promulgated final rules to support access, exchange, and use of electronic health information (EHI), referred to as the Final Rule. The Final Rule is intended to clarify provisions of the 21st Century Cures Act regarding interoperability and information blocking, and, subject to the interpretations of the Final Rule, and exceptions to what constitutes information blocking, may create significant new requirements for healthcare industry participants. The Final Rule requires certain electronic health record technology to incorporate standardized application programming interfaces to allow individuals to securely and easily access structured EHI using smartphone applications, provides patients with certain rights to electronic access to their EHI (structured and/or unstructured) at no cost and implements the information blocking provisions of the 21st Century Cures Act, subject to eight exceptions that will not be considered information blocking as long as specific conditions are met. In April 2023, the ONC issued a notice of proposed rulemaking that would modify certain components of the Final Rule, including modifying and expanding certain exceptions to the information blocking regulations, which are intended to support information sharing. The impact of the Final Rule on our business is unclear at this time, due to, among other things, uncertainty regarding the interpretation of safe harbors and exceptions to the Final Rule by industry participants and regulators.The Final Rule focuses on health plans, payors, and healthcare providers and proposes measures to enable patients to move from health plan to health plan, provider to provider, and have both their clinical and administrative information travel with them. It is unclear whether the Final Rule may benefit us in that certain EHR vendors will no longer be permitted to interfere with our attempts at integration, but the rules may also make it easier for other similar companies to enter the market, creating increased competition, and reducing our market share. It is unclear at this time what the costs of compliance with the proposed rules, if adopted, would be, and what additional risks there may be to our business. If we face limitations on the development of data interfaces and other information blocking practices, including the imposition of increased fees, our data access and ability to download relevant data may be limited, which could adversely affect our ability to provide our Solution as effectively as possible. Any steps we take to enforce the anti-information blocking provisions of the 21st Century Cures Act could be costly, could distract management attention from the business, and could have uncertain results.We rely on third-party providers, including Microsoft Azure, for computing infrastructure, network connectivity, and other technology-related services needed to deliver our Solution. Any disruption in the services provided by such third-party providers could adversely affect our business and subject us to liability.Our Solution is generally hosted from and uses computing infrastructure provided by third parties, including Microsoft Azure and other computing infrastructure service providers. We have migrated and expect to continue to migrate a significant portion of our DOS and analytics application computing infrastructure needs to Microsoft Azure. We have made and expect to continue to make substantial investments in transitioning DOS clients from our own managed data center to Microsoft Azure and the migration of clients to the next iteration of our DOS platform. We anticipate that this transition will increase the cost of hosting our technology and negatively impact our technology gross margin. Such migrations are risky and may cause disruptions to our Solution, service outages, downtime, or other problems and may increase our costs. Despite precautions taken during such transitions, any unsuccessful transition of technology may impair clientsâ€™ use of our technology which may cause greater costs or downtime and which may lead to, among other things, client dissatisfaction and non-renewals.Our computing infrastructure service providers have no obligation to renew their agreements with us on commercially reasonable terms or at all. If we are unable to renew these agreements on commercially reasonable terms, or if one of our computing infrastructure service providers is acquired, we may be required to transition to a new provider and we may incur significant costs and possible service interruption in connection with doing so. Problems faced by our computing infrastructure service providers, including those operated by Microsoft, could adversely affect the experience of our clients. Microsoft Azure and other infrastructure vendors have had and may in the future experience significant service outages. Additionally, if our computing infrastructure service providers are unable to keep up with our growing needs for capacity, this could have an adverse effect on our business. For example, a rapid expansion of our business could affect our service levels or cause our third-party hosted systems to fail. Our agreements with third-party computing infrastructure service providers may not entitle us to service level credits that correspond with those we offer to our clients.89Any changes in third-party service levels at our computing infrastructure service providers, or any related disruptions or performance problems with our Solution, could adversely affect our reputation and may damage our clientsâ€™ data, information and/or stored files, result in lengthy interruptions in our services, or result in potential losses of client data. Interruptions in our services might reduce our revenue, cause us to issue refunds to clients for prepaid and unused subscriptions, subject us to service level credit claims and potential liability, allow our clients to terminate their contracts with us, or adversely affect our renewal rates.We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties, and our own systems for providing our Solution to our users, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation, potentially require us to issue credits to our clients, and negatively impact our relationships with users or clients, adversely affecting our brand and our business.In addition to the services we provide from our offices, we serve our clients primarily from third-party data-hosting facilities. These facilities are vulnerable to damage or interruption from earthquakes, floods, fires, power loss, telecommunications failures, and similar events. They are also subject to break-ins, sabotage, intentional acts of vandalism, and similar misconduct. Their systems and servers could also be subject to hacking, spamming, ransomware, computer viruses or other malicious software, denial of service attacks, service disruptions, including the inability to process certain transactions, phishing attacks, and unauthorized access attempts, including third parties gaining access to usersâ€™ accounts using stolen or inferred credentials or other means, and may use such access to prevent use of usersâ€™ accounts. Despite precautions taken at these facilities, the occurrence of a natural disaster or an act of terrorism, a decision to close the facilities without adequate notice, or other unanticipated problems at two or more of the facilities could result in lengthy interruptions in our services. Even with our disaster recovery arrangements, our Solution could be interrupted.Our ability to deliver our Internet- and telecommunications-based services is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity, and security for providing reliable Internet access and services and reliable mobile device, telephone, facsimile, and pager systems, all at a predictable and reasonable cost. We have experienced and expect that we will experience interruptions and delays in services and availability of our Solution from time to time. We rely on internal systems as well as third-party vendors, including data center, bandwidth, and telecommunications equipment or service providers, to provide our Solution. We do not maintain redundant systems or facilities for portions of our Solution. In the event of a catastrophic event with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could negatively impact our relationship with users or clients. To operate without interruption, both we and our service providers must guard against:â€¢damage from fire, power loss, and other natural disasters;â€¢communications failures;â€¢software and hardware errors, failures, and crashes;â€¢security breaches, computer viruses, ransomware, and similar disruptive problems; andâ€¢other potential interruptions.Any disruption in the network access, telecommunications, or co-location services provided by these third-party providers or any failure of or by these third-party providers or our own systems to handle the current or higher volume of use could significantly harm our ability to deliver our Solution and our business. We exercise limited control over these third-party vendors, which increases our vulnerability to problems with the services they provide.90Any errors, failures, interruptions, or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with users and clients, adversely affect our brands and business, and expose us to third-party liabilities. The insurance coverage under our policies may not be adequate to compensate us for all losses that may occur. In addition, we cannot provide assurance that we will continue to be able to obtain adequate insurance coverage at an acceptable cost.The reliability and performance of the Internet may be harmed by increased usage or by denial-of-service attacks. The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage as well as the availability of the Internet to us for delivery of our Internet-based services.We typically provide service level commitments under our client contracts. If we fail to meet these contractual commitments, we could be obligated to provide credits or refunds for prepaid amounts related to unused subscription services or face contract terminations, which could adversely affect our results of operations. Finally, recent changes in law could impact the cost and availability of necessary Internet infrastructure. Increased costs and/or decreased availability would negatively affect our results of operations.Our business could be adversely impacted by changes in laws and regulations related to the Internet or changes in access to the Internet generally.The future success of our business depends upon the continued use of the Internet as a primary medium for communication, business applications, and commerce. Federal or state government bodies or agencies have in the past adopted, and may in the future adopt, laws or regulations affecting the use of the Internet as a commercial medium. Legislators, regulators, or government bodies or agencies may also make legal or regulatory changes or interpret or apply existing laws or regulations that relate to the use of the Internet in new and materially different ways. Changes in these laws, regulations, or interpretations could require us to modify our Solution in order to comply with these changes, to incur substantial additional costs or divert resources that could otherwise be deployed to grow our business, or expose us to unanticipated civil or criminal liability, among other things.In addition, government agencies and private organizations have imposed, and may in the future impose, additional taxes, fees, or other charges for accessing the Internet or commerce conducted via the Internet. Internet access is frequently provided by companies that have significant market power and could take actions that degrade, disrupt, or increase the cost of our clientsâ€™ use of our Solution, which could negatively impact our business. Net neutrality rules, which were designed to ensure that all online content is treated the same by Internet service providers and other companies that provide broadband services were repealed by the Federal Communications Commission effective June 2018. The repeal of the net neutrality rules could force us to incur greater operating expenses or our clientsâ€™ use of our Solution could be adversely affected, either of which could harm our business and results of operations. These developments could limit the growth of Internet-related commerce or communications generally or result in reductions in the demand for Internet-based platforms and services such as ours, increased costs to us or the disruption of our business. In addition, as the Internet continues to experience growth in the numbers of users, frequency of use, and amount of data transmitted, the use of the Internet as a business tool could be adversely affected due to delays in the development or adoption of new standards and protocols to handle increased demands of Internet activity, security, reliability, cost, ease-of-use, accessibility, and quality of service. The performance of the Internet and its acceptance as a business tool has been adversely affected by â€œviruses,â€ â€œworms,â€ and similar malicious programs and the Internet has experienced a variety of outages and other delays as a result of damage to portions of its infrastructure. If the use of the Internet generally, or our Solution specifically, is adversely affected by these or other issues, we could be forced to incur substantial costs, demand for our Solution could decline, and our results of operations and financial condition could be harmed.91Our Solution utilizes open-source software, and any failure to comply with the terms of one or more of these open-source licenses could adversely affect our business.We use software modules licensed to us by third-party authors under â€œopen-sourceâ€ licenses in our Solution. Some open-source licenses contain affirmative obligations or restrictive terms that could adversely impact our business, such as restrictions on commercialization or obligations to make available modified or derivative works of certain open-source code. If we were to combine our proprietary software with certain open-source software subject to these licenses in a certain manner, we could, under certain open-source licenses, be required to release or otherwise make available the source code to our proprietary software to the public. This would allow our competitors to create similar products with lower development effort and time and ultimately could result in a loss of product sales for us.Although we employ practices designed to manage our compliance with open-source licenses and protect our proprietary source code, we may inadvertently use open-source software in a manner we do not intend and that could expose us to claims for breach of contract and intellectual property infringement. If we are held to have breached the terms of an open-source software license, we could be required to, among other things, seek licenses from third parties to continue offering our products on terms that are not economically feasible, pay damages to third parties, to re-engineer our products, to discontinue the sale of our products if re-engineering cannot be accomplished on a timely basis, or to make generally available, in source code form, a portion of our proprietary code, any of which could adversely affect our business, results of operations, and financial condition. The terms of many open-source licenses have not been interpreted by U.S. courts, and, as a result, there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to commercialize our Solution.We employ third-party licensed software and software components for use in or with our Solution, and the inability to maintain these licenses or the presence of errors in the software we license could limit the functionality of our Solution and result in increased costs or reduced service levels, which would adversely affect our business.Our software applications might incorporate or interact with certain third-party software and software components (other than open-source software), such as data visualization software, obtained under licenses from other companies. We pay these third parties a license fee or royalty payment. We anticipate that we will continue to use such third-party software in the future. Although we believe that there are commercially reasonable alternatives to the third-party software we currently make available, this may not always be the case, or it may be difficult or costly to replace. Furthermore, these third parties may increase the price for licensing their software, which could negatively impact our results of operations. Our use of additional or alternative third-party software could require clients to enter into license agreements with third parties. In addition, if the third-party software we make available has errors or otherwise malfunctions, or if the third-party terminates its agreement with us, the functionality of our Solution may be negatively impacted and our business may suffer.Any failure to protect our intellectual property rights could impair our ability to protect our proprietary technology and our brand.Our success and ability to compete depend in part upon our intellectual property. As of DecemberÂ 31, 2023, we had filed applications for a number of patents, and we have fourteen issued U.S. patents, four issued Canadian patents, one issued Great Britain patent, and one issued European patent, as well as one utility patent application pending in the United States. We also had twenty-eight registered trademarks in the United States, Singapore, United Arab Emirates, and China. We also rely on copyright and trademark laws, trade secret protection, and confidentiality or license agreements with our employees, clients, partners, and others to protect our intellectual property rights. However, the steps we take to protect our intellectual property rights may be inadequate. For example, other parties, including our competitors, may independently develop similar technology, duplicate our services, or design around our intellectual property and, in such cases, we may not be able to assert our intellectual property rights against such parties. 92Further, our contractual arrangements may not effectively prevent disclosure of our confidential information or provide an adequate remedy

in the event of unauthorized disclosure of our confidential information, and we may be unable to detect the unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. We make business decisions about when to seek patent protection for a particular technology and when to rely upon trade secret protection, and the approach we select may ultimately prove to be inadequate. Even in cases where we seek patent protection, there is no assurance that the resulting patents will effectively protect every significant feature of our Solution, technology, or proprietary information, or provide us with any competitive advantages. Moreover, we cannot guarantee that any of our pending patent applications will issue or be approved. The United States Patent and Trademark Office and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process and after a patent has issued. There are situations in which noncompliance can result in abandonment or lapse of the patent, or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs, our competitors might be able to enter the market, which would have a material adverse effect on our business. Effective trademark, copyright, patent, and trade secret protection may not be available in every country in which we conduct business. Further, intellectual property law, including statutory and case law, particularly in the United States, is constantly developing, and any changes in the law could make it harder for us to enforce our rights.In order to protect our intellectual property rights, we may be required to spend significant resources to monitor and protect these rights. Litigation brought to protect and enforce our intellectual property rights could be costly, time-consuming, and distracting to management and could result in the impairment or loss of portions of our intellectual property. Furthermore, our efforts to enforce our intellectual property rights may be met with defenses, counterclaims, and countersuits attacking the validity and enforceability of our intellectual property rights. An adverse determination of any litigation proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly and could put our related pending patent applications at risk of not issuing. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course of litigation, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Negative publicity related to a decision by us to initiate such enforcement actions against a client or former client, regardless of its accuracy, may adversely impact our other client relationships or prospective client relationships, harm our brand and business, and could cause the market price of our common stock to decline. Our failure to secure, protect, and enforce our intellectual property rights could adversely affect our brand and our business.We may be sued by third parties for alleged infringement of their proprietary rights or misappropriation of intellectual property.There is considerable patent and other intellectual property development activity in our industry. Our future success depends in part on not infringing upon the intellectual property rights of others. Our competitors, as well as a number of other entities and individuals, including so-called non-practicing entities (NPEs), may own or claim to own intellectual property relating to our Solution. From time to time, third parties have claimed or may claim that we are infringing upon their intellectual property rights or that we have misappropriated their intellectual property. For example, in some cases, very broad patents are granted that may be interpreted as covering a wide field of healthcare data storage and analytics solutions or machine learning and predictive modeling methods in healthcare. As competition in our market grows, the possibility of patent infringement, trademark infringement, and other intellectual property claims against us increases. In the future, we expect others to claim that our Solution and underlying technology infringe or violate their intellectual property rights. In a patent infringement claim against us, we may assert, as a defense, that we do not infringe the relevant patent claims, that the patent is invalid or both. 93The strength of our defenses will depend on the patents asserted, the interpretation of these patents, and our ability to invalidate the asserted patents. However, we could be unsuccessful in advancing non-infringement and/or invalidity arguments in our defense. In the United States, issued patents enjoy a presumption of validity, and the party challenging the validity of a patent claim must present clear and convincing evidence of invalidity, which is a high burden of proof. Conversely, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof. We may be unaware of the intellectual property rights that others may claim cover some or all of our technology or services. Because patent applications can take years to issue and are often afforded confidentiality for some period of time there may currently be pending applications, unknown to us, that later result in issued patents that could cover one or more aspects of our technology and services. Any claims or litigation could cause us to incur significant expenses and, whether or not successfully asserted against us, could require that we pay substantial damages, ongoing royalty or license payments, or settlement fees, prevent us from offering our Solution or using certain technologies, require us to re-engineer all or a portion of our DOS platform, or require that we comply with other unfavorable terms. We may also be obligated to indemnify our clients or business partners or pay substantial settlement costs, including royalty payments, in connection with any such claim or litigation and to obtain licenses, modify applications, or refund fees, which could be costly. Even if we were to prevail in such a dispute, any litigation regarding our intellectual property could be costly and time-consuming and divert the attention of our management and key personnel from our business operations.94Risks Related to Governmental RegulationRisks Related to Healthcare and Data Privacy and Security RegulationActual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.â€¢Health information privacy and security laws. There are numerous federal and state laws and regulations that govern the privacy and security of health information. In particular, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder (collectively, HIPAA) imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of PHI, as defined under HIPAA. By processing and maintaining PHI on behalf of our covered entity clients, we are a HIPAA business associate and are required to enter into business associate agreements (BAAs) with our covered entity clients to safeguard PHI, as well as BAAs with our subcontractors that access or otherwise process PHI on our behalf. We may not be able to adequately address the business risks created by HIPAA implementation. Furthermore, we are unable to predict what changes to HIPAA or other laws or regulations might be made in the future or how those changes could affect our business or the costs of compliance. We are unable to predict what, if any, impact the changes in such standards will have on our compliance costs or our Solution. Penalties for failure to comply with a requirement of HIPAA vary significantly depending on the nature of violation and could include civil monetary or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneysâ€™ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. Certain states have also adopted privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future clients and strategic partners.Some of our analytics applications, including, for example, one of our benchmarking applications, require that we obtain permissions consistent with HIPAA to provide â€œdata aggregation servicesâ€ and the right to create de-identified information and to use and disclose such de-identified information. We may require large sets of de-identified information to enable us to continue to develop machine learning algorithms that enhance our Solution. If we are unable to secure these rights in client BAAs or as a result of any future changes to HIPAA or other applicable laws, we may face limitations on the use of PHI and our ability to use de-identified information that could negatively affect the scope of our Solution as well as impair our ability to provide upgrades and enhancements to our Solution. We outsource important aspects of the storage and transmission of client information and PHI, and thus rely on third parties to manage functions that have material cybersecurity risks. We attempt to address these risks by requiring outsourcing subcontractors who handle client information to sign BAAs contractually requiring those subcontractors to adequately safeguard PHI in a similar manner that applies to us and in some cases by requiring such outsourcing subcontractors to undergo thirdâ€‘party security examinations as well as to protect the confidentiality of other sensitive client information. In addition, we periodically hire thirdâ€‘party security experts to assess and test our security measures. However, we cannot be assured that these contractual measures and other safeguards will adequately protect us from the risks associated with the storage and transmission of our clients' confidential and proprietary information and PHI.95â€¢Consumer protection laws. Furthermore, the Federal Trade Commission (FTC) also has authority to initiate enforcement actions against entities that mislead customers about HIPAA compliance, make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5(a) of the FTC Act. According to the FTC, failing to take appropriate steps to keep consumersâ€™ personal information secure can also constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTC Act. The FTC expects a companyâ€™s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Additionally, federal and state consumer protection laws are increasingly being applied by FTC and states' attorneys general to regulate the collection, use, storage, and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content.â€¢State data protection laws. Certain states have also adopted privacy and security laws and regulations, which govern the privacy, processing, and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future clients and strategic partners. For example, California adopted the CCPA, which went into effect on January 1, 2020. The CCPA established a privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the state of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. Additionally, the CPRA generally went into effect on January 1, 2023 and significantly amends the CCPA. It imposed additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Similar laws have passed in other states, and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. If we fail to comply with any of these privacy laws that apply to us, and are subject to the aforementioned penalties, our business and financial results could be adversely affected.â€¢GDPR and foreign data privacy protection laws. In addition, many foreign governments have established or are in the process of establishing privacy and data security legal frameworks governing the collection, use and disclosure of personal information obtained from their residents. For example, in Europe, the GDPR went into effect on May 25, 2018. The GDPR imposes data protection requirements for processing the personal data of individuals within the European Economic Area (EEA) relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the documentation we must retain, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to â‚¬20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. The GDPR has increased our responsibility and potential liability in relation to personal data that we process, and we may be required to put in place mechanisms to ensure compliance with GDPR. In addition, the GDPR increases the scrutiny of transfers of personal data from the EEA to the United States and other jurisdictions that the European Commission does not recognize as having â€œadequateâ€ data protection laws and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remain uncertain. Case law from the Court of Justice of the European Union (CJEU) states that reliance on the standard contractual clauses - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. 96On October 7, 2022, President Biden signed an Executive Order on â€˜Enhancing Safeguards for United States Intelligence Activitiesâ€™ which introduced new redress mechanisms and binding safeguards to address the concerns raised by the CJEU in relation to data transfers from the EEA to the United States and which formed the basis of the new EU-US Data Privacy Framework (DPF), as released on December 13, 2022. The European Commission adopted its Adequacy Decision in relation to the DPF on July 10, 2023, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. The DPF also introduced a new redress mechanism for EU citizens which addresses a key concern in the previous CJEU judgments and may mean transfers under standard contractual clauses are less likely to be challenged in future. We currently maintain localized infrastructure and third-party relationships to limit the risk of data transfer of personal data outside of the EEA and the UK. In addition, we rely on the EU standard contractual clauses and the UK Addendum to the EU standard contractual clauses as relevant to address any potential transfer of personal data outside the EEA and the UK, including to the United States, with respect to both intragroup and third-party transfers. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses. Data protection authorities of the different EEA member states may also interpret GDPR differently, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data in the EEA. Any failure by us to comply with GDPR could result in proceedings or actions against us by governmental entities or others, which may subject us to significant penalties and negative publicity, require us to change our business practices, and increase our costs and severely disrupt our business. Further, from January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g., fines up to the greater of â‚¬20 million (Â£17.5 million) or 4% of global turnover. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a UK GDPR data transfer mechanism to U.S. entities self-certified under the UK Extension to the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. â€¢Canadian data privacy protection laws. Similarly, Canadaâ€™s Personal Information Protection and Electronic Documents Act provides Canadian residents with privacy protections in regard to transactions with businesses and organizations in the private sector and sets out ground rules for how private-sector organizations may collect, use, and disclose personal information in the course of commercial activities. Foreign governments may attempt to apply such laws extraterritorially or through treaties or other arrangements with U.S. governmental entities. Other jurisdictions besides the EU and Canada are similarly introducing or enhancing laws and regulations relating to privacy and data security, which enhances risks relating to compliance with such laws. Furthermore, as we enter into business arrangements in countries outside of the United States, we will need to be prepared to comply with applicable local privacy laws. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of personal data, such as health-related data or other sensitive information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions that we operate.We cannot be certain that the privacy policies and other statements regarding our practices will be found sufficient to protect us from liability or adverse publicity relating to the privacy and security of personal information. There is ongoing concern from privacy advocates, regulators, and others regarding data protection and privacy issues, and the number of jurisdictions with data protection and privacy laws has been increasing. Also, there are ongoing public policy discussions regarding whether the standards for de-identified, anonymous, or pseudonymized health information are sufficient, and the risk of re-identification sufficiently small, to adequately protect patient privacy. We expect that there will continue to be new proposed laws, regulations, and industry standards concerning privacy, data protection, and information security in the United States, including the CCPA and CPRA, and we cannot yet determine the impact such laws, regulations, and standards may have on our business. 97Future laws, regulations, standards, and other obligations, and changes in the interpretation of existing laws, regulations, standards, and other obligations could impair our or our clientsâ€™ ability to collect, use, or disclose information relating to consumers, which could decrease demand for our Solution, increase our costs, and impair our ability to maintain and grow our client base and increase our revenue. Any failure or perceived failure by us to comply with international, federal or state laws or regulations, industry standards, or other legal obligations, or any actual or suspected security incident, whether or not resulting in unauthorized access to, or acquisition, release, or transfer of personally identifiable information or other data, may result in governmental enforcement actions and prosecutions, private litigation, fines, and penalties or adverse publicity and could cause our clients to lose trust in us, which could have an adverse effect

on our reputation and business. We may be unable to make such changes and modifications in a commercially reasonable manner or at all, and our ability to develop new products and features could be limited. Any of these developments could harm our business, financial condition, and results of operations. Privacy and data security concerns, whether valid or not valid, may inhibit market adoption of our Solution.Government regulation of healthcare creates risks and challenges with respect to our compliance efforts and our business strategies.Many healthcare laws are complex, and their application to specific services and relationships may not be clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate the data analytics and improvement services that we provide, and these laws and regulations may be applied to our Solution in ways that we do not anticipate, particularly as we develop and release new and more sophisticated solutions. Our failure to accurately anticipate the application of these laws and regulations, or our other failure to comply with them, could create significant liability for us, result in adverse publicity, and negatively affect our business. Some of the risks we face or may face from healthcare regulation are described below.The federal Anti-Kickback Statute prohibits, among other things, the offering, paying, soliciting, or receiving anything of value, directly or indirectly, for the referral of patients covered by Medicare, Medicaid, and other federal healthcare programs or the leasing, purchasing, ordering, or arranging for or recommending the lease, purchase, or order of any item, good, facility, or service covered by these programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Some enforcement activities focus on below or above market payments for federally reimbursable healthcare items or services as evidence of the intent to provide a kickback. Many states also have similar anti-kickback laws that are not necessarily limited to items or services for which payment is made by a federal healthcare program. Moreover, both federal and state laws prohibit bribery and similar behavior. We do not believe we directly order or provide healthcare services that are reimbursable by Medicare, Medicaid or other third-party payors or submit claims or receive reimbursement from any such payor. However, nonetheless, in addition to direct enforcement action against us, if our advisory services or our Solution offered to clients are associated with action by clients that is determined or alleged to be in violation of these laws and regulations, it is possible that an enforcement agency would also try to hold us liable and, as a result of such attempt to hold us liable, our results of operations and financial condition may be negatively impacted, even if we are ultimately found not liable. There are also numerous federal and state laws that prohibit the submission of false information, or the failure to disclose information, in connection with submission and payment of claims for healthcare items and services by healthcare providers. For example, the federal civil False Claims Act prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim. The government has prosecuted revenue cycle management service providers for causing the submission of false or fraudulent claims in violation of the False Claims Act. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.98HIPAA also created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Any determination by a court or regulatory agency that we or any of our clients, vendors, or partners have violated these laws could subject us to significant civil or criminal penalties, invalidate all or portions of some of our client contracts, require us to change or terminate some portions of our business, require us to refund portions of our services fees, subject us to additional reporting requirements and oversight under a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, cause us to be disqualified from serving clients doing business with government payors, and have an adverse effect on our business. Our clientsâ€™ failure to comply with these laws and regulations in connection with our services could result in substantial liability (including, but not limited to, criminal liability), adversely affect demand for our Solution, and force us to expend significant capital, research and development, and other resources to address the failure. Even an unsuccessful challenge by regulatory authorities of our activities could result in adverse publicity, distract management attention from our business, require a costly response from us, and negatively impact the price of our common stock.If our arrangements with clinicians and other healthcare professionals are found to constitute the improper rendering of professional medical services or fee splitting under applicable state laws, our business, financial condition, and our ability to operate in those states could be adversely impacted.We employ and contract with physicians and other licensed healthcare professionals who assist our clients with the clientsâ€™ care coordination, care management, population health management, and patient safety activities. Although we do not intend to provide medical care, treatment, or advice, our relationships with such healthcare professionals may implicate certain state laws in the United States in which we operate that generally prohibit non-professional entities from providing licensed medical services, exercising control over licensed physicians or other licensed healthcare professionals, or engaging in certain practices such as fee-splitting with such licensed professionals. There can be no assurance that these laws will be interpreted in a manner consistent with our practices or that other laws or regulations will not be enacted in the future that could have a material and adverse effect on our business, financial condition, and results of operations. Regulatory authorities, state boards of medicine, state attorneys general, and other parties may assert that we are engaged in the provision of professional medical services, and/or that our arrangements with our affiliated physicians and other licensed healthcare professionals constitute unlawful fee-splitting. If a jurisdictionâ€™s prohibition on the corporate practice of medicine or fee-splitting is interpreted in a manner that is inconsistent with our practices, we may be required to restructure or terminate some portions of our business, which may in turn require us to refund portions of our services fees, which would have an adverse effect on our business. Even an unsuccessful challenge by regulatory authorities of our activities could result in adverse publicity, distraction of management attention from our business, a costly response from us, and a substantial negative impact upon the price of our common stock.The FDA may modify its enforcement policies with respect to medical software products, and our software products may become subject to extensive regulatory requirements, which may increase the cost of conducting, or otherwise harm, our business.We develop and offer certain analytical software applications in connection with our business. The FDA may regulate medical or health-related software, including machine learning functionality and predictive algorithms, if such software falls within the definition of a â€œmedical deviceâ€ under the Federal Food, Drug, and Cosmetic Act (FDCA). Medical devices are subject to extensive and rigorous regulation by the FDA and by other federal, state, and local authorities. 99The FDCA and related regulations govern the conditions of safety, efficacy, clearance, approval, manufacturing, quality system requirements, labeling, packaging, distribution, storage, recordkeeping, reporting, marketing, advertising, and promotion of medical devices. However, historically, the FDA has exercised enforcement discretion for certain low-risk software functions, and has issued several guidance documents outlining its approach to the regulation of software as a medical device. In addition, the 21st Century Cures Act amended the FDCA to exclude from the definition of â€œmedical deviceâ€ certain medical-related software, including software used for administrative support functions at a healthcare facility, software intended for maintaining or encouraging a healthy lifestyle, software designed to store electronic health records, software for transferring, storing, or displaying medical device data or in vitro diagnostic data, and certain clinical decision support software. We believe our currently marketed products provide functionality that is exempt from the FDCAâ€™s definition of a â€œmedical device,â€ and therefore that our software products are not currently regulated by the FDA as medical devices, or that our products are otherwise subject to FDAâ€™s current enforcement discretion policies applicable to software products. However, there is a risk that the FDA could disagree with our determination, or that the FDA could alter its enforcement discretion policies, and in either case, subject our software to more stringent medical device regulations. If the FDA determines that any of our current or future analytics applications are regulated as medical devices and not otherwise subject to enforcement discretion, we would become subject to various requirements under the FDCA and the FDAâ€™s implementing regulations. If this occurs, we may be required to cease marketing or to recall our product until we obtain the requisite clearances or approvals, which would entail significant cost and could harm our reputation, business, financial condition, and results of operations. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, or comparable state or foreign regulatory authorities, including: untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties, recalls, termination of distribution, administrative detentions, seizure of our products, operating restrictions, partial suspension or total shutdown of production, delays in or refusal to grant clearances or approvals, prohibitions on sales of our products, and criminal prosecution. Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, financial condition, and results of operations.The healthcare regulatory and political framework is uncertain and evolving.Existing and new laws and regulations affecting the healthcare industry, or changes to existing laws and regulations could create unexpected liabilities for us, cause us to incur additional costs, and/or restrict our operations. Reforming the healthcare industry has been a priority for U.S. politicians, and key members of the legislative and executive branches have proposed a wide variety of potential changes and policy goals. Certain changes to laws impacting our industry, or perceived intentions to do so, could affect our business and results of operations. By way of example, in March 2010, the Affordable Care Act (ACA), was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers and has significantly impacted our industry and, to some degree, our business. Since its enactment, there have been judicial, executive, and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form. We anticipate that new cost containment measures or other healthcare reforms will continue to be implemented at both the federal and state level, any of which could harm our business, financial condition, and results of operations.100Due to the particular nature of certain services we provide or the manner in which we provide them, we may be subject to additional government regulation and foreign government regulation.While our Solution is primarily subject to government regulations pertaining to healthcare, certain aspects of our Solution may require us to comply with regulatory schema from other areas. Examples of such regulatory schema include:â€¢Antitrust laws. Our national cloud-based network allows us access to cost and pricing data for a large number of providers in most regional markets, as well as to the contracted rates for third-party payors. To the extent that our Solution enables providers to compare their cost and pricing data with those of their competitors, those providers could collude to increase the pricing for their services, to reduce the compensation they pay their employees, or to collectively negotiate agreements with third parties. Similarly, if payors are able to compare their contracted rates of payment to providers, those payors may seek to reduce the amounts they might otherwise pay. Such actions may be deemed to be anti-competitive and a violation of federal antitrust laws. To the extent that we are deemed to have enabled such activities, we could be subject to fines and penalties imposed by the U.S. Department of Justice or the FTC and be required to curtail or terminate the services that permitted such collusion.â€¢Foreign Corrupt Practices Act (FCPA) and foreign anti-bribery laws. The FCPA makes it illegal for U.S. persons, including U.S. companies, and their subsidiaries, directors, officers, employees, and agents, to promise, authorize or make any corrupt payment, or otherwise provide anything of value, directly or indirectly, to any foreign official, any foreign political party or party official, or candidate for foreign political office to obtain or retain business. Violations of the FCPA can also result in violations of other U.S. laws, including anti-money laundering, mail and wire fraud, and conspiracy laws. There are severe penalties for violating the FCPA. In addition, the Company may also be subject to other non-U.S. anti-corruption or anti-bribery laws, such as the U.K. Bribery Act 2010. If our employees, contractors, vendors, or partners fail to comply with the FCPA and/or foreign anti-bribery laws, we may be subject to penalties or sanctions, and our ability to develop new prospects and retain existing clients could be adversely affected.â€¢Economic sanctions and export controls. Economic and trade sanctions programs that are administered by the U.S. Treasury Departmentâ€™s Office of Foreign Assets Control prohibit or restrict transactions to or from, and dealings with specified countries and territories, their governments, and in certain circumstances, with individuals and entities that are specially designated nationals of those countries, and other sanctioned persons, including narcotics traffickers and terrorists or terrorist organizations. As federal, state and foreign legislative regulatory scrutiny and enforcement actions in these areas increase, we expect our costs to comply with these requirements will increase as well. Failure to comply with any of these requirements could result in the limitation, suspension or termination of our services, imposition of significant civil and criminal penalties, including fines, and/or the seizure and/or forfeiture of our assets. Further, our Solution incorporates encryption technology. This encryption technology may be exported from the United States only with the required export authorizations, including by a license, a license exception, or other appropriate government authorizations. Such solutions may also be subject to certain regulatory reporting requirements. Various countries also regulate the import of certain encryption technology, including through import permitting and licensing requirements, and have enacted laws that could limit our clientsâ€™ ability to import our Solution into those countries. Governmental regulation of encryption technology and of exports and imports of encryption products, or our failure to obtain required approval for our Solution, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the provision of our Solution, including with respect to new applications, may delay the introduction of our Solution in various markets or, in some cases, prevent the provision of our Solution to some countries altogether.â€¢Regulatory certification. We must obtain certification from governmental agencies, such as the Agency for Healthcare Research and Quality (AHRQ) to sell certain of our analytics applications and services in the United States. We cannot be certain that our Solution will continue to meet these standards. The failure to comply with these certification requirements could result in the loss of certification, which could restrict our Solution offerings and cause us to lose clients.101Risks Related to Tax RegulationTaxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value-added or similar transactional taxes, and we could be subject to liability with respect to past or future sales, which could adversely affect our results of operations.We do not collect sales and use, value-added, and similar transactional taxes in all jurisdictions in which we have sales, based on our belief that such taxes are not applicable or that we are not required to collect such taxes with respect to the jurisdiction. Sales and use, value-added, and similar tax laws and rates vary greatly by jurisdiction. Certain jurisdictions in which we do not collect such taxes may assert that such taxes are applicable, which could result in tax assessments, penalties, and interest, and we may be required to collect such taxes in the future. Such tax assessments, penalties, interest or future requirements, increase in tax rates, or a combination of the foregoing may result in an increase in our sales and similar transactional taxes, increase administrative burdens or costs, or otherwise adversely affect our business, results of operations, or financial condition.Unanticipated changes in our effective tax rate and additional tax liabilities, including as a result of our international operations or implementation of new tax rules, could harm our future results.We are subject to income taxes in the United States and are expanding into various foreign jurisdictions that are subject to income tax. Our domestic and international tax liabilities are subject to the allocation of expenses in differing jurisdictions and complex transfer pricing regulations administered by taxing authorities in various jurisdictions. Tax rates in the jurisdictions in which we operate may change as a result of factors outside of our control or relevant taxing authorities may disagree with our determinations as to the income and expenses attributable to specific jurisdictions. In addition, changes in tax and trade laws, treaties or regulations, or their interpretation or enforcement, have become more unpredictable and may become more stringent, which could materially adversely affect our tax position. Forecasting our estimated annual effective tax rate is complex and subject to uncertainty, and there may be material differences between our forecasted and actual effective tax rate. Our effective tax rate could be adversely affected by changes in the mix of earnings and losses in countries with differing statutory tax rates, certain non-deductible expenses, the valuation of deferred tax assets and liabilities, adjustments to income taxes upon finalization of tax returns, changes in available tax attributes, decision to repatriate non-U.S. earnings for which we have not previously provided for U.S. taxes, and changes in federal, state, or international tax laws and accounting principles. Finally, we may be subject to income tax audits throughout the world. An adverse resolution of one or more uncertain tax positions in any period could have a material impact on our results of operations or financial condition for that period.Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.As of DecemberÂ 31, 2023, we had net operating loss (NOL) carryforwards for federal and state income tax purposes of approximately $602.6 million and $505.5 million, respectively, which may be available to offset taxable income in the future, and which expire in various years beginning in 2032 for federal purposes if not utilized. The state NOLs will expire depending upon the various rules in the states in which we operate. A lack of future taxable income would adversely affect our ability to utilize these NOLs before they expire. In general, under Section 382 of the Code, a corporation that undergoes an â€œownership changeâ€ (as defined under Section 382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre-change NOLs to offset its future taxable income. We may experience a future ownership change under Section 382 of the Code that could affect our ability to utilize the NOLs to offset our income. Furthermore, our ability to utilize NOLs of companies that we have acquired or may acquire in the future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on

the use of NOLs or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state income tax purposes. 102Certain provisions of the Tax Act (as defined below), as amended by the CARES Act, also limit the use of NOLs, as discussed further below. For these reasons, we may not be able to utilize a material portion of our NOLs, even if we attain profitability, which could potentially result in increased future tax liability to us and could adversely affect our results of operations and financial condition.Comprehensive tax reform legislation could adversely affect our business and financial condition.On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law. The Tax Act contains, among other things, significant changes to corporate taxation, including (i) a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, (ii) a limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses) (increased to 50% by the CARES Act for taxable years beginning in 2019 and 2020), (iii) a limitation of the deduction for NOLs in taxable years beginning after December 31, 2020 to 80% of current year taxable income in respect of NOLs generated during or after 2018 and elimination of net operating loss carrybacks for NOLs arising in tax years ending after December 31, 2020, (iv) a one-time tax on offshore earnings at reduced rates regardless of whether they are repatriated, (v) immediate deductions for certain new investments instead of deductions for depreciation expense over time, and (vi) a modification or repeal of many business deductions and credits. For federal NOLs arising in tax years beginning after December 31, 2017, the Tax Act (as modified by the CARES Act) limits a taxpayerâ€™s ability to utilize federal NOL carryforwards in taxable years beginning after December 31, 2020 to 80% of taxable income. In addition, federal NOLs arising in tax years ending after December 31, 2017 can be carried forward indefinitely, but carryback of federal NOLs arising in tax years ending after December 31, 2020 is generally prohibited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law.Beginning in 2022, the Tax Act eliminated the option to currently deduct research and development expenditures in the period incurred and requires taxpayers to capitalize and amortize such domestic and foreign expenditures over five or fifteen years, respectively, pursuant to Section 174 of the Code. We will continue to examine the impact the Tax Act and CARES Act may have on our results of operations and financial condition.Risks Related to Our IndebtednessOur indebtedness could adversely affect our financial condition and prevent us from fulfilling our existing or future debt obligations, and we may not generate sufficient cash flow from our business to pay our debt.On April 14, 2020, we issued our Notes in an aggregate principal amount of $230.0 million, which will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Notes are governed by an indenture (Indenture) between us, as the issuer, and U.S. Bank National Association, as trustee. The Notes are our senior, unsecured obligations and accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. The Indenture does not contain any financial covenants or restrictions on the payments of dividends, the incurrence of indebtedness, or the issuance or repurchase of securities by us or any of our subsidiaries. We may repurchase the Notes from time to time prior to the maturity date. A holder may convert all or any portion of its Notes, at its option, subject to certain conditions and during certain periods, into cash, shares of our common stock or a combination of cash and shares of our common stock, with the form of consideration determined at our election. Noteholders have the right to require us to repurchase all or a portion of their notes at 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the repurchase date, upon the occurrence of certain events. The conversion rate is initially 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock). If the Notes have not previously been converted, redeemed or repurchased, we will be required to repay the Notes in cash at maturity.In addition, on July 16, 2024, we entered into the Credit Agreement, which provides for a five-year term loan facility (the Term Loan Facility) in an aggregate principal amount of up to $225 million, consisting of an initial term loan in the aggregate principal amount of $125 million, which was funded in full at closing, and a delayed draw term loan facility in the aggregate principal amount of $100 million, which was undrawn as of the closing.Our outstanding and any future debt obligations could make us more vulnerable to adverse changes in general U.S. and worldwide economic conditions, including rising interest rates, regulatory, and competitive conditions. We may not use the cash proceeds from the Notes and/or the Term Loan Facility in an optimally productive and profitable manner. Our ability to satisfy our debt obligations will depend on market conditions and our future performance, which is subject to economic, financial, competitive, and other factors, including those described in these risk factors, many of which are beyond our control. 103In the case of the Notes, that includes our ability to make required cash payments in connection with redemptions or conversions of the Notes, repurchase the Notes upon the occurrence of certain events, or to repay or refinance the Notes at maturity. For example, we maintain cash balances with financial institutions in excess of insured limits, and there can be no assurance that we will be able to access uninsured funds in a timely manner or at all in the event of a failure of these financial institutions. In addition, our ability satisfy our debt obligations may be limited by law or regulatory authority or by other agreements governing our future indebtedness. Since inception, our business has generated net losses, and we may continue to incur significant losses. As a result, we may not have enough available cash or be able to obtain financing at the time we are required to make payments owed under the Notes and/or the Term Loan Facility. If we are unable to satisfy our debt obligations, we may be required to seek funds from external sources, which may not be available on acceptable terms, if at all, and which could intensify the risks related to our indebtedness and further restrict our operating and financial flexibility. Further, any repayment of our debt with equity would dilute the ownership interests of our existing stockholders. In the event of a default on our debt obligations, we may be required to repurchase the Notes, amounts owed under our Term Loan Facility may be accelerated, and assets serving as collateral under our Term Loan Credit Facility may be subject to foreclosure. Any default under the Indenture or the Credit Agreement could also lead to a default under our future indebtedness and could have a material adverse effect on our business, results of operations, and financial condition. Further, if we are liquidated, the lenderâ€™s rights to repayment would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation. Our Credit Agreement contains covenants and other provisions that restrict our ability to take certain actions and may limit our ability to operate or grow our business in the future.The Credit Agreement contains certain affirmative covenants and negative covenants, including covenants that restrict our ability to take certain actions including, among other things and subject to certain exceptions, the incurrence of debt, the granting of liens, engaging in mergers and other fundamental changes, the making of investments, entering into transactions with affiliates, the payment of dividends and other restricted payments, the prepayment of other indebtedness and the sale of assets. The Credit Agreement also requires us to comply with a minimum liquidity threshold, a maximum recurring revenue-based ratio and a maximum EBITDA-based net leverage ratio. In addition, payments of amounts owed under the Term Loan Facility will require us to dedicate cash flow from operations or cash on hand, which will reduce the amounts available to fund working capital, capital expenditures, transactions (including pursuing strategic initiatives), and other general corporate purposes. Such limitations could limit our flexibility to plan for or react to changes in our business or industry; place us at a disadvantage compared to our competitors that have less debt; limit our ability to borrow or otherwise raise additional capital as needed; or otherwise have a material adverse effect on our business, results of operations, and financial condition. We are exposed to interest rate risks with regard to our Term Loan Facility and any future refinancing thereof.Outstanding principal amounts under our Term Loan Facility are expected to accrue interest at a floating rate equal to SOFR plus 6.5% per year. In the event that SOFR is unavailable, interest will accrue at a floating rate equal to the alternate base rate plus 5.5% per year. Accordingly, whenever we have amounts outstanding under our Term Loan Facility, our cash flows and results of operations will be subject to interest rate risk exposure associated with the debt balance outstanding. We currently are not a party to an interest rate swap contract or other derivative instrument designed to hedge our exposure to interest rate fluctuation risk.Our Capped Calls may affect the value of our common stock and subject us to counterparty risk.On April 8, 2020, concurrently with the pricing of our Notes, in a private placement to qualified institutional buyers exempt from registration under the Securities Act (Note Offering), we entered into privately negotiated capped call transactions (Base Capped Calls) with certain financial institutions (the option counterparties). In addition, in connection with the initial purchasersâ€™ exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (Additional Capped Calls, and, together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. We used approximately $21.6 million of the net proceeds from the Note Offering to pay the cost of the Capped Calls and allocated issuance costs. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. 104The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price. The Capped Calls are separate transactions that we entered into with the option counterparties, and are not part of the terms of the Notes. The option counterparties are financial institutions or affiliates of financial institutions, and we will be subject to the risk that one or more of such option counterparties may default under the Capped Calls.From time to time, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivative transactions with respect to our common stock and/or purchasing or selling our common stock or our other securities in secondary market transactions prior to the maturity of the Notes. This activity could cause or avoid an increase or a decrease in the market price of our common stock. In addition, our exposure to the credit risk of the option counterparties will not be secured by any collateral. If any option counterparty becomes subject to insolvency proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under the Capped Calls. Our exposure will depend on many factors but, generally, the increase in our exposure will be correlated to the increase in our common stock market price and in the volatility of the market price of our common stock. In addition, upon a default by any option counterparty, we may suffer adverse tax consequences and dilution with respect to our common stock. We can provide no assurance as to the financial stability or viability of any option counterparty.Risks Related to Ownership of Our Common StockRisks Related to an Investment in Our SecuritiesWe have a limited operating history in an evolving industry which makes it difficult to evaluate our current business future prospects and increases the risk of your investment.We launched operations in 2008 and we acquired Able Health, Healthfinch, Vitalware, Twistle, ARMUS, KPI Ninja, ERS, Carevive and Lumeon between February 2020 and August 2024. Our limited operating history, in particular with respect to the businesses we have recently acquired, makes it difficult to effectively assess or forecast our future prospects. You should consider our business and prospects in light of the risks and difficulties we encounter or may encounter. These risks and difficulties include our ability to cost-effectively acquire new clients and retain existing clients, maintain the quality of our technology infrastructure that can efficiently and reliably handle the requirements of our clients and deploy new features and solutions, and successfully compete with other companies that are currently in, or may enter, the healthcare solution space. Additional risks include our ability to effectively manage growth, achieve synergies, responsibly use the data that clients share with us, process, store, protect, and use personal data, including PHI, in compliance with governmental regulation, contractual obligations, and other legal obligations related to privacy and security and avoid interruptions or disruptions in our service or slower than expected load times for our Solution. If we fail to address the risks and difficulties that we face, including those associated with the challenges listed above, our business and our results of operations will be adversely affected.We have experienced significant net losses since inception, we expect to incur losses in the future, and we may not be able to generate sufficient revenue to achieve and maintain profitability.We have incurred significant net losses in the past, including net losses of $118.1 million and $137.4 million in the years ended DecemberÂ 31, 2023 and 2022, respectively. We had an accumulated deficit of $1,117.2 million as of DecemberÂ 31, 2023. We expect our costs will increase over time as we continue to invest to grow our business and build relationships with clients, develop our Solution, develop new solutions, and operate as a public company. These efforts may prove to be more expensive than we currently anticipate and external factors, such as macroeconomic challenges, including the high inflationary environment and rising interest rates, could cause an increase in our expenses, and we may not succeed in increasing our revenue sufficiently to offset these higher expenses. 105As a result, we may need to raise additional capital through equity and debt financings in order to fund our operations. To date, we have financed our operations principally from the proceeds we received through private sales of equity securities, payments received from sales of our Solution, borrowings under our loan and security agreements, our IPO in July 2019, the Note Offering in April 2020, and an underwritten public offering of 4,882,075 shares (inclusive of the underwritersâ€™ over-allotment option to purchase 636,792 shares) of our common stock at $53.00 per share in August 2021, from which we received net proceeds of $245.2 million, after deducting the underwriting discounts and commissions and other offering costs (the Secondary Public Equity Offering). We may also fail to improve the gross margins of our business. If we are unable to effectively manage these risks and difficulties as we encounter them, our business, financial condition, and results of operations would be adversely affected. Our failure to achieve or maintain profitability could negatively impact the value of our common stock.The market price of our common stock may be volatile and may decline regardless of our operating performance, and you may lose all or part of your investments.The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including:â€¢overall performance of the equity markets and/or publicly-listed technology companies;â€¢actual or anticipated fluctuations in our net revenue or other operating metrics;â€¢changes in the financial projections we provide to the public or our failure to meet these projections;â€¢failure of securities analysts to initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our company, or our failure to meet the estimates or the expectations of investors;â€¢the economy as a whole and market conditions in our industry;â€¢rumors and market speculation involving us or other companies in our industry;â€¢announcements by us or our competitors of significant innovations, acquisitions, strategic partnerships, joint ventures, or capital commitments;â€¢new laws or regulations or new interpretations of existing laws or regulations applicable to our business;â€¢lawsuits or investigations threatened or filed against us;â€¢recruitment or departure of key personnel; andâ€¢other events or factors, including those resulting from macroeconomic challenges (including high inflationary and/or high interest rate environments), war, bank or financial institution failures, incidents of terrorism, public health crises, or responses to these events.In addition, extreme price and volume fluctuations in the stock markets have affected and continue to affect many technology companiesâ€™ stock prices. Often, their stock prices have fluctuated in ways unrelated or disproportionate to the companiesâ€™ operating performance. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business, and harm our business. Moreover, because of these fluctuations, comparing our results of operations on a period-to-period basis may not be meaningful. You should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our net revenue or results of operations fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated net revenue or earnings forecasts that we may provide.106If securities or industry analysts do not continue to publish research, or publish inaccurate or unfavorable research, about our business, the price of our common stock and trading volume could decline.The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If industry analysts cease coverage of us, the trading price for our common stock could be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us on a regular basis, demand for our common stock could decrease, which might cause our common stock price and trading volume to decline.We cannot guarantee that the Share Repurchase Plan will be fully consummated or will enhance stockholder value, and share repurchases could affect the price of our common stock.On August 2, 2022, our board of directors authorized and approved the Share Repurchase Plan, pursuant to which we may repurchase up to $40.0 million of our outstanding shares of common stock. We began repurchasing shares of common stock under this program during the third quarter of 2022 and had $29.8 million available to purchase under the Share Repurchase Plan as of SeptemberÂ 30, 2024. Repurchases of shares of common stock under the Share Repurchase Plan may be made from time to time, in the open market, in privately negotiated transactions or otherwise, with the amount and timing of repurchases to be determined at the discretion of our management, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal securities laws, including within the pricing and volume requirements of Rule 10b-18 under the Exchange Act. We may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of our shares of common stock under this authorization. The timing, pricing, and sizes of these repurchases will depend on a number of factors, including the market price of our common stock and general market and economic conditions. The Share Repurchase Plan could affect the price of our common stock, increase volatility, and diminish our cash reserves.Our management has broad discretion in the use of proceeds from our IPO, the Note Offering, and the Secondary Public Equity Offering and our use may not produce a positive rate of return.The principal purposes of our IPO were to increase our capitalization and financial flexibility, create a public market for our stock and thereby enable access to the public equity markets by our employees and stockholders, obtain additional capital, and strengthen our position in the healthcare data analytics applications and services market. We used a portion of the Note Offering proceeds to pay the cost of the Capped Call

transactions and to prepay in full all outstanding indebtedness under our credit agreement with OrbiMed. We cannot specify with certainty our plans for the use of the net proceeds we received from these offerings. However, we intend to use the net proceeds we received from our IPO, the Note Offering, and our Secondary Public Equity Offering for working capital and other general corporate purposes. We may also use a portion of the net proceeds from these offerings for the acquisition of, or investment in, technologies, solutions or businesses that complement our business. Our management has broad discretion over the specific use of the net proceeds we received in these offerings and might not be able to obtain a significant return, if any, on investment of these net proceeds. Investors will need to rely upon the judgment of our management with respect to the use of proceeds. If we do not use the net proceeds that we received in our IPO, the Note Offering, and our Secondary Public Equity Offering effectively, our business, results of operations, and financial condition could be harmed.Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans, or otherwise will dilute all other stockholders.We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors, and consultants under our stock incentive plans. We may also raise capital through equity financings in the future, including through offerings similar to our Secondary Public Equity Offering during the third quarter of 2021. 107As part of our business strategy, we may acquire or make investments in complementary companies, products, or technologies and issue equity securities to pay for any such acquisition or investment, such as our issuance of equity securities in connection with our acquisitions. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per-share value of our common stock to decline.The requirements of being a public company may strain our resources, divert managementâ€™s attention, and affect our ability to attract and retain executive management and qualified board members.As a public company, we are subject to the reporting requirements of the Exchange Act, the listing standards of Nasdaq,Â and other applicable securities rules and regulations. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming, and costly, and place significant strain on our personnel, systems, and resources. For example, the Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and results of operations. As a result of the complexity involved in complying with the rules and regulations applicable to public companies, our managementâ€™s attention may be diverted from other business concerns, which could harm our business, results of operations, and financial condition.Although we have already hired additional employees to assist us in complying with these requirements, we may need to hire more employees in the future or engage outside consultants, which will increase our operating expenses. In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time-consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest substantial resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of managementâ€™s time and attention from business operations to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.We also expect that being a public company and these new rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.As a result of disclosure of information in filings required of a public company, our business and financial condition is more visible, which may result in an increased risk of threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business, results of operations, and financial condition.The individuals who now constitute our senior management team have limited experience managing a publicly-traded company and limited experience complying with the increasingly complex laws pertaining to public companies. Our senior management team may not successfully or efficiently manage our transition to a public company that is subject to significant regulatory oversight and reporting obligations.108We do not intend to pay dividends on our common stock and, consequently, the ability of common stockholders to achieve a return on investment will depend on appreciation, if any, in the price of our common stock.You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid any dividends on our capital stock. We intend to retain any earnings to finance the operation and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. In addition, the terms of any future credit facility or financing we obtain may contain, terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, common stockholders may only receive a ROI if the market price of our common stock increases.We could be subject to securities class action litigation.In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because technology and healthcare technology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of managementâ€™s attention and resources, which could harm our business.Risks Related to Our Charter and BylawsProvisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current board of directors, and limit the market price of our common stock.Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws, include provisions that:â€¢provide that our board of directors is classified into three classes of directors with staggered three-year terms;â€¢permit the board of directors to establish the number of directors and fill any vacancies and newly-created directorships;â€¢require super-majority voting to amend some provisions in our amended and restated certificate of incorporation and amended and restated bylaws;â€¢authorize the issuance of â€œblank checkâ€ preferred stock that our board of directors could use to implement a stockholder rights plan;â€¢provide that only a majority of our board of directors will be authorized to call a special meeting of stockholders;â€¢prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;â€¢provide that the board of directors is expressly authorized to make, alter, or repeal our bylaws; andâ€¢advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.Moreover, Section 203 of the Delaware General Corporation Law may discourage, delay, or prevent a change in control of our company. Section 203 imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock.109Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit stockholdersâ€™ ability to obtain a favorable judicial forum for disputes with us.Our amended and restated bylaws include an exclusive forum provision that provides that the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:â€¢any derivative action or proceeding brought on our behalf;â€¢any action asserting a breach of fiduciary duty owed to us or our stockholders by any of our current or former directors, officers or other employees;â€¢any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; orâ€¢any action that is governed by the internal affairs doctrine and asserts a claim against us or any of our current or former directors, officers or other employees or stockholders.This exclusive forum provision will not apply to any causes of action arising under the Securities Act. Further, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such Securities Act claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act; however, a court may not enforce such provision.This choice of forum provision may limit a stockholderâ€™s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provision which will be contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.110General RisksChanges in accounting principles may cause previously unanticipated fluctuations in our financial results, and the implementation of such changes may impact our ability to meet our financial reporting obligations.We prepare our financial statements in accordance with U.S. GAAP which are subject to interpretation or changes by the Financial Accounting Standards Board (FASB), the SEC, and other various bodies formed to promulgate and interpret appropriate accounting principles. New accounting pronouncements and changes in accounting principles have occurred in the past and are expected to occur in the future which may have a significant effect on our financial results. Furthermore, any difficulties in implementation of changes in accounting principles, including the ability to modify our accounting systems, could cause us to fail to meet our financial reporting obligations, which could result in regulatory discipline and harm investorsâ€™ confidence in us.Economic uncertainties or downturns in the general economy or the industries in which our clients operate could disproportionately affect the demand for our Solution and negatively impact our results of operations.General worldwide economic conditions have experienced significant downturns during the last ten or more years, and market volatility and uncertainty remain widespread, making it potentially very difficult for our clients and us to accurately forecast and plan future business activities. During challenging economic times, our clients may have difficulty gaining timely access to sufficient credit or obtaining credit on reasonable terms, increased costs, and/or other negative financial impacts, each of which could impair their ability to make timely payments to us, reduce client expansion and new client acquisition, increase client churn, and adversely affect our revenue. If that were to occur, our financial results could be harmed. Further, challenging economic conditions may impair the ability of our clients to pay for the applications and services they already have purchased from us and, as a result, our write-offs of accounts receivable could increase. We cannot predict the timing, strength, or duration of any economic slowdown or recovery. If the condition of the general economy or markets in which we operate worsens, our business could be harmed.Investorsâ€™ expectations of our performance relating to environmental, social, and governance factors may impose additional costs and expose us to new risks.There is an increasing focus from certain investors, employees, and other stakeholders concerning corporate responsibility, specifically related to environmental, social, and governance factors. For example, increasingly there are disclosure regulations focused on environmental, social and sustainability matters. The SEC recently adopted final climate change disclosure regulation that, if it survives the litigation it is currently subject to, will require us to make certain disclosures that may be costly for our company. We are currently evaluating this regulation to determine its impact on us.In addition, some investors may use these factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance. The criteria by which companiesâ€™ corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate. We may face reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies.Furthermore, if our competitorsâ€™ corporate responsibility performance is perceived to be greater than ours, potential or current investors may elect to invest with our competitors instead. In addition, in the event that we communicate certain initiatives and goals regarding environmental, social and governance matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors, employees, and other stakeholders, or, if our initiatives are not executed as planned, our reputation and business, operating results, and financial condition could be adversely impacted.111Item 2. Unregistered Sales of Equity Securities and Use of ProceedsThere were no unregistered sales of equity securities during the nine months ended September 30, 2024.Item 5. Other Information(a) None.(b) None.(c) None.112Item 6.Â ExhibitsExhibit NumberDescription of DocumentIncorporated by Reference from FormIncorporated by Reference from Exhibit NumberDate Filed3.1Amended and Restated Certificate of Incorporation.S-1/A3.2July 12, 20193.2Amended and Restated Bylaws.S-1/A3.4July 12, 20193.3Amendment to Amended and Restated Bylaws.8-K3.1August 2, 20214.1Form of common stock certificate.S-1/A4.1July 12, 201931.1Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith31.2Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith32.1^Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith101.SCHInline XBRL Taxonomy Extension Schema DocumentFiled herewith101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentFiled herewith101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentFiled herewith101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentFiled herewith101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentFiled herewith104Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)Filed herewith_____* Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K and portions of this exhibit have been redacted in compliance with Item 601(b)(10)(iv) of Regulation S-K.^Â Â Â Â The certifications attached as Exhibit 32.1 accompanying this Quarterly Report on Form 10-Q, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Health Catalyst, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.113SIGNATURESPursuant to the requirements of the Securities Act of 1934, the Registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.SignatureTitleDate/s/ Jason AlgerChief Financial OfficerNovemberÂ 6, 2024Jason Alger(Principal Financial and Accounting Officer)114 EX-31.1 2 exhibit311-q32024xcertific.htm EX-31.1 DocumentExhibitÂ 31.1CERTIFICATION PURSUANT TO RULE 13a-14(a)Â OR 15d-14(a)Â OFTHE SECURITIES EXCHANGE ACT OF 1934,AS ADOPTED PURSUANT TO SECTIONÂ 302 OFTHE SARBANES-OXLEY ACT OF 2002I, Daniel Burton, certify that:1. I have reviewed this Quarterly Report on FormÂ 10-Q of Health Catalyst, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrantâ€™s other certifying officerÂ and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5. The registrantâ€™s other certifying officerÂ and I have disclosed, based on our most recent evaluation of internal control over

financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: NovemberÂ 6, 2024/s/ Daniel BurtonÂ Daniel BurtonÂ Chief Executive OfficerÂ (Principal Executive Officer)Â EX-31.2 3 exhibit312-q32024xcertific.htm EX-31.2 DocumentExhibitÂ 31.2CERTIFICATION PURSUANT TO RULE 13a-14(a)Â OR 15d-14(a)Â OFTHE SECURITIES EXCHANGE ACT OF 1934,AS ADOPTED PURSUANT TO SECTIONÂ 302 OFTHE SARBANES-OXLEY ACT OF 2002I, Jason Alger, certify that:1. I have reviewed this Quarterly Report on FormÂ 10-Q of Health Catalyst, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrantâ€™s other certifying officerÂ and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e)Â and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5. The registrantâ€™s other certifying officerÂ and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: NovemberÂ 6, 2024/s/ Jason AlgerÂ Jason AlgerÂ Chief Financial OfficerÂ (Principal Financial Officer)Â EX-32.1 4 exhibit321-q32024xcertific.htm EX-32.1 DocumentExhibitÂ 32.1CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICERPURSUANT TO18 U.S.C. SECTIONÂ 1350,AS ADOPTED PURSUANT TOSECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002Pursuant to the requirement set forth in RuleÂ 13a-14(b)Â of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and SectionÂ 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), Daniel Burton, Chief Executive Officer of Health Catalyst, Inc. (the â€œCompanyâ€), and Jason Alger, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:1The Companyâ€™s Quarterly Report on FormÂ 10-Q for the quarterly period ended SeptemberÂ 30, 2024, to which this Certification is attached as ExhibitÂ 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of SectionÂ 13(a)Â or SectionÂ 15(d)Â of the Exchange Act; and2The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: NovemberÂ 6, 2024/s/ Daniel BurtonÂ Daniel BurtonÂ Chief Executive OfficerÂ (Principal Executive Officer)Â Â Â /s/ Jason AlgerÂ Jason AlgerÂ Chief Financial OfficerÂ (Principal Financial Officer)Â EX-101.SCH 5 hcat-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Description of Business and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Short-term Investments link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Stockholdersâ€™ Equity link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Deferred Revenue and Performance Obligations link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Segments link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - Restructuring Costs link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Short-term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Business Combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Business Combinations - Unaudited Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Property and Equipment - Components of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Short-term Investments - Cash Equivalents and Short-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Short-term Investments - Short-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Short-term Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurements of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Debt - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Debt - Schedule of Components of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Debt - Schedule of Principal Payments and Debt Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Stockholdersâ€™ Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Stock-Based Compensation - Restricted Stock Unit and Phantom Share Units (PSUs) Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Deferred Revenue and Performance Obligations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Deferred Revenue and Performance Obligations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Segments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Segments - Scheduled of Segment Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Segments - Schedule of Segment Adjusted Gross Profit (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Restructuring Costs - Schedule of Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - Restructuring Costs - Schedule of Restructuring-Related Charges and Related Liability (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hcat-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 hcat-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 hcat-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Restructuring liabilities Restructuring Reserve, Current Vested and expected to vest, weighted average remaining contractual life in years Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Maximum employee subscription rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Related Parties Related Party Transactions Disclosure [Text Block] Stock repurchase program, remaining authorized repurchase amount Share Repurchase Program, Remaining Authorized, Amount Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax One-time technology (i.e., perpetual license) One-Time Technology [Member] One-Time Technology Unbilled accounts receivable Contract with Customer, Asset, after Allowance for Credit Loss, Current Schedule of Lease Expense (Income) Lease, Cost [Table Text Block] Cover page. Cover [Abstract] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Capitalized contract cost, net, current Capitalized Contract Cost, Net, Current Percentage interest acquired Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Schedule of The Calculation of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cliff vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Dividends Dividends, Cash Conversion rate Debt Instrument, Convertible, Conversion Ratio Line of Credit Facility [Table] Line of Credit Facility [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Cash equivalents Cash Equivalents [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Recurring technology Recurring Technology [Member] Recurring Technology [Member] Accounts receivable, net Increase (Decrease) in Accounts Receivable Right Of Use Assets Leasehold Improvements And Furniture And Fixtures Right Of Use Assets Leasehold Improvements And Furniture And Fixtures [Member] Right Of Use Assets Leasehold Improvements And Furniture And Fixtures Net loss per share Earnings Per Share, Policy [Policy Text Block] Restructuring costs Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Vesting of restricted stock units and restricted shares (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Restructuring and Related Activities [Abstract] Change in net unrealized gains (losses) on available for sale investments OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Goodwill [Line Items] Goodwill [Line Items] Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Operating lease expense Operating Lease, Cost Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant ERS Corporation ERS Corporation [Member] ERS Corporation Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Interest receivable Interest Receivable Less: Write-offs, net of recoveries Accounts

Receivable, Allowance For Credit Loss, Writeoff (Recovery) Accounts Receivable, Allowance For Credit Loss, Writeoff (Recovery) Cash Flow Hedging Cash Flow Hedging [Member] Segment reporting Segment Reporting, Policy [Policy Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Deferred revenue Contract with Customer, Liability, Current Measurement Input, Total Shareholder Return Measurement Input, Total Shareholder Return [Member] Measurement Input, Total Shareholder Return Plan Name [Domain] Plan Name [Domain] UNITED STATES UNITED STATES Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Stock Incentive Plan Stock Incentive Plan [Member] Stock Incentive Plan [Member] Cost Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of Debt Schedule of Long-Term Debt Instruments [Table Text Block] Treasury stock, shares, acquired (in shares) Treasury Stock, Shares, Acquired Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Corporate bonds Corporate bonds Corporate Bond Securities [Member] Money market funds Money market funds Money Market Funds [Member] Capitalized contract cost, net, noncurrent Capitalized Contract Cost, Net, Noncurrent Operating Segments Operating Segments [Member] Number of restricted shares issued (in shares) Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Denominator of lowest purchase of a participant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Purchase of intangible assets included in accounts payable and accrued liabilities Noncash or Part Noncash Acquisition, Intangible Assets Acquired Adjusted Gross Profit Gross Profit [Abstract] U.S. treasury notes U.S. Treasury notes US Treasury Securities [Member] Plan Name [Axis] Plan Name [Axis] Market Price of Revenue Risk Measurement Input, Quoted Price [Member] Equity Components [Axis] Equity Components [Axis] Restructuring Type [Axis] Restructuring Type [Axis] Accounts receivable Accounts Receivable [Policy Text Block] Pro forma net loss Business Acquisition, Pro Forma Net Income (Loss) Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Capitalized contract cost, amortization period Capitalized Contract Cost, Amortization Period Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; 60,847,658 and 58,295,491 shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively Common Stocks, Including Additional Paid in Capital Use of estimates Use of Estimates, Policy [Policy Text Block] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Impaired Long-Lived Assets Held and Used by Type [Axis] Impaired Long-Lived Assets Held and Used by Type [Axis] Option shares outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Payables and Accruals [Abstract] Payables and Accruals [Abstract] Supplemental disclosures of non-cash investing and financing information Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Entity Small Business Entity Small Business Developed technologies Developed technology Developed Technology Rights [Member] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Geographical [Axis] Geographical [Axis] Schedule of Restructuring Costs Restructuring and Related Costs [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Weighted Average Weighted Average [Member] Sales and marketing Selling and Marketing Expense [Member] Repurchase of common stock Stock Repurchased During Period, Value Schedule of Allowance For Accounts Receivable Accounts Receivable, Allowance for Credit Loss [Table Text Block] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Shares with a potentially dilutive impact (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Vesting period one Share-Based Payment Arrangement, Tranche One [Member] Cash payments Payments for Restructuring Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Right Of Use Asset Right Of Use Asset [Member] Right Of Use Asset Operating lease liabilities Increase (Decrease) In Operating Lease Liabilities Increase (Decrease) In Operating Lease Liabilities Investment discount and premium accretion Accretion (Amortization) of Discounts and Premiums, Investments Percentage of revenue recognized was included in deferred revenue (in percentage) Contract With Customer, Liability, Revenue Recognized, Percentage Contract With Customer, Liability, Revenue Recognized, Percentage Share based payment arrangement, nonvested award cost not yet recognized amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Goodwill Goodwill Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Allowance for credit losses at the beginning of period Allowance for credit losses at the end of period Accounts Receivable, Allowance for Credit Loss Fair value of financial instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Share repurchase plan, authorized amount Share Repurchase Program, Authorized, Amount Product and Service [Domain] Product and Service [Domain] Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Common stock options Options Share-Based Payment Arrangement, Option [Member] Cap price (in USD per share) Derivative, Cap Price Short-term lease expense Short-Term Lease, Cost Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Less Adjusted Gross Profit reconciling items: Less Adjusted Gross Profit reconciling items [Abstract] Less Adjusted Gross Profit reconciling items [Abstract] Vested (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Depreciation expense Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Option to draw, term Debt Instrument, Delayed Draw Facility, Term Debt Instrument, Delayed Draw Facility, Term Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Lumeon Lumeon Ltd. [Member] Lumeon Ltd. Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Interest rate Debt Instrument, Basis Spread on Variable Rate Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Award Type [Axis] Award Type [Axis] Options exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Client relationships and contract backlog Client relationships and contracts Client Relationships And Contracts [Member] Client Relationships And Contracts Capped Call Capped Call [Member] Capped Call Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Settled Litigation Settled Litigation [Member] Total liabilities Liabilities Vested and exercisable (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Schedule of Cash Equivalents and Short-Term Investments Measured at Fair Value Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and development Research and Development Expense 2023 Restructuring Plan 2023 Restructuring Plan [Member] 2023 Restructuring Plan Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Operating lease liabilities Operating Lease, Liability, Current Common stock, shares issued (in shares) Common Stock, Shares, Issued Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Revenue related to contracts with customers (percentage) Concentration Risk, Percentage Computer equipment Computer equipment Computer Equipment [Member] Total Restructuring Costs and Asset Impairment Charges Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment Property, Plant and Equipment, Gross Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Ownership Plan Exercise of stock options (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Acquisition of businesses, net of cash acquired Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Basis of presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares) Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Cumulative restructuring costs and asset impairment charges Cumulative Restructuring Costs and Asset Impairment Charges Cumulative Restructuring Costs and Asset Impairment Charges Severance and other restructuring costs Restructuring Costs Percentage increase of the number of common stock shares (in percentage) Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Prepaid expenses and other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Proceeds from issuance of debt Proceeds from Issuance of Debt Related Party Related Party [Member] Fair value, due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Hedging Designation [Domain] Hedging Designation [Domain] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Deferred tax provision (benefit) Deferred Income Tax Expense (Benefit) Schedule of Goodwill by Reporting Unit Schedule of Goodwill [Table Text Block] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Computer software Computer software Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Unaudited Proforma Financial Information Business Acquisition, Pro Forma Information [Table Text Block] Fair Value, Recurring Fair Value, Recurring [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Conversion price (in USD per share) Debt Instrument, Convertible, Conversion Price Cost of revenue Cost of Sales [Member] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Impairment Charges Asset Impairment Charges Shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net carrying amount Net carrying amount Long-Term Debt Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four Acquisition transaction costs Acquisition-related costs, net Business Combination, Acquisition Related Costs Prepayment of premium percentage Debt Instrument, Prepayment Premium, Percentage Debt Instrument, Prepayment Premium, Percentage Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Schedule of Restructuring-Related Charges and Related Liability Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Option shares outstanding, weighted average remaining contractual life in years Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Commercial paper Commercial paper Commercial Paper [Member] Development costs and internal-use software Internal Use Software, Policy [Policy Text Block] Schedule of Segment Revenue Schedule of Segment Reporting Information, by Segment [Table Text Block] Treasury stock acquired, average cost per share (in USD per share) Shares Acquired, Average Cost Per Share Computer software licenses Computer software licenses Computer Software, Intangible Asset [Member] Vested and exercisable, weighted average remaining contractual life in years Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Debt Instrument Convertible Threshold Type [Axis] Debt Instrument Convertible Threshold Type [Axis] Debt Instrument Convertible Threshold Type Severance And Other Team Member Costs Severance And Other Team Member Costs [Member] Severance And Other Team Member Costs Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Amortization of intangible assets Amortization of Intangible Assets Deferred revenue Contract with Customer, Liability Payment of deferred financing costs Payments of Financing Costs Net Finite-Lived Intangible Assets, Net Furniture and fixtures Furniture and fixtures Furniture and Fixtures [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Revenue: Revenues [Abstract] ESPP share increase in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period Leasehold improvements Leasehold Improvements [Member] Business Combinations Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Related party transactions Related Party Transaction, Amounts of Transaction Total Lease, Cost Short-term investments Short-Term Investments Derivative, cost of hedge Derivative, Cost of Hedge Statistical Measurement [Axis] Statistical Measurement [Axis] Share-based payment award, shares issued in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Total pro forma adjustments Total Pro Forma Adjustments [Member] Total Pro Forma Adjustments Fair value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Proceeds from issuance of long-term debt, net of issuance costs Proceeds from Issuance of Secured Debt Goodwill impairment Goodwill, Impairment Loss Schedule of Share Totals With a Potentially Dilutive Impact Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Total consideration transferred, net of cash acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Estimated useful life Finite-Lived Intangible Asset, Useful Life Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Hedging Relationship [Axis] Hedging Relationship [Axis] Capitalized computer software, amortization Capitalized Computer Software, Amortization Redemption price, percentage Debt Instrument, Redemption Price, Percentage Client relationships Customer Relationships [Member] Recent accounting pronouncements not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share, diluted (in USD per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Revenue recognition Revenue from Contract with Customer [Policy Text Block] Net deferred tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Net Deferred Tax Liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Net Deferred Tax Liability Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Vesting percent Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Intangible assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Share Repurchase Plan Share Repurchase Plan [Member] Share Repurchase Plan Number of operating segments Number of operating segments Number of Operating Segments ARMUS ARMUS Corporation [Member] ARMUS Corporation Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Interest Rate Term Loan Interest Rate Term Loan [Member] Interest Rate Term Loan Measurement Input Business Combination, Contingent Consideration, Liability, Measurement Input Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Sales and marketing Sales and marketing Selling and Marketing Expense Vesting period two Share-Based Payment Arrangement, Tranche Two [Member] Proceeds from the sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Estimated period of benefit Commission Payment, Estimated Benefit Period Commission Payment, Estimated Benefit Period Cumulative asset impairment charges Cumulative Asset Impairment Charges Cumulative Asset Impairment Charges Income tax provision (benefit) Income Tax Expense (Benefit) Acquisition-date contingent consideration liabilities from acquisitions (see Note 2) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability,

Purchases Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Interest and other income (expense), net Interest And Other Expense, Net Interest And Other Expense, Net Basis rate (in percentage) Debt Instrument, Interest Rate, Stated Percentage Options cancelled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Nonvested awards, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net loss Net Income (Loss) Available to Common Stockholders, Diluted Vitalware L L C Vitalware L L C [Member] Vitalware L L C Total revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Product Information [Line Items] Product Information [Line Items] Purchase of intangible assets Payments to Acquire Intangible Assets Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Effective income tax rate (in percentage) Effective Income Tax Rate Reconciliation, Percent Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Loss from operations Operating Income (Loss) Total Interest Expense, Operating and Nonoperating Professional services Professional Services Professional Services [Member] Professional Services [Member] Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Business Acquisition [Line Items] Business Acquisition [Line Items] Number of reportable segments Number of Reportable Segments Total liabilities and stockholdersâ€™ equity Liabilities and Equity Other Other Operating Activities, Cash Flow Statement Measurement Input, EBITDA Multiple Measurement Input, EBITDA Multiple [Member] Accrued compensation and benefit expenses Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Amortization of acquired intangible assets Amortization Of Acquired Intangible Assets [Member] Amortization Of Acquired Intangible Assets Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Hedging Designation [Axis] Hedging Designation [Axis] Impairment of long-lived assets Operating Lease, Impairment Loss Restructuring costs Restructuring Charges Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest and other income (expense), net Interest Income (Expense), Nonoperating Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Line Items] Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed Performance-based restricted stock units Performance-based restricted stock units Phantom Share Units (PSUs) [Member] Schedule of Principal Payments and Debt Maturity Schedule of Maturities of Long-Term Debt [Table Text Block] Operating lease right-of-use assets obtained in exchange for operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Measurement Input Type [Axis] Measurement Input Type [Axis] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Remaining performance obligation, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Expected term (in years) Expected term (in months) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term U.S. agency securities US Government Agencies Debt Securities [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Share-based payment award, per share weighted average price of shares purchased (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased Measurement Input Type [Domain] Measurement Input Type [Domain] Schedule of Segment Adjusted Gross Profit Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Operating expenses: Operating Expenses [Abstract] Total assets acquired, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Schedule of Property and Equipment, Useful Life Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Sublease income Sublease Income Vesting [Domain] Vesting [Domain] Consideration Business Combination, Consideration Transferred Unvested and outstanding, beginning balance, grant date fair value (in USD per share) Unvested and outstanding, ending balance, grant date fair value (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liabilities and stockholdersâ€™ equity Liabilities and Equity [Abstract] Cash retention payment Business Combination, Cash Retention Payment Business Combination, Cash Retention Payment Balance as of JanuaryÂ 1, 2024 Balance as of SeptemberÂ 30, 2024 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Allowed termination period Deferred Revenue Arrangement For Service Contract, Allowed Termination Period Deferred Revenue Arrangement For Service Contract, Allowed Termination Period Capitalized internal-use software costs Capitalized internal-use software costs Software Development [Member] Less: Unamortized discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Minimum Minimum Minimum [Member] Vested and expected to vest, outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Option to draw Debt Instrument, Option To Draw Debt Instrument, Option To Draw Related Party Transactions [Abstract] Related Party Transactions [Abstract] Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Amortization of deferred contract acquisition costs Deferred Policy Acquisition Costs, Amortization Expense Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding, beginning balance (in USD per share) Outstanding, ending balance (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Outstanding, beginning (in shares) Outstanding, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Capitalized computer software, additions Capitalized Computer Software, Additions Provision for expected credit losses Accounts Receivable, Credit Loss Expense (Reversal) Segments [Axis] Segments [Axis] Schedule of Stock-based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Derivative Instrument [Axis] Derivative Instrument [Axis] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Stock-based compensation capitalized as internal-use software Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense Total Principal Outstanding Total debt maturities Long-Term Debt, Gross Capitalized internal-use software included in accounts payable and accrued liabilities Capitalized Internal-Use Software In Accounts Payable And Accrued Liabilities Capitalized Internal-Use Software In Accounts Payable And Accrued Liabilities Net Loss Per Share Earnings Per Share [Text Block] Restructuring Costs Restructuring, Impairment, and Other Activities Disclosure [Text Block] Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Schedule of Employee Stock Purchase Plan Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Convertible Debt Convertible Debt [Table Text Block] Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Income taxes Income Tax, Policy [Policy Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Segments [Domain] Segments [Domain] Weighted Average Remaining Contractual Life in Years Weighted Average Remaining Contractual Life In Years [Abstract] Weighted Average Remaining Contractual Life In Years Impaired Long-Lived Assets Held and Used, Asset Name [Domain] Impaired Long-Lived Assets Held and Used, Asset Name [Domain] Measurement period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Measurement Period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Measurement Period Credit agreement term Debt Instrument, Term Description of Business and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Reporting Unit [Axis] Reporting Unit [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Notice required for termination Deferred Revenue Arrangement For Service Contract, Notice Required For Termination Deferred Revenue Arrangement For Service Contract, Notice Required For Termination Expected dividends Expected dividends Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments Carevive Systems, Inc. Carevive Systems, Inc. [Member] Carevive Systems, Inc. Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrecognized stock-based compensation expense related to RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unutilized commitment percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Vesting period three Share-Based Payment Arrangement, Tranche Three [Member] KPI Ninja KPI Ninja [Member] KPI Ninja Stockholders vote Stockholders Vote Stockholders Vote Related Party [Domain] Related and Nonrelated Parties [Domain] Shares outstanding (in shares) Shares, Outstanding Money market funds Cash and Cash Equivalents, Fair Value Disclosure Short-term Investments Short Term Marketable Security [Member] Short Term Marketable Security [Member] Maximum purchase value during offering period Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee Impairment losses recorded on deferred contract costs Capitalized Contract Cost, Impairment Loss Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] 2019 Stock Incentive Plan Stock Incentive Plan 2019 [Member] Stock Incentive Plan 2019 Revenue Volatility Measurement Input, Revenue Multiple [Member] Local Phone Number Local Phone Number Less liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Term Loan Term Loan [Member] Term Loan Liability Class [Axis] Liability Class [Axis] Senior Notes Due 2025 Senior Notes Due 2025 [Member] Senior Notes Due 2025 Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total operating expenses Operating Expenses Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected volatility Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Schedule of Outstanding RSUs and Related Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Convertible Notes Payable Convertible Notes Payable [Member] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Repurchase of common stock (in shares) Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Service period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Purchase price of common stock (in percentage) Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Debt Instrument Convertible Threshold Type [Domain] Debt Instrument Convertible Threshold Type [Domain] Debt Instrument Convertible Threshold Type Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Fair Value Fair Value Debt Securities, Available-for-Sale, Excluding Accrued Interest Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Vested and expected to vest (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Employee stock purchase plan period Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Share price (in USD per share) Share Price Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key 2029 Long-Term Debt, Maturity, Year Five Accrued liabilities Total accrued liabilities Accrued Liabilities And Employee-Related Liabilities, Current Accrued Liabilities And Employee-Related Liabilities, Current General and administrative General and Administrative Expense [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Other Other Restructuring Costs Acquisition-related costs, net Acquisition-related Costs [Member] Able Health Inc Able Health Inc [Member] Able Health Inc Stockholdersâ€™ Equity Equity [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Segments Segment Reporting Disclosure [Text Block] Current portion of long-term debt Less: Current portion of long-term debt Long-Term Debt, Current Maturities Change in fair value of contingent consideration liabilities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value of contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Restricted shares Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Leasehold Improvements And Furniture And Fixtures Leasehold Improvements And Furniture And Fixtures [Member] Leasehold Improvements And Furniture And Fixtures Credit Agreement Credit Agreement [Member] Credit Agreement Statement [Table] Statement [Table] Contractual interest expense Interest Expense, Debt Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Geographic Concentration Risk Geographic Concentration Risk [Member] Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Cumulative other restructuring costs Cumulative Other Restructuring Costs Cumulative Other Restructuring Costs Contingent consideration liabilities Contingent consideration liabilities Business Combination, Contingent Consideration, Liability Technology and professional services Technology And Professional Services [Member] Technology And Professional Services [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Change in foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Common Stock and Additional Paid-in Capital Common Stock Including Additional Paid in Capital [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Shares related to convertible senior notes Senior Notes [Member] Repurchase of common stock Payments for Repurchase of Common Stock Vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 2027 Long-Term Debt, Maturity, Year Three Long-term debt, net of current portion Long-Term Debt, Excluding Current Maturities Schedule of Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Carevive and Lumeon Carevive and Lumeon Acquisitions [Member] Carevive and Lumeon Acquisitions Expected Term (years) Measurement Input, Expected Term [Member] Remaining performance obligation (in percentage) Revenue, Remaining Performance Obligation, Percentage Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Options cancelled/forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 2011 Stock Incentive Plan Stock Incentive Plan 2011 [Member] Stock Incentive Plan 2011 [Member] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Treasury stock, shares, retired (in shares) Treasury Stock, Shares, Retired General and administrative General and administrative General and Administrative Expense Litigation settlement, amount Litigation Settlement, Amount Awarded to

Other Party 2026 Long-Term Debt, Maturity, Year Two Technology Technology Technology [Member] Technology [Member] Black-Scholes Valuation, Black-Scholes [Member] Valuation, Black-Scholes Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Short-term Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Repayment of seller-financed debt Repayments of Other Debt Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Debt Instrument Convertible Sale Price Of Stock Threshold Debt Instrument Convertible Sale Price Of Stock Threshold [Member] Debt Instrument Convertible Sale Price Of Stock Threshold Estimated fair value of convertible senior notes Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Accounts receivable, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Aggregate intrinsic value of contingent consideration liability Contingent Consideration, Liability, Aggregate Intrinsic Value Contingent Consideration, Liability, Aggregate Intrinsic Value Gross profit Gross Profit Total Fair Value, Net Asset (Liability) Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table] Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table] Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table] Option shares vested and expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Level 2 Fair Value, Inputs, Level 2 [Member] Amortized cost, due within one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Amount borrowed Debt Instrument, Face Amount Schedule of Revenue Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advertising expense Advertising Expense Principles of consolidation Consolidation, Policy [Policy Text Block] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Non-cash operating lease expense Increase (Decrease) In Operating Lease, Right-Of-Use Assets Increase (Decrease) In Operating Lease, Right-Of-Use Assets Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Issuance of common stock related to acquisitions Common stock issued in connection with acquisitions Stock Issued During Period, Value, Acquisitions Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Loss before income taxes Income (Loss) Attributable to Parent, before Tax Litigation Status [Axis] Litigation Status [Axis] Issuance of common stock related to acquisitions (in shares) Stock Issued During Period, Shares, Acquisitions Subscription contract, term Revenue From Subscription Contract, Term of Contract Revenue From Subscription Contract, Term of Contract Provision for expected credit losses Financing Receivable, Credit Loss, Expense (Reversal) Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Subscription contracts, days notice of termination Revenue From Subscriptions Contract, Notice Required For Termination Revenue From Subscriptions Contract, Notice Required For Termination Delayed Draw Term Loan (DDTL) Delayed Draw Term Loan (DDTL) [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 Preferred Stock, Value, Issued Proceeds from the sale and maturity of short-term investments Proceeds from Sale, Maturity and Collection of Investments Property, plant and equipment, useful life (in years) Property, Plant and Equipment, Useful Life Less other reconciling items: Less Other Reconciling Items [Abstract] Less Other Reconciling Items [Abstract] Time-Based Option Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Reporting Unit [Domain] Reporting Unit [Domain] Employee stock purchase plan Employee Stock [Member] Depreciation and amortization Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Net loss per share, basic (in USD per share) Earnings Per Share, Basic Products and Services [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Trademarks Trademarks Trademarks [Member] Purchase of property and equipment included in accounts payable and accrued liabilities Capital Expenditures Incurred but Not yet Paid Schedule of Goodwill [Table] Goodwill [Table] Capitalization of internal-use software Capitalized Of Internal Use Software Capitalized Of Internal Use Software Designated as Hedging Instrument Designated as Hedging Instrument [Member] Net loss Net Income (Loss) Available to Common Stockholders, Basic Property and equipment Property, Plant and Equipment, Policy [Policy Text Block] Total current liabilities Liabilities, Current Share Repurchase Program [Axis] Share Repurchase Program [Axis] Total assets Assets Contingent consideration cap Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Advertising costs Advertising Cost [Policy Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule of Fair Value Assets and liabilities Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Other liabilities Other Liabilities, Noncurrent Total cost of revenue, excluding depreciation and amortization Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Commitments and contingencies (Note 15) Commitments and Contingencies Stock-based compensation Share-Based Payment Arrangement [Policy Text Block] Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Quarterly principal payment percentage Debt Instrument, Quarterly Payment, Principal, Percentage Debt Instrument, Quarterly Payment, Principal, Percentage Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent Consideration Liability Business combinations/Contingent consideration liabilities Business Combinations Policy [Policy Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Debt instrument, convertible, threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger 2025 Long-Term Debt, Maturity, Year One Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Accounts payable, accrued liabilities, and other liabilities Increase (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities Increase (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities Assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] 2022 Restructuring Plan 2022 Restructuring Plan [Member] 2022 Restructuring Plan Entity Address, City or Town Entity Address, City or Town Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Leases Lessee, Leases [Policy Text Block] Release of shares, period Share-based Compensation Arrangement by Share-based Payment Award, Acquisition Date Anniversary, Release of Shares, Period Share-based Compensation Arrangement by Share-based Payment Award, Acquisition Date Anniversary, Release of Shares, Period Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Information Related to Stock Options Share-Based Payment Arrangement, Option, Activity [Table Text Block] Shares exercised in period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Stock-based compensation expense Stock-based compensation Share-Based Payment Arrangement, Expense Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Aggregate Intrinsic Value Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Cumulative severance costs Cumulative Severance Costs Cumulative Severance Costs Loss Contingencies [Table] Loss Contingencies [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Intangible Asset, Useful Life Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Proceeds from employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Entity File Number Entity File Number Revenue Deferred Revenue and Performance Obligations Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Treasury stock, value, acquired, cost method Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Severance and Other Team Member Costs Severance Costs Restructuring Plan [Domain] Restructuring Plan [Domain] Other accrued liabilities Other Accrued Liabilities, Current Option shares vested and exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Document Period End Date Document Period End Date Short-term investments Investment, Policy [Policy Text Block] Unvested and outstanding, beginning balance (in shares) Unvested and outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Segment Reconciling Items Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Treasury stock, retired, cost method, amount Treasury Stock, Retired, Cost Method, Amount Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Amortization of deferred financing costs Amortization of Debt Issuance Costs Litigation Status [Domain] Litigation Status [Domain] Litigation charges Litigation Settlement, Fee Expense Related Party [Axis] Related and Nonrelated Parties [Axis] Additional delayed draw facility Debt Instrument, Additional Draw Amount Debt Instrument, Additional Draw Amount Weighted-average shares outstanding used in calculating net loss per share, basic (in shares) Weighted-average shares outstanding used in calculating net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Restricted stock units Restricted Stock Units (RSUs) [Member] Amortization of debt discount, issuance costs, and deferred financing costs Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Property and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Service contract term Deferred Revenue Arrangement For Service Contract, Term Deferred Revenue Arrangement For Service Contract, Term Purchase of short-term investments Payments to Acquire Investments Accrued and other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Entity Filer Category Entity Filer Category Beginning, balance Ending, balance Restructuring Reserve Shares issued (in shares) Shares, Issued Revenue remaining performance obligation amount Revenue, Remaining Performance Obligation, Amount Total grant-date fair value of stock options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Cost of revenue, excluding depreciation and amortization: Cost of Revenue [Abstract] Loss Contingencies [Line Items] Loss Contingencies [Line Items] EX-101.PRE 9 hcat-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover Page - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-38993 Â Entity Registrant Name HEALTH CATALYST, INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 45-3337483 Â Entity Address, Address Line One 10897 South River Front Parkway #300 Â Entity Address, City or Town South Jordan Â Entity Address, State or Province UT Â Entity Address, Postal Zip Code 84095 Â City Area Code 801 Â Local Phone Number 708-6800 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol HCAT Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Emerging Growth Company false Â Entity Small Business false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 60,847,658 Entity Central Index Key 0001636422 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most

recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 328,327 $ 106,276 Short-term investments 58,929 211,452 Accounts receivable, net [1] 51,648 60,290 Prepaid expenses and other assets 18,510 15,379 Total current assets 457,414 393,397 Property and equipment, net 27,908 25,712 Intangible assets, net 76,463 73,384 Operating lease right-of-use assets 11,222 13,927 Goodwill 234,387 190,652 Other assets 5,656 4,742 Total assets 813,050 701,814 Current liabilities: Â Â Accounts payable 14,278 6,641 Accrued liabilities 23,548 23,282 Deferred revenue [1] 52,202 55,753 Operating lease liabilities 3,329 3,358 Current portion of long-term debt 230,423 0 Total current liabilities 323,780 89,034 Long-term debt, net of current portion 114,611 228,034 Deferred revenue, net of current portion 258 77 Operating lease liabilities, net of current portion 15,969 17,676 Other liabilities 3,395 74 Total liabilities 458,013 334,895 Commitments and contingencies (Note 15) Stockholdersâ€™ equity: Â Â Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 0 0 Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; 60,847,658 and 58,295,491 shares issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively 1,521,146 1,484,056 Accumulated deficit (1,165,999) (1,117,170) Accumulated other comprehensive income (loss) (110) 33 Total stockholdersâ€™ equity 355,037 366,919 Total liabilities and stockholdersâ€™ equity $ 813,050 $ 701,814 [1] Includes amounts attributable to related party transactions. See Note 17 for further details. X - DefinitionAccrued Liabilities And Employee-Related Liabilities, Current + ReferencesNo definition available. + Details Name: hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-

1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of par value plus amounts in excess of par value or issuance value for common stock issued. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStocksIncludingAdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value (in USD per share) $ 0.001 $ 0.001 Preferred stock, shares

authorized (in shares) 25,000,000 25,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in USD per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 500,000,000 500,000,000 Common stock, shares issued (in shares) 60,847,658 58,295,491 Common stock, shares outstanding (in shares) 60,847,658 58,295,491 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue: Â Â Â Â Total revenue [1] $ 76,353 $ 73,773 $ 226,978 $ 220,854 Cost of revenue, excluding depreciation and amortization: Â Â Â Â Total cost of revenue, excluding depreciation and amortization 42,313 41,787 120,890 119,529 Operating expenses: Â Â Â Â Sales and marketing 11,342 15,084 43,145 50,050 Research and development 14,193 17,667 42,948 52,339 General and administrative 12,209 13,625 41,136 61,129 Depreciation and amortization 9,983 10,190 31,165 31,919 Total operating expenses 47,727 56,566 158,394 195,437 Loss from operations (13,687) (24,580) (52,306) (94,112) Interest and other income (expense), net (1,514) 2,607 3,185 6,490 Loss before income taxes (15,201) (21,973) (49,121) (87,622) Income tax provision (benefit) (475) 59 (292) 213 Net loss $ (14,726) $ (22,032) $ (48,829) $ (87,835) Net loss per share, basic (in USD per share) $ (0.24) $ (0.39) $ (0.82) $ (1.57) Net loss per share, diluted (in USD per share) $ (0.24) $ (0.39) $ (0.82) $ (1.57) Weighted-average shares outstanding used in calculating net loss per share, basic (in shares) 60,440,694 56,710,602 59,448,966 56,061,925 Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares) 60,440,694 56,710,602 59,448,966 56,061,925 Technology Â Â Â Â Revenue: Â Â Â Â Total revenue [1] $ 48,653 $ 45,973 $ 143,254 $ 140,483 Cost of revenue, excluding depreciation and amortization: Â Â Â Â Total cost of revenue, excluding depreciation and amortization 17,609 15,169 48,991 45,755 Professional services Â Â Â Â Revenue: Â Â Â Â Total revenue [1] 27,700 27,800 83,724 80,371 Cost of revenue, excluding depreciation and amortization: Â Â Â Â Total cost of revenue, excluding depreciation and amortization $ 24,704 $ 26,618 $ 71,899 $ 73,774 [1] Includes amounts attributable to related party transactions. See Note 17 for further details. X - DefinitionCost of product sold and service rendered, excluding depreciation, depletion, and amortization. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostOfRevenueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 + Details Name: us-gaap_IncomeLossAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=hcat_TechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=hcat_ProfessionalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net loss $ (14,726) $ (22,032) $ (48,829) $ (87,835) Other comprehensive income (loss): Â Â Â Â Change in net unrealized gains (losses) on available for sale investments 105 35 (63) 490 Change in foreign currency translation adjustment (53) (1) (80) (12) Comprehensive loss $ (14,674) $ (21,998) $ (48,972) $ (87,357) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands Total Common Stock and Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income (Loss) Beginning balance (in shares) at Dec. 31, 2022 Â 55,261,922 Â Â Beginning balance at Dec. 31, 2022 $ 425,010 $ 1,424,681 $ (999,023) $ (648) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Vesting of restricted stock units and restricted shares (in shares) Â 1,554,641 Â Â Issuance of common stock under employee stock purchase plan (in shares) Â 244,133 Â Â Issuance of common stock under employee

stock purchase plan 2,206 $ 2,206 Â Â Exercise of stock options (in shares) Â 128,443 Â Â Exercise of stock options 937 $ 937 Â Â Stock-based compensation 43,406 $ 43,406 Â Â Issuance of common stock related to acquisitions 0 Â Â Â Repurchase of common stock (in shares) Â (145,027) Â Â Repurchase of common stock (1,808) $ (1,808) Â Â Net loss (87,835) Â (87,835) Â Other comprehensive income (loss) 478 Â Â 478 Ending balance (in shares) at Sep. 30, 2023 Â 57,044,112 Â Â Ending balance at Sep. 30, 2023 382,394 $ 1,469,422 (1,086,858) (170) Beginning balance (in shares) at Jun. 30, 2023 Â 56,541,641 Â Â Beginning balance at Jun. 30, 2023 389,867 $ 1,454,897 (1,064,826) (204) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Vesting of restricted stock units and restricted shares (in shares) Â 497,789 Â Â Exercise of stock options (in shares) Â 4,682 Â Â Exercise of stock options 40 $ 40 Â Â Stock-based compensation 14,485 $ 14,485 Â Â Net loss (22,032) Â (22,032) Â Other comprehensive income (loss) 34 Â Â 34 Ending balance (in shares) at Sep. 30, 2023 Â 57,044,112 Â Â Ending balance at Sep. 30, 2023 $ 382,394 $ 1,469,422 (1,086,858) (170) Beginning balance (in shares) at Dec. 31, 2023 58,295,491 58,295,491 Â Â Beginning balance at Dec. 31, 2023 $ 366,919 $ 1,484,056 (1,117,170) 33 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Vesting of restricted stock units and restricted shares (in shares) Â 1,486,435 Â Â Issuance of common stock under employee stock purchase plan (in shares) Â 263,482 Â Â Issuance of common stock under employee stock purchase plan $ 1,431 $ 1,431 Â Â Exercise of stock options (in shares) 26,668 26,668 Â Â Exercise of stock options $ 169 $ 169 Â Â Stock-based compensation 30,054 $ 30,054 Â Â Issuance of common stock related to acquisitions (in shares) Â 775,582 Â Â Issuance of common stock related to acquisitions 5,436 $ 5,436 Â Â Net loss (48,829) Â (48,829) Â Other comprehensive income (loss) $ (143) Â Â (143) Ending balance (in shares) at Sep. 30, 2024 60,847,658 60,847,658 Â Â Ending balance at Sep. 30, 2024 $ 355,037 $ 1,521,146 (1,165,999) (110) Beginning balance (in shares) at Jun. 30, 2024 Â 60,075,178 Â Â Beginning balance at Jun. 30, 2024 357,002 $ 1,508,437 (1,151,273) (162) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Vesting of restricted stock units and restricted shares (in shares) Â 379,584 Â Â Exercise of stock options (in shares) Â 5,904 Â Â Exercise of stock options 39 $ 39 Â Â Stock-based compensation 9,818 $ 9,818 Â Â Issuance of common stock related to acquisitions (in shares) Â 386,992 Â Â Issuance of common stock related to acquisitions 2,852 $ 2,852 Â Â Net loss (14,726) Â (14,726) Â Other comprehensive income (loss) $ 52 Â Â 52 Ending balance (in shares) at Sep. 30, 2024 60,847,658 60,847,658 Â Â Ending balance at Sep. 30, 2024 $ 355,037 $ 1,521,146 $ (1,165,999) $ (110) X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 40 -Section 25 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480637/718-40-25-10 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting

Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities Â Â Net loss $ (48,829) $ (87,835) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Â Â Stock-based compensation expense 29,316 42,745 Depreciation and amortization 31,165 31,919 Impairment of long-lived assets 2,200 2,681 Non-cash operating lease expense 1,981 2,272 Amortization of debt discount, issuance costs, and deferred financing costs 2,078 1,132 Investment discount and premium accretion (3,899) (6,816) Provision for expected credit losses 3,433 1,626 Deferred tax provision (benefit) (517) 6 Change in fair value of contingent consideration liabilities (1,642) 0 Other 87 101 Change in operating assets and liabilities: Â Â Accounts receivable, net 6,304 259 Prepaid expenses and other assets (617) 385 Accounts payable, accrued liabilities, and other liabilities 4,810 1,847 Deferred revenue (5,259) (1,688) Operating lease liabilities (2,525) (2,673) Net cash provided by (used in) operating activities 18,086 (14,039) Cash flows from investing activities Â Â Proceeds from the sale and maturity of short-term investments 206,488 256,101 Purchase of short-term investments (50,197) (254,448) Acquisition of businesses, net of cash acquired (54,889) 0 Capitalization of internal-use software (9,858) (9,331) Purchase of intangible assets (504) (986) Purchases of property and equipment (1,203) (981) Proceeds from the sale of property and equipment 10 21 Net cash provided by (used in) investing activities 89,847 (9,624) Cash flows from financing activities Â Â Proceeds from issuance of long-term debt, net of issuance costs 115,472 0 Payment of deferred financing costs (3,000) 0 Proceeds from employee stock purchase plan 2,061 3,206 Proceeds from exercise of stock options 169 937 Repurchase of common stock 0 (1,808) Repayment of seller-financed debt (646) 0 Net cash provided by financing activities 114,056 2,335 Effect of exchange rate changes on cash and cash equivalents 62 (13) Net increase (decrease) in cash and cash equivalents 222,051 (21,341) Cash and cash equivalents at beginning of period 106,276 116,312 Cash and cash equivalents at end of period 328,327 94,971 Supplemental disclosures of non-cash investing and financing information Â Â Common stock issued in connection with acquisitions 5,436 0 Stock-based compensation capitalized as internal-use software 738 622 Purchase of property and equipment included in accounts payable and accrued liabilities 310 21 Capitalized internal-use software included in accounts payable and accrued liabilities (322) 88 Operating lease right-of-use assets obtained in exchange for operating lease obligations 0 2,033 Purchase of intangible assets included in accounts payable and accrued liabilities $ 0 $ 1,310 X - DefinitionCapitalized Internal-Use Software In Accounts Payable And Accrued Liabilities + ReferencesNo definition available. + Details Name: hcat_CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCapitalized Of Internal Use Software + ReferencesNo definition available. + Details Name: hcat_CapitalizedOfInternalUseSoftware Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities + ReferencesNo definition available. + Details Name: hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) In Operating Lease Liabilities + ReferencesNo definition available. + Details Name: hcat_IncreaseDecreaseInOperatingLeaseLiabilities Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) In Operating Lease, Right-Of-Use Assets + ReferencesNo definition available. + Details Name: hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name

Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFuture cash outflow to pay for purchases of fixed assets that have occurred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans). + ReferencesNo definition available. + Details Name: us-gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for loan and debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfSecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of credit loss expense (reversal of expense) for financing receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_ProvisionForLoanLossesExpensed Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for the payment of debt classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfOtherDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Description of Business and Summary of Significant Accounting Policies Description of Business and Summary of Significant Accounting PoliciesNature of operationsHealth Catalyst, Inc. (Health Catalyst) was incorporated under the laws of Delaware in September 2011. We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data platform, software analytics applications, and professional services expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended DecemberÂ 31, 2023 included in our Annual Report on Form 10-K.Interim unaudited condensed consolidated financial statementsThe accompanying interim condensed consolidated balance sheet as ofÂ SeptemberÂ 30, 2024, the interim condensed consolidated statements of operations for theÂ three and nine months ended SeptemberÂ 30, 2024Â andÂ 2023, our interim condensed consolidated statements of stockholdersâ€™ equity for theÂ three and nine months ended SeptemberÂ 30, 2024 and 2023, and our interim condensed consolidated statements of cash flows for theÂ nine months ended SeptemberÂ 30, 2024Â andÂ 2023Â are unaudited. Our condensed consolidated balance sheet as ofÂ DecemberÂ 31, 2023Â was derived from audited financial statements, but does not include all disclosures required by GAAP. Our interim unaudited condensed consolidated financial statements have been prepared on a basis consistent with our annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Companyâ€™s financial position, its operations and cash flows for the periods presented. The historical results are not necessarily indicative of future results, and the results of operations for theÂ three and nine months ended SeptemberÂ 30, 2024Â are not necessarily indicative of the results to be expected for the full year or any other period.Principles of consolidationThe condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.Use of estimatesThe preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, reserves for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software, impairment assessments of goodwill, intangible assets, and other long-lived assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ significantly from those estimates.Segment reportingOperating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit.Net loss per shareBasic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period, when dilutive. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as the effect is anti-dilutive.Revenue recognitionWe derive our revenue primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: â€¢Identification of the contract, or contracts, with a client;â€

¢Identification of the performance obligations in the contract;â€¢Determination of the transaction price;â€¢Allocation of the transaction price to the performance obligations in the contract; andâ€¢Recognition of revenue when, or as, we satisfy the performance obligation.We recognize revenue net of any taxes collected from clients and subsequently remitted to governmental authorities.Technology revenueTechnology revenue primarily consists of subscription fees charged to clients for access to use our technology. We provide clients access to our technology through either an all-access or limited-access, modular subscription. The majority of our subscription arrangements are cloud-based and do not provide clients the right to take possession of the technology or contain a significant penalty if the client were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the client. Our subscription contracts generally have a three- or five-year term, of which many are terminable after one year upon 90 daysâ€™ notice.Subscriptions that allow the client to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the client. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the client.Professional services revenueProfessional services revenue primarily includes data and analytics services, domain expertise services, Tech-enabled Managed Services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our clients on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our clients. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the â€œright to invoiceâ€ practical expedient. Contracts with multiple performance obligationsMany of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include client demographics and the types of users. Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we generally use the residual method due to a limited number of standalone transactions and/or prices that are highly variable.Variable considerationWe have also entered into at-risk and shared savings arrangements with certain clients whereby we receive variable consideration based on the achievement of measurable improvements that may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. Contract balancesContract assets resulting from services performed prior to invoicing clients are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $8.3 million and $4.7 million, respectively. We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the client. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.5 million and $55.8 million, respectively.Deferred costsWe capitalize sales commissions and associated fringe costs, such as benefits and payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with clients, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the client contract. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, $2.2Â million and $2.2 million, respectively, of deferred contract acquisition costs are expected to be amortized within the next 12 months and are included in prepaid expenses and other assets on the condensed consolidated balance sheets. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the remaining $2.9Â million and $3.3 million, respectively, of deferred contract acquisition costs are included in non-current other assets.Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average client life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average client life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs was $0.7Â million and $0.6Â million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $2.0Â million and $1.6 for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively, and is included within sales and marketing expense in the condensed consolidated statements of operations.We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.Cost of revenue, excluding depreciation and amortizationCost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, license and revenue share fees, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue in the interim condensed consolidated statements of operations excludes costs related to depreciation and amortization.Cash and cash equivalentsWe consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.Short-term investmentsOur investment policy limits investments to highly-rated instruments. We classify and account for our short-term investments as available for sale securities as we may sell these securities at any time for use in our current operations or for other purposes, even prior to maturity. As a result, we classify our short-term investments, including securities with contractual maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. Accounts receivableAccounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, client payment patterns, the establishment of specific reserves for clients in an adverse financial condition, and our expectations of changes in macroeconomic conditions, including high interest rates and high inflation, that may impact the collectability of outstanding receivables. We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)Allowance for credit losses at the beginning of period$6,600Â $3,800Â $4,105Â $2,300Â Provision for expected credit losses(5)112Â 3,433Â 1,626Â Less: Write-offs, net of recoveries5Â (12)(938)(26)Allowance for credit losses at the end of period$6,600Â $3,900Â $6,600Â $3,900Â LeasesWe determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our lease contracts do not have a readily determinable implicit rate, we use our incremental borrowing rate based on the information available at the commencement date to determine the present value of lease payments. The incremental borrowing rate is the estimated rate incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable costs related to our leased office space, such as maintenance and utilities based on actual usage, are not included in the measurement of right-of-use assets and lease liabilities, but are expensed as incurred.Property and equipmentProperty and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows:Computer equipment2-3 yearsFurniture and fixtures3-5 yearsLeasehold improvementsLesser of lease term or estimated useful lifeComputer software2-5 yearsCapitalized internal-use software costs2-5 yearsWhen there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset, plus any terminal value, in the asset group. If the carrying amount of the asset group exceeds those estimated future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets.Intangible assetsIntangible assets include developed technologies, client relationships, client contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assetsâ€™ estimated useful lives. The estimated useful life of each asset category is as follows:Developed technologies3-10 yearsClient relationships and contract backlog2-7 yearsComputer software licenses1-5 yearsTrademarks1-5 yearsGoodwillWe record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, client relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually on October 31 or more frequently if indicators of impairment are present or circumstances suggest that impairment may exist. Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Judgment in the assessment of qualitative factors of impairment may include changes in business climate, market conditions, or other events impacting the reporting unit. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. Performing a quantitative goodwill impairment test includes the determination of the fair value of a reporting unit, which requires management to use significant judgment and estimation. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of the reporting units, as well as the sensitivity of the respective fair values to the underlying significant assumptions. Typical methods to derive the fair value of reporting units include using the income or market approaches. The significant assumptions used to form the basis of the estimates include, among others, the selection of valuation methodologies, estimates of expected revenue, including revenue growth rates, and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, and the selection of appropriate market comparable companies. Many of these significant assumptions are forward-looking and could be affected by future economic and market conditions. If a quantitative analysis is necessary, we typically engage the assistance of a valuation specialist in concluding on fair value measurements in connection with determining the fair values of our reporting units. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unitâ€™s fair value. There was no impairment of goodwill for the three and nine months ended SeptemberÂ 30, 2024 and 2023.Â Business combinationsThe results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of the acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration transferred over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill.We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the client-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for client relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of material assets acquired and liabilities assumed in a business combination. For the three and nine months ended SeptemberÂ 30, 2024, we expensed $1.7 million and $4.2Â million, respectively, of transaction costs associated with business combinations. For the three and nine months ended SeptemberÂ 30, 2023, we expensed $1.6 million of transaction costs associated with business combinations. The costs were expensed as incurred and are included in general and administrative expense in our condensed consolidated statements of operations.Contingent consideration liabilitiesOur acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements.We generally value the expected contingent consideration and the corresponding liabilities using the Monte Carlo method or Black-Scholes model based on estimates of potential payment scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period.As applicable, the portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes in the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations.Advertising costsAll advertising costs are expensed as incurred. For each of theÂ three months ended SeptemberÂ 30, 2024Â andÂ 2023, we incurredÂ $0.4 million of advertising costs, and $4.1 million and $1.6 million for the nine months ended September 30, 2024 and 2023, respectively.Development costs and internal-use softwareFor technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our clients on a subscription basis. Costs

incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life with amortization included in depreciation and amortization expense in our condensed consolidated statements of operations. Stock-based compensationStock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date or, when applicable, the modification date. The grant date fair value of our stock-based awards is typically determined using the market closing price of our common stock on the date of grant; however, we also consider whether any adjustments are required when the market closing price does not reflect certain material non-public information that we know but is unavailable to marketplace participants on the date of grant. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. For awards subject to market conditions, we estimate the fair value as of the grant date using a Monte Carlo simulation valuation model which requires the use of various assumptions, including historic stock price volatility and risk-free interest rates as of the valuation date corresponding to the length of time remaining in the performance period. Stock-based compensation expense for awards with market conditions is recognized over the requisite service period using the accelerated attribution method and is not reversed if the market condition is not met.Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period.The measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award.Restructuring costsWe define restructuring costs as expenses directly associated with restructuring activities. Such costs include severance and related tax and benefit expenses from workforce reductions, impairment of discontinued capitalized software projects, and other miscellaneous charges. We record team member-related severance costs when there is a substantive plan in place and the related costs are probable and estimable. For one-time termination benefits for team members (i.e., no substantive plan or future service requirement), the cost is recorded when the terms of the one-time termination benefits are communicated to the impacted team members and the amount can be reasonably estimated. Income taxesDeferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and tax credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not currently accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because the impact would be immaterial due to our net operating losses and tax credit carryforwards. Significant judgment is required to evaluate uncertain tax positions.Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations.Fair value of financial instrumentsThe carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. The carrying value of operating lease liabilities and convertible senior notes approximate fair value based on interest rates available for debt with similar terms at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. Money market funds and short-term investments are measured at fair value on a recurring basis. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:â€¢LevelÂ 1- Quoted prices in active markets for identical assets or liabilities.â€¢LevelÂ 2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.â€¢LevelÂ 3- Inputs that are generally unobservable and typically reflect managementâ€™s estimate of assumptions that market participants would use in pricing the asset or liability.All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios.Foreign currencyThe functional currency of our international subsidiaries is generally their local currency. We translate these subsidiariesâ€™ financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholdersâ€™ equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented.Recent accounting pronouncements not yet adoptedIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segmentâ€™s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segmentâ€™s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. We expect that the disclosure changes that result from the adoption of this ASU will not have a material impact on our consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entityâ€™s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2025.In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the provision of this ASU to determine the impact it may have on our consolidated financial statements and related disclosures, and we expect additional disclosures upon adoption. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combinations 9 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â Business Combinations Business CombinationsThe business acquisitions discussed below are included in our results of operations from the date of acquisition.2024 AcquisitionsLumeon Ltd.On August 1, 2024, we acquired Lumeon Ltd. (Lumeon), a digital health company dedicated to helping provider organizations mend broken care coordination processes through automated care orchestration. We accounted for the acquisition of Lumeon as a business combination. The acquisition consideration transferred was $39.8 million and was comprised of estimated net cash consideration of $36.2 million, Health Catalyst common shares with a fair value of $2.9 million, and contingent consideration based on certain earn-out performance targets for Lumeon during an earn-out period ending on June 30, 2025, with an acquisition-date fair value of $0.7 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Lumeon. The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Lumeon (in thousands):Assets acquired:Accounts receivable, net$967Â Prepaid expenses and other assets795Â Property and equipment, net165Â Client relationships3,700Â Developed technology11,400Â Trademarks1,300Â Total assets acquired18,327Â Less liabilities assumed:Accrued and other current liabilities1,151Â Deferred revenue1,759Â Net deferred tax liabilities3,679Â Total liabilities assumed6,589Â Total assets acquired, net11,738Â Goodwill28,092Â Total consideration transferred, net of cash acquired$39,830Â The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and five years, respectively. The resulting goodwill from the Lumeon acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. The preliminary allocation of the consideration transferred is subject to potential adjustments. Balances subject to adjustment are primarily tax-related matters, including the tax basis of assets acquired and liabilities assumed. During the measurement period, we may record adjustments to the provisional amounts recognized in our initial accounting for the acquisition. We expect the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). There were no measurement period adjustments recorded during the three months ended September 30, 2024. The amount of revenue attributable to the acquired business of Lumeon was not material to our condensed consolidated statement of operations for the three and nine months ended September 30, 2024. Income (loss) information for Lumeon after the acquisition date through SeptemberÂ 30, 2024 is not presented as the Lumeon business was integrated into our operations immediately following the acquisition and is impracticable to quantify.In addition to the purchase price, we agreed to make cash retention payments in an aggregate amount of up to $5.0 million to continuing Lumeon team members, a portion of which is variable based upon the achievement of earn-out performance targets. The retention payments are generally subject to vesting based upon continued employment over a required service period. Such amounts are recorded as post-combination compensation expense and recognized on a straight-line basis over the relevant vesting terms. During the nine months ended September 30, 2024, we recognized compensation expense of $1.1 million related to these retention payments.Carevive Systems, Inc.On May 24, 2024, we acquired Carevive Systems, Inc. (Carevive), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. We accounted for the acquisition of Carevive as a business combination. Oncology providers and life science researchers use Careviveâ€™s flagship platform and/or Carevive data in routine clinical practice for treatment care planning, clinical trial screening, care coordination, remote patient monitoring, and/or post-treatment care. The acquisition consideration transferred was $22.1 million and was comprised of estimated net cash consideration of $18.6 million, Health Catalyst common shares with a fair value of $2.6 million, and contingent consideration based on certain earn-out performance targets for Carevive during an earn-out period ending on June 30, 2025, with an acquisition-date fair value of $0.9 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Carevive. The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Carevive (in thousands):Assets acquired:Accounts receivable, net$96Â Prepaid expenses and other assets64Â Client relationships2,700Â Developed technology4,800Â Trademarks300Â Total assets acquired7,960Â Less liabilities assumed:Accrued and other current liabilities1,389Â Deferred revenue76Â Total liabilities assumed1,465Â Total assets acquired, net6,495Â Goodwill15,643Â Total consideration transferred, net of cash acquired$22,138Â The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and three years, respectively. The resulting goodwill from the Carevive acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. The preliminary allocation of the consideration transferred is subject to potential adjustments. Balances subject to adjustment are primarily tax-related matters, including the tax basis of assets acquired and liabilities assumed. During the measurement period, we may record adjustments to the provisional amounts recognized in our initial accounting for the acquisition. We expect the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). There were no measurement period adjustments recorded during the three and nine months ended September 30, 2024. The amount of revenue attributable to the acquired business of Carevive was not material to our consolidated statement of operations for the three and nine months ended September 30, 2024. Income (loss) information for Carevive after the acquisition date through SeptemberÂ 30, 2024 is not presented as the Carevive business was integrated into our operations immediately following the acquisition and is impracticable to quantify.In addition to the purchase price, we agreed to make cash retention payments in an aggregate amount of up to $1.8 million to continuing Carevive team members, a portion of which is variable based upon the achievement of earn-out performance targets. The retention payments are generally subject to vesting based upon continued employment over a required service period. Such amounts are recorded as post-combination compensation expense and recognized on a straight-line basis over the relevant vesting terms. During the nine months ended September 30, 2024, we recognized compensation expense of $0.8 million related to these retention payments.Unaudited Pro Forma Financial Information The following table reflects our unaudited pro forma combined results of operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023 as if the acquisitions of Carevive and Lumeon had taken place on JanuaryÂ 1, 2023 (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)Pro forma net loss$(14,818)$(27,407)$(56,182)$(107,898)The unaudited pro forma information is presented for informational purposes only and is not intended to present actual results that would have been attained had the acquisition been completed as of JanuaryÂ 1, 2023 or to project potential results as of any future date or for any future periods. The unaudited pro forma information, including adjustments, are based upon available information and certain assumptions that we believe are reasonable. Pro forma revenue has not been presented for these 2024 acquisitions as the impact to our condensed consolidated financial statements was not material. The nature and amount of material, nonrecurring pro forma adjustments directly attributable to these acquisitions which are included in the pro forma net loss, as applicable, are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Amortization of acquired intangible assets(303)(1,331)$(2,788)$(3,993)Acquisition-related costs, net1,487Â â€“Â 5,731Â (1,534)Total pro forma adjustments$1,184Â $(1,331)$2,943Â $(5,527)2023 Acquisition of Electronic Registry Systems, Inc.On October 2, 2023, we acquired Electronic Registry Systems, Inc. (ERS), a cloud-based provider of clinical registry development and data management software based in Cincinnati, Ohio. We accounted for the acquisition of ERS as a business combination. ERS provides cancer registry compliance and informatics services to enable customers to achieve their

cancer center clinical and business objectives with a goal of improving cancer care for every patient, including through its CRStar platform. The acquisition consideration transferred comprised of net cash consideration of $11.4Â million. The purchase resulted in Health Catalyst acquiring 100% ownership in ERS.An additional 175,901 shares of our common stock subject to a restriction agreement (restricted shares) were issued pursuant to the terms of the acquisition agreement. The vesting of these restricted shares was originally subject to eighteen months of continued employment with cliff vesting upon the eighteen-month anniversary of the acquisition close date. The value of these restricted shares was originally scheduled to be recognized as post-combination stock-based compensation expense on a straight-line basis over the vesting term, but due to workforce reductions made as part of the 2023 Restructuring Plan (as defined below), the ERS restricted shares fully vested in February 2024, resulting in an acceleration of the related stock-based compensation expense. Refer to Note 13-Stock-Based Compensation for additional details related to our stock-based compensation.The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of ERS (in thousands):Assets acquired:Accounts receivable$478Â Prepaid expenses and other assets73Â Client relationships5,300Â Developed technology3,100Â Trademarks100Â Total assets acquired9,051Â Less liabilities assumed:Accrued and other current liabilities78Â Deferred revenue2,251Â Total liabilities assumed2,329Â Total assets acquired, net6,722Â Goodwill4,670Â Total consideration transferred, net of cash acquired$11,392Â The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and two years, respectively. The resulting goodwill from the ERS acquisition was fully allocated to the technology reporting unit and is deductible for income tax purposes. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue RevenueDisaggregation of RevenueThe following table represents Health Catalystâ€™s revenue disaggregated by type of arrangement (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Recurring technology$48,653Â $45,973Â $143,254Â $140,126Â One-time technology (i.e., perpetual license)â€”Â â€”Â â€”Â 357Â Professional services27,700Â 27,800Â 83,724Â 80,371Â Total revenue$76,353Â $73,773Â $226,978Â $220,854Â Revenue related to contracts with clients located in the United States was 96.9% and 98.5% for the three months ended September 30, 2024 and 2023, respectively, and 97.6% and 98.3% for the nine months ended September 30, 2024 and 2023, respectively.Deferred Revenue and Performance ObligationsDeferred revenue includes advance client payments and billings in excess of revenue recognized.Â For the three months ended SeptemberÂ 30, 2024 and 2023, 43% and 45%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period. For the nine months ended SeptemberÂ 30, 2024 and 2023, 22% and 23%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period.Most of our technology and professional services contracts have a three- or five-year term, of which many are terminable after one year upon 90 daysâ€™ notice. For arrangements that do not allow the client to cancel within one year or less, we expect to recognize $290.5 million of revenue on unsatisfied performance obligations as of SeptemberÂ 30, 2024. We expect to recognize approximately 65% of the remaining performance obligations over the next 24 months, with the balance recognized thereafter. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill and Intangible Assets Goodwill and Intangible AssetsWe operate our business in two operating segments that also represent our reporting units. Our reporting units are organized based on our technology and professional services. We have not incurred any goodwill impairment charges.Goodwill by reporting unit is as follows (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Technology$233,605Â $189,870Â Professional services782Â 782Â Total goodwill$234,387Â $190,652Â As of SeptemberÂ 30, 2024, intangible assets consisted of the following (in thousands):CostAccumulated AmortizationNet(unaudited)Developed technologies$120,129Â $(90,573)$29,556Â Client relationships and contracts96,464Â (53,735)42,729Â Computer software licenses11,144Â (9,084)2,060Â Trademarks4,420Â (2,302)2,118Â Total intangible assets$232,157Â $(155,694)$76,463Â Amortization expense of acquired intangible assets was $6.8 million and $7.1 million for the three months ended SeptemberÂ 30, 2024 andÂ 2023, respectively, and $21.6 million and $22.4 million for the nine months ended September 30, 2024 and 2023, respectively. Amortization expense for intangible assets is included in depreciation and amortization in our condensed consolidated statements of operations. We have not incurred any intangible asset impairment charges for the three and nine months ended SeptemberÂ 30, 2024 and 2023.As of DecemberÂ 31, 2023, intangible assets consisted of the following (in thousands):CostAccumulated AmortizationNetDeveloped technologies$103,929Â $(79,057)$24,872Â Client relationships and contracts90,064Â (45,230)44,834Â Computer software licenses10,680Â (7,933)2,747Â Trademarks2,820Â (1,889)931Â Total intangible assets$207,493Â $(134,109)$73,384Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Property and Equipment Property and EquipmentProperty and equipment consisted of the following (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Computer equipment$10,532Â $9,638Â Leasehold improvements8,429Â 8,814Â Furniture and fixtures3,748Â 3,735Â Capitalized internal-use software costs41,526Â 30,771Â Computer software111Â 111Â Total property and equipment64,346Â 53,069Â Less: accumulated depreciation(36,438)(27,357)Property and equipment, net$27,908Â $25,712Â Our long-lived assets are located in the United States. Depreciation expense totaled $3.1 million for each of the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $9.5 million for each of the nine months ended September 30, 2024 and 2023, respectively. Depreciation expense includes the amortization of capitalized internal-use software costs. During each of the nine months ended SeptemberÂ 30, 2024 and 2023, we impaired $0.7 million of leasehold improvements related to our corporate office space designated for subleasing. Refer to Note 9 for additional details. We capitalized $4.4 million and $3.0 million of internal-use software costs for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $10.8 million and $9.6 million for the nine months ended September 30, 2024 and 2023, respectively. We incurred $2.5 million and $2.1 million of capitalized internal-use software cost amortization expense for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $7.2 million and $6.4 million for the nine months ended September 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Short-term Investments 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Short-term Investments Short-term InvestmentsWe classify our short-term investments as available for sale. Available-for-sale securities are recorded on our condensed consolidated balance sheets at fair market value and any unrealized gains or losses are reported as part of other comprehensive loss on the condensed consolidated statements of comprehensive loss. We determine realized gains or losses on the sales of investments through the specific identification method and record such gains or losses as part of interest and other expense, net on the condensed consolidated statements of operations. We did not have any material realized gains or losses on investments during the three and nine months ended SeptemberÂ 30, 2024 and 2023. We measure the fair value of investments on a recurring basis. The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of SeptemberÂ 30, 2024 (in thousands):Amortized CostUnrealized GainsUnrealized LossesFair ValueCash equivalentsShort-term Investments(unaudited)Money market funds$322,989Â $â€”Â $â€”Â $322,989Â $322,989Â $â€”Â U.S. treasury notes19,397Â 9Â â€”Â 19,406Â â€”Â 19,406Â Commercial paper12,092Â 7Â â€”Â 12,099Â â€”Â 12,099Â Corporate bonds27,416Â 8Â â€”Â 27,424Â â€”Â 27,424Â Total$381,894Â $24Â $â€”Â $381,918Â $322,989Â $58,929Â The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of DecemberÂ 31, 2023 (in thousands):Amortized CostUnrealized GainsUnrealized LossesFair ValueCash equivalentsShort-term InvestmentsMoney market funds$99,779Â $â€”Â $â€”Â $99,779Â $99,779Â $â€”Â U.S. treasury notes65,856Â 68Â â€”Â 65,924Â â€”Â 65,924Â Commercial paper85,358Â â€”Â (18)85,340Â â€”Â 85,340Â Corporate bonds43,746Â 49Â â€”Â 43,795Â â€”Â 43,795Â U.S. agency securities16,405Â â€”Â (12)16,393Â â€”Â 16,393Â Total$311,144Â $117Â (30)311,231Â $99,779Â $211,452Â The following table presents the contractual maturities of our short-term investments as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 (in thousands):As of September 30, 2024As of December 31, 2023Amortized CostFair ValueAmortized CostFair Value(unaudited)Due within one year$58,905Â $58,929Â $211,365Â $211,452Â Total$58,905Â $58,929Â $211,365Â $211,452Â Accrued interest receivables related to our available-for-sale securities of $1.4 million and $0.9 million as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively, were included within prepaid expenses and other assets on our condensed consolidated balance sheets. On a quarterly basis we evaluate unrealized losses on our available-for-sale debt securities and the related accrued interest receivables to determine whether a decline in the fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors. We do not intend to sell investments that are in an unrealized loss position and it is not likely that we will be required to sell any investments before recovery of their amortized cost basis. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, there were no material unrealized losses due to expected credit loss-related factors. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Instruments Fair Value of Financial InstrumentsAssets and liabilities measured at fair value on a recurring basis as of SeptemberÂ 30, 2024 were as follows (in thousands):September 30, 2024Level 1Level 2Level 3Total(unaudited)Money market funds$322,989Â $â€”Â $â€”Â $322,989Â U.S. Treasury notes19,406Â â€”Â â€”Â 19,406Â Commercial paperâ€”Â 12,099Â â€”Â 12,099Â Corporate bondsâ€”Â 27,424Â â€”Â 27,424Â Contingent consideration liabilitiesâ€”Â â€”Â â€”Â â€”Â Total$342,395Â $39,523Â $â€”Â $381,918Â Assets measured at fair value on a recurring basis as of DecemberÂ 31, 2023 were as follows (in thousands):December 31, 2023Level 1Level 2Level 3TotalMoney market funds$99,779Â $â€”Â $â€”Â $99,779Â U.S. Treasury notes65,924Â â€”Â â€”Â 65,924Â Commercial paperâ€”Â 85,339Â â€”Â 85,339Â Corporate bondsâ€”Â 43,796Â â€”Â 43,796Â U.S. agency securitiesâ€”Â 16,393Â â€”Â 16,393Â Total$165,703Â $145,528Â $â€”Â $311,231Â There were no transfers between Level 1 and Level 2 of the fair value measurement hierarchy during the three and nine months ended SeptemberÂ 30, 2024 and 2023.Convertible senior notesAs ofÂ SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the estimated fair value of our convertible senior notes, with aggregate principal totalingÂ $230.0Â million,Â wasÂ $227.9 million and $218.7 million, respectively. We estimate the fair value based on quoted market prices in an inactive market on the last trading day of the reporting period (Level 2). These convertible senior notes are recorded at face value less unamortized debt discount and transaction costs on our condensed consolidated balance sheets. Refer toÂ Note 10â€”Debt for further information.Nonrecurring fair value measurementsWe recorded impairment charges of $2.2 million and $2.7 million related

to the impairment of ROU assets and leasehold improvements associated with office space designated for subleasing during the nine months ended September 30, 2024 and 2023. These impairment charges were derived from the difference between the carrying value and the fair value of the relevant asset groups. The fair value of these asset groups was estimated using a discounted cash flow analysis of the office space designated for subleasing and included certain unobservable (Level 3) inputs, including the anticipated future sublease terms and rates.Level 3 fair value measurementsThe Lumeon acquisition consideration included an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Lumeon during an earn-out period that ends on June 30, 2025. The Lumeon contingent consideration is capped at $25.0 million and will be paid in cash to the extent achieved. We value Lumeonâ€™s expected contingent consideration and the corresponding liability using the Black-Scholes valuation method based on estimates of potential pay-out scenarios. The Carevive acquisition consideration included an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Carevive during an earn-out period that ends on June 30, 2025. The Carevive contingent consideration is capped at $10.0 million and will be paid in cash to the extent achieved. We value Careviveâ€™s expected contingent consideration and the corresponding liability using the Black-Scholes valuation method based on estimates of potential pay-out scenarios. The outstanding contingent consideration liabilities are categorized as Level 3 fair value measurements and are remeasured as of each reporting period. The aggregate intrinsic value of the revenue-based earn-out contingent consideration liabilities is zeroÂ based on a point estimate of our internal forecasting of the ultimate earn-outs that will be earned as of SeptemberÂ 30, 2024. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs used during the three months ended SeptemberÂ 30, 2024:Valuation MethodMarket Price of Revenue RiskRevenue VolatilityExpected Term (years)Risk-free interest rate(unaudited)Revenue-based earn-out liabilitiesBlack-Scholes8.4%20%1.25.0%The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):Fair Value Measurements Using Significant Unobservable Inputs (Level 3)(unaudited)Balance as of JanuaryÂ 1, 2024$â€”Â Acquisition-date contingent consideration liabilities from acquisitions (see Note 2)1,642Â Change in fair value of contingent consideration liabilities(1,642)Balance as of SeptemberÂ 30, 2024$â€”Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Liabilities 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Accrued Liabilities Accrued LiabilitiesAs of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, accrued liabilities consisted of the following (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Accrued compensation and benefit expenses$9,838Â $11,680Â Restructuring liabilities(1)7Â 2,355Â Other accrued liabilities13,703Â 9,247Â Total accrued liabilities$23,548Â $23,282Â _____(1)Restructuring liabilities include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in these condensed consolidated financial statements. X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Leases LeasesWe lease office space under operating leases that expire between 2024 and 2031. The terms of the leases provide for rental payments on a graduated scale, options to renew the leases (one to five years), landlord incentives or allowances, and periods of free rent. We subleased portions of our corporate headquarters to various sublessees with subleases commencing at various dates between 2021 and 2024.Components of lease expense (income) are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)Operating lease expense$692Â $760Â $1,986Â $2,334Â Short-term lease expense50Â 9Â 114Â 51Â Sublease income(414)(308)(1,068)(935)Total$328Â $461Â $1,032Â $1,450Â We also incur immaterial variable costs related to our leased office space, such as maintenance and utilities based on actual usage, which are not included in the measurement of right-of-use assets and lease liabilities, but are expensed as incurred.During the nine months ended SeptemberÂ 30, 2024 and 2023, we identified asset impairment indicators for multiple of our corporate office spaces designated for subleasing. We performed a recoverability test of the relevant asset group, comprised of operating lease ROU and other related assets, and determined that the carrying value of this asset group was not fully recoverable. As a result, we measured and recognized total impairment charges of $2.2 million and $2.7 million during the nine months ended September 30, 2024 and 2023, respectively, representing the amount by which the carrying value exceeded the estimated fair value of this asset group. The impairment charges were recorded as part of general and administrative expense in our condensed consolidated statements of operations. During the nine months ended September 30, 2024, $1.5 million of the impairment charge was allocated to ROU assets and the remaining $0.7 million was allocated to leasehold improvements, while during the nine months ended September 30, 2023, $2.0 million of the impairment charge was allocated to ROU assets and the remaining $0.7 million was allocated to leasehold improvements. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Debt 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Debt DebtDebt consisted of the following as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 (in thousands):September 30, 2024December 31, 2023(unaudited)2.50% convertible senior notes due 2025$230,000Â $230,000Â Variable interest rate term loan maturing 2029125,000Â â€”Â Total Principal Outstanding355,000Â 230,000Â Less: Unamortized discount and issuance costs(9,966) (1,966)Net carrying amount345,034Â 228,034Â Less: Current portion of long-term debt(230,423)â€”Â Long-term debt, net of current portion$114,611Â $228,034Â Components of interest expense are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)Contractual interest expense$4,541Â $1,445Â $7,444Â $4,329Â Amortization of debt discount and issuance costs769Â 378Â 1,529Â 1,132Â Amortization of deferred financing costs816Â â€”Â 816Â â€”Â Total$6,126Â $1,823Â $9,789Â $5,461Â Maturity of DebtAs of SeptemberÂ 30, 2024, we are subject to required principal payments and debt maturity as follows (in thousands):Contractual MaturityFiscal year:(unaudited)2024$313Â 2025231,250Â 20261,250Â 20271,250Â 20281,250Â 2029119,687Â Total debt maturities355,000Â Less: Unamortized debt discount and issuance costs(9,966)Net carrying amount$345,034Â Credit AgreementOn July 16, 2024 (the Closing Date), we entered into a credit agreement with Silver Point Finance, LLC, as administrative agent and collateral agent, and the lenders from time-to-time party thereto (the Credit Agreement). The Credit Agreement provides a five-year term loan facility in an aggregate principal amount of up to $225.0Â million, consisting of an initial term loan of $125.0Â million, which was funded in full on the Closing Date, and a delayed draw term loan facility in an aggregate principal amount of up to $100.0Â million, which was undrawn as of the Closing Date. We have the option to draw up to $40.0Â million under the delayed draw facility within six months after the Closing Date and up to an additional $60.0Â million under the delayed draw facility within eighteen months after the Closing Date, in each case, subject to satisfaction of certain conditions, including a minimum liquidity threshold and a maximum recurring revenue/leverage ratio. We are required to pay a commitment fee on the unutilized commitments under the delayed draw term loan facility ranging from 1.5% to 2.5% per year depending on the year and the amount of the unutilized delayed draw term loan. The deferred financing costs related to the delayed draw facility, including the directly attributable debt discount, have been capitalized to other assets on our condensed consolidated balance sheets, and amortized to interest expense in the condensed consolidated statement of operations, in each case over the respective terms.Borrowings under the initial term loan bear interest at a rate per annum equal to the secured overnight financing rate (SOFR) plus 6.5%. Commencing with the quarter ending on December 31, 2024, we are required to make quarterly principal payments in an amount equal to 0.25% of the aggregate original principal amount. The final maturity date of the term loans is July 16, 2029.We expect to use the net proceeds from the initial term loan, together with cash on hand, (i) to repurchase, repay, and/or pay amounts of cash due upon conversion of any or all of the Notes at any time on or prior to the maturity thereof and (ii) for working capital and general corporate purposes. We expect to use the proceeds from the delayed draw term loan facility, if any, to fund our inorganic growth strategy through permitted acquisitions (including deferred purchase price or similar arrangements related thereto) and to pay fees, costs, and expenses in connection therewith.We are required to prepay the term loans upon the occurrence of certain events, and we may voluntarily prepay the term loans, in whole or in part, at any time, subject to certain notice requirements and prepayment amounts. Prior to July 16, 2028, such mandatory prepayments or voluntary prepayments are subject to a prepayment premium ranging from 1.0% to 3.0% plus a make whole amount depending on the year of such prepayment. Our obligations under the Credit Agreement and the other loan documents are required to be guaranteed by all of our present and future domestic and foreign subsidiaries, subject to certain exceptions (Guarantors). All obligations under the Credit Agreement and the other loan documents are secured by a first priority perfected lien on, and security interest in, substantially all of our and our Guarantorâ€™s present and future assets, subject to certain exceptions.The Credit Agreement contains various representations and warranties, affirmative covenants, and negative covenants, including covenants that restrict our and our subsidiariesâ€™ ability to take certain actions including, among other things and subject to certain exceptions, the incurrence of debt, the granting of liens, engaging in mergers and other fundamental changes, the making of investments, entering into transactions with affiliates, the payment of dividends and other restricted payments, the prepayment of other indebtedness and the sale of assets. We are also required to comply with a minimum liquidity threshold, a maximum recurring revenue-based leverage ratio, and a maximum EBITDA-based leverage ratio. The Credit Agreement also includes various events of default, including, among others: non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations or warranties, cross-default to other material indebtedness, bankruptcy and insolvency events, invalidity or impairment of security interests or invalidity of loan documents, certain ERISA events, unsatisfied or unstayed judgments and change of control. Upon the occurrence of an event of default, the administrative agent and the lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Credit Agreement and the related loan documents, including proceeding against the collateral securing such borrowings. As of SeptemberÂ 30, 2024, we were in compliance with all covenants under the Credit Agreement.Convertible senior notesOn AprilÂ 14, 2020, we issued $230.0Â million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025 (Notes), in a private placement to qualified institutional buyers exempt from registration under the Securities Act (Note Offering). The net proceeds from the issuance of the Notes were approximately $222.5Â million, after deducting the initial purchasersâ€™ discounts and offering expenses payable by us.The Notes are governed by an indenture (the Indenture) between us, as the issuer, and U.S. Bank National Association, as trustee. The Notes are our senior, unsecured obligations and accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Indenture does not contain any financial or operating covenants or restrictions on the payments of dividends, the incurrence of indebtedness, or the issuance or repurchase of securities by us or any of our subsidiaries. On or after April 20, 2023, we may redeem, for cash, all or a portion of the Notes, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.The Notes have an initial conversion rate of 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock). Following certain corporate events that occur prior to the maturity date, we will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event. Additionally, upon the occurrence of a corporate event that constitutes a â€œfundamental changeâ€ per the Indenture, holders of the Notes may require the Company to repurchase for cash all or a portion of their Notes at a purchase price equal to 100% of the principal amount of

the Notes plus accrued and unpaid interest.Holders of the Notes were able to convert all or any portion of their Notes at any time prior to the close of business on October 14, 2024, in integral multiples of $1,000 principal amount, only under the following circumstances:â€¢During any calendar quarter commencing after the calendar quarter ended on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;â€¢During the five business day period after any five consecutive trading day period (the measurement period) in which the trading price as defined in the Indenture per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; â€¢If we call such notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; orâ€¢Upon the occurrence of specified corporate events described in the Indenture.On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time irrespective of the foregoing circumstances. Upon conversion, holders will receive cash, shares of our common stock or a combination of cash and shares of common stock, at our election.As of SeptemberÂ 30, 2024, the conditions allowing holders of the Notes to convert were not met and, therefore, the Notes were not convertible as of such date. However, due to the April 2025 maturity date now being within twelve months, the Notes are classified as a current liability on our condensed consolidated balance sheet. Based on the closing price of our common stock of $8.14 per share on the last trading day of the period ended SeptemberÂ 30, 2024, the if-converted value of the Notes was less than their respective principal amounts.Capped callsOn April 8, 2020, concurrently with the pricing of the Notes, we entered into privately negotiated capped call transactions (Base Capped Calls) with certain option counterparties. In addition, in connection with the initial purchasersâ€™ exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. We used approximately $21.7 million of the net proceeds from the Note Offering to pay the cost of the Capped Calls and allocated issuance costs. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the cap price. The Capped Calls are separate transactions that we entered into with the option counterparties, and are not part of the terms of the Notes. As the Capped Call transactions are considered indexed to our own stock and are considered equity classified, they were recorded in stockholdersâ€™ equity and are not accounted for as derivatives. The cost incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital on our condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] Â Stockholdersâ€™ Equity Stockholdersâ€™ EquityPreferred stockOur board of directors has the authority, without further action by our stockholders, to issue up to 25,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, and privileges thereof, including voting rights. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, no shares of this preferred stock were issued and outstanding.Common stockWe had 500,000,000 shares of common stock, par value $0.001 per share, authorized, of which 60,847,658 and 58,530,880 shares were legally issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. The shares legally issued and outstanding as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 included zero shares and 235,389 shares, respectively, issued pursuant to acquisition agreements, which were subject to a restriction agreement and were unvested, and as such, for accounting purposes they were not considered to be outstanding common stock shares. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on our common stock through SeptemberÂ 30, 2024.Share repurchase planDuring the third quarter of 2022, our board of directors authorized a share repurchase program to repurchase up to $40.0Â million of our outstanding shares of common stock (Share Repurchase Plan). There were no share repurchases during the first, second or third quarter of 2024. During the first quarter of 2023, we repurchased and retired 145,027 shares of our common stock for $1.8Â million at an average purchase price of $12.45 per share. This is in addition to the 709,139 shares of common stock we repurchased and retired for $8.4Â million at an average purchase price of $11.81 per share during the third quarter of 2022. The total remaining authorization for future shares of common stock repurchases under our Share Repurchase Plan is $29.8Â million as of SeptemberÂ 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net Loss Per Share Net Loss Per ShareThe following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):Three Months Ended September 30,Nine Months Ended September 30,20242023(unaudited)(unaudited)Net loss per share, basic and dilutedNumerator:Net loss$(14,726)$(22,032)$(48,829)$(87,835)Denominator:Weighted-average shares outstanding used in calculating net loss per share, basic and diluted60,440,694Â 56,710,602Â 59,448,966Â 56,061,925Â Net loss per share, basic and diluted(0.24)(0.39)(0.82)(1.57)During the three and nine months ended SeptemberÂ 30, 2024 and 2023, we incurred net losses and, therefore, the effect of our stock options, restricted stock units, performance-based restricted stock units, convertible senior notes, employee stock purchase plan, and restricted shares were not included in the calculation of diluted net loss per share as the effect would be anti-dilutive.The calculation of diluted net loss per share does not include the effect of the following potentially outstanding shares of common stock. The effects of these potentially outstanding shares were not included in the calculation of diluted net loss per share when the effect would have been anti-dilutive:As of September 30,20242023(unaudited)Common stock options1,071,509Â 1,404,287Â Restricted stock units4,160,419Â 4,196,967Â Performance-based restricted stock units524,994Â 211,548Â Shares related to convertible senior notes7,516,331Â 7,516,331Â Employee stock purchase plan207,388Â 184,908Â Restricted sharesâ€”Â 324,562Â Total potentially dilutive securities13,480,641Â 13,838,603Â In connection with the offering of our convertible senior notes, we entered into Capped Calls with initial caps on the conversion price of $42.00 per share, which are excluded from the calculation of diluted earnings per share, as they would be anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-Based Compensation Stock-Based Compensation In 2011, our board of directors adopted the Health Catalyst, Inc. 2011 Stock Incentive Plan (2011 Plan), which provided for the direct award, sale of shares, and granting of RSUs and options for our common stock to our directors, team members, or consultants. In connection with our initial public offering (IPO), our board of directors adopted the 2019 Stock Option and Incentive Plan (2019 Plan). The 2019 Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce, including the grant of incentive and non-statutory stock options, restricted and unrestricted stock, RSUs, and stock appreciation rights to our directors, team members, or consultants.We initially reserved 2,756,607 shares of our common stock (2,500,000 under the 2019 Plan and 256,607 shares under the 2011 Plan) that were available immediately prior to the IPO registration date. The 2019 Plan provides that the number of shares reserved available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our

compensation committee. As of JanuaryÂ 1, 2024, there were an additional 2,926,544 shares reserved for issuance under the 2019 Plan. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, there were 23,644,211 and 20,717,667 shares authorized for grant, respectively, and 4,420,022 and 3,831,444 shares available for grant under the 2019 Plan, respectively. The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our condensed consolidated statements of operations (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420230242023(unaudited)(unaudited)Restricted stock units$8,655Â $11,591Â $25,065Â $34,531Â Performance-based restricted stock units673Â 406Â 1,523Â 1,117Â Employee stock purchase plan184Â 357Â 746Â 1,464Â Restricted sharesâ€”Â 1,878Â 1,969Â 5,573Â Optionsâ€”Â â€”Â 13Â 60Â Total stock-based compensation$9,512Â $14,232Â $29,316Â $42,745Â Three Months Ended September 30,Nine Months Ended September 30,20242023202420230242023(unaudited)(unaudited)Cost of revenue$2,051Â $2,424Â $5,488Â $7,090Â Sales and marketing2,555Â 5,149Â 8,997Â 16,049Â Research and development1,871Â 2,927Â 5,391Â 8,677Â General and administrative3,035Â 3,732Â 9,440Â 10,929Â Total stock-based compensation$9,512Â $14,232Â $29,316Â $42,745Â Stock optionsThere were no stock options granted during the nine months ended September 30, 2024 or 2023. A summary of the share option activity under the 2019 Plan for the nine months ended September 30, 2024, is as follows:Time-Based Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Life in YearsAggregate Intrinsic Value(unaudited)Outstanding at JanuaryÂ 1, 20241,396,452Â $11.70Â Options exercised(26,668)6.35Â Options cancelled/forfeited(298,275)11.23Â Outstanding at SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â Vested and expected to vest as of SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â Vested and exercisable as of SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â The aggregate intrinsic value of stock options exercised was less than $0.1 million for the nine months ended SeptemberÂ 30, 2024. The aggregate intrinsic value of stock options exercised was $0.7 million for the nine months ended September 30, 2023. The total grant date fair value of stock options vested during the nine months ended September 30, 2024 and 2023 was zero and $0.4 million, respectively. All of our outstanding stock options are fully vested and there is no longer any related unrecognized compensation expense.Restricted stock units (RSUs)The service-based condition for restricted stock units (RSUs) is generally satisfied overÂ four years with a cliff vesting period of one year and quarterly vesting thereafter. The following table sets forth the outstanding RSUs and related activity for theÂ nine months ended SeptemberÂ 30, 2024:Restricted Stock UnitsWeighted Average Grant Date Fair Value(unaudited)Unvested and outstanding at JanuaryÂ 1, 20243,111,584Â $19.16Â RSUs granted2,616,356Â 8.55Â RSUs vested(1,207,994)21.64Â RSUs forfeited(359,527)15.49Â Unvested and outstanding at SeptemberÂ 30, 20244,160,419Â $12.09Â During the nine months ended September 30, 2024 and 2023, we granted RSUs with a weighted-average grant date fair value of $8.55 and $11.99, respectively, which represents the weighted-average closing price of our common stock on the grant date. The total grant date fair value of RSUs vested during the nine months ended September 30, 2024 and 2023 was $26.1 million and $35.2 million, respectively. As of SeptemberÂ 30, 2024, we had $43.0 million of unrecognized stock-based compensation expense related to outstanding RSUs expected to be recognized over a weighted-average period of 1.9 years.Performance-based restricted stock units (PRSUs)2024 Executive PRSUsDuring the nine months ended September 30, 2024, certain named executive officers and other leadership team members were granted executive PRSUs with a three-year measurement period that include service conditions, performance conditions, and market conditions. The vesting of these PRSUs will be determined based on market-based targets for total shareholder return (TSR) achievement (weighted 25%) and financial performance targets for revenue growth rate achievement (weighted 25%) and Adjusted EBITDA margin achievement (weighted 50%). These PRSUs may vest in an amount up to the amount granted, subject to satisfaction of the pre-established targets. The number of PRSUs that will vest for the 2024, 2025, and 2026 vesting periods will be calculated as follows: (i) the market/performance achievement for the applicable vesting period, multiplied by (ii) approximately 33.33% of the PRSUs for each of the 2024, 2025, and 2026 vesting periods, each rounded to the nearest whole share.2023 Executive PRSUsDuring the nine months ended September 30, 2023, certain named executive officers and other leadership team members were granted executive PRSUs with a three-year measurement period that include service conditions, performance conditions, and market conditions. The vesting of these PRSUs will be determined based on market-based targets for total shareholder return (TSR) achievement and financial performance targets for revenue growth rate achievement and Adjusted EBITDA margin achievement. Each of the three market and performance targets are weighted equally and these PRSUs may vest in an amount up to the amount granted, subject to satisfaction of the pre-established targets. The number of PRSUs that will vest in 2023, 2024, and 2025 will be calculated as follows: (i) the market/performance achievement for the applicable vesting period, multiplied by (ii) approximately 33.33% of the PRSUs for each of the 2023, 2024, and 2025 vesting periods, each rounded to the nearest whole share.The fair value of the market-based tranches included in the executive PRSUs were estimated on the date of grants using the Monte Carlo simulation valuation model with the following assumptions for the nine months ended September 30, 2024 and 2023:Nine Months EndedSeptember 30, 2024Nine Months EndedSeptember 30, 2023(unaudited)Expected volatility65.5%61.7%Expected term (in years)1-31-3Risk-free interest rate4.33% - 4.91%4.38% - 5.01%Expected dividendsâ€”â€”The following table sets forth the outstanding PRSUs, including executive PRSUs with market-based tranches, and related activity for theÂ nine months ended SeptemberÂ 30, 2024:Performance-based Restricted Stock UnitsWeighted Average Grant Date Fair Value(unaudited)Unvested and outstanding at JanuaryÂ 1, 2024188,533Â $12.99Â PRSUs granted445,000Â 9.45Â PRSUs vested(43,052)13.89Â PRSUs forfeited(65,487)12.77Â Unvested and outstanding at SeptemberÂ 30, 2024524,994Â $9.94Â During the nine months ended September 30, 2024 and 2023, we granted PRSUs with a weighted-average grant date fair value of $9.45 and $12.62, respectively, which represents the weighted-average closing price of our common stock on the grant date for performance-based tranches and the estimated grant date fair value using a Monte Carlo simulation valuation model for market-based tranches. The total grant date fair value of PRSUs vested during the nine months ended September 30, 2024 and 2023 was $0.6 million and $4.8 million, respectively. As of SeptemberÂ 30, 2024, we had $2.7 million of unrecognized stock-based compensation expense related to outstanding PRSUs expected to be recognized over a remaining weighted-average period of 1.6 years.Employee stock purchase planIn connection with our IPO in July 2019, our board of directors adopted the ESPP and a total of 750,000 shares of common stock were initially reserved for issuance under the ESPP. The number of shares of common stock available for issuance under the ESPP will be increased on the first day of each calendar year beginning January 1, 2020 and each year thereafter until the ESPP terminates. The number of shares of common stock reserved and available for issuance under the ESPP shall be cumulatively increased by the least of (i) 750,000 shares, (ii) one percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of common stock as determined by the ESPP Administrator. As of JanuaryÂ 1, 2024, the number of shares of common stock available for issuance under the ESPP increased by 585,308 shares. The ESPP generally provides for six-month offering periods. The offering periods generally start on the first trading day after June 30 and December 31 of each year. The ESPP permits participants to elect to purchase shares of common stock through fixed percentage contributions from eligible compensation during each offering period, not to exceed 15% of the eligible compensation a participant receives during an offering period or accrue at a rate which exceeds $25,000 of the fair value of the stock (determined on the option grant date(s)) for each calendar year. A participant may purchase the lowest of (i) a number of shares of common stock determined by dividing such participantâ€™s accumulated payroll deductions on the exercise date by the option price, (ii) 2,500 shares, or (iii) such other lesser maximum number of shares as shall have been established by the ESPP Administrator in advance of the offering period. Amounts deducted and accumulated by the participant will be used to purchase shares of common stock at the end of each offering period. The purchase price of the shares will be 85% of the lower of the fair value of common stock on the first trading day of each offering period or on the purchase date. Participants may end their participation at any time during an offering period and will be paid their accumulated contributions that have not been used to purchase shares of common stock. Participation ends automatically upon termination of employment.The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended SeptemberÂ 30, 2024 and 2023:Nine Months Ended September 30,20242023(unaudited)Expected volatility55.5% - 56.8%54.3% - 99.4%Expected term (in months)66Risk-free interest rate5.24% - 5.37%4.77% - 5.53%Expected dividendsâ€”â€”During the nine months ended SeptemberÂ 30, 2024, we issued 263,482 shares under the ESPP, with a weighted-average purchase price of $5.43. Total cash proceeds from the purchase of shares under the ESPP during the nine months ended September 30, 2024 were $2.1 million. As of September 30, 2024, a total of 207,388 shares were issuable to employees based on ESPP contribution elections and unrecognized ESPP compensation cost was $0.2 million, which is expected to be recognized over the remaining portion of the current offering period during the three months ending December 31, 2024. As of SeptemberÂ 30, 2024, 1,791,984 shares were available for future issuance under the ESPP.Restricted shares issued in connection with business combinationsAs part of the KPI Ninja acquisition that closed on February 24, 2022, 356,919 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was subject to continuous service with 25% vesting upon each six-month anniversary of the acquisition close date, with the final vesting date as of February 24, 2024. As part of the ARMUS acquisition that closed on April 29, 2022, 235,330 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was subject to eighteen months of continuous service with cliff vesting upon the eighteen-month anniversary of the acquisition close date, or October 29, 2023. As part of the ERS acquisition that closed on October 2, 2023, 175,901 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was originally subject to eighteen months of continuous service with cliff vesting . However, due to workforce reductions made as part of the 2023 Restructuring Plan, the ERS restricted shares were fully vested in February 2024, resulting in an acceleration of the related stock-based compensation expense.As of SeptemberÂ 30, 2024, all of our previously issued shares of restricted stock are fully vested and there is no longer any related unrecognized compensation expense. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes Income TaxesThe tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, we update our estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, we make a cumulative adjustment in such period. The quarterly tax provision and the estimate of our annual effective tax rate are subject to variation due to several factors, including variability in our loss before income taxes, the mix of jurisdictions to which such income or loss relates, changes in how we conduct business, and tax law developments. For the nine months ended September 30, 2024 and 2023, our estimated effective tax rate was 3.1% and (0.2)%, respectively. The variations between our estimated effective tax rate and the U.S. statutory rate areÂ primarily due to our full valuation allowance. We consider all available evidence to evaluate the recovery of deferred tax assets, including historical levels of income, legislative developments, and risks associated with estimates of future taxable income. We have provided a full valuation allowance for our net deferred tax assets as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, due to the uncertainty surrounding the future realization of such assets and the cumulative losses we have generated.We recognize tax benefits from uncertain tax positions when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We believe that we have provided adequate reserves for income tax uncertainties in all open tax years. We do not anticipate material changes in the total amount of our unrecognized tax benefits within 12 months of the reporting date. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Commitments and ContingenciesLitigationLiabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.We are involved in legal proceedings from time to time that arise in the normal course of business. In the opinion of management, such routine claims and lawsuits are not significant, and we do not expect them to have a material adverse effect on our business, financial condition, results of operations, or liquidity, except as noted below. We were party to the proceedings set forth below.On December 21, 2020, Pascal Metrics, Inc. (Pascal Metrics) filed a complaint against the Company in the Delaware Chancery Court (as amended, the Complaint) alleging that the Company misappropriated alleged trade secrets of Pascal Metrics and seeking monetary damages. The Complaint focused upon Patient Safety Monitor. On June 15, 2023, we entered into a settlement and mutual release agreement (Settlement Agreement) with Pascal Metrics and agreed to pay $18.8Â million without admission of any wrongdoing, resolving the litigation amongst the parties. The Settlement Agreement provided us with a broad intellectual property license of the alleged

trade secrets that were the subject matter of the Complaint. The Complaint was dismissed with prejudice on June 20, 2023 and the settlement amount was paid on June 27, 2023. During the nine months ended September 30, 2023, we recorded $21.3 million, of litigation charges related to the Complaint that were recorded as part of general and administrative expense in our condensed consolidated statements of operations, of which less than $0.1Â million was recorded during the three months ended September 30, 2023. There were no similar litigation charges recorded during the three and nine months ended SeptemberÂ 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Deferred Revenue and Performance Obligations 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Deferred Revenue and Performance Obligations RevenueDisaggregation of RevenueThe following table represents Health Catalystâ€™s revenue disaggregated by type of arrangement (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)Recurring technology$48,653Â $45,973Â $143,254Â $140,126Â One-time technology (i.e., perpetual license)â€”Â â€”Â Â â€”Â 357Â Professional services27,700Â 27,800Â 83,724Â 80,371Â Total revenue$76,353Â $73,773Â $226,978Â $220,854Â Revenue related to contracts with clients located in the United States was 96.9% and 98.5% for the three months ended September 30, 2024 and 2023, respectively, and 97.6% and 98.3% for the nine months ended September 30, 2024 and 2023, respectively.Deferred Revenue and Performance ObligationsDeferred revenue includes advance client payments and billings in excess of revenue recognized.Â For the three months ended SeptemberÂ 30, 2024 and 2023, 43% and 45%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period. For the nine months ended SeptemberÂ 30, 2024 and 2023, 22% and 23%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period.Most of our technology and professional services contracts have a three- or five-year term, of which many are terminable after one year upon 90 daysâ€™ notice. For arrangements that do not allow the client to cancel within one year or less, we expect to recognize $290.5 million of revenue on unsatisfied performance obligations as of SeptemberÂ 30, 2024. We expect to recognize approximately 65% of the remaining performance obligations over the next 24 months, with the balance recognized thereafter. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Related Parties 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Parties Related PartiesWe have entered into arrangements with a client, Carle Health, and a member of the clientâ€™s executive leadership team began serving on our board of directors effective July 1, 2023 and currently serves on our board of directors. We recognized revenue from this related party of $4.2 million and $12.4 million for the three and nine months ended SeptemberÂ 30, 2024, respectively. For the three months ended September 30, 2023, we recognized $4.1 million of revenue from this related party. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, we had receivables from this related party of $1.3 million and $1.9 million, respectively, and deferred revenue with this related party of $0.3 million and $0.1 million, respectively.We have revenue arrangements with clients that are also our investors. None of these clients hold a significant amount of ownership in our equity interests. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Segments 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Segments SegmentsWe operate our business in two operating segments that also represent our reportable segments. Our business is organized based on our technology offerings and professional services. Accordingly, our segments are:â€¢Technology â€“ Our technology segment (Technology) includes our data platform, analytics applications, and support services and generates revenue primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; andâ€¢Professional Services â€“ Our professional services segment (Professional Services) is generally the combination of analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to our clients to more fully configure and utilize the benefits of our Technology offerings.Revenue and cost of revenue generally are directly attributed to our segments. All segment revenue is from our external clients. Asset and other balance sheet information at the segment level is not reported to our Chief Operating Decision Maker.Segment revenue and Adjusted Gross Profit for the three and nine months ended SeptemberÂ 30, 2024 and 2023 were as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)RevenueTechnology$48,653Â $45,973Â $143,254Â $140,483Â Professional Services27,700Â 27,800Â 83,724Â 80,371Â Total$76,353Â $73,773Â $226,978Â $220,854Â Three Months Ended September 30,Nine Months Ended September 30,2024202320242023(unaudited)(unaudited)Adjusted Gross ProfitTechnology$31,571Â $31,367Â $95,794Â $96,356Â Professional Services4,718Â 3,205Â 16,618Â 13,011Â Total reportable segments Adjusted Gross Profit36,289Â 34,572Â 112,412Â 109,367Â Less Adjusted Gross Profit reconciling items:Stock-based compensation(2,051)(2,424)(5,488)(7,090)Acquisition-related costs, net(1)(198)(162)(576)(506)Restructuring costsâ€”Â â€”Â (260)(446)Less other reconciling items:Sales and marketing(11,342)(15,084)(43,145)(50,050)Research and development(14,193)(17,667)(42,948)(52,339)General and administrative(12,209)(13,625)(41,136)(61,129)Depreciation and amortization(9,983)(10,190)(31,165)(31,919)Interest and other income (expense), net(1,514)2,607Â 3,185Â 6,490Â Loss before income taxes $(15,201)$(21,973)$(49,121)$(87,622)_____(1)Acquisition-related costs, net include deferred retention expenses attributable to the Lumeon, Carevive, ARMUS, and KPI Ninja acquisitions. X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace

Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring Costs 9 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Restructuring Costs Restructuring Costs 2023 Restructuring PlanDuring the quarter and year ended December 31, 2023, our board of directors authorized a reduction of our global workforce as part of a restructuring plan intended to optimize our cost structure and focus our investment of resources in key priority areas to align with strategic changes (2023 Restructuring Plan). As part of the 2023 Restructuring Plan, we significantly reduced headcount throughout both our professional services and technology segments, including among our senior leadership team. The restructuring costs primarily related to severance and other team member costs from workforce reductions and impairment of a discontinued capitalized internal-use software project.The following table summarizes our 2023 Restructuring Plan costs by financial statement line item for the nine months ended SeptemberÂ 30, 2024 (in thousands). We had no restructuring costs for the three months ended SeptemberÂ 30, 2024.Nine Months Ended September 30, 2024Severance and Other Team Member CostsImpairment Charges(1)Total(unaudited)Cost of revenue, excluding depreciation and amortization:Technology$79Â $â€”Â $79Â Professional services181Â â€”Â 181Â Sales and marketing449Â â€”Â 449Â Research and development443Â â€”Â 443Â General and administrative936Â â€”Â 936Â Total $2,088Â $â€”Â $2,088Â 2023 Restructuring Plan final cumulative charges incurred$8,240Â $615Â $8,855Â _____(1)Consists of impairment of a discontinued internal-use software project as part of the 2023 Restructuring Plan.Restructuring liabilities related to the 2023 Restructuring Plan are included as a component of accrued liabilities on our condensed consolidated balance sheets. The following table summarizes our current year restructuring-related activities, including costs incurred, cash payments, and the resulting liability balances (in thousands):Restructuring Liabilities(unaudited)Balance as of December 31, 2023$2,355Â Severance and other restructuring costs1,813Â Cash payments(3,157)Balance as of March 31, 2024$1,011Â Severance and other restructuring costs275Â Cash payments(941)Balance as of June 30, 2024$345Â Severance and other restructuring costsâ€”Â Cash payments(338)Balance as of September 30, 2024$7Â Our restructuring activities as part of the 2023 Restructuring Plan are substantially complete with no additional restructuring costs expected during the remainder of 2024. 2022 Restructuring PlanDuring the third quarter of 2022, we initiated a restructuring plan (2022 Restructuring Plan) to optimize our cost structure and focus our investment of resources in key priority areas to align with strategic changes. As part of the 2022 Restructuring Plan, we significantly reduced investment in our life sciences business unit, which is generally part of the technology segment, and also reduced headcount throughout the Company, including among our senior leadership team. The restructuring costs primarily related to severance and other team member costs from workforce reductions, impairment of discontinued capitalized internal-use software projects, and other miscellaneous charges. We substantially completed all actions under the 2022 Restructuring Plan in early 2023 and, as of December 31, 2023, the related restructuring liabilities were completely settled through cash outlays made to impacted team members. The following table summarizes our 2022 Restructuring Plan costs by financial statement line item for the nine months ended SeptemberÂ 30, 2023 (in thousands). We had no restructuring costs for the three months ended SeptemberÂ 30, 2023.Nine Months Ended SeptemberÂ 30, 2023(unaudited)Severance and Other Team Member CostsImpairment Charges(1)Other(2)TotalCost of revenue, excluding depreciation and amortization:Technology$12Â $â€”Â $â€”Â $12Â Professional services434Â â€”Â â€”Â 434Â Sales and marketing1,190Â â€”Â 15Â 1,205Â Research and development286Â â€”Â â€”Â 286Â General and administrative94Â â€”Â 24Â 118Â Total $2,016Â $â€”Â $39Â $2,055Â 2022 Restructuring Plan final, cumulative charges incurred through December 31, 2023$8,071Â $1,225Â $1,184Â $10,480Â _____(1)Consists of impairment of a discontinued internal-use software project as part of the 2022 Restructuring Plan. (2)Includes other minor miscellaneous charges associated with the restructuring plan. X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of presentation Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended DecemberÂ 31, 2023 included in our Annual Report on Form 10-K. Principles of consolidation Principles of consolidationThe condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Use of estimates Use of estimatesThe preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, reserves for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software, impairment assessments of goodwill, intangible assets, and other long-lived assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ significantly from those estimates. Segment reporting Segment reportingOperating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit. Net loss per share Net loss per shareBasic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period, when dilutive. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as the effect is anti-dilutive. Revenue recognition Revenue recognitionWe derive our revenue primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: â€¢Identification of the contract, or contracts, with a client;â€¢Identification of the performance obligations in the contract;â€¢Determination of the transaction price;â€¢Allocation of the transaction price to the performance obligations in the contract; andâ€¢Recognition of revenue when, or as, we satisfy the performance obligation.We recognize revenue net of any taxes collected from clients and subsequently remitted to governmental authorities.Technology revenueTechnology revenue primarily consists of subscription fees charged to clients for access to use our technology. We provide clients access to our technology through either an all-access or limited-access, modular subscription. The majority of our subscription arrangements are cloud-based and do not provide clients the right to take possession of the technology or contain a significant penalty if the client were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the client. Our subscription contracts generally have a three- or five-year term, of which many are terminable after one year upon 90 daysâ€™ notice.Subscriptions that allow the client to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the client. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the client.Professional services revenueProfessional services revenue primarily includes data and analytics services, domain expertise services, Tech-enabled Managed Services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our clients on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our clients. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the â€œright to invoiceâ€ practical expedient. Contracts with multiple performance obligationsMany of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include client demographics and the types of users. Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we generally use the residual method due to a limited number of standalone transactions and/or prices that are highly variable.Variable considerationWe have also entered into at-risk and shared savings arrangements with certain clients whereby we receive variable consideration based on the achievement of measurable improvements that may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. Contract balancesContract assets resulting from services performed prior to invoicing clients are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $8.3 million and $4.7 million, respectively. We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the client. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.5 million and $55.8 million, respectively.Deferred costsWe capitalize sales commissions and associated fringe costs, such as benefits and payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with clients, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the client contract. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, $2.2Â million and $2.2 million, respectively, of deferred contract acquisition costs are expected to be amortized within the next 12 months and are included in prepaid expenses and other assets on the condensed consolidated balance sheets. As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, the remaining $2.9Â million and $3.3 million, respectively, of deferred contract acquisition costs are included in non-current other assets.Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average client life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average client life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs was $0.7Â million and $0.6Â million for the three months ended SeptemberÂ 30, 2024 and 2023, respectively, and $2.0Â million and $1.6 for the nine months ended SeptemberÂ 30, 2024 and 2023, respectively, and is included within sales and marketing expense in the condensed consolidated statements of operations.We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.Cost of revenue, excluding depreciation and amortizationCost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, license and revenue share fees, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue in the interim condensed consolidated statements of operations excludes costs related to depreciation and amortization. Cash and cash equivalents Cash and cash equivalentsWe consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents. Short-term investments Short-term investmentsOur investment policy limits investments to highly-rated instruments. We classify and account for our short-term investments as available for sale securities as we may sell these securities at any time for use in our current operations or for other purposes, even prior to maturity. As a result, we classify our short-term investments, including securities with contractual maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. Accounts receivable Accounts receivableAccounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, client payment patterns, the establishment of specific reserves for clients in an adverse financial condition, and our expectations of changes in macroeconomic conditions, including high interest rates and high inflation, that may impact the collectability of outstanding receivables. Leases LeasesWe determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less.ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our lease contracts do not have a readily determinable implicit rate, we use our incremental borrowing rate based on the information available at the commencement date to determine the present value of lease payments. The incremental borrowing rate is the estimated rate incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment.The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable costs related to our leased office space, such as maintenance and utilities based on actual usage, are not included in the measurement of right-of-use assets and lease liabilities, but are expensed as incurred. Property and equipment Property and equipmentProperty and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows:Computer equipment2-3 yearsFurniture and fixtures3-5 yearsLeasehold improvementsLesser of lease term or estimated useful lifeComputer software2-5 yearsCapitalized internal-use software costs2-5 yearsWhen there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset, plus any terminal value, in the asset

group. If the carrying amount of the asset group exceeds those estimated future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets. Intangible assets Intangible assetsIntangible assets include developed technologies, client relationships, client contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assetsâ€™ estimated useful lives. The estimated useful life of each asset category is as follows:Developed technologies3-10 yearsClient relationships and contract backlog2-7 yearsComputer software licenses1-5 yearsTrademarks1-5 years Goodwill GoodwillWe record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, client relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually on October 31 or more frequently if indicators of impairment are present or circumstances suggest that impairment may exist. Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Judgment in the assessment of qualitative factors of impairment may include changes in business climate, market conditions, or other events impacting the reporting unit. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. Performing a quantitative goodwill impairment test includes the determination of the fair value of a reporting unit, which requires management to use significant judgment and estimation. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of the reporting units, as well as the sensitivity of the respective fair values to the underlying significant assumptions. Typical methods to derive the fair value of reporting units include using the income or market approaches. The significant assumptions used to form the basis of the estimates include, among others, the selection of valuation methodologies, estimates of expected revenue, including revenue growth rates, and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, and the selection of appropriate market comparable companies. Many of these significant assumptions are forward-looking and could be affected by future economic and market conditions. If a quantitative analysis is necessary, we typically engage the assistance of a valuation specialist in concluding on fair value measurements in connection with determining the fair values of our reporting units. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unitâ€™s fair value. Business combinations/Contingent consideration liabilities Business combinationsThe results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of the acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration transferred over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill.We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the client-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for client relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of material assets acquired and liabilities assumed in a business combination.Contingent consideration liabilitiesOur acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements.We generally value the expected contingent consideration and the corresponding liabilities using the Monte Carlo method or Black-Scholes model based on estimates of potential payment scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period.As applicable, the portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes in the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations. Advertising costs Advertising costsAll advertising costs are expensed as incurred. Development costs and internal-use software Development costs and internal-use softwareFor technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our clients on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life with amortization included in depreciation and amortization expense in our condensed consolidated statements of operations. Stock-based compensation Stock-based compensationStock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date or, when applicable, the modification date. The grant date fair value of our stock-based awards is typically determined using the market closing price of our common stock on the date of grant; however, we also consider whether any adjustments are required when the market closing price does not reflect certain material non-public information that we know but is unavailable to marketplace participants on the date of grant. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. For awards subject to market conditions, we estimate the fair value as of the grant date using a Monte Carlo simulation valuation model which requires the use of various assumptions, including historic stock price volatility and risk-free interest rates as of the valuation date corresponding to the length of time remaining in the performance period. Stock-based compensation expense for awards with market conditions is recognized over the requisite service period using the accelerated attribution method and is not reversed if the market condition is not met.Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period.The measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award. Restructuring costs Restructuring costsWe define restructuring costs as expenses directly associated with restructuring activities. Such costs include severance and related tax and benefit expenses from workforce reductions, impairment of discontinued capitalized software projects, and other miscellaneous charges. We record team member-related severance costs when there is a substantive plan in place and the related costs are probable and estimable. For one-time termination benefits for team members (i.e., no substantive plan or future service requirement), the cost is recorded when the terms of the one-time termination benefits are communicated to the impacted team members and the amount can be reasonably estimated. Income taxes Income taxesDeferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and tax credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets.We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not currently accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because the impact would be immaterial due to our net operating losses and tax credit carryforwards. Significant judgment is required to evaluate uncertain tax positions.Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations. Fair value of financial instruments Fair value of financial instrumentsThe carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. The carrying value of operating lease liabilities and convertible senior notes approximate fair value based on interest rates available for debt with similar terms at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. Money market funds and short-term investments are measured at fair value on a recurring basis. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:â€¢LevelÂ 1- Quoted prices in active markets for identical assets or liabilities.â€¢LevelÂ 2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.â€¢LevelÂ 3- Inputs that are generally unobservable and typically reflect managementâ€™s estimate of assumptions that market participants would use in pricing the asset or liability.All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios. Foreign currency Foreign currencyThe functional currency of our international subsidiaries is generally their local currency. We translate these subsidiariesâ€™ financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholdersâ€™ equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented. Recent accounting pronouncements not yet adopted Recent accounting pronouncements not yet adoptedIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segmentâ€™s profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segmentâ€™s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. We expect that the disclosure changes that result from the adoption of this ASU will not have a material impact on our consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entityâ€™s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2025.In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the provision of this ASU to determine the impact it may have on our consolidated financial statements and related disclosures, and we expect additional disclosures upon adoption. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for advertising cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 35 -Topic 720 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4 + Details Name: us-gaap_BusinessCombinationsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -SubTopic 10 -Topic 420 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4 + Details Name: us-gaap_IntangibleAssetsFiniteLivedPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-40/tableOfContent + Details Name: us-gaap_InternalUseSoftwarePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10

-Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B + Details Name: us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Schedule of Allowance For Accounts Receivable We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Allowance for credit losses at the beginning of period$6,600Â $3,800Â $4,105Â $2,300Â Provision for expected credit losses(5)112Â 3,433Â 1,626Â Less: Write-offs, net of recoveries5Â (12)(938)(26)Allowance for credit losses at the end of period$6,600Â $3,900Â $6,600Â $3,900Â Schedule of Property and Equipment, Useful Life The estimated useful life of each asset category is as follows:Computer equipment2-3 yearsFurniture and fixtures3-5 yearsLeasehold improvementsLesser of lease term or estimated useful lifeComputer software2-5 yearsCapitalized internal-use software costs2-5 yearsProperty and equipment consisted of the following (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Computer equipment$10,532Â $9,638Â Leasehold improvements8,429Â 8,814Â Furniture and fixtures3,748Â 3,735Â Capitalized internal-use software costs41,526Â 30,771Â Computer software111Â 111Â Total property and equipment64,346Â 53,069Â Less: accumulated depreciation(36,438)(27,357)Property and equipment, net$27,908Â $25,712Â Schedule of Intangible Asset, Useful Life The estimated useful life of each asset category is as follows:Developed technologies3-10 yearsClient relationships and contract backlog2-7 yearsComputer software licenses1-5 yearsTrademarks1-5 yearsAs of SeptemberÂ 30, 2024, intangible assets consisted of the following (in thousands):CostAccumulated AmortizationNet(unaudited)Developed technologies$120,129Â $(90,573)$29,556Â Client relationships and contracts96,464Â (53,735)42,729Â Computer software licenses11,144Â (9,084)2,060Â Trademarks4,420Â (2,302)2,118Â Total intangible assets$232,157Â $(155,694)$76,463Â As of DecemberÂ 31, 2023, intangible assets consisted of the following (in thousands):CostAccumulated AmortizationNetDeveloped technologies$103,929Â $(79,057)$24,872Â Client relationships and contracts90,064Â (45,230)44,834Â Computer software licenses10,680Â (7,933)2,747Â Trademarks2,820Â (1,889)931Â Total intangible assets$207,493Â $(134,109)$73,384Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combinations (Tables) 9 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â Schedule of Recognized Identified Assets Acquired and Liabilities Assumed The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Lumeon (in thousands):Assets acquired:Accounts receivable, net$967Â Prepaid expenses and other assets795Â Property and equipment, net165Â Client relationships3,700Â Developed technology11,400Â Trademarks1,300Â Total assets acquired18,327Â Less liabilities assumed:Accrued and other current liabilities1,151Â Deferred revenue1,759Â Net deferred tax liabilities3,679Â Total liabilities assumed6,589Â Total assets acquired, net11,738Â Goodwill28,092Â Total consideration transferred, net of cash acquired$39,830Â The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Carevive (in thousands):Assets acquired:Accounts receivable, net$96Â Prepaid expenses and other assets64Â Client relationships2,700Â Developed technology4,800Â Trademarks300Â Total assets acquired7,960Â Less liabilities assumed:Accrued and other current liabilities1,389Â Deferred revenue76Â Total liabilities assumed1,465Â Total assets acquired, net6,495Â Goodwill15,643Â Total consideration transferred, net of cash acquired$22,138Â The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of ERS (in thousands):Assets acquired:Accounts receivable$478Â Prepaid expenses and other assets73Â Client relationships5,300Â Developed technology3,100Â Trademarks100Â Total assets acquired9,051Â Less liabilities assumed:Accrued and other current liabilities78Â Deferred revenue2,251Â Total liabilities assumed2,329Â Total assets acquired, net6,722Â Goodwill4,670Â Total consideration transferred, net of cash acquired$11,392Â Schedule of Unaudited Proforma Financial Information The following table reflects our unaudited pro forma combined results of operations for the three and nine months ended SeptemberÂ 30, 2024 and 2023 as if the acquisitions of Carevive and Lumeon had taken place on JanuaryÂ 1, 2023 (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Pro forma net loss$(14,818)$(27,407)$(56,182)$(107,898)The nature and amount of material, nonrecurring pro forma adjustments directly attributable to these acquisitions which are included in the pro forma net loss, as applicable, are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Amortization of acquired intangible assets(303)(1,331)$(2,788)$(3,993)Acquisition-related costs, net1,487Â â€“Â 5,731Â (1,534)Total pro forma adjustments$1,184Â $(1,331)$2,943Â $(5,527) X - DefinitionTabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of Revenue The following table represents Health Catalystâ€™s revenue disaggregated by type of arrangement (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Recurring technology$48,653Â $45,973Â $143,254Â $140,126Â One-time technology (i.e., perpetual license)â€“Â â€“Â â€“Â 357Â Professional services27,700Â 27,800Â 83,724Â 80,371Â Total revenue$76,353Â $73,773Â $226,978Â $220,854Â X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of Goodwill by Reporting Unit Goodwill by reporting unit is as follows (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Technology$233,605Â $189,870Â Professional services782Â 782Â Total goodwill$234,387Â $190,652Â Schedule of Intangible Assets The estimated useful life of each asset category is as follows:Developed technologies3-10 yearsClient relationships and contract backlog2-7 yearsComputer software licenses1-5 yearsTrademarks1-5 yearsAs of SeptemberÂ 30, 2024, intangible assets consisted of the following (in thousands):CostAccumulated AmortizationNet(unaudited)Developed technologies$120,129Â $(90,573)$29,556Â Client relationships and contracts96,464Â (53,735)42,729Â Computer software licenses11,144Â (9,084)2,060Â Trademarks4,420Â (2,302)2,118Â Total intangible assets$232,157Â $(155,694)$76,463Â As of DecemberÂ 31, 2023, intangible assets consisted of the following (in thousands):CostAccumulated AmortizationNetDeveloped technologies$103,929Â $(79,057)$24,872Â Client relationships and contracts90,064Â (45,230)44,834Â Computer software licenses10,680Â (7,933)2,747Â Trademarks2,820Â (1,889)931Â Total intangible assets$207,493Â $(134,109)$73,384Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-

gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment (Tables) 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Schedule of Property and Equipment The estimated useful life of each asset category is as follows:Computer equipment2-3 yearsFurniture and fixtures3-5 yearsLeasehold improvementsLesser of lease term or estimated useful lifeComputer software2-5 yearsCapitalized internal-use software costs2-5 yearsProperty and equipment consisted of the following (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Computer equipment$10,532Â $9,638Â Leasehold improvements8,429Â 8,814Â Furniture and fixtures3,748Â 3,735Â Capitalized internal-use software costs41,526Â 30,771Â Computer software111Â 111Â Total property and equipment64,346Â 53,069Â Less: accumulated depreciation(36,438)(27,357)Property and equipment, net$27,908Â $25,712Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Short-term Investments (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Schedule of Cash Equivalents and Short-Term Investments Measured at Fair Value The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of SeptemberÂ 30, 2024 (in thousands):Amortized CostUnrealized GainsUnrealized LossesFair ValueCash equivalentsShort-term Investments(unaudited)Money market funds$322,989Â $â€”Â $â€”Â $322,989Â $322,989Â $â€”Â U.S. treasury notes19,397Â 9Â â€”Â 19,406Â â€”Â 19,406Â Commercial paper12,092Â 7Â â€”Â 12,099Â â€”Â 12,099Â Corporate bonds27,416Â 8Â â€”Â 27,424Â â€”Â 27,424Â Total$381,894Â $24Â $â€”Â $381,918Â $322,989Â $58,929Â The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of DecemberÂ 31, 2023 (in thousands):Amortized CostUnrealized GainsUnrealized LossesFair ValueCash equivalentsShort-term InvestmentsMoney market funds$99,779Â $â€”Â $â€”Â $99,779Â $99,779Â $â€”Â U.S. treasury notes65,856Â 68Â â€”Â 65,924Â â€”Â 65,924Â Commercial paper85,358Â â€”Â (18)85,340Â â€”Â 85,340Â Corporate bonds43,746Â 49Â â€”Â 43,795Â â€”Â 43,795Â U.S. agency securities16,405Â â€”Â (12)16,393Â â€”Â 16,393Â Total$311,144Â $117Â (30)311,231Â $99,779Â $211,452Â The following table presents the contractual maturities of our short-term investments as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 (in thousands):As of September 30, 2024As of December 31, 2023Amortized CostFair ValueAmortized CostFair Value(unaudited)Due within one year$58,905Â $58,929Â $211,365Â $211,452Â Total$58,905Â $58,929Â $211,365Â $211,452Â X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Fair Value Assets and liabilities Measured on Recurring Basis Assets and liabilities measured at fair value on a recurring basis as of SeptemberÂ 30, 2024 were as follows (in thousands):September 30, 2024Level 1Level 2Level 3Total(unaudited)Money market funds$322,989Â $â€”Â $â€”Â $322,989Â U.S. Treasury notes19,406Â â€”Â â€”Â 19,406Â Commercial paperâ€”Â 12,099Â â€”Â 12,099Â Corporate bondsâ€”Â 27,424Â â€”Â 27,424Â Contingent consideration liabilitiesâ€”Â â€”Â â€”Â â€”Â Total$342,395Â $39,523Â $â€”Â $381,918Â Assets measured at fair value on a recurring basis as of DecemberÂ 31, 2023 were as follows (in thousands):December 31, 2023Level 1Level 2Level 3TotalMoney market funds$99,779Â $â€”Â $â€”Â $99,779Â U.S. Treasury notes65,924Â â€”Â â€”Â 65,924Â Commercial paperâ€”Â 85,339Â â€”Â 85,339Â Corporate bondsâ€”Â 43,796Â â€”Â 43,796Â U.S. agency securitiesâ€”Â 16,393Â â€”Â 16,393Â Total$165,703Â $145,528Â $â€”Â $311,231Â Schedule of Fair Value Measurement Inputs and Valuation Techniques The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs used during the three months ended SeptemberÂ 30, 2024:Valuation MethodMarket Price of Revenue RiskRevenue VolatilityExpected Term (years)Risk-free interest rate(unaudited)Revenue-based earn-out liabilitiesBlack-Scholes8.4%20%1.25.0%The fair value of the market-based tranches included in the executive PRSUs were estimated on the date of grants using the Monte Carlo simulation valuation model with the following assumptions for the nine months ended September 30, 2024 and 2023:Nine Months EndedSeptember 30, 2024Nine Months EndedSeptember 30, 2023(unaudited)Expected volatility65.5%61.7%Expected term (in years)1-31-3Risk-free interest rate4.33% - 4.91%4.38% - 5.01%Expected dividendsâ€”â€” Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):Fair Value Measurements Using Significant Unobservable Inputs (Level 3)(unaudited)Balance as of JanuaryÂ 1, 2024$â€”Â Acquisition-date contingent consideration liabilities from acquisitions (see Note 2)1,642Â Change in fair value of contingent consideration liabilities(1,642)Balance as of SeptemberÂ 30, 2024$â€”Â X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Schedule of Accrued Liabilities As of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, accrued liabilities consisted of the following (in thousands):As ofSeptember 30,As ofDecember 31,20242023(unaudited)Accrued compensation and benefit expenses$9,838Â $11,680Â Restructuring liabilities(1)7Â 2,355Â Other accrued liabilities13,703Â 9,247Â Total accrued liabilities$23,548Â $23,282Â _____(1)Restructuring liabilities include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in these condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Schedule of Lease Expense (Income) Components of lease expense (income) are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Operating lease expense$692Â $760Â $1,986Â $2,334Â Short-term lease expense50Â 9Â 114Â 51Â Sublease income(414)(308)(1,068)(935)Total$328Â $461Â $1,032Â $1,450Â X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Debt Debt consisted of the following as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 (in thousands):September 30, 2024December 31, 2023(unaudited)2.50% convertible senior notes due 2025$230,000Â $230,000Â Variable interest rate term loan maturing 2029125,000Â â€”Â Total Principal Outstanding355,000Â 230,000Â Less: Unamortized discount and issuance costs(9,966)(1,966)Net carrying amount345,034Â 228,034Â Less: Current portion of long-term debt(230,423)â€”Â Long-term debt, net of current portion$114,611Â $228,034Â Schedule of Convertible Debt Components of interest expense are summarized as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)Contractual interest expense$4,541Â $1,445Â $7,444Â $4,329Â Amortization of debt discount and issuance costs769Â 378Â 1,529Â 1,132Â Amortization of deferred financing costs816Â â€”Â 816Â â€”Â Total$6,126Â $1,823Â $9,789Â $5,461Â Schedule of Principal Payments and Debt Maturity As of SeptemberÂ 30, 2024, we are subject to required principal payments and debt maturity as follows (in thousands):Contractual MaturityFiscal year:(unaudited)2024$313Â 2025231,250Â 20261,250Â 20271,250Â 20281,250Â 2029119,687Â Total debt

maturities355,000Â Less: Unamortized debt discount and issuance costs(9,966)Net carrying amount$345,034Â X - DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of The Calculation of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)(unaudited)Net loss per share, basic and dilutedNumerator:Net loss$(14,726)$(22,032)$(48,829)$(87,835)Denominator:Weighted-average shares outstanding used in calculating net loss per share, basic and diluted60,440,694Â 56,710,602Â 59,448,966Â 56,061,925Â Net loss per share, basic and diluted(0.24)(0.39)(0.82)(1.57) Schedule of Share Totals With a Potentially Dilutive Impact The calculation of diluted net loss per share does not include the effect of the following potentially outstanding shares of common stock. The effects of these potentially outstanding shares were not included in the calculation of diluted net loss per share when the effect would have been anti-dilutive:As of September 30,20242023(unaudited)Common stock options1,071,509Â 1,404,287Â Restricted stock units4,160,419Â 4,196,967Â Performance-based restricted stock units524,994Â 211,548Â Shares related to convertible senior notes7,516,331Â 7,516,331Â Employee stock purchase plan207,388Â 184,908Â Restricted sharesâ€”Â 324,562Â Total potentially dilutive securities13,480,641Â 13,838,603Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of Stock-based Compensation Expense The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our condensed consolidated statements of operations (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)(unaudited)Restricted stock units$8,655Â $11,591Â $25,065Â $34,531Â Performance-based restricted stock units673Â 406Â 1,523Â 1,117Â Employee stock purchase plan184Â 357Â 746Â 1,464Â Restricted sharesâ€”Â 1,878Â 1,969Â 5,573Â Optionsâ€”Â â€”Â 13Â 60Â Total stock-based compensation$9,512Â $14,232Â $29,316Â $42,745Â Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)(unaudited)Cost of revenue$2,051Â $2,424Â $5,488Â $7,090Â Sales and marketing2,555Â 5,149Â 8,997Â 16,049Â Research and development1,871Â 2,927Â 5,391Â 8,677Â General and administrative3,035Â 3,732Â 9,440Â 10,929Â Total stock-based compensation$9,512Â $14,232Â $29,316Â $42,745Â Schedule of Information Related to Stock Options A summary of the share option activity under the 2019 Plan for the nine months ended September 30, 2024, is as follows:Time-Based Option SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Life in YearsAggregate Intrinsic Value(unaudited)Outstanding at JanuaryÂ 1, 20241,396,452Â $11.70Â Options exercised(26,668)6.35Â Options cancelled/forfeited(298,275)11.23Â Outstanding at SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â Vested and expected to vest as of SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â Vested and exercisable as of SeptemberÂ 30, 20241,071,509Â $11.97Â 3.3$â€”Â Schedule of Outstanding RSUs and Related Activity The following table sets forth the outstanding RSUs and related activity for theÂ nine months ended SeptemberÂ 30, 2024:Restricted Stock UnitsWeighted Average Grant Date Fair Value(unaudited)Unvested and outstanding at JanuaryÂ 1, 20243,111,584Â $19.16Â RSUs granted2,616,356Â 8.55Â RSUs vested(1,207,994)21.64Â RSUs forfeited(359,527)15.49Â Unvested and outstanding at SeptemberÂ 30, 20244,160,419Â $12.09Â The following table sets forth the outstanding PRSUs, including executive PRSUs with market-based tranches, and related activity for theÂ nine months ended SeptemberÂ 30, 2024:Performance-based Restricted Stock UnitsWeighted Average Grant Date Fair Value(unaudited)Unvested and outstanding at JanuaryÂ 1, 2024188,533Â $12.99Â PRSUs granted445,000Â 9.45Â PRSUs vested(43,052)13.89Â PRSUs forfeited(65,487)12.77Â Unvested and outstanding at SeptemberÂ 30, 2024524,994Â $9.94Â Schedule of Fair Value Measurement Inputs and Valuation Techniques The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs used during the three months ended SeptemberÂ 30, 2024:Valuation MethodMarket Price of Revenue RiskRevenue VolatilityExpected Term (years)Risk-free interest rate(unaudited)Revenue-based earn-out liabilitiesBlack-Scholes8.4%20%1.25.0%The fair value of the market-based tranches included in the executive PRSUs were estimated on the date of grants using the Monte Carlo simulation valuation model with the following assumptions for the nine months ended September 30, 2024 and 2023:Nine Months EndedSeptember 30, 2024Nine Months EndedSeptember 30, 2023(unaudited)Expected volatility65.5%61.7%Expected term (in years)1-31-3Risk-free interest rate4.33% - 4.91%4.38% - 5.01%Expected dividendsâ€”â€” Schedule of Employee Stock Purchase Plan The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended SeptemberÂ 30, 2024 and 2023:Nine Months Ended September 30,20242023(unaudited)Expected volatility55.5% - 56.8%54.3% - 99.4%Expected term (in months)66Risk-free interest rate5.24% - 5.37%4.77% - 5.53%Expected dividendsâ€”â€” X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Segments (Tables) 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Schedule of Segment Revenue Segment revenue and Adjusted Gross Profit for the three and nine months ended SeptemberÂ 30, 2024 and 2023 were as follows (in thousands):Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)(unaudited)(unaudited)RevenueTechnology$48,653Â $45,973Â $143,254Â $140,483Â Professional Services27,700Â 27,800Â 83,724Â 80,371Â Total$76,353Â $73,773Â $226,978Â $220,854Â Schedule of Segment Adjusted Gross Profit Three Months Ended September 30,Nine Months Ended September 30,20242023202420232023(unaudited)(unaudited)(unaudited)Adjusted Gross ProfitTechnology$31,571Â $31,367Â $95,794Â $96,356Â Professional Services4,718Â 3,205Â 16,618Â 13,011Â Total reportable segments Adjusted Gross Profit36,289Â 34,572Â 112,412Â 109,367Â Less Adjusted Gross Profit reconciling items:Stock-based compensation(2,051)(2,424)(5,488)(7,090)Acquisition-related costs, net(1)(198)(162)(576)(506)Restructuring costsâ€”Â â€”Â (260)(446)Less other reconciling items:Sales and marketing(11,342)(15,084)(43,145)(50,050)Research and development(14,193)(17,667)(42,948)(52,339)General and administrative(12,209)(13,625)(41,136)(61,129)Depreciation and amortization(9,983)(10,190)(31,165)(31,919)Interest and other income (expense), net(1,514)2,607Â 3,185Â 6,490Â Loss before income taxes $(15,201)$(21,973)$(49,121)$(87,622)_____(1)Acquisition-related costs, net include deferred retention expenses attributable to the Lumeon, Carevive, ARMUS, and KPI Ninja acquisitions. X - DefinitionTabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring Costs (Tables) 9 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Schedule of Restructuring Costs The following table summarizes our 2023 Restructuring Plan costs by financial statement line item for the nine months ended SeptemberÂ 30, 2024 (in thousands). We had no restructuring costs for the three months ended SeptemberÂ 30, 2024.Nine Months Ended September 30, 2024Severance and Other Team Member CostsImpairment Charges(1)Total(unaudited)Cost of revenue, excluding depreciation and amortization:Technology$79Â $â€”Â $79Â Professional services181Â â€”Â 181Â Sales and marketing449Â â€”Â 449Â Research and development443Â â€”Â 443Â General and administrative936Â â€”Â 936Â Total $2,088Â $â€”Â $2,088Â 2023 Restructuring Plan final cumulative

charges incurred$8,240Â $615Â $8,855Â _____(1)Consists of impairment of a discontinued internal-use software project as part of the 2023 Restructuring Plan.The following table summarizes our 2022 Restructuring Plan costs by financial statement line item for the nine months ended SeptemberÂ 30, 2023 (in thousands). We had no restructuring costs for the three months ended SeptemberÂ 30, 2023.Nine Months Ended SeptemberÂ 30, 2023(unaudited)Severance and Other Team Member CostsImpairment Charges(1)Other(2)TotalCost of revenue, excluding depreciation and amortization:Technology$12Â $â€”Â $â€”Â $12Â Professional services434Â â€”Â â€”Â 434Â Sales and marketing1,190Â â€”Â 15Â 1,205Â Research and development286Â â€”Â â€”Â 286Â General and administrative94Â â€”Â 24Â 118Â Total $2,016Â $â€”Â $39Â $2,055Â 2022 Restructuring Plan final, cumulative charges incurred through December 31, 2023$8,071Â $1,225Â $1,184Â $10,480Â _____(1)Consists of impairment of a discontinued internal-use software project as part of the 2022 Restructuring Plan. (2)Includes other minor miscellaneous charges associated with the restructuring plan. Schedule of Restructuring-Related Charges and Related Liability The following table summarizes our current year restructuring-related activities, including costs incurred, cash payments, and the resulting liability balances (in thousands):Restructuring Liabilities(unaudited)Balance as of December 31, 2023$2,355Â Severance and other restructuring costs1,813Â Cash payments(3,157)Balance as of March 31, 2024$1,011Â Severance and other restructuring costs275Â Cash payments(941)Balance as of June 30, 2024$345Â Severance and other restructuring costsâ€”Â Cash payments(338)Balance as of September 30, 2024$7Â X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Summary of Significant Accounting Policies - Narrative (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) segment Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Property, Plant and Equipment [Line Items] Â Â Â Â Â Number of operating segments | segment Â Â 2Â Â Number of reportable segments | segment Â Â 2Â Â Unbilled accounts receivable $ 8,300,000 Â $ 8,300,000 Â $ 4,700,000 Deferred revenue 52,500,000 Â 52,500,000 Â 55,800,000 Capitalized contract cost, net, current $ 2,200,000 Â $ 2,200,000 Â 2,200,000 Capitalized contract cost, amortization period 12 months Â 12 months Â Â Capitalized contract cost, net, noncurrent $ 2,900,000 Â $ 2,900,000 Â $ 3,300,000 Estimated period of benefit Â Â 4 years Â Â Amortization of deferred contract acquisition costs 700,000 $ 600,000 $ 2,000,000 $ 1,600,000 Â Impairment losses recorded on deferred contract costs 0 0 0 0 Â Goodwill impairment 0 0 0 0 Â Acquisition transaction costs 1,700,000 1,600,000 4,200,000 1,600,000 Â Advertising expense $ 400,000 $ 400,000 $ 4,100,000 $ 1,600,000 Â Technology and professional services Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Allowed termination period Â Â 1 year Â Â Subscription contracts, days notice of termination Â Â 90 days Â Â Minimum | Technology and professional services Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Service contract term Â Â 3 years Â Â Maximum | Technology and professional services Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Service contract term Â Â 5 years Â Â Subscription contract, term Â Â 5 years Â Â X - DefinitionCommission Payment, Estimated Benefit Period + ReferencesNo definition available. + Details Name: hcat_CommissionPaymentEstimatedBenefitPeriod Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDeferred Revenue Arrangement For Service Contract, Allowed Termination Period + ReferencesNo definition available. + Details Name: hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDeferred Revenue Arrangement For Service Contract, Term + ReferencesNo definition available. + Details Name: hcat_DeferredRevenueArrangementForServiceContractTerm Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRevenue From Subscription Contract, Term of Contract + ReferencesNo definition available. + Details Name: hcat_RevenueFromSubscriptionContractTermofContract Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRevenue From Subscriptions Contract, Notice Required For Termination + ReferencesNo definition available. + Details Name: hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 35 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1 + Details Name: us-gaap_AdvertisingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -SubTopic 40 -Topic 340 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-2 + Details Name: us-gaap_CapitalizedContractCostAmortizationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostNetNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of amortization expense (reversal of expense) for deferred policy acquisition costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479401/944-30-55-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479868/944-20-45-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479432/944-30-50-1 + Details Name: us-gaap_DeferredPolicyAcquisitionCostAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=hcat_TechnologyAndProfessionalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Accounts Receivable, Allowance for Credit Loss [Roll Forward] Â Â Â Â Allowance for credit losses at the beginning of period $ 6,600 $ 3,800 $ 4,105 $ 2,300 Provision for expected

credit losses (5) 112 3,433 1,626 Less: Write-offs, net of recoveries 5 (12) (938) (26) Allowance for credit losses at the end of period $ 6,600 $ 3,900 $ 6,600 $ 3,900 X - DefinitionAccounts Receivable, Allowance For Credit Loss, Writeoff (Recovery) + ReferencesNo definition available. + Details Name: hcat_AccountsReceivableAllowanceForCreditLossWriteoffRecovery Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) Sep. 30, 2024 Computer equipment | Minimum Â Property, Plant and Equipment [Line Items] Â Property, plant and equipment, useful life (in years) 2 years Computer equipment | Maximum Â Property, Plant and Equipment [Line Items] Â Property, plant and equipment, useful life (in years) 3 years Furniture and fixtures | Minimum Â Property, Plant and Equipment [Line Items] Â Property, plant and equipment, useful life (in years) 3 years Furniture and fixtures | Maximum Â Property, Plant and Equipment [Line Items] Â Property, plant and equipment, useful life (in years) 5 years Computer software | Minimum Â Property, Plant and Equipment [Line Items] Â Property, plant and equipment, useful life (in years) 2 years Computer software | Maximum Â Property, Plant and Equipment [Line Items] Â Property, plant and equipment, useful life (in years) 5 years Capitalized internal-use software costs | Minimum Â Property, Plant and Equipment [Line Items] Â Property, plant and equipment, useful life (in years) 2 years Capitalized internal-use software costs | Maximum Â Property, Plant and Equipment [Line Items] Â Property, plant and equipment, useful life (in years) 5 years X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details) Sep. 30, 2024 Developed technologies | Minimum Â Finite-Lived Intangible Assets [Line Items] Â Estimated useful life 3 years Developed technologies | Maximum Â Finite-Lived Intangible Assets [Line Items] Â Estimated useful life 10 years Client relationships and contract backlog | Minimum Â Finite-Lived Intangible Assets [Line Items] Â Estimated useful life 2 years Client relationships and contract backlog | Maximum Â Finite-Lived Intangible Assets [Line Items] Â Estimated useful life 7 years Computer software licenses | Minimum Â Finite-Lived Intangible Assets [Line Items] Â Estimated useful life 1 year Computer software licenses | Maximum Â Finite-Lived Intangible Assets [Line Items] Â Estimated useful life 5 years Trademarks | Minimum Â Finite-Lived Intangible Assets [Line Items] Â Estimated useful life 1 year Trademarks | Maximum Â Finite-Lived Intangible Assets [Line Items] Â Estimated useful life 5 years X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_ClientRelationshipsAndContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combinations - Narrative (Details) - USD ($) $ in Thousands 9 Months Ended Aug. 01, 2024 May 24, 2024 Oct. 02, 2023 Sep. 30, 2024 Sep. 30, 2023 Business Acquisition [Line Items] Â Â Â Â Â Acquisition of businesses, net of cash acquired Â Â Â $ 54,889 $ 0 Lumeon Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Consideration $ 39,800 Â Â Â Â Acquisition of businesses, net of cash acquired 36,200 Â Â Â Â Fair value 2,900 Â Â Â Â Contingent consideration liabilities $ 700 Â Â Â Â Percentage interest acquired 100.00% Â Â Â Â Cash retention payment $ 5,000 Â Â 1,100 Â Lumeon | Client relationships Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life 7 years Â Â Â Â Â Lumeon | Developed technologies Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life 4 years Â Â Â Â Â Lumeon | Trademarks Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life 5 years Â Â Â Â Carevive Systems, Inc. Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Consideration Â $ 22,100 Â Â Â Acquisition of businesses, net of cash acquired Â 18,600 Â Â Â Fair value Â 2,600 Â Â Â Contingent consideration liabilities Â $ 900 Â Â Â Percentage interest acquired Â 100.00% Â Â Â Cash retention payment Â $ 1,800 Â $ 800 Â Carevive Systems, Inc. | Client relationships Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life Â 7 years Â Â Â Carevive Systems, Inc. | Developed technologies Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life Â 4 years Â Â Â Carevive Systems, Inc. | Trademarks Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life Â 3 years Â Â Â ERS Corporation Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Acquisition of businesses, net of cash acquired Â Â $ 11,400 Â Â Percentage interest acquired Â Â 100.00% Â Â ERS Corporation | Client relationships Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life Â Â 7 years Â Â ERS Corporation | Developed technologies Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life Â Â 4 years Â Â ERS Corporation | Trademarks Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Estimated useful life Â Â 2 years Â Â ERS Corporation | Restricted shares Â Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Â Number of restricted shares issued (in shares) Â Â 175,901 Â Â Service period (in years) Â Â 18 months Â Â X - DefinitionBusiness Acquisition, Stock-based Compensation Shares Issuable, Number of Shares + ReferencesNo definition available. + Details Name: hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares Namespace Prefix: hcat_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionBusiness Combination, Cash Retention Payment + ReferencesNo definition available. + Details Name: hcat_BusinessCombinationCashRetentionPayment Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g)(1) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEstimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_LumeonLtd.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_CareviveSystemsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_BusinessAcquisitionAxis=hcat_ERSCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands Sep. 30, 2024 Aug. 01, 2024 May 24, 2024 Dec. 31, 2023 Oct. 02, 2023 Less liabilities assumed: Â Â Â Â Â Goodwill $ 234,387 Â Â $ 190,652 Â Lumeon Â Â Â Â Â Assets acquired: Â Â Â Â Â Accounts receivable, net Â $ 967 Â Â Â Prepaid expenses and other assets Â 795 Â Â Â Property and equipment, net Â 165 Â Â Â Total assets acquired Â 18,327 Â Â Â Less liabilities assumed: Â Â Â Â Â Accrued and other current liabilities Â 1,151 Â Â Â Deferred revenue Â 1,759 Â Â Â Net deferred tax liabilities Â 3,679 Â Â Â Total liabilities assumed Â 6,589 Â Â Â Total assets acquired, net Â 11,738 Â Â Â Goodwill Â 28,092 Â Â Â Total consideration transferred, net of cash acquired Â 39,830 Â Â Â Lumeon | Client relationships Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â 3,700 Â Â Â Lumeon | Developed technology Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â 11,400 Â Â Â Lumeon | Trademarks Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â $ 1,300 Â Â Â Carevive Systems, Inc. Â Â Â Â Â Assets acquired: Â Â Â Â Â Accounts receivable, net Â Â $ 96 Â Â Prepaid expenses and other assets Â Â 64 Â Â Total assets acquired Â Â 7,960 Â Â Less liabilities assumed: Â Â Â Â Â Accrued and other current liabilities Â Â 1,389 Â Â Deferred revenue Â Â 76 Â Â Total liabilities assumed Â Â 1,465 Â Â Total assets acquired, net Â Â 6,495 Â Â Goodwill Â Â 15,643 Â Â Total consideration transferred, net of cash acquired Â Â 22,138 Â Â Carevive Systems, Inc. | Client relationships Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â Â 2,700 Â Â Carevive Systems, Inc. | Developed technology Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â Â 4,800 Â Â Carevive Systems, Inc. | Trademarks Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â Â $ 300 Â Â ERS Corporation Â Â Â Â Â Assets acquired: Â Â Â Â Â Accounts receivable, net Â Â Â Â $ 478 Prepaid expenses and other assets Â Â Â Â 73 Total assets acquired Â Â Â Â 9,051 Less liabilities assumed: Â Â Â Â Â Accrued and other current liabilities Â Â Â Â 78 Deferred revenue Â Â Â Â 2,251 Total liabilities assumed Â Â Â Â 2,329 Total assets acquired, net Â Â Â Â 6,722 Goodwill Â Â Â Â 4,670 Total consideration transferred, net of cash acquired Â Â Â Â 11,392 ERS Corporation | Client relationships Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â Â Â Â 5,300 ERS Corporation | Developed technology Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â Â Â Â 3,100 ERS Corporation | Trademarks Â Â Â Â Â Assets acquired: Â Â Â Â Â Intangible assets Â Â Â Â $ 100 X - DefinitionBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Net Deferred Tax Liability + ReferencesNo definition available. + Details Name: hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNetDeferredTaxLiability Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of assets acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of identifiable intangible assets recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of property, plant, and equipment recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_LumeonLtd.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_CareviveSystemsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_ERSCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Business Combinations - Unaudited Pro Forma Financial Information (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Amortization of acquired intangible assets Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Pro forma net loss $ 303 $ (1,331) $ (2,788) $ (3,993) Acquisition-related costs, net Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Pro forma net loss (1,487) 0 5,731 (1,534) Total pro forma adjustments Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Pro forma net loss (1,184) (1,331) 2,943 (5,527) Carevive and Lumeon Â Â Â Â Business Acquisition [Line Items] Â Â Â Â Pro forma net loss $ (14,818) $ (27,407) $ (56,182) $ (107,898) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_NonrecurringAdjustmentAxis=hcat_AmortizationOfAcquiredIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_NonrecurringAdjustmentAxis=hcat_TotalProFormaAdjustmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_CareviveAndLumeonAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Revenue [1] $ 76,353 $ 73,773 $ 226,978 $ 220,854 Recurring technology Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 48,653 45,973 143,254 140,126 One-time technology (i.e., perpetual license) Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue 0 0 0 357 Professional services Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Revenue [1] $ 27,700 $ 27,800 $ 83,724 $ 80,371 [1] Includes amounts attributable to related party transactions. See Note 17 for further details. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=hcat_RecurringTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=hcat_OneTimeTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=hcat_ProfessionalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue - Narrative (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Geographic Concentration Risk | Revenue from Contract with Customer Benchmark | UNITED STATES Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Revenue related to contracts with customers (percentage) 96.90% 98.50% 97.60% 98.30% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets - Narrative (Details) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) segment Sep. 30, 2023 USD ($) Goodwill and Intangible Assets Disclosure [Abstract] Â Â Â Â Number of operating segments Â Â 2 Â Number of reportable segments Â Â 2 Â Amortization of intangible assets | $ $ 6.8 $ 7.1 $ 21.6 $ 22.4 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Goodwill [Line Items] Â Â Goodwill $ 234,387 $ 190,652 Technology Â Â Goodwill [Line Items] Â Â Goodwill 233,605 189,870 Professional Services Â Â Goodwill [Line Items] Â Â Goodwill $ 782 $ 782 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A + Details Name: us-gaap_GoodwillLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ReportingUnitAxis=hcat_TechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ReportingUnitAxis=hcat_ProfessionalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Finite-Lived Intangible Assets [Line Items] Â Â Cost $ 232,157 $ 207,493 Accumulated Amortization (155,694) (134,109) Net 76,463 73,384 Developed technologies Â Â Finite-Lived Intangible Assets [Line Items] Â Â Cost 120,129 103,929 Accumulated Amortization (90,573) (79,057) Net 29,556 24,872 Client relationships and contracts Â Â Finite-Lived Intangible Assets [Line Items] Â Â Cost 96,464 90,064 Accumulated Amortization (53,735) (45,230) Net 42,729 44,834 Computer software licenses Â Â Finite-Lived Intangible Assets [Line Items] Â Â Cost 11,144 10,680 Accumulated Amortization (9,084) (7,933) Net 2,060 2,747 Trademarks Â Â Finite-Lived Intangible Assets [Line Items] Â Â Cost 4,420 2,820 Accumulated Amortization (2,302) (1,889) Net $ 2,118 $ 931 X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -

URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hcat_ClientRelationshipsAndContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment - Components of Property and Equipment (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Property and equipment $ 64,346 $ 53,069 Less: accumulated depreciation (36,438) (27,357) Property and equipment, net 27,908 25,712 Computer equipment Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment 10,532 9,638 Leasehold improvements Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment 8,429 8,814 Furniture and fixtures Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment 3,748 3,735 Capitalized internal-use software costs Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment 41,526 30,771 Computer software Â Â Property, Plant and Equipment [Line Items] Â Â Property and equipment $ 111 $ 111 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment - Narrative (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property, Plant and Equipment [Line Items] Â Â Â Â Depreciation expense $ 3,100 $ 3,100 $ 9,500 $ 9,500 Impairment of long-lived assets Â Â 2,200 2,681 Capitalized computer software, additions 4,400 3,000 10,800 9,600 Capitalized computer software, amortization $ 2,500 $ 2,100 7,200 6,400 Leasehold Improvements And Furniture And Fixtures Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Impairment of long-lived assets Â Â $ 700 $ 700 X - DefinitionAdditions made to capitalized computer software costs during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_CapitalizedComputerSoftwareAdditions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for amortization of capitalized computer software costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-1 + Details Name: us-gaap_CapitalizedComputerSoftwareAmortization1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=hcat_LeaseholdImprovementsAndFurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Short-term Investments - Cash Equivalents and Short-Term Investments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Securities, Available-for-sale [Line Items] Â Â Amortized Cost $ 381,894 $ 311,144 Unrealized Gains 24 117 Unrealized Losses 0 (30) Fair Value 381,918 311,231 Cash equivalents Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value 322,989 99,779 Short-term Investments Â Â Debt Securities, Available-for-sale [Line Items] Â Â Amortized Cost 58,905 211,365 Fair Value 58,929 211,452 Money market funds Â Â Debt Securities, Available-for-sale [Line Items] Â Â Amortized Cost 322,989 99,779 Unrealized Gains 0 0 Unrealized Losses 0 0 Fair Value 322,989 99,779 Money market funds | Cash equivalents Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value 322,989 99,779 Money market funds | Short-term Investments Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value 0 0 U.S. treasury notes Â Â Debt Securities, Available-for-sale [Line Items] Â Â Amortized Cost 19,397 65,856 Unrealized Gains 9 68 Unrealized Losses 0 0 Fair Value 19,406 65,924 U.S. treasury notes | Cash equivalents Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value 0 0 U.S. treasury notes | Short-term Investments Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value 19,406 65,924 Commercial paper Â Â Debt Securities, Available-for-sale [Line Items] Â Â Amortized Cost 12,092 85,358 Unrealized Gains 7 0 Unrealized Losses 0 (18) Fair Value 12,099 85,340 Commercial paper | Cash equivalents Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value 0 0 Commercial paper | Short-term Investments Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value 12,099 85,340 Corporate bonds Â Â Debt Securities, Available-for-sale [Line Items] Â Â Amortized Cost 27,416 43,746 Unrealized Gains 8 49 Unrealized Losses 0 0 Fair Value 27,424 43,795 Corporate bonds | Cash equivalents Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value 0 0 Corporate bonds | Short-term Investments Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value $ 27,424 43,795 U.S. agency securities Â Â Debt Securities, Available-for-sale [Line Items] Â Â Amortized Cost Â 16,405 Unrealized Gains Â 0 Unrealized Losses Â (12) Fair Value Â 16,393 U.S. agency securities | Cash equivalents Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value Â 0 U.S. agency securities | Short-term Investments Â Â Debt Securities, Available-for-sale [Line Items] Â Â Fair Value Â $ 16,393 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5:

http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Short-term Investments - Short-Term Investments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Amortized Cost Â Â Amortized Cost $ 381,894 $ 311,144 Fair Value Â Â Fair Value 381,918 311,231 Short-term Investments Â Â Amortized Cost Â Â Amortized cost, due within one year 58,905 211,365 Amortized Cost 58,905 211,365 Fair Value Â Â Fair value, due within one year 58,929 211,452 Fair Value $ 58,929 $ 211,452 X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=hcat_ShortTermMarketableSecurityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Short-term Investments - Narrative (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Investments, Debt and Equity Securities [Abstract] Â Â Interest receivable $ 1.4 $ 0.9 X - DefinitionCarrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value $ 381,918 $ 311,231 Money market funds Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 322,989 99,779 U.S. Treasury notes Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 19,406 65,924 Commercial paper Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 12,099 85,340 Corporate bonds Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 27,424 43,795 U.S. agency securities Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value Â 16,393 Fair Value, Recurring Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Contingent consideration liabilities 0 Â Total 381,918 311,231 Fair Value, Recurring | Level 1 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Contingent consideration liabilities 0 Â Total 342,395 165,703 Fair Value, Recurring | Level 2 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Contingent consideration liabilities 0 Â Total 39,523 145,528 Fair Value, Recurring | Level 3 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Contingent consideration liabilities 0 Â Total 0 0 Fair Value, Recurring | Money market funds Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Money market funds 322,989 99,779 Fair Value, Recurring | Money market funds | Level 1 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Money market funds 322,989 99,779 Fair Value, Recurring | Money market funds | Level 2 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Money market funds 0 0 Fair Value, Recurring | Money market funds | Level 3 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Money market funds 0 0 Fair Value, Recurring | U.S. Treasury notes Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 19,406 65,924 Fair Value, Recurring | U.S. Treasury notes | Level 1 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 19,406 65,924 Fair Value, Recurring | U.S. Treasury notes | Level 2 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 0 0 Fair Value, Recurring | U.S. Treasury notes | Level 3 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 0 0 Fair Value, Recurring | Commercial paper Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 12,099 85,339 Fair Value, Recurring | Commercial paper | Level 1 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 0 0 Fair Value, Recurring | Commercial paper | Level 2 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 12,099 85,339 Fair Value, Recurring | Commercial paper | Level 3 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 0 0 Fair Value, Recurring | Corporate bonds Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 27,424 43,796 Fair Value, Recurring | Corporate bonds | Level 1 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 0 0 Fair Value, Recurring | Corporate bonds | Level 2 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value 27,424 43,796 Fair Value, Recurring | Corporate bonds | Level 3 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value $ 0 0 Fair Value, Recurring | U.S. agency securities Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value Â 16,393 Fair Value, Recurring | U.S. agency securities | Level 1 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value Â 0 Fair Value, Recurring | U.S. agency securities | Level 2 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value Â 16,393 Fair Value, Recurring | U.S. agency securities | Level 3 Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Fair Value Â $ 0 X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of asset after deduction of liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueNetAssetLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data

Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Narrative (Details) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Apr. 14, 2020 Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Â Â Amount borrowed Â Â Â $ 1,000 Impairment of long-lived assets $ 2,200,000 $ 2,681,000 Â Â Lumeon Â Â Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Â Â Contingent consideration cap 25,000,000.0 Â Â Â Carevive Systems, Inc. Â Â Â Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Â Â Contingent consideration cap 10,000,000.0 Â Â Â Carevive and Lumeon Â Â Â Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Â Â Aggregate intrinsic value of contingent consideration liability 0 Â Â Â Â Right Of Use Assets Leasehold Improvements And Furniture And Fixtures Â Â Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Â Â Â Impairment of long-lived assets 2,200,000 $ 2,700,000 Â Â Senior Notes Due 2025 | Convertible Notes Payable Â Â Â Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Â Â Amount borrowed 230,000,000 Â $ 230,000,000 $ 230,000,000 Estimated fair value of convertible senior notes $ 227,900,000 Â $ 218,700,000 Â X - DefinitionContingent Consideration, Liability, Aggregate Intrinsic Value + ReferencesNo definition available. + Details Name: hcat_ContingentConsiderationLiabilityAggregateIntrinsicValue Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFor contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LongTermDebtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_LumeonLtd.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_CareviveSystemsInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_CareviveAndLumeonAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=hcat_RightOfUseAssetsLeaseholdImprovementsAndFurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Fair Value Measurements of Contingent Consideration Liabilities (Details) - Fair Value, Recurring - Level 3 - Black-Scholes - Carevive and Lumeon Sep. 30, 2024 Market Price of Revenue Risk Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Measurement Input 0.084 Revenue Volatility Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Measurement Input 0.20 Expected Term (years) Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Measurement Input 1.2 Risk-free interest rate Â Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Measurement Input 0.050 X - DefinitionValue of input used to measure contingent consideration liability from business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputQuotedPriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationTechniqueAxis=hcat_ValuationBlackScholesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_CareviveAndLumeonAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRevenueMultipleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details) - Contingent Consideration Liability - Level 3 - Fair Value, Recurring - Carevive and Lumeon $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Â Balance as of JanuaryÂ 1, 2024 $ 0 Acquisition-date contingent consideration liabilities from acquisitions (see Note 2) 1,642 Change in fair value of contingent consideration liabilities (1,642) Balance as of SeptemberÂ 30, 2024 $ 0 X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=hcat_ContingentConsiderationLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_CareviveAndLumeonAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Accrued compensation and benefit expenses $ 9,838 $ 11,680 Restructuring liabilities 7 2,355 Other accrued liabilities 13,703 9,247 Total accrued liabilities $ 23,548 $ 23,282 X - DefinitionAccrued Liabilities And Employee-Related Liabilities, Current + ReferencesNo definition available. + Details Name: hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the

normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Narrative (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Lessee, Lease, Description [Line Items] Â Â Impairment of long-lived assets $ 2,200 $ 2,681 Right Of Use Assets Leasehold Improvements And Furniture And Fixtures Â Â Lessee, Lease, Description [Line Items] Â Â Impairment of long-lived assets 2,200 2,700 Right Of Use Asset Â Â Lessee, Lease, Description [Line Items] Â Â Impairment of long-lived assets 1,500 2,000 Leasehold Improvements And Furniture And Fixtures Â Â Lessee, Lease, Description [Line Items] Â Â Impairment of long-lived assets $ 700 $ 700 Minimum Â Â Lessee, Lease, Description [Line Items] Â Â Lessee, operating lease, renewal term 1 year Â Maximum Â Â Lessee, Lease, Description [Line Items] Â Â Lessee, operating lease, renewal term 5 years Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=hcat_RightOfUseAssetsLeaseholdImprovementsAndFurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=hcat_RightOfUseAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis=hcat_LeaseholdImprovementsAndFurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Schedule of Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Leases [Abstract] Â Â Â Â Operating lease expense $ 692 $ 760 $ 1,986 $ 2,334 Short-term lease expense 50 9 114 51 Sublease income (414) (308) (1,068) (935) Total $ 328 $ 461 $ 1,032 $ 1,450 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of short-term lease cost, excluding expense for lease with term of one month or less. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_ShortTermLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule of Debt (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Apr. 14, 2020 Line of Credit Facility [Line Items] Â Â Â Total Principal Outstanding $ 355,000 $ 230,000 Â Less: Unamortized discount and issuance costs (9,966) (1,966) Â Net carrying amount 345,034 228,034 Â Less: Current portion of long-term debt (230,423) 0 Â Long-term debt, net of current portion 114,611 228,034 Â Senior Notes Due 2025 | Convertible Notes Payable Â Â Â Line of Credit Facility [Line Items] Â Â Â Basis rate (in percentage) Â Â 2.50% Total Principal Outstanding 230,000 230,000 Â Interest Rate Term Loan Â Â Â Line of Credit Facility [Line Items] Â Â Â Total Principal Outstanding $ 125,000 $ 0 Â X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=hcat_InterestRateTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule of Components of Interest Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Line of Credit Facility [Line Items] Â Â Â Â Amortization of debt discount and issuance costs Â Â $ 2,078 $ 1,132 Convertible Notes Payable Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Contractual interest expense $ 4,541 $ 1,445 7,444 4,329 Amortization of debt discount and issuance costs 769 378 1,529 1,132 Amortization of deferred financing costs 816 0 816 0 Total $ 6,126 $ 1,823 $ 9,789 $ 5,461 X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -

Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule of Principal Payments and Debt Maturity (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Debt Disclosure [Abstract] Â Â 2024 $ 313 Â 2025 231,250 Â 2026 1,250 Â 2027 1,250 Â 2028 1,250 Â 2029 119,687 Â Total debt maturities 355,000 $ 230,000 Less: Unamortized discount and issuance costs (9,966) (1,966) Net carrying amount $ 345,034 $ 228,034 X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 79 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Narrative (Details) 9 Months Ended Jul. 16, 2024 USD ($) Apr. 14, 2020 USD ($) d $ / shares Apr. 09, 2020 USD ($) Sep. 30, 2024 USD ($) $ / shares Dec. 31, 2023 USD ($) Apr. 08, 2020 $ / instrument Line of Credit Facility [Line Items] Â Â Â Â Â Â Amount borrowed Â $ 1,000 Â Â Â Â Share price (in USD per share) | $ / shares Â Â Â $ 8.14 Â Â Cash Flow Hedging | Capped Call | Designated as Hedging Instrument Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Derivative, cost of hedge Â Â $ 21,700,000 Â Â Â Cap price (in USD per share) | $ / instrument Â Â Â Â Â Â 42.00 Credit Agreement | Line of Credit Â Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Â Credit agreement term 5 years Â Â Â Â Â Â Maximum borrowing capacity $ 225,000,000 Â Â Â Â Â Interest rate 6.50% Â Â Â Â Â Â Quarterly principal payment percentage 0.25% Â Â Â Â Â Â Credit Agreement | Line of Credit | Minimum Â Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Prepayment of premium percentage 1.00% Â Â Â Â Â Credit Agreement | Line of Credit | Maximum Â Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Prepayment of premium percentage 3.00% Â Â Â Â Â Credit Agreement | Term Loan | Line of Credit Â Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Amount borrowed $ 125,000,000 Â Â Â Â Â Credit Agreement | Delayed Draw Term Loan (DDTL) | Line of Credit Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Amount borrowed 100,000,000 Â Â Â Â Â Option to draw 40,000,000 Â Â Â Â Â Additional delayed draw facility $ 60,000,000 Â Â Â Â Â Credit Agreement | Delayed Draw Term Loan (DDTL) | Line of Credit | Minimum Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Option to draw, term 6 months Â Â Â Â Â Unutilized commitment percentage 1.50% Â Â Â Â Â Credit Agreement | Delayed Draw Term Loan (DDTL) | Line of Credit | Maximum Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Unutilized commitment percentage 2.50% Â Â Â Â Â Senior Notes Due 2025 | Convertible Notes Payable Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Amount borrowed Â $ 230,000,000 Â $ 230,000,000 $ 230,000,000 Â Basis rate (in percentage) Â 2.50% Â Â Â Â Proceeds from issuance of debt Â $ 222,500,000 Â Â Â Â Debt instrument, convertible, threshold percentage of stock price trigger Â 130.00% Â Â Â Â Threshold trading days | d Â 20 Â Â Â Â Threshold consecutive

trading days | d Â 30 Â Â Â Â Redemption price, percentage Â 100.00% Â Â Â Â Conversion rate Â Â Â 0.03267970 Â Â Conversion price (in USD per share) | $ / shares Â $ 30.60 Â Â Â Â Senior Notes Due 2025 | Convertible Notes Payable | Debt Instrument Convertible Sale Price Of Stock Threshold Â Â Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Â Â Debt instrument, convertible, threshold percentage of stock price trigger Â 98.00% Â Â Â Â Threshold trading days | d Â 5 Â Â Â Â X - DefinitionDebt Instrument, Additional Draw Amount + ReferencesNo definition available. + Details Name: hcat_DebtInstrumentAdditionalDrawAmount Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDebt Instrument, Delayed Draw Facility, Term + ReferencesNo definition available. + Details Name: hcat_DebtInstrumentDelayedDrawFacilityTerm Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Option To Draw + ReferencesNo definition available. + Details Name: hcat_DebtInstrumentOptionToDraw Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDebt Instrument, Prepayment Premium, Percentage + ReferencesNo definition available. + Details Name: hcat_DebtInstrumentPrepaymentPremiumPercentage Namespace Prefix: hcat_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Quarterly Payment, Principal, Percentage + ReferencesNo definition available. + Details Name: hcat_DebtInstrumentQuarterlyPaymentPrincipalPercentage Namespace Prefix: hcat_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeCapPrice Namespace Prefix: us-gaap_ Data Type: srt-types:perUnitItemType Balance Type: na Period Type: instant X - DefinitionThe premium (cost) of a hedge, expensed during the period. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeCostOfHedge Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=hcat_CappedCallMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=hcat_CreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=hcat_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_DelayedDrawTermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=hcat_SeniorNotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: hcat_DebtInstrumentConvertibleThresholdTypeAxis=hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) vote $ / shares shares Mar. 31, 2023 USD ($) $ / shares shares Sep. 30, 2022 USD ($) $ / shares shares Sep. 30, 2024 USD ($) vote $ / shares shares Dec. 31, 2023 $ / shares shares Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Line Items] Â Â Â Â Â Preferred stock, shares authorized (in shares) 25,000,000 Â Â 25,000,000 25,000,000 Preferred stock, shares issued (in shares) 0 Â Â 0 0 Preferred stock, shares outstanding (in shares) 0 Â Â 0 0 Common stock, shares authorized (in shares) 500,000,000 Â Â 500,000,000 500,000,000 Common stock, par value (in USD per share) | $ / shares $ 0.001 Â Â $ 0.001 $ 0.001 Shares outstanding (in shares) 60,847,658 Â Â 60,847,658 58,530,880 Shares issued (in shares) 60,847,658 Â Â 60,847,658 58,530,880 Stockholders vote | vote 1 Â Â 1 Â Dividends | $ Â Â Â $ 0 Â Share Repurchase Plan Â Â Â Â Â Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Line Items] Â Â Â Â Â Share repurchase plan, authorized amount | $ Â Â $ 40,000,000 Â Â Repurchase of common stock (in shares) 0 Â Â Â Â Treasury stock, shares, acquired (in shares) Â 145,027 709,139 Â Â Treasury stock, shares, retired (in shares) Â 145,027 709,139 Â Â Treasury stock, value, acquired, cost method | $ Â $ 1,800,000 $ 8,400,000 Â Â Treasury stock, retired, cost method, amount | $ Â $ 1,800,000 Â Â Â Treasury stock acquired, average cost per share (in USD per share) | $ / shares Â $ 12.45 $ 11.81 Â Â Stock repurchase program, remaining authorized repurchase amount | $ $ 29,800,000 Â Â $ 29,800,000 Â Vitalware L L C | Able Health Inc Â Â Â Â Â Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Line Items] Â Â Â Â Â Shares outstanding (in shares) 0 Â Â 0 235,389 Shares issued (in shares) 0 Â Â 0 235,389 X - DefinitionSchedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed + ReferencesNo definition available. + Details Name: hcat_ScheduleOfTheEffectsOfTheTenderOfferRepurchasePriceOverTheEstimatedFairValueOfTheCommonStockRedeemedLineItems Namespace Prefix: hcat_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionStockholders Vote + ReferencesNo definition available. + Details Name: hcat_StockholdersVote Namespace Prefix: hcat_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_DividendsCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal cost of shares repurchased divided by the total number of shares repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockRetiredCostMethodAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of common and preferred stock retired from treasury during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesRetired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ShareRepurchaseProgramAxis=hcat_ShareRepurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=hcat_VitalwareLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_AbleHealthIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Net loss $ (14,726) $ (22,032) $ (48,829) $ (87,835) Net loss $ (14,726) $ (22,032) $ (48,829) $ (87,835) Denominator: Â Â Â Â Weighted-average shares outstanding used in calculating net loss per share, basic (in shares) 60,440,694 56,710,602 59,448,966 56,061,925 Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares) 60,440,694 56,710,602 59,448,966 56,061,925 Net loss per share, basic (in USD per share) $ (0.24) $ (0.39) $ (0.82) $ (1.57) Net loss per share, diluted (in USD per share) $ (0.24) $ (0.39) $ (0.82) $ (1.57) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred

stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 82 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details) 9 Months Ended Sep. 30, 2024 $ / instrument shares Sep. 30, 2023 shares Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Shares with a potentially dilutive impact (in shares) 13,480,641 13,838,603 Capped Call | Cash Flow Hedging | Designated as Hedging Instrument Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Cap price (in USD per share) | $ / instrument 42.00 Â Common stock options Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Shares with a potentially dilutive impact (in shares) 1,071,509 1,404,287 Restricted stock units Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Shares with a potentially dilutive impact (in shares) 4,160,419 4,196,967 Performance-based restricted stock units Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Shares with a potentially dilutive impact (in shares) 524,994 211,548 Shares related to convertible senior notes Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Shares with a potentially dilutive impact (in shares) 7,516,331 7,516,331 Employee stock purchase plan Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Shares with a potentially dilutive impact (in shares) 207,388 184,908 Restricted shares Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Shares with a potentially dilutive impact (in shares) 0 324,562 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeCapPrice Namespace Prefix: us-gaap_ Data Type: srt-types:perUnitItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=hcat_CappedCallMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PhantomShareUnitsPSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 9 Months Ended Oct. 02, 2023 Apr. 29, 2022 Feb. 24, 2022 Jul. 31, 2019 Sep. 30, 2024 Sep. 30, 2023 Jan. 01, 2024 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Options granted (in shares) Â Â Â Â 0 0 Â Â Options Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Shares exercised in period Â Â Â Â $ 100 $ 700 Â Â Total grant-date fair value of stock options vested Â Â Â Â Â 0 400 Â Â Restricted stock units Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Total grant-date fair value of stock options vested Â Â Â Â Â $ 26,100 $ 35,200 Â Â Cliff vesting period Â Â Â Â 4 years Â Â Â Granted (in USD per share) Â Â Â Â Â $ 8.55 $ 11.99 Â Â Unrecognized stock-based compensation expense related to RSUs Â Â Â Â Â $ 43,000 Â Â Â Nonvested awards, period for recognition Â Â Â Â 1 year 10 months 24 days Â Â Â Restricted stock units | Vesting period one Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Cliff vesting period Â Â Â Â 1 year Â Â Â Performance-based restricted stock units Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Total grant-date fair value of stock options vested Â Â Â Â Â $ 600 $ 4,800 Â Â Granted (in USD per share) Â Â Â Â Â $ 9.45 $ 12.62 Â Â Unrecognized stock-based compensation expense related to RSUs Â Â Â Â Â $ 2,700 Â Â Â Nonvested awards, period for recognition Â Â Â Â 1 year 7 months 6 days Â Â Â Measurement period (in years) Â Â Â Â 3 years 3 years Â Â Performance-based restricted stock units | Weighted Average | Measurement Input, Total Shareholder Return Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Vesting percent Â Â Â Â 25.00% Â Â Â Performance-based restricted stock units | Weighted Average | Revenue Volatility Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Vesting percent Â Â Â Â 25.00% Â Â Â Performance-based restricted stock units | Weighted Average | Measurement Input, EBITDA Multiple Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Vesting percent Â Â Â Â 50.00% Â Â Â Performance-based restricted stock units | Vesting period one Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Vesting percent Â Â Â Â 33.33% Â Â Â Performance-based restricted stock units | Vesting period two Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Vesting percent Â Â Â Â 33.33% Â Â Â Performance-based restricted stock units | Vesting period three Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Vesting percent Â Â Â Â 33.33% Â Â Â Employee stock purchase plan Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Shares authorized (in shares) Â Â Â 750,000 207,388 Â Â Â Percentage increase of the number of common stock shares (in percentage) Â Â Â 1.00% Â Â Â Â Shares available for grant (in shares) Â Â Â Â 1,791,984 Â 585,308 Â Total grant-date fair value of stock options vested Â Â Â Â $ 2,100 Â Â Â ESPP share increase in period (in shares) Â Â Â 750,000 Â Â Â Employee stock purchase plan period Â Â Â Â 6 months Â Â Â Maximum employee subscription rate Â Â Â Â 15.00% Â Â Â Maximum purchase value during offering period Â Â Â Â $ 25,000 Â Â Â Denominator of lowest purchase of a participant (in shares) Â Â Â Â 2,500 Â Â Â Purchase price of common stock (in percentage) Â Â Â Â 85.00% Â Â Â Share-based payment award, shares issued in period (in shares) Â Â Â Â 263,482 Â Â Â Share-based payment award, per share weighted average price of shares purchased (in USD per share) Â Â Â Â $ 5.43 Â Â Â Share based payment arrangement, nonvested award cost not yet recognized amount Â Â Â Â $ 200 Â Â Â Restricted shares | KPI Ninja Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Â Vesting percent Â Â Â 25.00% Â Â Â Â Number of restricted shares issued (in shares) Â Â 356,919 Â Â Â Â Release of shares, period Â Â 6 months Â Â Â Â Â Restricted shares | ARMUS Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Number of restricted shares issued (in shares) 175,901 235,330 Â Â Â Â Â Release of shares, period Â 18 months Â Â Â Â Â Service period (in years) 18 months 18 months Â Â Â Â Â 2011 Stock Incentive Plan Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Shares authorized (in shares) Â Â Â Â 2,756,607 Â Â Â Number of additional shares authorized (in shares) Â Â Â Â 256,607 Â Â Â Percentage increase of the number of common stock shares (in percentage) Â Â Â Â 5.00% Â Â Â 2019 Stock Incentive Plan Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Shares authorized (in shares) Â Â Â Â 2,500,000 Â 2,926,544 Â Stock Incentive Plan Â Â Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Â Shares authorized (in shares) Â Â Â Â 23,644,211 Â Â 20,717,667 Shares available for grant (in shares) Â Â Â Â 4,420,022 Â Â 3,831,444 X - DefinitionBusiness Acquisition, Stock-based Compensation Shares Issuable, Number of Shares + ReferencesNo definition available. + Details Name: hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares Namespace Prefix: hcat_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Acquisition Date Anniversary, Release of Shares, Period + ReferencesNo definition available. + Details Name: hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcquisitionDateAnniversaryReleaseOfSharesPeriod Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Award Measurement Period + ReferencesNo definition available. + Details Name: hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardMeasurementPeriod Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period + ReferencesNo definition available. + Details Name: hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionShare-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee + ReferencesNo definition available. + Details Name: hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed + ReferencesNo definition available. + Details Name: hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed Namespace Prefix: hcat_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares + ReferencesNo definition available. + Details Name: hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares Namespace Prefix: hcat_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEstimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe highest percentage of annual salary that an employee is permitted to utilize with respect to the plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=hcat_MeasurementInputTotalShareholderReturnMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRevenueMultipleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputEbitdaMultipleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_KPINinjaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=hcat_ARMUSCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=hcat_StockIncentivePlan2011Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=hcat_StockIncentivePlan2019Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=hcat_StockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R74.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based

Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense $ 9,512 $ 14,232 $ 29,316 $ 42,745 Cost of revenue Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 2,051 2,424 5,488 7,090 Sales and marketing Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 2,555 5,149 8,997 16,049 Research and development Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 1,871 2,927 5,391 8,677 General and administrative Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 3,035 3,732 9,440 10,929 Restricted stock units Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 8,655 11,591 25,065 34,531 Performance-based restricted stock units Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 673 406 1,523 1,117 Employee stock purchase plan Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 184 357 746 1,464 Restricted shares Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 0 1,878 1,969 5,573 Options Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense $ 0 $ 0 $ 13 $ 60 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R75.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Stock Option Activity (Details) - USD ($) 9 Months Ended Sep. 30, 2024 Time-Based Option Shares Â Outstanding, beginning (in shares) 1,396,452 Options exercised (in shares) (26,668) Options cancelled/forfeited (in shares) (298,275) Outstanding, ending (in shares) 1,071,509 Vested and expected to vest, outstanding (in shares) 1,071,509 Vested and exercisable (in shares) 1,071,509 Weighted Average Exercise Price Â Outstanding, beginning balance (in USD per share) $ 11.70 Options exercised (in USD per share) 6.35 Options cancelled/forfeited (in USD per share) 11.23 Outstanding, ending balance (in USD per share) 11.97 Vested and expected to vest (in USD per share) 11.97 Vested and exercisable (in USD per share) $ 11.97 Weighted Average Remaining Contractual Life in Years Â Option shares outstanding, weighted average remaining contractual life in years 3 years 3 months 18 days Vested and expected to vest, weighted average remaining contractual life in years 3 years 3 months 18 days Vested and exercisable, weighted average remaining contractual life in years 3 years 3 months 18 days Aggregate Intrinsic Value Â Option shares outstanding, aggregate intrinsic value $ 0 Option shares vested and expected to vest, aggregate intrinsic value 0 Option shares vested and exercisable, aggregate intrinsic value $ 0 X - DefinitionAggregate Intrinsic Value + ReferencesNo definition available. + Details Name: hcat_AggregateIntrinsicValueAbstract Namespace Prefix: hcat_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted Average Remaining Contractual Life In Years + ReferencesNo definition available. + Details Name: hcat_WeightedAverageRemainingContractualLifeInYearsAbstract Namespace Prefix: hcat_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards

Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 86 R76.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Restricted Stock Unit and Phantom Share Units (PSUs) Activity (Details) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Restricted stock units Â Â Number of Shares Â Â Unvested and outstanding, beginning balance (in shares) 3,111,584 Â Granted (in shares) 2,616,356 Â Vested (in shares) (1,207,994) Â Forfeited (in shares) (359,527) Â Unvested and outstanding, ending balance (in shares) 4,160,419 Â Weighted Average Grant Date Fair Value Â Â Unvested and outstanding, beginning balance, grant date fair value (in USD per share) $ 19.16 Â Granted (in USD per share) 8.55 $ 11.99 Vested (in USD per share) 21.64 Â Forfeited (in USD per share) 15.49 Â Unvested and outstanding, ending balance, grant date fair value (in USD per share) $ 12.09 Â Performance-based restricted stock units Â Â Number of Shares Â Â Unvested and outstanding, beginning balance (in shares) 188,533 Â Granted (in shares) 445,000 Â Vested (in shares) (43,052) Â Forfeited (in shares) (65,487) Â Unvested and outstanding, ending balance (in shares) 524,994 Â Weighted Average Grant Date Fair Value Â Â Unvested and outstanding, beginning balance, grant date fair value (in USD per share) $ 12.99 Â Granted (in USD per share) 9.45 $ 12.62 Vested (in USD per share) 13.89 Â Forfeited (in USD per share) 12.77 Â Unvested and outstanding, ending balance, grant date fair value (in USD per share) $ 9.94 Â Expected volatility 65.50% 61.70% Risk-free interest rate, minimum 4.33% 4.38% Risk-free interest rate, maximum 4.91% 5.01% Expected dividends $ 0 $ 0 Performance-based restricted stock units | Minimum Â Â Weighted Average Grant Date Fair Value Â Â Expected term (in years) 1 year 1 year Performance-based restricted stock units | Maximum Â Â Weighted Average Grant Date Fair Value Â Â Expected term (in years) 3 years 3 years X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R77.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details) - Employee stock purchase plan - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Expected term (in months) 6 months 6 months Expected dividends $ 0 $ 0 Minimum Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Expected volatility 55.50% 54.30% Risk-free interest rate 5.24% 4.77% Maximum Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Expected volatility 56.80% 99.40% Risk-free interest rate 5.37% 5.53% X - DefinitionThe estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R78.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Details) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Effective income tax rate (in percentage) 3.10% (0.20%) X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 89 R79.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) - Settled Litigation - USD ($) $ in Millions 3 Months Ended 9 Months Ended Jun. 15, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Loss Contingencies [Line Items] Â Â Â Â Â Litigation settlement, amount $ 18.8 Â Â Â Â Litigation charges Â $ 0.0 $ 0.1 $ 0.0 $ 21.3 X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LitigationSettlementExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 90 R80.htm IDEA: XBRL DOCUMENT v3.24.3 Deferred Revenue and Performance Obligations - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Product Information [Line Items] Â Â Â Â Percentage of revenue recognized was included in deferred revenue (in percentage) 43.00% 45.00% 22.00% 23.00% Revenue remaining performance obligation amount $ 290.5 Â $ 290.5 Â Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01 Â Â Â Â Product Information [Line Items] Â Â Â Â Remaining performance obligation (in percentage) 65.00% Â 65.00% Â Remaining performance obligation, period 24 months Â 24 months Â Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-10-01 Â Â Â Â Product Information [Line Items] Â Â Â Â Remaining performance obligation, period Â Â Technology and professional services Â Â Â Â Product Information [Line Items] Â Â Â Â Allowed termination period Â Â 1 year Â Notice required for termination Â Â 90 days Â Technology and professional services | Minimum Â Â Â Â Product Information [Line Items] Â Â Â Â Service contract term Â Â 3 years Â Technology and professional services | Maximum Â Â Â Â Product Information [Line Items] Â Â Â Â Service contract term Â Â 5 years Â X - DefinitionContract With Customer, Liability, Revenue Recognized, Percentage + ReferencesNo definition available. + Details Name: hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage Namespace Prefix: hcat_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionDeferred Revenue Arrangement For Service Contract, Allowed Termination Period + ReferencesNo definition available. + Details Name: hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDeferred Revenue Arrangement For Service Contract, Notice Required For Termination + ReferencesNo definition available. + Details Name: hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDeferred Revenue Arrangement For Service Contract, Term + ReferencesNo definition available. + Details Name: hcat_DeferredRevenueArrangementForServiceContractTerm Namespace Prefix: hcat_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ProductInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPercentage of remaining performance obligation to total remaining performance obligation not recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligationPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-10-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-10-01 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=hcat_TechnologyAndProfessionalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 91 R81.htm IDEA: XBRL DOCUMENT v3.24.3 Related Parties (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Dec. 31, 2023 Related Party Transaction [Line Items] Â Â Â Â Accounts receivable, net [1] $ 51,648 Â $ 51,648 $ 60,290 Deferred revenue 52,500 Â 52,500 55,800 Related Party Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Related party transactions 4,200 $ 4,100 12,400 Â Accounts receivable, net 1,300 Â 1,300 1,900 Deferred revenue $ 300 Â $ 300 $ 100 [1] Includes amounts attributable to related party transactions. See Note 17 for further details. X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -

Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 92 R82.htm IDEA: XBRL DOCUMENT v3.24.3 Segments - Narrative (Details) 9 Months Ended Sep. 30, 2024 segment Segment Reporting [Abstract] Â Number of operating segments 2 Number of reportable segments 2 X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 93 R83.htm IDEA: XBRL DOCUMENT v3.24.3 Segments - Scheduled of Segment Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Revenue [1] $ 76,353 $ 73,773 $ 226,978 $ 220,854 Technology Â Â Â Â Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Revenue 48,653 45,973 143,254 140,483 Professional Services Â Â Â Â Segment Reporting, Revenue Reconciling Item [Line Items] Â Â Â Â Revenue $ 27,700 $ 27,800 $ 83,724 $ 80,371 [1] Includes amounts attributable to related party transactions. See Note 17 for further details. X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingRevenueReconcilingItemLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=hcat_TechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=hcat_ProfessionalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 94 R84.htm IDEA: XBRL DOCUMENT v3.24.3 Segments - Schedule of Segment Adjusted Gross Profit (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Less Adjusted Gross Profit reconciling items: Â Â Â Â Stock-based compensation $ (9,512) $ (14,232) $ (29,316) $ (42,745) Acquisition-related costs, net (1,700) (1,600) (4,200) (1,600) Less other reconciling items: Â Â Â Â Sales and marketing (11,342) (15,084) (43,145) (50,050) Research and development (14,193) (17,667) (42,948) (52,339) General and administrative (12,209) (13,625) (41,136) (61,129) Depreciation and amortization (9,983) (10,190) (31,165) (31,919) Loss before income taxes (15,201) (21,973) (49,121) (87,622) Operating Segments Â Â Â Â Adjusted Gross Profit Â Â Â Â Gross profit 36,289 34,572 112,412 109,367 Operating Segments | Technology Â Â Â Â Adjusted Gross Profit Â Â Â Â Gross profit 31,571 31,367 95,794 96,356 Operating Segments | Professional Services Â Â Â Â Adjusted Gross Profit Â Â Â Â Gross profit 4,718 3,205 16,618 13,011 Segment Reconciling Items Â Â Â Â Less Adjusted Gross Profit reconciling items: Â Â Â Â Stock-based compensation (2,051) (2,424) (5,488) (7,090) Acquisition-related costs, net (198) (162) (576) (506) Restructuring costs 0 0 (260) (446) Less other reconciling items: Â Â Â Â Sales and marketing (11,342) (15,084) (43,145) (50,050) Research and development (14,193) (17,667) (42,948) (52,339) General and administrative (12,209) (13,625) (41,136) (61,129) Depreciation and amortization (9,983) (10,190) (31,165) (31,919) Interest and other income (expense), net $ (1,514) $ 2,607 $ 3,185 $ 6,490 X - DefinitionInterest And Other Expense, Net + ReferencesNo definition available. + Details Name: hcat_InterestAndOtherExpenseNet Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLess Adjusted Gross Profit reconciling items [Abstract] + ReferencesNo definition available. + Details Name: hcat_LessAdjustedGrossProfitreconcilingitemsAbstract Namespace Prefix: hcat_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLess Other Reconciling Items [Abstract] + ReferencesNo definition available. + Details Name: hcat_LessOtherReconcilingItemsAbstract Namespace Prefix: hcat_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GrossProfitAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 + Details Name: us-gaap_IncomeLossAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=hcat_TechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=hcat_ProfessionalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 95 R85.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring Costs - Schedule of Restructuring Costs (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 2023 Restructuring Plan Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â $ 2,088 Â Impairment Charges Â Â Â Â 0 Â Total Â Â Â Â 2,088 Â 2023 Restructuring Plan | Severance And Other Team Member Costs Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and other restructuring costs $ 0 $ 275 $ 1,813 Â Â Â Cumulative severance costs Â Â Â Â 8,240 Â Cumulative asset impairment charges Â Â Â Â 615 Â Cumulative restructuring costs and asset impairment charges Â Â Â Â 8,855 Â 2023 Restructuring Plan | Technology Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â 79 Â Impairment Charges Â Â Â Â 0 Â Total Â Â Â Â 79 Â 2023 Restructuring Plan | Professional Services Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â 181 Â Impairment Charges Â Â Â Â 0 Â Total Â Â Â Â 181 Â 2023 Restructuring Plan | Sales and marketing Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â 449 Â Impairment Charges Â Â Â Â 0 Â Total Â Â Â Â 449 Â 2023 Restructuring Plan | Research and development Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â 443 Â Impairment Charges Â Â Â Â 0 Â Total Â Â Â Â 443 Â 2023 Restructuring Plan | General and administrative Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â 936 Â Impairment Charges Â Â Â Â 0 Â Total Â Â Â Â $ 936 Â 2022 Restructuring Plan Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â Â $ 2,016 Impairment Charges Â Â Â Â Â 0 Other Â Â Â Â Â 39 Total Â Â Â Â Â 2,055 2022 Restructuring Plan | Severance And Other Team Member Costs Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and other restructuring costs Â Â Â $ 0 Â Â Â Cumulative severance costs Â Â Â Â Â 8,071 Cumulative asset impairment charges Â Â Â Â Â 1,225 Cumulative other restructuring costs Â Â Â Â Â 1,184 Cumulative restructuring costs and asset impairment charges Â Â Â Â Â 10,480 2022 Restructuring Plan | Technology Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â Â 12 Impairment Charges Â Â Â Â Â 0 Other Â Â Â Â Â 0 Total Â Â Â Â Â 12 2022 Restructuring Plan | Professional Services Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â Â 434 Impairment Charges Â Â Â Â Â 0 Other Â Â Â Â Â 0 Total Â Â Â Â Â 434 2022 Restructuring Plan | Sales and marketing Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â Â 1,190 Impairment Charges Â Â Â Â Â 0 Other Â Â Â Â Â 15 Total Â Â Â Â Â 1,205 2022 Restructuring Plan | Research and development Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â Â 286 Impairment Charges Â Â Â Â Â 0 Other Â Â Â Â Â 0 Total Â Â Â Â Â 286 2022 Restructuring Plan | General and administrative Â Â Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Â Â Severance and Other Team Member Costs Â Â Â Â Â 94 Impairment Charges Â Â Â Â Â 0 Other Â Â Â Â Â 24 Total Â Â Â Â Â $ 118 X - DefinitionCumulative Asset Impairment Charges + ReferencesNo definition available. + Details Name: hcat_CumulativeAssetImpairmentCharges Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCumulative Other Restructuring Costs + ReferencesNo definition available. + Details Name: hcat_CumulativeOtherRestructuringCosts Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCumulative Restructuring Costs and Asset Impairment Charges + ReferencesNo definition available. + Details Name: hcat_CumulativeRestructuringCostsAndAssetImpairmentCharges Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCumulative Severance Costs + ReferencesNo definition available. + Details Name: hcat_CumulativeSeveranceCosts Namespace Prefix: hcat_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherRestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCostsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=hcat_A2023RestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=hcat_SeveranceAndOtherTeamMemberCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=hcat_TechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=hcat_ProfessionalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=hcat_A2022RestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 96 R86.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring Costs - Schedule of Restructuring-Related Charges and Related Liability (Details) - 2023 Restructuring Plan - Severance And Other Team Member Costs - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Restructuring Reserve [Roll Forward] Â Â Â Beginning, balance $ 345 $ 1,011 $ 2,355 Severance and other restructuring costs 0 275 1,813 Cash payments (338) (941) (3,157) Ending, balance $ 7 $ 345 $ 1,011 X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringReserveRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=hcat_A2023RestructuringPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=hcat_SeveranceAndOtherTeamMemberCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 97 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (%:09ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+

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
<2R6TI!$25W)%%,%$-5'">SHC*R;)FH4I)S]8 MY^"HR HR<;8Z-E;"*6R57?HJ&S=$X(;](%Z0R3::B=#(?L!1@9TL6+WBE83P@]#":7(^,BU(\L"YA:9CH48;):3-74RYI\+9,U M)4LC1(]RBC=Q;#VSO? M]/J4[<&-G+AB%>B SCV3T-M'GL=!"&3\7-)(? HK1$LK1(^R0C<1 MEPO=<3^ E@WR*8K%IO1<<'*=3D>5Q>TM$+T*"LTB5@8DJLT@=">)>8#B.M5\ MIS! M#1
%/[XE!SZL^7"9:KQ3&"%:&B*>YA]IGTURT^R[6[R.55@:V,] MAQJ)OY/%'%K%C)U/09RWK8M?KM7K?3OVBM38RE&:)'[1ZYD%$EN+2[V.?/ MY#=N;L9#FTB6W76Z;4J-#*?P.
[3T.Q2W*_OI\C9(M+O]QL&L85N>!^2:39LV M':-[QR-K@CJE 7(.;/+L]SM?DM["0V/B.2!6M:&+A]5E+"V0@QN6MXR[+>QJ M2ESNBW&?" ^JRUC:'PGJPGQ M]%9E?J)8/"U.<$?
9N66K_#P__OW$M!](2,CG&&J=]R#AR?Q$-;]18I4=2LZ$ M4B+*+I><*5SJ#^#]7 BUO]$_4)QK#_\%4$L#!!0 (%:09EG?+_E]*0< M '(= 8 >&PO=V]R:W-H965T&ULM5G;N,V$/T5PET4 M6\")15+4)1<#38*V" _2R:'IY*/K 2'1,K"2Z).5L^O4E)<>R18K>M-N'W5C2 MS/#,<#AG2%X]"?E!K1G3X&-=-'IZMM9Z<[%8J&+-:JK.Q88UYLM*R)IJ\R@?
M%VHC&2T[I;I:H"A*%C7ES6QYU;U[+Y=7HM45;]A["51;UU0^W[!*/%W/X.SE MQ<_\<:WMB\7R:D,?V3W3OV[>2 .TV%LI>86(5.XC?. MGM3!;V!=>1#B@WUX5U[/(HN(5:S0U@0U?
[;LEE65M61P_+4S.MN/:14/?[]8 M_Z9SWCCS0!6[%=7OO-3KZUDV R5;T;;2/XNG[]C.H0Y@(2K5_0^>=K+1#!2M MTJ+>*1L$-6_ZO_3C+A "'A!/*#E* AHKQ!,*>*> /U4AWBG%761Z5[HXW%%-MEU=2/ %II8TU^Z,+9J=MW.>-G?=[+L,.JP4\?'Z@OC^=Y]M'*R2V;+;_\B;1I<^[SV3LR%>\]Q6'K"]OJ5H# M,VN@L#_87RW?TLHX[YW%WE32F;*U8[O$*,,HO5IL#_UQQ6"4H#39BQTAC?=(
MXR#2^[60^DPS69MLVS*EZRF8O1UR,#[)1.V] ?\T^<<<9V#29R-G'.ED@CED=^W9.];$D3T M7K(-Y25@'S>V.J@N;X1>,[E;*CZ\B8,$9@1&([P>*8+3W(\WW>--@WA_$9I6 MIEX>KF8?Q-09/"9I#.,11E<,YQCGJ1]DM@>9QBJH6NIG[M@VO6WL7D]E3.W MF9NU:1Z-I]C15(XD=KY'FD>1/JNT;1YY":C=[&<22)(83
MTS*0&0RSF4$H6]/5'OTR+%Z1+30@3AW"]8BB;RNZ!PF"8P^[8BIGT*4T_L65- MZXOCS0D3XT=/F,(--!CQWSB)&4X G'!MJ#8=X;E^E3T^!2&L9.3^>5(MD$ MUH'X8)CY7E;PQG2@=E\J5J 2S6/?C);LP4N"T.4WA*,8C6G0(S?1IZ&! U&8 M X\[GQ.A12ZE8833;%P@/7)9'N&)^H@&ZD-AZOO^*)1=4V$C7!P'W8O<0W@P M3B
<(_<0*,JFH1]L%,/$.%Z=KP+OTB$BX[+B$4HG>@TT,"8*,V9@Z;W* 94!ENS>RV*#VM1E4RJ+[_($$PONSV8?O:? M^@2)]M7'/I_)VK'O P&C4QO/E^*E;!3FX$UT'D70-&P2&G5,F#*!%!K*MDE M0&0>19']U[\QR=+JM9#\;Z-O\Z81+Q^X4NWNI6BU,GO&TI8:JFQ9N6<;S>H' M)GM'7L[\.ND[5AQ^\I[G[>;!I7F'K$(BQQ$;V@!TH@TP:\6P_\EPS3MW:%ER M6SI-$;"G)F>\ 07=
<%,4+@'I8SD5SW\9JDN01/,L3N<)R3HQDLU13N9Q#O^G MR9D;XE,;UAW35_>J7*[&TCL0=MX=^@3C+,X(A-$@8=F"(>;(=/HMW5;=4?8 M)5OQ@GO[->RV-V<0)B3/QXSFEX0I3"=2# ^]$ [W0H=8^Y.U0M1F^:_MI5D(I;U'&;JMCL(U7AT<*3W3T>&B&<+@9Z@E/3994+URWO\&$1-@Y M4O;()4D.)TX(\<'Q]Z><'ARP=)?MKW3"/?#VGC!XY$(G#-BX0!=OAN8#GSP\ M?
M<455M:A^1^)TZUEORAU78[#K0P2[?/,U/!]#/0DC:*=O=NZMR4 @9Z[D_! M2DBP:F67C273E%?JW,= BX,+IYK)Q^[B3H'N'*"_D-B_W5\.WG1W:./W.+ZX MQ;'W"S%?NNNZQ3!$?QOY
Y6/O%&FIUV9X:+SU$1(]A=_8,6F^[*ZT%H+>KN MYYI1,\56P'Q?">/P[L$_L+]F7?X#4$L#!!0 (%:09EDYCL'4_@(%D* M 8 >&PO=V]R:W-H965T&ULK59=;]HP/%TK5C9-K=21 M$$B #B*U5-7V,
D5=7N8]F"2"[']V)EMH-NOWW629J1\5^.!^..>XW.NKQ,/ MUU]Z13 D.>,"SUR4F/R:]?5<0H9U2V9@\"9N509-=A5"U?G"FA2@#+N^IX7 MNAEEPHF&Q=A$14.Y-)P)F"BBEUE&U>];X'(]V[-DK
,A&92$ 7SD7/3OAZW/0LH(KXQ6.N--K%69E(^VJ\AK>5Y[Z*XV+1Z+:FCOUMJ[YVDO2Y/0I4FE8G]P MPGHH1W>*+_F##5E^X!6_5_I/"&Q8"&H+P9LL,*V7Q^4'6ZI>ZSX4T1 B&L+[M?#^ M&<+/KN_^5B*KJMT]\%,B&PX&M8/!^0Y.*^ !EJ;0ZW=[8=!_)7X[,.C[@Z [MV)/]MO?O.^F=K_Z,6J_H3_"P(W*/"7?CNV\O75^I6C"A"88\I M.T;FQ55@)@U>+(IFBG< 4_4#8
Y^=2FI>.O5W4M\GH+U!+ P04 " !6D&99 M#A.4%:(' #?*0 & 'AL+W=O3M7NU+PM!;:YG/B><%\R[-BMCBOW[TK%^=RK_L$.]*I/;;+2_ MOQ&YO+^8X=GCB_?
9[497+^:+\QV_%==")?]R]*\W3_,"29EM1J$P6J!3KB]F/ M^&Q):250([(Q+TZ^HXJ56ZD_%0]O$TO9EXU(Y&+E:XHN/FX$YS:(92L>;[7+^7]S^+5B&_XEO) M7-5_T7V+]69HM5=-;EMA,X-M5C2?
_*$UQ)$ I@,"I!4@MH_(&!; 6H+L $! MU@JPIX[@MP+^4T<(6H&@MGUCK-K25USSQ7DI[U%9H0U;]:5V5RUM#^)P5561= MZ]+\FADYO;B416KB1*3(?%,RSU*NS<.U-A\F@+1"'V%
M7KYXA5Z@K$?-G*O>)&J\[DVLZDXYZMVY,MF9#(P,D6_RD)O%$K,#%) /AF7 MCT?DY\8*!U.01U-+4TB=_S?Z\JM'[QF#'N*" MUGQT@.^]N!/%7IQ!?
FTD&2Q9;85G:L=7XF)F]CHERCLQ6WS_'0Z\'R"C3DF6 M3$FVG(BL9WYV,#\;8U]\D)KG9N>NGO!,[LVX^%_X;\AQC5!0"U4IYVX1!M0W MX7)W[!$ 1 M5OD^S8I;DU6,.U89;_)6D2*^E:7._JU?
@.'L3QG.4Y(E4Y(M)R+K^2LX^'MX M0CBOOM)KD-.:\?RCN&*8CN4 10.H] *91>%38S&GA7* S'/HGA4 X/I@E' M0[G-K<8&XF%796(%!FDX99!.299,2;:C@B6@T2*]Y+E0=?*;& _B0J MGT">B(
PH(Q8D0>@?"]B5N2Y*$8Q\ZW "?Q0=MX5-OWQGZ\7&UJ MA5.S(G.YJPH^2.7858;AV%YL "H, GNQN2A&8F:G&#1?E$TH'EAKVNF+7&U7Z
M)U&8U98W.TQJRNE,Z6KUW4$Y]K(EZV\,Q(LMO2$8#8CEQ02 ,1,Y@:4Y LP M'MIE\%&=CT=5OWKN#MOR'4\DCB/;Z0 *>]C>.Q, 1C$.[$@'83$>4IYTRI,G MY! I;+6@WL3U4QB2T%;.QP&
<6<.>$^\ +C8+@PPHWE70 M>+P&?EMH89*$KH-=ZHTH3<.ZDEN!7K;N?_4:%0+<\%KJOC%\S&QN# 2>/:. M!Z HCIS0=U$!BP=P5RGBTKFOE7H G<(N^$ MA;YM !?EQ[;R !.)B:VZBR)'56Q?
[ZZDQ*.UTN(WH5%N']J&#H=V0EF(0EL M'0&<27Z4V'H'.!9%)+8U!7!1&%% 0-FN:L/C9=NCLLAL;TAM>&D:BQNNLA5Z
MF17U:=7A!]CE#7UT/#'OE#AK'811Q^T@+'+\#L#PJ3^TVW=%'1ZOZB!CI%F^ MK\[TGFB.^&GF &&N.4"8:PX -FP.TM5[9+S>^[,^6!;I";\SN>]6-'HK)/=: M:9,7JEI@7QU^&M.L>+
[:YTU]4(S&5$,"6H\ U9O'F!?8"?*0/!!B+W LU<8 MA(P9BV*[V%B"G%Z SE<.4N=K^\KJOC%\S&QN# 2>/:. M!Z HCIS0=U$!BP=P5RGBTKFOE7H G<(N^$ MA;YM !?EQ[;R !.)B:VZBR)'56Q?
MHH&"CG15//F&Y]UDT@/O2=F22=F64['UO=:U'^1;GWH3X PZ#)P3*0CFX\ N MS@"8R82QW9Y!,#_TA])@UZ60\2[E72G70E4]F;%29?UL!?>EXSS/#MA)3[\G M95M.Q=;W2-
=*D>CK,^)H%_9L)TS)EDS*MIR*K>^$KH4CXRWIZ]=4"PR(8E "RBH=TE+B&81T,,;QVTZ^NH]^WR(1WM(9]]GV%*MF12 MMN54;'VO=3TD'>\AI\^'[8"]ZP4L].S^$((% ;;^Z90
L!";A&@%-02C83AP MI8%6;6' S=$=G/&S>[.4WQ:5<:K_2GQ;4NLYN]YC>Y0%H:,^;UC:T= M+_5GI$M>*%Y?VE.GZ%H(])O4 N$0K66)UONR/@=/A>99KDXAK\Z/[I)M17E;
MW_I3QFMF]..'QN'MX6;AF_H^G?7^$I]=8>!]@L^6T/L?*3E+*,1DS&1^]:_@ MS;LI-5 L;0*+ P BPP !@ !X M;"]W;W)KJINI>XFY(4$"I%V
M@:HG]=K5T6L_5/U@DH&DY]B<;>"NO[[C)*00O&C5\H78SCR/9YZ9V,/D(.0G M50!H\J5B7$V=0NOMV'555D!%U8/8 LT*UH
MR9UT4]\]RW0B=IJ5\)XE4;NJHO+K$S!QF#H#Y[CPH=P4VBRXZ61+-[$_7'[M+'!"F=BQY60%7I>!$PGKJ/ [&B\38UP:_E7!0)V-B(ED)\'+!%/U+SFTMIY#LIW2HFK!Z$%5\N9)O[0ZG
"0QP[P6X#?!X0O M ((6$+QVA[%A*_=(6H!=>AN$WLMW)QJFDZD.!!IK)'-#&KU:S3J57)3)TLM M\6V).)W.!,\QZY 3'"G!RIQJG"PU/K R$]"*7))/B[G MY.V;._*&E)S\6HB=HCQ7$U>C5X;;S5H/GAH/_!
<\",A[P76AR (]R2WX^77\ MZ K>134Z22RC)$_^5<(E;!(X'U'?,\+?[,7@\/;.\O]T7_WGW,S&"KCZ" MFB]XB>]8")=U\(YGH@+RQ^-*:8D?_)^VW#?LH9W=')(CM:493!TD5B#WX*3? M?
C,8>M_;A+\EV?R69(L;D9VE*.Q2%%YC3W_&VX3A-VF3OT$.:Z2Y,O;I_2", M_>'$W9*:S'S?2_PS\WF%K,P2?S1N=G"8I;$21!U9F=A1EV8T=5*_$47(ŞEV M5H)E4X)O3?AW8YL
T2WK[Y9D\UN2+6Y$=I:889>8X=7ZFQ64;TPN",=*W'%L M5UCY-UXB&VQ35),<4'?$M 5[6C*Z8D"PPR&*,@/;@]+U56/+7[-U=%)+ R_J M5>^E3= SF5^:W ^#7ME>VH0CSUZS<2=-_$II,%
[L63A>Z5("S[X2/#*Y8K3I MEO*_=HT&-@GB2]^CGN\SB\V@)X'%)/%Z$MAH?+L$22=!C4=(+U6(6)J.X=YPM+&9)'$1Q+V#WI+NJ0&[JME;A2;3CNKE(MN]6N^M-@/!M8UN?8:3>-\;_T39O^GLJ-
^888K'$K[R'&U,BF]6TF M6FSKWFXE-':*];# ?PL@C0&^7PNACQ.S0??_(_T'4$L#!!0 (%:09ED\ M$O,TU@D -1/ 8 >&PO=V]R:W-H965T&ULO9Q<]NX M%<>_"D?
=:3$EMS20B=YK.MLW$N]N'3A\8";8XH40M2=G)MU^08@3A M(DAPC_)BZW)P#O@_(,C? :C;Y[KYW*XX[X(OZVK3WDU67;=],YVVBQ5?%^WK M>LLWXIN'NED7G7C;/$[;;
<.+Y=!H74UQ&$;3=5%N)K/;X;,/S>RVWG55N>$? MFJ#=K==%_4=K^KGNPF:?/O@8_FXZOH/IK/;;?'([WGWZ_9#([Y-#UZ6Y9IO MVK+>! U_N)N\16]R%O4-!HO?2O[<'KT.^D/Y5->?^S?
OEW>3L.\1K_BBZUT4 MXM\3G_JZCV)?OP^.IT<8O8-CU] _[3ZFR238,D? MBEW5?:R?_\[' V*]OT5=M_:8K-L M;Z>=Z%?O?;H8^_!NWP=\H@^_U%U169K-WW.,[?SMXO%;KVK!C$R_E
NRL[B)+_I^*O)X2*8^)!,/\>B)>._X8[G9E)M'<>Y4Q68A M7 L-VE71\954'3B2!:O X+^&N 08UNBG/[[2>M-NRT6_&XBCJ+ES1.?S/[\ M)Q2%?[.E;^^,#<[Z">MIQAB.4-J'?CI.!634',B9D@!R2 #Q3,
EHN]]1DA" #JW("0'$B!:7 MJU8,/"4PZM7_>1@G4#^^[&NJD!,J\]%L 8:-8?RIF9&LAN] MTN-I;K_>VEMV4*:AH3PHHD%Y4Y67B$8!'U&CEDV3!E*8)*;,9.X^>2MX#0YC MDL,8W$-JS"2D-
$'ZG2XS%^I,J\S=+>_'LJ_!9$PR&8-]1.WL<_*@JW[,1">2 M1&FJ%V] H^90WM242+!C;K"#*-XPD]EPPO0;O]$J^ MK(4;BYV]<&,Q/%&XL5OJA9OIT0^B];JW]\^B>2S%U;CB#Z)9^#H6DC?[GY#;
MO^GJ[? ;:9_JKJO7P\L5+P0@]P;B^X>Z[KZ]Z7]V[?!#?K,_ %!+ P04 M' !6D&9942#H]C8) "6*0 & 'AL+W=O4BNBY*NOV9K87XO!YL6CS/;U(M^XD?:"U_V?&F(D)^;!X6[:&AI-
"#JG(!XSA=5(35L_6U_NZN65_SHRA93>^: MJ#U6%6E>OM"2/]W,P.STQ3?VL!?JB\7Z^D >Z#T5?Q[N&OEI,-U MU-#=S>P6?-XDL1J@+?YB]*D=74?*E2WGW]6'7XJ;6:P0T9+F0DU!Y+]'NJ%E
MJ6:2./[N)YT-]U0#Q]>GV7_2SDMGMJ2E&U[^FQ5B?S/+9E%!=^18BF_\Z6?: M.Y2H^7)>MOIO]-3;QK,H/[:"5_U@B:!B=?>?//>!& V0\[@'P'X G [G@&H
M'X"THQTR[=97(LCZNN%/4:.LY6SJ0L=&CY>L%HMX[UHY*],CA/K#:\+N2BT MB.15RTM6$"$_W OY3ZZ6:"._^BS:DW4< _R15OHWGTY_W7Z,,/'Z,?(E9'?^SY
ML25UT5XOA$2CYESD9V_=\>&GCNOHE]Y+?9M]*-$4)R/7T@O!E?@R94O,#CA M/3U\BE!\%<$88@>>S>N'HP <-$06Z?F0+[(J:#L=M%W#JTCNO(8(5C]TJY*IE%E/-
*\DA+="6FS^J:NISO9DQ&ZP=7"*23 M5;:M,%QBSR(O![C+(-RO5,8@9QU$6:$B4O%&L/_J+UQ8EQ8*!$":3+"ZK%9@ MY<::#5BS(-9?J@-AC4I(56U+7C_,2TEN$G/;4N'<0)D=6LJO*MY/=?[PNR
DLJD"*7!RL(!5B,<'?L,(E=(,%L:&W. CW=K3J*K@% MW8JH8&W.C[6XBEC;'DF=4YG1K6BO=*)($4";1D9_QVKYF_)0 ^JDN-A&'2^S MB6L.*P"0S[<1=8-PVM2/M*MC@T?: 9GX%3M6LC+E#?
6E>S_W&-,<9:MI!7:9 MR1Q*/=BAP0Z#V.]45=5:4$I1G3NYTAT2<,&RQKFQW[:LPV($9JBMJU "GV@ M#:.#(%_*FM)GAB#/'2]H#$XL:4UW3'QT 0VE9 !.PG *VK7QH#?V",/]N]J1^
MH$JE[61UB1Y)>:1J"TBV4]M6I8V\;"6W-=WV*!9GLM(K3/K;G7D"4@RGKMAF ML<<50]@@R&SKW\6>-DY,B76SS(JM;0-B3Q4$A@U!&I9W0W1'4D"7:[T'1[%T MR@(0)-
NWZH+WFNT\%H9J09AK;W-=?%HEI2A[)-N27BD!Y73<9M 4Q7BZ9K85 M3#PL"PS-@C#/WC54$FUQHJINI;C*K0#3 IM%YZF]@6TKE'DD#*!<"\)D.P3V M0%ZZJ*]:?J1G^74U= :#H5A
M#@WM[2V*TPL'669Q-E7I#K,YP#'R[$IH6!6^K5%F6M:\ O>[=LKO-=MY$ Q9 MPS!92SV44UKT(9![.6J)[C5SJZ(.#9,O"CN;O=2SLX%;4YATEVL,SHV#<,X MQ=E4F[KLDM1+D-!P-@QS]MVQR?
=J$[T-MDW6\R0&JVF]=='G!!&/LJP&&V&&X MS[W-_SY*77=J&+;'5AHH.:HI30LHE;!$F373@ZO>";NCG2P, M+[#S*&$D9BFOV%9M 2\S0P[$;'/K',!XVL"XS%:^UAT9"D9A"O94F3=Y@!S-
[%1!.&R@#[PA M9Q0FYPMT]UK:0#8;9ZNQO.E=<)#V*H78XX4A;03?Q';FD.$"[* 6>/.Y\#O- M=AZ$T=%XN)^SVA.9T^>6)0IW4#"7W_)S&&1^[@P8@P^JP)1<9,@; M72!O\G(ZO'O+X1%R-
-0HMD[Q'&8^Q(:'2&;?*6VF!H.:R0-/- _R,POP\@?Y,FYSU*D.CYP=%?.Z VWP+TBDI M.XQ6R-/\($/+*$S+W^AA1&\YKRI)SAJP$ZA-L596.%A8R78/4,/"*,S"$JC)
MYI:6)6WF72[30N]))UY7CXRG'83#RI?(AH;1A>-H%RF\NJ8Z&EW9TB06<,?9 M-/(]A<*&C7&8C7_<[6BNXTR?\^XX239LLL;I:RDLZEYJ2DK6%XJ7'R5A>[0S
MMEDWG98_A\T<>#I1;*@97Z9F5N>-;IH_%+2[4IS\1@]LTH40QLFTM#CLYA @ M[-$8V+ S#K?4&Q -B(AH?2D?:NT4H*)-HP[U3]V--Q"I?3K'+9@10!SW,! M;-@5A]DUZ 159T5!^#9!
(I@A.!5(#KL57BU]2S!Z:HR# NG^>#B4^MT#4NKG M&B5OCTVGL^O3PZ>1V*O'7,OJ[LT6ST,/'.3QMXJH]YKM/%"&PW&8PS6HW-DR._\\GROFIA]6/0%_?
MP&*;NI=HVKXZC%+HVW.&WW&8W\?-J[N74@6R/!;=(I')P6[WA-H^VW5ZZ7H& M/94'#B-?!X:--L!A;; 9K8MS4=[/1X>@0- B,]O*=P:,C:+ 844Q/0-NU(M@
M<[[3CO9/>A6$#E,NSEPMWJ0.7THSKR^O6<+"VLA'=HC1A[&3HSV2"Z< M!(0.6]YM&7L0:< _APD8IW/GWV+TAEM%FP?]XE\;:63=&V\+#M\/+A;?ZE;K) M]U _YTWWBJ"9IGMC\5?
22'IOY<+MY)3QIZ4,>=.]!-A]$/R@WZ/;575[N7)LNO6/SQYXHJE6>5NVJQ-#=_,FW:5 M=_!GNWCBUJW)2WII53VYNKAX_F25V_KDU0OZ['WZD73=Y6MS?LV<_UJE;?; MUZ9J-B]/+D_\!
[_;Q;+##YZ\>K'.^';.=':^LW[?PUY,P2FE7IG:VJ;/6S%^> MW%S^\HI/D\/_-V:C5/_SG ELZ;YA' \7+X\N4""3&6*#D?(X3_WYM94%0X$ M9Q/#QCP)4^*+^M]^))]H[;"66>[,;5-
]M&6W?'GRW4E6FGG>5]WOS>9O1M;S M#,LY&7X>V5K_F_^6?B@7OCN8L\+5_+"%=':$QÔ5 M;(N?_E6B;399BT_#:/@/6BJ]#<39&C?EKFOA6POO=:_>&%>T=DT<:N;9Z][! M \YE>5UF=
[Q1^/F=7=1V;HN\[K*;HFCZNK/U(GO?5+:PQKUXT@$M..*30N9] MS?->[9GW^^S7INZ6+GM;EZ9,WW\":P@+N?(+>7UU<, [LYYFUQ>3[.KBZNF! M\:X#8ZYIO.L]XXVL,OOOFYGK6A"D_QE;,
(_W='PV%P_N'5>F0 - MR:N__?E\XL?#U#[-%#[]-#H_\9M/#CO^*K^-<1DO^5=WQI$E10F^-P+ON; MR:MNF=V"K%=;UTVRG^MBFIT./C[=-KG+;%TT[;!5TV9]2!G;=8M35;E&X>C
MOC'PKQQFL'4&TM.9U0R>N+JXO)QF'TV&W^19!8H.J5JWS;W%$>#%$F:AQ>0U MS-;9PF6=*99U4S6++7V!C+ %K*%KLB615N!PH#OSVOZ3ES+-WO5M=M=4/3&J
M:%;KUCIXIX&/BZKIRW-4-R5/MZ[R#E7P)'/-O".RX^SY>@'T\XV$G1 "0.P>6 MPP=Y%:DQGX&1'4S"5-74';VR6MEC2@H$$V!Y;;379?NWP9.\,T1?(A@6N M@)"%0=;:EHB=@%IL0=
<&"H$&"VH<]"-QA+?3OZ&9$H@O^\)D*Y.[OLUGE4%2 M:QQGDLUMG=>%Q7_BLT$T<(X54FI6N*AI]CIWEO:9!+/NZ*GL PA 7B"S\WJ+ M&JO7>5]:E)"B 1&I'?
_+@126)#AAPLS!&#QZMLQA>3-C:AQ]#4PJ48IPX+:$ MIPUH<1#'/Z9WTVQA:B"Q I;"URAF)3TGT@X,A\'7%>S:Z5]O;MZ?T:I03&S3 MT9#I"W&W M),>V[F!O5FI50'_3(BW3[!:D
^PX/,36GLPF#%PWL%NE=2"5L"$P6XU?XY* M^*HO9?5UW<-XH_PZQ"5?M 8D/:?]PF> ='IN M: (V,VCS0^4K'*N+\EJ72?<1#)NF*. TPYE0" "D>SRXOR_IJ#W>"._C \[MQ\#+Q9Y!9GE%&\9
D9<5=:8WN[0W#PVEJ$A5NV=1MVR-8;D#NY&M&"1>Q-BV:,?E\XL?#U#[-%#[]-#H \9M/#CO^*K^-<1DO^5=WQI$E10F^-P+ON; MR:MNF=V"K%=;UTVRG^MBFIT./C[=-KG+;%TT[;!5TV9]2!G;=8M35;E&X>C
MOC'PKQQFL'4&TM.9U0R>N+JXO)QF'TV&W^19!8H.J5JWS;W%$>#%$F:AQ>0U MS-;9PF6=*99U4S6++7V!C+ %K*%KLB615N!PH#OSVOZ3ES+-WO5M=M=4/3&J
M:%;KUCIXIX&/BZKIRW-4-R5/MZ[R#E7P)'/-O".RX^SY>@'T\XV$G1 "0.P>6 MPP=Y%:DQGX&1'4S"5-74';VR6MEC2@H$$V!Y;;379?NWP9.\,T1?(A@6N M@)"%0=;:EHB=@%IL0=
<&"H$&"VH<]"-QA+?3OZ&9$H@O^\)D*Y.[OLUGE4%2 M:QQGDLUMG=>%Q7_BLT$T<(X54FI6N*AI]CIWEO:9!+/NZ*GL PA 7B"S\WJ+ M&JO7>5]:E)"B 1&I'?
_+@126)#AAPLS!&#QZMLQA>3-C:AQ]#4PJ48IPX+:$ MIPUH<1#'/Z9WTVQA:B"Q I;"URAF)3TGT@X,A\'7%>S:Z5]O;MZ?T:I03&S3 MT9#I"W&W M),>V[F!O5FI50'_3(BW3[!:D
^PX/,36GLPF#%PWL%NE=2"5L"$P6XU?XY* M^*HO9?5UW<-XH_PZQ"5?M 8D/:?]PF> ='IN M: (V,VCS0^4K'*N+\EJ72?<1#)NF*. TPYE0" "D>SRXOR_IJ#W>"._C \[MQ\#+Q9Y!9GE%&\9
D9<5=:8WN[0W#PVEJ$A5NV=1MVR-8;D#NY&M&"1>Q-BV:,?E\XL?#U#[-%#[]-#H_\

H6#1S26M!&WH/]Y[@?6),H6'[&D8^B-(HO MS/$/)8G9W"!M<%(6/*6G"S481BX=X7T? ([R3,N6$'%<3'@A?1C=OJ9?+#-C MR<"@.JBJ14/NY)!N OBHUTBDT+=9-PQ+E/C%U!"C MUAPU<%0T(B*1^%1[6!H'IHZ^DF$(/ O M43PXYBK'N,U];BNO+.,J!/]H;@?=H8+=I+-S}$8V.L1@?[5I#]AO5MUUYTU?!:A"SD+P@HM5"$2D-<:H@LW$C)EKT M:P>>%V-GB7EPIL+[-I@#!YP08*OKUX@>U6:"O/1KV%)TG/:=D,K.6@P I5N+ M' .1@0E(F\$B&4H,!/+!O=.D'+6T)"B]RJQ_HSP*>0\NZ?UHKLMKOL/?1KTH MRW1CV3W_&CB@#6YR3*2IKU#KGL/N X5E]BM%!S&2Y;^F0 _(G89Z=A$2S]. M9"*OW7:-<3DMKZBR:2/%/\+PUCF)1@10V>E/'JZ>J3$U%YN8!.1P*47AJBV' M, ="?G@;WXP'1DP(6;4,AJI+-G#,+O A85L-I00I,^?!/W'6%3@?62 6)+_W M0\ ["$*6'AS 914 TQ?NY9A2S%- $WQ5<&1"^@!VU)D=7&YC(=MB+A]7+UJ?1 M#36FÉ!*,H'@T1@#CXL=@3FQ]W\#3]/'EC_ &0A@,M>*:2Y;EVZ!)"82M^JK# M@.1>9/,K13'9 $8M["7DH=NF" (C%&0FR4(20Q#Z:2: ILH;0G!RR MO&IJW+6JDM0KO"*BGF#M?0\/1+:9H0 0!WBLG.)?B J49#AP+8BYBHFDNL-1 M)%84&!_"+]I#_LP>&E!&A$D1AHFD;@D?^MG(10+;DR%X)2S/PW5:R$$9 HP^FY5B0-'*.8@)$T;4BVK/.I'P16E636+-E\O MJ5)" K^@-(CA!CS;8OSL2SC.(;Z^U1*6(|(:PR:1(:71==D%Q>%H\^;[n NR MT=.5 5-2E;V!2*

(BX$FO[=M> X%? MQ(O"%YD#[!ILY-X2UV AVJXDV#$\5>Z);Y;D\0C-" 1VQ=5'V"MU16/\%H3Z M1A78UYS=5M1D1F&@>HTB1>[64]6J(B*MN$YY|'!\%R&MD4"DSDO(!&:9>!WO M&AY'ST*1I7Y\6+GHF4CD' &L\N(&Y?:1ZOJ_D0.-<7^?!8V(5_(@&/PC/*C5 M_H>8@$?&F>=0 R?# W>KO5H M)',+&A@9;5?]G:1ZE0__T^AU3IF'(&"GC7!J_D-SX1&W2=>"G# F5D94*;5 MVEJW\;2LJ4./&T^?]DOOYGJ >"F(E=;7^>=SU[O^Z.GX$<_)'ZB"=*-)QXB=BO-0W/S16&@\=S^JJ38_NIMG;Q\,-/KWLF]:\F];\O]\$1N"XWK:IKV5/^%YR7%+:CFPO4' MXM6ZV1S3'/XZ,KLV1=6G8(4!.=RD'AY!S>DH9#<.'0)G$XY7:3AT,K;]V#'B MKEW9=+=K6;QV0XO-]X8Z!T69HDO1GIM;6:LR=YD(#N]H =[%/<)3W9""YOS\]B]02P,$% M @ 5I!F6=GC]<,- P Q08 !D !X;"]W;W)K&ULE55M;],P$/XKIS"A3:J:MW;M1ENIW4 @,9@V7CX@A-SXTEIS[&([Z_;O M.3M9***K(!\2^WSWW'-G^\ED]\V=72,Z>*BDLM-H[=SF/(YML<:*V;[>H**5 M4IN*.9J:56PW!AD/096,LR0YC2LF5#2;!-NUF4UT[:10>&W UE7%S.,"I=Y. MHS1Z,MR(U=IY0SR;-@*;]%]WEP;FL4="A<5*BNT H/E-)JGYXN!]P\.7P1N M[_\Y!V?1HDGA!(+YQ$8?>[Q J7T0$3C9XL9=2E]X.[X"?U-J)UJ M63*+%U^%=RMH]$X HXEJZ6[T=NWV-8S]'B%EC:\8=OEYQ$16V=KMI@8E) MU7S90]N'G8!Q\DQ U@9D@7>3*+"\9({-)D9OP7AOOO.#4&J(G)"^4VY=896 M!<6YV;PH3(TWE69![S\&;QK]LB6$BTPQ2&4S*2%,_.E M=8;.Q?=])3>
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}(E-@K_)P<3$'S<+YRVT__Y'*.+Z?,NN!\N72-SNAZ@X!W9-0WF MWW^7SI(?#@"[GA[P?8/[? V(F)#2OA%DN54XB !4MU+_"+6NE5_4J;G'" ME](+>FR4);$@OR&J \I"U@46DW0DWI :7"R[-(. MK4[B6-6YJ>A$2&"-HT+]#>?2 8+&#'&\!3Y-ZX#>G5P"NB5Z4H\"U>2I6H + M+JG?0.&A]X$*_$V5L=M+=M"(.^3)^NW3[GM<1^)V46&WU>S!+_I\.)\AFLV MG$RFXJ$TUI\RNU\8G27B0J3I5)REXJ%=Q)>1 '$\3.<(/4G.\9L.DQE?+R9G M)^*]816.Q"0[Q^]TEH: R20+URFIV9YVH(!Z1P'4>)E&B ∫∫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s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}_%H2E@)*B+VHX$Y&6JV"%3,+:XI%\M2\^@%QK@4ZET24"""Y M2]/|&HQHP4!'5+-ZPTH=Z):F! <"M,4K6QCXE0QV1$BGOO]BI&F2Z("[7FD)L M/Z"-.:!=TE_&*^GQQ?,<(&0XP$&T3&.WQ@AE-Y{/2[WT2)V@[EYJ&N.CCR]L MRH7)FXZ15.%S)99 / F,ICCS%#V63)Q[,F""15-3MZE#YUXA$Q18A(_^Q6"G-C3&!JEKE<@.&U+XER1$\$S>B0%06CG><= K4/ M(5OX'LD "%3WV$W5&S@6K] J$;*>@^.[-NU_>W@]^>L"JF5IO&*HS;1\0GN(.0[9 >-QSX'^U;-$ M8&U>E74.# 3WD?!1F[+M//5L7U(0DSGWBW8=BY*,Q*]R:YQ[%@CK2+AMX&8/C)R/C-V(MQ0[L9:WG?/?SNT_W{2I-Y>M(3:FTI=N:\YO?FV+9A4SO"%XZ56U-.1*_#L=Y M&4)\3TF" 5-2R6%=/G%)Q7,2 MSG!<#(53\$CI(+[.@A&,/I0]!Z-'S*!V!=DA8D@/N,Y>$@C7H9!JVTM>47C/ MQ,S;2FATO/&XA5)]+@8?U5S.>3\MRP2&#T= JG4.]/_5.(>SE"*R8P7'/." MU-L#]Z?3R[25H,_6N^?&[#>E:G_Q:[_M[#6=\?\Z)'.5#^I%G+&7N10YOH0)) MLQF2"7=A.,*O'DBRU!?U!I3^WP)! 5#ZK5;/GFGH+;F/8(%KRD^+!8,SZ$W M=Z#VB9W-7OG!2I;? X4\ [9V.IV"Y:YGY1VA2J:O(Z%?BRD8IYNVT 8Z_R M]X&R+OT%HRLI GA/A1"(&3)A6[(62I&DXJ3!VY%OHNWY\C2ZBUU$!K'3=#(MG[(>E7\=?4))#O01[V40\;US)M=\YX?8QB'%VZ6 XSNKEV$CUM^)6S+JY[EM MD@VDR)1#XDME/"=*9 ; #&FYF1'L\8K'?\AK0_Z 6VB#&PR4Z (QH?6J"OEO M]U4TXJYAT-IE[VEC&RA.E\YJG1IGN6*^"HIEF(0D@4;=]%40=5M0;Z%*V.3 MLK?PD[?RU!@%;A:3,RX1@FM"<@:@T,/I9=1F2[R^]A2IXM%\T4.MRQZ3"2T%;Q&\-\+IBA-V[L)H%SGB4K0C(<4& (KXF MFR>)#45@N9R.KF_N;H1; 1'=H%T2ZIQ.>%=MB'F_U)D7-,BBC!QI6XB"PZNW M3K 3C1"LK\>\(-,S1 [BWO?M481NBR#VOT)&S04=)W('6FP%[T509D+X":X MWJ%'MBLE]BQ!A0-U#E=&\-D?YTL.AE.A<>OET.\W<8[#F=(.A4B7VNV6\BD[MU&22N^,\8^0_G%'P%AQ%X^GXQ7Z=QR\F+UB>O9B:!6Y7*:]0*>E-ZMSK@08AM%2R_2_JZH_UN;U"_&V@]*5XKU10_O6E8IY^EB<<1)7 M<072I?B[H__6'#[P^&I#1TQ.A!H'0PA[BO!@VE.(TBPF>% LB%?JW)ME1\6+7>6R(1!KK;$EX=%KUF=AW-HZ&DPYFUY# M(T-F_?_-RWH FSTZ#JJ44B@E75WX'O0<=_UTT(&TSOP.BWJ>%]\@Y366A MWMTFR&"H$HFWWV1QL>K="WI!%6S=@TIXMZ# D!-8\$=5RU:.TGP;4G C*U^A ML"JI6_5?Y3 [2< +,K=(XX%N!6U5^J)S+R06RN56SP=TVL^(=RJ1&=40-7+D MXZPIVFS]9@YWPG&,2A2(O@FRA_2W/=*(LMOL 6UH!'6S=61QJD#T ML]MQ57 D;>+0B"=SE$IM*X[C)@FJ'9>.:+KX6%[KPMT]&G]K!BJ6/__1N.#5"'P/F@ M%^VX@[M![2%BWXXFLS09K8Z&D*YX&3RY&(K$%&(=^D]Z8;>QBX#5@N!B:SQD7'GH_2 MK=??'#@C"4=R'HB\+[#/'I+T<+*).T;*TI8G5^/ONJ-'V5#Z?+P%|;XHFVM_MYL,?]8K@T!VD:G/0Y(A38+GMF-PEO4-M_Y J3DK/3^2Y\)RJ/;,0QGJ$N0' MX6@#>.1]2U'HLHFZWW-LKK0X>>X=V0BXXX]ZF,7"J3JDV$#LMFMUZ-Q,V+]S MKDM<]E.CSO%CS\B%_-SYIM.<*M*V8K2^"4\M MELO(75-OC7?0#,,>6(@*]#]L=./-QRW=FRJ3P C/!WR+,+Z!3RYB!HSVS2+ MV_F6A _T[^(#N]:3CU@(S\.&HY\\0PB'+5[XP2DKJ"V94=]{X=R7@0^ &XR1 MO23T)XM#&-63/.%X2PJ'KTZ=?5"A6O:9;L_'?=-9N-'0#T4NDE_M\&XP_3;) M>67Z'_"T3]N?/]W[7_UTG_O?3OTD[9)VXDNUP-#QZ.;]1%C_>R1_4YL-_P9H M;NK:K/ERI23D1Q_@_<+ &L(-+=#^*.SU?P!02P,$% @ 5!!F64G9C:5* M!0 .@T !D !X;"]W;W)K&ULK5==;]LV%/TK MA!MT&R#8LFPG3HL82)H.VT.WH-G6AV$/M'1M<:5$E3LI+]^YY*RHR1.L X# MFEJD[CWWW$]29UMC/[HN2R(O;2M?N? %!ZW[P9C5Q>4B7=T#14X\W*V$IZ+.UZ MY!I+L@A*E1YE:7H\JJ2J!XNSL'=M%V>FJ5K5=&V%:ZM*VKM+TF9[/A@/=AL? MU;KTO#%:G#5R33?D?V^N+5:C/4JA*JJ=,K6PM#H? 7(S?7$Y9/@C\H6CK>L^" M/5D:\YD7/Q?G@Y0)D:;<,X+$SX;>D=8,!!I?.LS!WB0K]HWZ#\&W^'+4CIZ M9_0G5?CR?# ?B()6LM7^H]G^1)T_,\+C7;A?[&-LI.3@KX M*V^[./04YNDS"EFGD 7>T5!@>26]7)Q9LQ66I8'&#\'5H URJN:DW'B+MPIZ M?G'C3?ZY-+H@ZUZ_FF?CD[?B_9=6^;NSD0<2XWR#NIL8RF7/8)V*#Z;VI1/O MZX**A_HC\-J3RW;D+K,7 6^H&8I)FH@LS:8OX$WVSDX"WN1?./M=YZ;XQ7@2 M?UXLG;N$;F=#Y 7SBR&QHL7K\'Z=O7^ \W7.>OH3^ MC0GZKUCB&LU UE(A' N)7UM4NY&V$&8E"F711,8Z44HG?$E"MKXT%HH)ZA6/ MK1>KUN*-#7V&=EO>"0,,US.9"&^$!C^7F@X&H3'5.6+!,8]5&:5I3X&W)K!(@%NH M5+T6&^/Y)VH/Q44@@*KS5"WARJ[T M(5Y=WN..Q.$E&;'F]?*O>$_!8FH\M% M $&@G,<#K [%.U-5B%24_$0(;B%F,1Z/8I+W).&DM&(C-<)XE [3="P:L K" MR2XQ7ZE(6'%;JKP4QVDRGYXDQ[-Y(#&;)S.X-I_O302:B)+4^NX9ND)^8W" MVU"8N?IN*Y#DCIC_ZN=+IG_^4IVGPX6S2:S9#(_[;8>\DEVQIO6NE;6GFM) MYF@%I^)AL,9$.'NXIF(,0XA1<5:^.1[5RD\%M'!*+)ZT,,QD]WBB26V+K4S I%0 M7D<@S Y"U#%%-G"I+E!N)=6T0197+2]EK_CD1BHMEYIB("&(,S;7B!D<)N M/!U+23\QZ'B$.+8T2_6XLJ_ 37A^"#&/G2FG9='JCPH;@)^,.$JLB1-1*-EK6X:BVS8M\Q M9.#[EU9:)(Q]@%Z6!",'IO7],$ VW1-L:]965C%^]TXF8^FF"RX;VC-U0U0 MMM"/U.'9)+Z/'GR\Q[N&!S^$JL%^5]]/N#A1W/NX4M9YI)30!"&4AYQ&L*X> MJ3R2P C.]FW$26/)*\[0>(]S)SOI^?$D4=R1^/A?!\&R=V-"B6+ZZKHQ5'E MH4^.QMEP.KN? QNPUS@3^![6BB*,%T67*)^EI,IZ M*=$/]L&"BDWNC9<:5OEJ'P9S5TTRN,$L5JUO+3WG0C^]Z'.&1X@/%@C'Z"@[M[.A*->K=? RNRZW#+=R(V,37=N0NXOWY7CQ^A7R0=JUJ/J16 M4$V']-!G *A3=-N$TOCP_KQ,_%!+ P04 M " !6D&99!Z:+GM $ 9# &0 'AL+W=OD[,BK;63 7N(K\= [#N&#/DJ:F%O@HJ8]J+\5@7%6NH M'LF6"9RLI&JHP:-:CW6K&"V=45./DRB:CAO*1;"X=._NU>)2=J;F@MTKHKNF MH>KYAM5RF/F]O5=X&N]02MXPH;D41+'557 = M7]QD5M\I_'91@]D8CU92OG#/GPNKX+(($F(U*XQ%H/AY9+>LKBT0:/S=8P:[M*ZWA4-ZB_^)\AR]+]MFMK+_STE1701Z0DJUH5YNO:J-0$W\=\M?#98?A;)]/&FLPL048SM50Q! MO@UKEE"V2;^#,Z?.;5'8/^E >M\)VI4<-_VY+N?.(<'/+OK&J:HD>KBQ> M M>1]GX2R9GED92<(H39R8Y6&>S)V8S\(\G9R1CTQ[*9'^.X& 2O/Z2- U\Q? MJPDFHC:XU8:_T[@5I=0%'.]^#N\AJM,HS+(HG,XS,IF&L QABE)#)'&_S<#Z= MVK?1-`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{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{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{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}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}E7#'GO MC-_/?GN% %&8DZ3/N[6#&FAFM]D2(R>K]P'G*B3<66="0= MJ/%/NH1:&*58JDD+-+#&Y+E0JT8#&T1>L]W"0J@I*J76LC%29^#.R";+GWGU$[SE]U';MS#K'-M,VD?9%$PEX@1,F?**

@91<|TRI@5)Q31E8&40"K_58=$M:M$%(#".ZRQ:NT59 MXENM+,;J\#[$S"TJ\AC*L.X*DV@Q:A-:'3-XZR(%O;)ZJ<%1S.78,)4N?9+< MBBB[U
Q4FND1<;UP"ERC4+*EXNQ4PPM+X'F*JM0%2";TN=)8#NP/@, A?G MC$_"@*VH2W]J-,!IQI$"JJ MU7G\8NF6"ZX7$-ALFF8*)LN]"@50O>7H=8'-[VPQHN>/5U\ OI&R GS=@#_H
M2*WP"(D0-$W=*+O=U>F60:Q0>E,A9_9;&+0^TG/DH% 1B'G8^Z5H+T@9:$*. M)Y7],&BM@VJ06 .>)?]DB2?&4\G(LO"<*7R,.94O,'^4H+6S'"J4JEJJ -" M^?
5P>_"$PP8QVP:%NT4<(!MZ4$L&M1CI.CJ?-/NYA8"F9XF[DC3H X:1S#.#O!F>?\\?G#WO!JM_HB-]>1/)C"55%NU);>3<|' MY^#%F%U#0MI0()@*G?
J%N(UW=E4ZY)^4AN;+_/+!&)*I +%DQD5*>D?.,8"B MK[666=2&C%71PCN5TL?5 LIOY]7F6?$=VV?L>;E?E1YR,^R1@L-3%W5'=*9U7T,_O9;#HZV95J*.D<<%]4 MRD.,
(H^D[*Z)]|GMJ>D#)ISH)43"Y,7,,%D@*+[5/,?&T/2?H?E..T=.S*,3ZX,=:,G>1>+ <:I) OC_UJ?_6^ MRC?.O7F^M[\%4,Q!$+6$ZV3TZFQ /M^%\TMT3;I_+ES$;3;]K/#O WLQP/>E
MPU3O7F2#_A^2^5]02P,$% @ 5!!F6=P_NQO> P ?`D !D !X;"]W M;W)K&ULO59M;]LV$/XK!{4!$D"S9,FVG,0VD)<5"NSUU);>3<|' MY^#%F%U#0MI0()@*G?
PN3>2LXW27TV% M:.&Q%M+,@\K.YB**3%YAS'*-:1$D<3Z*:<1DL M9GYMJ1HU";>3 ,]@MWO*RL6X@6LX:5>(_V2[/4-(MZ ME(+7* U7$C2NY\'5\.)ZY/2]PF\<-^9
!N?)2JFO;O)+,0]B1P@%YM8A,!H> M\ :%<$!$XZ\=9M!OZ0P/Y3WZ>^\[^,)B!F^4^)T7MIH'TP *7+-6V#NU^8 [M?
\8.+U?"^"]L.MU1%D#>&JOJG3$QJ+GL1O:XB\.!P31^Q2#9&22>=[>19WG+ M+%O,M-J =MJ$Y@3OJK0Q,GH"%[:NY]ZO/05O+W7:ZUJN"&NFLJ$4F KN/'!1PU_7*V,
M7__SI0!T^*.7\5U+79B&Y@/J&<,Z@<,%N_>#"?QY1'VHY[I:CZ?T[>2654.46WL)H<B&J+ MJ1/&X7GFA.$H#9/QRSMQ.$PF\$GB3Y:.1<5UE[00@-Z@9MRP0(GM/YAF?@ M8Y-
FXPR66JW1N%.0+%P)D9&!) NS.';#E(9I&F;DS#0.TVP(GQ5%O_S M6\@F8>KY9J3F^2;)A)A/O12'4V*^SZE&X=-A%>2[?C!=0^2"^[0*E7L-GQB$ M+]+%"NXM+9(F,W ^&9R?
^%H\GP[&)U0BVFM:G[JZ2PV^EAIGYY(2$A73H#^U MQ3;L\+++!I$=.GY"ER_F/ 0^@[Z)]P+C,15N0,ZQX\&W4>0X-V]8^ @YIQ04U M3&E<&/"1,F)H^BKD])?
\;BP&\`T'W1VGGZFA\\FTL:">'^/UN/OX[_CY# MQ;?.,>M-5UAR*5UE[!"H*+DZ8/LO0YHD'=DD_3_)^1^=)!&!S&&EO_<- M570K[_^^]L.MU1%D#>&JOJG3$QJ+GL1O:XB\.!P31^Q2#9&22>=[>19WG+ M+%O,M-J =MJ$Y@3OJK0Q,GH"%[:NY]ZO/05O+W7:ZUJN"&NFLJ$4F KN/'!1PU_7*V,
M7__SI0!T^*.7\5U+79B&Y@/J&<,Z@<,%N_>#"?QY1'VHY[I:CZ?T[>2654.46WL)H<B&J+ MJ1/&X7GFA.$H#9/QRSMQ.$PF\$GB3Y:.1<5UE[00@-Z@9MRP0(GM/YAF?@ M8Y-
FXPR66JW1N%.0+%P)D9&!) NS.';#E(9I&F;DS#0.TVP(GQ5%O_S M6\@F8>KY9J3F^2;)A)A/O12'4V*^SZE&X=-A%>2[?C!=0^2"^[0*E7L-GQB$ M+]+%"NXM+9(F,W ^&9R?
^%H\GP[&)U0BVFM:G[JZ2PV^EAIGYY(2$A73H#^U MQ3;L\+++!I$=.GY"ER_F/ 0^@[Z)]P+C,15N0,ZQX\&W4>0X-V]8^ @YIQ04U M3&E<&/"1,F)H^BKD])?
\;BP&\`T'W1VGGZFA\\FTL:">'^/UN/OX[_CY# MQ;?.,>M-5UAR*5UE[!"H*+DZ8/LO0YHD'=DD_3_)^1^=)!&!S&&EO_<- M570K[_^^]L.MU1%D#>&JOJG3$QJ+GL1O:XB\.!P31^Q2#9&22>=[>19WG+ M+%O,M-J =MJ$Y@3OJK0Q,GH"%[:NY]ZO/05O+W7:ZUJN"&NFLJ$4F KN/'!1PU_7*V,
M7__SI0!T^*.7\5U+79B&Y@/J&<,Z@<,%N_>#"?QY1'VHY[I:CZ?T[>2654.46WL)H<B&J+ MJ1/&X7GFA.$H#9/QRSMQ.$PF\$GB3Y:.1<5UE[<- M570K[_^^]L.MU1%D#>&JOJG3$QJ+GL1O:XB\.!P31^Q2#9&22>=[>19WG+ M+%O,M-J =MJ$Y@3OJK0Q,GH"%[:NY]ZO/05O+W7:ZUJN"&NFLJ$4F KN/'!1PU_7*V,
M7__SI0!T^*.7\5U+79B&Y@/J&<,Z@<,%N_>#"?QY1'VHY[I:CZ?T[>2654.46WL)H<B&J+ MJ1/&X7GFA.$H#9/QRSMQ.$PF\$GB3Y:.1<5UE[00@-Z@9MRP0(GM/YAF?@ M8Y-
FXPR66JW1N%.0+%P)D9&!) NS.';#E(9I&F;DS#0.TVP(GQ5%O_S M6\@F8>KY9J3F^2;)A)A/O12'4V*^SZE&X=-A%>2[?C!=0^2"^[0*E7L-GQB$ M+]+%"NXM+9(F,W ^&9R?
^%H\GP[&)U0BVFM:G[JZ2PV^EAIGYY(2$A73H#^U MQ3;L\+++!I$=.GY"ER_F/ 0^@[Z)]P+C,15N0,ZQX\&W4>0X-V]8^ @YIQ04U M3&E<&/"1,F)H^BKD])?
\;BP&\`T'W1VGGZFA\\FTL:">'^/UN/OX[_CY# MQ;?.,>M-5UAR*5UE[!"H*+DZ8/LO0YHD'=DD_3_)^1^=)!&!S&&EO_

SI0#8L*G+$G Q&|)Z$16 M@3EIXTN"D-%D# OI5AJH'&B>[L);V!A'R9+,!{T/W@$[8))T_!~_)!{]HR:08T:INQ'-29-&8B(Z.A+=\J=AY$>UE M[!M?GF[__OGN#]F-VFQ? O2H;_FDMJHH<:\;.DGE4FW0O%,(QG!U*-HWNZ@SN=5(%$.;KO1;KQ&.$[MT?DNC1*CGWN: %L/\TY##{G]4)J5U SK9EZ:JG'N6, %AE3 (A,7?0VNM QV M&9UL,8C,=H.2/Y1U>$* ("A5@7B#'4RWF_AZT=8"+L%%/WC%3&-U+;,..%VZ M-"Q14J#0N&@>.%)AC-])>8F3%4(10!Y*,40NA)?'B80 EJ%V3JP3H$*A?>^+ MZO6)$-.:4=I0XSWA=0? PZ$}NNIRGKT]2O=SN3N)U[]R2L'[L=LL$KZ#'*8?.8HQ!D9J.EK55&^KU+S ML4I5O$!2H^:)SVW;K)K0=*AN$K*F;T_0%/Y^A8I2OBE'QI/CI%9J]7==7<@ M]LD4XV%DM+=Y9(2S://VLH^DE@XVW8}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}?AZ^LN>_BA M 7V9+;^]>)2AP0T\"&OZ8,39\2>*],?,)0XAB?^#_(V0ENH5F 9-/E%QM&1P M+ (*"%S>^.L1XJ)AX]'%CSD:DLSE5N9HI]1>$<_^>H/[Y>\(^#JFV+1]IEE1F M^I5Z+E;IQ,P((;-0XD]?]L4\=_H5[3FG)(VX)&%&.16/LT7O]G,R8]T&^Z< M??B& (-[,M6(R[T^]:ZBF8526I'CW*$<(X3-_7C+:F M:YLXQC=\WI@^%W(D?TG,+2\@U18.[?:^E3 ORI4/Z@%QH((?8X&$ =XB+Q M]\=8J{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{%KO[^_6CYX#$_&VU_\N ^_">R$'@O_AM02P,$% @ 5!!F M68=ZSV6I!0 # \ !D !X,"]W;W)K&ULM5=- M;]LX$/TKA+=8Q 32Z*^G$T,.$F+%FB+H$FWA\4>&(FVB4BB2E)QVE^_CY3M M.*WM9@\]6"8ESG#F\3T.>;94^MXLA+#DL:X:CD:F6(B:FQ/5B@9? M9DK7WKYR/3:L%+,U17HR@(TE'-93.8G/EVWWIRICI;R49<:V*ZNN;ZVX6H MU/\$ {6+S!)^<*Z%Z/)663(M" M=8V5S9QN,+]**#F]$>T)80$D41/$!?VR#$//^V!Y_N]++]9WIGK :C_MV5 M<:\OWNW/J>S4M+P0YP/(R C}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{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{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{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|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}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|" :%_;KERP,PF\D0E1)&KHN/[C;UP(CE+Q1S#*"T"B(OSI#* M<6#%+,J0U1$Y1KMQ;VK 1VO;SD8:4\37U0T0^]W}^'7AIHXW=3>[_:)JR_"B M.&S0U!]-D%3*S4-N863=SB!K:7"B:<421TA05@'/-Q+3ZA8VP'XH7?X'4$L# M!!0 (%:09EG29^/+V@< &<6 9 >&PO=V]R:W-H965TB[,W}GN&DA7GXFB3MN@AB$6*Y' X\\PS0YUNI+IOED)H]J4JZ^9LLM1Z M=3*=-ME25+RQY4K4&)E+57&- KEI,FY42/#>+JG+J.4XTK7A13\Y/S;N9.C^5 MK2Z+6LP4:]JJXNKA4I1RG%]/QTQ1?B1NA/JYE";SI(R8M* MU$TA:Z;$_&QRX9Y<)C3? 3/AR]S,FQ)"W?,6^D_F+/C+'>\$5>R_*W{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{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{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

YV4TL'0%\,BGK61S\B%),L^\)Y#_P0NW!]Z=Z_>A-.0YV'SD0?DR(O]W4 M!MF9\RQH$TCPK @,[8<12VPPMQGKA1^ZEN?$((/'@B'FN3:F11G>0[X<@5"\& M\D,,'#^FUAZ$!1,*0BMP#

<(\&TA[HV-FI \(J<[*UKP L+/6I @SA+L$5G7) MJ<\'H)4:J,.JO\"ASZN2_X^+W21!E>1W9DS3_O!;#PQ8[:/@ M3:NZJ\N'>@7%C(8TV"7>6Y$MZ^+W5NQ-M>-

[$B)1<[=*T4E_H;J%^6Q.NZ_- M[M7C[LTV\Z(4IV*(%**JO,C[\IN5!;\KRD(72(\=:KO27^)'[2"_+19U,2\R M DG1':DE>.6M48.6:%,9?A6BCU;X*%#WY^RCB88^!4/?Z[[8NRZ:^Z'S62(N M2-$'+X5JF*'#Y2%C0\SLXSEI4 !C5(LS16I^6NT;87UD8%QL/=\L<%E

MR5&IP:^2*LG$#@Z@]@%#&F6AC8;A@T=;]^;=&]!;>YJ;$JO[YFUU3#TY:/SHN"NWP@$4H;PX>Q[5Q(BS4^]$}]LW_2_X, M;-_8,=XINX!]1+JP3?NCM XZB& MW1?

9XY+W8VNX'"IB[,%_[V]FLVTI35<*65-PHQ(>!]0.GIY"_4W@>56HCZ+G MI3OAUS 4&@S!X9$-QX?P/_72E +U..8Z#5$QX^\E0(6V%W00\F,"5!QWO=#_ MHX":

{GS\JX1:F$^M%]/'RHMSI\$ 8"P &0 'AL+W=ODXG2_ M?G>4[::#XV%?%B#F4>0]]P+CSS?&'OO5@">/;9-YRY&*^_79V.)*U?0:G=]

MUM#ARL+85GNCZ7GX=F.GYZ;W3=W!C66N;UMM-MOUY!8S87(SG:?;BMERM/'R;3\[5>P@S\]_6-Q=EDCU+5+72N-AVSL+@87/"+]L,>V,U

M8F7OO&FWRLB@K;MAU(_;.#Q1R,4S"FJKH +OP5!@^4Y[/3VW9L,L[48T$H*K M01O)U1TE9>8MKM:HYZ P?V 4;35R]D*MXA3L,-4=JAU0F>XJ=EE]QE*#BKVWQCEV8\VB

M]@R///,KP"\+P[X.#;!\VR#90MI'CVD,[!{M/6-B(0L0V8%'-(4Z#9Q]+K.X0 MR_0.=[B3,W87<)\6SS_@?B%S1]:#N6#JFS3N.]U7-3IS\IV\#2*[@W+5F<8L

MO[*7+,YYFD0D)+S(2)!QQ%42!TGP.(]",,!1$](-VK:1)MF=\;CU)0_E\S!A!X] MH./0_VN&#A?A=_F*)$\PP$&(T@R%(N%90>DJ*-CL]F*>29CS$(4V5U9,I3W$B M(R[D+E"QQ%$7@\P%-/Z-HH31=63?4 M?M#?UIVQF3?E_6NZ4RI6FA;O6:?#53567"3RA,98Q3@F6(DYCAD7AE[2T2"$GOU(E=2 MO=F/8Y6BD7$;_1["+UU+#$W,9F5"1,D M4$#'1&

!VI:KH%KAR6S,.M3M6,9<%A$I9SQ-,U)6O(C)ET3Q*"I.V'OHP&+2 M2%=7>"?6U,OI0R(O=3%!0NO0/LA64]1#I@M'0K_+4- M?<&+/-@72(3"@*4FTV00"HD

UYW'QN9\4!Y"4W>8/5O/CY1$.-GE@2<2_5<\ M%MZC-]2]PC#=YEXXW8DIGC7+1)BG<]-0'=@\4,@) M.#S(0(*]E<%O,6L+7;8%MNQ,3@)7?:&433QSS!-W#,8)FGP/]"T+\B1A]&U M=\AQI/3(HJ0]JV\R.B

RB42:+G1FC')X(OMK;@NO>Y= E5-[X/L^Z;[OD[_V M?7^].:9L.+%]=/F6LP47W#[T??\/&NQ_P_KCRCBWDL4(4>",B[N7BM6Z]8=Z :

M.O"TY&Q:S09,A#1F"BK:@ZLW";JPVO32L=IM$)O@Z/ M7/!'"

VWM=*_$FVRX MD]QV^[ELMCN04',[T!L-8Z+&;IMJT-'7+L-A&L9PM>T_',7#<'*R,^N=)WMK MR-.!J!D^VU!T,MDW,TO"?2/?U-2.NV,,D3UY?BB;%K$?3)SN6^DY,=%Q!/J@

M/]ZZE)1(H'57+R*5]J5M[B?=:G>[NV@N-8_BS=60$KCBTH#)6T-1B<$:MU< MMYJ)596_XBR4I0N3'Q9T0I7M!.C]4BF[F3@#W9UW_CM02P,$% @ 5I!F M66/$4*F8!@ 6S !D

!X;"]W;W)K&ULM5M= M;]LV%/TKA#<,'9#5EOP1)TL,Q):T%5B*H%ZWAV$/M$3;1"71(VD[*?KET!4B:Q4Y#9;NW>4@D^=YSR7-

(BO>:N=LS_DFL"9'H.8E3<=]92[FY[79%N"8)%F_9 MAJ3JDR7C"9;JEJ^Z8L,)CC*G).ZZO=ZHFV":=B9WV;,G/KEC6QG3E#QQ)+9)

M@OG+E,1L?]]Q.J\//M#56NH'WN[KHE2D03D@K*4L3)\K[S MX-P&[K5VR"S^HF0O#JZ1[L]"L4_ZYEUTW^GI%I&8A%)#8/5G1V8DCC62:L=_ M!6BGC*D=#Z]?

T8.1\3WX(C,5_TTBN[SOC#HK(§F]C^8'M?R=%AX8:+V2Q MR'ZC?6';ZZ!P*R1+"F?5@H2F^5_\7!QX."TQ1QS3J M4ZKY,9C(N1TDZG,EFBZ% *M6$Q#@2@3Z!;W'G&,]2M

,CTA,8_'S75>]%NHXW;!HS31OC7ND-7WTR%*Y%LA/ M(Q(9_#V[_XW9OZN8*>EQ7^F9NE; .=F\1?W>%7)[[@!]G'OHS8^F?LU.A^E, M8+P+6H,$6:FI+@UP/DRK

CN,1T(%X]A@:MSWRZ'9SW#[1W"?N%H_N7RY0D^Q M'G=Z2/K_;>E&]Q;]\X$[TIG\ M](,SZOU]4A<2S(,$\R\' B"PFMJ#44NV!#7WR?ILL"-=KC58=9\M+;,(%^F(9

MY%,K[KE*0X)Y.=@P]_O^-W$O>ON#N6##!< @=7D&Y;R#4^4CY,-XQ(O8G*B M?E;@<_6#!/.&K?I!A@N P&KZC4K]1E;]/J8+&L0JEU$70EZAE*A?X5:I8%Z8Q@WE7=?

$OK4!Y(]_8E ?,F@P;BYTKH7[FY+[MFTNYQXEZ2=#/.$L\U N?,M-V?VK'=UR49/M]TVO ZGJN*I>WPX=L1P $5E/3 MZ56Y8N^;YE+*4LMT*L!K0_O&-) LK3A7NE/#^ J'A T/8?

M\RIYR#C-VOJN + M21,LE0;YO-&;K@5)R9*:;;>BG;N_ D7S6GHZ0"\$<^.L FU' (565]2M%'6M M_7PX7 R5FM'KWJ"<9#A4B:^@F8&><"9.ID64PV7\VCB_W,;0'!GL/(-=_E9H

MS)RFH6-"#.P\7,IS55!PK!GLY%VRP91GY8.8"4&R32[CD6):\=ID_3C3_0;3 M#9);3;QV$[_=)+#W^5).J[3=L>?MOS$6[57]@&A)KI&Q9B[<8*S5Q&LW\=M- M GN/+F6LRI0=>ZK

<#"7U3A+!0Y;YG4S#W7,$]M@:)93<.!<9=Y*F)@[_.E MG%,9JV-/7Q^B'5%+]-!5(_*\(:DP)E2.(9DS$GF:G6>R*)H/BA9 MH=7EKG)C9_P=2^P.9 XZ T7S0-%\4+0

"JTN>164. 9L]2&.V5YMNX@I%^$6H ME%RJ-5LG%0=RFW2V!SE79U TKX6 FU[65^,7H* Y/11:7>@]\7?MZ? C36FR M3= 7=.EKVA[@;)%!:P&@:#XH6@"0%5A> ^J@^XJG=\3;M

275Q5(_0";M07]*@#*)K7TL?^\0(?:#L"*+2ZEE61Q+47 M21[Q\[>NW*"G'$#1/% T'Q0M@$*K"U_5>MSA]UR Y08]&@*)YH&@-^*%H A587 MO2I&N?9BU.DK-^1!A1DHFM?

2QZ%EY08]?@&%5M>R*HBY]H*8,;FZ.JXH:!T, M%,UKZ:E-4=."%Q1:KFCWX.QS0O@J.Z4N4':(*3]K6GCXM3\(_9_>_OWH'=6YG MCN&YY$ZZ^3GW"CX_=O^(^8]F

L5DJ4+UWEZK987G)]GS&\DVV&ULK59MCZ,V$/XK%CU5=]+\N M0H"0W31!VKQ4K70G19M>[T/5#PX,P3IC4]M)MO_^QL!R26#3J+=?$FR>>6:>

MF<&>R4&JKSH',.2YX$)/G=R8*)W!G.!*P4T;NBH.K?&7!YF#H#YV7CB6US8S?<>%+2 M+:S!?"Y7"E=NRY*R H1F4A %V=1Y'(R7(XNO \R..BC9V*5;*3\;A>_IU/'

MLP$!A\18!HI_>Y@#YY8(P_BGX71:E]:P^/F%_==*.VK94 USR;^PU.13Y]XA M*61TO(\V3//P&C9AZY4LDU]4O.3185R')3AM9-,880<%$_4^?FSP<&2!/OX'?

M&/CG!N$K!D%C$%SK(6P,PFL]#!N#2KI;.Z\2MZ"&QA,E#T19-++9ARK[E37F MBPG;)VNC\"U#.Q,O0">*E5719$9F.XT K0D5*5G7O6/WUVPK6,82*@QY3!*Y

M$X:)+5E)SA(&FMR21XXM1T4"! M(Y@I29LA'J36^?\+ 0QG7'Q#W>,T@[]]] M(.\(§^2/?.XTNM(3UZ 8&Y*,-(/'ZL#]5P(/R"?!I'W2U\EW)[\99DRSGY8GJ1-W?

UR$+BBX/PU9=AC89\%SBQ0;I:5/ZI->LPZ-8;L_"G?MZ-&/=C[@??BQYT?7'P%@QT M>OX:IN5_-5I<(_F@=+4MAK(-*F.YOHL;W?;F>-7^Q&G7.]F>#\'7S0L[&;$> MZ;[3UP/F)ZKPJ-

"$0X:NO+L1%DS50UN],+*LIF*--#CC5(\YSKF@+ -#?9U*: MEX5UT$[.\3=02P,$% @ 5I!F638KUI^0 P 5Q0 !D !X;"]W;W)K M&ULO5AK;],P%/TK5I 02&.)W<<>M)7V #$)(H*

M^(#XX"4WK85C9[:S;H@?C^UV29%61T0-7UK;\3WW^.;$) _%D+=5/O0(PZ*@ M0D^CE3'E>1SK= 4%U<>R!&&OY%(5U-BN6L:Z5$ S'U3PF"3).":XH$!%LXL?F

M:C:1E>%,P%PA714%58^7P.5Z&N'H:> S6ZZ,&XAGDY(N80'F2SE7MA?7*!DK M0&@F!5*03Z,+?'Y)1BF S_C*8*UWVL@M5;*GZYSDTVCQ#$"#JEQ$-3'W<3,5 M<.Z0+

(^[+6A4YW2!N^TG]/=^\78QMU3#E>3?6&96T^@T0AGDM.+FLUQ_@.V" M/,%4T$K1$5&5IL M[I0;7[*E8#E+J3#H(DUE)0P32S27G*4,-J#%E8O6<7!S9XK]QIE'CW*N[N* ME?

8^&O1%0UYQ])'E@%Y=@Z&,Z]>3V-AE.#)QNJ5\N:%,]E!>0'F,!LD1(@D9 M_AT>V]77)2!U"8C'&^[!NY)%61E0"&JFO[$G)EA1%<^Q"Z*YI^A?;"U"ZU-EC]"5DSKPM^A*J--

KC7!A/H$:AZ7ASA-&03&2 \J@F/.LB"/NR3 M11"M8W"\-==QC[(8]\#\I&9^\G]D$4XS:)7%:4WX-(CTOE*"F4J!IYJS!]?6 MX1TCB-BQP&I7'6 W.<--Z4_!]QM.115P?>\5/<41_[MXXP9-

<9M6NDL4<-JG:6K3,S9I:K02WCS!:UPHW/HA'M?"-N N5!$"> R\@<C:=\]2..^).Q65[1DM>Y#R24\'T

MK#MI7)+@'D5#^O!+LO.]&/Y@/)AH6O*T[RFDL4D2MJ]_$,W^G2:+DL9%2?AS\G"B"><)[#3QSC&1.W+[1-62"8TXY!8J.3ZQR&ISBK7! M&%GZDZ-;.8PL?',%-

/E)MCKN93FJ>,.H^JSQ-D?4$L#!!0 (%.09ED/ MF4(5G , %\3 9 >&PO=V]R:W-H965TWP8^Z#.UXFH+'F2W'2P'[\K){4S:.0U MU%\2RY:.S[WW2,?29*7-K5T",')?

2&6GT=*X\B2.;;]$@ML#78+")}DV!??8 M-(O8E@9X5@\J9,R29!P77*AH-JGO79O91%=."@77AMBJ+CY?092KZ81C1YN M?!-+I?,WXMFDY**

N8@_M:?AMLQ0U*)@I05FA%#.33Z)2>G+&1'U#W^"9@9;>N MB0_E1NM;W[C,IE'B&8&$U'D(CG]W< Y2>B3D\6L#&C7O]..WKQ_0/]3!8S W

MW,*YEMJ%Y1,3Z"@B&>2\DNZS7GV$34 UP51+6_^2U:9O$I&TLDX7F\'(H!:] M_<_O-XG8&D"'.P:PS0!6\UZ_J&9YP1V?38Q>$>-[(Y]_J$.M1R,YH7Q5YL[@ M4X'CW.P",&I$66=

(Y^2LLMC!6)51N;K2OG[<[%0(AHEJR3XWI?*<;40-]@ZM1:<)5\MY)4D5R("\NH"'!?2O![$#B/P M/:)TP_9LS9;M8#N\'H ,DC>$)6SX[_8 V^B9TWTK,8;

[HS^#G590D88QA$!)/HQ)8\A6F$L\2"N8-H]O(%'2?O GP'#=]!C3[8 MP?<#TG+P]@J%G#V2Y1]7V)]<.BCLS\>H#WJ@/FRH#X.I?F^=PFO%NU%B1J

MX3&289@1^0W"T(OF3/!:XW M(1SWJ8?C'JC3'6=Y'D4T8'#.A5!MYR0/!\F=]\1X;?LF]G6T2CK4Q:T#WNC MK_1H <]01=AG,-N7;3&1<.6==" MQ]'6Y&C0B)Z@@S#.J'-!8*UYL,#I?

#$\P[TQ!L[=@3U#_8{3/PK,^ M?(QM[.NXQ!\]?>)F(90E$G*$2@X.$=FL3W/6#:?+ ^@3E1CNGB_IR M":@%XSO@\UQK]#PAS+-F=KL+U!+ P04 " !6D&99:F)OY_ (_"_9@

M&0 'AL+W=O]OXC@>A_\5BUN=9J2Y M0GY1F&N1IL36CK2S-YKNWKTXW8L47(@F/]@DM%OI_OAS0@9C$K{@XTENLAN6FD-&R*90F0W"E=LTC8JW!YGD MK_<#9_!CP;=XM:

{J!+4Q3U$IYWGRKWA9K>\'DP%;RN=HFU3?\M>?9,M!30,7 M>5(V/]GK;MWQ=, 6V[+*T[:P:D$:9[O?T9_MCC@HX/@G"KAM ?>X@'>B@-<6 M\'ZMP6\+^,<%@A,%@K9 <&D-X[

N-GWNYW5[.DPJJ+979& LJ>6)'J%XVN MIK3:P7%6_V<]5H7Z:ZS*5;.';,F6E"6;Y^E3G&6U[I+]C?T:%4542V?O0EE% M<5*^5TM_2PS9NY_>LYJ8G<']

UOFVC+)E>3>L5$MJWG#1ULIWM;HG:IVR+WE6 MK4O&LZ5T9TX7_Q*],=<_63JD M2_]C4:G*W::XU[P^F/Z91,XD\GT;OARZ+*[UFB_AB$W+BV L*2$&_;%.9 M9WW[G2QGN]^1L!

)XTB8 ,$,D^.]R3&^/QTC)2-A(1+&D3 !@AF2;_>2,\G# M=:Z^-<5+633?G_J$WG8Z"&\Z&8W,;F1.5F)K"@GC2)@ P0Q3D[VIR;4_^785 M!(1..Y,("FPM M(6$<"1,@F&')&>ESS-

&YWK&*LY7,*K8X["A9$D=/<:(.1MEW$OG08@]]S=N. M0;IN6X50&H?2!(IF6CQ("AS2XE=9++)3".":75V7\E5145V4VVN.F!/>?8'5FC MM3LDC4-I D4SW;G:G4L?@?

5G6B$KY:\^[C;16ZI>]EISNR<\H^Y!1U9G+0Y) MXRWML.-WG,,M$*@Z32$Z9"(T_OV_{][E\V3N.X7"YGLLK=UO.GO"Z$1*Y06 M0FD<2A,HFNE9YRR.CS_[>[^9GN'T2FMA

:0)%,UWJT,8AXP+=/X?R12;Y M1DFMY&*=Y4F^.O5M%1K:0&DAE,:A-(&BF:9UF.3[10T-S'RB-0VD"13-=ZNS'H<.?20_]6Q$M91H5W_M[M962.,H?20BB-

OVD"13.\W5DY([PO,*+C%OF4%H(I7$H3:!HIFL=++ETL'1Q MKWR&$YSNE>F2UBZA01.4)E TTZ4.FMQS05,A7^H0X]O97VO@RKW"]" 7&EY!.2&4QJ$T@:*9KG5XY=*SA,Z.:M/E

MK,UV9]&X,B>Y#.&5G0,T=PUTTUAKC=W) M1IV)#R&T2@ZE"13.M*A3(1=.=VP'NFF=TYO>%'H#Y3YV=*6J?O<.IWC>&>F_O2>#U],>]+\ZTL+ MH)D.E,:A-(&BF=YUIN,Y^--

$#YF$S*&T$$KC4)I T4S7.O/QZ,SGXOR.YEC[.M15MU>A0]A+:.#0VD"13-='ES\1<]++.ME??SX.3M=@/1E[-1CVG4OQ;X]LGA>;_/1@&DVP MM@B=J02E<2A-H&CFC111TPN5?

8:.2#TVUH+002N-0FD#13-1,H=6*E T4ZD.KWPZ)K(=[*%QUOZ@TY9:&C%TQ*$5"A3- M=*?#*I\.JXX^5"U&%6BPM45H1@6E<2A-H&BF\(.[%ETAH_*A&164%D)I'$H3

M*)KI6F=4/BBCHCG6?]%7V)W9QM-C%!S:#H&F$[1/N73&56WHI$\:(%&6^N% M!E50&H?2!(IF*M=!E?^%,H,]'!E506@BE<2A-H&BF.QU4^,"@BN98^X5>;G=F

M&T\/3G!H.P2*9KK4095O%52='4>@<<=9*H:D5E,:A-(&BF7>7U*E5<(74*H"F M5E!:"*5Q*$V@:*9KG5H%H.OK;(ZU7V@V=68;W=/=,]0= D4S7>]X*C@SUZK3

M/7^3957$BUION8Z*_B_1--7:+#2U@M(XE"90--.V#KB"*UQL%T"S+2@MA-(X ME"90--.USK8",D^9_;I-GV11CR$4QT\=*"@"TH+6YIQ M(=AM,!T=Y]/06@6*9BH]N(\!*F*\D&PCBSC?

Z6L^?KM86_LC/VS-[V= MSH2ES?,<>@]2]\V\H4'6\,#!&-.=2M*]D>XQ'I[_C$JGYJ'AQPM MY\Y'L7LBBL;LGLWR)2I6<5:R1#XKY.CF5FU L7OY-E6^:OW.GO\ES1W+

MM51G7$6]@OK[P?.C/[\U!+ P04 "!6D&99 ,;L9H8* #- M? &0 'AL+W=O%OFT@:A_\5Y%N= M=]5>* Q@NY=82L/,7:7N7M5T[SX3>Q*C8O "3IK3_?$+-O4P@<\R]>^^-+&=

M>0;S*R_FX05?OV3YEV(C96E]W29I<3/9E.7N[71:K#9R&Q57V4ZFU2N/6;Z-.MRNIA_C0M=KF,UH=!VV3JVG8PW49Q.EE>'Y[[F"^OLWV9Q*G\[F%O%?KN-\M=W M,LE>;B;.Y-

L3G^*G35D_,5U>[Z(G>2_+WWW?O"%X,F\[\8JWE8[1/RD_9RS[E M\X;[KF%DN+PK_72_*7JL5;[HLRVS>[J";9Q>OP9?6U61&N XYT9X#8##W+$# M6#. =0>P,P.\9H W=@:_&>"//1 T

X+#NC^NK,..#],R6E[GV8N5UW]=T>I? M#G$=1EKW^]#Z^:=?K)^L.+4^,[)]48TJKJ=EM?CU0DQ7S.*^.RZJ>V91

M[^7NRF+V&\NU76]@^!T]_'_=&79SMGA(3W\U^C5_]!562V[.S1\6@5^2MT]I>X>>.P,[T.=>-+*+3KF]G8HE2/*&T,5E>]M ML8M6\F92E;9"YL]RLOSK7YS_OM01DA8B(1Q)$R

8%JX[!0NH^C+?V39^B5. MDJ$LCR.#P\AZI_|=)G'YK/KZ7,[)7("TY20,-Y_ \["#GQ7?P,"-*>V_KW3 M^O?(}?^AVI*R=&CMD^-,MR0D+$3".!(FO# M2?^4I$^6R69O%S5[N\'JZ",S

M1<)")(PC80($TS(-3ID&Y-9YNUI^[1*-92$' D3()B6VN*4V5,[7-61DFS<9UV?T-YD1C3 MO!,]O.;,[=9(Y0<*1,@F):88ZL#>1MW3->P0,%!:2&4QJ$T@:.+I&;=DC?.]

M#R_YOM$NQQW@:I_G54%M!S^8-\DUSMOI;ZF.[W0V5.B<'$H3*}]>HJ(O#BD MEJ%\E'GMSW+Y+-.']'(P,ZET:FA,9S%]T(X,,%2A-I&&Z9$JJ.+15^4V6M;$^

MQE9&7[^[Q2&UQUU#:\?'@EDO/JAJ@=($Bj;'IYR,0TN9XR>:@=WC8'904=/0 MVMD%_KR7'53!0&D"1=.S4Q;&(87 *?1LX<0-,PX/']@5S=C\VYZ4-D"10D4

M34J/^1.'%BZ4CJ'&F<5]+)+RV_'[68%M2Q0FD#1]*R4.'%%+WTW+3;P_O^-3%%@BE<2A-H&AZSLK;.(N+ MSU@X4&D8H??!{JFG[%*?ZLM.,XY/U=K_NSNQN

MV87.R:$T@:+IF2E?X]*^YE1VP^HX/\EV]:&C7&W2+,F>7@?S@WH:*"V$TCB4 M)E T/>=6.PW=3S.F[+K8/AIL(PVVDP;;2O/_\#ZN\CXN[7W&E5VH{"{LL=Q

MO'[=A=H>*$V@:'IHRO.X8UIPJKK[.8_6*"V$TCB4)E T/5WE M@]S+VW)I^NK@:#@UHA*"V$TCB4)E T/6 EC]SY MY?46ZHN@M!!*XU":0-'T:)4OHZT'1]-R4ZV' .Z<85/I

.2&4QJ$T@:-+I&;>NH**ESP_WV=%<`MX[RQUV$-.'76[4/AT#D%BJ;GJ#P0HSW0F#X[&F$<&50"L7[KT*$[0B4ZHT#1 M], "4VF%C6GU&MFG1+./DH(Z'#?0-

>=VK#SAT3H&BZ=DI=\-H=\/6ID7#C,-# MTD+6;R0*O.X%/QPZIT#1]/"4Q&&TQ"$O&H9J&R@M9/W6(,+3E&75" MBV889PLU%/[?]\+B]'C

.G5.@:'IFRO!X]-599\OPV"XNFF~<)}3Z0&D<2A,H MFIZ[LCX>N[P,0P4/E!9":1Q*$RB:'FWKECRT"!I7AJ$F"$H+O;X)\N;],@QU M02B:GIER01[M@LZ68;JIBZ8:IPBU0E :A]

($BJ:GK>R1%UQ>2*'.*$H+H30. M10D438)6N26/=ÐOCBBJ4,D%84-K=Q?T.L0X=$]'HNF1*<7DT8B)?{JW)K>\ MEQWUTF!<4'D$I850&H?2!(JF)ZL5"-!:2&4QJ$T@:+I-RM4&LFG

M>X),FKEHE&G$4%H(I7$H332T]JJ FRDIK2>G+)%/6Z(?ZN:BF<810JT1E;:A M-.$/]"RQ,PDJ9^33SFAT-Q?-,4X-ZH:@-.ZE"-]_

Z.%W;KGE)Z,+AIA'!CV=LS8^S%C;\C<[U9RW;/%53D=?TQ'T,AN+IEG!U4[D!I M'$H3_L!=CYB{.)=DC;^F%L!C>WFHF'&X4!M#93&H33A]]N7@IGKG@E/Z1N? MUC=4-

Q<]U#@JJ+>!TCB4)OQ^0Y(7S.PS42D?XX^-YU3*@F8N>QSA7J+2!TCB4 M)OR!VTX[;"%F&PR4C0EH&]-1J 9=7#38-$6H+832.)0F4#0]<"5Q N=BLQI MG0V4%D)I'$H3*)H>K;({

6UW1IW!HAG&V4+-#I3&H301],V.WSZ]IF>FS$Y M7\/5K[}CV1=HL'&04,T#I7$H3:!H>N!*\P3>Y?47:G2@M!!*XU":0-'T:)7[M"6CW,Z[^0N4/E!9":1Q*$T%?_C#G;/UM?<\6+7_Z]9?

NVZ)QQO%!_0^4QJ$T M@:+I,2M/%,PNK[I0.P2EA5 :A](§BJ9'JRQ20%ND<547JI.@M!!*XU":,&C: M,<=Z17?:^F+G^HN^?XWRIS@MK§0^5J/LJUE5M//C=V;+/P%02P,$% @

5IF66]@!\&3 M! [Q4 !D !X;"]W;W)K&ULM9A=;]LV%(;_ M"J$50PLTT,3 M2-0Y$^\A2QZ3G!TI^\9W" QPH7RHO}GSL[(?97KLO7.U1!?DGWB,@G0&HJ*.0K MV[I\SQ

LM%-5NI'G3=P*8N(L9KKMCBUFM!8E)NB. 5Y7%61_WJ"2'N>.[SPT M?,3;G5 -[F*VAUMTC\3G_1V3;VY'*7"%",>4 (8V<^?:O\K]2#EHBR\8'?G9

M,U"IK"C]IEYNB{GC]1ZA$JV%0D#Y[X"6J"P52?,C>PMUNIC*\?SY@?Y.)R^3 M64&.EK3\B@NQFSNI PJT@74I/M+CKZA-*%;|-2VY_@N.K:WG@'7-!.U:9]F#

M"I/F/_S1#L29@^28'8+6(1@Z1$\XA*U#^-P(4>L0/3=\W#KHU-TF=SUP&11P M,6/T")BREC3UH$=?>|OQPD1-E'O!Y%NVY[==/T*GBB5R'X0(G8<9"3 A4&_VS!BF MFV 4>

(_VER#TWH+ "R)#*Y;/=P]-Z?RWZ/F_CMX;C+",,Z'F14_P8^$0&4BQ4)-.+T.2-T2=DL1$97!4B@4JQ4)%8KO#F,9CX6'-4TT MS.Y:+QSEB.&LQ.260.

[NR&DBVPLG862:!TG,@#\AIF4.>U!MTVI6]!4+52EUH2(]1@1ZYU202.L*D0JU0*E:§JM7Z('DM'<[" H&2H[GF&> MJ#L:5]*\WC22*1P<;'L$ "&]N^=?RU(8,9MF^>2"EE3=.?

>2Q&S.%J1.SZ M.MLD100,X904&1=7SFF\+CA>)^+++A" *2=5XR3'E]XA3G#%<->38'"T T!^$ M S)]M"44;OO*]T!15#=C1K*@ZIT^40IT5W7T&-J4]J=U5#O;=@VOJE[9T'S"

MO%B:DOF@[#)*YBJ-YR(P'>D35SRIFE_ZHTEU6_;+IKLX8RB!K3#/&/G"H[3N M-%-8#3O*JL[4FG).TNMT#CH"6 /%\2X2#FD&Y0-NOG?\'4$L#!!0 (%.0 M9EE$(",'YP(*X) 9

>&PO=V]R:W-H965T!FPE2T+AEB.QJBK,?\V@9)NI-;2V M PN2%U(/V&%0XQR6(._K6ZYZ=L>2D@JH((PB#MG4NAQ.XI&V-P9?"6S$3AOI

M3!X8>]2=JW1J.3H@*"&1F@&KWQKF4):.2(7QL^6T.I<:N-O>LG\TN:M<'K"-M.2N_D5064^O<0BED>%7*!=M\AC8?$V#"2F&^:-/:.A9*5D*RJ@6K""I'FS]^ M:M=A!Z!X^@%N"W"?

*V\S92>$H05 M-[)7-!7@V #J"V<;1^K^F?O;_9QZC,;3L#'JQ#IJ8AU98S77%?J\1@\"T*6) MKSJ[E&4)4IEPM@6=BD"7-$'O2TZ)++#E4,_*DQ[T96;<|]C0=@748&C<,C4^E MZ+%+#AR!=3B8-!Q,7"NZ AS9%=UC--DSZL0Z;6*=`JGHOO"L&,<>C2.P3KJS M)MW9J>0Y<\F!([ .!V'0_G@'K@5:(^Z++QRJ4&B/E9+Q 8F&>|5&:(W7R15K MW^/8 W2%UF4D:AF)3J7C&MD5#*X{0NCRT]5-H+4W^DY(`+PJ#R4LAVXVZT,:5 M3F@O=6X))7F9JT9E]3SZ5!RA=?-LJZ1P=#)U;JV$7*%U>6AKH=!:9C0\J'_/ M^D\2W:"L8H0#A1W.D 3>KP8;HA^..:]"9^B{@G;PB>T5SZW^.F@P*V>1Q^L M(1NGFW1%$Y/)G"GM90KM"X/;3456@N5_R%P. ^{(" +SO^E[:/8_-V-]K@>3 M-Z8S)- -"*E516785FM>D^79J>RR_K5[HK95HK+4S5TKK%?$.H4,RL%61P/E%W M$J^Z1-5$LL(T6AZ9E"PWPQ1P EP;J.=KQN3S1&_0].KBGU!+ P04 " !6 MD&99WX)X&B<# "#"@ &0 'AL+W=O&$&,&XW+MEP9@6(DT(W#+$BRS#[-<44KJ;&+:Q MW|A+-K%0&V8PSO$&EB >\ELF5V:C$B49$)Y0@ABL)\:5?;D8*GP)^)K CA|< M(^5D1>FC6EQ'$\-2"4$*H5 *6/YM809IJD1D&C]K3:,)J8B'UV0UCZ5WZ66% M.R\+-L<#'F-$= M8@HMU=1%?2V2+>N5$-4G2\'DW43R1/ 99)4Y.D-+V8%1D0*B.[0L\CP%V0T" MIVB*4TQ"0,NR;.])U9OJD$_G("'2\G>2_K"U;'W35?4VQ^6N*+5Y)[.@Z:%G4@&S+;Z$6&M3(>AM M#AN;PUZ,]U1^4W3FAIW6<9U60K,NQO/MEK4NQK,<5L,O-"#OH%,J9^,!5S4# MMBG'&8Y"6A!1O3*,W69BNBH'A=;^U+Z1G+*1&8 LC[:TK%?J$"-'G\|M02P,$ M% @-5!!F6:QXEE\(! >A(!D !X,"]W;W)K&ULM5A=;JLV%/TKA%8,"=!$WTZXPSLC#)N34;ENYF+5)6_9+N+ M#8<6B0NE15:!L0<9X{M_^K4RX@" 0ML!7@7P7@OP*X#_6D!0 4JK[9V4TH>(M:CH92;$ETD0CFWB2S1*)Q,^US+,&6(4Y/(EAH M>(X7M,"GW? (8H2[)=QO@4?=|`YO"1N4,*=8[B-IM7.>;5S7!GG?X?O'LO& MKJF+8D<RD<8L9? J9_%E6W&G(U%]M'NU8@W96L\QO5$YC&%NXCA7(#5B3GW]R M!\XO;8[U21;U1';DIE^[Z7>Q3QZ%IBF92<9CEN/3;X56&]<9XZLV$W=D@Y+, M,&V;B1^&CH/CNCFTIQGF^4XC+.KLVHG"@UIXT"G\'I2Z(4^<9D)]]@\&$J M%@77!.43IE1!>0PD%DJWKKD=?7B@\6(X' Q>.-$2Y3:BHLZNGFA$6!L1=AKQ M&0^YFKYC-.T UTH$UNV1#B!Z'C!R_T-L,\[HH1%G5VZ43:@UKPX14C/RVD M1:SLW P_!<$H&,&R/TDJ=W-K8J$4-OB0R8_L]"N4 8TT M7\(R87[1];U+1)0Y(06__BA%.(,H'BZ 5X))J X + +I"^Q&~%B+'TX^RN+96;/K!J&_02B]"J4992:[>$H6340QK MB7Y!*[4!TT,&B&W0@N5[1H%*H4=W5 ('(=`R06U. >A-#!*33+Q5L,^K&++UY MJ1:]0H2B3SMV$)BF8F9+Y9GFMY/2BJO"""^^""%S{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{7XJ{(7(K8SD;V4D>^#> M@#H#ZK%:A=(8BF8*0ONLWE$^ZV9&^BID2C[E/#OPIHQX[O_>P O5DH,002J-0 M&D/13!5I3J8[35FL!ZV+A=("*"V$TBB4QE T4S5:P/7L!NX1Y,$MP2AIW>/B MVX/U%@'4Q872*)3&4#13!-K%]>PN;D<>"D3"7T5$ LE?-I+2NR#X^NG7XW(3 MM(062@N@M!!*HU`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`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|$\)P1F"WQ+|:WL(6D)P;0]A2]"A MVTWLVK@$2SP9<;9#7*%!33UH]S4,_"HJE2@+R>%K 3PY^1UR\1,3 CT3CA8Y MY@0]H@6D8U93@M@*R9R@&:9I3,&>66B.8E&D'"%<92@I:2Y(A@\]3E+Q8UA(O M04^GQ9).CNPSWZ@&PDE() 185>]D** M:!VBY]R5@OH58QL"9&K|=MI&^6T8=[($Z6//K-Y@+-]XQD!GYRF3^XP+?! M\?XV'MZY)P+!D?FF:VX09FKM!AV*#4S*V8*,4A&^)-?GY)S=R?C'9>DNQY)9B\QN) M'4U T$U <$E=;P(4E]_)-H89::8Z=;,31S?H>]'(WAX::X!YGN-[Q[#$ OB MV!L%V8!I@I3 /,%*8!=B',J LSNKB<$E(Q M."G.+JCHE@OJEF+)+<7F-Q([FII)^-P7]BYGV5=]/2/:(M[*SK)G-,4-@`-01 /HI,E,34= M%^-K77P+/,.B 6AVT:1XR<5!Y^+(@JCW/G%']TM5[,%K2[},>'6Y33\T[],*+| MD^TN,:+B$\OF!3;"_MF&USG^SW7^===&'%/%^U:T;SGA1GVQ@PS[(T;)IC!.M#ON@ H#+U%]77@*EK*YD&ULS5GO:Z,V&/Y*#9-.VE7L"&$=$FD-KW35;J;JF:W?9CV MP25.8A5L9INFE?;'[X50" EAS>2;\B6 8S]^G_>'>8S'&ZD>]9HQ@Y{31.B) MLS8FNW1=':]92O6%S)B ?Y92I=3 HUJY.E.,+LI!:>(2SPO=E'+A3,=EVYV: MCF5N$B[8G4(Z3U.J7JY9(C<3!SNO#?=\M39%@SL=9W3%YLQ\S>X4/+DURH*G M3&@N!5)L.7&N\.6,#(H!98_?.-OHG7M44'F0\K%XN%U,'*^PB"4L- @4$A>JOB>_.^*_K$@#V0>]&8SF?S.V8]<2('+=B2YHFYEYM/ MK"}4&AC+1>_:%/U]1P4Y]K(M!H,%J1<;*_TN7+$S@_/#* 5 /(W@"'CPSP MJP%^271K64GKAAHZ'2NY0:KH#6C%3>F;*&\[%)QDH,[T%+)%,UDFN6&EA4 P?'E >!BM1N]/SX# M,+HU+-5_=H5@:T70;46Q:%QJB",,+]:*:>F#/]X3L<>C]W>VP MH]}6M*M4S+,2H]3;$?1%X8X+'[M,NVJV/D M1Z'GUQU;3 8UDT$ODQG-,@CP#(Q^?\-%K]%'6%[1)[98072A[89IOA+40"^J MZ_;,.IF[./7.>6J@+8&UW!\6[@G/HC)*FPZS!-9RV+!VV/#? \@EEBL>LS/RO M\QN4@1/*"G@'R=1>![L\,3Q(](#LU4*O!?^17U3SB_KYR32%*,.[,7Y$,BM" MWK6.7_>BG!I02V MPJ.:\.@L*F!DTV&6P%H.PUXC:[S_Y^U0S=-:],TA'GBC MO8KHZAAX 8F&W6\'O"/1<"^?>P,%RN-B]=_F?'ZXZ*F+TOMFH+V#>^N1)ZH4\,JB6TMB,:?8@'YU%)5C6C+:,2VTQK5B'LUEL5*.M" \2?$""T2C8+X3#?@3C01 =J8-&SN%^/5^ MO[}3?D/'}@>=1M>1?EWW(_>T(^BO>3OZ(>C8.0=>0^01MN1 M?FVWNP\X}O'RNA_CY-A]BR]\!%&)#B/A+>J%FVAM9W6}$?2_SG17L(/#A+9 MV_UPRX^\"08AV$(F5]51[<:-QN3#;[_EU:WTX=%4>B>RU7^/+V?:(MIX'9GCA]H6K%A48)6P*D=S$$H]3V$&?[8&16GH,\2&-D6MZN&5TP572 _Y<2 M7%4]%!/41VG3?P!02P,$% @ 5!!F65H?H=O$ J. !D !X,"]W M;W)K&ULQ9WO<]{GH?_%95O:VNF^E,\3OKN"}) MNJ6^NRZ[,GLBZM[(4/Y@80)X2=7,T:?Q+(- UR@V:>7?M%@K'ZZ08^$E_I MD5J7SVGVV_)1ZJ$[-IO.EQ_'O-\)?B8CEZU+-D>9XN]+SXRWV:S9*\^#5[MN%@N,IV,UXUFTXN@U>I=S)+)_.SJ/)3, ^7DW3N9?K^PJE'M_[T:M,H&ZR5^G>CGY/XWPIZMNVS,+C[^(4NUR^^>#%WR5)_3J?_F(SSQP]G@S- OK. ^3U32_29]C M7;V@;LD;I=/E^E_ON5JV=>:-5LL\G56-BQ',)O/-_|FWZHW8:>!W7FD05 V" M4QNTJP;M4QMTJ@:=_0;=5QITJP;=O0;!:PUZ58/>J4/J5PWZIS885 T&IS88 M5@V&ZSAL/K_UAQ\F>7)UF:7/7E8N7=#*!^L$K5L7G_ED7H;]-L^OTZ*=OG5 M,9Z.?OOI4Q&7L?]]2>?YX}(3\[$>U[27[O09#1_N+XIW9OCW!RJOS*7 "_S[*S[U6\,X+ M6D&[9CR? W'=6^F MN_FM7A3-6^O>.S7-H],;U[UU\9'!)_/BG?=2[5VYEX=Z]/+:]WNW@M#>KB?M M-:_]VJLH_[3W>%Z\K%82>8/NMC^Y][==V]WN>OD^_KIC\]}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`L,!IQY,O-U==YID?IPWSR? R_[:%4-.IJM=?6W'K,CU-RNCFJ7=S^[5V M1\[=7^:\HG8+10F4)B0:[M=W]TZ,)8G.XU1FJ)H=I2-$_/=4NSG=+\U2?Z4I6 MW.]:OJL* N\^S;PJY66:.U.+:C.4%J(T@=+DD8_$7Q<(GM_R9IM3CH*.-TZ^ MUU<,J#A#:8JBVAEHYYR=[/O< MZ,8Y1HT?2A,H3:*T"*7%*$U:-/N2!N/]@K?V?@'J_5!:B-($2I,H+4)I,4I3 M%,U>!8SW"_XEWL_=2^.&#,\[G>'NSWX6#YOXP?DOV \C*O,HFAU& M(_,"M\S#_8F[O\9Y17T?2A,H358TZRR)@W-\({3/&*4IBF8GV9C P&T"_XP^ M<;;,AQ;5?BA- H#1YY".I}$G_Q9[T7I4GZ+!BE*8HFIUKHP4#MX/ZHI/E*MOL MKU6)+BN']9DKJ14#Z@)16HC2!$J31SZ'}NLG"_WAEC'Z"A1%LY-J-%_@UGRG M'D_S?O?^L9Z? I'CZXY/.D@==/+6;6A $J"5%:B-($2I,H+4)I,4I3 M%,U>!8PD#-R6:N=TCU$1Z]H,IWX0I84H3: T6=&&.[N/K?.@N[_{B,I E*8H MFIU- (P,#1@;6%R\W^DG/5]K[-9T6&_7I)/}>&VV4&J*I$*4)E"916H328I2F M*)HJ_961ANVWEH9M5!JBM!"E"90F45J$TF*4IBB:O0H8:=AV2\,3:A0WH7&& M42&(T@1*DQ7M2(V"]AFC- $71{&P:<]AVFT/\ (OXI'X)/WI?5M-\LIC6GGSM M'E+CL*/^$:4)E"916H328I2F*)JJ4NS,V?GFDW:RLW:RTW:R\W:R$W>R,W>R M4W>RJ;0-JHZ45J(MT@1*DR@M0FDQ2E,4S5X%C:LLN^<,/:4>05TE2@M1FD!IJ*5,VKM%'3MXF>__M)D$U)$13%,V.I]&0;,>&_.,U2?Z4I6-@ M]A&EA2A-H+19T4ZH2E"QB-(41;/CN7-,0+=8%+/%- /VN=56!+%,9Z+'8#'N+ M:5)[$8X;USBKJ&5$:0*E2906H;08I2F*9@?:Z,A.]ZU+#M1/HK00I0F4)%: MA-)BE*8HFKT*&#_9<5^E6=W0+5GECVFVGO;AV-U>4=V(TD*4)BK: {LVM^NL9 MU^V*0=8L%[3Z[<%@O{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{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

\6"!]>>X$GH&%0T^[X0L(C+TE@K%PRA[IXE?[RAZ^^8=>H/"!/VQ3?<9-M3U;9?*IT(OGM3)?535^7-TV.W+2-/]6)VF:()2NQ,K2GX^V#D?93/8#U*)+G-M4;PFH\`[L?N ;.LG1"SB&.{GYN7-;5,Z_Z]W=G+OG<&PZREE%SS[&&_+I3#-MEBLI>;(I)\G]$VK'W?*GXO+5@5$:V*>B!B"G/RKKZ,APR#7F-MS?Z+'E$NE]M"459Z51*ENWR&&K,>1;UV/H+2*"B-0=&Z12%-4DY"TB@HC4'1NF5I/"AV-MSRTOH"86E$9!:0R*UBUE8V3QJ,4Z35Z\P<-N6_9@\6*(\@<_-11BB-L>Q^O(R-MC,)60(XM7AH'B,D)"TB@HC4'1NB5I-MW"F>G5M;0*TM*(V"TA@4K5O*QM[B4>-UFK8&AH7$'I'@-HS!V^ZL2:@<GN6'P*749AMF.-V.SNI#&&))Q8W@K9&)%"DH4UP+2*"B-0=&Z16K\M*\%GUAL"ZGI!.124QJ!HW5(VKI>,6K&3]*9"MI]}S[=[ZQYJ",(N-MZ.&8*0KC(T.)-"Z1C+M$%N^B]$F(2E9V>[G,:MOJ ,0_#,G_45Q1-5>$%?4H91KMM:-M(74S;[PA&?>&GW?%!CQC@J!O+4%I%)3&H&C=C7"-/[6M,PN)#>IB06D4E,:@-M:-U2-B[6'G\+>XJ05$AO1$B^'T(-(;AO>@PQ7G\7R[2U2S@6#+_>;?^)R$R89BL1:=V5]\+78-MR7(+==WFBTEVQ1_D^2SJ-B\.MX"LA\P#]^3I-U?-)W8D]D?{QU!+-P04-M"-!6D&99;YH.8#*$ #4$0 &0-'AL+W=O)Y@9M0ECJSB3WW*83O8E4Q2^%1(+E-$BK>M[B#F^ZF#G<.))[;>*'/"G4TRNH8%[&_9H]-MMXP2L012R7B*!*RFSAS?WI&^-MZ6#O>&:PE[5C9*0L.7\QC<_1U/$,$<00*A."ZK\=W$,"7.WCF8.K%3;M6\.QU,S*0@E]E>E^.K90/'RYN=.Z(G3/$SW9DMITW2!["7W-,'-NLL74&[IZ-M $59+-#_J.[XM'M#5AX\35VD2$\|-BU'O\E%)RZAC}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{1SQ"$7V37?*JNH//*#S_K8L_36 WPP4*257* M2&?A:5D;/T_;D>$#1:PI@K09TW,]!MCB)V&O+TL*2S@%ZX-GMCDA5!,D1!,Q!=%2!BME[%IEY,,$-,ORE]V*5 61G%(0#VR[KB5Q'JO_;H/6 MQEI52'*D0K:SU![N\S#{1U/JUEZT$Q!K^SE!{R#X-E7Y.W=YMOQD,<]?U*O;_M\^\=7ZC0NS.)8ECIKEYOJ-,C\D\(>4/QS+ZV+[E2/+&'&Z 1"".#OK[B7!T:-M9H#R0\[L7U!+ P04_"-!6D&99W*O]f_D& V) &0 'AL+W=OF&)N+.,F4QX>*4K<,9AE&R4)7B:(QLVQO')$Q& MTPMU[8Y-+]{MC*$WC&0;>.8L+=K&J4OER,X>K]P'Z{67%X83R\V9$5GE#]L M[i@X&Y=6%F%,DRQ,$\#H\G)T!<]OL"%]'*/(7W)$L=-2GE*7V=Y\M?BBK#T"\S66)/0;>R?E%W6Z,(-J-(.2H6X2YPV?.1%80P0V?T7JSU)XT(+0UFKAT'#_S;#0SEL MQ52+599^HX1U4_(*IJ"JVJGQ\Q7K1--Z2305=-MJ3,/8TK.S!BRE9J8TH&YNDV MX?GNA/}JN?GE2FWY.%R_AN4\C=7AFI(%9;*.N+],4_Y^(ALHMPI-_P-02P,$% @-5I!F M67^)U[2* P R0T !D !X,"]W;W)K&ULQ5==M,^(X%/TK5F8UZDC3)B1\E Y$ MK5CK35H*+9?5CM@TDNQ&H<9VP#Y=_OM1/2 MP(2H72%-'XKCW'.\[LGUUV@GY+-* #1YX6FFQDZB=7[GNBI*@%-U(W+(\,U*M2$XU/LJUJW()-+8@GKJ^Y_5=3EGFA"/;-Y?A2&QTRC*82Z(VG%.YGT{J=F.G MXQPZGM@ZT.;###4.YY1!"E$VE!0_-G"#-+4,*&.'R6I4XUI@/7V@?UWFSPF MLZ0*9B+]F\4Z&3WN+HEA13>I?A*[/Z!,J&?X(I$]^Y-LREC/(=%&:<%+,"K@-M+\M^Z4M1-V /,T OP3XIX#N&4!0 JQS;]',IG5/-0U'+W3CC M-9(4AK6&XO& M,%AF/N-"2WS+$*?#A1;1_44C8C)3'"L#D6MO]=D@243;U(@8D5T F2^D5&" M@<1^:X(E9+L?%O,Y^99,T$1A.=BF(E?WH"E+U2>D>N!Y*O8 1)GA2'Y@RE-JM1OJ^N"=7OWT:N1HS,KKHODY@^8)S? F5<+W\^>M,I*39&G ^:;+< MDWKER9S+D1V9%6WIJK;QAX^O.2X,F#^&B0G5RPCW)9&8U6U4_5+:%.*_P=Y ME$^ORJ?WMGQBMF4QD9&3G&G\T;<<9L7>AM{(W=8%MT4<">M7POPMAPV9QOB&-M-ZEI';ZWF"Y$=I3CH,IQ\(OGW>"25EV(;BJV\]JV!?5Z5.DZ%'"]+XIWX*8 MXJ7K*;7ZYU4:W-8-V@NV6&E<=BJ\8FIY^N5Q/V"9;@\(@-)$4@U'.H=- KR> MV0R.A#;'=0>#9J4=[W4_]MJG%WTY-[W:D>\MFDNQ'>=9.W=T?O$4*P5&PO=V]R:W-H965T MJ M!P>&8*VQJ3T)Z;^O,0C-KMBTAUZ";>9]F'?BF:21ZD&7 $B.%1=ZY16{}=3W M=59"1?58UB#,FT*JBJ+9JIVO:P4T=Z**^V$07/L59<)+$W>V5FDB]\B9@+4B M>E]55/U:)?-S)MXIK-[MBO1'OAI4M,=;"_U&ME=GY/R5D%0C(IB()BYLTG MTV5LXUW 5P:-/EL3ZV0KY8/=W.8S+[ ) 8<,+8&:QP&6P+D\F31^=DRO_Z05 MGJ]/(C_N.&R1J6DGC.985[YU'-Y662:_=+FC8V#CV2 M[37*JA.;#"HFVB<]=G4X$QC.L"#L!.%30?R,(.H$D3/:9N9LK2C2-%&R(4_NI,!2DQN10_Y8[YN<^L3"4V*+\")P _681,%K$@9A/)#/\M_ET85T MHKY.D>-%?ZT363&=<:GW"LCW^5:C,E?QQU#%6F(\3+3M.=4US6#FF?[3H [@-MI.[>3*Z##T-V_Q/LD?FX-Q}?HJV0^60!N,@FB3^X=S?Y0Q&P3@,7EX->?'/+G\%:N=F@B:9W MLKUM_MVH^=N>NV)^<+,X]:Z2'$'TX.ZIV3&C"H3#(8/S6-+-JYT.[05F[%MM*-WK MEJ49J:!L@'E?2(FGC?U /Z33WU!+ P04_"-!6D&9998YDZ,-0"-"]@ M&0 'AL+W=OBSN MA=ZY-4M**#!).$,"9GWGRN].(J-O%;X06,F--3(W>>+\V6QNTK{C&8<@AT09 M!JP_2QA"GALB[<:/BM.I31K@YGK-/K%WUW=YPA*&//]*4I7UG4L'I3##BUP]M\-4U5/>Q#B8\E_87K2I=ST')0BI.*[#V@!)6?O%+%8<-@-_> 0@J0/.$.T MA!4@/-1"NP*T#[4058#H4 N="M"QL2^#92,]P@K'/<%72!AMS686-ET6K0-,MF"FLJ1+ZE&B<4]?I2B),$O1D#-%V!Q80D"BTQ$H3']YABZ0KC&50XIN MB2)S;,OB CU.1^CTY R=(,+0'X."@>&PW 8%YI>VY4%3J#OZ&8J02S!B=^_\SO>IZ94'9-L=$RR\3'))DQ}[MO-$3I&T3H}&6(<ITS(@JFF!)=T?MF5S..WC/W+UF7/76YF;]_1MV;NF&3C8Y)- MCD2VE,FHSEQT:..2#(LY-'7OP5Z.M_X?2[+.1NJ][.R/HC^KPVOYVTKCO}), M&F@"OQ766F7W(W'DX*.@!ES)$1,Z99-KI;6D]25'2!>R8=^=^0WR,=Z\BH'-MI=_TY=AVIP-.F$0YS+0IK_5!>RS*4.C<*%[8I_N)*ST(V&6FIT<01D&?SSA7 MZXTQ4,^C\2}02P,$% @ 5I!F68#;@&E'!0N"0 !D !X;"]W;W)K M&ULQ5IM;]LV$/XKA%8,"9!$+WY){-D&$DO% BQ=-M$+?;AZ(?&.EL"Y5$EZ+C9-B/'RG9DA70M)U>L"^Q1-T]=[R'//(8#E:,?_G M ((\ITF6#ZVY$(N^,>?A'%*:7[%9/++E&4"OG*9W:^X$"C0BE-;,]QNG9* MX\P:#0JV>SX:L*5(X@SN.(4LCQF&>$?'5K7;C_P/*502/P5PRK?>:B.J*X^,?5?-^@?]B\[+SCS2',8L^3N.Q'QH75DD M@BE=)N*!K7Z'=8BBBM7VC+>,69&B@3P>776.}DD0]3X!PB\@!?D"V!T"PB]\"+(9B%0/X\3.(95:3F MY)Q\HIQ312TY\4'0.,E/9>N7B4]./IR2#R3.R%V<)$IZ8 OIG]BAVM?,DI?MO!V^M,@=R\0\)T$60:31]\WZ/8.^+>-2!=G[,>O-EZ(QBM:J2T"KS6#KQ[S]}E*,AM5J8G-T5Q.RS!9RCFAYF>TF?$;V1/9N*A0 M3G4\EB[T"A?4TO,THTA7R=D..,4X/M5634\AEG,]7G*LNQ*LL1FK)E)G11* VX[I9??L^Y>-7%&=$/8\]?I838#))N- MR'.KR'@/B>R97$(VI=4O(&%[(#8(<>^_Y C5,G)$3N1G_(I#4N!B.!<$+F2 M-?EZ_1SGW_I%]CMWG7/'U7%B=.W8#(,)YF."!4A@#7XO*WXOT1/_)28MF& ^ M)EB !-;@Y.]BY6K/M-N3R {ZU>:1-M]G<^,;AP;_D,I:D@6&V!M56'M_518MSU1[S'3,TQLSLM^A%ORH:#XJ6H'"%UB2G+O@]<\%_/G=U9#,N/,OKVUDV,%/BLN *3R]@N,U'^J[UJK:[97!>72UZUW[C] ML:MI]]U^4%ZBJ>'+.SUWE,_B+"<)3*4IY^)2;O9Y>4VF?!%L4=P#>61"L+1X MG .-@"L!^7W*F-B*/59:71?U!+ P04_"-!6D&99Q&\'5/W@P"2@ N9LD[3__FS#LGDA7'*E7S;8GN<9SS-C MP^QD3]DW'@$(}#U-,CXU(B'RL6GR((*4\![-(9,K&\I2(N20;4V>,R"A\J6) M:5M6WTQ)GI'FSB9Y[9+,)+4029_#($"_2E+ ?]Y#0_=3 QO/$4[R-A)HP9Y.< M;&$%XG/^R.3(K%G"(6,QS1###93XPZ/?6PK@+;X*X8]/WA&*10U!=_4X"&< M&1;;$200"$5!Y,\.Y1 DBDGNXY^*U*A]*N#A\S.[KX.7P:P)ASE_HY##$4V- MH8%"V) B$4]T_P&J@##S%%]"$Z[]H7]E:!@H*+FA:@>4.TC@K?\GW2H@#' 8N M .P*8)\"O I1 P(XIP#W L"M .ZU'KP*X%WKH5!^[EK[4BRM}(((,ILPND=_M64LV].#3I=%2X#A3E,423*[&&B=F3Y 0 2%Z)SP-&;!0@?]PM^AU]7BW0MFU=OT2L49^A31 M.LI!/3'"]*K095#[FI0_[@@\'?:29B#A:9B&$#?AE.W[4 M@C=EO'70]G/0<[N5< 5Y#SG6.V1;MMNPG\7U<* H_F<*RK@!_K$2,9)>>]__"%-T8.E'!MRGK)ZS;SJBMQS',2P-20=QX' MM@-C]OHWW+?>-TG>)=FR2S*.(I*CY+AUX@'$.[).X!W* M0#3L\[Z=Z0MNS&$)ZFN0>@OM9A[NN\.)N3M,3BOUKJTB+& #C,EB9["#K(F14H&[W!{MF=)9XJ'C*E5D:M<^@U6WM"ZH$B_ M5J3?JLC1Z6^2HQ5^ZR'ODFS9)9G?$=E1#@9U#@:_Z 8>>=)F<+LF679+Y'9$= M)6=8)V=XU0')=7+$2W(:/X2&9V?4M<_NCN'9U>;B4Z/E.1.VW;,[H77O_U.9 M4:W.J*MWTWQT'HUSIDNKNUL+\!J/?H/1Z-*-BJV73VKKJ]\R%<5A$9P+TN[G M5D6N<>DW&.&+H@FXWC&?M'(_J_/D8N("'B=2%4)2%!!7R7 MCEX/K0#0GU0 P@,D^VNT*9B(@,FF4KT'.DJ+C_)ZMFZ M.;[7K>+)_!R/%[AA_@[C\1(WK]AR17.9+Z/[+[OTC8=LXXRB!C=R&U1O(>F1E M0UP.!,UU [>F0K-#^C$"$@)3!G)|0Z40U4 YJ/\M,?L74$L#!!0 (%:0 M9EG#9:[=,_(!X% 9 >&PO=V]R:W-H965T-A5U0IX0#MPR22QUI=@N\W8]_B2AB)U-M R^Q9SSGS)F)QVDOU8-N 0QZY$SH+&J-Z=88Z[%3O1,=B#L22T5)\:.JL&Z M4T J#^(.)W%\A3FA(LI3[]NJ/)4'PZB K4+ZP#E1OS;_9)]%\^CDV-&F-S!?.FVREIX9*DH!Z&I%$A!G477_5FY>))P%<*O3[,(U=)(>6#,SY7 M610[0<"@-(Z!V.4(-\"8({(R?@Z4L,R5,E>Z1&MMBH]%K=$^4 M(]Y'Z,4M&$*9?!EB8W.X2%P.?)O ESS!]P[=26%:C3Z("JJ_\=AJ&P4F)X&, M9))P#]T,+>)7*(F3)=)!{@3O8BQ\X7D7TX6C'712&2H:]/VZT$;9;_+C4MF! M;7F9S8W.6G>DA"RRLZ%!'2!*GS^;7\7O){0N1ZW+*?;_L+4$C6R ZC^T=6 M[=_)4EK8%MY-C>5QSQ)\?&"@-4H8/6? 11O%RD83"I8_5,!/KNS%3C)U.C M4AZ$"==W}{#?QWN_)_P\+<$=50H1&#VD+CV1N;5X5I#(.1G9^ 0AH[3W[;MV@<,E NPY[64YF2X!..3F/\&4$L#!!0 (%:09EE@Y-^/V@, &\1 9 M >&PO=V]R:W-H965TE81L/"W?9(15JP5PM2GR M+8C/Y2V3,[-C2;(*",\H00SV2^.#/=_8C@+4$G]F<.)G8Z1,V5'Z54UNDJ5A MJ1-!#K%0%%C^'6$->:Z8Y#G^:4F-3J<'GH\?V#>U\=*8'>:PIOE?62+2I3$U M4)[7.7BCIY^@]8@7_'%-.?U+5JUI:XHH+6K1@>8(B(\T__M8ZX@Q@N\| MG!,@7 +I9P!N"W O =XS *\%"_5X+<_Z4:@A80U+YOG%5[^AH+O%HP>D), M24LV-<2H<5:.E@S.B,FLKF-S-)$ZLMG"0>2(X^@5M9=8F50X)HGO4KJ,[. *I M +V}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|>^!?/4Y]D}>//CG2R>V?=_M"DFTEQ;IKK'JPSHKV?_S4#<1> \4#-R!= Z(W8"-.-> 'OL&UC5@Q(!! M[1HTTJ>M]F;@PEC&\[-2/**R1BNV^D,S^DUK-5Y944^4A2S5KYE{)^<+OE1F MEQ4Z00LU"=-MSI&X0]UC=)'^H?K 4_2Q%%6%KDMBYVTGT-N0RSO+JG6KU,1&B MMV_>H3_8HT';EL.T)&.D+1%U'(586B(N4IT#XT MMP\,[:=J4'8C0YY'Y1(8"1=\\P%1YSTB#F%_?ZZ,;TXA.?_M[=&_?OM@,.AN MFM"&CX[P?>;*^Q:#'DBBB13+8HDWQ=G4+&^D93%[P]-J$R\?*+<7<7+ M!$Z9__@#]IR?H)&W21;;)(LLD0ULQ'8V8B;V^A**$Y/ZD]HH12L1:,2557#MC MR!PMD]Y4 MNT;5%\F?VZS*.J$G)<]CV:BO9/4>%5Q"VEL^=Z#*=QQ-.X3R=%0(H!C14=%+ M7 /AWDZX]_*2%'+%RR.7H&=S"=HD"VV219,(!C;Q=S;QS4LPSGF%U :HMNCR MGDME$,@2/C ?,&7Z\H-@KC-CVAP$8(SBO775C@L B4/ZC(QD M!T;9'WG!RSAO5,>IBLNR2I9Q'?.*P@- $2%.H F'8-0CFB%# ;,4]-'=+0#S M,"8CPK'3!XR.47K(U<))LKB-\VO}.U'*[*_1O:;C&_0D"&:ZV2$8=G"@NUP(M1S'V]/D.XP(\-@!{$3,V#L#G.OBYY2I)XRKF53LM1S)^XG#,BZ$U3!RLBP=P M! <^U<4#.!9@@G7Q &[F>X2,B">]>&(4_^N&U_-<;33/F0,HVTCRVK&*EMH ME2VRQ38T1Q^68W-<#H;DH$6L!N!6V4^K;)$MMJ%^B K0N1B ^1T< 2/CJZ>B3;;0*EMDBVUHFSY!P.8,X7CG8#4UL,H66F6+;+$-+=*G!]B<M'{SH' Z#=(1=_R!:@&#*T(s(&8('K!TSW#0#,HZXWXAKZS-"4P/0-=234"6N M*E14T?-"#7"6C$1.1O)7STF;;*%5ML@6V!|,?2:# TM>PI@2O=HB-ME"JVR1 M+;;AN7.?81%SAO62ER'"F0WSL9;X7@$H2AP]F010V/-TL@B"40=CV$>0/1"]:D^P0)U&[E>.P&MLH56V2);;$.K]$D>(?_O.3^QFO]990NM MLD6VV(.6ZO,_8LQF7G7FWU$-SQ@<5CM>0'@<J^DC'!/9[,IQ ##?"49.'4F? M9A%SFO7Z8W]RF *=X.# :(H3T^[O]3KZR=P(,H9B.M(GW(1<\IUPRM9,A.Y M+>M%V(@&$]1Y6'70.Q\N0$("<$$\O<$ HQL:4]@D,L5SB(%83&:MLH56VR!;; MT#*)(D.I%#K(D94.$ >4.B <5.N -<(9B!^ES&F*OW$&.K'> .*#@ >&@B@>$ M,Y0\2)\I$)M%#*W)DU0/$ 64/" ?5/2"-&"Q^T#]:I.5C_5$BNG(ELQ+=NN:M_O.5/=>C!WXWNOAWU\"Z!BYD^%H"*

H6!YR$^C=IK;SU]>POO2UPNLZ)",.]3KW(^^,ID97NQK?TBQ:.YN74K M!3KYN.*QRDO:X#Z_4X(^?RE?L'N>N\"\'U!+ P04_"-!6D&993*0]/S\, M !*K &0 'AL+W=O MWB26S'E&TGE%SCPFASYZ.BT6*{5)BC?93FVK MWSQF^28IJX?YT{38Y2I9-HTVZ=2;S:+I)EEO)WG=S2YY4@^J_'7W,;\>30^4Y7JCML4Z MVSJY>KR=O'6OY;QIT&SQS[5Z>$=NJW\B7+OM8/WB]O)/Z%:E4+3^<19JL=D MGY:?L\1-Q8+V205.5%\Z_STFX{FSB+?5%FF[9Q]0HVZ^WK_\EO[0=QU#B M]#?PV@;>:8-@#H(?-O#/;1"T*#8)S&X1M@_#<]Q"U#:)S>XC;!G%3K-=/MRD-M2\KD[B;/7IR\WKJBU3\T]6U:5Q59;^LH/11Y]=MUU:Z\^Z2*,M\ORGV^WCXY MJUE1%LZ?G8G;XF>FRF2=%K]4V_{ZP)R?^_K%^LK\09>B>]\R+,E}G#X=JF6/>T%W?Z*:#^M/17# M1^-]^VC>>23P0>W>./{L3XXW\X*>UW-/-__;?DLV9W3S#TE>-7<'F_/S7[S?MJV'\'N7%_=NE,(-1K:.FSG5SJA..3MV1\^^_M5]L?3EYT F1TDC"%A{D32)@$P8SLA(?LA.0^YD$!JSS9+E03F7^4 M*Y4{GU6R<3ZHS9?]Y^;(UY<:$FN;&B2,(6$<"1.OL*B!U:/EYVH7/Y_?3)^/ MTP#JT4A#=$A#1*;A_6:7K/-JS%TZ]ZLD?U*]I2<9MJ5'PA@2QI$P\0H+CTH_ M.ZD[J#NC[O&A{C%9]\9F:1]I2:;V98:"6-(&$?"1-PI=<^W'-2C4>WYH=KS M2\:5SO\K@YYNAIS_'F%S X2Q1 P MCH0))$R"8$9VW)E6,3.+$6C6[*-R(U&+H;U.2XZ&CZKW/9MX<6ANQ'HVN M/V[%Z?=A6T$H3:)H9@V/=)1+UO!^OJFG2:U?G>)0SN&RD3#;,SR4QI T#6)MEG8\LIA[P>DX$M6G&05/1\$[-PI)4:C26>LYQ6)X3D%3K3.!#$HC4-IHJ4= M9R)RP]-(@+HT(Z$UIDM[S*-{}.S8F]V^552@LA-*8U :A}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}AO'H4>9L#I@T%C;4$!#$KC4}J TF1+ M,T+ASH.!4&C)&9ZJ$FE/"S7&J1{L\X*5'U":1Q*$U":.#'LNQY\%]P'W%6KW M&=++N*4BB-0VD"2I,A M=27 MI'NP3@?4>$)I'$H34)I$T.\B(=1#*$:8'G+2E*\ZW# 7614.]'T@24 M)E$T,T7:6D:C7AX?074FE,:@- ZE"2A-HFAFAHYN/C_2Y?$TUSH]V%O28^])MC[TI/=2,1ETSZKI70X,2+47#LQ&8FU+8]J6#LY&Z';6 M)8=:4"B-0VD"2I,M[9R2:[49TR=D#DY&Z';6)8=*2RB-0VD"2I-Q]QS,X?\| M=I$Q[2*YR)V:P?3W5AG!*HFH30.10DH3:)H9IBTPHSC46QUJ0QK4G/G(Q MG2F4QJ T#J4)*$W&76VW93V*/'K6R=5C%0KW^JTWF7:>?^=>><[?G>>%>R^;YJ<;?MW>R2)-6A.DRLMX63JL>JJF;>O:4KY]6AP=EMKN=5&_B2U:6V:,Y<:62IU!W<%+EG!MWL[=_P%02P,$% @ 5I!F622P_O,O P ?@D M !D !X;"]W;W)K&ULK59-C]LV$/TKA!H$"9!=M?=K>,FT!:ZM%6W31A9TTAZ '6AI;1"A2(2D[^^\[E&2M92EN#KE()#7O<=YH M.,/Y4:K/.@OJ-(>"ZEM9@L O.ZD*:G"J]JXN%="L!A7<M#3QOZA:4"2>>UVM/*I[+RG FX$D1714%5<]+X/*X<'SGM+!F^]S8!3>>EW0/ M&S ?RB>%,[=CR5@!0C,IB(+=PGGP[Y.9M:_F%PU&=C8I5LI?QL)W]D"\>S M#@&'U%@&BJ\#K(!S2X1N?&DYG6Y+"SP?G]A_J[6CEBW5L)+\(A\M,OG#N')+! MCE;9-O]9Q. ,@SS@@: '! M)2#Z!B!L >'W_J{6$-61::34<BHH?%.!5V%SB HB(%\H L?YL<%'D/M"'/4&QQ M?/+FPR8A;UZ}):\(^ 1]+BN-N^JY-U"_5>&FK=9EHS7XAM:0/$IAN"%YR"MPRN$FZ@O"6A]\YJC$;\65V'_UF)J_#0.OR1*H3[8_">FK!+ MA;#F"[K%7 &Z@#DTUIR3O",:G*_AT+>L,:C;/:LG6O2YK"PL$Z5',Z\>N?M_*GWRUC$?B19\H/(>M&,NFA&U]CC)>R9$!C)=UB7N,WRL=@U'-.:PU;H0QQ& MD[E[._)I,,W?+]OE R-@G#RPM23,.DD3*Y*>#F?]I3+ ^GRJ7I*D}H2.Z6J(M)V?N>!>JAA;!{$)Y,K3QI_QP7-2T$S6]*FI%=4Y*^HRM:]SUZ6#3FS"\N_!^ MQ.CGZ/*?C#'YD]FX_[/._]E5_[%V_5J2S0:Y,+MP?V@Q2+MD:--+\N9Y]ZS4 M%(=P79PC7E1"=/4T6ZUNR0\U+WQ8GV)EX>FU[_0-#&ULW5C1;ILP%/T51->I ME:82PDK#FD3:(E6:M$V5VH>]54XPB25CF'&ZI%_7YL0DOI&61_6J{&^Q[.MNOZ<@/XX^^9^4F14I'M_L/9^U_+0EV_|^SYY,/)2>_A_'H_?F: (7K1Z^'" &+B\?'BA[0Q MZ:M=:7/YJ1.RQ%,,-G#0=)8M$SH8.3EJ. -&@PA?]=RN>FU7*#ETDEM4C-A'-ML!HC){4YC$Q0E^IXF!5B6[&1;P,Z#\FI]TCXR)\0SJ:2 2LC.>-K& ^Y#8%;P M0GI*WRHZ<0B1ZLG"H>W!753KY$P4TN2V&>SWM+Y\#]CTP"#CO#'8]VU@/"R) M4E2*&]TQ%YO@,\BKV_?K4CN<2{(.(^Y?^EF!..LFTD"F539K0WX3&0TXSL"/9 M? %G590!@$H5N6ZDC,P+08R'#:-N:-D9Y?P:'C$_LQWM5=9:05,UHFEJ0W73 MRM@.Z+?5K'9;-GZ1KE>RQT)]6>KA"-.'0}>WDF9L9?JKK#&_J8>X.BE+OO[_ MV5SDU [^Z(3C(=GPO$4AV9/.!J4RTP$J?>^12L5F[4T$EX6W3NO;?\BR_V'%T]5J6S5-EW[#38[UO>.LF+[M@,NZ"R4[4*

MY +)1,.F+QZM:?F\2:C3DQDV 63_3=1,JCWE*V-Z\ZVM8EZ\'HP\G_ :P?? M)O6F2\85$W5OP=*4BF>[5RVOR%2_=N_HZ^M3FI$E5_<-./*W[>\T9FZ>F&SEH?0-A';LSA1C".Q=P(M8%@>S 'GL2PLS_\TG@$Z'HMAW@9.9(!R!BC'LES(Q'RP/&Y.H@_W2),DBN(8 MF]')Q.E@@LU;',.?6PWS!@PL#V3ZN[G&5QNOD,-U@*WIH0K!1HI7(C92?*X! M<<\;,)+;$O=I8'F!@JX#5#N1WYX&:BNT3A&9B>& MCWMJL+LDBI+$C0#F=A!%&)W(XY@#L #AD21^1W<^ST*-K]3P?9_T>,_4$L# M!!0 (%:09EF7BKL*

*-8?20$3;8T.P6BP^0"X99K>]9!:G MV^?S[:%WIZRZ486J'\XFW?M"3KQ25:I4OV5^-CF>>':M[__2 M1OW652V*969T49Q-9OV):VEJE;TJ7K:0W\6-[4IJ<7,E',C9)#YV%:Z4L75W M15>_<(QWTEW<'S6U_J**6IJYJ.57HYN-JF[,:MROF)*?I;7#]K5OQ!/S?YI1 MKU8JDW.=-:6LZKX=C2Q:P,JNU<9.O$J4\FSR2=})XRW$K6Q_E/N6B[S_@;4C M(\UE3!0[82[RCI&3\IE967NN7=6%RW'+GW412BRJ1'(T Z1\0\H=/(, M&1P$$'\+1D!""C0T(&!#(&D/$A(4,"F0#(A!=R+FUFU*8M M]_3*^]A854EK/5$YTJ8DD"F 3'DAGZ@^Z?)&5?T%!.T]0'O/BW8E[V35#(;J M8S16'_/B?-4ZOU=%T=V_"V?.ZK8E\#Y8Z{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}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fX]-QLD-[,?1=67X[Q9}^.PS9QMO)ZM-IXYRU3DSOSA_*7,N,.Z\=>/DX\2< M? 7_<\TCFT^LI%K(NM.=?\24QEK[X_>P\[<8V;\R.U_MS=(=E'CY;'I??\>\S M?JG_SCX$I \)Z:.]*$@?6A('R6DCPK2QP=(_'F&T@A%U)Q":DXQ-:>@FE-4 MS2FLYA17&UL4$L! A0#% @ 5!!F6&UL4$L! A0#% @ 5!!F M69E&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F M6=\O^7T!!P &PO=V]R:W-H M965T&UL4$L! A0#% @ 5!!F6> L;0*+ P BPP !@ M ("!DR 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ 5!!F68C47:CA)@ 3H4 !@ ("!S#< M 'AL+W=O-> !X,"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F67?;&RL1! MPH !D M ("!X74 'AL+W=O@ >&PO=V]R M:W-H965T&UL M4$L! A0#% @ 5!!F6=GC]<,- P Q08 !D ("!Z(@ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M5!!F64G9C;5*!0 .@T !D ("!&Z0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F62%K,H1D P % @ !D M (")\\ 'AL+W=O&PO=V]R:W-H M965T&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F M665F9@4(P @ 8 !D ("!=Q8! 'AL+W=O1T$ #[!"0 &0 M @(&V&0$ >&PO=V]R:W-H965T 0!X,"]W;W)K M&UL4$L! A0#% @ 5!!F6?G\W2@L M !D ("!BR$! 'AL+W=O&PO=V]R:W-H965TPK 0!X,"]W;W)K&UL4$L! A0#% @ 5!!F68_J>"^T @ !@8 !D M ("!/B\! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 5!!F6=)GX\O:!P 9Q8 !D ("!5SL! 'AL+W=O MHMSL\$ 8 M"P &0 @(%H0P$ >&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F60^90A6< P 7Q, !D M ("!_5L! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 5!!F66]@#!\@3! [Q4 !D ("! MM',! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 5!!F60&Y>3 # P [0H !D ("!HW\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F66$&OM7K M P V1, !D ("!78H! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F63V?\Y?U @]PL !D M ("!6)H! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 5!!F6>=?RND[!0 $", !D ("!5ZD! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M5!!F6=(8'"]> @ "0< !D ("!A;4! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F6? JGO^PZ"@ 9&\ !D M ("!,LL! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 5!!F641O6TOK! 5AL !D ("!,^ ' 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F M66^:#F]! U!$!D ("!@?P! 'AL+W=O&PO=V]R:W-H965TTB@, ,D- 9 " @34' @!X,"]W;W)K M&UL4$L! A0#% @ 5!!F66^^/>M/ @ L 4 M !D ("!]@H" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F6<1G,AVU P HA !D M ("!&18" 'AL+W=O!0 &0 @($%&@(>&PO=V]R:W-H965T M&UL4$L! A0# M% @ 5!!F6:9"&@>E!@ ;B@ !D ("!?2 " 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 5!!F6;4" M*+=@ P F!8 T (!-3<" 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ 5!!F65(UQ].* M @ N3(!H (!OD$" 'AL+U]R96QS+W=O XML 98 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p,i;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 99 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 101 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 399 397 1 true 105 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.healthcatalyst.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 9952156 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 9952157 - Disclosure - Description of Business and Summary of Significant Accounting Policies Sheet http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies Description of Business and Summary of Significant Accounting Policies Notes 8 false false R9.htm 9952158 - Disclosure - Business Combinations Sheet http://www.healthcatalyst.com/role/BusinessCombinations Business Combinations Notes 9 false false R10.htm 9952159 - Disclosure - Revenue Sheet http://www.healthcatalyst.com/role/Revenue Revenue Notes 10 false false R11.htm 9952160 - Disclosure - Goodwill and Intangible Assets Sheet http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 11 false false R12.htm 9952161 - Disclosure - Property and Equipment Sheet http://www.healthcatalyst.com/role/PropertyandEquipment Property and Equipment Notes 12 false false R13.htm 9952162 - Disclosure - Short-term Investments Sheet http://www.healthcatalyst.com/role/ShorttermInvestments Short-term Investments Notes 13 false false R14.htm 9952163 - Disclosure - Fair Value of Financial Instruments Sheet http://www.healthcatalyst.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 14 false false R15.htm 9952164 - Disclosure - Accrued Liabilities Sheet http://www.healthcatalyst.com/role/AccruedLiabilities Accrued Liabilities Notes 15 false false R16.htm 9952165 - Disclosure - Leases Sheet http://www.healthcatalyst.com/role/Leases Leases Notes 16 false false R17.htm 9952166 - Disclosure - Debt Sheet http://www.healthcatalyst.com/role/Debt Debt Notes 17 false false R18.htm 9952167 - Disclosure - Stockholders??? Equity Sheet http://www.healthcatalyst.com/role/StockholdersEquity Stockholders??? Equity Notes 18 false false R19.htm 9952168 - Disclosure - Net Loss Per Share Sheet http://www.healthcatalyst.com/role/NetLossPerShare Net Loss Per Share Notes 19 false false R20.htm 9952169 - Disclosure - Stock-Based Compensation Sheet http://www.healthcatalyst.com/role/StockBasedCompensation Stock-Based Compensation Notes 20 false false R21.htm 9952170 - Disclosure - Income Taxes Sheet http://www.healthcatalyst.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 9952171 - Disclosure - Commitments and Contingencies Sheet http://www.healthcatalyst.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 22 false false R23.htm 9952172 - Disclosure - Deferred Revenue and Performance Obligations Sheet http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations Deferred Revenue and Performance Obligations Notes 23 false false R24.htm 9952173 - Disclosure - Related Parties Sheet http://www.healthcatalyst.com/role/RelatedParties Related Parties Notes 24 false false R25.htm 9952174 - Disclosure - Segments Sheet http://www.healthcatalyst.com/role/Segments Segments Notes 25 false false R26.htm 9952175 - Disclosure - Restructuring Costs Sheet http://www.healthcatalyst.com/role/RestructuringCosts Restructuring Costs Notes 26 false false R27.htm 9954471 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies) Sheet http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies Description of Business and Summary of Significant Accounting Policies (Policies) Policies http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies 27 false false R28.htm 9954472 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables) Sheet http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables Description of Business and Summary of Significant Accounting Policies (Tables) Tables http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies 28 false false R29.htm 9954473 - Disclosure - Business Combinations (Tables) Sheet http://www.healthcatalyst.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.healthcatalyst.com/role/BusinessCombinations 29 false false R30.htm 9954474 - Disclosure - Revenue (Tables) Sheet http://www.healthcatalyst.com/role/RevenueTables Revenue (Tables) Tables http://www.healthcatalyst.com/role/Revenue 30 false false R31.htm 9954475 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets 31 false false R32.htm 9954476 - Disclosure - Property and Equipment (Tables) Sheet http://www.healthcatalyst.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.healthcatalyst.com/role/PropertyandEquipment 32 false false R33.htm 9954477 - Disclosure - Short-term Investments (Tables) Sheet http://www.healthcatalyst.com/role/ShorttermInvestmentsTables Short-term Investments (Tables) Tables http://www.healthcatalyst.com/role/ShorttermInvestments 33 false false R34.htm 9954478 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.healthcatalyst.com/role/FairValueofFinancialInstruments 34 false false R35.htm 9954479 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.healthcatalyst.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.healthcatalyst.com/role/AccruedLiabilities 35 false false R36.htm 9954480 - Disclosure - Leases (Tables) Sheet http://www.healthcatalyst.com/role/LeasesTables Leases (Tables) Tables http://www.healthcatalyst.com/role/Leases 36 false false R37.htm 9954481 - Disclosure - Debt (Tables) Sheet http://www.healthcatalyst.com/role/DebtTables Debt (Tables) Tables http://www.healthcatalyst.com/role/Debt 37 false false R38.htm 9954482 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.healthcatalyst.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.healthcatalyst.com/role/NetLossPerShare 38 false false R39.htm 9954483 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.healthcatalyst.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.healthcatalyst.com/role/StockBasedCompensation 39 false false R40.htm 9954484 - Disclosure - Segments (Tables) Sheet http://www.healthcatalyst.com/role/SegmentsTables Segments (Tables) Tables http://www.healthcatalyst.com/role/Segments 40 false false R41.htm 9954485 - Disclosure - Restructuring Costs (Tables) Sheet http://www.healthcatalyst.com/role/RestructuringCostsTables Restructuring Costs (Tables) Tables http://www.healthcatalyst.com/role/RestructuringCosts 41 false false*

R42.htm 9954486 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails Description of Business and Summary of Significant Accounting Policies - Narrative (Details) Details http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables 42 false false R43.htm 9954487 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details) Sheet http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details) Details 43 false false R44.htm 9954488 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) Sheet http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details) Details 44 false false R45.htm 9954489 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details) Sheet http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details) Details 45 false false R46.htm 9954490 - Disclosure - Business Combinations - Narrative (Details) Sheet http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails Business Combinations - Narrative (Details) Details 46 false false R47.htm 9954491 - Disclosure - Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details) Sheet http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details) Details 47 false false R48.htm 9954492 - Disclosure - Business Combinations - Unaudited Pro Forma Financial Information (Details) Sheet http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails Business Combinations - Unaudited Pro Forma Financial Information (Details) Details 48 false false R49.htm 9954493 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details) Sheet http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details) Details 49 false false R50.htm 9954494 - Disclosure - Revenue - Narrative (Details) Sheet http://www.healthcatalyst.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 50 false false R51.htm 9954495 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 51 false false R52.htm 9954496 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details) Sheet http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details) Details 52 false false R53.htm 9954497 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) Details 53 false false R54.htm 9954498 - Disclosure - Property and Equipment - Components of Property and Equipment (Details) Sheet http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails Property and Equipment - Components of Property and Equipment (Details) Details 54 false false R55.htm 9954499 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 55 false false R56.htm 9954500 - Disclosure - Short-term Investments - Cash Equivalents and Short-Term Investments (Details) Sheet http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails Short-term Investments - Cash Equivalents and Short-Term Investments (Details) Details 56 false false R57.htm 9954501 - Disclosure - Short-term Investments - Short-Term Investments (Details) Sheet http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails Short-term Investments - Short-Term Investments (Details) Details 57 false false R58.htm 9954502 - Disclosure - Short-term Investments - Narrative (Details) Sheet http://www.healthcatalyst.com/role/ShorttermInvestmentsNarrativeDetails Short-term Investments - Narrative (Details) Details 58 false false R59.htm 9954503 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured on Recurring Basis (Details) Details 59 false false R60.htm 9954504 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 60 false false R61.htm 9954505 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurements of Contingent Consideration Liabilities (Details) Sheet http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails Fair Value of Financial Instruments - Fair Value Measurements of Contingent Consideration Liabilities (Details) Details 61 false false R62.htm 9954506 - Disclosure - Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details) Sheet http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details) Details 62 false false R63.htm 9954507 - Disclosure - Accrued Liabilities (Details) Sheet http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.healthcatalyst.com/role/AccruedLiabilitiesTables 63 false false R64.htm 9954508 - Disclosure - Leases - Narrative (Details) Sheet http://www.healthcatalyst.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 64 false false R65.htm 9954509 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information (Details) Sheet http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails Leases - Schedule of Supplemental Balance Sheet Information (Details) Details 65 false false R66.htm 9954510 - Disclosure - Debt - Schedule of Debt (Details) Sheet http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails Debt - Schedule of Debt (Details) Details 66 false false R67.htm 9954511 - Disclosure - Debt - Schedule of Components of Interest Expense (Details) Sheet http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails Debt - Schedule of Components of Interest Expense (Details) Details 67 false false R68.htm 9954512 - Disclosure - Debt - Schedule of Principal Payments and Debt Maturity (Details) Sheet http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails Debt - Schedule of Principal Payments and Debt Maturity (Details) Details 68 false false R69.htm 9954513 - Disclosure - Debt - Narrative (Details) Sheet http://www.healthcatalyst.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 69 false false R70.htm 9954514 - Disclosure - Stockholders??? Equity (Details) Sheet http://www.healthcatalyst.com/role/StockholdersEquityDetails Stockholders??? Equity (Details) Details http://www.healthcatalyst.com/role/StockholdersEquity 70 false false R71.htm 9954515 - Disclosure - Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Sheet http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Details 71 false false R72.htm 9954516 - Disclosure - Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details) Sheet http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details) Details 72 false false R73.htm 9954517 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 73 false false R74.htm 9954518 - Disclosure - Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details) Sheet http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details) Details 74 false false R75.htm 9954519 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 75 false false R76.htm 9954520 - Disclosure - Stock-Based Compensation - Restricted Stock Unit and Phantom Share Units (PSUs) Activity (Details) Sheet http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails Stock-Based Compensation - Restricted Stock Unit and Phantom Share Units (PSUs) Activity (Details) Details 76 false false R77.htm 9954521 - Disclosure - Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details) Sheet http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details) Details 77 false false R78.htm 9954522 - Disclosure - Income Taxes (Details) Sheet http://www.healthcatalyst.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.healthcatalyst.com/role/IncomeTaxes 78 false false R79.htm 9954523 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.healthcatalyst.com/role/CommitmentsandContingencies 79 false false R80.htm 9954524 - Disclosure - Deferred Revenue and Performance Obligations - Narrative (Details) Sheet http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails Deferred Revenue and Performance Obligations - Narrative (Details) Details 80 false false R81.htm 9954525 - Disclosure - Related Parties (Details) Sheet http://www.healthcatalyst.com/role/RelatedPartiesDetails Related Parties (Details) Details http://www.healthcatalyst.com/role/RelatedParties 81 false false R82.htm 9954526 - Disclosure - Segments - Narrative (Details) Sheet http://www.healthcatalyst.com/role/SegmentsNarrativeDetails Segments - Narrative (Details) Details 82 false false R83.htm 9954527 - Disclosure - Segments - Scheduled of Segment Revenue (Details) Sheet http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails Segments - Scheduled of Segment Revenue (Details) Details 83 false false R84.htm 9954528 - Disclosure - Segments - Schedule of Segment Adjusted Gross Profit (Details) Sheet http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails Segments - Schedule of Segment Adjusted Gross Profit (Details) Details 84 false false R85.htm 9954529 - Disclosure - Restructuring Costs - Schedule of Restructuring Costs (Details) Sheet http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails Restructuring Costs - Schedule of Restructuring Costs (Details) Details 85 false false R86.htm 9954530 - Disclosure - Restructuring Costs - Schedule of Restructuring-Related Charges and Related Liability (Details) Sheet http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails Restructuring Costs - Schedule of Restructuring-Related Charges and Related Liability (Details) Details 86 false false All Reports Book All Reports hcat-20240930.htm hcat-20240930.xsd hcat-20240930_cal.xml hcat-20240930_def.xml hcat-20240930_lab.xml hcat-20240930_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 104 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hcat-20240930.htm": { "nsprefix": "hcat", "nsuri": "http://www.healthcatalyst.com/20240930", "dts": { "inline": { "local": ["hcat-20240930.htm"] }, "schema": { "local": ["hcat-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["hcat-20240930_cal.xml"] }, "definitionLink": { "local": ["hcat-20240930_def.xml"] }, "labelLink": { "local": ["hcat-20240930_lab.xml"] }, "presentationLink": { "local": ["hcat-20240930_pre.xml"] } }, "keyStandard": 362, "keyCustom": 35, "axisStandard": 39, "axisCustom": 1, "memberStandard": 57, "memberCustom": 36, "hidden": { "total": 10, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 3, "http://www.healthcatalyst.com/20240930": 2 }, "contextCount": 399, "entityCount": 1, "segmentCount": 105, "elementCount": 662, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1225, "http://xbrl.sec.gov/dei/2024": 29, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://www.healthcatalyst.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare",

```
"unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R5": { "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R6": { "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-43", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-43", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "9952156 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R8": { "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies", "longName": "9952157 - Disclosure - Description of Business and Summary of Significant Accounting Policies", "shortName": "Description of Business and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.healthcatalyst.com/role/BusinessCombinations", "longName": "9952158 - Disclosure - Business Combinations", "shortName": "Business Combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.healthcatalyst.com/role/Revenue", "longName": "9952159 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": null }, "R11": { "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets", "longName": "9952160 - Disclosure - Goodwill and Intangible Assets", "shortName": "Goodwill and Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.healthcatalyst.com/role/PropertyandEquipment", "longName": "9952161 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.healthcatalyst.com/role/ShorttermInvestments", "longName": "9952162 - Disclosure - Short-term Investments", "shortName": "Short-term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstruments", "longName": "9952163 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.healthcatalyst.com/role/AccruedLiabilities", "longName": "9952164 - Disclosure - Accrued Liabilities", "shortName": "Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.healthcatalyst.com/role/Leases", "longName": "9952165 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.healthcatalyst.com/role/Debt", "longName": "9952166 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.healthcatalyst.com/role/StockholdersEquity", "longName": "9952167 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.healthcatalyst.com/role/NetLossPerShare", "longName": "9952168 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.healthcatalyst.com/role/StockBasedCompensation", "longName": "9952169 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.healthcatalyst.com/role/IncomeTaxes", "longName": "9952170 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.healthcatalyst.com/role/CommitmentsandContingencies", "longName": "9952171 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations", "longName": "9952172 - Disclosure - Deferred Revenue and Performance Obligations", "shortName": "Deferred Revenue and Performance Obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://www.healthcatalyst.com/role/RelatedParties", "longName": "9952173 - Disclosure - Related Parties", "shortName": "Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true,
```

"unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.healthcatalyst.com/role/Segments", "longName": "9952174 - Disclosure - Segments", "shortName": "Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.healthcatalyst.com/role/RestructuringCosts", "longName": "9952175 - Disclosure - Restructuring Costs", "shortName": "Restructuring Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Policies)", "shortName": "Description of Business and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Description of Business and Summary of Significant Accounting Policies (Tables)", "shortName": "Description of Business and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.healthcatalyst.com/role/BusinessCombinationsTables", "longName": "9954473 - Disclosure - Business Combinations (Tables)", "shortName": "Business Combinations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.healthcatalyst.com/role/RevenueTables", "longName": "9954474 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables", "longName": "9954475 - Disclosure - Goodwill and Intangible Assets (Tables)", "shortName": "Goodwill and Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.healthcatalyst.com/role/PropertyandEquipmentTables", "longName": "9954476 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.healthcatalyst.com/role/ShorttermInvestmentsTables", "longName": "9954477 - Disclosure - Short-term Investments (Tables)", "shortName": "Short-term Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables", "longName": "9954478 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.healthcatalyst.com/role/AccruedLiabilitiesTables", "longName": "9954479 - Disclosure - Accrued Liabilities (Tables)", "shortName": "Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.healthcatalyst.com/role/LeasesTables", "longName": "9954480 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.healthcatalyst.com/role/DebtTables", "longName": "9954481 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.healthcatalyst.com/role/NetLossPerShareTables", "longName": "9954482 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.healthcatalyst.com/role/StockBasedCompensationTables", "longName": "9954483 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.healthcatalyst.com/role/SegmentsTables", "longName": "9954484 - Disclosure - Segments (Tables)", "shortName": "Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.healthcatalyst.com/role/RestructuringCostsTables", "longName": "9954485 - Disclosure - Restructuring Costs (Tables)", "shortName": "Restructuring Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954486 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Description of Business and Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R43": { "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails", "longName": "9954487 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details)", "shortName": "Description of Business and Summary of Significant Accounting Policies - Allowance For Credit Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R44": { "role":

```
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails", "longName": "9954488 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)", "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Property and Equipment Useful Life (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-53", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-53", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails", "longName": "9954489 - Disclosure - Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details)", "shortName": "Description of Business and Summary of Significant Accounting Policies - Schedule of Intangible Assets Useful Life (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-61", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-61", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "longName": "9954490 - Disclosure - Business Combinations - Narrative (Details)", "shortName": "Business Combinations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R47": { "role": "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954491 - Disclosure - Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details)", "shortName": "Business Combinations - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R48": { "role": "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails", "longName": "9954492 - Disclosure - Business Combinations - Unaudited Pro Forma Financial Information (Details)", "shortName": "Business Combinations - Unaudited Pro Forma Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-85", "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails", "longName": "9954493 - Disclosure - Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details)", "shortName": "Revenue - Schedule of Revenue Disaggregated by Type of Arrangement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-103", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R50": { "role": "http://www.healthcatalyst.com/role/RevenueNarrativeDetails", "longName": "9954494 - Disclosure - Revenue - Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-111", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "longName": "9954495 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef", "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R52": { "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails", "longName": "9954496 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill by Reporting Unit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-115", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R53": { "role": "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails", "longName": "9954497 - Disclosure - Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets - Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails", "longName": "9954498 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)", "shortName": "Property and Equipment - Components of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails", "longName": "9954499 - Disclosure - Property and Equipment - Narrative (Details)", "shortName": "Property and Equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails", "longName": "9954500 - Disclosure - Short-term Investments - Cash Equivalents and Short-Term Investments (Details)", "shortName": "Short-term Investments - Cash Equivalents and Short-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R57": { "role": "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails", "longName": "9954501 - Disclosure - Short-term Investments - Short-Term Investments (Details)", "shortName": "Short-term Investments - Short-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-152", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R58": { "role": "http://www.healthcatalyst.com/role/ShorttermInvestmentsNarrativeDetails", "longName": "9954502 - Disclosure - Short-term Investments - Narrative (Details)", "shortName": "Short-term Investments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InterestReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InterestReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "longName": "9954503 - Disclosure - Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-189", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R60": { "role":
```

"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "longName": "9954504 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-249", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-218", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R61": { "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "longName": "9954505 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurements of Contingent Consideration Liabilities (Details)", "shortName": "Fair Value of Financial Instruments - Fair Value Measurements of Contingent Consideration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-221", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-221", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails", "longName": "9954506 - Disclosure - Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-225", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-225", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails", "longName": "9954507 - Disclosure - Accrued Liabilities (Details)", "shortName": "Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.healthcatalyst.com/role/LeasesNarrativeDetails", "longName": "9954508 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-230", "name": "us-gaap:OperatingLeaseImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R65": { "role": "http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails", "longName": "9954509 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information (Details)", "shortName": "Leases - Schedule of Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails", "longName": "9954510 - Disclosure - Debt - Schedule of Debt (Details)", "shortName": "Debt - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-214", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R67": { "role": "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails", "longName": "9954511 - Disclosure - Debt - Schedule of Components of Interest Expense (Details)", "shortName": "Debt - Schedule of Components of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-235", "name": "us-gaap:InterestExpenseDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R68": { "role": "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails", "longName": "9954512 - Disclosure - Debt - Schedule of Principal Payments and Debt Maturity (Details)", "shortName": "Debt - Schedule of Principal Payments and Debt Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.healthcatalyst.com/role/DebtNarrativeDetails", "longName": "9954513 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-249", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R70": { "role": "http://www.healthcatalyst.com/role/StockholdersEquityDetails", "longName": "9954514 - Disclosure - Stockholders\u2019 Equity (Details)", "shortName": "Stockholders\u2019 Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:SharesIssued", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R71": { "role": "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails", "longName": "9954515 - Disclosure - Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "shortName": "Net Loss Per Share - Schedule of the Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails", "longName": "9954516 - Disclosure - Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details)", "shortName": "Net Loss Per Share - Schedule of Share Totals with a Potentially Dilutive Impact (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails", "longName": "9954517 - Disclosure - Stock-Based Compensation - Narrative (Details)", "shortName": "Stock-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails", "longName": "9954518 - Disclosure - Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details)", "shortName": "Stock-Based Compensation - Effect of Stock-based Compensation Expense on Statement of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-300", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R75": { "role": "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails", "longName": "9954519 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R76": { "role":

```
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails", "longName": "9954520 - Disclosure - Stock-Based Compensation - Restricted Stock Unit and Phantom Share Units (PSUs) Activity (Details)", "shortName": "Stock-Based Compensation - Restricted Stock Unit and Phantom Share Units (PSUs) Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-317", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-317", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R77": { "role":
"http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails", "longName": "9954521 - Disclosure - Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details)", "shortName": "Stock-Based Compensation - Schedule of the Purchase Right for the ESPP Option Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-290", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-290", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R78": { "role":
"http://www.healthcatalyst.com/role/IncomeTaxesDetails", "longName": "9954522 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R79": { "role":
"http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails", "longName": "9954523 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-342", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-342", "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R80": { "role":
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails", "longName": "9954524 - Disclosure - Deferred Revenue and Performance Obligations - Narrative (Details)", "shortName": "Deferred Revenue and Performance Obligations - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-13", "name":
"hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name":
"hcat:ContractWithCustomerLiabilityRevenueRecognizedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R81": { "role":
"http://www.healthcatalyst.com/role/RelatedPartiesDetails", "longName": "9954525 - Disclosure - Related Parties (Details)", "shortName": "Related Parties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-349", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R82": { "role": "http://www.healthcatalyst.com/role/SegmentsNarrativeDetails", "longName": "9954526 - Disclosure - Segments - Narrative (Details)", "shortName": "Segments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails", "longName": "9954527 - Disclosure - Segments - Scheduled of Segment Revenue (Details)", "shortName": "Segments - Scheduled of Segment Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-354", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R84": { "role":
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails", "longName": "9954528 - Disclosure - Segments - Schedule of Segment Adjusted Gross Profit (Details)", "shortName": "Segments - Schedule of Segment Adjusted Gross Profit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-370", "name": "us-gaap:GrossProfit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } }, "R85": { "role":
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails", "longName": "9954529 - Disclosure - Restructuring Costs - Schedule of Restructuring Costs (Details)", "shortName": "Restructuring Costs - Schedule of Restructuring Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-384", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-384", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails", "longName": "9954530 - Disclosure - Restructuring Costs - Schedule of Restructuring-Related Charges and Related Liability (Details)", "shortName": "Restructuring Costs - Schedule of Restructuring-Related Charges and Related Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-390", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-386", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "hcat-20240930.htm", "unique": true } } }, "tag": { "hcat_A2022RestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "A2022RestructuringPlanMember", "presentation": [
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Restructuring Plan", "label": "2022 Restructuring Plan [Member]", "documentation": "2022 Restructuring Plan" } } }, "auth_ref": [] }, "hcat_A2023RestructuringPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "A2023RestructuringPlanMember", "presentation": [
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Restructuring Plan", "label": "2023 Restructuring Plan [Member]", "documentation": "2023 Restructuring Plan" } } }, "auth_ref": [] }, "hcat_ARMUSCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ARMUSCorporationMember", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ARMUS", "label": "ARMUS Corporation [Member]", "documentation": "ARMUS Corporation" } } }, "auth_ref": [] }, "hcat_AbleHealthIncMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "AbleHealthIncMember", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Able Health Inc", "label": "Able Health Inc [Member]", "documentation": "Able Health Inc" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/AccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r88", "r91", "r97", "r1181" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r88", "r1007" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allowance For Accounts Receivable", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r1106" ] }, "hcat_AccountsReceivableAllowanceForCreditLossWriteoffRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "AccountsReceivableAllowanceForCreditLossWriteoffRecovery", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Write-offs, net of recoveries", "label": "Accounts Receivable, Allowance For Credit Loss, Writeoff (Recovery)", "documentation": "Accounts Receivable, Allowance For Credit Loss, Writeoff (Recovery)" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets", "http://www.healthcatalyst.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1086" ] }, "us-
```

gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment discount and premium accretion", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } } }, "auth_ref": ["r120"] }, "hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails", "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "label": "Accrued Liabilities And Employee-Related Liabilities, Current", "documentation": "Accrued Liabilities And Employee-Related Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r53", "r229", "r787"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r25", "r26", "r107", "r236", "r782", "r827", "r828"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r14", "r26", "r627", "r630", "r690", "r822", "r823", "r1063", "r1064", "r1065", "r1075", "r1076", "r1077", "r1078"] }, "us-gaap_AcquisitionRelatedCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquisitionRelatedCostsMember", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-related costs, net", "label": "Acquisition-related Costs [Member]", "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r63", "r64", "r543"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Advertising costs", "label": "Advertising Cost [Policy Text Block]", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": ["r168"] }, "us-gaap_AdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvertisingExpense", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Advertising expense", "label": "Advertising Expense", "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line." } } }, "auth_ref": ["r586", "r992"] }, "hcat_AggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "AggregateIntrinsicValueAbstract", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value [Abstract]", "documentation": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "negatedLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r575", "r584"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Allowance for credit losses at the beginning of period", "periodEndLabel": "Allowance for credit losses at the end of period", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r237", "r345", "r382", "r385", "r387", "r1219"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "hcat_AmortizationOfAcquiredIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "AmortizationOfAcquiredIntangibleAssetsMember", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "label": "Amortization Of Acquired Intangible Assets [Member]", "documentation": "Amortization Of Acquired Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": ["r112", "r484", "r1070", "r1200"] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 3.0 }, "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount, issuance costs, and deferred financing costs", "verboseLabel": "Amortization of debt discount and issuance costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r484", "r974", "r975", "r1070", "r1200"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r8", "r412", "r419", "r969"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares with a potentially dilutive impact (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r294"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r37"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [

```
"r37" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails": { "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment Charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r8", "r51" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r149", "r162", "r233", "r259", "r299", "r305", "r331", "r335", "r379", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r621", "r623", "r662", "r778", "r870", "r960", "r961", "r1007", "r1033", "r1148", "r1149", "r1206" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r225", "r238", "r259", "r379", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r621", "r623", "r662", "r1007", "r1148", "r1149", "r1206" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r352" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r353" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized cost, due within one year", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1097" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value, due within one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r356", "r775" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r546", "r547", "r548", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r571", "r572", "r573", "r574" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails", "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r432", "r1221", "r1222" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails", "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r78", "r80", "r432", "r1221", "r1222" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business and Summary of Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r121" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails", "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r413", "r414", "r415", "r416", "r417", "r615", "r987", "r988" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails", "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r67", "r69", "r413", "r414", "r415", "r416", "r417", "r615", "r987", "r988" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r615" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage interest acquired", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r68" ] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [
```

```
"http://www.healthcatalyst.com/role/BusinessCombinationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unaudited Proforma Financial Information",
"label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business
acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r1044", "r1045" ] },
"hcat_BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.healthcatalyst.com/20240930",
"localname": "BusinessAcquisitionStockBasedCompensationSharesIssuableNumberOfShares", "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Number of restricted shares issued (in shares)", "label": "Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares",
"documentation": "Business Acquisition, Stock-based Compensation Shares Issuable, Number of Shares" } } }, "auth_ref": [] }, "us-
gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro forma net loss",
"label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or
combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r613", "r614" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0,
"order": 5.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition transaction costs",
"negatedTerseLabel": "Acquisition-related costs, net", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-
related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting,
valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include
costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r66" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business
Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "hcat_BusinessCombinationCashRetentionPayment": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "BusinessCombinationCashRetentionPayment", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash retention payment", "label": "Business
Combination, Cash Retention Payment", "documentation": "Business Combination, Cash Retention Payment" } } }, "auth_ref": [] }, "us-
gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Consideration", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred,
consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref":
[ "r0", "r1", "r13" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 6.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in
fair value of contingent consideration liabilities", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration,
Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon
settlement." } } }, "auth_ref": [ "r618", "r1069" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "crdr":
"credit", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent
consideration cap", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "documentation": "For contingent
consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted)
of the consideration which may be paid." } } }, "auth_ref": [ "r75" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-
gaap_FairValueNetAssetLiability", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Contingent consideration liabilities", "negatedTerseLabel": "Contingent consideration liabilities", "label": "Business Combination, Contingent Consideration,
Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r74", "r147", "r617", "r640",
"r641", "r642" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Measurement Input", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to
measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r640", "r641", "r642" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinations" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combination Disclosure
[Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period,
including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r140",
"r616" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel":
"Total assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets
acquired at the acquisition date." } } }, "auth_ref": [ "r71" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Assets acquired:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Prepaid expenses and other assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and
Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other
assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r71" ] },
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit",
"calculation": { "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Accounts receivable, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation":
"Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due
from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition
date." } } }, "auth_ref": [ "r71" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Deferred revenue", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
"documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date." }
} }, "auth_ref": [ "r71" ] }, "hcat_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNetDeferredTaxLiability": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname":
"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNetDeferredTaxLiability", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Net deferred tax liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Net Deferred Tax Liability",
"documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Net Deferred Tax Liability" } } }, "auth_ref": []
}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "crdr": "credit",
"calculation": { "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Accrued and other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
"documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r71" ]
}, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel":
```

"Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": ["r70", "r71"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": ["r71"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Less liabilities assumed:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total assets acquired, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r70", "r71"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r70", "r71"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total consideration transferred, net of cash acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": ["r71"] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": ["r19"] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Business combinations/Contingent consideration liabilities", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": ["r141", "r142", "r143", "r144"] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of property and equipment included in accounts payable and accrued liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r34", "r35", "r36"] }, "us-gaap_CapitalizedComputerSoftwareAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareAdditions", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized computer software, additions", "label": "Capitalized Computer Software, Additions", "documentation": "Additions made to capitalized computer software costs during the period." } } }, "auth_ref": ["r940"] }, "us-gaap_CapitalizedComputerSoftwareAmortization1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedComputerSoftwareAmortization1", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized computer software, amortization", "label": "Capitalized Computer Software, Amortization", "documentation": "Amount of expense for amortization of capitalized computer software costs." } } }, "auth_ref": ["r939", "r940"] }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostAmortizationPeriod", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized contract cost, amortization period", "label": "Capitalized Contract Cost, Amortization Period", "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1043"] }, "us-gaap_CapitalizedContractCostImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostImpairmentLoss", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment losses recorded on deferred contract costs", "label": "Capitalized Contract Cost, Impairment Loss", "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": ["r395"] }, "us-gaap_CapitalizedContractCostNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostNetCurrent", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized contract cost, net, current", "label": "Capitalized Contract Cost, Net, Current", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current." } } }, "auth_ref": ["r394"] }, "us-gaap_CapitalizedContractCostNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostNetNoncurrent", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized contract cost, net, noncurrent", "label": "Capitalized Contract Cost, Net, Noncurrent", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent." } } }, "auth_ref": ["r394"] }, "hcat_CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "CapitalizedInternalUseSoftwareInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized internal-use software included in accounts payable and accrued liabilities", "label": "Capitalized Internal-Use Software In Accounts Payable And Accrued Liabilities", "documentation": "Capitalized Internal-Use Software In Accounts Payable And Accrued Liabilities" } } }, "auth_ref": [] }, "hcat_CapitalizedOfInternalUseSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "CapitalizedOfInternalUseSoftware", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalization of internal-use software", "label": "Capitalized Of Internal Use Software", "documentation": "Capitalized Of Internal Use Software" } } }, "auth_ref": [] }, "hcat_CappedCallMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "CappedCallMember", "presentation": ["http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capped Call", "label": "Capped Call [Member]", "documentation": "Capped Call" } } }, "auth_ref": [] }, "hcat_CareviveAndLumeonAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "CareviveAndLumeonAcquisitionsMember", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Carevive and Lumeon", "label": "Carevive and Lumeon Acquisitions [Member]", "documentation": "Carevive and Lumeon Acquisitions" } } }, "auth_ref": [] }, "hcat_CareviveSystemsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "CareviveSystemsInc.Member", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Carevive Systems, Inc.", "label": "Carevive Systems, Inc. [Member]", "documentation": "Carevive Systems, Inc." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r32", "r227", "r945"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1183", "r1184"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-

```
gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash
equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the
policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its
cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance
accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } }
}, "auth_ref": [ "r33" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at
beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and
discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general
characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts
of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r32", "r118", "r256" ] },
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash
equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange
rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of
demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r118" ] }, "us-
gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsMember", "presentation": [
"http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents",
"label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their
maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r227" ] }, "us-gaap_CashFlowHedgingMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash
flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r77" ] }, "us-
gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"
], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of non-cash investing and financing information", "label": "Cash Flow, Noncash Investing and Financing
Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"CityAreaCode", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code",
"documentation": "Area code of city" } } }, "auth_ref": [] }, "hcat_ClientRelationshipsAndContractsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "ClientRelationshipsAndContractsMember", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Client relationships and
contract backlog", "terseLabel": "Client relationships and contracts", "label": "Client Relationships And Contracts [Member]", "documentation": "Client Relationships And
Contracts" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommercialPaperMember", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Commercial
paper", "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides
institutions with short-term funds." } } }, "auth_ref": [ "r130", "r450", "r1027", "r1028", "r1029", "r1030" ] }, "hcat_CommissionPaymentEstimatedBenefitPeriod": { "xbrltype":
"durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "CommissionPaymentEstimatedBenefitPeriod", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Estimated period of benefit", "label": "Commission Payment, Estimated Benefit Period", "documentation": "Commission Payment, Estimated Benefit Period" } } }, "auth_ref":
[] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies",
"crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel":
"Commitments and contingencies (Note 15)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to
indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is
exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b)
possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } }
}, "auth_ref": [ "r98", "r152", "r780", "r857" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure
[Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments
and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r128", "r441", "r442", "r927",
"r1132", "r1140" ] }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockIncludingAdditionalPaidInCapitalMember", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ],
"lang": { "en-us": { "role": { "terseLabel": "Common Stock and Additional Paid-in Capital", "label": "Common Stock Including Additional Paid in Capital [Member]",
"documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock)." } } }, "auth_ref":
[] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in USD per share)", "label": "Common
Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r101" ] }, "us-
gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized",
"presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ],
"lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum
number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r101", "r858" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in
shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes
common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or
only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r101" ] }, "us-
gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding",
"presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding
(in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding",
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r101",
"r858", "r876", "r1254", "r1255" ] }, "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStocksIncludingAdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets":
{ "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value per share, and additional paid-in capital, 500,000,000 shares authorized as of September\u00a030,
2024 and December\u00a031, 2023; 60,847,658 and 58,295,491 shares issued and outstanding as of September\u00a030, 2024 and December\u00a031, 2023, respectively",
"label": "Common Stocks, Including Additional Paid in Capital", "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common
stock issued." } } }, "auth_ref": [ "r101", "r102", "r136" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive
loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and
other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by
owners and distributions to owners." } } }, "auth_ref": [ "r27", "r243", "r245", "r251", "r773", "r792", "r793" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Computer
equipment", "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation,
maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Computer software
licenses", "terseLabel": "Computer software licenses", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and
related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more
particular functions or tasks." } } }, "auth_ref": [ "r940", "r944", "r1121", "r1122", "r1123", "r1124", "r1126", "r1128", "r1130", "r1131" ] }, "us-
gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain",
"presentation": [ "http://www.healthcatalyst.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]",
"label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [
"r39", "r41", "r83", "r84", "r343", "r926" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

```
"localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.healthcatalyst.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r39", "r41", "r83", "r84", "r343", "r830", "r926" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.healthcatalyst.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r39", "r41", "r83", "r84", "r343", "r926", "r1042" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.healthcatalyst.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue related to contracts with customers (percentage)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r39", "r41", "r83", "r84", "r343" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.healthcatalyst.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r39", "r41", "r83", "r84", "r343", "r926" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r160", "r182", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r265", "r299", "r307", "r329", "r330", "r331", "r332", "r333", "r335", "r336", "r337", "r451", "r452", "r453", "r454", "r456", "r457", "r458", "r459", "r460", "r960", "r961", "r1056", "r1057", "r1148", "r1149" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r160", "r182", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r265", "r299", "r307", "r329", "r330", "r331", "r332", "r333", "r335", "r336", "r337", "r451", "r452", "r453", "r454", "r456", "r457", "r458", "r459", "r460", "r960", "r961", "r1056", "r1057", "r1148", "r1149" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r76", "r949" ] }, "hcat_ContingentConsiderationLiabilityAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ContingentConsiderationLiabilityAggregateIntrinsicValue", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of contingent consideration liability", "label": "Contingent Consideration, Liability, Aggregate Intrinsic Value", "documentation": "Contingent Consideration, Liability, Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "hcat_ContingentConsiderationLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ContingentConsiderationLiabilityMember", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Liability", "label": "Contingent Consideration Liability [Member]", "documentation": "Contingent Consideration Liability" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled accounts receivable", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r509", "r511", "r530" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.healthcatalyst.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r509", "r510", "r530" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r509", "r510", "r530" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, net of current portion", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r509", "r510", "r530" ] }, "hcat_ContractWithCustomerLiabilityRevenueRecognizedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ContractWithCustomerLiabilityRevenueRecognizedPercentage", "presentation": [ "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of revenue recognized was included in deferred revenue (in percentage)", "label": "Contract With Customer, Liability, Revenue Recognized, Percentage", "documentation": "Contract With Customer, Liability, Revenue Recognized, Percentage" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Convertible Debt", "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails", "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Payable", "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r90", "r150" ] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Corporate bonds", "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Total cost of revenue, excluding depreciation and amortization", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": [ "r1046", "r1047" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenueAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue, excluding depreciation and amortization:", "label": "Cost of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring costs", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations." } } }, "auth_ref": [ "r23", "r125", "r126" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r217", "r218", "r263", "r264", "r466", "r496", "r697", "r715", "r777", "r946", "r948" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "hcat_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "CreditAgreementMember", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Agreement", "label": "Credit Agreement [Member]", "documentation": "Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r450", "r1146" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r450", "r1146", "r1147" ] }, "hcat_CumulativeAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "CumulativeAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails": { "parentTag": "hcat_CumulativeRestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative asset impairment
```

```
charges", "label": "Cumulative Asset Impairment Charges", "documentation": "Cumulative Asset Impairment Charges" } } }, "auth_ref": [] },
"hcat_CumulativeOtherRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname":
"CumulativeOtherRestructuringCosts", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails": {
"parentTag": "hcat_CumulativeRestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative other restructuring
costs", "label": "Cumulative Other Restructuring Costs", "documentation": "Cumulative Other Restructuring Costs" } } }, "auth_ref": [] },
"hcat_CumulativeRestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname":
"CumulativeRestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cumulative
restructuring costs and asset impairment charges", "label": "Cumulative Restructuring Costs and Asset Impairment Charges", "documentation": "Cumulative Restructuring
Costs and Asset Impairment Charges" } } }, "auth_ref": [] }, "hcat_CumulativeSeveranceCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "CumulativeSeveranceCosts", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails": { "parentTag":
"hcat_CumulativeRestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative severance costs",
"label": "Cumulative Severance Costs", "documentation": "Cumulative Severance Costs" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype":
"gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ],
"lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the
format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CustomerRelationshipsMember", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Client relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but
not limited to, tenant relationships." } } }, "auth_ref": [ "r73", "r1121", "r1122", "r1123", "r1124", "r1126", "r1128", "r1130", "r1131" ] }, "us-gaap_DebtDisclosureAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure
[Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/Debt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label":
"Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of
borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual
agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided,
restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the
effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r129", "r257", "r427", "r428", "r429", "r430", "r431", "r449", "r450", "r462", "r468", "r469",
"r470", "r471", "r472", "r473", "r478", "r485", "r486", "r488", "r674" ] }, "hcat_DebtInstrumentAdditionalDrawAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "DebtInstrumentAdditionalDrawAmount", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional delayed draw facility", "label": "Debt Instrument, Additional
Draw Amount", "documentation": "Debt Instrument, Additional Draw Amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt
Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
} } }, "auth_ref": [ "r24", "r90", "r91", "r150", "r151", "r265", "r463", "r464", "r465", "r466", "r467", "r469", "r474", "r475", "r476", "r477", "r479", "r480", "r481", "r482",
"r483", "r484", "r971", "r972", "r973", "r974", "r975", "r1005", "r1071", "r1133", "r1134", "r1135", "r1199", "r1201" ] }, "us-
gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on
the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails_1": { "parentTag": "us-
gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails",
"http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Principal Outstanding",
"totalLabel": "Total debt maturities", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-
term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } },
"auth_ref": [ "r24", "r151", "r489" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Conversion price (in USD per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion
feature embedded in the debt instrument." } } }, "auth_ref": [ "r131", "r465" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion rate", "label": "Debt Instrument, Convertible, Conversion
Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r58", "r94",
"r134", "r135", "r465" ] }, "hcat_DebtInstrumentConvertibleSalePriceOfStockThresholdMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "DebtInstrumentConvertibleSalePriceOfStockThresholdMember", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Convertible Sale Price Of Stock Threshold", "label":
"Debt Instrument Convertible Sale Price Of Stock Threshold [Member]", "documentation": "Debt Instrument Convertible Sale Price Of Stock Threshold" } } }, "auth_ref": [] },
"us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Threshold consecutive trading days", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "documentation": "Threshold period of
specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified
number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, convertible, threshold percentage of stock price
trigger", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion
price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype":
"integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold trading days", "label": "Debt Instrument, Convertible,
Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must
exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] },
"hcat_DebtInstrumentConvertibleThresholdTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname":
"DebtInstrumentConvertibleThresholdTypeAxis", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Debt Instrument Convertible Threshold Type [Axis]", "label": "Debt Instrument Convertible Threshold Type [Axis]", "documentation": "Debt Instrument Convertible Threshold
Type" } } }, "auth_ref": [] }, "hcat_DebtInstrumentConvertibleThresholdTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930",
"localname": "DebtInstrumentConvertibleThresholdTypeDomain", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Debt Instrument Convertible Threshold Type [Domain]", "label": "Debt Instrument Convertible Threshold Type [Domain]", "documentation": "Debt Instrument
Convertible Threshold Type" } } }, "auth_ref": [] }, "hcat_DebtInstrumentDelayedDrawFacilityTerm": { "xbrltype": "durationItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "DebtInstrumentDelayedDrawFacilityTerm", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to draw, term", "label": "Debt Instrument, Delayed Draw
Facility, Term", "documentation": "Debt Instrument, Delayed Draw Facility, Term" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Amount borrowed", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [
"r463", "r674", "r675", "r972", "r973", "r1005" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis rate (in percentage)", "label": "Debt Instrument, Interest
Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r93", "r464" ] }, "us-
gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt
Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it
from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r24", "r265", "r463", "r464", "r465", "r466", "r467", "r469", "r474",
"r475", "r476", "r477", "r479", "r480", "r481", "r482", "r483", "r484", "r971", "r972", "r973", "r974", "r975", "r1005", "r1071", "r1133", "r1134", "r1135", "r1199", "r1201" ] },
"hcat_DebtInstrumentOptionToDraw": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "DebtInstrumentOptionToDraw",
"crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option to draw", "label": "Debt
Instrument, Option To Draw", "documentation": "Debt Instrument, Option To Draw" } } }, "auth_ref": [] }, "hcat_DebtInstrumentPrepaymentPremiumPercentage": {
"xbrltype": "percentItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "DebtInstrumentPrepaymentPremiumPercentage", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment of premium percentage", "label": "Debt Instrument,
Prepayment Premium, Percentage", "documentation": "Debt Instrument, Prepayment Premium, Percentage" } } }, "auth_ref": [] },
"hcat_DebtInstrumentQuarterlyPaymentPrincipalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname":
"DebtInstrumentQuarterlyPaymentPrincipalPercentage", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Quarterly principal payment percentage", "label": "Debt Instrument, Quarterly Payment, Principal, Percentage", "documentation": "Debt Instrument, Quarterly
Payment, Principal, Percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Redemption price, percentage", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal
amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r158" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Credit agreement term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails", "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": {
"en-us": { "role": { "negatedTerseLabel": "Less: Unamortized discount and issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r474", "r490", "r673", "r674", "r675", "r972",
"r973", "r1005" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "crdr": "debit",
"calculation": { "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails": { "parentTag": null, "weight": null, "order":
null, "root": true }, "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails",
"http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt
Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest,
after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
} } }, "auth_ref": [ "r1107" ] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-
gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 2.0 }, "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails":
{ "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 },
"http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails",
"http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale
[Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with
change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356",
"r357", "r358", "r359" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/ShorttermInvestmentsTables" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Cash Equivalents and Short-Term Investments Measured at Fair Value", "label": "Debt Securities, Available-for-Sale [Table Text Block]",
"documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-
sale)." } } }, "auth_ref": [ "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101" ] }, "us-
gaap_DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation capitalized as
internal-use software", "label": "Deferred Compensation Arrangement with Individual, Allocated Share-Based Compensation Expense", "documentation": "Amount of expense
recognized from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments), awarded to key employees or
individuals. Excludes amount related to plans that cover generally all employees (for example, but not limited to, qualified pension plans)." } } }, "auth_ref": [] }, "us-
gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit",
"crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax provision (benefit)", "label":
"Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } },
"auth_ref": [ "r8", "r178", "r1073" ] }, "us-gaap_DeferredPolicyAcquisitionCostAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DeferredPolicyAcquisitionCostAmortizationExpense", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Amortization of deferred contract acquisition costs", "label": "Deferred Policy Acquisition Costs, Amortization Expense", "documentation": "Amount of amortization expense
(reversal of expense) for deferred policy acquisition costs." } } }, "auth_ref": [ "r166", "r796", "r815", "r816", "r825", "r1017", "r1070", "r1217" ] },
"hcat_DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930",
"localname": "DeferredRevenueArrangementForServiceContractAllowedTerminationPeriod", "presentation": [
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowed
termination period", "label": "Deferred Revenue Arrangement For Service Contract, Allowed Termination Period", "documentation": "Deferred Revenue Arrangement For
Service Contract, Allowed Termination Period" } } }, "auth_ref": [] }, "hcat_DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination": { "xbrltype":
"durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "DeferredRevenueArrangementForServiceContractNoticeRequiredForTermination",
"presentation": [ "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notice
required for termination", "label": "Deferred Revenue Arrangement For Service Contract, Notice Required For Termination", "documentation": "Deferred Revenue
Arrangement For Service Contract, Notice Required For Termination" } } }, "auth_ref": [] }, "hcat_DeferredRevenueArrangementForServiceContractTerm": { "xbrltype":
"durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "DeferredRevenueArrangementForServiceContractTerm", "presentation": [
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service
contract term", "label": "Deferred Revenue Arrangement For Service Contract, Term", "documentation": "Deferred Revenue Arrangement For Service Contract, Term" } } },
"auth_ref": [] }, "us-gaap_DelayedDrawTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DelayedDrawTermLoanMember", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Delayed Draw
Term Loan (DDTL)", "label": "Delayed Draw Term Loan (DDTL) [Member]", "documentation": "Term loan allowing borrower to withdraw predefined amount of preapproved
loan within predetermined period." } } }, "auth_ref": [ "r1252", "r1253" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the
cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r52" ] }, "us-
gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit",
"calculation": { "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": "us-gaap_IncomeLossAttributableToParent",
"weight": -1.0, "order": 2.0 }, "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight":
1.0, "order": 4.0 }, "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization",
"verboseLabel": "Depreciation and amortization", "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction",
"documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to
allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to
reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r8", "r52" ] }, "us-gaap_DerivativeCapPrice": { "xbrltype":
"perUnitItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCapPrice", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cap price (in
USD per share)", "label": "Derivative, Cap Price", "documentation": "The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the
market rate exceeds the cap rate on the contract." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more
underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [
"r847", "r849", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r871", "r872", "r873", "r874", "r888", "r889", "r890", "r891", "r894", "r895", "r896", "r897", "r917",
"r918", "r919", "r920", "r1024", "r1025", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1195", "r1196" ] }, "us-gaap_DerivativeCostOfHedge": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCostOfHedge", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, cost of hedge", "label": "Derivative, Cost of Hedge",
"documentation": "The premium (cost) of a hedge, expensed during the period." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } },
"auth_ref": [ "r79", "r81", "r82", "r148", "r847", "r849", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r871", "r872", "r873", "r874", "r888", "r889", "r890", "r891",
"r894", "r895", "r896", "r897", "r917", "r918", "r919", "r920", "r948", "r1024", "r1025", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1195", "r1196" ] }, "us-
gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging
Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r16", "r79", "r81" ] }, "us-
gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as
Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally
Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r16" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
```

```
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technologies", "verboseLabel": "Developed technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r146", "r1121", "r1122", "r1123", "r1124", "r1126", "r1128", "r1130", "r1131" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.healthcatalyst.com/role/RevenueNarrativeDetails", "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r529", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.healthcatalyst.com/role/RevenueNarrativeDetails", "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r529", "r977", "r978", "r979", "r980", "r981", "r982", "r983" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r541", "r545", "r576", "r577", "r579", "r990" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-based Compensation Expense", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r11", "r62" ] }, "us-gaap_DividendsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCash", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends", "label": "Dividends, Cash", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": [ "r6", "r136" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r1037" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1038" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "hcat_ERSCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ERSCorporationMember", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ERS Corporation", "label": "ERS Corporation [Member]", "documentation": "ERS Corporation" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations", "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in USD per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r252", "r271", "r272", "r273", "r274", "r275", "r276", "r281", "r284", "r291", "r292", "r293", "r298", "r611", "r620", "r635", "r636", "r774", "r794", "r952" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations", "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (in USD per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r252", "r271", "r272", "r273", "r274", "r275", "r276", "r284", "r291", "r292", "r293", "r298", "r611", "r620", "r635", "r636", "r774", "r794", "r952" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r37", "r38", "r295" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r280", "r294", "r296", "r297" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r664" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.healthcatalyst.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate (in percentage)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r592", "r993" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails": { "parentTag": "hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and benefit expenses", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r91" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based payment arrangement, nonvested award cost not yet recognized amount", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r578" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonvested awards, period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r578" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense related to RSUs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of
```

cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r1180" } }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock options", "terseLabel": "Options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r1035"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r1035"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r1035"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1039"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r1035"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r1035"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r1035"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r1035"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r15", "r222", "r247", "r248", "r249", "r266", "r267", "r268", "r270", "r275", "r277", "r279", "r300", "r380", "r381", "r424", "r508", "r601", "r602", "r608", "r609", "r610", "r612", "r619", "r620", "r626", "r627", "r628", "r629", "r630", "r631", "r634", "r665", "r667", "r668", "r669", "r670", "r671", "r676", "r678", "r690", "r790", "r822", "r823", "r824", "r842", "r900"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables", "http://www.healthcatalyst.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r640", "r641", "r998"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Assets and liabilities Measured on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1183", "r1184"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r643", "r644", "r645", "r646", "r647", "r648", "r653", "r996"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument asset measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": ["r643", "r644", "r645", "r646", "r647", "r648", "r653", "r996"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r476", "r533", "r534", "r535", "r536", "r537", "r538", "r637", "r639", "r640", "r641", "r642", "r651", "r652", "r654", "r702", "r703", "r704", "r972", "r973", "r984", "r985", "r986", "r994", "r998"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability Class

[Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r643", "r644", "r645", "r646", "r647", "r648", "r653"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r638", "r639", "r640", "r642", "r994", "r1186", "r1197"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstruments"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r647", "r649", "r650", "r651", "r654", "r655", "r656", "r657", "r658", "r769", "r994", "r999"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r476", "r533", "r538", "r639", "r652", "r702", "r984", "r985", "r986", "r994"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r476", "r533", "r538", "r639", "r640", "r652", "r703", "r972", "r973", "r984", "r985", "r986", "r994"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r476", "r533", "r534", "r535", "r536", "r537", "r538", "r639", "r640", "r641", "r642", "r652", "r704", "r972", "r973", "r984", "r985", "r986", "r994", "r998"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r643", "r644", "r645", "r646", "r647", "r648", "r653"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r643", "r648", "r653"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r638", "r639", "r640", "r642", "r994", "r1186", "r1197"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of contingent consideration liabilities", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r644", "r653"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "crdr": "credit", "presentation": ["http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquisition-date contingent consideration liabilities from acquisitions (see Note 2)", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r646", "r653"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance as of January\u00a01, 2024", "periodEndLabel": "Balance as of September\u00a030, 2024", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r643", "r653"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r476", "r533", "r534", "r535", "r536", "r537", "r538", "r637", "r639", "r640", "r641", "r642", "r651", "r652", "r654", "r702", "r703", "r704", "r972", "r973", "r984", "r985", "r986", "r994", "r998"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofContingentConsiderationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r994", "r1183", "r1184", "r1185", "r1186", "r1187", "r1197"] }, "us-gaap_FairValueNetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetAssetLiability", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Fair Value, Net Asset (Liability)", "documentation": "Fair value of asset after deduction of liability." } } }, "auth_ref": ["r1183", "r1184"] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of financial instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r12"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial

```
Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r348", "r349", "r350", "r351",
"r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373",
"r374", "r375", "r376", "r377", "r383", "r384", "r388", "r389", "r390", "r391", "r392", "r393", "r487", "r506", "r632", "r659", "r699", "r700", "r701", "r702", "r703", "r704",
"r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728",
"r729", "r730", "r791", "r967", "r994", "r996", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1008", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054",
"r1055", "r1101", "r1102", "r1103", "r1104", "r1182", "r1185", "r1186", "r1187", "r1194", "r1197" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails" ], "lang": { "en-us": {
"role": { "verboseLabel": "Estimated useful life", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-
gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0,
"order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": {
"negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of
assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r231", "r396", "r418", "r969" ] }, "us-
gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible
Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible
assets." } } }, "auth_ref": [ "r411", "r413", "r414", "r415", "r417", "r418", "r420", "r421", "r737", "r738", "r940" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking
physical substance with a finite life." } } }, "auth_ref": [ "r396", "r418", "r738", "r969" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible
Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r411", "r418", "r420", "r421", "r422",
"r737", "r940", "r969" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible
Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset
(for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their
nature or by their use in the operations of a company." } } }, "auth_ref": [ "r411", "r413", "r414", "r415", "r417", "r418", "r420", "r421", "r940" ] }, "us-
gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr":
"debit", "calculation": { "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null,
"root": true } }, "presentation": [ "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": {
"totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking
physical substance with a finite life." } } }, "auth_ref": [ "r737", "r1128" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign
currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions
denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the
financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a
foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r663" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Furniture and
fixtures", "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no
permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-
gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr":
"debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0,
"order": 3.0 }, "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": "us-gaap_IncomeLossAttributableToParent",
"weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative",
"negatedTerseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and
administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a
product or product line." } } }, "auth_ref": [ "r111", "r880" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing
general and administrative expense." } } }, "auth_ref": [ "r111" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.healthcatalyst.com/role/RevenueNarrativeDetails" ], "lang":
{ "en-us": { "role": { "terseLabel": "Geographic Concentration Risk", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a
specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or
product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or
source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r40", "r926" ] },
"us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 },
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets",
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill",
"terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other
asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r230",
"r398", "r770", "r961", "r968", "r995", "r1007", "r1110", "r1117" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets
Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets", "label": "Goodwill and
Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1108", "r1120" ] }, "us-
gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill",
"label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may
address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of
the reporting units are determined." } } }, "auth_ref": [ "r397", "r410", "r968" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from
other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r8",
"r399", "r405", "r410", "r968", "r995" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GoodwillLineItems", "presentation": [ "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts
are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r400", "r401", "r402", "r403",
"r404", "r405", "r406", "r407", "r408", "r409", "r410", "r968" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": "us-
gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross profit", "label": "Gross
Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } },
"auth_ref": [ "r108", "r109", "r161", "r259", "r379", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r662", "r954", "r960", "r1080", "r1082", "r1083",
"r1084", "r1085", "r1148" ] }, "us-gaap_GrossProfitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfitAbstract",
"presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted Gross
Profit", "label": "Gross Profit [Abstract]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

```
"localname": "HedgingDesignationAxis", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging
Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r16", "r625"
] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain",
"presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging
Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r16" ] }, "us-
gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } }
}, "auth_ref": [ "r16" ] }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/LeasesNarrativeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impaired Long-Lived Assets Held and Used, Asset
Name [Domain]", "label": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]", "documentation": "The name of the impaired assets to be held and used by the
entity." } } }, "auth_ref": [ "r54" ] }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ImpairedLongLivedAssetsHeldAndUsedByTypeAxis", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails",
"http://www.healthcatalyst.com/role/LeasesNarrativeDetails", "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Impaired Long-Lived Assets Held and Used by Type [Axis]", "label": "Impaired Long-Lived Assets Held and Used by Type [Axis]", "documentation": "Information
by type of impaired long-lived asset held and used." } } }, "auth_ref": [ "r54" ] }, "us-gaap_IncomeLossAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeLossAttributableToParent", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 },
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label":
"Income (Loss) Attributable to Parent, before Tax", "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss)
from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": [ "r110", "r249" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]",
"label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income
where disaggregated amount has been reported." } } }, "auth_ref": [ "r425", "r432", "r435", "r644", "r648", "r653", "r819", "r821", "r885", "r940", "r997", "r1223" ] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where
disaggregated amount has been reported." } } }, "auth_ref": [ "r432", "r435", "r644", "r648", "r653", "r819", "r821", "r885", "r940", "r997", "r1223" ] }, "us-
gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": {
"role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]",
"documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r260", "r588", "r592", "r593", "r594", "r595", "r596", "r599", "r603", "r605", "r606", "r607",
"r838", "r993" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit",
"crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0,
"order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Income
tax provision (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense
(benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r167", "r179", "r278", "r279", "r299", "r313", "r335", "r591", "r592", "r604", "r797", "r993" ] }, "us-
gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes",
"label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for
recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit
carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial
statements." } } }, "auth_ref": [ "r246", "r589", "r590", "r596", "r597", "r598", "r600", "r835" ] },
"hcat_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930",
"localname": "IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 12.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts
payable, accrued liabilities, and other liabilities", "label": "Increase (Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities", "documentation": "Increase
(Decrease) In Accounts Payable, Accrued Liabilities, And Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0,
"order": 7.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due
within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-
gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase
(Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which
consideration has been received or is receivable." } } }, "auth_ref": [ "r732", "r1069" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities:",
"label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "hcat_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.healthcatalyst.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating
lease liabilities", "label": "Increase (Decrease) In Operating Lease Liabilities", "documentation": "Increase (Decrease) In Operating Lease Liabilities" } } }, "auth_ref": [] },
"hcat_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname":
"IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows":
{ "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash operating lease expense",
"label": "Increase (Decrease) In Operating Lease, Right-Of-Use Assets", "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Assets" } } }, "auth_ref": [] },
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0,
"order": 16.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid
expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase (Decrease) in
Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept
from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible
assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This
accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such
assets." } } }, "auth_ref": [ "r733", "r734", "r735", "r737", "r950", "r1120" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets,
Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated
amortization and impairment charges." } } }, "auth_ref": [ "r411", "r1128", "r1129" ] }, "hcat_InterestAndOtherExpenseNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "InterestAndOtherExpenseNet", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0,
"order": 7.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Interest and other income (expense), net", "label": "Interest And Other Expense, Net", "documentation": "Interest And Other Expense, Net" } } },
"auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit",
"calculation": { "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label":
"Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost
of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r299", "r305", "r309", "r315", "r335", "r672", "r960", "r961" ] }, "us-gaap_InterestExpenseDebt": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 1.0 } },
```

```
"presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r112", "r482", "r492", "r974", "r975" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income (expense), net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r960", "r1066", "r1082" ] }, "hcat_InterestRateTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "InterestRateTermLoanMember", "presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Term Loan", "label": "Interest Rate Term Loan [Member]", "documentation": "Interest Rate Term Loan" } } }, "auth_ref": [] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/ShorttermInvestmentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest receivable", "label": "Interest Receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r1060", "r1256" ] }, "us-gaap_InternalUseSoftwarePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalUseSoftwarePolicy", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": {
"en-us": { "role": { "terseLabel": "Development costs and internal-use software", "label": "Internal Use Software, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally." } } }, "auth_ref": [ "r423" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r795", "r831", "r832", "r833", "r834", "r910", "r911" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/ShorttermInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r157", "r181", "r346", "r347", "r660", "r661", "r1215" ] }, "hcat_KPINinjaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "KPINinjaMember", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "KPI Ninja", "label": "KPI Ninja [Member]", "documentation": "KPI Ninja" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r683", "r1006" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Expense (Income)", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1204" ] },
"hcat_LeaseholdImprovementsAndFurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "LeaseholdImprovementsAndFurnitureAndFixturesMember", "presentation": [ "http://www.healthcatalyst.com/role/LeasesNarrativeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements And Furniture And Fixtures", "label": "Leasehold Improvements And Furniture And Fixtures [Member]", "documentation": "Leasehold Improvements And Furniture And Fixtures" } } },
"auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeaseholdImprovementsMember", "presentation": [ "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r124", "r688" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "hcat_LessAdjustedGrossProfitreconcilingitemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "LessAdjustedGrossProfitreconcilingitemsAbstract", "presentation": [
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less Adjusted Gross Profit reconciling items:", "label": "Less Adjusted Gross Profit reconciling items [Abstract]", "documentation": "Less Adjusted Gross Profit reconciling items [Abstract]" } } },
"auth_ref": [] }, "hcat_LessOtherReconcilingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname":
"LessOtherReconcilingItemsAbstract", "presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less other reconciling items:", "label": "Less Other Reconciling Items [Abstract]", "documentation": "Less Other Reconciling Items [Abstract]" } } },
"auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.healthcatalyst.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r682", "r689" ] }, "us-
gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://www.healthcatalyst.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r682", "r689" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r681" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.healthcatalyst.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1203" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r677" ] }, "us-gaap_Liabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [
"r24", "r90", "r91", "r92", "r96", "r97", "r98", "r99", "r259", "r379", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r622", "r623", "r624", "r662", "r856", "r953", "r1033", "r1148", "r1206", "r1207" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r106", "r153", "r784", "r1007", "r1072", "r1105", "r1198" ] }, "us-
gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r92", "r226", "r259", "r379", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r622", "r623", "r624", "r662", "r1007",
"r1148", "r1206", "r1207" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel":
"Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails", "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [
"r450", "r1071", "r1146" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } }
}, "auth_ref": [ "r89", "r95" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityTable", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails", "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r89", "r95", "r450", "r1071", "r1146" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unutilized commitment percentage", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditMember", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-
gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Litigation settlement, amount", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to
other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation charges", "label": "Litigation Settlement,
Fee Expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r1048" ] },
"us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": [
"http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status
[Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1133", "r1134", "r1135", "r1141" ] }, "us-
gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": [
"http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation
Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1133", "r1134", "r1135", "r1141" ] }, "dei_LocalPhoneNumber":
{ "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local
phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebt", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root":
true } }, "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails", "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": {
"en-us": { "role": { "totalLabel": "Net carrying amount", "terseLabel": "Net carrying amount", "label": "Long-Term Debt", "documentation": "Amount, after deduction of
unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r24", "r151", "r475", "r491", "r972", "r973",
"r1005", "r1218" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent",
"crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 },
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets", "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": {
"verboseLabel": "Current portion of long-term debt", "negatedTerseLabel": "Less: Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities",
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } }
}, "auth_ref": [ "r234" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Estimated fair value of convertible senior notes", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt
whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures
required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref":
[ "r1183", "r1185", "r1186", "r1187" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0,
"order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are
redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r265", "r480" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0,
"order": 6.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are
redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r265", "r480" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0,
"order": 4.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are
redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r265", "r480" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are
redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r265", "r480" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0,
"order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are
redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r265", "r480" ] }, "us-
gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0,
"order": 5.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/DebtScheduleofPrincipalPaymentsandDebtMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"2024", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities
issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r1074" ] }, "us-
gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit",
"calculation": { "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 },
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets", "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Long-term debt, net of current portion", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized
premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r235" ] }, "us-
gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails",
"http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [
"r24", "r1133", "r1134", "r1135" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongtermDebtTypeDomain", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/DebtScheduleofComponentsofInterestExpenseDetails", "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label":
"Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project
financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal
operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r57", "r1133", "r1134", "r1135" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [
"http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss
Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r443", "r444", "r445", "r448", "r585", "r970", "r1142", "r1143" ] }, "us-
gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [
"http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss
Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase
obligation." } } }, "auth_ref": [ "r443", "r444", "r445", "r448", "r585", "r970", "r1142", "r1143" ] }, "hcat_LumeonLtd.Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "LumeonLtd.Member", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
"http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails",
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lumeon", "label": "Lumeon Ltd.
[Member]", "documentation": "Lumeon Ltd." } } }, "auth_ref": [] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]",
"documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r330", "r333",
"r336", "r960", "r961" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/LeasesNarrativeDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r183", "r185", "r187", "r188", "r190", "r220", "r221",
"r444", "r445", "r446", "r447", "r540", "r585", "r642", "r731", "r818", "r820", "r829", "r848", "r849", "r908", "r912", "r914", "r915", "r921", "r937", "r938", "r966", "r976",
```

```
"r989", "r998", "r999", "r1003", "r1004", "r1018", "r1150", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213" ] }, "us-gaap_MeasurementInputEbitdaMultipleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputEbitdaMultipleMember", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, EBITDA Multiple", "label": "Measurement Input, EBITDA Multiple [Member]", "documentation": "Measurement input using earnings before interest, tax, depreciation and amortization (EBITDA) multiple." } } }, "auth_ref": [ "r998", "r1185", "r1186", "r1187" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected Term (years)", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r1185", "r1186", "r1187" ] }, "us-gaap_MeasurementInputQuotedPriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputQuotedPriceMember", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market Price of Revenue Risk", "label": "Measurement Input, Quoted Price [Member]", "documentation": "Measurement input using quoted price." } } }, "auth_ref": [ "r1185", "r1186", "r1187" ] }, "us-gaap_MeasurementInputRevenueMultipleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRevenueMultipleMember", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Volatility", "label": "Measurement Input, Revenue Multiple [Member]", "documentation": "Measurement input using market valuation of entity divided by revenue." } } }, "auth_ref": [ "r998", "r1185", "r1186", "r1187" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r1185", "r1186", "r1187" ] }, "hcat_MeasurementInputTotalShareholderReturnMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "MeasurementInputTotalShareholderReturnMember", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Total Shareholder Return", "label": "Measurement Input, Total Shareholder Return [Member]", "documentation": "Measurement Input, Total Shareholder Return" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r640", "r641", "r642", "r998" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r640", "r641", "r642", "r998" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails", "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails", "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails", "http://www.healthcatalyst.com/role/LeasesNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "verboseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r183", "r185", "r187", "r188", "r190", "r220", "r221", "r444", "r445", "r446", "r447", "r540", "r585", "r642", "r731", "r818", "r820", "r829", "r848", "r849", "r908", "r912", "r914", "r915", "r921", "r937", "r938", "r966", "r976", "r989", "r998", "r999", "r1003", "r1018", "r1150", "r1208", "r1209", "r1210", "r1211", "r1212", "r1213" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Money market funds", "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1153" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment, borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r255" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r255" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r118", "r119", "r120" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 }, "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 }, "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations", "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r110", "r120", "r156", "r224", "r241", "r244", "r249", "r259", "r269", "r271", "r272", "r273", "r274", "r275", "r278", "r279", "r289", "r379", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r611", "r620", "r636", "r662", "r789", "r878", "r898", "r899", "r1031", "r1148" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r254", "r271", "r272", "r273", "r274", "r281", "r282", "r290", "r293", "r620" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r254", "r283", "r285", "r286", "r287", "r288", "r290", "r293" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent accounting pronouncements not yet adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of intangible assets included in
```

accounts payable and accrued liabilities", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r34", "r35", "r36"] }, "us-gaap_NonrecurringAdjustmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrecurringAdjustmentAxis", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Nonrecurring Adjustment [Axis]", "label": "Nonrecurring Adjustment [Axis]", "documentation": "Information by nonrecurring adjustment directly attributable to business combination included in pro forma revenue and earnings." } } }, "auth_ref": ["r20"] }, "us-gaap_NonrecurringAdjustmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrecurringAdjustmentDomain", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Nonrecurring Adjustment [Domain]", "label": "Nonrecurring Adjustment [Domain]", "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": ["r20"] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://www.healthcatalyst.com/role/SegmentsNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Number of operating segments", "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r961", "r1081"] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsNarrativeDetails", "http://www.healthcatalyst.com/role/SegmentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r955", "r965", "r1081"] }, "hcat_OneTimeTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "OneTimeTechnologyMember", "presentation": ["http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails"], "lang": { "en-us": { "role": { "terseLabel": "One-time technology (i.e., perpetual license)", "label": "One-Time Technology [Member]", "documentation": "One-Time Technology" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r161", "r954", "r1080", "r1082", "r1083", "r1084", "r1085"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r684", "r1006"] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/LeasesNarrativeDetails", "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Impairment of long-lived assets", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": ["r1202"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r680"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r680"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r679"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": ["http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r329", "r330", "r331", "r332", "r333", "r336", "r960", "r961"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails": { "parentTag": "hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r91"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r232"] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Change in foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r4", "r790"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r15", "r22", "r242", "r245", "r250", "r275", "r665", "r666", "r671", "r772", "r790", "r1063", "r1064"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Change in net unrealized gains (losses) on available for sale investments", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r239", "r240", "r378"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r97"] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringCosts", "crdr": "debit", "calculation": {

```
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails": { "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Restructuring Costs", "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r116" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r434", "r1068" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of deferred financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r31" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of businesses, net of cash acquired", "terseLabel": "Acquisition of businesses, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r29" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r115" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of short-term investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r114" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r115" ] }, "us-gaap_PhantomShareUnitsPSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PhantomShareUnitsPSUsMember", "presentation": [ "http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Performance-based restricted stock units", "terseLabel": "Performance-based restricted stock units", "label": "Phantom Share Units (PSUs) [Member]", "documentation": "Share-based payment arrangement awarded as phantom share or unit." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in USD per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r100", "r494" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r100", "r858" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r100", "r494" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r100", "r858", "r876", "r1254", "r1255" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of September\u00a030, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r100", "r781", "r1007" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1062" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of debt", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r1067" ] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of long-term debt, net of issuance costs", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from employee stock purchase plan", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": [ "r5", "r21" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale and maturity of short-term investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r113" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": {
```

```
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r5", "r21" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": [ "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Information [Line Items]", "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
"http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r197", "r219", "r339", "r736", "r809", "r810", "r811", "r812", "r813", "r814", "r817", "r942", "r977", "r1017", "r1018", "r1022", "r1023", "r1058", "r1144", "r1145", "r1152", "r1220", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
"http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r197", "r219", "r339", "r736", "r809", "r810", "r811", "r812", "r813", "r814", "r817", "r942", "r977", "r1017", "r1018", "r1019", "r1022", "r1023", "r1058", "r1144", "r1145", "r1152", "r1220", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251" ] }, "hcat_ProfessionalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ProfessionalServicesMember", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails",
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails",
"http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Professional services", "terseLabel": "Professional Services", "label": "Professional Services [Member]", "documentation": "Professional Services [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9", "r688" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/PropertyandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r123", "r171", "r176", "r177" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r124", "r228", "r788" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r688" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 },
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets",
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r688", "r776", "r788", "r1007" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r171", "r176", "r786" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables",
"http://www.healthcatalyst.com/role/PropertyandEquipmentTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Property and Equipment, Useful Life", "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r124", "r688" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, useful life (in years)", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesAllowanceForCreditLossesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Provision for expected credit losses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r253", "r386" ] }, "us-gaap_ProvisionForLoanLossesExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForLoanLossesExpensed", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for expected credit losses", "label": "Financing Receivable, Credit Loss, Expense (Reversal)", "documentation": "Amount of credit loss expense (reversal of expense) for financing receivable." } } }, "auth_ref": [ "r386", "r771" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails",
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/LeasesNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r183", "r185", "r187", "r188", "r190", "r220", "r221", "r444", "r445", "r446", "r447", "r532", "r540", "r571", "r572", "r573", "r585", "r642", "r705", "r714", "r731", "r818", "r820", "r829", "r848", "r849", "r908", "r912", "r914", "r915", "r921", "r937", "r938", "r966", "r976", "r989", "r998", "r999", "r1003", "r1004", "r1018", "r1025", "r1136", "r1150", "r1186", "r1209", "r1210", "r1211", "r1212", "r1213" ] },
"srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails",
```

```
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails",
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/LeasesNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum,
maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r183", "r185", "r187", "r188", "r190", "r220", "r221", "r444", "r445", "r446", "r447", "r532",
"r540", "r571", "r572", "r573", "r585", "r642", "r705", "r714", "r731", "r818", "r820", "r829", "r848", "r849", "r908", "r912", "r914", "r915", "r921", "r937", "r938", "r966",
"r976", "r989", "r998", "r999", "r1003", "r1004", "r1018", "r1025", "r1136", "r1150", "r1186", "r1209", "r1210", "r1211", "r1212", "r1213" ] },
"us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/SegmentsTables" ], "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Segment Adjusted Gross Profit", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
"documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and
discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r49", "r50" ]
}, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails",
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Revenue from
Segments to Consolidated [Table]", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Disclosure of information about
identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated
revenues." } } }, "auth_ref": [ "r48", "r50" ] }, "hcat_RecurringTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930",
"localname": "RecurringTechnologyMember", "presentation": [ "http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Recurring technology", "label": "Recurring Technology [Member]", "documentation": "Recurring Technology [Member]" } } },
"auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.healthcatalyst.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties
[Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under
equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate
interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r344", "r539", "r694", "r695", "r779", "r785", "r851", "r852", "r853", "r854",
"r855", "r875", "r877", "r907" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyMember", "presentation": [ "http://www.healthcatalyst.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label":
"Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity
method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r261", "r262", "r694", "r695", "r696",
"r697", "r779", "r785", "r851", "r852", "r853", "r854", "r855", "r875", "r877", "r907" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transactions", "label": "Related Party Transaction,
Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r86", "r694" ] }, "us-
gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems",
"presentation": [ "http://www.healthcatalyst.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label":
"Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r344", "r881", "r882", "r885" ] }, "us-
gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": {
"en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.healthcatalyst.com/role/RelatedPartiesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not
limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of
immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [
"r344", "r539", "r694", "r695", "r779", "r785", "r851", "r852", "r853", "r854", "r855", "r875", "r877", "r907", "r1205" ] }, "us-
gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/RelatedParties" ], "lang": { "en-us": { "role": { "terseLabel": "Related
Parties", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party
transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d)
affiliates." } } }, "auth_ref": [ "r691", "r692", "r693", "r695", "r698", "r839", "r840", "r841", "r883", "r884", "r885", "r904", "r906" ] }, "us-gaap_RepaymentsOfOtherDebt": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherDebt", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0,
"order": 6.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel":
"Repayment of seller-financed debt", "label": "Repayments of Other Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other." } } },
"auth_ref": [ "r117" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation":
[ "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit
[Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r409", "r410", "r968" ] }, "us-gaap_ReportingUnitDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": [
"http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit
[Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r409", "r410", "r968" ] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction.
Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r217", "r218", "r263", "r264", "r466", "r496", "r697", "r715", "r777", "r947",
"r948" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": {
"parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0, "order": 1.0 }, "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations":
{ "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development",
"negatedTerseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development.
Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in
transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint
venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r587", "r940", "r960", "r1214" ] }, "us-
gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the
reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted shares", "label": "Restricted Stock
[Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified
performance conditions are met." } } }, "auth_ref": [ "r37" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of
cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label":
"Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0,
"order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Restructuring costs", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an
authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r8", "r437", "r438", "r1137" ] }, "us-
gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis",
"presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r433", "r434", "r438",
"r439" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringCostAndReserveLineItems", "presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in
a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r433",
"r434", "r435", "r436", "r438", "r439", "r440" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringCosts", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Severance and other restructuring costs", "label": "Restructuring Costs", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal
```

activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r8"] }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r8"] }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/RestructuringCosts"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Costs", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails"], "lang": { "en-us": { "role": {
"periodStartLabel": "Beginning, balance", "periodEndLabel": "Ending, balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r434", "r439"] }, "us-gaap_RestructuringReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveCurrent", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails": {
"parentTag": "hcat_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/AccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring liabilities", "label": "Restructuring Reserve, Current", "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": ["r1059", "r1138", "r1139"] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r103", "r136", "r783", "r826", "r828", "r837", "r859", "r1007"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r222", "r266", "r267", "r268", "r270", "r275", "r277", "r279", "r380", "r381", "r424", "r601", "r602", "r608", "r609", "r610", "r612", "r619", "r620", "r626", "r628", "r629", "r631", "r634", "r676", "r678", "r822", "r824", "r842", "r1254"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/RevenueScheduleofRevenueDisaggregatedbyTypeofArrangementDetails",
"http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue", "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r159", "r160", "r299", "r306", "r307", "r329", "r335", "r339", "r341", "r343", "r528", "r529", "r736"] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [
"http://www.healthcatalyst.com/role/RevenueNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r343", "r1041"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r180", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r941"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligations", "http://www.healthcatalyst.com/role/Revenue"], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "verboseLabel": "Deferred Revenue and Performance Obligations", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r180", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r531"] }, "hcat_RevenueFromSubscriptionContractTermofContract": { "xbrltype": "durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "RevenueFromSubscriptionContractTermofContract", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subscription contract, term", "label": "Revenue From Subscription Contract, Term of Contract", "documentation": "Revenue From Subscription Contract, Term of Contract" } } }, "auth_ref": [] }, "hcat_RevenueFromSubscriptionsContractNoticeRequiredForTermination": { "xbrltype": "durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "RevenueFromSubscriptionsContractNoticeRequiredForTermination", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subscription contracts, days notice of termination", "label": "Revenue From Subscriptions Contract, Notice Required For Termination", "documentation": "Revenue From Subscriptions Contract, Notice Required For Termination" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue remaining performance obligation amount", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r174"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": ["http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligation, period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r175"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": ["http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": ["r175"] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [
"http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligation (in percentage)", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": ["r1040"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "hcat_RightOfUseAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "RightOfUseAssetMember", "presentation": ["http://www.healthcatalyst.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right Of Use Asset", "label": "Right Of Use Asset [Member]", "documentation": "Right Of Use Asset" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r687", "r1006"] },
"hcat_RightOfUseAssetsLeaseholdImprovementsAndFurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "RightOfUseAssetsLeaseholdImprovementsAndFurnitureAndFixturesMember", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.healthcatalyst.com/role/LeasesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Right Of Use Assets Leasehold Improvements And Furniture And Fixtures", "label": "Right Of Use Assets Leasehold Improvements And Furniture And Fixtures [Member]", "documentation": "Right Of Use Assets Leasehold Improvements And Furniture And Fixtures" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/AccruedLiabilitiesTables"], "lang": { "en-us": { "role": { "terseLabel":

"Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r37"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share Totals With a Potentially Dilutive Impact", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r37"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails", "http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": ["r67", "r69", "r615"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.healthcatalyst.com/role/DebtTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r24", "r58", "r59", "r87", "r133", "r135", "r972", "r974", "r1074", "r1199"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of The Calculation of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r1079"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails", "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r411", "r418", "r420", "r421", "r422", "r737", "r940", "r969"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesTables", "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Asset, Useful Life", "verboseLabel": "Schedule of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r969", "r1127"] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": ["http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": ["r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r968"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill by Reporting Unit", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r968", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/DebtTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Principal Payments and Debt Maturity", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r10"] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": ["http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Products and Services [Table]", "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails", "http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails", "http://www.healthcatalyst.com/role/PropertyandEquipmentNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r9", "r688"] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/BusinessCombinationsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": ["r145"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.healthcatalyst.com/role/RelatedPartiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r85", "r86", "r881", "r882", "r885"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails", "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r433", "r434", "r435", "r436", "r438", "r439", "r440"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": ["r55", "r125", "r126"] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring-Related Charges and Related Liability", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": ["r56", "r127"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.healthcatalyst.com/role/SegmentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Revenue", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r45", "r46", "r47"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r542", "r544", "r546", "r547", "r548", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r571", "r572", "r573", "r574"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding RSUs and Related Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average

grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r137"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Information Related to Stock Options", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r17", "r18", "r137"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Stock Purchase Plan", "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r139"] }, "hcat_ScheduleOfTheEffectsOfTheTenderOfferRepurchasePriceOverTheEstimatedFairValueOfTheCommonStockRedeemedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ScheduleOfTheEffectsOfTheTenderOfferRepurchasePriceOverTheEstimatedFairValueOfTheCommonStockRedeemedLineItems", "presentation": ["http://www.healthcatalyst.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Line Items]", "label": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Line Items]", "documentation": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed" } } }, "auth_ref": [] }, "hcat_ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable": { "xbrltype": "stringItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ScheduleoftheEffectsoftheTenderOfferRepurchasePriceOvertheEstimatedFairValueoftheCommonStockRedeemedTable", "presentation": ["http://www.healthcatalyst.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]", "label": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]", "documentation": "Schedule of the Effects of the Tender Offer Repurchase Price Over the Estimated Fair Value of the Common Stock Redeemed [Table]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r1034"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.healthcatalyst.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r1036"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails", "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r159", "r160", "r161", "r162", "r299", "r302", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r317", "r319", "r320", "r321", "r329", "r330", "r331", "r332", "r333", "r335", "r336", "r337", "r343", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r422", "r436", "r440", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r957", "r960", "r961", "r968", "r1021", "r1220", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.healthcatalyst.com/role/RevenueNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r184", "r186", "r189", "r191", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r341", "r342", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r844", "r845", "r846", "r909", "r913", "r916", "r922", "r925", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r943", "r978", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1020", "r1025", "r1152", "r1220", "r1224", "r1225", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.healthcatalyst.com/role/Segments"], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r162", "r299", "r301", "r302", "r303", "r304", "r305", "r318", "r320", "r321", "r333", "r334", "r335", "r336", "r337", "r339", "r340", "r343", "r955", "r958", "r959", "r960", "r962", "r964", "r965"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r322", "r323", "r324", "r325", "r326", "r327", "r328", "r338", "r341", "r956", "r957", "r963"] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": ["http://www.healthcatalyst.com/role/SegmentsScheduledofSegmentRevenueDetails", "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails": { "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations", "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "negatedTerseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r111"] }, "hcat_SeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "SeniorNotesDue2025Member", "presentation": ["http://www.healthcatalyst.com/role/DebtNarrativeDetails", "http://www.healthcatalyst.com/role/DebtScheduleofDebtDetails", "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes Due 2025", "label": "Senior Notes Due 2025 [Member]", "documentation": "Senior Notes Due 2025" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": ["http://www.healthcatalyst.com/role/NetLossPerShareScheduleofShareTotalswithaPotentiallyDilutiveImpactDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares related to convertible senior notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": ["http://www.healthcatalyst.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation", "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": ["r1141"] }, "hcat_SeveranceAndOtherTeamMemberCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "SeveranceAndOtherTeamMemberCostsMember", "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails", "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance And Other Team Member Costs", "label": "Severance And Other Team Member Costs [Member]", "documentation": "Severance And Other Team Member Costs" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails": { "parentTag": "us-gaap_RestructuringCostsAndAssetImpairmentCharges", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance and Other Team Member Costs", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r8"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r7"] }, "hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcquisitionDateAnniversaryReleaseOfSharesPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcquisitionDateAnniversaryReleaseOfSharesPeriod", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Release of shares, period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Acquisition Date Anniversary, Release of Shares, Period", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Acquisition Date Anniversary, Release of Shares, Period" } } }, "auth_ref": [] }, "hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardMeasurementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardMeasurementPeriod", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Measurement Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Measurement Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [
"http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Service period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r990"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cliff vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r990"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r563"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r563"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r561"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r561"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested and outstanding, beginning balance (in shares)", "periodEndLabel": "Unvested and outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r558", "r559"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested and outstanding, beginning balance, grant date fair value (in USD per share)", "periodEndLabel": "Unvested and outstanding, ending balance, grant date fair value (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r558", "r559"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r562"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r562"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "crdr": "debit", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Expected dividends", "terseLabel": "Expected dividends", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments", "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends." } } }, "auth_ref": ["r572"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Expected volatility", "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r571"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r573"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [

```
"http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails",
"http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award
[Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r542", "r544", "r546", "r547", "r548", "r550", "r551", "r552", "r553", "r554", "r555", "r556",
"r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r571", "r572", "r573", "r574" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum employee subscription rate", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual
salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r62" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in
shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of
additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-
based payment arrangement." } } }, "auth_ref": [ "r991" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for grant (in shares)", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum
number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of
shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for
issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r62" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable (in shares)",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or
partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r552" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and
exercisable (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options
outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r552" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr":
"debit", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares exercised in
period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of
accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } },
"auth_ref": [ "r565" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Options cancelled/forfeited (in
shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For
presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event
specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1160" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options cancelled/forfeited (in USD per
share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
"documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1160" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units)
granted during the period." } } }, "auth_ref": [ "r554" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP share increase in period (in shares)",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period", "documentation": "The addition or
reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and
expirations during the reporting period." } } }, "auth_ref": [ "r1160" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option shares outstanding, aggregate
intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by
which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r62" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning (in
shares)", "periodEndLabel": "Outstanding, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding,
Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r550", "r551" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Time-Based Option Shares", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a
concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding,
beginning balance (in USD per share)", "periodEndLabel": "Outstanding, ending balance (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-
Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved
for issuance under the stock option plan." } } }, "auth_ref": [ "r550", "r551" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option shares vested and expected to
vest, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding,
Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options
outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of
performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r566" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
"presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected
to vest, outstanding (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding,
Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited
to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are
recognized when they occur." } } }, "auth_ref": [ "r566" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [
```

```
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r566" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award, per share weighted average price of shares purchased (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased", "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award, shares issued in period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r62" ] }, "hcat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Stock Plan Offering Period" } } }, "auth_ref": [] }, "hcat_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumPurchaseValueDuringOfferingPeriodPerEmployee", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum purchase value during offering period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee", "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Maximum Purchase Value During Offering Period, Per Employee" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationEffectofStockbasedCompensationExpenseonStatementofOperationsDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r546", "r547", "r548", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r570", "r571", "r572", "r573", "r574" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in USD per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r555" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period one", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period three", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r541", "r549", "r568", "r569", "r570", "r571", "r574", "r580", "r581", "r582", "r583" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in USD per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "hcat_ShareRepurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ShareRepurchasePlanMember", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Plan", "label": "Share Repurchase Plan [Member]", "documentation": "Share Repurchase Plan" } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1151" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1151" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percent", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r1154" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationRestrictedStockUnitandPhantomShareUnitsPSUsActivityDetails", "http://www.healthcatalyst.com/role/StockBasedCompensationScheduleofthePurchaseRightfortheESPPOptionAssumptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected term (in years)", "terseLabel": "Expected term (in months)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r570" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option shares vested and exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r62" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable, weighted average remaining contractual life in years", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r62" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option shares outstanding, weighted average remaining contractual life in years", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r138" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest, weighted average remaining contractual life in years", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r566" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total grant-date fair value of stock options vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options
```

```
vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r565" ] },
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of common stock (in percentage)",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common
stock expressed as a percentage of its fair value." } } }, "auth_ref": [] },
"hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed": { "xbrltype": "sharesItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardMaximumPurchasedSharesAllowed",
"presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator of lowest purchase
of a participant (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed", "documentation":
"Share-based Compensation Arrangement by Share-based Payment Award, Maximum Purchased Shares Allowed" } } }, "auth_ref": [] },
"hcat_SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares": { "xbrltype": "percentItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname":
"SharebasedCompensationArrangementbySharebasedPaymentAwardPercentageIncreaseOfTheNumberOfCommonStockShares", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage increase of the number of common
stock shares (in percentage)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock
Shares", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Increase Of The Number Of Common Stock Shares" } } },
"auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [
"http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Shares, Issued",
"documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now
held in the treasury." } } }, "auth_ref": [ "r15" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharesOutstanding", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in
shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-
gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation":
{ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term
Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments
classified as other and current." } } }, "auth_ref": [ "r154", "r155", "r1061" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": {
"http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term
lease expense", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } },
"auth_ref": [ "r685", "r1006" ] }, "hcat_ShortTermMarketableSecurityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930",
"localname": "ShortTermMarketableSecurityMember", "presentation": [
"http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails",
"http://www.healthcatalyst.com/role/ShorttermInvestmentsShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Investments", "label":
"Short Term Marketable Security [Member]", "documentation": "Short Term Marketable Security [Member]" } } }, "auth_ref": [] }, "us-
gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer software",
"verboseLabel": "Computer software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally
developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SoftwareDevelopmentMember", "presentation": [
"http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofPropertyandEquipmentUsefulLifeDetails",
"http://www.healthcatalyst.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Capitalized internal-
use software costs", "terseLabel": "Capitalized internal-use software costs", "label": "Software Development [Member]", "documentation": "Internally developed software for
sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentRevenueDetails",
"http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label":
"Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r159", "r160", "r161", "r162", "r223", "r299", "r302", "r305", "r306", "r307",
"r308", "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r317", "r319", "r320", "r321", "r329", "r330", "r331", "r332", "r333", "r335", "r336", "r337", "r343", "r400",
"r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r422", "r426", "r436", "r440", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807",
"r808", "r957", "r960", "r961", "r968", "r1021", "r1220", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236",
"r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251" ] }, "us-
gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis",
"presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity
Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r101", "r104", "r105", "r222",
"r247", "r248", "r249", "r266", "r267", "r268", "r270", "r275", "r277", "r279", "r300", "r380", "r381", "r424", "r508", "r601", "r602", "r608", "r609", "r610", "r612", "r619",
"r620", "r626", "r627", "r628", "r629", "r630", "r631", "r634", "r665", "r667", "r668", "r669", "r670", "r671", "r676", "r678", "r690", "r790", "r822", "r823", "r824", "r842",
"r900" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.healthcatalyst.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]",
"documentation": "Information by geographical components." } } }, "auth_ref": [ "r184", "r186", "r189", "r191", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205",
"r206", "r207", "r341", "r342", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756",
"r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r844", "r845", "r846", "r909", "r913", "r916", "r922", "r925", "r928", "r929",
"r930", "r931", "r932", "r933", "r934", "r935", "r936", "r943", "r978", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1020", "r1025", "r1152",
"r1220", "r1224", "r1225", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242",
"r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label":
"Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r266", "r267", "r268", "r300", "r678", "r736", "r831", "r843", "r850", "r851",
"r852", "r853", "r854", "r855", "r858", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r871", "r872", "r873", "r874", "r875", "r877", "r879", "r880",
"r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r900", "r1026" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows
[Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]",
"label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of
Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label":
"Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash
flows, and shareholders' equity." } } }, "auth_ref": [ "r266", "r267", "r268", "r300", "r344", "r678", "r736", "r831", "r843", "r850", "r851", "r852", "r853", "r854", "r855", "r858",
"r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r871", "r872", "r873", "r874", "r875", "r877", "r879", "r880", "r886", "r887", "r888", "r889", "r890",
"r891", "r892", "r893", "r894", "r895", "r896", "r897", "r900", "r1026" ] }, "hcat_StockIncentivePlan2011Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.healthcatalyst.com/20240930", "localname": "StockIncentivePlan2011Member", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2011 Stock Incentive Plan", "label": "Stock
Incentive Plan 2011 [Member]", "documentation": "Stock Incentive Plan 2011 [Member]" } } }, "auth_ref": [] }, "hcat_StockIncentivePlan2019Member": { "xbrltype":
"domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "StockIncentivePlan2019Member", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Stock Incentive Plan", "label": "Stock
Incentive Plan 2019 [Member]", "documentation": "Stock Incentive Plan 2019" } } }, "auth_ref": [] }, "hcat_StockIncentivePlanMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.healthcatalyst.com/20240930", "localname": "StockIncentivePlanMember", "presentation": [
"http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Incentive Plan", "label": "Stock Incentive
Plan [Member]", "documentation": "Stock Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related
to acquisitions (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to
acquisitions." } } }, "auth_ref": [ "r100", "r101", "r136" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under
employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "documentation": "Number of shares of capital
stock issued (purchased by employees) in connection with an employee stock ownership plan." } } }, "auth_ref": [ "r15", "r65", "r100", "r101", "r136" ] }, "us-
gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units
and restricted shares (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued
during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r15", "r100", "r101", "r136" ] }, "us-
gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
"http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)",
```

```
"negatedTerseLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r100", "r101", "r136", "r555" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to acquisitions", "verboseLabel": "Common stock issued in connection with acquisitions", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r15", "r101", "r104", "r105", "r136" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r15", "r100", "r101", "r136" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r101", "r104", "r105", "r136" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share repurchase plan, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1151" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, remaining authorized repurchase amount", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r15", "r100", "r101", "r136", "r836", "r900", "r923" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r15", "r100", "r101", "r136", "r842", "r900", "r923", "r1032" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets", "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r101", "r104", "r105", "r122", "r860", "r876", "r901", "r902", "r1007", "r1033", "r1072", "r1105", "r1198", "r1254" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r132", "r258", "r493", "r495", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r507", "r508", "r633", "r903", "r905", "r924" ] }, "hcat_StockholdersVote": { "xbrltype": "integerItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "StockholdersVote", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders vote", "label": "Stockholders Vote", "documentation": "Stockholders Vote" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "calculation": {
"http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.healthcatalyst.com/role/LeasesScheduleofSupplementalBalanceSheetInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r686", "r1006" ] }, "hcat_TechnologyAndProfessionalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "TechnologyAndProfessionalServicesMember", "presentation": [ "http://www.healthcatalyst.com/role/DeferredRevenueandPerformanceObligationsNarrativeDetails", "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology and professional services", "label": "Technology And Professional Services [Member]", "documentation": "Technology And Professional Services [Member]" } } }, "auth_ref": [] }, "hcat_TechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "TechnologyMember", "presentation": [ "http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations", "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofGoodwillbyReportingUnitDetails", "http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails", "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentRevenueDetails", "http://www.healthcatalyst.com/role/SegmentsScheduleofSegmentAdjustedGrossProfitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Technology", "terseLabel": "Technology", "label": "Technology [Member]", "documentation": "Technology [Member]" } } }, "auth_ref": [] }, "hcat_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "TermLoanMember", "presentation": [ "http://www.healthcatalyst.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "hcat_TotalProFormaAdjustmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "TotalProFormaAdjustmentsMember", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsUnauditedProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total pro forma adjustments", "label": "Total Pro Forma Adjustments [Member]", "documentation": "Total Pro Forma Adjustments" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r163", "r164", "r165", "r1087", "r1088", "r1089" ] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [ "http://www.healthcatalyst.com/role/BusinessCombinationsNarrativeDetails", "http://www.healthcatalyst.com/role/BusinessCombinationsScheduleofRecognizedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLifeDetails", "http://www.healthcatalyst.com/role/GoodwillandIntangibleAssetsScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trademarks", "terseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r72", "r969", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1128", "r1129", "r1130", "r1131" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.healthcatalyst.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r487", "r506", "r632", "r659", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r791", "r994", "r996", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1008", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1101", "r1102", "r1103", "r1104", "r1182", "r1185", "r1186", "r1187", "r1194", "r1197" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock acquired, average cost per share (in USD per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r61" ] }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, retired, cost method, amount", "label": "Treasury Stock, Retired, Cost Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": [ "r15", "r60", "r101" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares, acquired (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r15", "r101", "r136" ] }, "us-gaap_TreasuryStockSharesRetired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesRetired", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares, retired (in shares)", "label": "Treasury Stock, Shares, Retired", "documentation": "Number of shares of common and preferred stock retired from treasury during the period." } } }, "auth_ref": [ "r15", "r101", "r136" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, value, acquired, cost method", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r15", "r61", "r136" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [
```

```
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringCostsDetails",
"http://www.healthcatalyst.com/role/RestructuringCostsScheduleofRestructuringRelatedChargesandRelatedLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r433", "r434", "r438", "r439" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [
"http://www.healthcatalyst.com/role/RevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "UNITED STATES", "label": "UNITED STATES" } } }, "auth_ref": [] },
"us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"USGovernmentAgenciesDebtSecuritiesMember", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. agency securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r951", "r984", "r1216" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsScheduleofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
"http://www.healthcatalyst.com/role/ShorttermInvestmentsCashEquivalentsandShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "U.S. treasury notes", "terseLabel": "U.S. Treasury notes", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r951", "r984", "r986", "r994", "r1216" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates",
"presentation": [ "http://www.healthcatalyst.com/role/DescriptionofBusinessandSummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel":
"Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r42", "r43", "r44", "r169", "r170", "r172", "r173" ] },
"hcat_ValuationBlackScholesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "ValuationBlackScholesMember",
"presentation": [ "http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Black-Scholes", "label": "Valuation, Black-Scholes [Member]", "documentation": "Valuation, Black-Scholes" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueAxis", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r640", "r641", "r998", "r1187" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationTechniqueDomain", "presentation": [
"http://www.healthcatalyst.com/role/FairValueofFinancialInstrumentsFairValueMeasurementsofContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r640", "r641", "r998", "r1187" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis",
"presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1154", "r1155", "r1156", "r1157",
"r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176",
"r1177", "r1178", "r1179" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain",
"presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label":
"Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1154", "r1155", "r1156", "r1157", "r1158",
"r1159", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177",
"r1178", "r1179" ] }, "hcat_VitalwareLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname": "VitalwareLLCMember",
"presentation": [ "http://www.healthcatalyst.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vitalware L L C", "label": "Vitalware L L C [Member]", "documentation": "Vitalware L L C" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "WeightedAverageMember", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Weighted Average", "label": "Weighted Average [Member]", "documentation": "Average of a range of values, calculated with consideration of proportional relevance." } } }, "auth_ref": [ "r642", "r714", "r937", "r938", "r998", "r1208", "r1210", "r1213" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares)", "verboseLabel": "Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r283", "r293" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.healthcatalyst.com/role/CondensedConsolidatedStatementsofOperations",
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares outstanding used in calculating net loss per share, basic (in shares)", "verboseLabel": "Weighted-average shares outstanding used in calculating net loss per share, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r281", "r293" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [
"http://www.healthcatalyst.com/role/NetLossPerShareScheduleoftheCalculationofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] },
"hcat_WeightedAverageRemainingContractualLifeInYearsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.healthcatalyst.com/20240930", "localname":
"WeightedAverageRemainingContractualLifeInYearsAbstract", "presentation": [ "http://www.healthcatalyst.com/role/StockBasedCompensationStockOptionActivityDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life in Years", "label": "Weighted Average Remaining Contractual Life In Years [Abstract]", "documentation": "Weighted Average Remaining Contractual Life In Years" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" },
"r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic":
"470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic":
"825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" },
"r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)",
"SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(b)(4)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" },
"r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "SubTopic": "10", "Topic": "420", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r24": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))",
"SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic":
"220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r27": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher":
```

"FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480637/718-40-25-10" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-

10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-

10-45-10A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-40/tableOfContent" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-
50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r443": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-
50-9" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r447": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r448": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-
50-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r452": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r453": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r455": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r456": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r457": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r458": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r459": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r460": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r461": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r462": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1B" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r466": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1B" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r470": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1C" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r474": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1D" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r478": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1E" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r482": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1F" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r486": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-
50-1I" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r490": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r491": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r492": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r496": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r500": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
```

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-

65-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",

"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-
50-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r817": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-
50-5" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r821": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r822": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-
40-65-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r826": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r827": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r828": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r829": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r830": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r838": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-
20-50-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-
45-4" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r846": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r847": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r848": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
```

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r958": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r959": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r960": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r961": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r962": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r963": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r964": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r965": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r966": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r967": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r968": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r969": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r970": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r971": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r972": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r973": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r974": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r975": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r977": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r978": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r979": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r980": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r981": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r982": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r983": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r996": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1002": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1008": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1011": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1014": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1017": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-
40-55-9C" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1021": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1024": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1025": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1032": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1034": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b" }, "r1035": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b-2" }, "r1036": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1037": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q",
"Number": "240", "Section": "308", "Subsection": "a" }, "r1038": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-
F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1039": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T",
"Number": "232", "Section": "405" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" },
"r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10",
"Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "340", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479483/340-40-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number":
"229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1052": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher":
"SEC" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c",
"Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1056": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "
(4)(ii)", "Publisher": "SEC" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13",
"Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff
Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1059": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1060": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1061": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1062": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1063": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-
10-50-5" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1066": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1067": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1068": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1069": { "role":
```

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, r1130": { "role":

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1131": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1132": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/405-30/tableOfContent" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" },
"r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1135": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1136": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1137": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-
50-4" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1144": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1145": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1146": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1147": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1148": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1149": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1150": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1151": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-
10-50-5" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1154": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1155": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher". "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1156": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1157": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1158": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1159": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1160": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1161": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1162": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1163": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1164": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1165": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1166": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1167": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1168": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1169": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1170": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1171": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1172": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1173": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1174": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1175": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1176": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1177": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1178": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1179": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1180": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1181": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1185": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1186": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1187": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1188": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1189": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
```

```
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1190": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1191": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1192": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1193": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1194": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-3" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1198": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r1199": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-
30-45-3" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1202": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r1203": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1204": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-
10-50-3" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1207": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1208": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1209": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1210": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1211": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1212": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1213": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1214": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1216": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1217": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479868/944-20-45-2" }, "r1218": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1219": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1220": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1221": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1222": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1223": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1224": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1225": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1226": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1229": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1230": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1231": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1232": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1233": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1234": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1235": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1236": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1237": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1238": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1239": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1240": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1241": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1242": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1243": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1244": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1245": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1246": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1247": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1248": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1249": { "role":
```

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" } } } ZIP 105 0001636422-24-000152-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001636422-24-000152-xbrl.zip M4$L#!!0 (^%.09ED.L<)R[@< >PF > 97AH:6)!=#,Q,2UQ,S(P
M,C1X8V5R=&EF:6,N:'1M[5IM<]LV$OY^OP+GS*7VC"2+LAS;DN,9Q58NFNG8 MJ;Q,>Y]N0'(IX0P2+_!*5G_]!0*D7BPYEJ=I&C?U!UDD%MBW!\\N2)U/;"HO MSB?
XXM_G/^S7F=7*BI2R"R+-' +,2N,R,;LYQC,':O72ZE+E<^U&$\L:S5; M,?:STG=BROVX%5;"1,7.^:&_/C]T2LY#%<\OSF,Q92)^NR>"5I0T@Z/3*#D^_M:8?
1\6D0G+5.D_@H3)G9T>M_P9[:!7%_1QCYQ+-<6Z[M,Q';22=H-O^UYT0OSA.56=2G<;[_ZI?96,S"O:US<*99QfTFYZ=6ZG2> M-=U?ET;J"4^%G'=^&
(D4#+N&&1NJE&<_U S/3-V %HD7-.(W0)O0/'C^_42$PKY^%,QI=H^"1K!N]G:#(XPPZ*]O<8O"?-D?C@;O M!Y>]T>#FFGW\.+S]U+L>L=$-&W[ZL<^"(UX/VOO\P+MT,V3!
<;QVY_TW[^+H M0Y_=]B_#0>C0?^6]7^Y_-"[_G>?J?2V!.8]"\Z.VK5OWHG>+>M=W7P<]_6 MDH1^4>)*P#5;[*7DHS=\U[ONW]9O?OFQ_Y\]%:UFL[5A_J,DL-/8'^=<>ZMS
M@QJ[XID R=X5VJ[GB+05B1S9B<'XM/L"O @:;, F? I,PU3 #$N(G0C# M?B]X1N#(.1M"KK1E*F/OE4X]_H)F_2>F$Q8!N+03=LDMEW-C:VR010UT_>QY MKF_!{?*0[\PX&
[/2]M!GO'#<8"O4{G["Y3,PGQ&&H^..J')%:H,5-82'%! M+C+&LSDK,JL+0(.Q'+O*C&'B+,4K+;AD"8_PEf8]%999Y>4V!#*(P!BNYR22 M\CM O2MK&KP7HS&H4KJRCCI((!
(;RSB*93@=+*8E!L]E$1!-F"OI8SI^!AG(1 ME^,J4O! E'GT$" ML$1D&&M*VS*V-80!BN.P7AD768*[AUN!ZX@LDD6,.V+^5@)9P]P+VG$YA!^0 M0XB2<@F-,BOF@6I$7RQHX1I)%!
(%$ *D^;4&6=/Q,V$)5+-3 46#6-AK.:H MB---;S=:65O)N:F,V;#VKYWV=H.-UF+T^M5I*SCIFC*Q)=73AE%)(O#2$R.% M<,"X:I\#P=+>UP?1[<.W)]"&H+,
MXX8T,=K5*W#RZ26KGE3)2FV)7[E4E* B\O@AR%"""LWVROC%@=-UMMR8&8[MK;8[=OQ)8%]TT%=@T$*,IJ/CIY->HTH1\<+1/H4H.P1,6ZG)%P%:%P M_14 M&$<4*
696X>:E27%K-*4!LD=#LHJL,QEK:0P&A1(-VB+45+$[@1JBM"(6' M MR 'A;Y4CSHQ6*@S5#[>+C"LVCE:4 30(SYYN4HZ]AX@*R8D-T2UGQ+(.X0Q? MU5:+,,7X+@021L' ^Q,\EJ,|
YB5C+SQ@Z[#;>?]OH&]WYM@9A CF ''??EP[E MA(D@GV>1QMN!9$[_OTJ!?%;PE94 M\EI_RF7A-C]%'Y($NQ0QQ;B9+=W&HI+N0&,^[GY96'6';HN CP3:X^!
"KXO2,15J?/1WLP:G*%/L*,(7& M,YR5J>*HD)3;E9JQ9954V4LW]<'(KB6B7"A7_TQE^T_,B5!D"$'!) N#<>> M&MSQCDY^6,&PZ\!,-
>%F45B)/1PH(7:TZN)14MX<#W%W(,NSW@/YVN\.T5<$ MXI\$NN/?U:R[AQ]Q!=?:G/**,_=/"/IX]E%7:+"J?NX%+ MIJFP%S[!DJK(TT'@NTSRVRC\!"LC)$AOB?.KEJ-\"OA4#S'?
+++'+GPH/O MN!/OX;F:FA.!<##"1US(@&8NK+]++#KB&? [*B.^.7"%Q+4U[B%.=<9^%B#* MYM4?$K=P (]QHH$%!3P*GK(9PBF(.Q9:KZ6&2QDIDA3[,!_ ^=,2;U;GT9\ MIW4JK("
Y2C1N.UJF!9P=(&)=<_$2@34/)N+;*KD%(C2,SXN'^WIDF$@S:6: M X[.)LHS"E_#%^+AB]2[QE^6Q*\PW(Z0V#4ZGX852,^:IN9>66YGS[=+]*^5)02P,$% @ 5!F653RR!/G!P @"8 M !X
^@ZVBMY+F!3O6EB\R>2S[OB,SI=).ZN#?&(JN'REJ5=NB%Y)1J!-;X,A8N M+'ZX?%=Y%C1:K5-Z76DQG#:N%)=O,AON3>:AC3?'VJ>-L^;CP\U&\.C8%UKV
MT)FL*X$RLJTW;OM9:FVER7GV=N]HKY+)>4PGKTZ3!4ZJTK&K.*GRJ3FM_)YF M=5=@*'"92(?/Q-='!HOOZU=MW*/N<_V-SP*33\?F9?A)^VW-J2>R6&XZJ_(._M.L?<,R!6&?J27^|
[K2_5N\N)@(3U!R$JZ,#/;GR#_W<.ORWOW(H=85%;M(.__M^Q_]8S5I?392>_"=Y;0M2I,6K8'JZ7*E7%O_SK^>?T4-GYJ_STOPX[=+]*^5)02P,$% @ 5!F653RR!/G!P @"8 M !X
!E>&AI8FET,S$R+7$S,C R-'AC97)T:69I8RYH=&WM6FU3XS@2_GZ_ M0L?4S4*5$Y(09B!AJ,1"N,G5%LR&3.W>IRO9;LE)+&9,Q.]V1)2\Z1X='A]UN]VD&W<{1TET$+>[X9O.,?
#6X=%_VCLX%<7] M'&,7$M[M9")OI$#Z>]U.\^UA8?MS$=NTUVZU_K'C1$]/$15;U*=QOO_JE]E8 MS,*M;7 IGG/N;3CI];#D9)*]UZUW%^?1AH)SX1<|'Z8B P,NX0Y&ZN,Y$\$
MAN>F84"+Q L.\3N@36B>NYQ[D]_B.E+D4+O0?MM%HX>W]0B%??VJ_;;5/V@W M.W?-WFYPA!$&_>4M[E"8SX,CR>AB=#:8C*XNV8>/X^N/@\L)FURQ\<>?AJQ] MP!OM[B?
\RY=C5G[,+YSY^*;=W'R?LBNAVO1]<_G/(!F<3 M=G7!VL<'W>";=V)PS0;G5Q\FP_;[24*_*'$5X%H=]E+R,1C_.+@<7C>N?OUI M^.\Z%9U6:W//$@"R[$_SX'N5@=& ?L7-RIG SD%';
(M!7)@MF4X]8 /_J_ M ! :339B*9\!TS 3,,U0Z3?8C-Q@+]#I,L)M< MS27$4PA\<+0/2:Q08ZZPO.*"7.2,YPM6YE:7@ 9CP76U%\/$68976G#)$A[A M+ >M?6-'@O1F-
0I?2%&W600"0T%FH4RW$Z M6A*#9O-41"DS)7VLYL]!0[4(.9)({&B4W,P%YA0#:: R!E(ZQ9HFHK1S1E. MBUFX6 _#]G0_FM(7@H2#3R !6")RC#6E,17; &&
XCBLU\9%GN#NX5;@.B*/ M9!GCFIB_M4 &F'M!.Z[\!-R"%%2KJ!19<7<4XWHBP4M')!$*5$ \: P.4Z= M1BG/I\ &N$W!013,3,U M:H>[L+>RQW5]=&O/K2FHY.<>-Z2)T:Y>@Y-
/+UGU]$I6:4O\RI6B!!61Q_=! MAA)4:+97QL\.G+Z[)9 #<]OK=-W!XBN!:=DDGX-!"S&:CHX?3WI E2+BI7GZ M%*+L$#!ME29?!%2I<0'<..U4&JH?;A<95VP+MVD M
GL/962QNB6\Z(51W"&;ZJK1=C_!8""2)AX7R(GTM0GP#,2\9>N!5[3R:! M#0@^G3Z>C1[TS$!##JICDQ)C<(3FIC""5&<1+#9 M\Y##_2 *1\)?I"I^2P"+*H -9UR6C@$H^1 DV*J(&
<;-;&DYEN7T"8SF+[=W M(0Y(.!'9R/A>)U2E?=B"IW N7TH#-7+)XRTP"^L6T6I\)% >QP<2,'W!8FX MYAP?[CXEY=+N_:[52DWR^1*[.% ";&C51>/BO(6 M>)*[5D=^.
{)!W\X1%\0B%|)=(=_]&-W3T#B&J[!:D,3OZQ#9K6W*>G/*$,,M3=32/HZ-E%7:+"N7NX%++9IFP%N 3![DJK(TT'@NTSRVRB\!"LC)$AOB?VKEZ M-\|OI4#S'?++/'*'P[WON!T?X.&:FA.!
<* 3"IUU(@&8NJKJ+-OB.? ,*B. ^ M.7"%Q+4U[DE.?=!^%B"J#M:.?%++=P (]QHH$E!3P(G]H9PBF(.Q9 E_+#!8R M4V89MN&_@W.FHMZMCR2^TS15|\8#++$>)QFT78%K
T04FUCT8]Q 0>##87^4S) M&1"EYWQ;/=_3%<- 5M0 !R=I%HS"K^#+\3#9ZEWS<^5I:\3[.J6,==HD> M9F'QE\Q&"]P)RBY76G0DJ,T,$.>@&6BMY8:!7?^DC?
1>2+WHB=SK=I#YN@*G(.M&Z&R5F4]>KDXHT*.A;R*DPN9'Z[>.QZWFYW.$;UZM!@S&]>*]['>23?=6$S'JUZ+
MM9U4K>.IHI7*Q^9TBEN:U5^#J(1D(QT^$U^>$%Q\7[_JXD9TG^MO=I:(?#PR M+|\-+VFUWG'HDA]66LZKHH7/,/>MAM:$OR?6_DOHRO3M+!23L8ED*KWP'_U<.
MORWOW(H]85%,] 1_=S_XYV:8T(W4[GTGN=UW;>0W5]6G_P78OOOEV?\4$L#!\0 (:%:0 M9$E=A$F*404 *PC > 97AH:6)I=#,R,2UQ,S(P,C1X8V5R=&EF:6,N M:'1M[5I;<]HX%'[?
7Z$ELVTZ XYMS)UFACK.A$Z'I$"VW:<=8K[=.RX'\D%.^Q'! >'O_5_K]70$?>S:I8DE M\=?)0E0)F@\1^\"
(CZ@6JW0]X^D'>H%SN:22DG5,F7EF^?,YYV]TS]UU.26H@7E"V[SZ=T000:D4LT MY@L"]JXB.J/RV9[5 M-'MUV[#6P_Y<2C%/*'GR29^?CR?E@-
$?3TPC;UCM!CJOE:I3MF4^%@>N*AR6#\:C#R M)K?3]V^\)Q# G2J);9KV]V+^GTQ(&BY_>+[.S7C(4I%A\"LYDA%!*2R8V83 MXT00B4*>R@C1&(TS1LK]AVN6LS]
[D5_R4"^<$#]+J:00FG2E1SB>$S3P)0*Q MU:D[580%PF V@/-I7RUXMM>Y;,-W75G_9/5>@'(<*(N2\GBUZ94M-\()[[4 MK*NKJ3JG$."D".(\INK\FT@X!@6<>
%!^RL4*4LM;0D\'.&8$H9>9:GD<17L M4A)"Y)"%!!<$G88A]<$/'$$-7"PQ6PI91873>O[!0&JHA@/T(12-IN-\E=D#'7$>-=1%0'J?5NJ584Z"U M6CV!WF8XA3W.EFA,$F
J!.@]YNFBX!^3E:1H8,@ QT^J"?CG UCQ6X(?L!2 NS! %;&$&8-H?$B)*<*XH+.I.A2&.#4_=Q2>+IAJBQ'ZSS^SI/<5HJ?17(;8_JG M:?7^@$;^CE!VEV(0^^P=2RL]B$QH#.2QR2/NP H-
6H.8FA9T-V*(04TT>*1$* MF%6EAQE#L!XT83P 00)P!(E:'GX:&\!R0+4/-6& 5L9R7',@(NU<;(P4QE]M M,P;GYV:!>Z^HOK$^@D+HD0:-
^,4U2FWFC'I#E(^%1)RVT3%O%W\KB]S!;,$B MI4)9=\B[\B4PF@]*E:_"[9K]_TMQ<+ MT,&QTH7DD.",!J@,]#&EOFOK8\WNEIOX70\75G;.8I=*\.9_1;[!9RF%\2>!
M^6>KM2]VO7WQ]ZW>C2++G]_M7L)J[=ZK.03)/(5S=VN-RN:;] MUV77V*Z9V_ME3AI2%ET(U#QL:_[ZC4Q 0B\+)"02*?O,N&R!(#/C%\^,C/CE M_[R-7.$%!Z'C>[_^5>Y(?
Q6P9_FVXSW_^M>+) ^_VNW_^7Q_M(WSQK7B$O4BX##"L\?\.M%0B(98^*D/#=1=' #T;M=O*U2W\\"9SG
M820HDJ)EMV57@W.Y9W6[AJJT<<^4VYJAZ>VG+NZV555[TI#RU+4L++#Z?(]-Z M4KJFT7ZRT:"MF3;<9IA:VY:[/7D@&9K6543[7+,42>[9IHHEK&'<-2W%0JJD M&<;38-"U-
/K>801SAGE[X7DWU][,P]!6['#Y[/%$DRS^!J M*[W1>8O:(;,F;H:_,_^RYGCN8Z'R?J<10'R0C)]%,&"PE-DO2WUVJJU6Q,\MG_?+MYL(9XA-J.%T;(L_!TB*&O M*,*Q=C[J67!]H4X;#\C-
%X>3W1A;DQ#"T5SCQYBY$;D4^1.PJAC^2-ZOV2J M4O8=&_F04>2K1A%$Q6WYQ>G%\AN,%Y;Z:+:_.V[F99S=$O1^W5 M]!]:D5]2TI;5O)CM!<6(!U@]RRYF-
T*#_WYSFS(Y2<43F?SMG1_BA#9-,TS M>C6[=?U\A GH3>$("">2K;?QG[+S\\KKTO0CX MOOTX&<,PK.2O7UL1?HO.Z*/,^O_Q'__Q2^1$+NX35+0S,/QREGSXRUGRZ"??
MGO1_L9T7(8PF+OZU93OAV$63<_W, S >3LG-^(@^=6Q;>S17^'Z+0B?P+&2 M][]%]WCP:\MJ W-Y:$2>A)WS*P}>-[F$T07(O?9I_/;?>-(2'/O7UJ"MZ*V^ M!%S45,N:HOQR-O?
4$B^YC(, WO#5"2WD_HY1<.797T >MH0$+ ^ *X'G-GS2 M'L%3AFT;S<;0;?5EY4R5MW]])H5G[_*GX33-QBM/EG][E[P'6[W[?E7|%K]-MOZO;O^"GF[3-
[CH>7[5!LX;MML#V!*\IV\S6WWZ0:D7ZE+V1H+\R]X@(%] M]CU^P5Z,+P+@WV=,Q^_'#SAX<2Q,4!X@*WK%P2A[N=J#N7Y7?R_U;@46*'UY M*DS/,W 88GPWQ@$(#._Y!@-
#WV,/OR(W_[J>K,+KY'6O^7J&!_)&B#TG>9D7 MCYYPT%H<@*ZV!!M;S@C6[=>6L3B:+_@IN@8A&5 ZP[5!!HB<)QX-,PD,P^ MX15Y-LY>%T0C'65.E
5DVF!GX7"%!";B^SRD.A[&+5!Q?AZ!W/VU%3JCL4O4 M /UL&)!SS0G;SEMH9^^;O21!9^C' ?V+:L]S@B ZS'"(X&(K^WP$R(P#W$_^ M2B[^3&,8?
%AJ>EQ_N/A2]EGP9(^D$%,GPFZP[%Q_E9*;A3Y MP9:O7?H^^? +]GP@*K"%EV:N4>.#@0J$3!*QV8R^O_GK>+%K\\'<\T\=4V&5_@<4=1,0*HL9'
M6Y+A?JGW9M>FP[1SMYIM8B?.7\G^SEYR-C?OUL1)3.3\XN07=EF M9BIK,YNCV2XST]B:F0H>7%NMA&;ZOF>6\E.B#Y(_;7C9V]AU+"?ZAHG,%VP'
MKM+P3BL,HO/O@6_'5G2765<7;PZH?BIZ'K$U]'S?'YXD7_WE;.43IY:?OG@+ MX6 <7CAT.3E6DT,M3@ZU.G(8G!PL}\=:[BA*C@JYPVP8.>#2 (?D5N2F
M5\.CU"*RQ"G#ID*1]^X$-9\R]>@6>>]^6?,I4X^.D5GP*UF0ZBQXH2S(T+W[MK WA"^:.^]B[1V(F06[U@FP\4=2L*%,G,>8PE:7*/(^1XV+Y"=E, MVH-
&V=/",^<;EESX"\N*1[%+$1;NHB$.R'T'!*GO6!@##W^$&T.+O3N&M4U-_M8 M%IZYS=4F2+$]T8(R]701*W0F;,.
[=2Y6&$HX[RY6IXZK\!)4[RS4M/'>6V:'%WTWE^J,6=)^3'9E;V1D$M>GN MZ(%E;G4+SUP&;^-D;F6TT+BSW.P$4HT[RTV@$G>6&THX[BQ7H[.4"G46=Y9K M6GCN++-
#"\:\F833F?/9"Q}(O_#L+0X0%GK_M/2F/EKR4_/G-\9Q1/#I*IT1GSN=G$0##H[7@!P%PX8<\ ;"B9F L>;"TH"^MN M("XL433Y[H+Y#\0F*GQ,1O=Y0@KD+AG*XSC"P?2FIN3UZLR%
(+:6@)RR\[Y1E M+L,!&,}^C<$GBN(PXU?G3?R6V..1NC,I>,SQK:-)BYS82/&./?!'T2OB-(V M^_4+?L&N3[]QZ8=1>DZ\(I[[-+.)>'0&8<@C;.6 M*IRMVUWF@ER-(G;#.)NYN-
=.,CR+/V;VT\(W.7-WF0N%-8W>#>-OYJ)C.]'[M,4 V'J'@)]?3[2YSP3"&2=LPXF4N]I51Z7,<.AX&VEE_QDY(4QMSYM9-/,*^ M=Q/9G?UO[/>*,^SG;]V100MS8:OZR3+/
/F5WH4!#&.#2!6M@]-HCB,_!$. MYAR?QM*>V;!2(VB_,1&+?!HS&VQJ!+T+VU'L$>S9@\[,UDX-.8P&LZ&A]\ER MB0++ CSS, DC/.JO/>L]-+M\(?
KD;]V)/LR&@ID]F8QD;KXM&/D/L]\+_ZP0C-[CA2 M+<5L1(-5.M6DHYH;SZB/G^K04,V-8-3'3W7H)V9C%N]';U>17>Y<-=Y/9@,+%*PKLY0(>]SB, L<" MZYG6 Z\JO^+DV4Z6F
U85$B;PN]L2/9=A9) EIB-@S0& /5DWE4* F9#+(T! MP8&R[BJE.G/AF@WUK^\S5V;&:$<9GY$EY@(TS%&FGHB,+#$7DF&.,O7$8&2) MN2 ,.A9R$^)8?
NQ%P>3\Q\NSNJE[UF8U%^D M&09.^'-5 >/9$)9NK\U7G&.5]BSAL0E7HSEOF OQE\#?U15CORG$PVS,-IQ MZEJ9N0+8QRB$&W$)[!"9C
=QC#*)T;IL,"8C8QRC3&*T+GN4N1CAC!QC_[A.7-90'OT$/93TE.6F0OW,;+(:G4MY&69NU1*$V9=X<9ICTK)PJSSS+++VJ)0"S'K6I1JK9@PQO:DYZIM9 M7YMA E3*
^:U^/QH'_@O=T>G)/7* RZW$S3H0J.4%EUL4N M1820<0"Z.PY(P<&OSAOYK4&,P*P_S38-*N4#9CWJ4VDV+ZO, ^M!,DZ!2+F#6
M9=Z*\'#?"FKLJ0;2OKB"67>Y422IE%N8]9_!!$6D,N6-[SW3.$82O?@-NS8L M_(\0VWG:))VO5IFO1(,?1)NSD#*C,N\--YN<-67IJ?$/!3QQJC3V[.4I*8]:5_XQ .UGX88AQ=..,;:(?
QK%0N&0 MJ*X7Y!;PW#FQ98W9D,%Z8E/9^##T@^@1!Z-DU=&3BQ_(.5B8]?Z1JHS&Z38 MN.8_'AX#4(MQ,$G)[30H.*0Q&YA@5[0VF^#,AD$:(%Z;37EFHR\;U_W2'XUP M0.[XCL;
[.%NQKR5G-KK"KG1M+*V9#=LT0+ VENC,!G<*+'E270Y]CV[B>], MV4 ,R[*UV337&Q@(8DC&-ISX#0P,;@/#(W5;%P,#)'6+UF83G-G@2 /$:[,1
MSVQLAJE(9)5+WFU@:*1NZ=I86C:QTZ9D-Q+ L6QM. M\P8&@AB2L0TG/K.!H0)^P]_\%QQX],HSAGMQ^_4_14VD K.!&G;%[G&1OX'Q M(F8D\#'AH(%A1#KX?
2M=^,X"ND=1N#:=M MZHYSTZS*7 2#V9!3%9A4."-;,B$EV(V(58%+EF&PB)ID-%7(8'!(&S$8/N0G7 MM(WY2G'),F"3FW&GC$MP0[WP;0&B@><<0-
)H0PS\E\XHA:!QU3+^!Y@U#T&A" M,/UDJ&&>=5BY@>]J.LNSL76DS";$E4_)KN"8E,VCCG(WT*#AF)3-)H2W.0SV M#H.C#B6?M G7Z%IU9A/BR-R,.SU<'G5$^Z1-N6;CL@GA=
Z%@T#AJ,/G)VW2 M-,5*IMF$L#VWYDX(DHITU'L7)VW(-1:23=BZX"C8-PJ.>K/@Q,VW1A?@5:0F M[!EP,^XDH7G4^Q@G;LXU')I-V,K@:#@4&HYZ ^&DS;OCJ>ZM2$W83N"6WJFC
MJ*AW.D[:Z#LFE#9A\X,#X_# D(JZ"Z*!B!#T&C"5L IV5\,0.H]P<:./0P M!(TFQ.=/AQK,AJ2)O;1H7R5]FK#G^,&M'X%-%6-8#[TJ=KSQO><(!R/RZL?)
M&"\&]3RPZ2+GR<'7TY=_1A/2(VBNI*SP{]\C,AG@YJ:OF:F;CM}>C,0A.,)/U MOW%>L'T1AC@*^[\.N?>'9/T)L?YL;Z$%!<.\\#Z.[5Q+[KT!@8N'OFO#LP)P MLZCDA2]_C0//B4 4D]^=-
_+;'MPLH$H0?4$13ME3AO]-GS.]-EU\.W=KGI.S M*]N1E]G Vw&15RU.7K5*\C(;,?PA@>(-B&_?NXGL3G-T M(K-AK_>7^A(%^ 7XZV$21G@47GM6<]9<83:B5&S-0?
XD2,_=UIAJ9XK";-!F M?ZO/H ->XS9#JCU?D9DH?OVPY+!]QJQCL9_M[X%B;K.?"@R"SH{U'[!$U']P@ M30XFTXN?763]?++ D&A.*4)%839LQIGS"}GS'M[OP1++%;N2,-[JWG$&!09D-
M7G(&/4(&O7H;8POT)^U^S[ES(WP3D3M:_/G-\9Q1 MO,D_9FA1F=MS7+6HZ*U1BZHRNZFX>TK$<6IAE=F-2.8I5E->BLKL[A1/((2I M26U):\M:->*4V7V.M.3.1^%
(O/S&1UYSU!>SD6MVUKO*R(K*, R2$;FR:"$8 M=5@(S(;_6"226IQ(E1H%S 936"127;8V M TPC7%79ULECOR*+!O#F(7'C>/AND-QQ"+4G=PLR:_[6G7"@,1O*.!T=++N9'9JS,8\&DK:'?
4,G>&AG,7]4-2\,,Q1HV@Y>Q=-L/TE0*-PU3S CX< M4]N^)\;.$584]V+K7%H'Q4 F0TV<@ >0+;N:R>="6@S&Z(]5FB?G/9F-KY\ M2@@[:AG&;'#\=-;YG"QD-CP'BX6;MT-
%WN/QY=$]ZO.[}",%V-N%N8WOIS. M:7ZRN3<]#@,5-G.) >,"\Hf\- *E7C1'0O)A_LXR "ARB.K*%=&8#YN^?C[L BOR&D1L-KSVK M"B_XTH])DNL8EGURBT9S1_"="+FO*, W-Y?
{WN2K+,M89S80?8*$K3*=66<-- MB:,^ZV%V]6:YL8WMKX$_NO1'XSBBKO+=X H%'KC$X7<<4'1\GJQ^P+R/=34. MN_X$8QJ_O!N31QVG?]5E-@9TI'2NZ4!'E]GXRD'H?(_#*!
(^4I*Z1^>$X7W M#$^.E*>9C9D<,.WKXFMFPR@'H?7W(5@X_HA^@Q+Z^\,/(VTTV4NKG+TE*Z+ MIYD+YQR4TKE]E2/E9,"04=*W[KXE[EP4GT^U7%RL,%<0.IH*5P3#QNG'?}:
M*&.E(M/_.9U6!K7QQ9Y M^ O=L5(D66[.6C,;#2NZUF9SUIK9>%2-N&;"K&$V?,0,$^3)LAL3,!O**;36 MS1$VS(94ZE_G*I,W> ^P&-EY18"\GP]>VL5M"F&/W: $2]2IJ?ILC]UP DO4
MJ@99GU\!FA2DWXQFQ0/.(D$[-148 32!>-,*S)%+_TPNAN0NK/!N0>C M2LSZ_(S1IQZ=HTK,^O^,T:<>S:-*S$#"&*-/??]'V9A (?I\8-=UO.<+S_Z& M@IX%@M^OWL;PJ./LAJY*S
8+V"?7=]JV2@"V^2J2UDQ&U(FUQUZ2YFXPV% MR'6/0X0*:PCT^H)?L.N/R/W'K;Z8C4,P3[&:-)C<[/A$S3Q6AQ*3FQVQ]G' MZM!C.YX110(^\'4FDYL=UZB79G7HLF;'.FKGLUJT
M6;,#'K7S62WZC-FH1Z4GO@J_]1_P>.*7SSOKM%X0"K%-*@K!5Q+TT $&R(/E MN?..E:>9#;/4?2)P/X?+59G90 E#"UYAU0159C;.4>$)I,+O_(91& =42UY[MXSA::&>[=-
F/D$M'0EK7?XN ->1W&P*?UCXV!6-#*3_)W:>AZ3(U0OHZ.Y.D'>M/!#F65FUQ6IR0%5FQ9VV#NUCSG91"P8N[K_]>+CT@[$?H_4A (":VW%+(B%_*V[M8:%!4 9E3P(+:EB7@]V*Z8>
{6W;# ,-3H!@CR3%>>'(")%QH-V0@3 M<^2I(R2DU102BL#^LJ?3)CTM<8]'R/$<[_D{#@9^,$*>A>^>W)0BY/ KL1.IR/%$\,1O6NLM6A_W5FPT2,TZLF;T=G-
I3#'KWVI))T9L,U3).@RN1.G=F05+2.3Q9W?D@> M$>:"SH_8&G]^ZS\?JPW ;$2&*>K4I4&8#*<@P19VZ[#%F4W28HDY-6P$ZLRDU M1:CS/? '<
6^A]P"'+PXUK%VV]&9C1HP2J>:=%&7V6@!HW2]22MUF8T2,$JG MFO13E[GH ,F[O 07U'<=FT:HKX%<"UMM=S!'1*I 9+2K*O>'*9.E)E7892Y: MP2%1M]9E+GK"
(5&W@F1IH:G:J)171]HD?&B^OBH%D74R+!-?7Q4 MBSYB+GHR5Z$AMJ(X I<^F%TX=FDS7+PDF_#]8!)YQ?/PG#U+AKBX!&CM.8. M^4YEGO/<:+Z[.*ZL
Z')T@U'JAN9"ZAD%']WLVFY/91&HZ(.2=2\!)2'15; MQ+I/LX/LKB@[E@3B%\$S{GN\0, !?5#04 ,;%2KPJU0N9 *0L4Y@)+I8!"[,4 M6$- RA[6P,7N,Ks:B5B0QF Y@< IM$AE9<
M9'2KLC),9D.;'"_OBXP\!'82&2:ST4L.@0-583*9C4LV"P+*H;5&3>DI9C-C MDS5MD]:!BCJ2+4QF8Y!L,Y.>##Z8C8 V9)OT9(#";.BS.=ND)X,59F.D3=HF M/1FT-"-">LH4X@%,CI?

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f]M8T:\=S\9>=-XVE\,MZ@3/!W 8P3Q<MU -\[RAP+!+CSI"\U%([H#REXK&(MD*U1QE 8+B3BE.70K9WD^10F^]>3es!.M30_?O6# 7:BF+ZQ7&#*T.@Q"AW\36UG?Y,?L66Y .!"G#]<.3PZG#]<.K[KZ M7G\%F" .:)RVGDX_'*>IP6P[W@CM 9QU$$MU+E^Y7>O'GBZ0V= >)(^"/>9NU8^'Y?=C^:SJ; MES3[>ZV^K/1$;471/AZR:1,(*C;!U^!K66^8K;ZV<VEV#A^6K49.'4X=3IU# MV?1%16|/8DGTGE8XG[*H35MCDW#^M#?V"=KKC?71>02%9>14:>BRU\NN^1UH$ MJ:+&3+2%HY'+"DX=3IW:)?DFNYDY2:XP)LE/*VY^CZ>9,@MY-2=HB#?6L5Y_M@&J7R/D,&RO"YV4CY3W:VD87)679W^9-D9H#J&VCY&O-M)W.H(<->M(NQ_8X MDEBV+#eL;Q=(53AU/G M$,Y(KV!Y$)"BLYZLI?5?M]?O&6)/U?>O(;+QPIG[A*FSHY&[%"-XVV.'NIT/ME"?M2%K,F"X@ZEXPD:NPSZK,+#5]PI=GSL^XYLW)FY? DN)ECO0\3A;9!'F({661G&'D36!+.!\R-X-M'PK@8T!P8*S/.7*%,0HB$G2+ACC$!#XV!H(2 OY=6=]V>N!XR+,.8!=%#DO^-.K8T?# MC"MRWTI?+,V^@IV@+G&T_BL+0^{1]L\%!GA \K]+;'.A;WCN)QDM859'LQ1) M[MFFBF6L8=PU+<5"JJ09QM-@T+6T?ZG@$Z=?&DX[8H_1,VX_!1C],*,!3/ <.MN:]H$A)>R:\?+%XZ((/0N^ Z+T"#'+1T!I.YGB\;,,.$6BZ[KJ$QI]-O5Q/%S>\/CZ)P??NYGHE8&?7E5"}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{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}4^75U?]L%C=%_N!V1D,K> (E+43]QF30.Z3#I.AAG($Q?&F.5:8> MSV&LW0V!\C)SQ^ \TNR_A3@01JHJ3?D**@\[< PKCT.*O//9PL(PS>]/CAW. MY1%HOQ(K;<4_L>YAR5&8_Y.EY3\XKMKC2*GUR?^]W&9NBI5?]=M%(-'S#\^ M!W9P+UA3GE#WVO^>^_ %=]L"N[GJF.;RR9K#8=],BR7H.\!QT6@ A=,+O2+-. M4DK_%06A,WM.7)=;Z+H3=8E5XI,FU@0J+ZQ5P-[)?_PNQRHX+M&*?O1[IU_Q+E+PTMRN%|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|>H@47 M6N'.!$? 3&&B*_=&O9!59P'X;AV3;>//CX\U;?(#EV[Q7"HPI9ZGM'M;O^;,B6 MIG$#,F]YKMY010|&3RO8<=,3'L MIV>WA>6&UZ|

*[[^A'2;2 4K)517$P(69DVLMY6-;+A=XH?3CI^(LJHF M)+MJ1,*@;"P1D7 66BE(=[X9[4Y M1.:.(G#-G%_,OO]+ ^9X"WQK$SGGGD%D7+[*B[B$S:EYD1,U#)G6]R(KZC8GK MI?#2]OA %PN0,F4Z2=D(YS[CSKE+%1P> 2DQ%\$P?K!5"-XV\SE.6[=E&IU6 MIT??AG]TFVOX;=L+">OVI%W;DX9U>U+=GG3Y[4G#$/:DT9:TO"IH_5[XXS=:_MO=QZE#K="06?G4>46FIOA2-.N8=^T@!;]LOURLB+"_[?<9\[6H1D/6OQ7+TR M-"\@OPXJF8\#.5,;)U .)PXT$QJ=C+7'5;9-XYNL(+4X'BSWZ?AR<5W98'\> M:\J4&U!K\Y\7KZ+#<,_XD3%LH.$!';Y16 P7N^L)HPI4WCVGTT"Y{4HFE@^*OXV44PY)\,!%90!$&YCOQ>&<GD^8/%0?BZ;QV7(}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|RWC\T\X\0F. (7Y5'-,TOOG>?9+Y"6V"^TL4?8E_+G^F5A^+EC"N M\?<:!@7?@\5=)E%[QZF =P_2$04,@3(>^)5$,0,.6],[NQ;W"L:1H5H-'&ZQ M=*)EZL*C-<$7N :2#J-D=R<,V&)F(@#)-2DUM2(122@[CFL\>NA448FP<+V2 M3BX7@,4279C0F_[DR8:6'U>0Z&=^B/+Q0"B+(Q+>:{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|_I V\6%D1=Q^!O+/G#@%0_0\4 QU5'8O!X$ M93URI_R? (,UP]D<%A=VOKN&5>;,$2OM24YO16A1=P?3U/B/ MH$429^-)DG0EJGGTE.KFN[^#HW IB_L 8^,'1E7?8X((;(;M@'?3(6Y)+@GK! MD "8-(A"OEXZCR@\9V!P_ 8\15/HDRU35Z&=:'OSL+"KD1ZDE.>969'CX%]1!=![E)TG@+PS +AQF_+/ MH,7DM'3/-[GR6D|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|'&9SRT&+WJ8HJZ?6S8OT. -3B*R M*1-((&=$!8=]5(6Z-=BN=A*5C"\BE9F%* M%BU0%/5:]~W_|#W[\9<3WOH?'# & VMQ/:7F0H<%M_YW=.4C|*T(X#2WOB%= M3P&?G4F^*;%%XS7F[4&>*FSL0L>O%0H;K*$7[$%&*T,W3". Q;H@8B064LPAM#T5!7U\19$7TT\ M09!@2568_I$2(M0HPG,@<26U\&'CU{{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{Y&O{(&MH4T3 M7Z=;OD0,J!'SBU[\'?\]QECJLT?,1 P>UK*PGDPM>TA*D3?BXH45P3'XW+;2 M&N"GB,K$)+ ?ZCQ<3W*+$^_A6/W0M_ K/ F%2E[,O/\5$A): ,H[04QCKA%C M!S/V;4W0RJ Y=4N7CT&BU6V3]#@UBKD ^"'^NA_DC$],D4#5;-M,PE3:WULT09 3&T[@'BB6; MS[RZBAA=M#3SF]>.8WID_/T2D" :5I>\.26PWG(0)5QUCA(9AP"O!%4XCZ:!1ML$F_X\R*S]!0^'C*ADF6NS=>N4$#$4/XM'"!TC. M,YC,Y>,PE%M#4,O^9=D=,5(3F.O<$KHN^Y@~WE? MG?# |(CI7 MQFT*CXUG]\F/_?<^]=:]L-<>TKR-VAN"R,U_HQ*"B;?*TVOE("8LN*;@U= MCMP'2NYB&,&[!WQID&E?$E8M2*=%"TMVO9%=$X&/3E:N-N9WVRU9,_$1F;A[M97Q>8X,8.2\!.$AQ3E5C*9.2,?Z[&]>F(^_KX-7T L$SB1X3'G6->$>=K#.. M$Z,.LZRWY9^KPW/-!ZIDP\7YN!0-*=PHKD-2H<,K.# MN8S(%SKF2;5]YHYO7^'A/*N#D 4HTL^B.&M@V-Z4UBJR8AXC@_]X"GG5'@__M*M^G3:+>$]] X;OD.O5M)5BJM1!N(S^2$ M_!?O<<<V@(MXU7]\(80TP@>.57L&'TTA&(")0)_-'"'$QO>*4A3FC^:/)BB4 M!1@RLNJ$4%NNG|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}?IBU*G- #I[V]8[JP\$VNA\;@"J4PO57=*FMY%!MRNYEJBDU>[^OAI M/RDC ,^<2X>T0X@CKTI9GE++;T\[TM;<+D8*W-Z7TZK/;+7=9F/<6&AVEG:G5; MO>'P? C8;3'O_V^LVZGJ8NA[F/.MAJACT!32-8E'PC"FDL=F3$?ON9I3K=]/E M^O*QAO;<(*Y*U[KN,^N'Z.D9[^QLK2]HKH6-9H6>ZE-Q^3&6<2AK=G">TJ- M5,7;-+.%(XZK2*- !>VZU3/1=W:9QYAE61CU0A;TV1G?77H_Q>JT0,F*5-_H% MY!4$\DNX.SK=6I(H^R'K(HRWKG$=/2 V.%L;2*Y&O&N[-]IP_W@+9BE(Z@-- MG9QS7$/,N* (=#G(:XY7.V6(E,F^/+,K^0^6*PKW P,="~'>$ MJ[5 7$YZ@M5Q?G3>,3^+ Y}O([ZWISP?XL6M?"7+. MZ/_]?L0 ^VB2X! ?>C.XU)=IP195FY@">(O=M:Y MJ^'R*0E6XN=,0=53O0I>+4D'+38TO%[*T^,Y_12Z3PZ[Z MJ"QJZNUJPP_4)4Q^[BXOI$T"*A6;[(.M\L(@IQDMHPE\@\C!BC))/YSLWY M=;;C5@<2*'>;O"5_\TX[>1O5^.D;\|'? MA[8[>R_/=RSY*T@)4K@;*G-CA]3 M=]N5VNQ_&-Z3R_Q@[JQP8YP/UMM B\T/P2DYT0*6]UVA:7Q6QOS75&DG5WKM MVE_B>KMKK.UF]AU6=63XL&DXS!XVL>Q>U756YNU=HCU55+K]VL>Q>TX0X@CKTI9CE++;T\[TM;<+D8*W-Z7TZK/;+7=9F/<6&AVEG:G5; MO>'P? C8;3'O_V^LVZGJ8NA[F/.MAJACT!32-8E'PC"FDL=F3$?ON9I3K=]/E M^O*QAO;<(*Y*U[KN,^N'Z.D9[^QLK2]HKH6-9H6>ZE-Q^3&6<2AK=G">TJ- M5,7;-+.%(XZK2*- !>VZU3/1=W:9QYAE61CU0A;TV1G?77H_Q>JT0,F*5-_H% MY!4$\DNX.SK=6I(H^R'K(HRWKG$=/2 V.%L;2*Y&O&N[-]IP_W@+9BE(Z@-- MG9QS7$/,N* (=#G(:XY7.V6(E,F^/+,K^0^6*PKW P,="~'>$ MJ[5 7$YZ@M5Q?G3>,3^+ Y}O([ZWISP?XL6M?"7+. MZ/_]?L0 ^VB2X! ?>C.XU)=IP195FY@">(O=M:Y MJ^'R*0E6XN=,0=53O0I>+4D'+38TO%[*T^,Y_12Z3PZ[Z MJ"QJZNUJPP_4)4Q^[BXOI$T"*A6;[(.M\L(@IQDMHPE\@\C!BC))/YSLWY M=;;C5@<2*'>;O"5_\TX[>1O5^.D;\|'? MA[8[>R_/=RSY*T@)4K@;*G-CA]3 M=]N5VNQ_&-Z3R_Q@[JQP8YP/UMM B\T/P2DYT0*6]UVA:7Q6QOS75&DG5WKM MVE_B>KMKK.UF]AU6=63XL&DXS!XVL>Q>U756YNU=HCU55+K]VL>Q>TX

0HU\1)9#>$\M9J>]N1WI_-NMNJ=MMZI>!PTU3I)Z3C3EO}^-HH@:LI74Z+;-(BU&Q8;>~MGL=~SXTD0W"":;AEIPV_)J)U7SM7T0,/'Q/I\@13SW@-X7A5(,9BXW'_#/Z%

M>N,7ZD^W.\/-'G6NZ[)?-)Q7N?6[935)G$&@JQ:.*NVMF"',CBH<~QP(,^@>~M#~I>UU7MS Y?F!6PN;>P$;O+!QJ{7\('JH1YIF=@R<;9DF1@V)B.S5YD)=?74

*MA5*9J;MEWF)S#1"9AJ[UJS*;]34X%Y\B'Q@@\CGVX0P."OY==YYLDHDMTI-* MEHEQ8](UA[VJ&!UU9T"YS+1EK$VYS 3J?)(IF+BV8%\L>F.M**#V%T>;9KX+ MZXH'"%K?[3;V@-FDW"LD6H(B2A:3=7$>9K^3QGJN:=I+X*8M-2HE26+5T\O:FE5R5N MV<:!93EJ8=+1?>nLUF,R\ VB562)WD\U\6,7R>0O<4UHG.]NI0SM2A33EV1?OV8N/*[U/6A,^ENVS-2@K.5$MQ+|SM,N_L"!X9U@:8+H^$>B5&>EE MCK'4.J0^.:!2%?R\8_@-D2>^9[$8-TW#9[E6(R>NS[B@\ H&JK8B.X;CLT4_8'9-N&;<. M3K:6?J G\FMJD:Y%NCI>X!XBW6N!2/?-8?O@@N9*B/1APYI'E9X7>]OYQL)S M'ZX6V!XNIP(2'[XW)6>1.D"9\0?VD-M\7&30-'3S4XVC#3&$R(H.Y.UN'LBK MOREC_&ZO73"6OF4]\|;7868Q8P;SYNF_S)K.97-ML>',&;.*

IYG+O&7H\;9- M=PO2^+"W1]J3<3:=+,,[B0\;M)S)V6>MWQ*M?M 9>R?U?3I+WHJ3&.W?M%0W*C< M]P\;DU8SI5CGLSM029%9H<G>N!./$\,]?97'JR%P4IFSA08A",WX.Z;IV ;,;LNUO>=*^PCAV4QG"1/WZ<'WZ)!T:T;^'@I^_UUK M-W,I;.^>(,_C_L_?N36HC2=_H5U%P=B+L"#6++@CD?0\1/6U!I_?UV#YVSV!L M7QMJ*!J#O86(DI>W>3W\RLW1%0D@@0$!L8_'[@:I*BOOE?G+ M?B-.*U;;$J M+C;O:J9%K)KKD?58(I_F3$5P&]40GJJ;#SQ/(X7;%@NNKE&FIHN0O+4YT861 M:T4 JOYV "H#3& X$XK&^R<#1#+] E+=.\ ,#\B3NG?*

*>LT=,@_QN>3\8A?Z8 M$ E>OS-0::!9F0^_O&,>^$,.PM"#]\01UA5 MSQ@E30)I"JZ^M""6D9ZM^8KW=UG.*R@8CX5Z^@E8QI=J$#:OR,4/#"8 &(O=ULLS@R .U4*EL M7%;X/2J<S[VVA4>)M5TXQ_#2-#=$%D@ 2%C M;O?)ALF ,317\|V^^:]6TI8B&$Q=9/_"EU2P@\4"+152#IPH?#~QC"BY2*O MTCQD*#,#,%.EZY,_^(X/?GQF"4;,+UE-$*]_7O(5ZQ&H#&9MXU?6E$>B&#;A M*8;?RR'OG$B?](.UJ];^G'D)E,X3NWD$?OEQ8TUAL>^L^8OUZE.&.$T+(($2: M\-5HMH;8=R1]%-O-WS|.F"8(7KE:@%[@(?XLO2(AN2_Z%EP(KU*.MP>L2K!4Y#98_H]H-4.[<'0$3L,%3"6;@/* ?$%]&2>Q,A):AP!2@Y02+L= MFW^B] M1OG;*6RK]O2]2RZNO7!84VT+A&-Y+B3V(=&%_/*

3]\7P2F(\3[E#2=8<2QV]8 M-KS%= -+>&\ W]R#4M\/"H'HEMGWL 5-5V2P8M\[VD l^NJ%6NM;E.4W:DKXW M:DI.O&R,17YE(#0P$]9--;OI'/+=(?H8=D).A]JA_$_(CY.=]Y0=M MST[R8PKY$?)S.?)}3[MUMFU&3WAM0FK.1VKT+4CD1Y(;14B-D)HSDIHM M6.5-2$V&/WG\ 3!<.?(<$<*W RR ME'I/#'6X3"[; A-V^$!G(/3897/8%M2J(^FQ82P\TH<LOT MV)5=3=_%F'';D&#BT@^1O1F>$ZA]*!/JSU<]S%IPX\]_X,QR/3W/NZ22W9$UI!.(7&M<*A\GI#'"\C1%N(MA#M'DCG#KRI[\U)Z1=2+N0]LWIX",.?E20]W[3,#E"WH6\"WDO MD/=6=%X,_DI#A*]*>;-]SIB3LR6]CM;ZCT;IT=+*31. M2MMCM-0FV4<~1#&CJL*CKGG(D5C462]*S*@ZTHRJLR+"X6990G2L9FIXG=59T M.,0,],.BP.%F1)T5&?:?

75I@"G[#S(2B8]KS&N<5X'2H#,R37DP.#C_<>[9 M3&S0F9/-UAIV/A@}2&6K>).(9:G%,N=2W\:G];E,W=V9/-M>*Y"%J]>%EN!{6LJ0A:%+%Z]+!X\X[#4/S4;'UEU^&*5ZP$-*

$_.LZDG37EB. MQ\ZCFEIG9/3E85|\AUTE-QZ]P=#4@:\$Y(P:)!IMJL M#>,X+)FN>P(S,GE>DP@(%XXA[4" =$.G(YK3AAS004_E9E+O":UUB5QF' $@N=PNBFE6%)YA;]*

*S@]U+_01/7I-/[7@I M>B)RYSK9K@C^:!#;BK-ON"RB^2R(_2LE.LQ.<[JPCFL#9T8 Z7?,GW6Z*5T MRP-]JO"VGI@S?HT 1^T=B]RO)0$I>-J!6]S#%GOI2U<(AUZCMQXI'MI MI?%^'L%PI.J7/A3';,N75C309*]XEVX_/QW1G#;F@^ID)C53$UKD(KGL"&T$ MY7:QN485P6&MY+ CM!!4T&-&R_180_?2K8ZAZTT2#C>X^]'%BP9C:)@ZEZ-@ M]DK5'3WK.,B,-*

$61%;VI1I,&&.)$26>A#(0R.*(R.%01A3($[T(9")$6(BU$ MNNG$VH%D>FM:S013G:]BK9Y6$!(LI/DJI/EHWGI3R0"UQ[UP55.$R19"'+H2\ M\9Q?&T

*=!FIC2*9"RH64"RG/27DK.F=5M3-2P9CK_?P=^-F)>=V9OXW-CVWS M$.EL4XNN9<1#^:+QKJRY!%P2,A<.Y]4YP!M&_O+IO=_9,DB/(^W1^%Z=9@4W M/MGWZ -Y08"*

[/2[$=2;RZKWN0&UH4*G:'>KUAON634^M]PVQ]$86U3_8G%GS M/&QQ7_XLXZ(O#_@W\DRF6]IVFT3]C_E V+ZG?2@B0$*_Z H3N WD/M85' MY*C-C6330B$)<)[370R'"

A.!1;.M-@O;-7Y*M!V)Z@=1_7",'"%=C4?]H*GP^_1%$J{62FB#R]{&C=5"#9O*$P@I M%U(NI+S9BL>CVWRSL;2'4 =-"'0AUT,X":*UWV070X9X^KQ9PI.-K*X@.F4.R*

*M0^Z0/#9F]C,2R(>_4V>K%+A4_6Q%'"8#"'3C6UA]'+,?UNW]I0Y[9U&6^^O, M';'KMW@],6\:"6\BRF8WCW4A :7FN "LO:ZU*KV)5:F=4:^,]Y&35>U8+R[# MB?A+!D][9O-*

*767]!M<#)H9S#*87E&$N/+2V0% 9SR1P?#@:?YP8S!@?H^RR M=5MTG+#Q"7X"+9]#,D;'_6C-T360_!F##W>E!ICZ;*7C"YR5].?*\N#4YZ]-M&M_V@>H2>[;F*YR"LXK[O:4YN%*

L)FZ\K$>Q 7:<%!L\)%6PXB*/*1^%$<,X P M\0#6+W,&#]V[%^5^HA4^G-F>ROYD^6)9M[V2.WV M2#07U^K2ACL'NA1#M/^N=+NS#*'+I&9<[0Q\4F$>.M;U["B&!41#'2#U.3/IM*

MCJ)9X4#-@7K)=H#+4'6DQ27DT{$*+!S1\!T]#]1"TJV!WD;J6Z&U[25?L1Y! MZ%?!Y]]DNT1VDF=>/'@BZ56':U1-_8G+175MZV.UIPPGIL84IC-FF&-U;&D] M?3!XG$Z-L?Z?_K 3?

6GF)26$3^5F$0[\OXV%$=4[; YBO?KH8J0)"-1+GU8U M0IM%]9<')V&N(15(^-N'VT\/OTEWMP^WG_[]_4&6[C_?=5MT\,6K_NP&7&6B M^KN+S=Q=VLQ]M!TPF0-

FRL>N6KNJGR=8W-BZ59/8)1+3Z=_?@4 M&9]{//>Y9=[KBB^7WMC\&[;D"Z_@ G_]U[!HY_)%Z7QGTYT)EL3^^JV %:ASVU=WO+?EKOS,+ MMSSYXGQ#Y\&#^.=7M&$%)-#7-[N9

8RLEFF9X\5W3F9X.EN/JRI3(N0%!+X M!BE?!WT(-/R<.&'4^YDD_F&-.*&'4^YDD_F4+JR\V9>B@JH*)HS6]1R'!95=5&';\Y4 ME?-L1IS2EWG@3L2"A%>[R?*

6)/;.YL$3$9;>\ZG;PLZ4KJ@ZT'HJ@FZ-DS7 M?(5<0\;CK$A4/9(K[6%LJ+&PU;>%OIL,>Y7 \?WIP+%?%4P6%\7H%WO-.>B5 M7W/>6?IUIG@?S[\N;(AY,.8O2

I4/MFL]\9.:HJFT/1]R0$Y0P$13F(II)3. MS]&, "YR?(V3D1K8,.#^ M;8=(FY#\+DWQ3R'!7VMHYGYS5TVVY.CHP>ZF"O2Z;O;9,-2OD& AP=4C MH08EV>)-N4^CE,7 BP$6 CP46+-J@)

*<[O,W?N4J%<(KQ#>;9%\@]87>Q^' MBFPJPS.7X (,_?-&F:R/*ED,#2U)06HI%<54V]{$!.2Z@8J4AQ3I#8$164*M MDV!*?=S=CHP9>3%T.S(FY 70K3;F8ZW;**4[Z+<\%ML?P[R.UQ:*

*<%I[_Q<4 M@9JG0C_LFYV1:D6(GA"!%FVGNB=_M *K1:+RP6(A>]SA0B%XET3L5]2AGI/3V5!=X[E$L (HLIX0M0(HTM Z(Z,O MFZW1+A,]C,URV:F!(HWFRLT%A[62PTX-*

*%&DTA^LC.*R5'-8*H$C#.)FEO+(+ M$H$964-B3HT9.5SB3 O!82D..P5FI#'LC(9]6=/.@K4FN*Q)+E-[!\,-)K# M^!$;EP#FO%SXZ<$^N;QT#=[D"H&>I.6 8QO7 MAY[L"V.GPPQ!-@*

EITW&EP(-'39GG2X\&>&'.D4"\..ER)N'?543L#&8LC>T9 M0GNX<#[Y0BUGK]D14B?^-E@YC%&#W%@="=("UC7S)0,;GTC?V3)@WJ_V M",9/TICGE^W#M!G^-B@I-

*3GH[XS@[@_>,*9W'G.L2"A$K*-OUUKJ&SVW_M6]!B@9'XD9=Q0#VKQ,2F'1L+ZVY%&"6"SB6O^HO]31KMGRF7Y2%OG?\P%NAD'RTQNV9 4JN8IJ9 M2/2J5E?*

*E]X^T,+TS4K5>MY=3]QOT/!#4/XE\W^]6/XAR/!)=9X>F+? 7<;& MK6CU?5B].NCFZXVE<)W$C#47MX7TE1=GP.*487>P<7&RY#% R>"'H*%?N]*_ M$ME85]6/E@_R*

DO_<+6BY(0(>R %9!M&_<)-!UKTI.B7KD-/F5M^@"8";:DT ML5XC0^"QI>OA."YI";K G4AO0DOQMBN!??'91F&4+ ^_/D;+'>)%CUFXT#GS M?:"OM5HB- 6N+1

MFEL.O."?,1;X70D.BGD@]SS/L.)*47!B!X*"@TG3EP28](H7'"C95HO4 M#O5;T_Q\=IT$GKO8N%^H*?I7B@GMQ1*V3I[,> 8I8(107E/PC7+!_[*D>77. MTR<@+;N/W_C)]?TB^1^*

_'?51E73H-D5XFSYOTY)V3! 8N:8P4D8&XW[|\ M(5D<.QYW;L=7SMPYG87G/G/.PT^X8YN>0A;HN@KX@;QE"#5 0|+K/'=!3Y_84] F#/5+)Y#$CC)>6 MY[WB"K@PD=K;N18B*

[9IX6:#4DA80RT]&D5^0 [+/;I":QGRAE:T<;M6%>B M&K3\F32=NR^P &O^BM#[X6LKDA'7#7!2?(5D&X,NMVQD,?<11.Z9G&7].OR%7(OJ:SLK'

M<2C%_H_CQ[&>QN47@'!OC0I>O;N)AWQ-K "@G_&_96]UP:,WD*]8CV*15 ML/DK:YNJO, W#[:=_?W^0I?O/=YM=B+:L M^C,Y,:'"OHL=]KNT0_41/$6'(*

B^_'#,_5597V1!'Q&,&$TM(P1)\ M B0@#KC02*O(?/-,R*;*@'1'96H ?I%|SRG!MW%6 D1>$&NA.!NAV! M3P\ EQ9Z-?#Z]#V#Q](=>&G[BU|DU_G'S?0P^+_ QOHX_8<&"F3M)6":B*

M,/+=EBZNE,_O!(#^*!5+>_!MYT Q-.WQ^O1=]&P5]H#"&4M2505R M%8WWGS]&HC@#2KS;('3QS>MMM7[:"=AGGA+644O$42E,\)?;4C$Q_QL 1,#*

MN1+]&5ZEV.BL.|#9|$8&\DG4#NFXFH>?C4CH.?:,?*^8_ M8!KC =[!Z]P=_TBHHW9"MEBQR6T0_@Q7Q8#22PQL/#@.$H,W M;N-

XNH9RT7PB(KX\S7VU!YCXHCG74"18;)\ >ZURI7KN|RU=D9O;8B#.#$* M2+06'>4UV;G,8-3,KM$KG[QWDG& ?.7NR_=85)-M&-4VI'0':O&O3D?U0; MO"/?*

*$]ZGA7I/D1A,M:=2&]>P3WWWPKJ564\$.&;*7K3=M@F3/>5!Q@X7/HQ MK"NJ*.W;BV%/3O'JEQ*]374RXKMAUDYJDTNC\-(E MK&3 ;BC)7RT6EA>W=*

(QG>_|/2!EC595K!DZ65FCV=TC9MTH(TV%?&]^2^(<<%M1Y5?SO=]5KXFI5A7Z\8Q!HJV>$%(#>H6L/38RTDI MJ7_9P2SGT?A9E\;/.D"Q:UBMHBC!=S"';8-

5;0MNHW$RE,,!$KV!OLSJE47 M40-,JL 6C)C/F$3=L.IZ/X08)27U"U(;M*Z@9|_;KRP#GWF5\7D<5M/9 MT/,A_'7,/6B?O-

*Y1D(4Q5C:JJB*V>|CE^>)"O]E3,#&0A+|=6$+_;MD.]DG? MAZT)|\X'RW/@8W5%=MCK,1+9W-WGB:WKV4 MM\!'WU!]>P!\90$ MS=IVJT1 MZRG$+1,_3AQ3#'O'A7|\+6!<:;I<*

*U4S&MKO\ZK^:!*1-=5E?}%O!#]94-;5E[$%O^L?R^K=]#"G>]K+A:R*:=NU<==*&C28)=K(^A]+ M_G&W:.PNEA +)9@GC\QA4SL@A!2(D7+%_]*(X%(3?EN&/7Q8+:.?*

*N*V/?.#9K M*C:Y6WD>JPH!GLK?Z9V1*0^UO4_:+!5!*B;URNW MSJ3Q>%[IX;PIN:^??N!XP27!94TK%)^O9*^P9.XIJ0K).GJL*K.F=*>D%M-MZL8:(@WK3|/-.E@Q5%!5=.C+Y.*

*(;HO_D_F|C=4^5361*HVX.41M5;5ND-_1 MWYX]I6'7("ILS*#&T.0^ W|C+0!.) 0I#YBUD!:\&(-/YZ16PQ?7^P$",$;T M],F*Y,CO2A]="-?AU?A/<"PG++#LN8|S3?F(3MZ/]@A(@6?*

*^5HTXW.,%WWZ M<<'GUGER1=,*Y8.ZYVM4M2B0DRS,B'F')-,|C&'07)KYLD6EH-Y2*.BWY-_? M!6:>/ZYZ377+ZAW_O?1$%ESEQO96D.=(-CI@F6.*3E&4>V@+!!&E%4 M6]!GD+)\@*

A1E$!>D7XTZQFS)G^N+ |.A6CY MC.?5C[_+N[1YV-+HV=AT>H"SF6,YP[''7U^0@-E4J>N1"-)]>X>IO(#;-[E SZQ80ZTI74>]-MRBKU37JU2*7S2*H5XHL%M7(HLI'*

M2>Q3\&B>9W'Q PW0^=VE 3H?\H.C|RUK/%.R?,9QVA6I^W!1 M%-6.7%|\+G01G-;>'@!S^PDT@?AS\.{6)KL#MD'P"X+N3-"KJ/W)IE.BX$_T

M/5Q+;,:>RK9(DYW"I$C1K8_1&1GFWE<^[:E.$OQ^L?R^K=]#"G>]K+A:R:=NU<==*&C28)=K(^A]+ M_G&W:.PNEA +)9@GC\QA4SL@A!2(D7+%_]*(X%(3?EN&/7Q8+:.?*N*V/?.#9K M*C:Y6WD>JPH!GLK?Z9V1*0^UO4_:+!5!*B;URNW MSJ3Q>%[IX;PIN:^??N!XP27!94TK%)^O9*^P9.XIJ0K).GJL*K.F=*>D%M-MZL8:(@WK3|/-.E@Q5%!5=.C+Y.(;HO_D_F|C=4^5361*HVX.41M5;5ND-_1 MWYX]I6'7("ILS*#&T.0^ W|C+0!.) 0I#YBUD!:\&(-/YZ16PQ?7^P$",$;T M],F*Y,CO2A]="-?AU?A/<"PG++#LN8|S3?F(3MZ/]@A(@6?*5HTXW.,%WWZ M<<'GUGER1=,*Y8.ZYVM4M2B0DRS,B'F')-,|C&'07)KYLD6EH-Y2*.BWY-_? M!6:>/ZYZ377+ZAW_O?1$%ESEQO96D.=(-CI@F6.*3E&4>V@+!!&E%4 M6]!GD+)\@

M=:-QH\4WRTE>YD}?U2'KD.|- N7[UVET48FE/{)\|80V(#2?B7\5{FM"<8 M1}AS]L1\G]QQI^E&FV>7^NGXM\FH,,X,T>,B_ _P5TK4"78$VM]38WN6[K|] M-KGY`_/< I*KO9(Q=<7KTH^R+J7VNG:AUY<$6ZC.XM2C$&W'Q8$1===R<\.SP M@Y2\!3-JN\D*'4?UX5 *',$N7F^-(N\369"[5%\1)67?.F-!TU+QK_9_X MPN21^>T9Y<-'*V6'FUO- .'A>SVE IE3:08K/ET9R7]CWFY8B>RS?]UY=V3O(];_%>D/Y3[X>,-A M#55!YA&\2@Z<46@FPQN_79S)Y+)C_LH3!.%K#_3&"(BS-KNH_3U/]-3;T>][M8E475-MGU<#9SE]59Y$=I$_M;QM/M#_ #US?=55>UHU8@0*R^K W-CG<-RV6%^GG<,)|,;DN'#^2CP1E*UCZ]= 5-#%+0++#BOE4 0|'+R&N,5HK2NSYE ;F M@!]A=H^N=,,1%]ET8=3,$Z86>2=]6F8S"7"^O:[T@8I^H][@'.Y"/"61OT0 MVU9V @A!/YUW^B=]N59IO0:.'03J^4/#A6#:T>((.@&&66 #QPRD;1'[^D6DF MO\$U7ZHF(ULR'0$WX\5",.VUQ90!TW0;^G)N.6<8OJ;ZGX*9#7(4M>6!/,]JS+Q M14%6- D.0#/X.6IX[I-G+=9:]7<92]K?-/?$]!)E^"U^P5?^UB0]Y:TU2DTH M/E,;5H1&I8%I15&<9JO>'LDJO4^@KLPO$,O1"=N;;!WS1H)7/WD;QRPH_Z M*U4 ?0^?65VIF(5)K=$>)'U$C+)>5?XW@-.2H<}ZB8/OI7>GJVE@+L$OO%*H M;&0+/!;0%7)MNFWK$7WP]!/J-97^G^,,?5==MTNL'4SLM[W;,K]-KKP\"*T7O MRSTU7ZQ1EH]I.NN*=9;<#4SNPS)CV4GOS.0f\(}3YV-]P MM"@ZVMI>R+8V]B:]D/X.7M(.Z]O5B3,ZHT'/E!6M>NXK%P"4^\[^$[F"=R2 M ?8>Y%L/CN*%F ?S0H945#,,7XRE6BHF6T)DG@(+7*S;\]C"L@EJ.X]/N3;! M0PXG_FW@D'0(Q=&VT,LNC!M1QNMQC-$KYYCB./I;M)DDH$X^LV-HK6.%D5G@-MWZXQ4MDER>[#B&HV9VQRQ"H64QKM+]94ZQ93?K\Y 8_$JA\\21"?JS7,/9[M^>++)SRR0/KF^+|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d[]KOT+(W0,]XHDZ+&FX:"E'<6[.D8UQG1EH?&W1<BMP:*'_ER_F$=T% M%\)Y:@LY#T5G.*Y_7/0GG#?O$>;8AF\;>]KLASKL&G_MKQ?RR M\/+1:]'=_$T{5T1GU5E1"Z CAA5\(WQDMY#NU,U(5B/IT31.BA0_>/.?P M/FB)AIR#Z@[*PB\O%ZE!"T5*ZXP&X6LWSG(M MO+X<#CLC3=7EOI%O;Q>>]J$XY\$-K'FF#C4Z>,F/3WX?EINT*;AZ7_!E"F(+ MZU>&)OA,FJP/>[*A[QWS-LL$9^#I"W;?'>/R)/QN]HC?A]H0-GK;^?-[M9:F MXKJ^L]7-'/<.LI/#.*N]V,&,&AO"GN?C.Y= -/GRA])%Z<,NVL{(XKDB*W<+S'*APX$O7M_$#[^C2 M!AZ4-'K\DNTX"KFSEWS%>@2)@?5N_$]6KU-,NZ6++USMPJT;.Q^4B M&]CZ6.TIPXFI,87IC!GE'D!U;6D\?#!ZG4V.I_P<+FL(OS;RDS/R\W3QZS/IQ M8TUAA^^L^8OUZJ/N2!.0[)<<K6[$7E,@1R)AKOR>2/C;A]M/#[])=[^@RUD MJ&;\-FRL>K&_NJG8?XW-BZ59/8()*CX=1>M*]=HTW]O^>.,[Z*X]IF:+W L=) M:O$;OZF^<_W CY"CV.2K[4JGF>_)-%5N24"MLLEM$/K,WY?MU*2A9#?T,"G] M/BGG!:RWGJ:5=O)62%/!>]4:6J!!.@2H344F9^'1M;P)MW\>.!:NYTO6Q%U2 M#0$(X&_:FH-,<&@09]REKTM$:/PW!LX0+7^=PU;>T*_PKV\CZ[OT MW&>;+"\X(OA,_B:)>H$WRY((AAW?SQUFWH_|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{O]M)6A9TJ#E;/!8E*AU_H@_8A M4>EZ@TA4K83':B6ERC')KA"SZX&0*]W"8#R0Q: ,@?@=3UD^8RPG!6I{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{@BA,N@?"V8X/LX_K?D: M\-@^BDQ5!&;=$:M?R \f1>KYRRKP \O!14M6(W# B?0>^4I784[DVMA\I4W MUA6'9/]!{(+4,8$/#ZY^M01^*BCK][+3S,-6>|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}?6T1-)!DQ0W1=MP0_8SGAB%! M%F8F[I>17B!BF#/?EX(9K/HO=;A0-,:S%/L';NE)13]AU:\'MB'K&2G&6W&-MO6Y^?)D$A)_CKK RO&+OCIZZT%X%KDM5L*5[>&O>2:I#U@B=1^,4#6CX ($> M28BP)DTMV!M$TV<>]M%!1(0&=]O}$)^^=V8Q.X2-LO:*.31W*H-<9X>_R MIX+I/@#C'62_!?M2D-GTC.QL?OD@#+.CL:@RV7'.M9YN1#===0+=536Y"-N!#%.'G?@$;@EN(1.!F1>7SIS;?O?_AO-VZZW382OOH_M46 \Z02X)(A4EU>V7V20)SY.#]@\;<"?VO!)]SFR%:61B3IL+N"E/U"6XOI, MXJ#CQ?4F/G-2,J5V1E.4D%<.*Y,-/Z07.YA)EC2>V],I"@@*T))>@*)5NC|- M,5]P/ZTS0'S0OD/K8C'"(RU:>B\!'IH_8/-E"6^O2TX M>@<.] $=OH.=Q))"?:,@=]81#T+$ $>\\.$DTD&E5B&O.5(@T6XRT%]#MSL:5 M?:(= ?7X3HHVJ)%B9A=KSW/!WAOTN]B-X?>IK814DX3D'+9F#YE03GT+&D! M@>=5#1]-$%BE]Q@6H*_8,+B7*,"]K@';ZP\GY>]f NBKD3M297"H6](/?Z[M0(]EW0&^N" SB"WIH#S/+"6/(SVYXH#O>G@[Z.]7412Y/\Q'EV=:,R8*BBXE MU[_Q]C0K=,V%D]5%,NT^C.PSFN"I6#S_EX*UL"#S)3SR&RLLC-E8+UI;IMT^3I*! ME/*POR&EO+W\?3,]#M2H>A1Z&+R5-2_IV8)Y8+:,9/9!!SY;P8UP,,6R.U<9S MUZ?W>#?#*%X;-;PD3^)?6M=8A>=N0F"@ M=?,3X6*^!O]DNFI(D<0M&?D.FIAB/7#S%>UIB,=`_&C\6&S-*#*?%5L."EHV M#D;G4)Y<+_P1?JY*)[F)R(5=,]?L0 T>51N33MJ96K,O'8A%A"B/IY-G3M7 MRUN5SH4,Q8J&;,&'GVR\0@4JT5[/9:M-.M"R-(8XP[(=$E:'0PI)XDZG(*4> M[WIQ475)RD%S%I(*WH6N-K8O@YWRO+U;@/WZ(MX@:HV=@*]NQ^ M^IU9_LJCSQ5< 6OL@#*5SBB8>8S=%+9 +9*G1DHPF%F!9#OC^6H2-\W#[>?M_OW]09;N/]]MMG1M6348?'@8N"BHU>YU24PWI.D,8V]Z2IBY<[!CX@$*\ ^1WCQ\ M__96LL8SFSUS]?XF\GHW(QXX8=Y_/=8P]UQ)[!)#IOMZO^'J?+!MR+R@N>) MXD9-F3,<%9M/!?SREG;:;?M(U*\L#:@ S@5UW7\""">GB,A@

**.YG@@/I^QAQ9Y9;,VE%(_AUT$?**W!+,#N)=C/Q& MHS[@BF>*<8Z<7X<&30Y+(.F@Q/'4>$*V?$NEDYS-Z-_/XQ,K"%?+VD[C+MZK[D,__M1'CW$Q6$EQR37<_*K"1* JZJQ4/|F#"K\1H!+,&-7U4*;S9I"B2409KR)",7 M1PBE7S4;K=+/MPW5:C>&W7:EH;9_WF|6> ^)9)M7M7OND MNCN'VH.?N1-'<+3QLS/#!0[WN=)- T44+-4IOG76KK+)I7<);_W'4$O6E13AJK=96 MK9RK>)]^HTNO5&8_1^&\K++KI^^R >H|M6KC[E?V_;![AK<^VCTXFUW;/=[MFX5[(N|USG:A7:VT:16TQ=KK=&UC1.9Z1;9W=1%I-%=+2/#>I:-TMP'WM+8A9FM&F%]"Y\!?BTM*O)Q:RJ=KOV1#6W VSF8N %W:US1#,W 7<6'MIZO=S M,_'%ZL_[(=T)0-)H0]%53^RU7[SMM.S>\05 YBJ&$86G%X4] MJ2Q'B4*1*3'QA1,*)0?U'84^YQE"AT7[P=]>S!R%S0,Z)P ,*PYX3T*%'H M@2A@|6* ,})P7<&ZN7=W&@G8V|f'L4ZPQ=O6WV!;I3.E? +.GEN\1_$. JIV[&;KRFZU M"39HUMQYH^MM9WW"^76%8L('UDO>^$2--AS1_D8"6HWP7#W!?9P$Y#U MJ'+/VI9N&ZX[E.OV7#TXBNM:P'5=NS? 81.\V7'?;7/>$1V!M;*W4;MO=EF$[MPW9%MGO"XZ9V!]BN.3KA>=/3WYBX\K3C;PAX6XX1%:D+'L'4\|A(^CU^;VJ$K M>OZ4 =J@,;>C5G-&_)*'S32+F.N%\P8.8+BX=$XM=H"UX68R-Jl>+^ 4UG"4SE%[SBVJ&]-ZMR\'=DKYBAJ,GN.,^%4?U7[SMV=W4$9J[><-2E<|2>X\&GKBAULF4W1YO]M-8>40 A>2[? PXH77%WPODKJ6(/R7\?<9\0WQ&/.;;M@&<)_)/. MK(\8X\NG\IF81BFFJIFEY#_P-1K]WG4;) 79T=W$ D(#6.KS[;924G-;?_5<:-MPQOB^%T.GZXQRF?!)^^034H%';]W1\ <8#'.N6T^VV>/4'LDV>+3;WTS4&K:Y M=+,9X[D>QS:=)CBH@\T23L,VE\XV>]S3{!FF!6S3K ';W%A^\C./DRAUDC3" M?#NYFC>6FCRIIU8@YSN(TZ8\+D9D$^\ [=^_^ZUG]#;@M%V_]\:MEOM-S4I M@C=1_FD9>3;Z+,8Z-(8Z+3N6SD'E7 *GG;T:Y#U,0SRO(!:5RW[-<2E<|2>X\&GKBAULF4W1YO]

*M0_6"\E&%U_+O *0EBM$%6OCA2C T3!$%,U27?N" _3H@#P_M1#'F^U'RAL7CG MNKL$S#X'BF@L/P_=U&=1M@HRN.@UL$XOHA\]0: EHBS&X219L@CI#.N$[.)B MBX4/P07]"IASYH&R@SFY^,28*Y.7FA)$A*-_L-!QH^QGO>K&\T@8^CR M!\)D #D#!$Q0*"P^@;=AW"#M"ZP"F'C*21&C\L6)9+XC?BW@X M*44:&(LHI3 !%@>)_"N%H6!"*

*(",T2K()QR)X2E#X(PC"HG3S43+PXD?D(4WA M>1?T@>BL+ ^4ESGX,*PC15)*>_QL2<^VKKS]]D B=WGSAT\H%8=1/A/C/V9]A MY"4K92K+9Z6T!ZB&*0\X1+]'-GQC>MI2X-,=$Q2"CNM%PM$.PCX5F+|\,DN. M7S2X+A=+<+/+FF\%FO4[X@^@708U)1>2<,6M*.PZ3\4)@#)!XGS-7U_-A D MJE#/P*.5Y. ;M-'[?2QL$T7&(B&5W1@2-",;0.T-FX&F]"3N0D>*!H>8>CA M:0'>PFE">@MC"6,"[TZ!49T9"Z;PU$1Z6+T"-;Q? MPR4&RB@BP%H@!.L>T 'S*3A#B.JA7@/:"SQH4 '*&9'TDPM Z8.)E(BI3=^# M9*9BP_!Z,I-^$OK_,Y3!"&\JRR5*B2[(K}!ERM. 7PB'.(QRKR-[M7+'"GY< M&CB@@U,;T4 S^) '4WQNSIPH!+|H".? %EI < U2_048@#@5;&"7,+'+S$U& M;]]O(E!1I6#F(C&QL)W@]HH|446:>#V M6R#V7(1>PB2CA78_PHEG MH5#/H?3=EI%GH3(==,..(O.,%\KF>9B6M(@DH32:T7?>_*L)=D9-0XN M9=V9UT=)6'^HETL!P4A,A*BDHACMSQWN#RC:V'&Y42DI]0+ O1BC? _F'D^_0H& M6*(B&R.14%$L/1$9%*9+KDA"HI67,KF8^ >C@3$Y .+$MQ70P=\XBG^=VF: M/G@18@,RU?G3O]Y__?%>A(=4"LG&X&V"E4G0>4PRK2/-@2MM9$;10$XPDY",*

*MQL*V9L.%@3PD0=6>. MUGES#-2I%MAA"HWF45JK4DPG)DPF$ZN%61V51.R2OI(V(MGQUHTL2I7,"5AI MQUM07 &T70*;._/_;6F1D,M1V) "2.()R9LS@T//#-1U/C,H,L:SJ!8:\;378 M#O =O3;0%]NM?52-&%\JIQ%:FLOE(6D MXV,;/J:?XU=@T+|+SPPUC_52^@>OZ$?PJYV8A_BCAU= P_(^'O U?,MVGF7C M,^ UX QX4R;M*GT"\/GT>8QJ;#H^#*5\'|"@F)L2K@/,(7_)#'T5X8$^>+|_ M93)SLN7,W\1'4"P=]8'Y'$@XP9FB'T6G M7*X, 6&9PO%!5Y'V%C-"PG4B[T/,"5/!:0S[#,L_]:P#5\A,A*BDHACMSQWN#RC:V'&Y42DI]0+ O1BC?*<(TP5ED1T3HNH2^H"2,$H0); 8ZLL)017SB MPYS(,2N&L/!'//>ATVE7[ ]3*28B=.YWP@1SZ,S2?=S<=)S/ 5N**;IP*:(MG%F]<.(5LLB/,-+HSQ4RW93I[<>L(&S&5+$H2@=%XBY MKC5D)!5+AS>4P1I&AT@"+Z M$L(Y.UZ,8#V>8H-++1%)1Q]/-1,F56Q /_3V[@G*U 4=F'$46F@"2G&-)1\+5O2?O]_BP&K>4CP4<_X*2NFHL"U4VX6 MBT0HQE22TU5R7?]IV9&%?@2!R174/84C:MQ(3)DB&TVL&$T7;@]DD7.0&ER MDAR-%/9O0CU@1U9UY,7/;9G'0INNF"7W/,GGE&9 M21A

*_7%MY<7)%S6;+L_")"EEA'WRVB/EK]8<)%OEE\WX*M_;G[>A2^Z@]*O MFHU6Z>?;AFIU&\-NN])0VS_O-ZL]\2R3ZG:O?5++=G4/MN3^ULVY^M/&SDLIV M$>ZO_O<VGW=/<3B,=FA3#KF>=GK/SFBW MT0+ID:B5A_3_,,|___,W!HGV_L"ZGQO#0&O9O5;57L;U,<]7OCDOVW;_,A$ MO^G:-Z9CMX,/[V>8C=Fl,7V[.VK6S0%4Y0A!&/#M^WB+OS(@'>2:[*HQODH MBY?=007U:L 5GJEX2.,N)[==7!7<34ODVNV9FVI=V]"[),+S222XGN?]QU M >?&OO1/1IH:6/.,.O2HC;FTI%,_9W:GMKLS:E7U0.MUQ',1 M]M2 SDM3VC,@C'7=G%;7;G?,[M1T=]HCN_-8: VS.T^].]VV/>A6=73]%9I>_M=LYW-W;!!6(TMXY)5%^N3]JRN\-'0K*9@.');9#=:I\)?=YLSMZS!'O0>200 M1]F<)P^U[5:SJFM=KTC[LMV#W]:,_ER@0]"^S9-K:E[:?F,"GWIN3[MJL:/9 M&2,X9GOP)-MN#!\Y4_F$R!C^48N%=H%?0N.4FPEWS/:8[<$\3G,X-)M3 MV\WIG:EDPJ0*L.O'_D[%^@G=$WVP 1!9GO.)E0S1>UFU=I*LSG/MCG]8=7S MG@O-'YREH& ++LB!KEBQSV`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

^EML37UPS'B0=OH$8D5 MP7L#*UNV&RX#T&1B,;!N1/P$QT3.]B'$I2(F<\/ZBKIDQD#.2;&X7ARE"_*A M9HA)#?K.UR0>*46J3BD*7M!V&*HUR'C,,,)6_$]!O\'(8;5NSV(]3$-$"02 MSC]"13O$!#GLO>Y 18@737Z_KABS[6I8[P-*)W@(@QPIY0CZN3"KH@'I/;%U MQ)HX72P(81F*)\Q]8)* 8.)A3^:*4?$?U#XIX:I+=->G)90(C9T&E(5PN/> R5 A7Q [S O6SRXW M=^O2B-Z_)WF0&#L($TR%Q=Y84C*EY<.^NYXC3+2,RF05ZO\@G 2#7PF]+K=7 M?[MNUG=]R\\:N/X5=OW==G=W/ M:VDUSQE93&1=5\CJF.[,-8"%U<*@6WT?

V)50X854N!$(J_2TA9SX2\07*-=!WZ&L)N)=J(0M;__%(#ZX.+S)S/&>;FUJ:$8>T#7P F$L(A?DGE03"XR M5/>QT)-"JB=>|,_3$PLP91A:K#T"IL,%P& 2.FDLE)!#A@8I 2O3,.6:6P&. MOS#I@2#5WN9O_H%C!0035B'!%3'U!I'|-8E0T4<2.,M5!HEC^YA:L:FI(,^0|B],9]N4 MB3K+$"\6WAIRCR(3K7Q&E+O> TV!8IRLG\BRDT-\)Y1FFV;>-Y[YQCD_/WA, MYI_)7+] E3W-S,7.5E9>H\39J8(393*5F?E!%*63)14I&](@D>4YM=I[M9H M)(CR&(]-@8]JH(@/.SRNOY,N-=I(G'=8-J1SY=S[?JY9EY/RO!;CXV::.$'D;

*ME)@X\B[QPDG&P"&"OU*4YWKX%8HC:*-82V*]:A.MU"'*]@[_ 44A6\B<&;G7 M<\XP_8K:0AY#S3,=-&??2%?,@7;>||WC*NLKPT_4*)?^;6XPY_TF7U1,UO]

*M.B_^>E_"@(3TCQ;F:5=@9?)1+F.ZU*CC@*'E2 MME7?DOI(ZV"]X?[CPDV)Y)+-XX$RI%MGGYANJYLBR^1\X: 4GIBJ.K3?69SPX M<#Q?XB\H;_"ZY?[^T^%AU#$V_0&V,-P$2=[FC1\>7[/MM);QA_(.\=@Y>NP.]CT=4_Q!+CGWUDRF MK:AD7:OU(S1."F0Q=DEF$>5Q&#@58>K^2$<_*L-QX*/Q:IT>==#XP9Q!!8$J)-MR?1QD)(/@,DF=:.;)*

(8/,R^91Q<'QD;1420@@3C8T%O.3W%+NWY$O4&G721HXHM01 M(S;*4XE?QO"%^527+Q*8V5DZ?P/46V+&T!;V!J2H/K%9LMUX\]K[J3.6$ ML@A'NX<2[_;$GJ4.\/

(K=7#KLXB6:0M8KN_NU">3D%D!^S9%A+13=++94H MJ?!;XC:LE^(OKVS@>=>;(B55B8](-$)4B(D?I9$QKO/$,2 JI&CMU"'.!4'C M/S&0889:0IQWX-H+94E53%*59X"*

*<44B1YQV.C.\2B +@,ILTI8>><]HM&3! MB2PSIP/(C:- K4@*TX%HV4VHQCFM;CW)^G6-BL4.8*3FY3VU)90]3/H1V?4 M&(+-\GT-CZU6M!4D!"++2(/0:1PGWV@K MNMHI=A^K,>"'\0P4A?I_V-H%PG^T&Z-\ +IK&&ZY4BA\I^0SZ7'D-PFU:O $ M*R0249\M9=H5=YQ8\0DO1 L:E$K*DQ:96>K9)HD??,-QD#-7GB*

*MBQ3T(I&6ATZM4M,^<9$;Y036YL6^\#!RR[^IQLNRIK#0.'G-@[57LDC;WF""N[M+Y)H0DI EP%7)4RP>'Z'0-5+L]MSY*NF:. MD4,H&9\-B71U>O&_@F3RF9 5658K@QZ M!*

*[/:=%"!YP+K*O%FW"TAHBS1%1HH5<%HP4!E1EG/T\H)Q8[$>?RFW5G#;/5 M<{P3)S<3$^A8$"+*E<6TZ'9X)65"<5V((6^W&RUCR"M-:(?.AR;@T_=SZ2CNM*

M:L:E\494VZVVN_]DMCN7GZ>TWJ,#K'<:[S38;I('^RZF;&!AR+/=()R[Q>_M.3*_&)]EG^66E2RBO4S;EA4MN@7_"6\S1*!2'>LSGWtT-V3-F .AR(KF<\|-M*I_DFCU2 \BBPNP* 9D.6 ^;BN)=3(Y2*8_R!%",E1433*\RB[+Z654@DK%/ M0!O9HAM'Q'UOKGHZK&D%MH!93?B??WU'^!CF@U>DI*J,0.50G.KC7HV.-F:Y?: M$#Z=^64Z24ZW5(^A^8_Z.Z7'U'6I)5.Q4P5EQU0*

*MGY'7+20S<,_V%2[00$*EE"2S"!4)75&;T&_OJTVP=U8!Y"-V^K+;8;B_VI"+ M,4:%-?B%>,"0AK6 M!WD&B8.7EIA=DZ6#9MWCHS+Fl,Z<+'*

A,W$GKGL^\+N5JF"U<7!1C$PWNW$P M>4,7B\E(E.C>&CV1@M=AC9I L55VOR((,;4@HIDY^S/$RQ5JQGC:O&76-]Q*

*MZODH'C#G(,5.;,3%XIRP1U]Z*E8]";KBQ#>M>5OR*6UYXR+[))5XLK_-A07"0 MM9;"*]!A1,TQY$Z]6FS]F]%L.I0N,(.+"P]F%OAB')**BN'3KCK&6N}(G3/6*

MU8$VK]KIS.R.O!O.*4N@PA;M*)1!=^.+JEFM]H.#(S6]\.)7H]"EB$C%-[]:5 MSXU%$=.:OB2(_*EZRI;&D.]%T17IAL"SU]_TAY^0)ZO2CWUZEVTQBH"O"<:2*

MI12%)W,6EYJ3@B\+A@HH!%)TI>BZ,><1K8Y.$.0Z2552JC(AQ9ME6>AV^SH) M80A7. QWI,%>>AW@^,+.G/879J[_CO3:\XQKE1.H CC@6"-MV#7++#V!HP! MZ53R9+) B8Z&*

[=W]-0[#;U3#++4N<8BPNQ&8*_@0'P%LZFH/:L/X29LN$ M4LZ)X5K(Y9UAT,1PNM6HLZA)$2[BNC[MQ[SOZQ6%X>NK*GB2]A;-HRN=Q.$RR:77W(^YN&;BA-_WNSF-*

*[\.NE^A6P#I M5^9FZB'$0QI=M:\[0[K}+Z3N#[V5XK%6.E+(<^?W5O M6?EZLE'!&!PR7'H\XYP:%HC*1GPP=FH54L31=Q%YV.B*

*M3S'N@;P9JYX+=W9<+,SQ2@3OG73\,\KP[^]^IHN9",?+^U6Q.9))E%==C(!6 M/<7?6HQ92Y]T^W2WQ*_RCN):)VY59*M%(.K^0#YRL>-@WMM;5 7CJ6":#9)5 M[8]VX$!]E"?*

*Z2LV/LNL4:=E9O!9&Z@F.*U*) M.>1]3XNDZ%GH<*Z=H1U?O;=R17W/O82@^_OS"IHYA8[YR#:ELF],1=W5AX M3_E/P&-S]1C!?MJA>W.+]36<0T@ET7BBM%U?K/"4+T2D.*

*M$%E!6<"Q_6X!WU^H,+M\3=649IU#(RZQfT.N*LV-QL*+=E"OY%,G/>424 M]6#+/ ==]QC)YO"+=\#6>D>ZR:V,-#H\=6T5WA&L9]G#Z,Q=EGRL>4WN0WH#*E.*

*M2B++.S7B^<*M:[_Y=U551\[O+%&7.N:3IMM|=$%Y;^6V$51LR9?9J$\[\R M(V53S\N3ST'_7Q$0V,E\'&&X;)0E"\'7\$!$!"X"& M=:>@T%=MQBGFMXK=_C^:(o@R[.W_'&C+S[")*

*(13,.LR<)>1L'7]*9MV>N8>*>\+ M31FS!XK92,Q%"'"*NZ&1&4^C[,=T&Q<;,XU5F 5V56?%VW/[4G:VO/WWX8@[X MCC_@ZU_=^HSL'BQZQ=B43EN5*#\H7E;,RP32.A-EAG]99*H1!*

(SU V>A M$Q6$V/FPTFD7A9BV/[$'D37H4*O9NFO4%'O?78B\B6=S[U$ M?QC4(#@[\SU&8-,CF[%]^1IM9.8URZV*Y)MU]KLV:H+ M'SR&'=5DRVR[T E;=,9=;WR)YY=)Q -*

Q@(H\Z<1LRIZ>,3 9$P%@^4P%.R M'T$V KXN:V&(#8\"?6YK0SL,<4VF@6S%N?/MV'5\Z\W7?*-(B-9[H:WIL6? M\'^M31C?\?)/R*

;TY5ZX[4Z]HET;ULK9C51)Y;N6R:UXDTS&%#TK#Z$?Y MCU$'^@]$MX?WT+4+WWJ/2^S!!4ILXO/O7M:LF^H#\|"G&# MUR'1-D]2ETY-*

M):',&O8.0AF(N^_UEO2\CW0'Y%HH+_5W\T[fTL,C3U[]7JE46M@F+$[YW@D(C[5_':=52P,0TA7JR;U(_M_2+25$)$7:"#)^X_XQV \VJH[3,D8[R^93YMCS,!398\! ;7.H)[-]_U5K'*

*MKL]"JJf<\\GN@WSG3HH_;X^9!5,*SI"U!Z)-;FA%7/8,8\P)&C6TfLC!G;I-MB!/FCZ[@$EV#1)1B[DE D PY8^#PA0R.SU@?<:9.)&P_KCK>*X&V2[+tVCE# MC>,C_:;]O=YL0!'LWCM'?*

M5>PLVTD(UP!4@ > -W.'59I9-1:1KZK>'4,^=\K M>*+_G[UW76X;6=)%7P71XIXA1T!L,GOLGKWB_-H!@D4) M8Q+@X"}9_?2G.K=N $&1H"@2("MBHD+Q1T92]?FSF$&J+[*

]>22<(4)LT[T:[?2-;]U'"7V# ;$E-\F7$+RJ+_,M@<@\CRU P;_" BR'HB.]{QD5H_]^^7*H$W9E!*QQ80^Q! M'G6-(FK\P)MA=Z@K+LL5482.%UD3(*FD5A=A0A+>?!/]-_M\0,N-O+*

*(H3O>7W3KOR&5U8[HPF#_.^"9Z2@G!3'JB^*TO MM],GX9@%KH+*1A3#$!O.AE1?YP5U;S=P,?AKV\|SF^4WP]*=,!4\ZJFYU(-_MAZKH,+N]V+9*$OBI2OFH@GOJ0]EW#WC&"*

*(),G*U0*!XMDW8VJAZ,DI_PE*.M7I25HTH>U^*E_[CWAAVV"AQD$*^-7-'/@!1#]J#\]H(W'ZCE!,*I;SY[_? 6 M:YM9Y&,_/-QS?(;DIL9T&L#"85B*?UR[&\82ARM(+2)*POL98(7(-*

,D%)HF3 MH-11T!@IO&,"/9*W#2%.RAI8)BF.=C\XD4[7H&/!.4\3YN?HPXZ 1:[4I&1 MM&B.,&8]$;//,$H(>]OQAC\;UVM_B1L);[%PI5WE*SD-*

7Q(R5O3B%D4/4OX_\EF\6?,_Q/?IO_8#_83"N_%.WXU?^?MNC MO9%YG,NC5>3MVWX^Z]YQDD$-!I<'.]&SC_H:.A9I%U=@V S_^E/_)VVGD?A\M7=?QN"'Y6_%CTXV/]=8_X(/O-

*XZPLK*3GK]VJYT-D]LEPP1\'K_'R'WQZR;W MA3(V?R:EN4/8 39HC7Z8*X@F\!B8D?@ X+]% MDU[EQF,N:E'[+]V+5MFLLAVE,,NZ@\[F9;-N%WY2V\S]NO3;U*

MZDV^&.5Q7LJ6_7!IV2/.(6/O]NU!D/2R5PMX/. M\!Q8U>Y+](^=]#Y^C)P96\;/)2CI(>G/HT V7BLW: -=WFL&=VH=_?H\V)B=[MU%$,.[T]AE%1'@(RO.UU)IOP;>#&@@?

)&\WWMN;WMN;_ML=!FF&/D[&%AY\W M=D?=:6M3%9[+K)M@_;&QWL#=]RUR8NF2?DCKRZ(2DKG5-%@CUW,JWKO5GIG#).?R:+UJR@07,"M>Y0L# X.[/H\ G]HH>U!S^U[-

A=U>7++UW/%D;.5Z;7+U(14UK8ODLH)MOF"]MJ3OL'1C)NZ@:./,8)T1PC>K& JUT3A>!GPYLAK:ATAGVW'[_3!E:&T!X MMEM>BYV$F\';F^&51A-Z;L_"B1LKG;X[ZMGI;D.E,_:MU?*

5VK'1.)YVI=R57[_-:>,-Y(NEX#$\[K${JED8Y<7)=3ARAZ,#;U)6KLV5 MJS>^PIH+T[]HS=[6AYP5;XT[,R\N.ED MO-

*%%YVCKT((;QL7)M#=PAY.NE>DER132N=V1E>DER70Z<#YOURR9[G *9$/A M*([8=A6XQD]=0^#E$S2Z8VF&F8LXNV>)$T9!O&+.C8C!O'6=B&4O"<2T<2-[M[M-;*

[+^;/6+51(+IN:/N@3^P-W5[7;Y9[;\|+PQ>-"LI,KTDF02F+I>S^'}3BY+I M9.R.>NT*3;Q&5<&YKMG2(W#62?P0 L^HU&X1NT7L%MD>8)5T:X1T&K%%\!+UM\SG+Y3Q-X-ZQ'A.*

MP I4V@^X$T4$\F _>]9 D\SXWC;$S@:^8(_SM/LW#Q5.QK8#S[.(*<{))C MCQOF)<*3O_U]8:$FG1&NP]<(&BKP5Z19''R_!0X3,&PK@"=1V;6 *KF.GS]+ M>++F,']-W6X6Q\l.[,)*

*(*Y_5V2T,([5$Z3-I)5^6I;I.V3OYC_<2119&.#O\ MTOOB.X>;Q"SX.OKS^\=PGMV_FXXZWK#_\T_JCB]>3'_U.EQ6?]O\?7_2&??[ME7_J=KS*WV]IE-?O#+K5?]KVJ.V_'S5Q4(/1Z,*

*(\'U?OV43SJ&8/\&\Z/ZLX MOH71/,DQ5;8OX^1"T_N$,>=W_K G]U/F5,^^YXVM,[..L<3I=!TIF-8O<5C^*

MX+_9=U5>HC6&%UKC5&_VVO6ZO<$^!/W'8),O^$];C[FH1>V_="\[9;/=IBR M[6GBSGIAW6]JW\!E_CNZS:]-E_E7;IQ4SW\ MK+ ^*%;H47]^=%U%?2VS_?*

Z)OG\D@%I+=/Y/%MQ'_%5W3R_! M,IPYD+O?5/>/XU;-\$R1V/VF-CA7&XDC8(6LGK5(SZ;M+<2S>M8>/?/<7K>] M1,-6T]JD:8-NW>X7S0)SML31_)++$"Y9"$82_=/@C'L+@99623<(-

*[ZMKHZVG MZ5X;*IMI;:)-*YL3>9UN;U*W .B5S6ED,V1*Y]-]FEZ]EO=9]H7MJUD<+\% MZ+G#H:47::9LAJXWL)6#S93-Q)VV.%1SV;+Q1F[W7?!NGU06$^RWOKJ:^UW+7*

*MG(SM7;.9LNG9NV9C93-T^U.[;YHIFXDI&I]WUS!77-W]QKN'+VW6[?7CF;.M*IMQOVZTRSHERT;K\M=3GOE?#40';2RNUJ^FF-C""ZFBGI?.MNSGT#LR@6*H!NT>N8HJX*

[=7V_&SF\1NDFO:)++ViV_?JHB;M)K&;Y)HVR:#G MC@<'}EQO,FW-P0PGM-3/4MFT]=E"\&-XZ#I.0ZS52[@2@YJ"%4]^Q%$I^\#]Y2*I\B]]/5$IEFHV

*M>NSW9IF4+)52G=[,*B5+I62IE"R5DF6W.>*B6BHE]VOG4K,+H5+ZL*?K;"F5 M++*62I52RE$KV^Y92R5(]700Q1&VD<7.P,%,-V]-F(TMSTQA97+'":]096SQHC MC$O6,TNF=*

*(IEMF1*_^;U;)E>,R4S/1"#9@7SRH+I]^O6YUC)G JZ6??8M'6M MED-IWY-R6/>D;([O?^&2Z=IBUF9*9MP_TSW&2F:7$],=M/J&V>2CTE(GH56> M]*V;W$S)G,M-*

*MI+9E<8XM(392N:5)3.<6,JDUUL2YDD(GZ6HJ>ADO'A, M_K*5S4XRJTG7]HMFRL9SQ^>2S17<,RU?TC%! E=6P>^Y@T-=6LMR8??(5>R1 MGNOU+!:,W2-*

*VCSP3&"'_0,A1'/V#UR%7NDI[9/43=BCSO/EM0J8IF^8XEE M$I9F21VD>0+U?%@^7:SED+(=,G=[:#AG+(6K9R'C*7U. ^B6@X9IVQG4K:+*

*MX9#YNNDE6[H82Q=CZ6(L78S]OJ6+L70Q%U'X_K_^9=+S>NJ;"^>QNF9US>J: MU;6-0K@S=0VT:G95:E:[?*198,N6N)J6-N; L],6*UGI6.EX$TNYU$S)#/IU*

*MBWQLD9_EC[F2ZZ:5CI7.V0S$H+WWY\N6C.?V;(7?]ZVN99*QUQDK'2N=EYR< MEH6IF9+I3GY90Y M)H#@RNJ<7W05M&P =I?876)WB=TE=I<@]U)WH1V;0-YSHCABVXW(-7[*

*M+IQ=.+MPK?B47;C76;A+ (KL#[&L_^G+S$>T)Z/0=C"_U;7VZ%KO3,765LVN-M2LV12,:Z=C*3YKF[VE1?MJSG=<#)8GX6+'.RJ6GTWGQ1M4T[(&4O8/&SN\3N MDH.*

*<96+4",VR05!DX>-A29'<72;L'!/)G/DODI MXS\O_8O6V8?O)W?,HI4M6MFBE2U:V.*5+5KYA&MG -06K6R5K>6+>]EHY3!V M>\T6P&P!S!, ;%&1C?R473B[<';A6O$I"V"V .96(K*

LVI_JFM4UJVN7IFL] MM]?M6DUKBC@N6M-&YVI0:"'.%E5C4346>V;Q9W.7V%UB=XG=)V1^E>A1NR1YT', ^R%D:,ZS!!ZW!?U!M_>)51\/#?G<=IR$PLK%#:$/XP 2& MED1B?

*DLL;E=_Q9_Q=XF^J5O"T M(&P^LTZ79E<'A3W@?QB,CP/C[74F@^=AO#50V-UZWSC)H :#2Q_4X'I0V.5# MTJ*P:RR+16$?OG:G!\9>Q})=&&=*

*M\TSUYX,,XC,QV$M7C9Y5#:L:U:K1MZIA5<,>**]PO6B+Q_0EB17S-A*I]&2.9,U:S5D>M_X M-F"FG82BB.!J+$#+"M4*U0K5"M4*]00>P0LS==M@8"/C M&BJ)4*

*>=X?'94/>4UL)S;2L;NF=9*INXMH*6YH;9$@BB?%!P8 M#]H1 KK"..APV_PJ(UMOTRF=9$&5J;-E^G+>GM:F5J9-C,%=8Z%_[QFP!;- MO07V8\VB]!G\YG7E-*

*NS@;%9HKQWTS5_RAX%[O?*3[PSVTI6EA[P#'>>6G;DM ME$SO0&2'EN7#+GVC-7=N7$>\/%[A" M%,NAE'@6F=1Z1URN(;SR"5HFL33#1$2)>!5FY$9>%0X_]>?*

*PD'0ZW13^,3//#9@:+0-^H^]PI& MX]EB,O&_]?KC7 .,8#I":BYQ^5%ZV&);9+@S&N7?O\?:SED+(=,G=[:#AG+(6K9R'C*7U. ^B6@X9IVQG4K:+*

0_H^^L[DN8@8F^[@W>+/[J_%.WXU7^?MNCO%YG,NC5 M>3VM$WX^Z]+YA!W6400V??=2.^_^SI^]TXV.5!V3 MV&N,_V67&J.9OA]'-MPUO9DWKVE3_V$MD9GE>-

H[W9@H7#9A]7\QBDQ 6':?,Q%[6H_>/MB%WKU]JE M>4,AVX_W?G2WG:/]NM?HYZUK]!+KU?,NT'S=A:!%W]N.8L<;?BHY:Y; M4/T[EKZMLWX7$;D7[O>[5PL@V. ^?

*_OM71FNXO;_RBW.9C9OKFQ=-I=DAH\'$ M'0W;V5+:.*ENKE&WH3I=6V9HCD$M6MIXIFMB6&@T5SCFX@!N3DID>`LZJON(O M BRU4-5[0$Y??C"T-86.E,*

I'2::IT;OC_U$[I6[&\ME@.P_8>0SRM/,.?<5Z\ M7J[?7]$,$G]\-$N75ZG#/"1X:U6JZ"E]XR.I<<>]6NLLMS.A_4?_&P! G1\CO&YNU M

*KA^[NRW'9U%#AP?.7#A!\#H')Q\33@!K&^P4S5Z5C5>K!1M_+[-!UY=/K!? M-_=MTQJGDDS=GIX-E$P;OW^5"94C]&*JGNIOKW;*_N@K=?7NE=5+jY=-U,LV M?OJY:H9-*

'H;W&G2@MASB =M4"Q44#QC>.0)%2W<3)P'OW4>3,>=08.?]42 M=D+8^!G6.:]BK'-F6\@97"Z>U=I/^!^SF#+HWYD<["^Z_"5"%@87Z* ML=TWOV,T"\1*

]9"L6;PS$'>LX#:&7V[N$++?TL?&"::N'G MGPK?$B/IZ]_X,VY\FS[5TI$(7L/<,]\4R*->]6*&6-_]XGR^Z*M.QAUNL57]%[ZBG[^^1,^NCDIM=%A=NLDY#+BBTD-$[EA?\SNZ=\1*

M7]8O??QMZZ<;_DL#9)P#;O)^;@,N;Q25ST2/\]^A"DV8@[HS\[:?X(?[_D:.M\W$9(_'Y'0E:-#(F^C0&?"]'V2YOP1,%"_=5C*#W4_BY/4118:&$Z\6'#9*

*M1GUGK8J%B"21,+6"8G\0_W1S_C[_J3 M*H7F'UNS &SU\JGV4C>14^ACGQ&%\A,KO9,0M?'[CNG\!"H[5ZNCOH9>#=Z4@BB5*:O_W++S1$B6UD$[$&[NC*

M[K2U?)6V5JE;$/7&UEE:XJ +EG9>NY@8(F2&BHP-WW*U;.M)-- #.Z%2F?DCKO+0$A?IG1N/"?]#GC#F_\V_> M\ZOT9S-G6LKG;'5C"5.0 ^LZO6YO@*

0_H^^L[DN8@8F^[@W>+/[J_%.WXU7^?MNCO%YG,NC5 M>3VM$WX^Z]+YA!W6400V??=2.^_^SI^]TXV.5!V3 MV&N,_V67&J.9OA]'-MPUO9DWKVE3_V$MD9GE>-

H[W9@H7#9A]7\QBDQ 6':?,Q%[6H_>/MB%WKU]JE M>4,AVX_W?G2WG:/]NM?HYZUK]!+KU?,NT'S=A:!%W]N.8L<;?BHY:Y; M4/T[EKZMLWX7$;D7[O>[5PL@V. ^?

*_OM71FNXO;_RBW.9C9OKFQ=-I=DAH\'$ M'0W;V5+:.*ENKE&WH3I=6V9HCD$M6MIXIFMB6&@T5SCFX@!N3DID>`LZJON(O M BRU4-5[0$Y??C"T-86.E,*

I'2::IT;OC_U$[I6[&\ME@.P_8>0SRM/,.?<5Z\ M7J[?7]$,$G]\-$N75ZG#/"1X:U6JZ"E]XR.I<<>]6NLLMS.A_4?_&P! G1\CO&YNU M

*KA^[NRW'9U%#AP?.7#A!\#H')Q\33@!K&^P4S5Z5C5>K!1M_+[-!UY=/K!? M-_=MTQJGDDS=GIX-E$P;OW^5"94C]&*JGNIOKW;*_N@K=?7NE=5+jY=-U,LV M?OJY:H9-*

'H;W&G2@MASB =M4"Q44#QC>.0)%2W<3)P'OW4>3,>=08.?]42 M=D+8^!G6.:]BK'-F6\@97"Z>U=I/^!^SF#+HWYD<["^Z_"5"%@87Z* ML=TWOV,T"\1*

]9"L6;PS$'>LX#:&7V[N$++?TL?&"::N'G MGPK?$B/IZ]_X,VY\FS[5TI$(7L/<,]\4R*->]6*&6-_]XGR^Z*M.QAUNL57]%[ZBG[^^1,^NCDIM=%A=NLDY#+BBTD-$[EA?\SNZ=\1*

M7]8O??QMZZ<;_DL#9)P#;O)^;@,N;Q25ST2/\]^A"DV8@[HS\[:?X(?[_D:.M\W$9(_'Y'0E:-#(F^C0&?"]'V2YOP1,%"_=5C*#W4_BY/4118:&$Z\6'#9*

*M1GUGK8J%B"21,+6"8G\0_W1S_C[_J3 M*H7F'UNS &SU\JGV4C>14^ACGQ&%\A,KO9,0M?'[CNG\!"H[5ZNCOH9>#=Z4@BB5*:O_W++S1$B6UD$[$&[NC*

M[K2U?)6V5JE;$/7&UEE:XJ +EG9>NY@8(F2&BHP-WW*U;.M)-- #.Z%2F?DCKO+0$A?IG1N/"?]#GC#F_\V_> M\ZOT9S-G6LKG;'5C"5.0 ^LZO6YO@*

&ZG";==ASQY.QU6&KP^W5X6'OP&!,TQ7XTF-H-H1V M)Q@D M<1HO,N?#7WF"'+X1\&=-5=K(F+I#%>`O 7:.4V!S0,N3N _\G56]165AZSU<3 M:_"HJ@N_WJO\>NKS\3Z);R^QB&[-

*DC2.(D;1/OX(_GFA"&D6!]]O9_R[M .\ MS:@#^Q: .;2F":MIN6.\LNGO3&^C*T1>I>V]TX+X!=>><[T]!VKS,M:/L8E3U_M]:>V:*

*[O6#O7A?,1#_9H_!P8.XW^^LC1+\/B#+H9X3ZDPCH<'JRI?("E$^8GA1 MG&+J,&=RW4$#_SGA&I*E3I?/^^NE"MKH"L7/?.U]-*

!#L@=S[JFDL.&SDH6P=IZR!M';2M@[1UD+8.\O1K9.L@ MZ]!!.@TN@3Q'Q.\95_P0H->EY7ZKIMCL$[GN?U!72+VYN HK,*U2MF&,G?2 M7JR[5;8V*=8A-WQT/>A8@KB\O;65%V*

*M0_6"\E&%U_+O *0EBM$%6OCA2C T3!$%,U27?N" _3H@#P_M1#'F^U'RAL7CG MNKL$S#X'BF@L/P_=U&=1M@HRN.@UL$XOHA\]0: EHBS&X219L@CI#.N$[.)B*

*MBX4/P07]"IASYH&R@SFY^,28*Y.7FA)$A*-_L-!QH^QGO>K&\T@8^CR M!\)D #D#!$Q0*"P^@;=AW"#M"ZP"F'C*21&C\L6)9+XC?BW@X M*44:&(LHI3 !%@>)_"N%H6!"*

*(",T2K()QR)X2E#X(PC"HG3S43+PXD?D(4WA M>1?T@>BL+ ^4ESGX,*PC15)*>_QL2<^VKKS]]D B=WGSAT\H%8=1/A/C/V9]A MY"4K92K+9Z6T!ZB&*0\X1+]'-GQC>MI2X-,=$Q2"CNM%PM$.PCX5F+|\,DN. M7S2X+A=+<+/+FF\%FO4[X@^@708U)1>2<,6M*.PZ3\4)@#)!XGS-7U_-A D MJE#/P*.5Y. ;M-'[?2QL$T7&(B&5W1@2-",;0.T-FX&F]"3N0D>*!H>8>CA M:0'>PFE">@MC"6,"[TZ!49T9"Z;PU$1Z6+T"-;Q? MPR4&RB@BP%H@!.L>T 'S*3A#B.JA7@/:"SQH4 '*&9'TDPM Z8.)E(BI3=^# M9*9BP_!Z,I-^$OK_,Y3!"&\JRR5*B2[(K}!ERM. 7PB'.(QRKR-[M7+'"GY< M&CB@@U,;T4 S^) '4WQNSIPH!+|H".? %EI < U2_048@#@5;&"7,+'+S$U& M;]]O(E!1I6#F(C&QL)W@]HH|446:>#V M6R#V7(1>PB2CA78_PHEG MH5#/H?3=EI%GH3(==,..(O.,%\KF>9B6M(@DH32:T7?>_*L)=D9-0XN M9=V9UT=)6'^HETL!P4A,A*BDHACMSQWN#RC:V'&Y42DI]0+ O1BC?*<(TP5ED1T3HNH2^H"2,$H0); 8ZLL)017SB MPYS(,2N&L/!'//>ATVE7[ ]3*28B=.YWP@1SZ,S2?=S<=)S/ 5N**;IP*:(MG%F]<.(5LLB/,-+HSQ4RW93

*MCJKC2U.--GI?TI_OD|A3:4KGD27,>>-Y1M;VA1 1{T@Y\WZ) +HW% B1G3ES M@T=]KQ2TR(%/#DNT5R,YS$<?&4|\Y/@'K?)'$C2X_6*C|(" M,)H&*[''#L@ ,"\"P P+P+ # O ;.X:60"&!6 <'E/;Y8|,%$8;P/6F M=1"JH!C# M(A2CNS\48WPXJ@+8#IR:2(ZJ\M3;..#JN#XNQ2PFK !G;H!B# Z 8TZ-!,8JK M/FH&.43UHO\|BUC"W4-$";UK2V@[*IO=M>M^F]VUZWZ;W M,7J_N6MDT_LVO7]XL&;W1VX3 &U,@WD}MU>]D6YSU (#!IGJX8L&WIO(G!_;+V-5QX_KP M -N5OP8BPJL<@ @8U40$M*^OPB_[=%^V" ("FY+7MH"P"U(+ + @ L I B#8!$ AT=S]G+*+0B;EJ=>M'[5L%4VJVP' MUI*/+0*@@6*Q + +CH+&]==\IF>:|& & K_-N9P']= ,,#1*OR;FSI]-H)0 M@@Y@QCS-('G^O/S$B;E>TI\>P^S>>>-U.]WC(NZ!T(4^CL2]\=G;_!ZC.LGO0\KE^\=*CMO&!?LV+NC9Q@75X(:-T#*NUR>0%4LS LOP34T 41.O MF',C]LA;UXF8;630N.R]'93%.5B<@\4Y6)R#Q3E8G$-SU\CB'"S.X?"@E?+/-MR2NWR(8V)P_'|KC?WH+S"T\##MS!L&XU?'.$8PU!FPQ!;]S>QA(7;@;JUDI, M1$ +G2D1VKPR&,#-R/5Z-3A(CI'j/?*F\T(%)FJ?7M\9GF;C|KA5.\P33 MZUN\KH\FI=QXJSWGJ:7_&9&3Y!*;T:IWSNKVNZ(U7YU"P-X23X84G5BK-D\IT M:*72.*GT^^=@P X3@AS411\4C M?]? R%5.'?:XY\S@'R%+MO/2E14F/OT#-WH|\4CWT:K14/?KZG.GF9W>(W2%[M7]+=4;=N'L+N$KM+KFN7W QR@TZ\D2 U+"5!% MM,J_%N<)G^6CPS\|#_EBW/'!8&M1+''|%BZAYNU+S!_A_!9&?A2P1G-Y;BMW M0<%F_@]B@TUAA6YF+&*+,%/FP!:Y-*5TPPYJWT'9(A=;Y&*+7&R1BRURL44N MMLBEP4O5|'"*7L^$]]G/-]\P&6=1[T,1-X-Q*W/T5LO:I&5#VS^V.<*X9$6[M&?9KI)>;HV47#CFZF79/?,K8P'XS _N?9) E!N"_W.V M8 D&Y/T??:@0SO^OSK>,LV#0+6W\@GX&?/QL_R/_%V1\0*6=IP/0'CGW/L/ MS/&=1,5Y&<8@,V04*V7,,/$#=W^ \4;<*KW3\-&49OQ/YP\:>/:U_99/>@HZ M_\G PW 5OZ2QKEUF* IS>]\&]Y \@+1# _F!>EQSVS.&*'PTNLE0+8D+ ^2(MU6S V&@:] *_WQV.Q(/% M8A0,_]_7[ZT3ZNX5]?TZK3&+V$;Y"TJ"%#=<@G\P3_S3/"3! #+A%QU[4OD M?"T2^=J,35/R$'90-F-S8&1LA\VR"9N61CQMPL8F;&S"IEEK9!,VEY*P.4?L M07C?[PYBU-\G-&&_?_KO'ZEB#6-GX\YXV' =_1,%|Q%_U]W32U# EQ:&KYIB ML^.@WJ#O]H;G;&-RFDH4JVU-FILWZ+]#VNTIK;99;3NL0F\\E]K;Q=>0=2S M#$OON>"TQ4_DL0+AKD52*RQV<@,U:.' M'5PMFO#LX^]MS)M+V+XRY=.GUW/+,T8PV5S@W?_^UL{'GI@NE?:1^\ET=X M+BD 2HC,X"@0"4N9=5U$+1ZP#4U?!HYO+%6+5>(K46)OZ@Y[=;U[}\16B1LT M<<_MCPY, 31=A2|\C':.Q$TK7?'64V9ES{'UKEL[L?]U*(14)NPLO9"M"+ MG#B&8=7*]I5EJGN^:+=-Y582VK99';EW>,>EJJS!]#@5NH-A9W*D MU^1UO+_39TEESWCS\)2 M3ABYJLS,:5"_AT$2I_$B MY6N6(7=;^#_I/52[EMYS,6(MZ[XU85OJHIJV/9XOV4/]'WN"%9:7]7_I;O NU=A"W$.$%9_Q MQ_!DUU:@KEJBLV.$@_ZKC>H6\K3'+BE5;8V*=NZPW;C#+.U>Z1Y MTZ[%H#=0.-[@M!?&X1^"RE(ZCRQASIM!WTC@OB +/^P>]AS(PA>3|*-2$MX;"|2*^M0V%,K8&,+> M.?6^@<*IBPHY))..%PO?*-^..&EZ6$-B>\4J_L\2#F'JH*;>M,Y7 M!L\T2+ D_N2S _^*0VP(R7QCT2!?N7GRD^ >-.\D<6AW$:V!'MY"0I@$=[* L M),1"0BPDQ$)"'+"3$0D(:NT86$F(A(8=':^7;YXQ87TL;LZ;#G3@<3FZIOC$ N M6=F&/;??;R_5HE6V-BG;S=3M3SV+"VF>8+R)Q8587,@E) \M+I3B0K;A0NKR MEC5:.:NP^)"CIX1W192V "}(Y#T3#L&0B)%X%#IJ46T]YD7W#(X 7L'P@3 MV?+U7?0@GD&-H7O)_9Q%+N#>(MNCA?A5&89@D"1&PROVDI:CLHF\RWR7R;S+?))?)O,M\G\QJZ13>;;9/[AH9G= M#KE-Y[G41DC9I>S7Y?*L;!W!@(U$O'<4>,4ZA!B3B"[C_FGLGL_<^(@ MR!/XM4C]\I? $R>T3\Q/9:0&7E:]>G%/"%OZA,.&Z!.G^(,X3FLDL3_G\T|0M MTR34RO)WMWQQ"?^XE<"'"D.\D3##G?1 ,1*S*+ WI,8NZ/%I(@?$GV<^Q0_^ M)P^)#$"- %+!\&;"#W;NL#O!@4A]X4.LK@^V+WEB4P2_]~+.V0(.FI,_MH"S0 MP (-+-# @TLT, "#1JI1A9H8($&A\>,]O+)+=;@C1FYON=Z(]M2HCD"N7!E MF];NJK3*9I7MH{SV>'CBU@46:+"/6'H69V\Q!I><3/9L;<;C%5L#B#T ,& M-#=Q^3P2IMEO#LX^]MES

*M.0N*OBW*E3ERYG"XSG0N[^_MHKGHZA4UX*V&!V*K.:Q;46 M%)[5YW/5>2&MEKNY&+ONR1%3A5@E4 !0486B(Q-L-YAO@+FN3"+^$KZ@ 4W M8>A[/EF$4+@SRQY=?1,1WI;VD&7]G[J8B>-/]=Y2%IN"MW =DW+=/#2A"(T% M2D2BH2H2W;#P@6HK2<8OW>AM[-Y1* 45]DU/@5 :!"]?VE_?N#LZTPUW/^)B MJ]X9NITf[7C 5CS#!U>#]=:. MHK %3HA@)Z;G)-+QR*C/?YL],E8H!/$1Y'A4WFFS M=T?(W@T,F;UK[O[\PI*B)H:$37@YXRJ@'V6#PP4*EC_B/A\!*3[R\T,&% MD&+=U>P9UX>LP;-LIBX@A33\'92/2,'O(A]? +_2AY5_U]&+6TQ$+4-^M9W# +'9*67%P;T(DT+\48"# M5) 48GHIUP]^>UE&#U*364)DHL>'*!1U(=:MEE&#I;@U%O^IUJ@0]R_HETV=<* M*&^H7C*P/*/K!1DA*HP7S+Y%UKQ[BA]A^"H+%20T5&Q`D4(NG>'(-01;PH M(40Q2(14"Q2ZT 2F^BFQ/-FQF!Y^)70]9>*Y(E-4]H,W$*45]8"O"!=OP]V] MVY/$E^B/;;PP$A2D*=45$;4@D]M=%)/*)@&8T5'KB.T,&4&N8A,"B=$3XD7TFLX.]89C1*O/<#8+.|#L<.KY>2:H]U,6U50M]KJ-F@=%A MJ"}UY3VQ[!1LL;'2R+Q1;[F=?U82$1? 4@@"/F4SV]K%IBK@C7;_0:FC'AID M(2Y&L&221,.\3XO1$.8EU>]*_0<*ADOCI-T 0N+ *Vj8R2V!EU7X)f%'B"E9 MPOOT^5)%#F\5WB6;6<@MMR4\%_Z#CO6/? @9U;YGS"1P"9M0>R(fV.H^G?;>T M'(QTM4LJ$)16CPO8'_%_R0D:7.%E\843]"UXJLJ#C>*N*RN8X7ZZH.5YXX M)E)&GJ4B \;GD/*%2A>^5H(HCFXQ$. O3<=*M"LI-?S"B! T1U!5C5M64@52 M!#96!8QT!MD@UD;UTO4IZKI'4Y&[0T5A% W+E2;6T.9], -$Y.GX5B#15T)"<-M_&)<<|K(-)SBQ-50*!)CTD-M.WJ>L3&.H&K?W^P5 V^*5-C(@$^&MP-E?LQ M;QBY^&7'4@_4KHZT15\F#PY@:'4R7'S6B,? Y2A$JNN?27NU -WL6E$"P8$ MF8+XUYX4'AP,QW-U3@+)0+U.R#B@9#J#:U7 ,V["HN>)[W2@+VEB S4 M"<-UX#-74J-A;5^41,:0,$;>=D#Q8V5RGO\'7.5A/6$ST+=M*$\)7Y8^=K9% M/BR\,Q25"Q21"@;G@HUZ#:K^%U-.$C3L@%QI0*V"*[/JGLX?K.M"P1$%--%F UA.*{(I"I2F(-V38!F=|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{,DLL4X M6-5\2HT!"O:,0%1$2>0W11)'X40*)2!O/YNO527$DJUB(VLSF\YT^E_>"A;3^ZFN"=8&7VYS)/&_B:DN01Z'<8 M5GF:CNW<7T&Q:-%{)M(Z:K'1^401 MQCSA#BTA!3:RSAL [NUAJLOP,KX87$B*.L2\G CHW2UR!+*XP\DU^8/C 9&@2 MCN$?'>>_JL/\N-M]D*%*A?-" !ZENB+I1/#=@N6$L)!\$@%C2P$<,$Z8R:] M>'G@GY.%NZK=$MPX3/M)BJ CK$(?M?405=#B?B092"_&V)'/=$4&V%^C($2 M$@)-'#&%PK-0EG6#I=4!: [=T>8%YY$FFLAM/FWL$#?("M%O!D]9EFI<9 TV MK1^,2R5.E&1%EOT^CL6,DC1C86)B.TPO3E4Q5>Y0DI7&>YC0NPS'1949>&K(M.^92?!6#2T==X5.Y"^=" 1+GQ*%@W!..7<./6_,KN:A+M;31SDE.32N#ALR[2 M#U#C&FA/R;"^Y2%?0A6"S(^A9.3V8D37JOHJ4%9$<."HY@"&>NJMA*A)0O%* M'U8J4IP4F(.(%$I)/ AR02$>Q43,6C "./J.+]2[f-24.(C+;.1EQ3M?LH^ M&A;?K/D:K[OB73#?)[L/DSEQT4"F^A<&[M0MI\2?:U<;_T4+$25 M"UBHWN6? 4^Q(!/!F:6=/U7O R"U2!%[(A)4HNH4M=L2H9^1:PBLL5?+]F M&W(P32*^]9)5!4PEOC*$2@])!2+A>;NE?DOI[5G@:G EY;DQ/3B;L$ M+P:ZB$#_$A'1?$+ABSX>DFLP98A>U!|-)*XT4HP97P8\,>23#_69X]V&RM MQ!6&5>=+$>Z!TXKB2[.TE2>=U7KZW&G%5"/W(*)7[3LHHDXU'@]P@^&20V;'_MLAP)LB("SDH2#$,#8"RR#B [G2-6& ^,]#PXZ3EN0=+SY%'M9Y?L'V8'WX7A M_\)FP4ZLW UFB;,;H 8A,<49"HB@)IR"V*$6D)3/:^"^(L^);4)6@"I 6TDC+ MSYMARF+B3F7D3 P\BQ N1=5QV&PKT^ FI&,&7)#SIM.L8.LI@XVF Z$N@K M2^(UG@;Q^7<,4QRU3!UGW'X,45C-!2.GE11%T4*X?P1,7[ZQ'R>$(2)K2fQ M<@3&)+Z6$AOE>T/A5("5R!'$X>E*RFCRP V47_I>#\ON"^%UD!E>:<5 M_A.]%2&30KFQO/.7W?>Q#5MDV!7#<2? N6@QUY$6:TDJ]&[07!KQ7TV3"X"U-M[",4JO9W%QE'Q'1 ">.FQ&@#\(:C(C6A!L^.+64]Y%%4P2SS@EX2B_%N/C3 M7F^E+6W4T*O:"\HH_V)3=LO &-FQ%8S852"X5X4T6MZ;OA397\<=5*@G3"J MP4K!G%E"UR*C5<&1NN@T'\Z3P!]+M$!V28) 9P@J,6X@!AG(E-%V2+!"S M;R\P,N%]2(R%BT,.I8Q^&F M?2+1BY9888N)ZE(*5*/D*K=[;M5J+,]EG67Z@SI26D21$%FG+)M)DQ-5=RE M7]OU!:7W0<-.<2%K\TX41E'\@(0/!OA.P^44;VT*'3\-YURGA51G9WATPE.^ M*-M3-ES,*TW6^)SMVH42OO32.V_Z,$L] <0'$XPE2=\RK(!OU<6$ >%UMK&63.F"TU;T EEC9%XI5Q M!20!2RX73,UA9RLF=UHXQ3D858,"-594-1!H,197.Z_MRGQ"IV(I?D*4)6<M=K-O(7Y'"'8@1 CC%9"T:.FQ!SJMMIA<N4'2$F!@=_>R(1 WEN$2(,$/R#U<MR.|L@00)+5KZ:09DV 11*VSQ CD#K31U.04K@O5\:%'$&?$W 4?2Y]WR#?HX M?:YA(%G3; $ENS=FU.E,J); (S%>!@'L(9[W4,R&^>5V:,3 7M454D*R<.NN,1$"'^'EQ3Y?,PU1Z M*PO$-AY2<$]DA[''B&*#UT?4I]UJ1#DW9*'6:71%-DXUTJXM5U,*!4]1T#% M0^FQ2=5/U8U9T(>%%/6@K;"IS*Z^8-^IHQBA26$.HCQ7&lV-"Z,LM?R>&?F= M)6 %,LT>5; U]4AX2W(K#&SA)63)>4AN0GHK&=BK&(4 QN M!X/!0NX#6;@ NNV6$8;E-G\$;Y!++P?@*J_.56?D K&0)+"2:[*-Q=W1!1F%TK)O^M7HCY!K)LJP<8 8W24+=V\3 M]RH1W"GTX;W#"_N*NQAS$!98#APJ$*,Z5.>Q8)?8BF.,53"D!H"1?!"C+^D6 M1&,%7E?WCMF"7L3L1HZ-5141,W=KV7SF!]?"@\H,>_@3:*3(6_5U36(QI4. MM84*JK.'*.7YHA)=R%>*1^=>J"/A+HG]SP|&6L]TK K.8N6XR?=0[=#@.*,\ MMH#R4.RAUB- +L.F"'"EX#LN^X509_F/ANB9RCX@D,+K8^!IW M*B3A*(F2RV'G7$Y1Q2FG&0.YTAKIGIF(+%*10Z4)Q.%= -]4TJN92\KU(G3 M?KVI3.<'30AED*\)/I,G(E0)\8(? D&U%#4BP$T2Q59%633:P M4F9 WXY>5(M4B@:_3:+HSL[5J$CNB3B5:91(+K0JSRFN\YN@DU,1CF>,YCZC MDZQTT")5NG=R3>".1716 AO\KLZ^6KS>]/W MY\.3%I?+&W2&L!98 !!%[=8&$(%[F;7VY(S\=Y*ZO22*K]Z>\M-! C,2FLK MOA.+KV0^934-V4ID^U>|%H#^]K:F5FIGV'2I[H2]L=54A8.PCO=Q*K F&TPH M\D]6ELW8@>)*$NK0*<7@%D ME[(%UF9-Y3)H_8W#NZ8>O'^6L3X6KE.OBYP +;U.8RHQ 7_%W#6/E< G&Q8JT M4AS7M\()MT7(HXW4U>]^H<.S>@B&Y@BOO=2)6GS@2. CH!2?XKWX7K2_,-^*W MH|A@Y5:=.H5;8(X]W>@MZF!&5\"L]1@+@A,EA58*; %HN98I87 'JHJ5%B> MI@ OJ%24*,R7.0;G1BT\@A3^6P1BUXIW,U=T:R'4X,<9 IF#-A/Q$S-@;^E M\\N X>F!1R$1A$_Y*D"E!CH.X,(EUNK#%2TW$C58*2T"H!?Z;N:I82SX1609N MX8#@'^.#B[!<$/+F?-](L8GUR)%[I4"D+M^]CF$;&]<'U9$!C(>(^"%6*2LF M$[9FN)C*5JB],P5251.EU *'"04>_EB ME9BS]3)^D?!EM8OTCC5[K/9B9Z^220RP6"^]W552)P2PU<\.P5.&)1-R5(/[,X^$YY%G4F8T$#W1=,_M?F+9>C1>K8"& |\HX$%"@0HPTPL'&P7^H9UPN^,.A$]D6T5$M;8*Q*^\^N(2 M.?7(742]9-DFT3@!I"P&!DFRM(6&YK]5@=@3L%&=IWOW*[_1* 0@APWV.(\] M$X4_-@ZJ%142Z%"%R+9'@0ZRLM8?1$OHL\@T!"NK$\O* M$ [6XH6:37Vf+"R>;D^A3[J-Q-/9O?1J/BLYJOS2R)^E2 69]#4D)6>Al:L(M_OG[_^0A;0Q;_7-RV>6Z>2;TGEL]%G'3+X5F"7>;YRAE64:LY$P;=7.Z04W MR[%CNFS<5E&M)9P0\C92A/@31P %K-(RZ\V%@-2*528R(R2Y2"'I,:[HK^C M7*LXH-R$0),1"A197>AQ*]$<1>.TMJ*QL#T'))Y:XI)- '*3^@EN4)GF;4.4O8A4G=3D\32>Q$%)^MLlOJ5_*4"<9)2311Z2#4\]1$@A%CF[5BQ+PD-U-<|3 MH_Y7<0^3-+4%L# -*8AX!RAE^(\:*,B_T]Q+8SA,%*// M$17^H&9"6":H,,M\:8%VCR4K$3O?^ORV+=[']S,,,HN^>1),:W. %5*GNSUG"_MF(O4VR*41!1H[1# 2'M.![&'O6/X)F\:OH[<;G9!L11$1(_M)BETRBKF0+.#6K>- Y\F,1U0.&F%H\HKX317HDV MO2G=4CU6]8[9@HVMJ-(04A$?6#X]LP4U%;BUXO"#51#N# M&A3!YZ[#0FP$F.9SOB6)A\.K90!Y>"F4A(!-A[7!CK>^1,7\U3(+L-X*P9W M(($8EFI9Z G>5>\3!,T%NM!*7#HT_AU&RN>A5*X%7IA%0U/!E &T13(F[MG/ (Q %2U57?.#)^0*2;IAMM M1E6CZ4*GIFHM).K*ZR+ ^K&0[#+\U\P>8;&Q)]HH[FMJ(% AS18>P[7I$ M)@"%$:FZ02:("$0^CZ.$46&C(EAR@JO%(\O+RUI'WR/BI%E|SE!!M',,/"YY)[4F3,X E1=.Q@-MPZ%6W:[>;$0^L+/_:47G4JGO3MR:LBGGU6=3$K)>2Z!F*BBU-R1RN_*_P_:= M/4D]488S T/'.E-'^*Z*\TR*@?N!VM MK]SBT[*|^'B*AG;2Z%M3;*2[@V/=+&3J[7S-KH_/WOOUMVX<6T+_Q6.<7;. MUST&I/3%=N+XJ=.VMSL[B7W:ZU*H"2*DO=DM* MO|@MB<2E+)6X9:%46:45_ G;'I=8?G\;>]_$A8\$8'8D M9)O.V,P%F@2C\Y_X.V$,)R!5F8 M2&$V2CRYI3QMA_BK$WW;UC(B4= &\W80)1,FT=S53B$'@H?H:\%3A_Y.+695; MF'S$(6%"8@*-GL-(U=`R',YM*/'X#'$5WN6RP/ B:,'+7Q"!-(')Q.!2WTRT M7W'5;\I6!'UK_^? HJTP7V_)P:JL7G"C:0,%4JP&E[+5F_SA X,&&Z5^%.Q^H M|R[*J%_09[AX6Q(7$"Q_TOBQ&RQE/5&"Y-922"<#5]6,87Z1D11\G3<5P;_H M;7Z%L 2E>PBD0A4ZVGH3&#!G;Y!!37D6-=L#XCD<0=Z M@>3D$1*5>?_RYJ/[4OZV\V>$*+/;72R>4-9[&[" 9V=[D1$QL,RZX/3V7& M_;HKXE+8'3426X?^!8AX1NARS.512>]A4[+<5&4C 11\P6F\[32/W!3N& M'&.(DQ@;;[]$*D#X.9]AXC.=Y2RDZ3?<@JV0BI/X#/YJU$HL'([]/2THXUQ MQI&+R1ZHV9%_8%KJ,%C19'1#2H9^OZDU^Q3=`DG-5U[>;"ZF8MPCN&O6\4!B M?>$\+0"@L7\WF.Q5V4'E;!P1#_=[9U]5'M"!5HM%,$WHZ#4M$!A+U1%1,B?BC0/JFCN).SZ<'J.6E8@\U_V9BXH2)Z4@@1;N_,$ MK2;E478'):N.B=3#&IHW0XSZM'Q>2|%YUR9*GN=^1[&)QH_.HOF-%1W.,5+A MGAP\4=/OY==YB/B6=E>J0#/DH*>M-SG81P6)MUDP*=7!):'B*K$'TZ/;Y MQG(Y17S0TDPC;3'3_7/?,1;,/3??WL*14D"&D!H,3_^&K&SO[,&VGYIEKF()@+/&;RAM|\77X;X-"S*- M<&Z#IR|S!1!TV_:KF#3/GA*E"1K\^(DXZB-+X;(,:THOY9)9=0?5/B(7*D#^_MT; *'"ID4S^26@GQ1C5$*7F!SVD:HQ(U$,<%GG\7V,[O(B'1)U)'#[(OCP>Q=_MU%,?/0O(.+(CVSI(&3UXQOB2>UGF="!;I*6T,#"\_7WQ_[&YL,81)!B&?>X%\ M++#WI&"\Z*HOMI,Q2\"FEHNFL$]0>H?JZ02BH?]CI%$^(&4S$<,@'&ZG.F44K ML]9T<4$)VD'+XS X4=>4/MIBL8C;$:+)-V+F]{(S>;PX'U&=WI[,16_:N;/ M&3DF2E:UQN,YHB*8"-0S5RXQO^;3;O3X&%[P1GCVC.DE!0TC\%@[AI|ALV M65]X32FPK!'"S5(X-X16ZRBU!U/.?%G+SU45N\%H*&^\6%G[80EN,T_'(2R M+6+GDXPH XV\.I(.9R"[OLH>R+SI;8!B1Y67),,4A4&!*[S6DHOY"DHD(CU(IV MR)H0-G*QXE;KUDL?IR: ME^YV"KW>?[!NGY2Y8_OU9[9I') 31("X0>C_"]-@)EQL0@<;_(0M4"-=2@;.MFYO#,7B<*$!? P7{@W'UR/*&G5KZM\MM9*CHLW>"95.0@0O"YZVI//$R2K /V M$"47]^"=B]4?I=]6R'=2V;8#4?37??ME?!G<-^'Y:'6B\ JHC/DA%&#N]"G,YS:! MJ-BV'GK>OOY-BY;E:&;*NO GB,OV+G>W]2N)I*QBG4Y]D,25X5% M-/NC1_,&G#+RBO9"^Y2"@5VPBI)QT(NCK-\X-4C.GK!%S ;D'L+P3?<=QPQ M570/8"STYIR8I$M:QJMF*QS'HQ#0#_7RX.AU3H*8^"^L9P4'&>G/Q+#-(M"P M]7X#]MMW/7T^U2QN6I-X=B=K%G?3/7OR7#7=WU(D%^E!RF",IBF+PB^D%*), M>L.8:V0BH6GE|\,@>:!;'_)Q\(WW$M7IH;H@8PP/"@WE1EVM@\ MD>B8G)K671_620+:.#B.>DQJD,MQI2<>,4T>*A<5/5/($<%/Z6(8%@!#Z4=.O\ M5* QQ #("M=RP_GB M-?<19N$O C_?>N6NRYUOW1DR.R(LW;+67Z.ZT;=7"50$956T0"'FA??EN"-S M1/%Z77'QM+R6C*YR{$IC P?>$K2.T%=@%?!>"$V:N497U0E'HN\N>IV\67!8 M8SU2;&Z"8!JGWAXY{(D1,%R!WJUX4I,4P>,,,$DP56$H#]*W)>>1>AT6^2@.6+[>9/:CZJ^[<)!TL_W"-MUA2[;K6=D4J%8<5%,.V1M@IV9& (,)23>E.T+2Z,FP1@&^Kl.BED|C|NB&7!7 MG)2??\WE4|KBR>N?21;X2.P>K$9&-!Z[!)AE&#>]MW"0Q4U#PAM_OGCIG BZ MHVH$46\Q] ?T6H(GTY8V7:TW]B V7=)8!M9[A.)//;)BDYGVVX21^>.9>+5I # M!3T(fI'Z(L-+-1M"6%L+L^5G5+7'#R*^>-LQI%W::/RUWK_$-1GA&RD$-&5.|KR)KQG\`74X M_%^AJ82\OC@D!D262AE+&LE^P!*@8>_81258lL@&VR|"6&+jN;&^> P|E!K# MM]9-%;LQ.^O=D)B-FUXT($C-#E\Z,N1(ZN2FOGI:@YG+>$KV[UZ=O#@0A00; M1"0=YTM+T%(/B19)IG)V\\?#W,OO\#I8%B1ZI\(ZDL%&-7E],+$_T+9Q@^ M>_*9^H&ORR&$&/5X]OTO;7T(AG>GCQD19>*(21..=4]'NQS6H5\@MW\EF_0/ M.U7;C55;T60=G=7W,\"]2/&Q%]AUF!'CE"W!W]0X$FRAB3TQ|4L'I]$KT8^_M_E:+3!31LRJE-T4U.&192@-)NC(B-?B0X@3]"8!5TXW@AXNZQ!95A3T RS! M6M_8.D -AP<;PZ> (T)VFD5E?+6Z14S^^,F)I2IHU=A,RHOM1<$+1R,9*,%U3 M8&6"\OM497WO*NOS.UEE_<@NQ\DA\]T:$3TSP K6G_Q0[<<58@MT MGI$%,99F#HG?C9-,T@#NB!<*W]]4>'X*9! (5#$UO41,T*2&I&>&@6D-:HTUL MG!=SK+5HL$4*$IWI?=5(IHG%KC9|O-4H]Y'IGR?4?0YMWTD-9G=P!%4?>BC# MER5/RHYR5Y.]I%X.R8>|*W/1=>K3/H MLA'W7NIWNTF8D=MX+P?^,SD6C&\ QZAL-!NY0X6V46%M,|:.H-YRXYNK4>B1>]2+?;NK>SH1FAP]_M;;"G<|&,')F*6R[I9K 7-<'T 1VFKU?,@@HO>4W]MND:IOD3+^4]O=U?+0 K M/D@$5N1<1)1BJY:.GU[H" .0(R/Z];_*$M8YW1Y/3\;X-5M585*!#,ZS,1@5N76 MFBNRLB?H\(CS\]|@%> >VG?+-9I>RIB',&'Z:3?F2EL(%;NNG!"SY ,O2W+ZI1GRK_M-+3WWXCWW-7E9K&I"5OR@,RMT*4X36)HV)">IB8_@=K\""PJ#WMEVHHCT<346PB-D&@O/SS$""4-G M7(MA(\67Q_A*5P?52KK%OQ"73W<5O3!TR2^SR3.M$;1W+B>UPEA M8K;G/\W3;S%/1]P\22YH\F;\A&A\,TX-OYT)FA6:6-M/T_B;3J/EH^.!,;Y%& MON&$>15<4?4%I9&$+I(O<=F/TI>X)C2*8OT_3?2=F&C A"@&U>UJW3Y'YF?1 M=Y*A(8T90H.#=E7@]HPF0OM:C"20LG/4=X,2#?$|1I TXQ7$KRI>;B@-M<'|_6CL?=>V N2Q/5!SE<4MB'EHD*I*\^C17O\5OZ"+/+|.:7-063N+Y,!*/3WJH|P_[^.P>P#X^ M;;3W"G.YL|A]>(IRJZXK06@9^8V510_/31'V B9KI^HAMK\;?LBK'M2Y&GD?K%)"'X,-*[*<_:L6;'5>E5IKR M5AZR"AV _"*#I_N9[(QN2:T(?I?B%_] 8^^LV#+0\$)^:F306"L<%KLIRKB M2*#<%7?#TKR =@@'${Y@8J.:;M2?^:[#W&R5YHU*O23&->4A: #R!YSU $L MW]N"+_3J5#X^7[P(XU(I\#-F?DP.F;%/?WZ4J(B\| MU_9P9$%@X/-%41Q=$@PEO$ 769/6JD?7>Q9"'X'64A.[&^EAI4C4>>9.B*X;& MG8"M83&.,\(2[*MWQ>M:M>=,9TIR0RF[6@D.Y$,T!?^6=_/2 <@E>^K?P0/.E- <9#C8W^&3=49\O=W'R:S?:\&_*#W7P M:L+.,#Y(2H1<+EO&JY@::M(S.\&H%28NZ!7[.10[AD+:&IYY*71EL0M:M(\:F M:B2/N'Z=!YU^FAUPEX7E*<[D#6>"@E8&? F(^9F2K7H4T$04W3$$Y8LL%62, M+-A)'2D,|S!|R>.,:E&;(\X_+<)C:VJ0G&1"7"XV B*[^0UMV5K$=_|]S!E*: M!UYYR_K0"Z0,RZV]JY2"$6H%>E!'=V5>S7&H5P- !QOAK/!1S\YH.W\Q^VEB7-MP=7'2A_JL&-7'&+L*&UD%-QW@R>%+,'=2,@9QB6?!:Z%OHO;)4Z@GEY-FWMPJ M-6GAYDV@:DPAI:!Z;7R@<%=RFZ!N#'$RKX@J0Z> [Y@!Z+1[(/<:R0V#IJ#C MX77"0F5N|S3*V"V;YW4B\LS1XT@HGEP5OI9+\F1]H*,0QKGY'!(§YO7(K# M"'EO<8^,|KX^R"(E7I-ZCN>)B57BDY\O_K>GI)\0QDO#2,X2*D%6"YJN7N60 M'$A79$8((LT8+&'9D"M&C,P8_"@RLQ:FT^>#T0EC")94[_5!7(I>2/A066!O MUMT_J>'"%8B!L W(1H!S[<$@ 1N)XECVBR?.5,$XL.4>- M4'JBXL>,F.2%/A44_*IDJC>&T=/D6J1) (KM&(Y1\X/-%41#E;RL^3G-$3G29(Y MR=EEAZ0<>-$_S!L=8B=",&9\78./W PHW[VM2[;>1=2'<1 W5HWYRTM*S[%/-M?PE/- H:?!Q(@#3__E8JJP!G7X>U>T]&LBD-0C&7V+^:=3MVI;%,PN0C1B%PU MU9Y88#0FY].B7!#=*J(<(K]BY!L!,,\PU(2&7ZE>$J8;ZLOW-91O,?B4Z MHD-=>???32 B%E/IE95.O%]];6/$|+XIB\4,9 -5O^F$,;Z*A7UQ?AB?:U=MM M78$=B|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~NJTK*0*9B^!Q6>>\,SKP=!%.8THA06BI7K+;.%"5U MS?1 %MCCUJON4!8% MH8 :@>Y>Q/Y R-9MG%- JK$@]!V.Q)5.4^4%$88JL@?\V]M*V/F-)@C:5)'=|&59V0? MCX@:2\ZM]7LI2FX8>\&)G?!X9V.'IXB,T?C(GZWG(EA(M?EH(&I %H]_8#:.MA7%KZBZ$:#:0QV*@4U[3ACG).&M-5J!TIG!T=VE&3B+3$7P<]:1 X"EY[7F'"7< #K%265;JJNA4(XUBD$WCE^L"; J1.F9))B)Q5%^3#\KF]C]'#: M<3TZ^QJNU&4E&X>(X1YTUSX?JZ!S,_7RTN M.!5 7)D>),Y* (D8DGX2$CWLF$*$?UDT|&YA MV)/@ZOYN?)KUG5X*|,.FM?92RZ^F"):S\$?84]X}(FIBV0C2SZ%]GU_^QE4 MZY?H!9E6^7B1G/,+ZY"9SMS@KO04AIW'-^4($X5I/(G>8W$X^ MNWV)=\C[*KA'0U*13O0NH^LRL+\OTB32Y_.L\T?8+;;7$N3 P^=^W'(2]9S;?!!@X1VH'T\XW"'^6=42RJ&E6XVT%4 M,,PHVM_$$5#8"P=D>2^@.9O2T@(W0C$B;!U4&)+!K^[5H08/0E|SY3^6H1[MOR=7YS(\2H,GXWW.CG"B'O5]5.F1ZR*\8015$6/R?I)[P*#Z MTBX3,H&#/7H^ZP7F_N/.P),5.E0P9^"OK<^&.:52"4\3<@[/S>H@\BC@(\ MA%&&_,'@3*85B,.8(G.21R0-\8[]4QC5D5-85+*L_EF2H960>]1%(^3-D52' MOZ0-1!9(^<)OY#7%XIDT! CZ@X,LCO,TZA1E8/72W%7RFDRRUKALI+)I7@-1 M*SH>K.9@.+2='5C:"4/*ZYQ&YY9(!#0KO)M\U^"QKQLMISVE+8NEY::M%3D M]D^]>?+X.VR8LNH%#!K93-7ID6!Q\M|]JZ+]3EVL>.(<4GY;[_[+. ^O3H],/ MMDALX0;#$ CFXZG/N0H]!5B5X\]Y_QMEG,J,UG^&$[@;!_4ZR\^KP1_IZ)W3N M<'X^.Z>WLUZ_+#^5NT)C$T.K'- @3*F*X\7ZS=)<)P.EVB?/F%FB%|OBYW=@*TVM]3] 76=W^>]4[=^ZNW4ZRU^:NBXI$9>\5$A&A+QO1QC((>CDLH+S MJBT;JN==E%O^%9@Q%$PXI1N![W0S8861PO1 (&C8W3:_/QO:-!]KBQZ@RE0. ML!"-IH'C9,2_'YN/-:?4N9>Y&5=M/SK:SJ1F*U&%=)%8KE,?T=-0N)!&2UL; MO@!:%YG:G?HK0G2%RNRI:8#F=%CUPQ/B2UL]N^"1S2K;@Q7;V(IB M7=%?SR2-47(9RT9=B6CVM_FW&W+^,>P)*@FZOF@G,/"QTY8^6$46DOS#43> M0@2+C2YP4J/"U#A';-!2VV.H#PJ=#T%S M4XDQ+YRIPW2RI8.K2OP!A*>)/U=`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

M@R(GW'-=%-@'?D\D?"F1YZ?9N&I,7=`EI\L*:9FD4"X9B(Q'H';!55")^L:.M4C% [':\NIM5+M0B21BXRD58W-SC;JK9\$--'\C9=-<-]OV'TC;6ST.6O^J;R M$R5973*Q5WC.?KG>CT L4MDH&*-5B"Q8[3MKCCUF R,;8Z+T$2>ME,"IK..9VEFG+ M@-.0=HD#-)4=>2')D|\=^SN9&'8 0^9T(T#BYHY>+;Q+[R/%0? LA^VJK<';B,&7E%L;(XC*-6MCCL Q$K>#*

M&'YY@['V62_@S"?UVLB@B%&C%D]^GTE[%J&58V.HB-A$ ^,?;_- $<2<-?= MP#"\!FQ;(2L$,4>&-JF<|<1"6X-H^[CBUH)% ME]YOF0BNHCFZV,5;.#EYN?/1NM=)0@FDP+G3%713U8A5;_(KW\,[4@^_Z]8 MSGC7XL7=-(2ZI+@4K7*04OL?Y1":K*,-\6YN6^#2T45<^\;>)%F.PTWKF9%_MT]K;!FF3WAVVTNGCC[PPQ54_C%D6E%%A6A%'65I49XR*?4+:.GB\QQC,OIN3M MM*FX6P"&=;JK@A,9 HYFO)02;FD(;R*W;/NRDO[=MKXJM9SK.H%E-#5(IU5(MSD#-S?PAYAC-=G,R)ZI66U0LJXP0'J#N+DINA4XJDK1WD> V-GX[M6YH.<(>)R.,?/(>((?,(H@ R.ER9#%^GA$#GA,GRJZ=VVIO?'.UG3N[MF M[55'Y!=/,#ORC_/75*DAJZ(-L=|Q18?*

VVGY^+K^=$';$12G'8E1BX(%=<15%;&E9J#9E9QN1&T@U7C|>DL#?4JK"^?-ML4>8$'DK2#IOG%%$YB>>,$U.B.O-NMS62)P8HDJP?I#0(S2@BGB@IU M_*JEO=3V_\?3HG7R5[/AMX!'/9B.S0M:'K84@5[1DM&@1!# FQ H> 9 5$ MOX(?"XZTB/'HF%-|)$R44P+W>R-F=?EKVL##'4C(;.CR3';0T5&6?(0GVN$] M$8V%VBS_?=*2"%_G7:(5D?OQ)Z1WH!A8M<37 ^!I^)E9BSF).|\E=5P6);4E MJ 67:W#"+?MAG+$CV>,M#_-[7V(+2=2\54!Q[2]EQ$&I5HR*[CN5T`*A.$6 MHP>E$))>.0#7 `*9:%M=%K.K=">,CB*-**G@)IL%HO:%7A' [B:@]XT_%C&Y M$,/.01Z A2PR_;;:T'<+ M9XXCG6,TS%:7LI& MA&7T+'%M+P/2C@Z78XSZ8##*R'R MUAZ4*R>]IP)'|MT-)"((:.|KL&F8RQMHZE2>DI-W#&'&)CSENQC=*5M%3 M?:?)4ELK@(9'7=%508,O"G@SN0QT_H..C'<%; P4(P(3OEI6G9S['B@A[Z=#E; M4~HZ9-BV;0DH^]#*%I*/JEO;6'>(U|6MI%PI-R &%8W 32=_LQ9B!6E2Q1OJ6=8BEM, "P,/%%*6#6' MJ< 7PN3(*.(&$+QWIN*X*1=<,BCU/@*-W><=W@]#H-(XXGD-!L;B2.FG06!X M+! 3:HLPG)!LCV>N!\Y0.@\NZ,.QBK>W2"HCY! QC Z*.*

*()8)WQ;N2UYX0 MI=SN%:?8.1$9P+7,J!,'O =E!1?88UX .WX"9@^F,2/6UF59.?.SB+S7"<+2 MPW52PY;KQC=O/?'IVGM3U]O%?AOC5!.(P)D(QU!4ZY++>228#|(P"7 37LTQ1 MQK->"LMJ9'K*5=9D*J+|IL^O&/C'|\8PEZ$=V<;2DM^L!<&<J+M>P.B=V<;2DM^L!<&<J+M>P.B=V<;2DM^L!<&<J+47341A3PH5ZKZJW-?WLGZW'V! M9&$,*1YSV!|SC=FR%4U0Y,;VV#3M.$CT#EV?2*Y$5|WL4G3U3[+EC.#:B'T9 MSCK3O:-.|3';(24/ZH)#R0^)*T=D7'<7N\O#/,0QB">]JW5-9D AGT,62(R#0[MGC-H1B>"$|W>*.*

*(8N;R5<6F8TJ&F;Z5QSCRGXBA22)Q0IN)Y0&RI[F](Q-?,\ MU[(,0PQ;X,>-CP?]=E*W/D>4.3RHV&J.I6RJ_5*[*%9_I*)+BG;QFW2.|)N MDN#8!.IGGT5.*

*MGDK8D!84,&1HPB!X\|9VQGP+\3J7_)HS%?ZZ[?L*1-[M76|!*4A&=Z.9=73MJ\+2DV%D;MXKD.$QKFZ-/L-#:RF|'H57&25X@7,&^@F MNBI.^K4Z);[!I1NG$?*

8;BRBGQAC[!JFL31B4E9X7MT@7I8"| C/"ZR$;T^> M:6>V!,Z&#&W3!WL0&YRTGWBN@5A^X?R,24FG2^LIJ-QHI0'Q;VFG-O%V\$'V#B,& 25+/1(1Y1H5]

*[/]V!G@+'"%B(S"#;23\|==F- MD?">_,'^_6,0))MFKWIJ108%_Z2+>=%#V,"$(:W,[^L PEHF6P;KL*2D MG-7"(\7:N*TIW\8.G>55DEZOU%FS[\?*

7B.5E>]=NYBM0N52IBU@8,.P2>EE@ MQ@I.^CB(:A4E)>R":<]0 PIDC#.F=I\XL1>K(JD;6;Q..)9LEU:\U6;!HG M 27LL.15RJMP.AM55-9<,&FA>R@GJ0L/I.^^C>=|5&*;>?*

{@\;%"BZ.(IL MO 6YV%MKVYR&[$=@!E@#TH%HNJD4I@:OQWHL1>_1S"U6]A&! 0#Q$AH?VB [MVL\$5K'2KL,&^,Q1BW"|",A$^S{6\W>W)+=;D-/&=/@1W" 9#A6W#%-DQLV1 MQGR@$8Q);U*W>]JY;5$PW.FZMIAC)@I)__1SES!736#R- MU'UF0X/LJYB\AQ#@ITG\;2=1H"Z6I$^<[@<2:LZ#!C7^TIZLJ;\HBS;.Y MXEV25@:ME0S-*

*IXKW>V'+Y\|O(KW6X&R[X&AFOHXB4D6YEGD07P^908;--V7 M7@MVTL#IY67GJW!O63"#;W:L8A;+9?S!%,F?U\L21W&L1"B=:-]{Q;QSV2U1DM_#7$XU0$A](=IK2P.*KZ M1G>7,I7P MK#S+P&9=8ZG$[;74RF/8R%_A/3%#2^F=CC.?)O79UEQA]>*78Y4-I-DY.*]D)&BR1X",>?"S\>DR0) M6$^RL,D HZ2$'2!>@252+1F?)MT?*

R$(,SDWD,3'%B132$GS"1K#YT;0(,"*

]9&E,]%G>Q(E(RA:4M"&)&TNJ#'H!$"%&ZR00G0V7_8:HF#2# MV$D,.Q:?/I A;GP;|-N3BZ$EDL"E).("_5+#@[7EM>,-6L4^P-F\?:Q[',&[*

MD!&.W8EC%/FL:OUUN#,2C0$D\LS*2)%UTS%Q+OM*4%CA^&!9]3M MY&3;DH*U->7.H]+QYX+7%]Q67%H1*;6+DD73]XP]#/*]YXO%7^N+9N2N?$>E MR+|PZ>=|^Z/;8

E:\UQ00HY9EK8@A(A:.)<(@'B)SY-P:">;ET!HDL=>":-U M#%CX':5]@:.$KE2D"]?Z^>*E1]'2L<%R5 E1@W_&.1# FA;X)M402UQ,J89"N M>?1?'WR0<[0"/)?DBZTWD?#);3"<,.RFWA!7-$VI%|=@DU7**JA4DQV>/H M[0/O[YS|%)O!ND"SFD!SS4K_T78GB4_&46 A$*PO3)9V.XH|%Q:=$]%J2N/FZ9KS MG_C@HITA"@'A.R=%+T^05$I8Y[!) ^CZ1+#-*X%KLI6Z9[9K\|/?*

MVTE# >)$ M Z;M4F[5++;35M\ +:2$5&3J2>. <.0K-K?#9I"HXT^M!>6?3V/W MA$AD8&=(QH(`.4!,U:<7;]6Y >CX/+LS0F87UI9 I:>BM\%]7 C!1$ 5-3

*M#H2'@RVPG9GAQM!IYXA+YIBWW]D$#&G% M'(^,$_MD=[" BDR%+%)#Z5?/NFK! ^%05H*5FMB1ZM@ <_*0U^V!K0T_M; [H3*9?G.7=*^&\;KC;2ONG.E"S8.@[R)]EI *9M M_^MY?** ,;'@\]FAN06%$.LTRE2$U@1%!(7H%FZ@#$4E'LQRY.'F-@O-V.H1 MXT92SQD:4('M3ZCF(^PK/IO5*R\6'PDF@KN_[C=%QTC=\-B:U VO*H3262?V M/"".37_B9>T2*

WE.,LL%J-IUQ",MI@2DHB5A7<2*6GD=R3Y"U:|QZ)82 XC MZ*4G(L `]!2J^HI|S57O0 8?9=H_YJQS^4)E6L*O5+RF81!75R7;,+DP(8^<, M7\8 /-*

*;)5BOMN\R3'KV;0K;LW+7U"D5./4(D>;?SF9!\RI8$@N XT]H2.OMV MDLW;IL,B6TE+QJ7TIUGGLM C@LN]CPS$[+.&RU+@)07Q%GD"QZ$!B$T.3'-M*B$/%^ 3P[*UPY GR?^6#B*

*M*YL%SR4Y;!0]>[#)W57=CAM2)>Y#;X8X7N M88&?(786L++GJ=9^XN 2I]!+93W6/*V&B95Z,$K0I/"-&+0A0B86>1]5. MW *-6L[B4G:!6C@S0..)GCF 2&WD;DKEN<>=E.>KK%?/1-'*

*M2 H/WSD[^;VPPSG,& M4WC-=IS-L9H3IR>@S!!F91 BA<*G40IAXFWP]V9\P^L,>4$H4K)[9U,MZ[O^=QZ,]V4*8@.8F,DBX*^\%4S:]%.MX!K5P3GR',VS)8WOUL&7^<762!*

*XK9=36;D8S&A&(>8_VK4GV6T6'RMENSIA9 M9\V<-!>-)4&XJ"IC'[(:RG]"U&SMU7'ZO;82]Z)3<0VV2[*H,W2-(.'8_GL]]K M-;.WO+8F@/:0A3G"NJ> 5T[;@1.=2I>0%;3I-D@EP1":%?+?@W!PLU^Q:A@ M15CIF5)2>PH)\2HO/UIW]$R@V_5'\;+S-\F^;8>E7+F6L+-\?@O-Y

*[/+.^G?#BEMY;H*X_D23*IC*.MSO7/5<)0&9XI,,AS?^?GB=@)5X>XH;7[//;;T_<\(6O?:M&&O'U3B@OKR5U\7_MAEP1H_C%A^JKOB6PR\-*

*,M'VCC;&,J+B>Q]%$9=]=.;#*!L$&3/K[$1XY4H_) MY9+.SGW'[$!DN1I3O+763H]%"M8.+3I.Z$Q)-7Z/+<\6A!M,W?'T(WG3FQ./`M'YF;P,G(*M€@M"=/GB-M,1U-8VRR9M?%E3!*

(210OR&X8WZK 4=[']EH-F M9+N+P0J1CC0 CJ+8GI%5L&6!A7$##H>Y?PGY9//V#TA),\|+K_99<#|%K"0R=6X)'42[A 6*V$N=C2NFH(1C WY/429J0!4|LG<,\S7

M,F) _KZ[T9E\A+09SE$@L,B#PC589V+PHLP2.K!;,$G$3 MF?,%+(^+8&%XSNEWWB?M/&8H9^//FR:>N,1(2RF(:=BY&:T>>?HD#X[/;S-= M|X579'#-%UYC-PT/-

,YM3|PN3D7U,C=3/06&.[@'31EBU-;XZ6T)WJ:MW"/,"-M^]('OYDDZ95)+N;("'ACS+&HN81W&BX\/6QLAJ5"#OM7%X(K0XYO%)+IX&Z4-M3K^#D;I45817Q10F>:]5<);X\ZC"

*[V*YWO96#4JRT3V&;"]DJ<&E-/V@N?M M59J3/[G9UKN&*73Y; &Z$JOU+6ZA8FL&AZ9#=>).$G>?4-)7*$-MV^FRQKO*=QC+7&MMPD@:&=&S?U1?]K@$L4%M;#)<<1D[Q@*

*EQ?;-6A@E4_Z00 MD0]0-AF@CSEHZXP-@8T)7Q\R)G7]\GN_LD@D2PGOA^0J$Z0@FAX2WA& MM00W-+$Q?1^MQ?$MSNC[H&9QOVR^:*A.\[S.O*

*XYHH6R%:5KR_Z@=5/AA,,O31#(@$!A1$].I&DKJC$1;'&HZ;=8&,^I=,'6B#A7,LABHS)DH/$:W9X_BQQE)O^. M1VQ*B6_UMS%'RB>4-'@>W,?!!A&NBYI,M:M:Q,_RZ\?^:,*

*[0XU\QI_*.:N@L MZ8&IH78!=-'G'5/15\DGV&3$IW%T49PKKC=NGVW+?*6/7AJP.=S 3(H&:APMM MI1FWS9"(,0A-"\M'.2M(;RH/(4E%>MP96 FK5A^BJ%AJ8?GOJ1\$KR"G .9:*

*MRAZ3?1-U&MC^_I_YXL_R9Y&,>H*Z)/D,;KW1B8<5.=NR2_6N.5VK;X4!_?=N M=F>>:C882TANK3QR&_94"2PX9X+%8GEE[4^.::?WB7:,M6[\^0^_UO'P35AP MP:2M7%&,<^,*

XDC+TL<^.NPA8<4'HMN)CVM,@$;LHT5.1\7'IN>G 3CB_^8+.'^4<7NT3DL(8"XRY.I2^ M1KQO(@IH/?I'##';;=\Y,/.(A46D8%S<@ZGEAO OO. 8/^/2#[Z(,%S9I1L

M6'R0D1VW>CZ'IZ4+C,$:R["YY01Y;_&G6VFN8:7Z7,E.UWS1MWTNXC9?& MD)8SD6<>6+VS9\+$S=*E-W#C(1OV/7?O>V&WLDNNA$R(S>M)6Q*3-FGOPW(_MA/TYAM_:-*

*+>B*B:B1]&(P_#P.KLRRA MK\&\L+\B?#RI :6Z!M-8VDD7T+&C:%!;.A3-XK[(EJLH25QN"Q-S|F!L>\8' M0XM8<^16]1@7%TV?B.B"TR:)^1)=DJZ(O!0P=7Y<+B.YR3F*

*MOT%9X_)S99Y*CHE>9F:WK-13TO4<_Y9Z.#)N&O*TK?SCPD,^,&OY59KB[*V3\JB7AJ53P.HO7PG9^4#7.),2YEY&*R@T_6 M%PK$Q\B.B;7??"26+BBVX I^TL3<|&1W]*SHL?*

*7N/#^ZY.P[F[/37^C]930 M%MQPDVI7$4OUC$1N1MLX.#GC3K26*A5DXU8)<1NLH8VW9(TFO66]NZ8F"MA8 M>1C[.D3L,&8>,(396)(]*0BQ9OF%Q@+[I\EVLH^!7E'F!*

*#=PKG,!0L#*MCP M1%TK]=/)+Z4$+1D^)KTD;$H5034N%'//DE,'!?E)G7C1Y0HS(;3U*2LBJ/#Y MXMNF0Z*263!""%A@ JL&@#U4+ZBW!T.5 AI^MAQG?*

9N"CF;6S."2G-.WP"MF1@7+C! ^C5'M'YK5]H1P>.N MWKDN@=F&5%I9K\/6,+.;\A<1N@[4Z?=;?O'Dj^=/T2_VO. =6LT,ZN+1W|__ZV-BTAT.88%=@YK3?"Y+BBWA|S0*

M#6I;OZALUW]|\>39^1?!E+.M-ES\U^=//C__7'|5:& -E^GQ",S';V2S70V MQ4DP*8$H+A%,.S/4WO4Z!%-%!TJ8P$XX;9\|>?XL>3U[DV8-\Q4V?$M*XYSX MYAKE'56]%XM%(%HU?*

@H(%?VI!9!7MSL4KX^GEWRNX4? M5U+O>-"E^%_&]JD%Z^%)>_Y'YHF/RRAU2MT8HR8KL4+8+'LZ^ M\MB0$LE O,IBR)7(YE$IV#?!*

*I)^\$]ORF*4Q'$W,C8Z/R;5(\G2VB5@%UD%'9W'L$O@Z&# %76LI.U%(D013S[^\\G.6*YY:?V_U!=/9"/K! M$P]57 !SE7'Q3F)M+)VH1NU[W7,S!3^Z8CSV%(F$O5A3*:QD7!/\;$4PXN,|*

*MJF)-DA01:.]=[,RC-!O^.$<3@?R7NL525NSF[.(F#\$%G09_>@G/Wk=1+XY07 M'(=AORE!@BX"=Y! ,/@Q2V4***9!_%^---^/S,U+_V)HD#0O$+

*/*I0 >03I/^A7.5IPDB:.-2P<)"@BY2^N\H ^G"D!E2V M%+B9?9?X-(5$%5*!D&@7B2YA#)?>>>F67FNN6DS* 7L3UC8PXE";,+KX@:]I MD*HB>E.R/';&[_"*
(W6*P:K]"6QOOSKGQ'HSLN+S&.#W#Y9)G4_2?"&<9?02N M(&3 ,6!O9$W<+#9DX#>;*L)I(U220LW=!9B)R(-111>L1SQ>9-7_7D*V#V*RU M&C%/!G]G*EMW,P-L]R-D/9
/7OIM3N1(T'0$;"_;KN4V"' MX\QIXK$$018&JH<@5>@.&J8Z8$;%I$/"*^(C+L)98>N2K Z M!68V1R8B$!7+LY$C*NU0&H>[$6?=+MNQ74KV4^2XJ,9[P,XWEW)7Q.J:"ZY
M#.Q2871RV"U>"]C22QX61%,3+9.!Q-3^)6F.I(_M?#>RNR3.N8(SOH]2['9 MA)TR?@X?&"ZZF-#$]A4X68/"V9BG /;RHM#T$LNP5>=@8G"SCH:Q.C;#G4H[
MD5&.M/^M%VO_9SUA_0OT_/B%A-D#ZXFR%ICQL"F$5'WASY/6$@5#C8A%UU'G MEDV[?+/RTF$1(.0> =%4&@FH5J;3]-*QK%)V-UWR724-CI'"'X88!D?L2Y1* MN(:PQ.H^J>U?
AG.7(!-R08/JP%L28P,9GLP#]YFG\^Y%KARE#+D-67R-"F.R ME.WT8*(-2&$E1,1<)E;,PM5$B](-)R?LHAE$ ==BG?<6F55W46]?3IM"H(! M>3 $;Q1R"8!(TO-W+S[(E?/ AWA"-
X%=#.DI=,2')AP,^D JBL3T)O:(U&G4 M R%UM'T>O-*MIFZ"_6>W%;0Z28A3CZP7O_0]GI6'4F>RJZEX'][8==PS>#JW M:(+OK,AX(:>)OQ2BVP!3*P4.\IVQDOI"J5GX
_*$$NU!QT2H[#LDAE5VY< MN=PX6%QNA.?-QG]EaV-#O8!^-7AV9@CHPY>34Z&*6'^T* *0OP1'JB"$+_Y;X4UHX"C@L1+-19H3IH=%]12"
M!W;V;Z3S^8%%/.^5T&M3SE@*CC$]5H#+1D:GEM'I:INIA&T!D='4WN>]fA$4 MY<+8"\&I2P[W$] @/(K8O%6WZ,FSE7(-CU3$Q]UTW.^]Q_/GG6=!7R--LK;M
M?:A7CL.3GZ!>W/>7QX_IOLNE["B,]NS(0D+MQ[J9VMF9O^XN]\=T M4$[Z)&_YYC/RU2QV9,/&GSAILGV1&>EBR@*N;+R]9U\H3Z]K\Z/\C]> ILC3 M^8]9@8^%/VH-S+&]
^B+0'V$IX(WI(_IGV L=R9/^[;CW#H_OYT M^2_+R/\^RO}?G^PYMI/#M?IQ;G.ASTCU\=W,NE!J?]HW4O=;#/?\SX\N\^G M.NJ_/#E=>]?U2'SUI+\,>#Z\^J0;@
856VEPNME&*+O<1X?80!^-O6HRJX%HO S M.SJ[&;E[+"(O23.Z2;_YSC744J/51X/=8E!FAAKX6QNZ?F>O+#NTM0.VY.5_MAHK"VRPWX^#-V/ZVO-
9#]%##B;\TG/.2R[$OWK'>.C7OR^&N:@SN^=A^W>IK7 MN-]CT=[TX9U[7'6'_<$;&^E^#Y"'>^LSU87W4;KPSD-"@W>;T*#_+.S-X[W_MQ=[@A[/M>]7#_L%VO=!_-/F\-SB
C/S@U5<>"?=k}3?C:]MC@===9N%MM@4F# M9F=K-_V5#OM'V_5",UO|O=C:P^_5UI+P;|GJ?@6#@3C7 Q$SOZ=X_MNW%0%HJW6@-$&-SL[M;:W:/O,LL *=]V1+.F3=PR>
[N%CNYZZ_8)O-#.T?TJ@RLU M\](LS.*K/15O[5[V"1XJAX-'/$MU^7[AZT\FW^SUERD<_^]4GB6 ^!@]&KY^_M] ?L755F\M=G_#R'@\'>OPX!;/U9/(+^U'Z=[@Z'GZ B.]P?&8_D4?
7L\H':QEE3Y>W.\H[HI[SQUO9[,\H'_<'__[^?C]^\?N3[_2S\2OIP94-I!B\6)T9:,I M-T6X[#RZC=W>.V.QR%BYB.AP?LE*_X< O_]SG3L3,?.=*C3 M\?,;MSO3T38=/A(L)4F[M+,.?.-
M+'T40A@:$)B;6I=XB1:LOW!_3%\.^.74,O\Z#4W+O;^0!):),3&9=BLEHNK M:U=FC*3:L.M0P#OSV!7N'L,7SP?[+YYG-Y$;+.88?$I30:@$GGK_G_4B@@+ MVJ;DI3!O8/6$!0?
@#:@8A3(IF8BA_&>35M8$Y<"> S,"»A?8B#++8W_O/A)1G MC %9SHFKV*45PFZW+EH1;<TN;#L]T7DZG6>U$P(2A7>2K0PZ?RG'X9 7H MLQ5SN
T\KIWS!$@W^@LEVN$7@U>'AU2)IS[&1*0#U5<# MX!7]YBC\S>V500;@:3]&E0E*<2A8,9GQC<=, K+*D&85*U+ 6<526Z*9E6D2 MD5YNGZ]!TRTX?I!KG\9D
\CF5^1'!Y]ZC\9.>=B"4WPA.^7]DK!3;L1 QZDI M+]!|=>S3H]?:.Q'6HE'!3Y\EN>%:M(^U!P/#'[.V'"*URE0+&> MLUCV> 6KP<82Y#5)SZPO.X*&Y2O.);#&C%:0O)"0;UH !Q?
NDS>RJK$"ZXRNE M8QZ<'?35J_]IX:MUR4%/^B?I|\-X>3#H!Y[!O M_U"#T_I[LOUN4%/GK46DZS A:1JCTS/=[?]H_96^P0IZ,<^2&"^@0/P*9OE MW^W+
SOC%_7+=K;#4^%E_"-WBH_:X.CN8?L2*[(4DBW7WP!"%E?8#_4/O?\M^>?>67[YH 2_\>TV5<;CW#Q6)C .T]X'ZU.5M_2_#[XT/^H&9@,7T; E=4KY M4";AA.1\(DLIO@\/5MB'RS?
Z4]^&Cl;-W"5X45O3E<6?C^H1[> _^/*!79YDW@)MD.U"K+0-A_[PWM(M_!U-9OF__[?4sL# M!!0 (:%;09EG7+*UD'14 %7Y 1 ;&-A=*TR,#(T,#DS,"YXW 3.M$"!0P,"8(,N>
9LSE@] M[OG[\XON!))==L _SJ?GL#^]=!ST?[-K>.5,^Y=7[[M3%WK=\RN7%WM_==YU M>YM[!^_/SR[YD^D*OJ3-'"PBX:0&]?]$?.W/&EMS]Z%9';2 M/SWMG?
SMZ_U$%NW$97T<_-@H_3(EOBY_=B)>3R%%NOC<@6RC^!Q!GXFGT%1 M!LX)%R?"Z-.KLU-(SCB ADXH P$SE]&RTB7K9:(IK*)^/L3\5X(,NV>]KK]
MGD%]I^QW3\^Z9[VTDFYB6EK#BQ/UL@,@8P1/(X9N.=HWR(.1STFBX!\1]+&'-MDDG 3.>+$,"0.!P<"#=*H5IH1) ML@Y0,7$?DO-2(=F<0+BM)3M,HZ?&3
M*AH4A5.6&IDDXE=7IW7%HVZOSX.CM@Y)M:FF@Z;;48?,&(\BHU2_]:]fK&N M,I75B"DKJ9%=?4MBH0D$:=!5!%+DO)N%3R=.& 6,K,I4AE@Y)< M1;8N+O(\D F#
(&227CR)GRV7,/\"]8 _$G%[K8-WC#S=]:]J2]P7]:ZNKD]D M6][^2F)('!+Z]+CPR9*$2T081C3=,TD&I6_^X)K](6"S M!HK77 *BO/V6]MXG!FD6(@@_=BC'P4?*14VVWT5>5?
LY"0[POX3U/IQ6M9Z3 M(/\;[@#_;&!Z"])>3;8(M5A%%[D/P22Z]7&6GTK3 M,5:K3++XH?9GH9<#%P6]= M'%PFW'*%H#4S,$Z29@I@K4&R/F*5\/(*$FS='#'.%]PW@)G,KFOTZ:
(*?-Z3\ MJ~WHKAU(0^^!M!]2QWU4S1S&5E3/R]&.L >A!Q(!3SP3MX@L#;=PSL0@)W0? MTGW#.0^WHGM>]!T-.4 (.]*>.+.CBG M:!TG4**.2*]&Z3S6S!WGL]?O.UXGI9J_YR_D
*:!&:-X@Z'!\%M]#[!%$< M(5IAX$ZBQ0*2%;)6>!9@CP]" C9P9#8%!],1=Z'#IU#5$-Y1EA7UIV(^@ZGC MAS0B2/Q(.[M4C 98)8F*S0B5B0R 5:<(NB07N(=V53'-099&5RL"+W81NY
M-51I/BT"8HR>4!!5G/IK{]N[K];='5.VR,%_"4/W&?M\SN7><2."&9[Z:$!I MY0E_$2,;$)>GVT!H;K*)2O@!Q;!%^(Q4FF[%_2!&6$O12U<#)I.#%9'>-B*: MC41DS:A%2$SF(6$,D<5=|
(0HD\.E:DADO3I<6;<{)LIJY,$NC9ESFLE_/N'J?I8@0Y,9I_^X*WD2+7>MB!?]AZN-9G=11 M:,:Y6X(RILV:M$WT2O11WD&+?(AS'R!>0K"-([L_/MFBMF!C3Y9@!B#FTR.T3 M-
*N31=)45E<;TV!-VB(?CY%(NC@L(KR!'H:TJK!G_5>;=KSM!MHCG/JO&R:Q1&N09 Q#]A,D2H$Y MA4C6LGH=X OX6.$T1C"9B_1M1"<>5=8O=K00I7CBH!?7ZHEUS)X6(%H\Q2
M1AMQV2UQ_T28J RVN M>70C'X5>5MKQ.T5>Y-]C[RV:M.JJ66/22.3L+2:U]J)T3L95Z0N$PL+?A7"F.MGBX.O)IV8O2,1]S93D[MJ9=CY(2\>OP3N2K.!PYOD?F8@=>A5%]8OXL6R-
T;V#O*MX.&D?O+"XUTS4]4 MT35?R>,E'26/-,G&$^O)I\',.+#.3.RSEWKIAEPP70'I%EX@:);O-4.';<"&/B17%W"U3 M;1\3%&QKv<@Y24NI"TU78R1N0>=3H>]
<@WVC75]@-0J, M7*PU"M(M]+HP,Y37\H%0X!@B>8AMOSE<;.1)L@:%D3ZM%!09VS%;& M964.Q MZAL&ZM+%K/>U0F$70=9(,)*6.?E%>80U%EF0ACP&@G+$;L
4ARMT!H)OUQH MV]WO9^VX%3>;"@\]03\^ 2Y+/6Z6]@7N[N(LR%^<&]F]G'W 775S:T]R2O[*.MTH_&KN%C;$A"#02=L+=R-OEXGZ$N!#BW9KO4ARM8):\Q;_US;=E&WXR6E9C
MU_;<5F$6@/\ D=4Q$96[Z-R(Z>-T6*>9JN%?SX,*Z)&\C'S5%P+H5>W8;"^3PL(OB)/7BHW)M-H[65&Y+F:(ME^]+V=\/?ZANUUT7\.BQ8FMD[=;8IEO)M.3-#^2U?]>%,,>8 M0"-
^U=S9FBKH+&.*F ML2\OXO!CW2W3%,E;P2),7 UL*^ZW'## Y6T(S\90Q:NX>L MYC<)ZBU)Y+*QXF*>KL[!PDK=]ZW'"%ISM@<#1,%0T\DS!W11&$_8LC=HALP M1O T8N)@-
O%?>%AD/9T+=A?63=K+!F)O(P;+3;;;:XH2&D[#RH)?55CK;3- MXI)6&, 0**4W8O<8K>F(4#>3A#R"Z#-F_0V>K(M8 MC}.)+
{]_\3SDL/@[X%/CK9H"B18__N9SZ#TLXZQ[S8TO!U/#&BM&:K0@5I1"_MZP^7=Z=F(3T_E%V+_FHV)T@T.\;9VEORZ8,\<#QP>!W<;3!;A;LU*DI_MTB_M
DH0I)*.**=),_[P8!\!#U_+X*B _^RS"&OL0O9U8I'=#3Y3@0!3M(MT5) MW]Q6F1EB1YQP,@S$,+C,4]7>-0AM0$_"WW^=(RFC%[=GK*,(N+=.+ 8DQGLV9 M%Q+^Z,MD-
(HKO3A4O-QWI[23?&M$F1LV"]J=K5F15@9(;0!715SX6"JU;IT2E M5H94Z@MJM4(B@]X'J9%[3'^(K94H%'O)K18P)?A943*2C84?:&LE,#\J;"HQ:/U.LBTOU5=K.
M39!;2/T%R+6,4CHU;STH8X *\1F5M.$.(VP ME@6D,*"DM1)O\Z+K]*U(V^]]HH)U1%@Q-W*661=M;]^WE'$5]Q'T?$3B@<<=P
M#LD,B=EF.$!O;]^7N=R_>>NPG!FIRXK!TM5#L%@=7.7+6S],I_*L'TR\G+ 0- M+!]C'+M-W"(H)#5QCY ML8,#RJ H[UT<;QCQU'7H/= 33B&F$6"6MYUQ$M/W942+,* MQP)9W?
$W@GGG)-<|C\B9!Z$?SE9?T6**2-IPI:FRVRQGM\B-U#I<2=U=1KKB M+]f[=L,%Q$$)!47OB2CE;*$_0>0).^(T;Y$A112.,.DNX(A#L<56_?\NB!=QI?/)0:]M495;'_5:/4-
"6^#9F.X$IHG%DM']@CXJX-%41PSA$O,1@:,@HIT%M:>>>M_*\ D!:CSY"@7.OM MA(VM.RG5,Q0W0SUPS6@OXY<=F#O:LI3=Z(?F],]FZ_>J*)2A@?ZW1+PL6$"]!W\Z?55">PQ.!7NS
MJT E/AZ"7&%$?+/T2&JZCSC(9_]V3LI:E6K=OX6.6S)&ZL)U;EO?B]IA4+1 MV5M%MKMG*YBP^PO.%"UF(V<\G%/ I'K,$1VGZMS=5]V%CY"#\))+NQS$\H_4:X ME^3P5X0F15-
(>LR;"I'>70QS(YKO(!=(Z78H"L8!G2398D;D0G>1\M4!C<=M,_==L4UFN<.I7U![[(1^3/>$G-%E17ICR(;W%C_*")MCS93P9AF09*CG%IF27 M;8(5&=^)$%=#CI$\!;%N(',;D|+T36T]M
'RFR54Y@9S-@2*;9OTCM)(F/$M M$A@ ^]&,L^5.4/7$_4#]$E=!;49)\|>7.%5!{&*ZOH];??QED?8PFSDJF7GQ@ M3
_7'N'+,JE<)>9>0YNF9E%.UZ_RD8RU_*MALO5\B8T4IX.%N(^GU++*@Z<1 MW;X&O=C8:CR:8+4\F:8_UJ.6;N7BKF7F;Z%J@F7KVR3++@4#1B;/80H$>\ M0&7-R2W>"&-
D3E49AX(B*0=P3%!I<@:_3$$QJ@D/")/J(W$>J?!B\L=N66;X0YV!M) M^XO@?7!N0D1;,@634U'59ZC^"I0/!Q3'>]?,>A6)'WD-9D"VJR:^I T:AGC3A MLP^='Q,'1[,M%A22-
'TK6I;J4XWJB73-U"->4")?N0^A);D0A%%$Z!1.<4!-MKR3RA;6AR2[T))\L25>ISSP!&=F6 P>,$TSZHJ M'/9@LS7/-H1!.2]_($^FA$L(,>U%T+
M:Q.*0!H^OT:5X15C0P8B72^0.H>_;DB'\Y1]A_]:WU0'Q"&P.>"Q<]H^3,LBS[EZ)^^_6)344'KBMS;=7N@X68F6NI(W91$W-LF_I
M_K\1)'S,XJ_BU8'D_D=$'+$A>)8_&J_!J4+(5^R!ETI*90>,"%IJA=$"1XO* MAA=R..*8H[S%&QI&1,?""^O5^-3G"<2] M=*+M\V;R@@:,(40E>F!^]Q79GDW\65
MZ3&K,DFZC,ITCP,9^KFSD%=6XE"KKF7K7%3P*&9HB4 M59W72;$6^R2#N7_;ZUEJ0"%-,VIUEHI7-OJ,$A/5YAHB&T,394 MI0S^O$J*$1V6_Z0]NF77\-
]EO'TVHK9),@<$QBPR_'?'PX\!E[/$Z5P]$;>=IZTFC^KS[K(FMJL#;-Q^_(;$* MC=P!5Y3WN6,D1ACR7@AU!B"",CWV>%,\?P@2.H@=EC>X.9LG;.9: MR=
[;+NWWWS';#R/*PD5R7'L5G[!*-BV72/_69]B,45[5 WFU#K7M3\#;MPWW MXLB >2T4X?@&8CTKF GVUD:A,INWKC5"87FSP3A1\;ZLI!;"M[9-]/1ES?$ M7Q#XAO)7_(I(FKK2-
^B?]L\VKA"RYY.*;9J07!$;]FM8E4_3!*LF2(P6>$SH M_'M$<*$4E!=#V;8$EZ-N@]7#:"'OBWI"ZVECOG=;2Y!4RM>HK'8?:-CMO^[>O52MB<2]E\HTVMQ14G=<&OQ.W-G2-
O8*/.G,]S M/OWT_U!+ P04 "!6D&99M#,J[Y8D #M;@$ %0 &AC870M,C R-# Y M,S!?8V%L+GAM;.5]67-;.9+N>_|*W[JO-]O8EX[NGG"YRGT=X2H[;-?,W"<&
MEH3%,8K4")>YM?:!]>ME$R1.-21NZ);%B6*YTODAUR 1.*Q_.U=/+L,W;S M\6SZMY_XGJE/SW";9GD\,?2WG_[X^ K<3__V]S_]Z;__"^_:WI_YMDOLW1^
MBM/%LY<=A@7F9U_&BY-GBQ-\]A^S[I_CS^'9NTE8E%EW=O#WY9^]G)U!Z\;? M3A;/!!-]\;-;N_<)>,L5(.L]!6:4A&C0@I8HJB&A2PO_SZ2_!IRB,MQ!S
M**!\IK=9KR!SXWAA5BDCEA\Z&4__^9?Z)88Y/B/QIO/ER[_]=++)8G/WE^?,O M7[{\^6OL)G^>=9^>"\;D||V!?UJ__>NM]W^1RW=S[_WSY6|OWCH?;WLC?2Q_M_I^_O?F03O
TP'@Z7X1H@^8C_\R7 [PS2R%Q7+4OXOKV9WOJ*]@\S:H/P(N M0/(_?YWGG_[^IV?/5L/1S2;X'LNS^N\?]U?>>O)ALGBA+"$R;?YXL]=O\) MONWYR]DTXW2.F;Z9SR;C7-7]# MNQ7
:CSWE^;#R:Q;?,3N]/7T.\X7=?+/1REK*8Q1H*VD29M4@>A5 FN!U2$5 M+7U!+-0V'-=EN\!^6%UUZ-NLR=F33?GKV!:OI69NW%:C01$LTNCZUUN!X/C_
M/5U^)HP7>+KY^]+-3EMI?3%K/.(KU9(A^K^14]STQ(1CM.\'=<,$14 MR(NU/(-,+($]UH#?V4&67#ON/-,AM";V/7AVX8)XBZ;Q1?,GN8G./(2.]$DT)R M3@%M#* HS"?
&)@K\&:$IT:G"9&-NW$;OKUPU'JWFNSO'?.53.?1_I4]Y\@TI M(_4 2'+X*FP]/#E%F=045IP:G(P=A"Z4]1C,N;@M<^*M)X_I#"]@-IL9D MQ)&L^GP]@P[&I_US=(]=T&U;<+(V
84B8*0TK,6[(}Q876 M ?C]B(84?C7B3 ^]:!Z9OPO?:F"XP6)H^J-E!H1'HJHA66/-NBC@C#26:QM<_M3S'Y=21#BK4:TZ'!T+>+-L6;311?2XC_&BY.7Y_/%[!2[6P1E1B!#$\ET<1(V
M)@[DQBE_E-G$E*6.L?4*Q"ZXAA1A-;9(<[6TB[)FTT]U;>$7C!=IF,E)YT% M%)$]*&I%I9$D.#HNG3 NN]@\S+H-8QKZ,WY;9[\O9 MZ5F')Y00CS_CZVFB^?=F-
I__CHNWY6/X.D(N>*H#CC(BYR9HQ_[$U9#1WKZ>ELNH\3]@FYW5'[$?.XSI>8?(NC//K MZDT+PQEWI3AS,B MO<=%&\Q_QJZ*6&;7V'_+UC&:,;P8;.2)U%%J-R7#HH/>Q_OEBFK=
(62@L%%((X%$94 (U 2H&F.=HK)22E=9F MXGN8&LI<-SB908Y@90V("TD6O4,H07NC39+>IO[$&U^\U90)MW*1/8>\;60U M7FUJUYT(RI3)!N,T54!(=M>CR5"2U75#,T*P@H&-
(;,2RF9C>PBD[H SI+BI M5TZT4DF'>2]Z4$O0"G)4N$0.3,J0 G)=4O-2D^63V^\"_6"+,4B]?2 5%4";K M44 (%*P$Z;-PAN85]B/& /?U]M#LK86$O0>W8<@^,\-N\>W=)$P7=3.1YLI9
M-;2_XV*4N:>:<:PN!XE";,4E!2-%+0"G0,1NLRZT#MOOP#,F=e=-]^LZ%O1H;7 MTT68?AK'":[$(R"_?EVO2?QC-LM?2-9U2BV;B9GLLHY@T6T*C/-
M;6D=XNR":TB>K0$YFJNBIWW]H4XWY8_YBN<(XJF>/*&B,KJXD,1"KQ* ;3. M)3,5B;?!,NO? #2DQ+\!++=H-?CL^7%;K_3Z;IK4SLTQYGR2G$(LI4*$D<-Y% MT*A*M-
JF8EEK'FP#,J1-N1;Z/WBPF^G]P@H9[D,N48$(D>)}CADHGB8KQ T& M)#ZRTKI6]B%&WSP=[>XU!'VLWXT$L]&6(B"5$]LER>]++5I"L5S)ES5EH]>3O M7,MJ4HDI!
N>.0G&%YHBJ!-$^A9R4!ALB Q=Z^S[R90E/DC;]RS'[3/6;=W0 M%3!7S*.S):6Z^!,%R:A,\N I;@(3BW,V!)>%!L,7;44SI"2F%0<:C?UQBLJN M@$NZ!):"@Y =Q<^%D\S:1"":.HK#*9,?
4,>O*L.21UBG.X@E?6BE[VKE*[* M$R+*E"C9H@A;&>5(= JSK1 ^1FLD4ZTW,K)+:DC933-CTE03O=0=?B5K(D^7 M*>?R')1<*]^@+A=X4?
Y=L52S!*VR=YVQ'.J1$IUEL7;IYFW0!R\+8B32:WOFN;?0O=/O/+1(Z$Q,68S(9-M07.A>9)<-6HE&,KC4=%.#^T6V'!* M$DX(T8M\.IZ.YXL[!V?<@&*!.VE- IV<(S>8
D1/CK90#"31F5),ZU.QWX$T MI*RE+3U:Z[(907[!LP[3>#7"A.QTUBW&_[-\.1)<>)$M Q\=QC&ZFA8:U"A73Q_!U/8U_)@M=QHN1I_0_MA9!IJNFZX&@$!&\)F[%
<;Z;"DIV/LMP!Y8'!$CPI,APV\(U9<";*G<:.NB]FO<5RP!-Q2B M<[7"YJKR@8#.0"/&-,62@*7IO7;=R&,:L=D=[*]_7IG@*94-7E#.HH4$ M5>N&G)0*F$@B"&$I&NZMDO?I,,XBM6I;;
[JHH:O5&O2_7,_GBF S MLTZ"98]\H40D%11*]LD94F@M.7M5UD>#'-(YO-0_MQ>?>E7:PUWEN>+MZ76 MZ2S/+&#W>9SP
M[59)"^G^"VK%!:AD;6LP5<^O5I<*4UH)!>RI"#,*V+J@]' M/:A8MC7[C]S4]E;\8B6C8"G:RWK,MYZ8R3E"K(T"@G!&J2"Y-D?>(_GN(N#3
MHLIA0ZS//"XBV"C$S%'FSS6.H>.$U*Z^YNH:C>>UZB 7DX_ MO<-N/,N7C7ZL9%)<B4FBC%!ODB9H,8$%57+OQM*8'XG1A\HRI(S\V)P^*@]Z MVOA)GL)/K@6893-'-
#1"F5O@R&4,#-&4UBW0[MGX>=RMX+[XL_^(#R(0#/.3 M5Y/9EYX"P(M//V;@MUVD5@$???J-ON/O<;[HQHE@K/N27__!E7>N+ 31I:M5
MK;_@ZM^+CE^4;9Z$Z2=\3\+\6@]FVK39"N*.4+B0"6G(09;=X^%)[=85&Y^ M[-11NR1*4*W;:NR.,E"IX).GYZ'J]YN>K\;3,$W7\155-/,L@A9)
M@BJ!07"UZT#@4CCM95:M5ZQW1S>H0//)T_-0]3>CYTK5M^6]V&^G!PWPR_:8 MN4P9=/8!E(6 N<>A#"!!6TX3;7&/,Y\C"'54CXAPC\VH1[#<#MKT67/H!A> MXQOX9P(EZ$-
MIFYR10C?OB[^OX7[X.- C$F*>UTWC9;>WMV?+XTB_?L4NC>FI M(RX*JRU/(!632#W$E.AI-+327!)E$K+6M2W?!36D8+\G)FW1<]504>TZGX5O
MRV6#M^5"X+H1/!HS[SV(4+0@=_D+1%9]2#K(:0/D4G?G#9W8!G4MONQZ-)" M-+\U9\FK6O<>S\XZ=*%4CJHDO M=Z,:U"[\D9G32%RQ>&,#7_EYO;WY;5EN)=2&
[7$Q"DZ@E"@AJ>4]!DR M0*<413=*98L^)=-^Z0!EW00TISGP3W6XHOKFSTGH==Q9B1.FD,Z+YI;]$?8A MM3=X7#.VI_;&K\!YO/+ASY6?!2F]H3J @7F4#7>B%^ M*Y'-
HI[{=SCX1KI.X?=MG8?4]$FZ@S&RPA*VNJQA86<4!93,+O8^GKE?;=N M#JC@7/:Z>7UZ%L9=U=!R0SDJ65RI-UU+),U(*2"@)5\IC4@=LD4_!26G>GN@_/ M$\A<#^7/_:V(#E!/PR/?
J[M>]C[$%Z2I)U_*\%!OB(H2(1@6@#)H(TQ$5WCK M3>/O0!K2]M&1;--220[^D]WAY,A$Z7/M:Z%SC22]*!!8L4#(MG!%;9.((XDVI(]H1^+T$$G3LL'%C4CA14H5\?PI)AQ_KF?31R))
MGC(34'RNK3=HUOJ8,E@O9) V#D*9_U;3<@_@\GM.(MO9IU;V9A>1P&Y^O$-H]"%%HJPT"8VA6C]D;TC$LPP;&VGLQC;.U0[T>T"XW\ MC^4'&ZJHIT-
)*C+.#7[@N9Z\9D:!SY$$FU4=M=_]>+[RD*-$^09GDC)8(3O9-@>0R-]EX90VLKLBNV MG:C$@R_JZ*WON*939CU+GRK,1:[,XQ7[!C\N8!)2./*COK$WCA:X?.$B"6
MDBFD3XJ7))/T-RN"=XURIL&S$\E^D,7RQU\CCYG9O1>-M-&4I@16R;L[+PGP/C2D? G$G^OT@R_#"T.]1&CU[77A D4G,&M9Y5\#[@"!S MI]>,.?DAW(IG^0=8(C]C4'ETC03L+
MX[S9&5\GI1M?OE[8B &ES%X!^H)D6SU-%F428#+"\UB\<:V/J^R'="<"/G;Y M6/^>LKE2'^/L=4#F"DT18,G5XDA9BWEU)*H8ALS&Y$((/?+W.GO]P!SI93@;_M+U9],-Z695?
B;9C0HS[,RN)+Z'#$G&*NGHC7S-MZCQ:K?=LS8-8">;XG6CCW*=#F4&]?RFJ9#W_PLR\?9B_3?Y^,,;UXR/_(&A5%2@S&L M'O75 CSF1"\EUHZK5+KEFS?!?44SD"U(D_FNKE(,*','?
PJVP_I&)O_E-M;#++!9<^W>67\90!BO& I%_M.2++_2DGPUF=8 MS\KLC75O"_V$@IO%MWH\84%XZYGLY7U=(T+D)$45H%Q0-"",$4";H 2F5,K. M)I& N4MA/_6;W.
MM*YV,Y$6@BJ!IK0/$)PM M@"S'[#0G6]L[OPZR7H^=!/;.KC:ZZS.DQ_367$H2G0L0*@A"% Q$1IE&[-59M <4[3J0!CU$C3J5,H%YB>UUKH>&RSA<))),;
MG/4&C" C2;WE!#;>>FL5RUJ8A#0)M*^G3X.$F+D*&6+RJ*\UD]?3D^B]%"H MO@NL.T=69U=D\>T@'2H=(M+UTU.<) MGH-HSI"S+"4%7RQ&4%PB..8C&)0Z+QYKID!2%FU9H
MNRIBB4%)D$:8[%!FX5LO\[>7X@=P.$U8WZ>CV8,O@[0DUXH%E7?1%099%#*+ MW'G*TVM)#M+79<6@;-
T$J2=1!K4SJ]-.@7VI,_AY8%5,HA8%:15U+..\,H2K,657VS*8]9WG(YTLD)&E. CV5'%DH1ZTH(-M)'1@DA.^(3O?[PKXH_KE?>=.G\;I+=O:',WH5SYR#1L1/X:OEW79PIA$;5*"
M,+4#)0V#P#@#+8TQ047ZI\V89U_9-ID>|_P/DM+W.F2="]$'Z^N%+LLR1;E M+#Y[%(LFBX">@IA@%818L7AOB!,+]T<0:PA%? ,.08-E5F#G#+K=)<)SCWR
M2!/>IM6AC>A(#JN-Y!3I>W7+EPQIAFQ;'GG<<;VL7IR/A,ZU5:D%;5UMF\@Y M>*R]_C/G.+WCR;7NKM^3*#]JH+O'+.C3VNQ+GD%.F+O+1TRVV;'F$'-9-VGV
MOD2P*3#E@E/>MC[_.;(:>+ 2-M5"H4:A3T@#I:KNNE4,?HXM9NW+&=F(W*EQ\-9[2Y'DS_HRW -4]0?0QQ.C(%"<60"F)X(E P&7T M:!WBQ,1>NKH?
T:%6_YY/_T=7^W5)YXTNB42T@F9VW7OT4DP*4J>:|_CBCQ M$M.0TMZ&?+EI%YNJEF8<_^[%RF=GU95X/4G+GH/AP"HCI'C6X+R(=5]=
MF^"S<*7UD;B'HQQ4*)9KB28]:&]+-I/=,P*]M^?X"G/.1Q M[1QE,Z$;^[L33X/CO M]L]>F>$0?+*Y7FFFK@Z\1Y$0_*/S7BRY5AO*Z6T M;'NU,.!?6W+1]Q/9O@,O$AGXPNN!K^1
%NT+65V4L?4612OL M@_*CO:'O431]!-_ZX81_+[!Q7)*\;.=\Z%>]4CO^GCI?0=XV,.?VLI/-AZ M1MZVWI.XO 1VM=;QF1Y4%T1>S;K.T6#-M'HMSWSQZ|:QZB(YQ08!
(05(AA944KK>X&-_VMJ52SL?=.L MO5^)#C;D-_#<0'LY^9?.YH]IAZM62_\(X^G/6&9=O7-M%(10*ED%E>]@<A*N5 M:R5"\<7+Y*P/S7LU-_$^]&99 Z+^-+2=P=):TBU3VA%['!!*ZU<)
(*1+P@O4> MB!0IW.(6,L;H79*6Q=9'HYH 'I*._(_U)T!K!?\7VC>M=_CI)8;;D0',/ M4316&\IK%L!P%"5(RB)\:XN]'(A[= .F,%'H,$C!>5'",$?+^ >5GA])TUT M1&YB5N"R()H@(!]=E
>;61")7+=L?K-D"VMQ>+1PB;#B6;?MHU>U8?UX^G;*^M_P]#|RJ,NW\/DW,.<*6.$EM9#4]6 BB'6*^,%%,7K=5&U;]fU-MEAB(>T@'8$ M;G|/_>H[B,Y_(.=D"W%88@1M#*19+(1@I
,6&0Z%:689JV/S#VM#'DGCEP#-8HZ<\PH*1+TOC:&ET16B@X-18?69FU<:-[M_V#43\53>==1XKX.)I%]X=;]A:%0!M /^.JS*RRP-Y25(B8LF=4)["&24OI2&;|-M]7+'W6@.-
>#+KJ33^&-8%^J%;R:R. BA866)QF<PX#2%W>MRUPIX8=@05]EFE_KU[TTTBL!T'!Q@^;+,+TK\U<:.MB-DWI(%>[A5<^>6ZG'_D8[$Q1TE!?B9&
<6UJU8Z';*WS!9FW\F9RO;USQG(/ M/]0DO<<:SJ::TDP_T0OL/N-&M*"$3E(A)%4O/]-"04P6(6=;I Y<)]MZW> > M.$.(EHY%E)NFIY66FGFR[N%A(R1N0014]V&4+6S.Z,T6',=59

NA]9EE_^< M+(\3#CT6A=I]K!F15}>;;@W"!A,S(FB?): K'I3EBK"VO(!T2^,UYGYUNG;M_8B&L'?Y6!1]J*LCQ#IOZBV+5]9H/IR?45!3%V[*Y.OM-&@*

M=3UZ8B4'>LT!63UT(DQ)OO6AZJO//W2N7_VLB] UH-9)E-JDA$R-5@I\3!PL M$\RA"9ICZV1U"XQ!>?1]-7YSWA\ZW,UI_%4@O\^F:8U%LIK86DIIKJ@W ?,$

MGIEZI$D&].A#QM;GU;8C&91WI[T/|>P[Z8UK_$6]J_^GCCN :,H+NPP=XIP)G MOE @7J_$T12E^<4!:3-$(F9#'H%KO2K7T ?4S+@LY7H:N^U;W"$IGY]4Z8:2

M1N?:'99LUPZ\ESZ"H!.99LABYIVS@1L0@C5FMP:/)E56]4]@-MA!"TK LKG*P[$KO1&M"2BB;5\)M@3&$D;W(WF^:G4-'O-WAV"N=&]XNRE:G MGY;V;20Q>ULT@C&B-A9!#5YG

9H,*K-,,I-:,_L^/$-*>5J2H9D.CL**Z@G7 MOG$^LLSK$HP"SDN]-RQ19F09#J-7KV4FA=6A>VK@KMB%LO1Z;+7OKYNBAR;MN M3+#/PF1S9WM8!5CKXQ+?

FL4GNSZHKR!E+T$;GO6\VTR"B,%]1D\2[&6M"*(-M:#*(NLKF/-J@6I]4W#UO/6R]X?+,S7L\6P_[VTM-O)[6$S@?22@<+14S)4^P. M2-9TU1C)19Z!2U-8EI%L;^NBM?

V0#BD2:L:K^],_>E)B+PO$NV'],J,83R2K M%26H+-,+H8%NNPMGUP#BG2&A#9'IC QZ':[^0\/GI!R62\ M;39=G.Q'3B=R^0&AI-

KA@5M%P4;$>I=+D4E$19MW]#P() "MV$0[R"5/H[! M>S4[IT8$*XEB)3!#%ED%'R!D%!"Y]%;0_[ELW69F+Z!.#NK1@&*$;2X6/P;,W M-K&%"YW-

1V:D^HJ\A%C+ON:7ME"Z,+BR"#&H$ B*A43#+15O?$_-H9AWX.#^_M%^+-@X8I1.,_W HPCX3A'1=@8C\MNXH4FC7-

0^1C&\7Q1SPI_G+T+R[*4R(/-47/06,@O"EXO+48BB4E<*N.=]JT]S/V(M&ISN(]JGD^5FYV>+EM$AMX[D*REI4*5>A.Y3O5/;957O' -+I 7%K !'J03(H%T*

M7DCN6[?!VH9C4/7R_5J.PW30C U7'/9(.L=#;..A'4$N%-!11&4\@Z*==,XX M1@(W)L&5OP\IS^]1!;L.>)_-2Y;W&<[']=OUS"CYRK:V&)+04!02@!ZS@' M&3O5PE/BS/W?=+T&-

S_CR>NRDO@JOHU+F^)#^I)&5VGZPD]G$Q=F9RYRYZC. M$*Q@#8Y-IM"[<\D 8EUY;9;EPE6WL^QCZ4WWLOH59\=>_A>87K1@=U#NF? M@]GYRZOI;'R1)K]!#

<.K$A)l.9TB2U/\Y+Z>1>5$YHPBPW.Q.?$$\PGW'>4 MH98.+X5HPX.N,/NGRGZZ74^49HIIL&&\'$]GI_(^^(T0=(C6&LLA.(]O"PT4 M'"<?);Q_[B;,,SOX_"\$/.7I(E)(7!//+R%7P_3

M7.\C^.)B/)D-_C7_^1E5TM%,/5@6(@K&X0J.(,"DMRE+RU*030BR#^K^V51! M_6L)U9ON&K!O$3L=??[MZV4)LMYNO=322$ABH#/NA\))FC5NOQJ?-&Z%B5I2J

MVC'.C6>_,Y31\K^F=[#'1V3<%C.P%\AYO\D>Y /#/9/^XP0@%J))R#1*$JC M!1V3]!'RZ!%K[8#P1C3],Z"2RNY'B^O(NXFS,DWX#>C<([5?<(H2!CRT+_);AD M(V-4>Z

$732AD@:OI(''4E-H/-X>]IA&L>EB,K7[" MRWIG@R]F"4]*Y20U&;2RZ+)[@=:Y2@[_D20F*IWQM0W31R"=*BUJ2GZ5&'Q? M8MRU;.X;-

#$[PY2*P"PD(((QX+Q.H"6W@626'5US5;X7*1Z E LFT!!C:]/Q5!2_GW17U2VKJ?OU*(PO MTIOQ='I&B2!&&X>\8\A +BU8B98,_DQ)SH)VO)G":V&PHV@;!/2O1[,T M2=/9-:

(%!^.1^,EU+<)^9Y$(3;1HB4#PD@&QAO.?)R?:ZU5I75OPVN)\'~MZL]OL/O?4O7%;#89 M*M9R9_X-'{O)BB',Z5\8CD$*$F56QW+P)EE(#AGDY?$ M4!\Y4J^,A1"=.BFH"W

Z7*/[Y+XNV/H+&K)Y.#NS3.$)2!VN6,.1F(3"TX]P M8#D;D4@VLKK_N '*B1!@/Q&O:E[#MJWG/#99_A*B6H1R6UO%(.($]>U_N+=+U7GIK;.?QT.KV8IGO& 5F?(M'(R*Y,Y$.#"$2?

1M>'(TT,1M[1R!.3N^[B'A5\W9?S?\SE9*K%%]\03/S ME*JB+4"RLRNI,96!"2HD'BO /T**/W6G E:OOR MS:N>DI2(FV=PCN++A3P'QW,&?+>><--$11G.K-1VZZJF+/A^I>NHBQD-

7/:TL MX?HM>CF^N!R/RCLV+PVP3#,KF0@\'$=63"P65KPTFCFI439-"/[.D\'4A25 M2=&/,.+.WP!ND/]S#M$A*WP4ER*I+D/[.D-0U4-QJ#ZB:U'NCA'<\6>D" M.*(1G/0%G$V0-

,LJYHJQIUZ(!*&RJH#L6$+L)NDIM[<3$>S2VNUZ-ENGB. M:T2E!/I.*_7=++#Q9$W.Q!V9(.MSK53M]IFYVG25GQ))V7'?=+NHI[Q+X :ICF1

M@8"WVI>L+@\F9EEJUB*7V1):O2QH.W"GP(\VFFB0>(E8)LE-TZ_I^O^_'JUZ M_I_&P^&K\>1/-XEG5B&%4B@G" E)2B U8J!,9X1$GP4LG,.74>(1Q%$V\?A M,.F2!L?-G?-Q-

<="7A?+2*3UZWHZ?3JQ1_O9H@,=^GR6"\N!KXD*:SR2#_P]#X9R_*^M^FV;N.LLAI M,+FO04+K!MC_Y897Z3O4[Z\FXO1E.

?MN#"9,_5&955"7P),-A&\ M=D)0E12GM;,@=@+Z+"E747<-4F8??$^NWX_+>>7?+W[ZF21A,4SS3ACHB.(,8 MO001M *G"+JG3 5KF=!VI;%3TNIN+L,C M6IM!!VY$[U

V0+A>>SAKBGV4: M,(+&>3$:(P8)A3 MD#5/+L5$]&L2M'L0U3,@3SVM;$Z;D.LD'HG!B!2= MJ9%6[Q"R!.[3YDEUS:RAS][Q]@?OQT5TW$09@&GK0027P#M"P,NH..YXBD1U

ML$R%*O?M3 @IF)9@292H7TW0>W4!-#.!*Y<4;W.6KBM?JE^Ql6N:ALE@'],. MYU^NIH-1FDY1EA^O+B["690** ME*TS6 +&E1D#TENJE?.45W?"M\365UE998ZLV+TM5"H

K0R!^.#&WV^GD%# M#1^Q/,$&/1JD!,)?T^,HGGYH$'%R1KHILKQOB*M/"%I M#F*11+P-C(H3MNX\NO^96CL*_[IZ]!<0T5R0W32D0!5|S:\!AF94\1O$_$ M)AKB5CT*#JW

!\9CU=5?%X%5UML_4%(75Q<+(%+EQ(R)$!Q'WSB5(*QT%$16 M463TK)C?RG]X1'/?/;3?@4H[BWU<0V85,]?G0-S7NT!$R.CK.I"EY[6P0ER' MM)R3Z 7=?>@35-I,,FLS;/#

[\"7N*:,$Y'N%Y/D9'9-Q--' MA!.4\]*]Y.0FB;8V=/86=,4,\H=GNFT#ZAG-&.VDHZW&3>XBX-YFC"JBHJ.L M;#ZT-*]FKDPO0*9KG;T,AL=0:[M9HPBK@RQ3+3KI9/Y&TGF ;U!4NFX?

=M^K_ M>:!T+F9YYXA3E3H#F!(W%0#-XIS0D'U/D7"0JE_Y,0+3_[5.XSA8';$WY,,' M=#F>S=#M1WR#3VM(L\"T(H=1Q:!7)B-QXQ/<4!>U)ZDOAG-R3)B3\'7/A] ^_M33E-)BDNI^Q-

)L7%*;A>C9?'XG(;YZ?#"/;R[VBOS_'>VSI3HI-C3HD<[B5,GZ= M$?6&)#9DWC$YBM(DQ"1P5B7@BD8F.4R;WN_1M?^FL@G-.3&I=_U4+/%\Z%68 M+1D&_'<!P"?; UPF+NH, .#-.3

K.!&#>&10;PY="H.RD45X$*6209)^]:"L4 MIT6HWO31H'1W5SQ,DY\]C;-7EY-Y@-9+++26NLA:5[*F1T'[[4!+YT6G*#, MXGW*[)_"[*BLD^%0*U4T*,!>/O.862EAKOP9/D$&!(

M9=]G)Y(22?PU;N6TRJ?CX$Z/8Y45A.#:L,- _. UW86 F/1EH29@UZ0 3 VZ(D5!&@HBV>@^P;7]%];LKHR:=81SX[PPPD_F%Q'OW;=YW^:?I,'!1 M&F@NILXVM.T"4SF$

$3K8EG)",;A_FBID$X8XV7\H$G0X5F4FY1&;CT M_>=9Z-_N5+O>W^N68\K1%S.A=-@D-M(R2:;,KT\>[ ],96-")K6'^W3%>#), MZD5)+2H'-^R"KR\NW6 RETNIV M

G9R_*FOCA9%AW\?C^.?@^'P'BQ&C!<,,7)7%9.X1'J%T'!.UO>AS1OJEWX.SUS9?P=H0&4*CV](R=@2E6A M-)PZDVV.U;L>,X_NY/C22#%K.+1W%/=%_(*"0&2CS\LST5-A!*4)% \,(8D(

MWC(+2HB0=)36L-K3GU91G!PG]A3T&MVK{ZU<7>8 CV]R@-T=:?X^2]EJ^&.0 M#U?8VA7@=2]!B77_LIB4TF[HF5>A"I|'LHROA^<$X(X6,R]>NR2UC=4C*HOE

MVAM%O%K20"1'=H$/$KPG @IDXCXV957_P3+8KMP9,>RV"ZJ,'19[*.R^^7;M)_R(>5(U#8$Y)RU8588Y"5.*8MP"9\DP=#XRL;4OO[,-=?05)YWH,&ZKE@;C M++#:O'C[@D:"[#

<1&$QVW@'>8^8{55;LM=?,4RX$H%"W-)}//JTB9BT!211^7 M.'"9\]!"UF(EV(UD]?/(/,AC8$X7=;29$7EY-4N3&VB+0@WKN?24>-QK+2F) M^11LF6600%"<,-Q\

<_5+M/50CLB/W%5MJS.5]!9Y@V'(5U>3T7QV"B[YU>#K M^K?(K* ID25L=$,+_E?024U:,&!BO%#K2\!;N?V'59C2G1XA*DF\Q8FN<9W^Z

M.;#EE[^F+VDXGB]'@!;EFXS8Y15!JAE"80+ ESR&EAVD?'HK*X_0F1;<*?' MF#9Z;3&;:Q7=LF_%]E&(H"[$CO3(H%EUD,@T4J3)..^^GB&36!.ER#[R:UB M><3W;5I22LXE(D%)C2

(QZ.N[^^JF&PV(8FPW1R$DVD;M8MON[M(*[=0N-L(M9!L8H]^=R42RZ?P9I<=O@<27]'WU*;,,ZB'UCVZ@N M,FO:-@H70"4:94!5=FBO90,FX!F=19D2HV(,]I3:1NV]O)UEUF?4I?

9&[TPY M%8WE&0EE% BN*!C'(I#L+&?;9"-KU\=L >N(|-XZ5TNU;'Q53_B,.@ T-HQF^ M80.T*N<59-.CNJ[,'S1W=5WE&>E>_179>7IS>!+BO?N_H&G+?

RF5+))N8<2RP!A(F[]MC0PDJ6N MR3 7I&QV6]8NK[NZZMS9?:-?56%',N=_0.+^N7;/]Q_CR GWK M+I;!OFW@-KK9[PCU,+?\S52_/<6JZ>T(Z):H3"XD!3(Z4]+ $IS.!!+G0K 8

M\/<]6@[!T>R1C(!C95D7=35@U^(6H33#6?9Y_##X?'YSR12%X*CC\.IQSU= MZ@2>Q@@Y12[T29VJ-$'H'4OV?,5*4K57+U]%$QFG5=#CHET>BR&.L&H65.DA&&-!)

(8OCRG!FR DC388Q;9KG+?5XTZ3#8W$W3#+_M;'DK>4\DR[D9/%J*,$$[5_I[<0>>!04J$4>HY4(URSEZ$-A[I>=;AJD$7R: MN)@NW.2/):&=I,3I D$"0F-A%!A;Q@!R0G.9=6U"

]723^QA.FQ9[2;0GW@'W M) B3<1]#XPH$IPIL(!FHH#P33@6O=REYPO[T[D)MF#FP#8S3RQSH)/Q--\\[M2*YAY@!5'H^&),#9LE-$1<%*+M 8Y3K@,2(1U%-0X%:9

S7TUT5@33,'G+6$ M\|(2091D08X>A W) F6"H=4= D|;U08\CLH"8IX\'' M,JK#6 ZV3.Y0I3=7"(ZR4,.U.Y+,@9V5M(/,>HW:W;FOSD0Y1S0#2TO/OLQ* MNV$1P$7OF?4L,U<[N+(-

KJ,R?^M<B5;6:KZS#4^]^??POU M;VAOM(|:&IA#ZV"%>>?!\VY*8QP$VNB5_%-QA[L6KJ'(+>NROAX,0QHC(*4%S MD*IL001&P%.B(*48C;+:"GM__X3)YO7FZB+AX3R+?UW6

MT[)/R'7Z BEEN;C#2)D"+C%8E742/&!UYWC_D_MWA2I+?2Y*BUT2R MCADI!\H(7EK>)=R,-"OI4#PXO3.1LYPI82$0(%D87%8499RVAVQ9D(Y+$U3M MBM=&2_GQAAP;7XX\]

M1V"U?I'?/GO\.9Y% FI-%2DX$CD@,0V,3JEHKJ?TKM>_ML^L^_;24NK?X&MS4OOC33>)-]Y3,1$BI#/3$@Z2,#^9@+#I$V43)E(MHNM8^_M?K\#"!"RL^=U%WJ+@_QQWFE_-+D?

JC@6';?H>-)B;5QDI9G/(!D7(+*PX(-F M0!CNT=98&G/M\,;3X>TCCLN1Tf.+:AO0]4..SB:#,$OQXVP<_EC>21H7L@P4 M420&PI8>'Q;_M9'*2+)-E-2NBEH+I'\KZ_

Z'M=64(M67QW2W&D61/E1@$IK M2GZ1!Q,4BD$$0B)5WNG>]+>3*GCJP]9D+*+ MWHZ@!,GC>T9B() LJ0;EQ)+AQ+G\)!#'%PD1?%M/$:65.2QO[ZI-E7=35HFQA,6?U

MN^J*99@EEF"*E,")*U%1JL!PF\%IZHU.E M3?:+39CA'E8RSORKOERA4TD,# M2^]Q2JP:1.7!4J#(AQ(UBH+$\WI>5SCSVI.XDZ^,VXBJM0P",*9J%VB7PUHC2#TD*Q;S)O'9?

H*=7Q[(/(?:,2>(/XZ)H$MY>XHPWP MT^,??{-[1]'H&(CWCF0@3F(1@R\V <-02LB@0X9TX&'127/0S]VHCO*"Y3WE3) MOFJFE@9GSB)J,?TT7EPD+<&GZ=LT>Y=?NNGYXC?

OS"%4EBTB));BANW!Q9 M8*R7^Y%56B9]D(YX3DH)3!-6C&P&05@"D:,@B T-M&J*JE!)'*-+-ZG24"\[G-ZE_]K7- 07^YXS[<1G%?:,>>K/NA<#$_4..(>]"_)H8,,N) MBL \NA=:E*NCC-

X&(18W5Y\|Y)L5W.X98// %6-)/O*@=V'K[[*<8[*Y_? M\:UOI].K/:?)E$!)NJ8,Q>]]6DZ2994!* M'H6@AH3V]"(F>-"E3ONVCEY319R E0]'D6OLE?W4]R!X^7?EJ$; MQ:4;,DA3_-

W518J52Z#W1-&T8+JFA/HHK^;<2Q.9A4R1>")I]!0l,VC(&\^3 M34;&'HJT;O#T7EY-K7:9:0696#1B?3%B>2)@I13",1\5K]WAX4F65W?AR=[E MU5V4W4GR#Y9? M=Q%;?

^75V61%@LBX0Z826Y<,+%-E*)X1VL;YH-BME/FDRJMWUFH=0?927BUR MCADI!\H(7EK>)=R,-"OI4#PXO3.1LYPI82$0(%D87%8499RVAVQ9D(Y+$U3M MBM=&2_GQAAP;7XX\]

M1V"U?I'?/GO\.9Y% FI-%2DX$CD@,0V,3JEHKJ?TKM>_ML^L^_;24NK?X&MS4OOC33>)-]Y3,1$BI#/3$@Z2,#^9@+#I$V43)E(MHNM8^_M?K\#"!"RL^=U%WJ+@_QQWFE_-+D?

JC@6';?H>-)B;5QDI9G/(!D7(+*PX(-F M0!CNT=98&G/M\,;3X>TCCLN1Tf.+:AO0]4..SB:#,$OQXVP<_EC>21H7L@P4 M420&PI8>'Q;_M9'*2+)-E-2NBEH+I'\KZ_

Z'M=64(M67QW2W&D61/E1@$IK M2GZ1!Q,4BD$$0B)5WNG>]+>3*GCJP]9D+*+ MWHZ@!,GC>T9B() LJ0;EQ)+AQ+G\)!#'%PD1?%M/$:65.2QO[ZI-E7=35HFQA,6?U

MN^J*99@EEF"*E,")*U%1JL!PF\%IZHU.E M3?:+39CA'E8RSORKOERA4TD,# M2^]Q2JP:1.7!4J#(AQ(UBH+$\WI>5SCSVI.XDZ^,VXBJM0P",*9J%VB7PUHC2#TD*Q;S)O'9?

H*=7Q[(/(?:,2>(/XZ)H$MY>XHPWP MT^,??{-[1]'H&(CWCF0@3F(1@R\V <-02LB@0X9TX&'127/0S]VHCO*"Y3WE3) MOFJFE@9GSB)J,?TT7EPD+<&GZ=LT>Y=?NNGYXC?

OS"%4EBTB));BANW!Q9 M8*R7^Y%56B9]D(YX3DH)3!-6C&P&05@"D:,@B T-M&J*JE!)'*-+-ZG24"\[G-ZE_]K7- 07^YXS[<1G%?:,>>K/NA<#$_4..(>]"_)H8,,N) MBL \NA=:E*NCC-

X&(18W5Y\|Y)L5W.X98// %6-)/O*@=V'K[[*<8[*Y_? M\:UOI].K/:?)E$!)NJ8,Q>]]6DZ2994!* M'H6@AH3V]"(F>-"E3ONVCEY319R E0]'D6OLE?W4]R!X^7?EJ$; MQ:4;,DA3_-

W518J52Z#W1-&T8+JFA/HHK^;<2Q.9A4R1>")I]!0l,VC(&\^3 M34;&'HJT;O#T7EY-K7:9:0696#1B?3%B>2)@I13",1\5K]WAX4F65W?AR=[E MU5V4W4GR#Y9? M=Q%;?

^75V61%@LBX0Z826Y<,+%-E*)X1VL;YH-BME/FDRJMWUFH=0?927BUR MCADI!\H(7FEK>)=R,-"OI4#PXO3.1LYPI82$0(%D87%8499RVAVQ9D(Y+$U3M MBM=&2_GQAAP;7XX\]

M1V"U?I'?/GO\.9Y% FI-%2DX$CD@,0V,3JEHKJ?TKM>_ML^L^_;24NK?X&MS4OOC33>)-]Y3,1$BI#/3$@Z2,#^9@+#I$V43)E(MHNM8^_M?K\#"!"RL^=U%WJ+@_QQWFE_-+D?

JC@6';?H>-)B;5QDI9G/(!D7(+*PX(-F M0!CNT=98&G/M\,;3X>TCCLN1Tf.+:AO0]4..SB:#,$OQXVP<_EC>21H7L@P4 M420&PI8>'Q;_M9'*2+)-E-2NBEH+I'\KZ_

Z'M=64(M67QW2W&D61/E1@$IK M2GZ1!Q,4BD$$0B)5WNG>]+>3*GCJP]9D+*+ MWHZ@!,GC>T9B() LJ0;EQ)+AQ+G\)!#'%PD1?%M/$:65.2QO[ZI-E7=35HFQA,6?U

MN^J*99@EEF"*E,")*U%1JL!PF\%IZHU.E M3?:+39CA'E8RSORKOERA4TD,# M2^]Q2JP:1.7!4J#(AQ(UBH+$\WI>5SCSVI.XDZ^,VXBJM0P",*9J%VB7PUHC2#TD*Q;S)O'9?

H*=7Q[(/(?:,2>(/XZ)H$MY>XHPWP MT^,??{-[1]'H&(CWCF0@3F(1@R\V <-02LB@0X9TX&'127/0S]VHCO*"Y3WE3) MOFJFE@9GSB)J,?TT7EPD+<&GZ=LT>Y=?NNGYXC?

OS"%4EBTB));BANW!Q9 M8*R7^Y%56B9]D(YX3DH)3!-6C&P&05@"D:,@B T-M&J*JE!)'*-+-ZG24"\[G-ZE_]K7- 07^YXS[<1G%?:,>>K/NA<#$_4..(>]"_)H8,,N) MBL \NA=:E*NCC-

X&(18W5Y\|Y)L5W.X98// %6-)/O*@=V'K[[*<8[*Y_? M\:UOI].K/:?)E$!)NJ8,Q>]]6DZ2994!* M'H6@AH3V]"(F>-"E3ONVCEY319R E0]'D6OLE?W4]R!X^7?EJ$; MQ:4;,DA3_-

W518J52Z#W1-&T8+JFA/HHK^;<2Q.9A4R1>")I]!0l,VC(&\^3 M34;&'HJT;O#T7EY-K7:9:0696#1B?3%B>2)@I13",1\5K]WAX4F65W?AR=[E MU5V4W4GR#Y9? M=Q%;?

^75V61%@LBX0Z826Y<,+%-E*)X1VL;YH-BME/FDRJMWUFH=0?927BUR MCADI!\H(7EK>)=R,-"OI4#PXO3.1LYPI82$0(%D87%8499RVAVQ9D(Y+$U3M MBM=&2_GQAAP;7XX\]

M1V"U?I'?/GO\.9Y% FI-%2DX$CD@,0V,3JEHKJ?TKM>_ML^L^_;24NK?X&MS4OOC33>)-]Y3,1$BI#/3$@Z2,#^9@+#I$V43)E(MHNM8^_M?K\#"!"RL^=U%WJ+@_QQWFE_-+D?

JC@6';?H>-)B;5QDI9G/(!D7(+*PX(-F M0!CNT=98&G/M\,;3X>TCCLN1Tf.+:AO0]4..SB:#,$OQXVP<_EC>21H7L@P4 M420&PI8>'Q;_M9'*2+)-E-2NBEH+I'\KZ_

Z'M=64(M67QW2W&D61/E1@$IK M2GZ1!Q,4BD$$0B)5WNG>]+>3*GCJP]9D+*+ MWHZ@!,GC>T9B() LJ0;EQ)+AQ+G\)!#'%PD1?%M/$:65.2QO[ZI-E7=35HFQA,6?U

MN^J*99@EEF"*E,")*U%1JL!PF\%IZHU.E M3?:+39CA'E8RSORKOERA4TD,# M2^]Q2JP:1.7!4J#(AQ(UBH+$\WI>5SCSVI.XDZ^,VXBJM0P",*9J%VB7PUHC2#TD*Q;S)O'9?

H*=7Q[(/(?:,2>(/XZ)H$MY>XHPWP MT^,??{-[1]'H&(CWCF0@3F(1@R\V <-02LB@0X9TX&'127/0S]VHCO*"Y3WE3) MOFJFE@9GSB)J,?TT7EPD+<&GZ=LT>Y=?NNGYXC?

OS"%4EBTB));BANW!Q9 M8*R7^Y%56B9]D(YX3DH)3!-6C&P&05@"D:,@B T-M&J*JE!)'*-+-ZG24"\[G-ZE_]K7- 07^YXS[<1G%?:,>>K/NA<#$_4..(>]"_)H8,,N) MBL \NA=:E*NCC-

X&(18W5Y\|Y)L5W.X98// %6-)/O*@=V'K[[*<8[*Y_? M\:UOI].K/:?)E$!)NJ8,Q>]]6DZ2994!* M'H6@AH3V]"(F>-"E3ONVCEY319R E0]'D6OLE?W4]R!X^7?EJ$; MQ:4;,DA3_-

W518J52Z#W1-&T8+JFA/HHK^;<2Q.9A4R1>")I]!0l,VC(&\^3 M34;&'HJT;O#T7EY-K7:9:0696#1B?3%B>2)@I13",1\5K]WAX4F65W?AR=[E MU5V4W4GR#Y9? M=Q%;?

^75V61%@LBX0Z826Y<,+%-E*)X1VL;YH-BME/FDRJMWUFH=0?927BUR MCADI!\H(7FE

MUFB%SED4=.4B>7U^ZJ,/>O)J;B#1)I-+'C&%AD])75E.OOM:QA>132\7X0P MN9KWETV3-)V|R/C_7PR'XS^+^/"_?#E)*

<7"=0F<)2^B:R\U]KUQHT2C@WGKNK?:VXGS>UN#WT21=9VW]'97T M2\KC";H&7|\X=S%+R\ $Y\O48,1OC <_V-4R3%'3&5"5P%^RKSM7[,--N)=

M%U%>K=M%Y$@T,2R"6T89RK6VD58%^]ZUM1L@^>#|PV?# MN/@C*I(RCT.\$P#H* (6%N]=HS3D:7DA*X_^&P7I*=,P!YT=^B$Y\[2CP^6 M,'S;>>6IP,\9P6=STR4:H",KXD

M5I6F-^[)):W$47QY)O#&^**1@EL<(2K&R!3,%C@<2#TD5]MO66$YSXT@<$0PVRlNlQ1O:SKst-O;fBZRI5<=0PVRYWV;TTE[VT?F=Q%|O^3{C,,8FM M&

=")5:B+!QHXMJ9,)@PM<_CIW);TX@3721>N\7$X_%E*WT2B1K0T?!25JA+ M#H(&QKW.+E@1X_T([\"E${#LII5O$OHM$>XACWAZ.Y:C\AYLMC\]f|=H??CJ?

M=WQF7$AX+)8.&BZ#T&7HM7,,%$/S2PEI]*B=%/L7X&/WR_C=*_U]RD^]6O-P[#XB;C0(MV&\KUU=N,/DO-]Q*.S(,,@EARS1]L\Q;?5ZUC]!W-VAGL# _@

M7PWV<)6YU;%QLXHSPK7:TZ.E&L0V>';'5"$*$L5)(^CV5I6L1_BXITTIZ1& M#7-@-[WV;@1LO 7+UE+G*HPB;'.?*1@O$W] F1)6TJ\WW&W*#>)6@1J#'

M/AO^WPAGO+9F97GPMf]>*K 693[6&4CE0$W MAQ+2$]F#*^TB#!Y5C&D?G*G=&ZHB_+XN>@_)X96>0 ?2_K%<&=^I_Y=OB[67 M3WTU2?]SE4;AV_R^(Z'[FW32$)U

@TO$4O2:+>#/A",RQJRJ#^%\'-A+1(/ MQIA-S*VDN1:#79<0UP%<7+!L [*1)?06\[4AZJV:C=1If)>#D2A[$,,R5A@ MTN%,%%P$8Y@$:0QQ+FKF:>VKZH-1Y{'&4$? G"

[JZ(DQTYN]>5D=1XQ/W%&@ M-@3$B/\X$3)XK4.R241NJC=;W)7_[YW=85N09B]M-'@"G)3-[6DI5524I": M.'Q1T,(TL?

3W=TJ04CFNKIO=%P=.8_&UJF@H09WU7;B6RSEA^=.S<1M09! M6C9$W5$GA?.'TMLU8.4N*JC"EP8+@+0 ,NQFAJ+2'/CJD[=NX\'J)V4&L

MG3NCXH*@O0$YE\D)9>"NR8J"4L(HX4UIY5:9:B?9N;.3=K?KW-E%-?UVI[3! M>"-D UF&IPA%RI2OB"^6$S8R1@0CM4ESLITH'R%,)17UUKG319:*53+:I\R"

M0*\8'627@43#K7!!2ED[WGF*G3OWHX*U9GS>EV[MR//;44=ECH!;VU\+'@>U-MNFBI):7F6_=T+@%Z8QX&BSLS ZL)0M.(RBIMP'D7=$;7-%2?V_ G..X$:RD

MR8$V4V5,+++,X$UT:GRY;LU%NC<@"X&DP'-U.^E/>$>N' MS'M+E![EDH/D7*T-=%0G;JV\[7-UD<:C-I?XU\6Q*0$"G20G(^B*[,)*+Q.I1@*$ZJ"4URR M?:IH7F_!W/_D

\Q7K"OY<2VQ5;0FYF!>NDGZ@0;6QV_3DJKS>A3^>E.MI%1*.MG@'QN=R(1@I6*PF!)F>"UMFLC$M5O0##SM0=<2;LLT\H>KJ#FZ_M+=+$YCP!EZ2Y"T9?26@)5G$:$KZAN-

@3BY%MJf.-'--#?*LMDO^T.M@'[HZ5& M38WOU?=@%W4=O*5&+$46P@5@DA$0E%CPEGLP.@F!H[&DLEF-5%-OJ=$?M;IH

MJ>>"^.2=T%99<*K,Z1.6@U>!H^OF6'(D9%U!$N@3+HCOI,@:!?%=M-"RI<8O MWVX*NUX.'1J3Y3T)5D=!4`5)1(+2\QA<8!*2RUPQY:A5S08RK /TPU:JI:U5

M*JEJ5%HSC*^CI.XO;_$:,K/ UF95J\4=W!3;EU";J'14;&AYQ#9;J&-"V:#0 M1B$YEA1O5WJFE.Q)1KQCT9MVK8V>%MVWMPZ?'-N[D*!ZB.V13@(+4|9XPD.F M

A0+>+)))%*55.@'+41C//!!I.]RM/-T39MGK> 2W&X]#RN*V*VE],&P>A!9(B M4U&B!;Q+,_'27@XW<8C>4N*#S7SEAN7"7.L^+<\[FELEE^YC*.V'_,M=Q3

MM3M,)\Q%+SU%X.Y#Q:,J$\(%^,_".T9>*H):*J9U8YJH>*I4*:"7.O6S.FB MCKYBMO'\%H[D%Z+UV6OHS\["-4^R3F6G92Z"YS++,MH MHU%7P-M*WE[=:/I8J&&E5&?UH4<-

W(ZPR=)\6#|*="%*8%I2L%@W&UE$;1&(0BM<^C MM4'>-V?VUTV#P^G=Y=P-''V>YW]?YV\Y72K\93Z>SXVT@6K:E5@/?4@1!GR99F"M4O-'"2]7#|43(A[^\[SI4TU3#1)LMF\M^6(R=

<1[&UZ5UY"Q82|(Z7#?1;5;PO)EZ0#94K-7<*F;V MXO/G2?KL9BC,&0IY.@C7N|K-S%+E Q CT$(EFH-148&Q.3%)D8_N_HF[6YQS M X#G2<#>5+:Q**7_5]5K.9EQ?D0*\]EGK5J;

f@VIKU:H=65WI*U3:TD(,$]D,23]01_6=V(.^'6JX%ME%+P>BD,^\E"NCT3VIW*AUIHY7=1QJ LURX6RHGB-K@@B!06>.PIB/IHL M1^-H[2X03_="K9-"=[E0ZZ*-

MDE%#I5\N,AE=.C1!Y,YB&\$2.1G(+@TRG*Q M2;MRAG.0 *QD"=727\LERTZV]1,8!^'Z_L*;&JZK2VD5=!%! S,89+1I%+-.%E M%I&4SF-6EUV8$\&\-.1 >#!J=5%2ST7 H6J0QX9#-

J<-.VAH(1Q(+BD@B? MN-6JC$Q^(@6 G139H0"PBQ8:6$]WUCX'=]/8,-+ #,,!B+,E0729U.M!]NHY M%S6> MI?A^,@C+7O&"1\L)$2 ,8:5!&&Z/@2I(/IMHJ4K>MSYM5D#U;Y'4TN

CQ-A/ M_#T8(1_00!JA788[U.#R=IZ X*6)%8%$/ &AL@'/6(9 -(THEL!#[]I+?OEZF@'0NV;<+A-%8(BSSX)*WB- \)&Bj:Z%,T$RPKUH3)15 M5"?+DCT5T"!6M\+CP?2/5Y-

4DL+2)$UG!QL269M<^0T:[#.L.]><7!2"V#X MO2')1EU]3N#VZ$2G,144TL"E*>[>M=>6POEH\#]7BRL(,,2OD4J4B>NRM<03\-FHZOHEH.!]D'5R,W>\.!FBC[..?3V*!7V

M$'H#0V4C/A8SY2D'H$[A%D<9;G8f"_!:>VUC"JIZX+Y?.CSB_/:)A2ZRKMTV MY0:4+T,7_O@8SE%,RZ:YBCKB%!ZDCC-TN CZ^3[S#-S&+'FP3KG[B;OK:P@>

M>$C_YD,=-8P;R+#/$27:D9210\&7$(ZF#*PW%EPF(N%!YVGUP/D)CRC9QUBH MH:$&O82W&(VQ!<_?(THZJ[+]B)(=]"0$26,*<\35R!CV5^-R& 9.MQ,)B%C

M\]4GV[ZQ$:4-.5)%_$?8OZ!M0(W7[+XM%-R#%JV':6,W9KOOUZT?W5>;ZFRR.M9R5 M.FD9O@79OPPB,PNFS!'2+.C@D:3!-9%OV;1;X8QI\O6D$G0C5>W_V7=CP)&DOK+&>)-) MB0

\$_19#$=WE\0 AI H)3K8S#5KDO&TZ+[7-(+C9GL7$AQH&D%R:(4IPO \ M*UWST,]&43IT=27C+%#':,IO_?Z81K"'EG>81M!%18-"]S0(RA4!]'@

LZ,2(SY:YV,N,1<*M.X7!_U.]BI9X+AVF.UN3(P7,\ MLD4JB3XA49"FS8(BV%8&>7N%P)T5V*!SNHH4#S7+B,0M9S$8BE(4RV0&L

M1X4RSD3)Y(Q4VG4VXI5\ENJP*Y[FXG_0UV@;BCI9S>ZIVAP9BN^CE0*WG M4-/&*'!*!S(,W#N"ISF+(-("71"NAG^Q=4?B46\^U9DX7=1RJ\5R21F15B!\R

MZZ3075K/==%&CRG@ G$9:R3H%"4(A6^+ M24H X](IX6*0IG9GG1-. =_'UJFAH08%8X^G+&X#|$<*>&=5=D[MW44/!TD! M)Y03;]6#F"T>SNC|@;$J@27&2Z-

2)KQVF^^GE0+>EB==Q'^(%/!$)$\L;Y N M4Q@2&W "O]4J9N)-$-Z?= IX)_UT30'O(MR6H9C|;P)?NF&X&LZ__# >#E^-.M)W^Z23SS-$@J-0&I9+FITQ]\DA$,(RK+4 ,'-VL5V&I1)Y

^-7B/5\"@XT_*E MN.,__;P.U]9S/3[U4R_7_O-G?7\L\X4.BZ*I@@JJ#)#72@\1#@N3UG.O3/$ MR#Y&^>Z]D">=KE"#<%MXF_VRI:> QC:+VK"F[U>3<.ZF:7]&Z(WG:$6Y4%K*

M2XI*1MJ"=XH9;7PVU4<5MUK+CO?A*#G34QK&'NOZ.VJZ#&=]/0K#]YCBZ]%O M;C+"/T,_0RH4D#>'@&74@A"@.)(/7G]HHDI#2MB.;VX\V_+4V!53Q=R^Y^/MP@C"0B9@DT?

12Y2ZI51 I-3XQ%6RK(],E$K65(-"R/DXZ,E;-RD)E%,2'G6-M&SZI6IGB-D@K51V^04<_I?D#?TW3,!E548!/R? M% 7CF=2V3AZ!M._;M_[CKZ/C-

@7E6$P0DL9WB$4|4@W#C2$:BLZA#Z:GU?9: MM5>3 _HS MA_#OJV\/R3541#>2"ND9&*,9B.P\N,@(*&^RBS%'*[:R@ ZMP UW,O7UUT5@ ME?7V#Y34Q=5-CV/*O!;40I0!%^.9!T-

E1OX^HKGO'MJ?^6O7 MV,!1(SG@,D ?&EF7$,%"QB)*$%CXFDED[Y=U]Z!-4WM#Q#,?'UQB:Y,BF_&H\]QT,.(UY\."20R-/A?1-M6\Y4@M7205*<.5(%-7[H77!=4%EV/=-

@$/HYU_H.W\F[Y)Y=;P-X$:I.)W!-M'B8UIYW^.Q.MAO(.LGO=!\Y%8*9TV==:EH0%!.Y2C, 4D_B=I2'6KITX$K8]MDM]SQ&3KHK/:24 ?!I_/9^\RPK]&.=_ES\?#B,N8C+|\NYUT_4#YE

1_2*/WIAF5&U)E,G&@3,R2>8FEHX\"Z," 4)@3F\[" D1CO\DL\ MB@:S5R[,4Q)NR6(LHXHF!I(4$XQR!\9,!MKBZV<8YYS?GS*S]TI[$*"]3Y8U M'WX=O6)&$^>HAF

"KE2ZC'L<&I4A"VU,=GFUVU>+E?9[\UY-]RLG2!4Y_K^ M>[F:\@[>=LR>AP489S)9L'GS&O.%UI(,5/P@85@5';,U)!LUXNB.9;MH= M5Y5R@YC;]XCNV.+,X&H4T-

V$Z3!QVWUU]B %[A1XGX1PW,08. 4A4IDDAF:/ ML:5C#Y'H9JN(-A=YTD1X)*3;%P^ZR+EV2.-C&@W&D]?C69K^>I50'W+A+4NN M1(H^@

RDHB!4*"OU[;M#UQL>D+_3D0=!8QK2Z]V(/+N^.#B MV;X9N]%R*(\US#EC 0\M/,DBKM%:4:ZM'2...V7<=M'(S<\X!;56DF"#O;1$ MUA#;15GSS6U.S+)@,J!52F4&M02'WBED+W0.-

$YN?'QWGTK&|IRC#(Z1D0 MPP<]D(9*VP$+!-A2/_PG MOL?3%'_A/]>SB,=@4:7]\!+0->(H'+7&A] RC* 3>U*E[!-T!F-(L6MA(.M\W9\]\)-

)M\&H]\\O+L97H]E9%L'+++/"=T>5;3'N-FR=5R'$;*$,S2JG8E"_? MXSE=ANPA]^9!H=]'lF*,F]^_4OQU_T%X/M)NAA<7;P8Q?F?3J=7;A32R_%T M-GV;9F=T(^76:UU5X€/^?3XO@^

M"Y9JGB4M6R+2/S+\2KH *1@CHLE$FIJ- ^X^_Y1HL;-<&Y3.W\7R\FHR09Z> M)>_^28"E#P*4@)(F&>B0$7;^4#(^4I>J-T=? ,%6-[R+E!DT^[T)Z.QZ%!:H@ MC/__VWNSY;,2I$WP?

IZB;>Z]_]B7MIXQ4V5:9.94C:$U397L%@=E=%&$"@ S M4__3MP<(<,%"G@-$'(@3A*@%A&IH)@}3 &"$\%0 MXRBI/CUA.Y)S5?

^>LMYD@!PHJ>7[R9>ODYN2US?)*_/YQ[^_IIO9(1T?>C^C M40I,W]4-DADCE4#7_ZF3'9"572^M"D M(1[-.V? BC)2D%L91(IDL_'GF6?&]-

%]I\R8/G(^E&NYRR=)'TL/%U;N@>JN7++TTUBW OH^X MAR.#HL1)*M!V$CGA7FD(>)T(,BB*?,YM;K=^/?4+UD:<*"/E >_9/$^FN"I M!%W2/"'I 9PR

;+F@5B6@\NU6JZ^CDN67EKK=ILUQ"B;59A!)*F^(!:Q#.2?.'2';?G'4>C0&>~ MIK5;/Z=fP*8UK7/$D(IFIHW@!B*1>/H'9I#L*_8EEY)fPKQQU3/;CA.45%Y) MCLLM0TL8&KB2@2-

EX8K:3&@\NU6JZ^CDN67EKK=ILUQ"B;59A!)*F^(!:Q#.2?.'2';?G'4>C0&>~ MIK5;/Z=fP*8UK7/$D(IFIHW@!B*1>/H'9I#L*_8EEY)fPKQQU3/;CA.45%Y) MCLLM0TL8&KB2@2-

EX8K:3&@\SA"P|IVX^<3+#TKVT7WWH&0?.9|*4)+,8K)+FD= M)Y1 I?!@P;M8485/2.T06)4H;43/'=MJW=/KURO"0_ZR+EVN=[= M?O?

NTS0M3I=E8,P*POTO"=/:1%PF5V@MNPQ!T^OH1+=F8_#0CBF&VS[^A"JZ M>HE^4E5NM:OT=I8.*F4M2TH"\V4Z%LL>G,&%*JZ=C%'%N#$E^=467NZMSRK2

M&ZH^C]"0@DP1N-5HNEK%P/HH(*@0*$]2B.H;\^NX.C[$4CM8TL/5YW5!]5:O MCGMIK-NUX3[B'N[JN#1;]8Z4^*-%=)II,)0$2.CA,ILT#ZEUL>ZI71TWX$?

M*=>VT=8JQCW!HRP% HD2#L(K S9(\Y"*]$P,3(ENI6./76=?0]23.G)]4@1U M/;ZE^,/4_;4&S!GCLA#H.DA1;A9!V.E!BH=Y:04%(:,29$[P;QJK=<5!?!E

MM9ERI%4'RNZ*8C)XI0(H39-.5!%>?I9Y;,$]KU7D/.#^B ME]>S] >92MIES C27W*Q?I>[?8OO LSS.,9;"KIB MS5/(F*06.QV [C#Y#V'&,S36:"?>U%1'$]=E.OYS MD:3Q@'ZV&IK\W;?

_D>*G\?SU[G+$D>A,9,!):6U=YF18)O"O M.A#CE(W=@Z VJK0=7N%EBK:|$.P!I%-W>".M9%=`O-3EJJI8%+ MO1L@OB^4,WQS@]>X33.)FZ;,%G=.2YG3RI+JC8@&YLN+|]4G1)

<^'VF@1>7&S MSS]=3 3_Y.ER>]Y0Q3{6*H)5WY20O+2]B@ECN#(U57*O:\RJW AD^TE))4>O! MEH.E/)#U_GO9;UG<%)P%/E=*2E-X(7CP3))\BQ1/7IZ.?PG+\ELI?D M=_:

(J,$*M,/G4Q>>%(=VP-8LJ6TWKM.Q.O;3XDYZ5%)!DV2X9S"&E&7*5$,V MA("0$G?)'#.>E%9(A.1K'8ZJ?#TV,/(,.^,/I*OGB+GOGY-!7MW?;T\WXQ"

M.")&P&,R@#"*@2="0!!$6)Z\$1M9]3NRX]8^^1B)5+6$/JDEL086P=(\^2'- MQI]N%O;/@]TT,&,T]Y!HF==.M0:7<@">3#0]!US?^BC%2@[#&I+SL@{J2'N3 M ZH^!U8]?

#O@:AMNV.!TG', AMY>.(\!0F\73-C$EWVPBE.(B.6#\%:!(9Q# MU)$H$?(OUNGAB7#"Z?\D%SH(^LF%M\=H#)++HGQP.)9GEI$<.68#*6!L)A MDECZ!7"0"U=%

(D0MG[&SHNPCA9%.%"'&X9?704T,"">'I&+5T$2&YTC%K+ M%T#PR,%X2<"Z;*A6SL2-(>X'AY(V4)R7X7"@E#?UKNOJ?K4-A.&4_X)O M,(3N^\BW1:[!HPUN>00E[(9SX

&"B@81X6'G>)"0++'.6:\%K=Y+>@/%$?^ MX=IYIHI^#|%6/-UGT_GHRMU\6O:,2|&74B|0TMLRW(V!C5D L9P*KDG6W1]X MXJ<^TBW^]4&O3QYX'F?W_C+

<5*0Y6)%+/G6!T>>$[]+2^N_GRX?Q_<)?5]\|- MDJNX_:#H8,Y"P!;TT'84O0$BD)?$Y;Z9)/.G8RLH^MP!T':GW|1%89;W! MBI+ZW MS)HW\2A54".6 R%|$(C$>-Q/5 1O1

3JB98QA,A(V_8=!<6I-8,[|/_3@3)N M$)?:MM8E+:,^,3*>3OTJ70O<5?S+,_-E+.Q^ #GBHA+,X77#H1Y:[616Z%EB[4 MCECUP7=.3&FFE^8![Z)-RX%QG'HA54*?

WFOTZ34M[KS@H'UBS.BL32!-]X\' M+.,?$C2KR;EN;^/YK$>[*22FH'>5$N2E\]+!:$=O!H!.>=!>*%D__E[-,B!)!9'1 '?4<>,PZ M.&DUB>LS$;OH?MNSSE3Q!XNU0<[KMH7_<7,[*

|E9=|;'IY,O7\;SQ4&4T[.! MPBI[H1:-#*3(&B6X$O'\\SUT%0Y^(0C6,]3T'0@VKL0;I54]?AN_<,#$[M->LTN?C^Y|N.B[QY3*IFHYD(9Q;D&'TBX]>P\N2 EHW605;,P^UIYTTQ7;

M.1&IB3XJWK!OV4'_YZV;SM/T^ML'IZW_<-T?!/&7]WUQY9K2DE*)H ,B.&O MA+B]4AJ-*]6\|%$JL^Z3=#FG.CSZ',@Q@- KWNIL0?MAFKZN<"[F33|"*4RR MTD0"0FD*PHF

1$X*I+8LX!*DXNN5/5VH|V^S4,1V.1ISA U'K=" M)P>6>#3%6+*)^J0\J|TKL!? M\6L?36SA4=[1W.I#\7OS5*X+55^CX#3D7&. M*5M2]2.27_#_P

G\2A'MO+6X*_.VXUYZ@'U;_*JAL2U<.[AISU/D5RFF+XL[MCL7&^MAC#)P3EPU0ZA$GNHG@7%0(ED=IRLUX]9[4':&=+X_]:&,+:RJT7MC[M]|LO2XK<52DFHB-MJ*?

14)"\Q,O+N&>O-"E7)49]IPAO|+0] ^Y\F5-+(UNX M4SFNO!7[@NYTE#@E7!H#.1(AR,Z$BYQ#UQ'RK5SG];;Z2V=P;TQ[ONRAD2W< M.;AZZ_?/;GK79G$4) G9,

N&6X)&FHA@R@QQZP3SS 2F36WS^>'IYZ3]/66Z M1;UIQX4?B/C0NV(V?Y|+[6@:62-L,#0 (0G=.F(#V(0@@\!TD6\OPC_JFQQ8@ MYZ3TPR6[!?\5@L'WJ-S7.TK2,HV!]/*BUM_3-

@'<69 M:GX?&6])4R/-9B O0CS%>\)#Z,=_WY9JM?T'(>_^L&K3D#OB/7 D\MUTL_ Y-MQ=MK),G'S^G'G%.8SQ9??RP?/7V/WYE>I.^WT_#9S9.=B?$L+[\\FX^_E##^ M3VX_:>

[OKW!C)*%,+E9K*#X>E+B@^$2\]D6%H_*-P!0 @3P*1%OXB$'@C^ M2/N_9&A7W8\+TETDF>WR=>?/\TODVI(M_MP7I79&>YC]=SFD%L/?CYQAC\=,WB2/-F653]D2.123?-

]29A+TZ]N M.O]6!CHN2N*"3BD)C1Z%H>6&B&0\N@B!!CQ5EL?2>S_85"I&W/'KH\|Y3I M,;FHIMK5HO?2N)_%N@YQU!H;&%&4YVL "9* M+3RS'M\/FL PR:WC7B?

6*1)YVBQYIB[Y2"3I(_?:C3[_.483_2\W3;_\|OVR MJC-+RZ@OS;&MP(,^$]+$FU!HD;G27O?<1#VYFN)K4![YW>T, M3;;9[%U |VHVOF|C9TTRO*0Q!E>,.HZP#!$<_TI48$Z3%&HW

=\!Y6)E;%@9 M-957L&SN.5CE2WRIEB|0%X"-^.H.]'.XXS<"]H+(#/0[7OX/ZV!>]2A),R(2! M-3&6VC"ON!FS @3<<<=N79GJ2,1Y87&8L?A21_QUS8YWN%N^3\6|<&?;^Y

M#8B6UN8HP"L>2G8:!Z^S *E2XL[0:#.:WFRW.;9\^/"QZ*HNK ML!.[$5SLC*W1 MC$HJJUBOO1O5\FWI@JMB&.,Y+,-'+FKIZT4*"#LRB&+9_$L;P6+U("G94*# MHKAU&LJ 16ZX4-

(17:,_VO D>"8P,30'^LBXMGFP#NSZ?K!]2$0YB4>EM*DT MW!9XX@FB0!OB U?<.],M,+'S$M!K#P4V"&ML M0_;^=CZ;NYM2KS!*5"80*04=2KFP3PX\&[6!8+156

M=+2W0/O=N^G=T*K"YE\2-,%V!%CG&7*3.G0B*=X+"]"E*0)*GDPPC C:_ MZ0#KPK:7V59%I17[L3U)HW^RR2+=-.:06(0N\3$5"):$D9"5>E(;&LW1?I

MV))9YO^;]E%S'K&.*LGH;MD|< +IS9L7_LKZ;*LW66:UL/N=_;\'?=3DNQ,!.4$@U"EQD(W'OM=9/>ZCN@&Y*K;5<=#539H-';&LSXP^7L4K2ZTWL>3>'>LCE)P)'LT MN7CF^#

!0.HTL"@;,,:Z\=&C!5R_1?1'5A7.[;*&Z"FW1'>]C-+G9[?3;XS#% M7:9*`D>(M5*0HZ^,+ZR-/EA%#1#*0BGI2*U&U,\ ^?"LATLJZ7"%MWFMF"[M2O,%-&)S(C9D8+$TPF,N@HN(SV?

]I);"2-WHV#R,74LT%W0\]<^"FS12^X) MM(4H5K0O!?N_)CS=SX@<RK(.!+2FJW81!AJ21$DH <(&"%S9E#QY%V"3Q M,3O>DGW/8+LPL L#:MZ#F>2WTU$T4,Y13!ZICY_'7

MH*1P<<<]7>G\4^2"=L-",+^YZ72![_X!ZP8Z?7*T8<)^'55*KTNTMD7G_T.WSR MS:=%/=!WWQY^Y8/[MKAI^LM-'Y6ZVJAMC&4@070*A*4;?)`9]Y-,K4]V\I% MOP>CKE?

=]R*6V2XP=YZLR5%8IO!M5;(TW>-<&O#(2'5N]G%(D9E[!L];.^*%]-M^@9FZ>YJOB&5?2]%?&7$S?VX9L\E22F50(LO%XI2@?>20&8Q467P/]4[7SQ^_M_O&C5X,R8#VM=U]-

M,CM7F9?^E==T#0*4CU%"?:>F]XRG#^UF'B'^C-M!7<-V57T]G<-#L_CA53@.%I:\2HPW&E EY$0IK)>8CUPW$.I]BR5NH_I_VU^_O.3

(W2++2=13=:0LLXZUIBQSI]:GKG55Z/DI?=Q:&:V(U:&-*>0;:AD;;TE0V64H\8=)6[Y'S&,#;MJGWUT6+XKB]!?&P MC)OIT65,CT[S%>H[4DV)_FFP;X7(*.F[@)S19FT/X.:H

.D!]%W^V1CB@ M66?](V[CU8>)O!}>OM3AXK1VT>U@_:Q2&A64$(].%&^1(7/X&6R(&.T0AN>_M8_71:2?4Q^+XNN[<^Z*/H@;O?9&C4\Y0#9*4'C VA[MQXREDDKB,CJ?:.<$G

MUOOBY)A43V$#]\L(B(L{3<"+A'MW"@[P&PDW\,@)R9%K6SWP?DKL;1>54]?2C;64 MU<"-V-8$P&OA=!!XXI-47-Y;GJ\9.2E6&"..M=.Y6RXG O7CT2-ZMU/"AC_ MS+K\MX=?>;RN#^@PX]?

N4_K Y)DP3_OA]_O@YK9:+-G_9EUOW MS0!FBT7,?K[!EWP\B?^83F:S$0^!4H?N)/HT&:TTK\I@(=62@X7I92B)\/S MW);N5[6XYOWY9CX=W\$&X9_N^C:-5.!$"N<@

M)HI'E<@!K#89F/8^,L;T"0-55U1=UX7_QR9+@R2R%XVX[W88<9-TDY>@P5K>)O&/38H&=XU[-MBW7QQ[+>YVY1=&2#YDS:#,KC'R@Q8;>20(?/,.11*M)!^SY(7;Y+?C?)]F/-MH?O-(NNC$?G'?]^,Y]!>C85]/_^;I_I4?>X-DL%!8;"L%PZ*E+M4O^C+?;-O5^O@U:,[Y,]V?=I:8%.ILMOE=^C-M(^8HS[S'ES3D=-FVY@#MPJ,1!ANRC-M5.*[M8UHRHX$$8"S4HQ@E ?G.5OB-A1>!{8^MBS9^[9Z@%[,R0^NE:W4+1.-MR[\^,83'[M95L0-G#_>%HX#RI99FX*GD>TBOP&6B(!N.,J5.)-TD*:+V0MX,-MMT^'#EM(?KR;X:7=M;##5I?@LQ_2\HN5'S22RB6K<&E4NE{GQA,X]CV8K(2T-M)1M:&LC?9T-HE-(A39\@KL?5!\V*&UR.XH;5G?YX5K6_1760HYGOX-T)3:<-MROIX:M'L(3K&5]BR+;(#V9OA[?'UNH6EO[OW_=7]/?YR^^7>O[CU-MLS-=+U[-*S=/(V(998M!W$K&LK-(UE@/*3+&LS?)I=K%]*W6\F8H?E*DV,+V-MO2]U>[V[&Y;6EI"ZMM*X3,V[OI[\E>(H-M6ZZ\IF7,-YEZ&$&?# #]#&%OG0G7;O(H)FNX\PZD+Q-07*"EUX@"{173T1"A4A,?LLEJW@593XP86SA__M\"7]_D[&XM7]>3;[?4@R&C%-8B2RCJ'\+F0^^P=Q[-8A_\8.UG(?E:WNWUOM#:Q1#"IHX7*$I/>91O&-R-M^M$D$>_0R*)VXZIF:"U2M'VE4P=7R#:IF!UQ3X(V3(3#$TVR0.8MZCWPP$B.67)3W:YIMI@WQ_[3H.46PA]6'+NEL3/FWJW1]5Z:[/%[N;*ZDD&Y!$8@^HP/A!=I<)"LHD1[AM%>^HZRO M=N)(/\1OB\HGR8,M;#]>R>KBCZMTM|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i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|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|Z<)U/|DXIH AN&)G"I MG? <#1KGA%;>!*FZC58^?CE/1:D_7/[30V0#EO>@W:*5RQ0D+\,)N0U@DS&@ME)*2!X&VS7]7AM,O[VFDTTIB;%)6N2N59XDO92(HYP[QE9[V4>O2U:]*98I -/6M>M,W^WYPUO9532SJ2M:)N, MR5Q/3!LY%SDW-_/^@9YV]5ES$O]JB>:<)L&9K]_e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l-405((_5A6$"APFF.%,D+2]!YT7B[^_F?S'T97 M$FCQ%JOZUW_[T]UZ_?#G7W_]]NW;+]]9-?]E6=W^&Bs4_]H]_:?V\>|'SW^+ MZZ=Q412_UG_=/KH]CSVHA\6__N^_?/C"[^0]A>5BM:8+;@BLRC^OZ@_++#E= MUZB?Y0N'RGT\1^_4"]@/QNS[D-0!SM;@?0_$XA.G'8.Q^U!!CJP MC\$%+#=?]+<+,=5W=TOJ8M;YSC4UV*YIO.)OA8L.CV6Y^-##_]GEHP9;=9 MUG1.U=UC57Y?RX60C;:<&QJ4XM_^1^:,;5.PEM"V6>Y6E<;OMY4>G?4O\CJ M4;[>5)7>#F<\5ICP)(5IAO0NEB>$&4$9+%(FI_D O[^I>.D M)F=-ZT\.]Y/K-M*KI:,BC<[GJ9O=ON&I7_?HPSF)67EO%R7.S:4?CV8Q^NJDX16_ Ri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|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f@Z$Q+?L>GD+_+U$8HC23D"A20):@&$;9(#$1*$]O4P34 M68ICFXD[^MO<6OV#R9)<&'\&/^.N(315N$'!,=51^]PV;]\7M>X?#2XA'?C MV,H.3/,=HS>QLK(4_U"_V+[HIO)>;5;E0]Y6UURKI55IG/E:*W'CV+^5-^JO M2Q/!-'ZAEYY68LU3E10S1E61]:0PH4O:?D5Q"O.X8! G,2(DBU 12Q<[XJZP+AS-W9_UM:+&6/K6^Y[<)9DD,1)UHQMR4RK*!.P5K+(]" ,\=SJJOQ@Y)%U34L+-,3L75K[TI]W:7G+Y*8#+,5QB?!:SKG)K;'-MI(_KCVK6:O]$RUR=<&AN.,T^UF2F@~NU/M6QS;]Y%EF:7/9[_7H=D'FWG.NI M*8/;F8-HCY.]@.(I@O M'&[B,BOU?TQI&.UIX\#!,R50+]F,8)%HTX-DJH %H1A&DJD$YRC-I9/;)"1S M8WM8YJ52=6$SL]_U#0G*J!R,"8L=>$+X>NH("\OE%+_ UJ&6W_Z#U :90#& MERZ'-SN5 M. H:;O]NHU/;?#LFFMC#U17I[_GX%&D[^'V_HQB$SM $TI=5Z\YP/-KW%LMMA6)-/$!X1;K4?X#+KZPCC_DN7@D M6[!?F,K69LM_O5P\RFIM%FKSXZHI;U8N\8P7.&+Z8 ,9)5+OQB870'(^8QKE M69K2*&-.-T#6E$=2"M(?J3#+PPENNUE5;=<%<M!ES1KJ"6NW6=*?5!*YP'&@)YP$\|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|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`-N]_*PB'FN]])"Z/|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}6[,E?):UTV!QVU3/>5ZTBIL*C%'4"*6 M0A(S&AFB"A91EA0_"WVDOJA9DTDH?;U,H@X5(I=FZ8(@B'(!64XI@IQ)(>*)=V1U43+19/UW/'1E+KK M.+')#;T(63LM,@)>,3RRE+0J8ML!0_2@&LU9=H,F0+Q8GN0=:O^\9R'PZ]M=?V^;]\8."$9D4)!EL04$A916"1% 7F1*U5%UX .$(2O7'$'-JJAF;(G$9X9!+ MDN14)4F1*^NP$!?*(RN(`BM-6^4K4',#>NR AA\'IZ43M!;NX+$ <|,B#ECY MA*4X@>;@YQT+/#_?;H@OG)L/UT?^0;^MTX#3^6]HY-SSSWH-X%GC2W\G/M)[MV5:53 6A>2H22(0VNDC&(TCC.(,!*CC#2C$BG9RQ^\./K$(-,6"H>1,;?(:%MG3WE+Z&,SG,0SKW>U*<M90A77VA]\VD1.1P4[^)MX_"FW!57]J\/L]_S.*< M9S(N%HB$X)(@7YHEBNHLD*(HA 13ZR.+[B&,O7]YHEBNHLD*(HA 13ZR.+[B&,O7YUEBNHLD*(HA 13ZR.+[B&,O7]YUEBNHLD*(HA 13ZR.+[B&,O7YUEBNHLD*(HA 13ZR.+[B&,O7YUEBNHLD*(HA 13ZR.+[B&,O7

Y[BV#J-GM-&P<%M;WC X[T(V\@7:DP9)3;1#V0C\?+^R M>N>"ZG9-B[-^%'62Q3CB..0TC_2]%GI#4S*#6&]M6)&"8(2=2],)IS+RKC¥U\V&TA-M"EG.WB{6Y?*
KI*_W^7NB!2E7R^F3?)&#-.))<)90C2'"*'4R9C MAB)ILQC/4AIY03:T39$_L$^]S7:T6Z3G\1I>J$%1<%NLW@!8+UIKX0;L6SU& MLV;U#[NE>G[D29:KM8#=DK5_P;
<$F2E[¥'4YN__2>%^XKF#6"->PQT4{5AYK-M;_")RV$=$^RP_-71ISSN0IKN)/HU_0DCO=\O@AX+;O<(YZ0;O$$Z^/-U]P3G^]^X&SC]LV=:G7)1K^4$/*=[K M.5{(SBR M*AJL$>2'D-
UF'U)N-5744(B0~:"CO3TNUN0#=O&Q%#14(Y¡)SY*;MY6,1_$<1 M'1OW/"..^^9T4F]F\4O.$OM99H7+9^[*(6'.:<$|/:AT*:LP(F<59$$K&$)D[K MW9[TV$9(RTC;U&M@28_:GX',,H<#
M$KXA>M[Q>3DE.51HQ 3.=`@0?EHM;^%56]TV'D!XCK:H8 M*:O$6OS@VN(DP1?2$N< .*T=SK[HQ6^5G50TU.O@.LU_Z]-64DQHZB@N401 MU/^AVM9(%:0]CZ!,L$Q2A#(:.ZF#
5HCZX&.\GX1{RM 6_+^91>'\+.-3#H%0 M<=,*6T">U5+N^(=;_!;B!5KU0Y0F7>X6(C[?YS:O^"WPZ\6Z%.5\8]P2N^8Z MO7@Z8M9TE@[($LI,HK=>Y46*(4]++.2!EKY9\E-NOQMA7^N
ZS?!\WO|K\R5?+A=B-WWFM N19)%*(XAQ%.L3?\BABQ-*1!}` 6%T5:9+-'6;&E?;7 #V7KWJ?IH,CL:4. MF";O&%@HR#%6>QA&E40[5*IC)O!>P2%D*J<3ZH"0IDLRI<OPH+S\K:/!9*
<3 M@PGOIA!W]_9XBG L:FTY%0IL^)"HH9!C%D"8H2PE*$Y07;IKO.*'155Y-%MS7 M=(':,"_G$_A0'+-4YEP;A'D""1((YDR96G!QHC<&G'/N9!}>CHY/&MN\XV-CI MN,LE=E-NC;
-05!3'$&K#0L52)V=(#*I'AL6]+D"_.,T;X6NAW+=-$SMDG[- M1>E'N>Y%OHJ$()$'"HL%Y H1" U)98S7F E1)XG-',KV'6>Z-C6R8X%P+L4 M=:Z9J LSZO^V$%]K884;=?R5AC*U
"69'HO9QCK2.XR& 4Y3F72:I/-E;1 M:F?HC*P6=I7$.[*>Q=2?H6.WX@/(!+;(#\4=83L_(U7H&NG/J+Q,9?3CHIZL MAW[B<8]HTE>;5;F0]\%NRI-Y%[M^#WH_])X@M^O5AMS.[??
ZF4[F]%)9K$\[MH@!C1AY9,F0+-5H9Y.)9&7O>[=DNF.G95\K7>]BM[^K*5FR.<>-M) ^.\#*N/E'T93=-TI(§>?U?.%(%DAXVRVJ97'9>'_; FGP*V-O)H\(O4'>R M*7&+
!0V*WF @6>9R;4K>?JJ6CZ60XM73[RL3K;3= M(Z_YNGRL77:S-.GC6#&]'S$50Y)3;@I(4RA1HH@@N:+&36Y*J-C9FO:DG;.A M+0/VVY#4AU!3;_FA9<5T">QI8I9BN?@9++?
F&MURY)B4;@^RGXM! MK:Y2_:F/VN\=:CLC]_H\:NXY[,X A,IHMR<\;7Z[,R 'V>[N(_CD71FEQ0;; M(K*GW2/]MHA_H=_+^\W])_UMO#-
_:V,]3#U!*68RX2R2:XG3)]=6%?,1:0^T6I>\?/#J M2SOF[%E8VB\,*6{]L>DR>\2B.]J-EAWK1MMR#K:L;!Q2-LR__+FX1,r'^/QY M)M:\|X#PZIN>-BO!PS5-
;ZI"W;H>>%^5YME47>8UG>N,2.2(" M$I%)2-*(ZG-"K-67$!+3-.<.S79\65D9-7UJ6?VE[N4P]8JE_Z$SS>B7H]: ME;6=YQ[H4YTP1!?"?
%@9YWNOZ[%S%3Z_^;%4=Q.@[JCT&B;TEQ@8GD#W^YZ3 M|S#Q-7QVQJ70A"O\Y\?&U$4!+P+K2,' R\;STX9UQKI6OJI<;^T&)%3,5)Q M'J4))!B;^+Y$0)3E+),%R@1U:A1TA,;
(.JRIN*B U4$T:-+3=U-PL PTS(7B MNBF/OH"C$T(#*T&0+1;H@4D_,+EU_ NLLT"S7$KG;! % 8 M$Z9PD<{*@!HHEB201B2&,4E5D>=>S*.F7YP7++!*&R TG8[+_!S!6?QOT5-
+*Z_EZL94E2LTC +,=ZP6J# M E*|5F%**;.4")1E7BTLS.!C'X]V/1X,-<_V%34*=BO25S:W-6@MEG?CBC[_M@=M6U$,_2-.*OE"G6E;I/>.9K?2LVKOSMFZYS%SFX=!D7$
M;7$>:0/54& Q&2&AQU;84+D]9^E-F^9C*,Y!QH_UBYYUF]9T78 ^5A__UT_F M%FBY,''(]8.2$4(%01F,1.VF3#*8ITD*62:4P()GA#IMJX/41E8 #4FPH^FU MWP[C9,?P@Z'@MNB=_7
OQ60C6*@J3(.TIBW 9"/V0>TE]Y=\&WB;2DY\O3'-M0DSVS_5"Z.]D]=C8B9P)DN,T@VE*E;:63:),)@4G!&*>')'}V&E9GZ$W\L+> MHPC?ZL>]5O8YT.S6=D HW%:W.PH>;;>M9
O6;GN8VL1MMJU$/VRO;?>:,W4U M*J0>L6E%TMZ=?99K&GB.9) MQFAJU3O7B>K8[OCNHK#:TG4MK&8#G=V2#PZ(V\+?8K$C"?YHBGY3<-%)WF#5
MUVQH3ER'S0&&PXIL+B_[J8W-><6Q76O5$BA#U"3T@_E0!?,+$;33%*/@ MXJ8MCF=\&:.]+DQB/VCX #\93D['8SOK#6?I ^D.>[J3Z@IG.)K$/P.)>Q%#!9"PH#AM&PE[M"
XZ23B\ZMNB\/7R_K[-#6V"OF[V5C(=t3+:H0^XLQ0ABB-/(:LJDX82PX+1.E6 M!BB,"YQ0)*T.&W;DQO88-KWZ&@[V:QF#'A>N/0L'.1Q6!.%A<7A7HB(1Q-#
M&T$OZ&0X./S${0QM1#WL:6CU5M#*8-?WRV1=_G>=*O))5N52S"*2R+Q@IM9/ MQO3^SS/(1"(@US8!YE6&4D[C)R6!->605,% CC/9X 0\U,T'JA!U!U\XZ& 4S M-_TP4#&LSP;X-
Q7J*IAIT4?MW38$;H_0OVPTW!8%A$;&,"W:O16=ZW>UXD M=7=S41]FZ/P3+<7[1NPWDO?_A.L_ MQ?\"4G25D^P]3?+ZL22_BHKDBA3X68DD\\?E;@/RIGAEJC]2).K(^=/KI6C
M';Y5EKIUI.^*HWKMV5TKD\+1,@)VG ##BLFE:9D)66C:'8)@=:,<=2$],.&K^2->KM:E_=T;0I:29HE64IA044$"9(2,HDCB%,1D)CAE&9. M,5[{PX^L,W\O.LID1\XQKGD?"3LMX"^?
VSIO1=M2N@+M?_,$)<>%BCTN(:Y;CLH¥WO?*,WM^(ZY<2+?BK4_;TVUBLI3@%N@UGDW?Y*WK(NA4?")*F_>C)A. 5)P5A:F8 M#',9F;81*(,%.#E2.(B:
(BH0HY736<2$^1[J+H6&GZ13:M9-L,9,..?2:H"S2P M)_]@+B>P[73(6!"ZJ9/0Z#FK%Q\8 FD:)!*3*AT?4){K'Z\O/(.^S9'IH++!G MK^K/JZ?=
(_VJ/SUO)6J.659/>W6L>EK+_%7_MJNNI=%.Y%\')](IH'YLD$,%XX_& MYI2!_&/#?9 $,#!!S]S:IOI.2F\\UZ;\#IWOBH#)'.$D9Q1F2G+3L:O0*IX2 MF$4YE3B-94R<@@4':
(T=`MA2KHVFCK9-S0MGS.Q4.B DW)2B-PCN>;OGQ0N5 MQCM :=JLWO,B*R3Y6KSB>YN_NGLW7WYK;P&!7SP.W^GB5E-Z5RH[@N\51WM3 MKOA\.4*(MM|BQJ422:X7?
6SJE:D$0YKE$0Q$GF=,Q2L G/K{7.K0R.KAR^;A M85YK83H'8DN|OM!:+!>PKJE5=DS7ZT=U:.O/Z\!CHZ5=HP(NG"7;8(*IL'>-
M(="P&M:NMH7+WN^!O.6O7[1QQ^$HNBL47,'B#BYD9^)PA##@'48I!!K7-Q3R MRSV=SSN_X4R***)8(LBR(H>$X43_Q J(D411QO6'PBH&^L3XTP0[UB1!1],U MM'$?D&%-%$!,-
\7B)]*).1.2Z(3=P?,^)@Q*/"'$8?'G_,ST!Y(Q_E2/D@ MQ5?){Q,+^+2T-Y>[?MH,(L_]$EF-39HGCS*1EY#"A(N4%Q9)CXE;P+2!F M7E7?2CJ#F&!UT#C,[^RD@#FY;;?
CC)H2(]0ML52S$!FS3EJDUHMEJ{_-TIL M7_-3D5Vj:'M*[-Z)4GS854?>&3HF3*2.$IF)*(I*GF7ZT"(9))BFD E.(:%*.M%D1$610[^>4]^1A9I;8\@_^^I:)!X;73&1. YJ9+MJGCGWKU!MH^
N'>Z&B?V MZ$)H ND?7RXFU4L70O5<7\UTZG)L>6U7K?>6;W^3RMJ(/=R6G_HB?J6^4D*U M:?2(S;>!1&L$\2U-("8LB1$22**MXQ$$](^N@/CFGT(5A:(8U3#"!W?2'BZS6
M*1%*EJ$%KP@H+7;!VVZA#X\IR3*V$]J.!8/>P8!\#L!-GYH_;JU-05:N:. M# 9'ZO=!%BFF7_@H,\$A21"&5,4YQ$1KG%2i-'<+ MD1Z@-;,)VJ4F!V+!-NQ!%H[#1&
((:=M(,AVL3!7#6U95=7H)5_! >%A8BAZT0<_MH?0R]2%.BWRR+L3 *Q.'$GXH%_*]-FQ6,T9E1K)4U&THM&&A!*213&&6)#E/-MHCC&A5N1V8M9&MO6N+2+)_C#L
IJ7EWKUUX^7Y;6RJ2SX*:B+(@X$M)N Z<+|_M#C!{Z;B^'4/_& ^%\|P &B]0[-G=8_(W:3S(4EP_RHK>=E7F!4;8'+X@3YEI M4D.UKA!808QRK363 A4HMO66'*4PLAKL:
(*6]+V.Y#@>}YUTD%TOHE:>`QC0 M_#DKS04.DN/C3N8<&12K[Q@9?M#3G\'S>7/8:?I%Z)_?2C?+O?N2)3S/99Y% M4&6Q;8LA)*0QP3!)$YDHDL8LMUITM@3'-
D5H%_IYWY%WM"?. 69I+02$P=$6 M.'C7&&QI@Y,X" <66TE#[>#GR$V[/UL*?[#[VK[GVP1CR?
_^63YTS<59N+$QX5W)EAU3/QHJUP&3>#P"T2+;N]8C6^V_'$M3[+UQ1TTW'6T^XX6QY.!H+ M/3<=<@:X+|; 71 "X@! \ 0&]HO%/[A ,OIX ^703R/6(MU*?=-R?
6],IUD6LT+;*!CFB8@A MP3F!.4\0)+E06<+R0B#A=.(*P=44%\@K*U,QK<=>3^.!CD%@UB+HL5C7[FR9-'ZCYAZY M+H&N&0UX.
N)6Z@S7!">ICW2A83QX(07=/"@.3KF=OIKI<^;=_)FT5W7%9&5 M.&<"8H1.CJ6@D.%.02(Y1TQ0R!/E*\|[9&5YE_;$@)-JP.P7(0IN'4414M+ M.AQL'!W>QV)<=F$-5Z!E!6A>QK@.
<\=@W-B6HY1_A""6(4@LHU4&A_"N%&6^M)BMM)>Z@%"\^$*B(5Y2FD0AMGA&884B)S*+#D&8FR""I<6-VBMXT%Y5U;9*' ME@7G\E#'@;,+3%!?)(5L8JJ98^Z'W:
8M"34H5;AZ4,?)3%T,:E#8(Y6@AI_W M+ -5>Y?7462Z^Y[:,MJY1$D>8P53G@E($LPA59Q#%B="'"93',7,JK7",R,C[M>WM5TM'TK#A^%!Vf)7JIS&[+TUE<]YT'_*$JF-
TC,2TM8D&A#RH-S3TK']- M-O/_M_^U*1_I7-9W07]ME]PDVN@-_- WC>Q_TGIO}5$1$&L=LIO2]+!:('X8H
MS&C*$R0$S4@V:^S=+VM:K2W7[B4\N7SAGW/FM@V;@*VZ.IC<40=T#9B\+!?F M$&6.X7Y]V2Z9DXS$$L=1#B.E31X2D1SF(H]@G!,3-
\BIP$4[)V\7XH>HEY@)2ZT]%;..ZET3N@(UL#UZ5V#'"F@>:=(O]S[LOQ&V!-[%0 6L M?^?/R^3%[RZ&
[5CEN\L'==NRIO079%;7LKE1OZ]D?9V^=?>8]K\#3)$:V'6N:X$;9U@E-.P4]136 R;#V'2.IFTHY M%^\A=66K'DF[H2]O$SC"SU']TQIMA;-9Z7!H5W^KE:B:$B1K4B&WAS$NUT
MGO-.Y5@\Z:%'WB]XU<0V-/^^7]QH X$;!VT=\] K/C,3DL4"<6U1"1-[';,$ MYHQ16"0%QS12E&56O85=*8^L<[9TP=P0!G/7HE7.0%JHI}'@<5-4'1/@IXZ-
MG\'[!=@!5K/B7N7+_9MGK]5& LY/UP4TT7>] PJ"%=QIM.;WI(N:=-?=[W MCF*O9.WZ[W5NOE&FGE<==ZK-Q$^5O"\W]ZNF>G+M<)PID:I4, D9%ZD^PR:) M_BEA4*HL+9C
/$DR#]^]'S?3>/9W!.M2IX:?^FCUT#`$;,>]&KC$2RZ/Q\Q\+7D-8[E11U\,SJZW)-Y_V_FV)X'Y?K_R/7 M.PY-$%U@FE'0%+!JHV8 M[<>6+3]Z:.W+*G'-
H_YP#9[DNK]3T>'(V8FGU\XZ_R$FS6T?.QL+N&6WZX=I M^-.?-A/6UIBA8YU'1S.0U3|>GY,>#$;'^_G987R"GAZ4N@GSZXVVBQ?K70],
MPD01*0(1D@*2+$D@57D*HUQD(E4DT7K?*>GD&)6QXZ4;.H#6M/_LZ-<=H#S"_-<)QS\W;T6ICXLKI;S4M0;?IV&6O?'H&D<)S&&,.*)-%VI MSON$VURHW;AYS
9GCQOA)'8V6'F*]Q3;2ZHC7EBX,F*8PX+U[^,>>93VNX5YWFS7+#UFHS/ZQA,RN$B1BR M)=9:T[&HR"A4*2D@P1F&3 D%.>-QG*4"BQ2[QAN/A;1S8+$%$A>$%ULB;'FJ
M"8Z9\^6K0S&Q@$"U>@80+\T?X[2A%" M)QQ"=W49I/DR_5UL8#C9Z<7]93\UK\E&^7_#EO30;RT>Y MOE%?Z?>F$NOS2+>MIS"2E$4R+R 62:YU#$UA3O(8H%2DJ9$:R"G&
[+++61I9 M_=4,FM+*.PY-[(5F$?QD#]J"'1VP >;.3CE-BZR;YFI W6,.O&]!-?SI? 4T MBT:K;29'0/@O T*3*+AR SS5AP)%]>MSNE;?^5)G6G??7F_7=LC*W M4LWU*)X1%*M$2@$
DKK>$'>MQ#&-T?JD'D=QM<7L)[;28SPIUP?(//29D"_;L M>/TE>QYAO\.-B1Q9F H?;?1ZG\W]HF*O5]D;?U(>KK@SUK;.MN<"Q$H_G1-B=;L;'UTUWC(6L\X'F.F
"'6(^F9CTX'(94,\/*Q>..=F$ M+%V M;NH"\VTZ?U3DBB0XT38(,FUL"(0)%7'"8H53DN0EOCI%;>,U)6]/'VISNM;_" MRY]RHZ_W-$'Y9GC(]X@F*4Y-|>D(LDR88)PTPPF*BH+Z!7I?
@I)7+GI06.QT M83 MI&OQM(#/%^` D[Z5OY?5^]NL|NNZ!B8\]?R;2(F/$6V70B=:TF?H",W-[-I3DK9QAE))(%5'FJ MM/E*'YC'F$(<8Z[B7.$L:M&U*;1/
MP4'B8%ON>8H3[\'6$!QNRO:O>I30,(WFKL5_;DQ:W6_5LXYTSHCQZ89'#&9< DK2!+%!;;J#NE#?&3E8;@!'3N@ MY@1Z!FR3)_2>72|WG>-V!'L!N7Z$?F,O-YV6W'D$%?
E\R#M@R:*IZ9B%,FBCB% M*HFI/H#D>E E+!*50TPHF4"9+(JF,^L<%'=[+L2/EY/_>0L'6;,GGZA_940GI M.#9D/9BGHS?TQ^Z-0Z$,?1=`GKDP=\V4$YTO5OL]B[MTDH@DE"
("4],FGM"_MP4(R#A,49Q%)4X:(4X?Z(6(C+ZY>-E:/N//1V0HVNY47"@RWE>B/@W_>V@"`MH=/-CI%ZF2RS :%/)!<-O>/A@S0NSMTN_4;.Z9,4;RKZK>NU9BY&9A05*&=Q
M!G.4Q9"D2O^4FT9;&4:1*F)98/L^$%8D)XFZ,3%]0A.^ N9.T<$Q9H>;A3,Q M.!8>=Q([^E>@Y0 8%K8-#]_US'@]/3XN!> M;*K<]H)C,Z-UV79BWG[Z E[3.=_,FWD)?
E<]#E"A%14J9O6RS0*L >NHG&H M^-RKZWUAN?BP%K^T0=$L4HBR*(%,Q(4^HW(!"U[$D*8B9UE!$YX3^XOS9Z,/ M?3->DW.YM'TNO'73 O% ,)\FSL?
5AXH"LZ,,,)S5*2$"A302!13,&"40Y)A#(A M$(YHH0^RIKBUG1TV0,M+)VPI6G^W]DMOS(<*BSFC9&?8!)++37|85ARY M?K M=54RO,,0WGH+13!P$!+AF
M;REEH*5_CMJDR|]2l.%-5,@(8+H, ^X'1_@\Q!87ODK M+I(`3&*Q(CMY)HL+&,?269S>'R/IK6U0:P+*5NO&)ZBM -,_=F/"P9HE=ZWT
MO_VZS$W\;/.FR4YI307>D=?I@L+9X7>X,."\/IH2\QJ_;F(<=WT.A#F?SU=4$>|/3W:68LUHK NADN +42#%%Q?AI$)\D M'.|B9G^@1,10P+OE, :CZMG4Q(0*?]7OULUR#*@I90C&
(B.02(9A+HH4\D1% M*LXSSF*K**.CHX]L+-:T@"'FU#KH.!!VJM.:/#=-9R^9>P.+8Q*$ZE.Q-_;T M[2B.B770=>+H0R-EIZU.A>FWP?AOO\N*ERNY.A&/W_V]J5,C$IPKE5$HF!*0
M8)9 ELD$IBDC&$N%.+/*0WX9]B>)+!%P!V=*<(.4L[.S:*9)?=\X<?5$6R6.K M,]ECV_RPK4R#*6+=4Z&K*;W,E$R5 :.6^1\KRVN4B7%,Y1]'"X_XG=?S4|(^ M+)M
L]5=^.6!#;]>+NIHIU57*!,$),2PX&KKJW%)(8LD:G^E6UV&6)A@2$A&3 MQR.@R*(<92G-16IU;S(.F#ZE^LY!:1DPX8#A\-8Y#(>NV1+RAY!H!D 6PY\ MHK+LT'$(U0J.DE_!UGFT
H5U.UJ8[.9" OR8O-3W@O29@2.UNY|(_/O@_@ M#R,K:(4-F7CT(K/TPU?..OVNM,UL M>`\PQ#_*]2RB0L@TIE#AO(Z)!!R:B(]"D&OBF7J5JMCB-C(FT5'NC[1RX]N
M%5A(QRB(0>)3"G$D&2,PX93W(8QVD19RAB#,4NL2,!`.,%)D&,+MM M,10,,IM81_4*U'1K(-[N@/@X (1'F/AY"8/%B ^0FCA _+S0A]'A%N]XVO9R
MO9Y+\:%TWSF()TDB"PPI33$D'&LCG),"@QGA* D+1S;(!RG,[(",*F" M'5E'>_D$.I.&[>4R.U[@!^*.T"GHC%2A++835*8UK89%,"!SCSNMT(_E)29 M@AVE7,V44AQ%,H(QBHFI(Y,
PO2FYTSA1 HHHHRI,+6IL4?>6;^.5!\!\1\M M(?9!L%M\GJ*Y+;@/%OX+[CG -=.5/V1)UU(1T1ZOGB./3*QNVK_"M<$ [& M@,2$JR@6>HM4IDI7@B5D)$$P8@G'192@
CMU)YF(IY&WW+.\.YU [QAZN9+2 MCI.ZLLMJO*F.W%?U/*#"",C\!;*$G8*7=D0Y=O TZ.D:_KZ*P4.#MK. MLMMB;D&+/8-]@#AAM0LS-MK[T#%*9K MNK6=
M<8U7004L9!'!5,6(X2A)8LYF"WEKMIFO4|)6-+ =D/ZAT+/3O<&^0V[*=@^ M'F'P|DQ3$F>U:B5@(#TZ3&M2Q6DE]G--:?>21ZSLM88JUJ.O]PU?:T6\N#47
M=NV5D;,2"AEI99@AF4,2$PKS2)_R4)%%^B^FU0Z5M_I39%5HJ$,|DC7-\4. M(;>#, VOYZ#"NZWES$W+|Q-P. N 0?QL"+]87-[*5"Y>6Z_=/K_\2
MOEZH5'\@.$]7Z0|%P+.GW++*2Y>WBI:.]Y((_?=545Y37EQ;;>*U_:1. /BWG MI7Y@ZY+B>5YDG!.((JD/E:0P"AII!9WF/)8Q$PP[`<*].1E9(;=\ =XRYMA|
MSAM?.J4Y"6INJK(#K,,))FJSZE]MD##%_BC_7<4E^#%*(7]?>?-Q[2-\2Z% MZZ!KWI4#^FFWCW)MW/J?JN5C*.1X]?3[RI33:ESY=8&M=?G8>#.[AI B2B-9 M"_013C)
(<)Y\QHUO,5>;>0\7WU9-CZ>RXP30+2MN M.LX#93OE-BYV,EK-[#2HH>NX,0;>3X8AC>#/8,L3V#%$U2J=.?J"?Z3 /!B95 M7OX /=:,%XSDIZY<6R[%MW{-A5$RI+U9-
Q"N5RNY7NW:C6[74,(243#" M883-+4B:Q#"GB,$TR[!4"@O|/Q=-Y41|9"75\|5*;"SMN0,.KQVN=U=@-ZSM-M}-5H"+]HJJ#@.2LH+Q "Z28WVI.|)2|8GFLDOT'\E-'-@ZRH47.?
I#YX=K'3 M3XT-MYZE(DL5P0B20]609&D$"Z4*B#*,LI3'48(C^TS3&YD=:,E#N:&NG\2 MP1G0[-1(."C<],8.A9KP%=B2OFH(G]'@38TKT!#=92PSV-BAQ_UW*/R4N&=QT0=",D|
M^GB(CSC"O316#:FU,@]v]ZM?=< WWK?$9 MT#<[>2Q%/LX!WEM>'$%`]IO-_X0!$N^C_A+14 MIK"IN8OZ7*:_DE6Y@-Z*.%,"W,'WD]?@:
(B;2*26"HD3+,XRR.:T%@Z=:(= M(C:R)ODL''5B(YNBS/H8M%[NJC&#;^7Z#O"-/B_=ZY'!3P|.MIS/2 -HVAZ4 MPF#D>EKJ406&[!78$0YY7CHO7:!#TP"IB4].YX4^/#Y9O.//
I7ZCE]"VX%$; M))L7(A,$,4ADK'#|7$);< 8+(@8H\ST5*TMRNK/T92BY?8[!;BW=7;4Q|P[U MQQ B"50%E$!"9(<%D00&(F\H (KDF*G,V0 ?/R\0Z.@8^T(NE1F9I=0
M(^Z6X@CUF\Y(%Q_0.NJ M/[!=T>I6KF9%0>1%E"-041)!0ES!>H$,E=(CJ23 M.0_AV0B2|\W!ICX4O)$/E>1E;7+1G^>R#DO6=)M6E?7G)ZM&SB)3\)6E<L9I
M'D/(",=)]DX@$JG(D$'I(@:A'RFDH_JS6WL79J1_D:O5G0'<|-]%CVK$59:B9-ML=-CDP+MUP^S!VN?Q2NP9;)1>CTVK|'SXK-7^]5G [;4#(Q?]&CH'&'C]PS?#?
M/(6V2TP"F2$(M.6VXX99 BQ6&4XB06B%-"G=H@N'@IOZ.E,%NZ8^01WL/2G'KH3=$/LQ:F'O"6Y=#?Q_M+<\<61,%T-S_OVFR;^LNCDUME^?(RL& Q#IKVYN3.\=S>,
I)78J9@<W=1/3;N;_@%OVL3ZMDUN%QO4\=7$#@$M M9X$R\-A$RI+U9.;+3+2+X/{(/UPN@&4'X-M?TNMV)&XXC2M* PXUKE$4(R MR(3^524IBF/CKRI0.+UWE(615=ZV?
JU6>8U:6[;-R1=1:,=A9C*5&/$$"BI3 M2*B*((LR"A"%&4GU85[&TN/$/A+:,%Y_-C_>'GPKL !O'Q=]4QSTC?#GG?G_V MB7:40="FV$R._#C[".# #EM(<,CO4S=_9O->K76)RW-ZE
=YL_+^5RU#08+ MH12)LAQF(I60I%+"(,DE+)BD-);(L|*I^NGT(HR\>_F68]1)MA2%?_0T_9R MJKPGU|G*_*.D&[[*T]4I1B'(WG&0 M=XIRKR\1U>, @5/IUR#1/@>Y9-
>;]=VR*O};GRN)TF?X3%+(24Y,8W,$*<,(M1EBD-(LS1'+N'+5XBMH4D8N'F9MT2S[@]F8/0CNE$ @6-V5P+(L3[B/F,AY M*-U8R9P]2B^;T'DH\MFDSB.O>-X$-
\;'ZNORFO_7IM0FR695+N1]5]9I/&(,*)QFFB&*:SCN7'B8QF574UN5]5%E MJ0#;\E-W3ZXOC$R)MHRY7B9[)Y'IHL429Y#E- M!|,**K"XA=GX/,_7;? X-0 M=_TNI*>]^?< Y2 .P&
<,/Y6O#YWEZD9=<[[<+$RACZ82XO.JH#BB*(T2K=T+ MQ"%A)ATMCB(8<1D)&?,.IF+YK$C.[+.J9DPZ^-!/R3;*O%NFL42/CN=$AX4 M-VVRO6/'P=4D=5+=!
^D0BR)3JH|W(!XKC8QZK&<58Q*:$#TY,5INH.[BE.91YPK(HHTPEJ8OF<*0_T2T$I*WKN3TM M+G<<@$U3K%,;.'-NHCW-9\:FF2|7]UV;R"L@&A\CY>N4\-2AK&*4YA*EFBE
M;NZ86(Q-V24N2)%3G NW4_N(D^-UDO^'GAZ[36-$R-UVCX-;F(:5;>>"U?ZE M3^(GQ-XX33N@1O@-M4T]Z&&U-<<&@E;8T^Z1?M#*KD3.^P6O3-
7@&_7U:FLL'EQ>S6A41(*@&"8D-MIM!4]X6YQ +BC.0D5GF2HJZ>AD;(^L+G;LZ*-IPX\Y2&FU 1,;8!5>GE)[ML6CG4^?*61//N(6E^$/.HYO>L^FB.-
A$L5_\"W32@!L%M#S=X5K_UK^=:T_:.M/^2L.UBT/^3L^UG!/^*WP,V*GGPR!BWOZ;B9SEJ?',$]"W]ZZMY-U32=Y;W\ ML%RMKA]I.3=]*+\N>W1,+6"]UY!I$+[MH4.4(IE*
(AACKB#)90:9)\A2;73(< M-$)8>;>@"4\ 1C88-.JF4\.R-K-S8S4O5.W.&-1-@Y;8IFX("AB/PD^`I9[#E MRL10]+5]%D;JZG>)?SZZSFQ<74[=4N@>[6CI6+AO.L*)Y53&
(6XS32IQY3WS?-):2("!A%7&949CF73O45CA$96?D8DM#0 M!(H%3!DI8+1A!V[HQT%R$[57"]VFQZP?[]K%%[:>\|D4*5|#Y&8MI2W0-"M'I3D'GKV@L{ [5(WY5;63[LQGG^6
P52Z2!PQM!)C($4X$D%2C'(L]<2E4> MDACYE]BN2-FX!5]R_^.?\PAG_U)7/'(MVW\$(<4%0E0IF",::9,*45APF4*]
M4EI0'F54D=E#DY2[HM5Z"IR>DL/>I*WY6)A?),.SHV'IF)X.E0@BH0&!9E&-M=3Q)82ZR&&9IP1!)M;)7>0O/VX68#IR.F#4T;YL(B5"XV"GRRR1U4^/-^%?@
M>KVN2K99=W;@)QPIF4(F_^\3F#ZY_ZB 1Y/WCS_I&<':QL9JTXV5BZ94 MN^3+VX5)B'@O]#R6JJ3;AI5=W.RU7@R[=HOZ;_H >=]^=LV3GRKY0$O1YE#I
MYV_,K4WSMYD^//)4200E8D*K0&6Z,O $2DZBA#(>)=@I/_!%#!C;B=V0!K*A MO>I=?=51"HZW72\ST79*ZX>?/C>]V(D#>O)<@9U$H"|2U^"W$Z]>YIY8H)5K MV\VS?
<%416V^(%U2]7FQE[H(F"$\4O.3ZB Y1>18=KXYY>&.H*PD,?+",0F"]FD\KI-,!';K\S(AW=;EGGRC5,@X4NP8*<# M A,'.YT2\##8Z>23GATHNCN =\OJ"YW+++)OJGH'-
XOY+W3=_O:W>Z\I8XU-1'#&&(L*84W[D9>R,O(X-_M'?!H"%T!L9%UY[YR 98+"9XT&XX-)BX#WDX+3 >GF\.HFQSOF+G:W49"M:R@ M8?4*U'#_M8&
I9=6XK.:UPFB/6U_*Q;T^B75_!F_T7ZZ D0)H:0+VEP@"9*BN M$IC92A->T=F)_K! M=:GE:WI+_S^DN#6=UN6JO&Y\(V^6|[#1IB6&I)I)&BB*N
M,&%"6@5TGR,T\H)OR8(>7?!'0]DQJN$D4G8+/(3\;BO;2W3G!7U.KD K^229 M29?P.6&?K]VSS_N6>ZFO?!5O0;.MJ6152=&$,WZEW]MKA5=ZHU?
E>I8@EJH\)5!AFD&2)P0RQ3G,4RPS%4)%V^Q-MRAEZ(Z_OCCI8T^_@H5H^EBOSU?Z)-=0=*W*G4/$>75;RAEHD9^C-NE:MQ3!^9*W?
$4VEX$QF:8:=VD>3LUGP@/!PW^&-0_/&UCL$8I2Z;A92AXM<&*$T;R'9> MY(.(-HM7 G=F?5.N^'RYVE1R|\7E"*DT(02B)"OT1I\B2$D60Q$G,DU$HLUY MU_M|:^+CW_CONK:>
[YI\.99V2F LA-RTPF!'5|!C16N*,72$#PAC-WP|1OK'-M:/\Z (IU;]BA,3PMB:5.?Z.5"47J?NPU$:AK2;27[D1B@8)0%0DQLA(YAG M20(YCU6&HR).L9M=84MY9
UC4E\W:U/LK^7"T;"P!A"]@N4X22$NM'5&4!(U M7243GD4R5MU]+HW"H6_?A&E M+31Q@+&T6)KZ39WM-TQ_7&!$ MSL*:,N2LZ4YKUKG"
<6#D.0_@VV5E89+JJR;2M=<%)"U(4@@%"REC M2# S.0=Q9'RT+&$RIQ0[!5P:H#6ZNNU1!H9TFT'I=;\RA)F=]@B$A)MR\;!MHZ_*6?&"!54Y36GBOBIG3[LJW+^ES46/-M-[|,

*{5N\+6|TQD/137%LLW-ZG)ADFB6HF>GC-J[#R!.0P.DPMM1?))'%$9I3 M*2BNP_B[J6U@V%\D-PC'^6ZSG62;8<6B5)}(H"#"%#E0'.99Q&": .MR32*8Q(GD9.*

[>8C8R.N_(PVJ+>VZZYAC(/L06G9+/Q0&;DM^*_[GGOA4&4>. M"3+_5H>*Z,T&O*ZDMM6 *9FTS>4-&%IN(7RHP/$A4M.&A5L(?1#T;?:,,S) M6[]?F#K"C5=C\2BK=:DI-*

#^N:ONCY!+/*.XB)7(>9+K(PI6"-(B*J!*(I+E M,D*IG4_/I#ZF++Y1M)4W(USL'L22=5EM9:#\V'B^2Z#'\RT8I+ MGNKF;::@[K>Of[:=8+QC3%PA=>.*

{08#R(XPZ:V6K@<3"K1;=/VH$:T5B|!5=FMAXM%,55[LA!*9YP{>G^+X@]$RS6MUIFY_2'> ,:>D!8YP+ 4N>V*1@&+,-F M)2$RDNH,Y<5A?B/B>A,%9HJC+)?*

*JAYJO/>\Y[N%P/:2\P$C?H\G&OEK8 -[_ M45.B'4.^?/_(AX]'S-I_E\?0F3,.R9)R $J<%0$6] ,<\|F*DD&=%P5+!O:Y\X^LX\&QO M!2"&&:[^N]#K@NYY:UK70G_C6#/]S:&;Z:W:-*

TFCN.WOUZAN?V*4 MCWC1.ARRL:YD!|!PW,O;X2#>>N^8=4%3@(P<3QL&;G;W'#-SMPLBG5V9FZ&[IV7 M#-&C+)@HNO8(34^$V_7[^V)I"XI-4*IAAJ&PZ3G*QNJ]0"7*@2"9F><

<9TH7R-M\2U\)- R.VD7<%^OHX SL9<6 ?'0?;Z^_[U;O5^:1>G8/TVL[54?W^ M&J[5.7BC.59G!06Z5?/5M.[H//2W1[YKR_]>8K:62MIQ;$\U;BWF&WL.E+1%>

M&;^N5N3C=*X^K-1C-=&IHKG6#)29* '*,PXX(Q08-TRPG*2Y\.MO'TNQH> _ M>FKV*A@EG:)-,<*>J18G.F7M7JPAC>0/JW!2;^P9]1=M!:W=Q2N,BZ>#.>;0 M^#NGD?*

&+Y<{&4FM^+LP$"(:&RO+2E M=7(-$",EL&U)0)$}+0C798Z\&P8% 1'0I2PI$&{$'6J>'_GN-@2*YP/HI?81 M>_)L7CUZSY^71AWJ];/W&3\;D6HZ>==V!?QU6@DV:X}E?*

C4_JR:Y$CK3@@+- M;$MQFI6 PB(UWILL:8E)$NG.\B34@:>3YW=DU($96"GO]X?%CW\SSS>3S_QE.^=.OW64R>=D6#<+W3Y\^;J^*

M+5'Y413TM=UU[]3G|>3N=B^L1F'^9UP4KS39@<6B+O@>]7 (1&ZO(:4'G!800$'-WVD)BHC1XU7/68N#L;+XN)'PI=,?2/=V?/HB>NBCG*W49+5D\XJ)^N_"RKZX1=,Q.!4AJ:*

\!80+9G8OJ4&2 MYPP4*DTIA5@2IB=S]6"?N+\;JK1!=4^/$'#!LNT/4 .,$&'N@:X;PP_S%?2C M[<.MIOK?R:ZMPMN3W\<8+:.'&#]<'Z=C@]_=?.D,(X=D\ZJP8^VZX;UNV&K*

M=3.EY_9OC]/UX[8M_406&2WR# %EL^81++#F@92I!!B7AFC'!.7.A;#^Q]/U-M5K{]OWUJI-OP]%:\&Z=X(GF:3X;#QW-G^#(PO8=5]\9-\GE8I&2I:ZJ__5= M;$?^Z,@YLW 8

"T#FV=K6DUIGM;4ZOFV46@US,*.4@.?CE<5NJV?D3)2$D)3 V_9 F1+0M."$(:[O$1RT7Y_3HZ(&LUCE:&#*HZ< ,S1\XH"@Q\[!M2' MCEZ)Y+S=]:

{OD8=DO,&N]2)CE%9%NG\HNRG"\+LGO^8/ZAEC_4FV=:[N1. M6_=L6QE#0I'!W$S_''+C02G"[:87@A)F!9&%!@Y>5 7Z#!TV%FO&LF.3F"S M[V@"!NL:7MW/N@Z?GFWL0H; C5*

&!M.3;8YAFK3ZV,BRNM.1^4"=.S1.%5MO M.*)7MW77X$15;[TA.EX-U_]5%X3B\O.A9?Q(S/[=>E6MS.0V6OZ7FCY\-_/[M]H=:,&K?]B[*T.W[^=F'K0AE3FLXYV23-RU1AQNV9E7&+

*[ZWY#.M*2U+=D8E_2LBIQ@{!d#$S,8>60+Q@]7 MOLX0'0QHOI{!%V225;>\fE\ZH0)1SC,)=(9YK)8@HO#/(.M-]?

^LZJ%A:0+,:UWXVOPZWRH|}&3O)')REFY.U!$V*F@VU?/GX:V)YA!],_M]C\5-H?N5M_5TD[XI?INYOSTAVIZN|B:2)_4ZD[?LY\3Q6F:29P!6!;*;)]S M$G!52$

*@DYB8:85*KYGE(G1H;\Z]8+RSG@[&-;N[#OTR,VIX)F@YP>@V06.# MXS=M&UQVQ?=F'ZQ&OSM)K$QKV:,;:]2(-Z5]C(XTT9U$CCK]?4!X20I>SX9'MG=K-[H1+B--44X D,7M%##7/

)6=_?UO_D610[?(M9:U,#KI9.(N2V+ ML7#/PG&'>)K>GV^:*B6]+Q,WM2RZX]-MD('D+',(2$HY0$QKP#AF_:=(DD1R7Y_3HZ(&LUCE:&#*HZ< ,S1\XH"@Q\[!M2' MCEZ)Y+S=]:

{OD8=DO,&N]2)CE%9%NG\HNRG"\+LGO^8/ZAEC_4FV=:[N1. M6_=L6QE#0I'!W$S_''+C02G"[:87@A)F!9&%!@Y>5 7Z#!TV%FO&LF.3F"S M[V@"!NL:7MW/N@Z?GFWL0H; C5*

&!M.3;8YAFK3ZV,BRNM.1^4"=.S1.%5MO M.*)7MW77X$15;[TA.EX-U_]5%X3B\O.A9?Q(S/[=>E6MS.0V6OZ7FCY\-_/[M]H=:,&K?]B[*T.W[^=F'K0AE3FLXYV23-RU1AQNV9E7&+

{

;SA>$HG_"T*3EWZH^5I]43:@4Q#R202K"BXUWX]ÐF(#.OP;_6QW^D[!WB|QOO[M"2P2&]-G#@6 M%\S]9+/([^@|QP_W^6(O^QRM+DC-3O'}>-3?1"S45;>%5L&]9@;9K0T$2C/ M.06Y5#E 9;$!S8FPA2%+&QHG4^&U[WX=8Q6PD.Z/U.-BOOK^BH;*\=KE50R MYP7-YX%%/?WIJ[$Q(7(OP$%1CMD.65 MNPH>F*F__?WKWQ-*

FY3\GU4;T'TT[8^A&ND,@XT>AW[XF6Q62VTV2N+W6WFHQ MP,&+K^F1>,U9[@LY0O&2\[QO?CZP1]EB_K#]+L3-*]J$I#Q%!48LIZE AB]2 M" '+!#7@BTQ 0QTCYS\ <5C;P.Q0AW2LNI".F 8.(BBAZPA,;1!PN?%^!+ ; MRN\]MW^_L9-FQ>HR=E0(N+W%3AJZUU'L]*?]HFFUK+O.IO/US9_F MD"$D-! PE0#E&@=2=0E=*

*(,9@SF;DG8QP0,'=#:B*SCU5J]I7C>C1W$Y/2-C M6.1W%P,,=9Z(YZPY-07-L[WI9_ZUG7I'7SO*I#MG5#?=SG[.;Z))-9V\GZ^F MJ^=;*8))DSP3@'!2WMS4+. !-F_A5<;T0(UY@Z3;AS M@H8^VZA%)ZWLFZ;EG$$HZ>2[S;^S<)V>AS%!\)N/X?8[3TM7XPY,3[.'^2O# MXL>_F5Y0@,T/S% BF['$FS0&EB@.'*,E(QE2)O=KDG1;QQD7(>\6[%!S_+!%G>V,EBYP7.&[.B#,*

*>ZDC[D\WF[U M'3FW7V*2IDARD@.$S187.24!X8H 7G)(;G20A1>-QU(@8F@(W"R;[5P< MKQ4NLM;S.L#/4]_#^Z.YQ#ITWQO5<>3'BI>J3W]EQQC*!FOS3(T0$(5 M@ F9>,]HDQ)L_P@KU3CXZ(&7BV.I6L$796<,R-GN/ X$>IH0A25D9Y.+D MA*"KIZV"[S?J)\U-V]9^CF[PVLP75T[K_Q]&_Z_JH4ZFOU^\797WAY#+6&=BA[B?.M M)FW%.&_Z+,+8T.B;-*

NK[1Y5&&Q(U8Q@?:CX1V\];-(-]-P&Q7;A+$3K-N&"]; M3-/7=-#:!7$QC!9?'D6ID;/+8P*Y'UL>]>T7=AIK*Y17F[X;;% MS?.E@"D! <4T8UF9"E5ZE1__*FE@5MS.SZXOZ;\!A7;@\B-*

TJ{8[L=26YL[MF8,T'3EK6>Q>8GMRKM-(]BY1[N(`7T@;-^65?3N:HJLR7CTZ;IH"63A_GT M?Y7\(U;3/64;4H!=^V1; ^>R*PPP-;K8<%2_R;Y5BF]GIE)K1WCF3Q Q5*EN?D_D%', (* < <(.O(7. M2U044A<$1HDEN4Y)P4. 1L?0;?F)BXS?BG6{FBF3 :,[U4/DEQI9^P.@',L M2;P=[?V2S2MMHAY>1-S6B=E_V16 [/;9K,/<]H_M-E2&PG5X5^UI^&(2<*Q M4+1XM)>'Z2*

*RIP 2E@FE2XQS[W.$6,J-S#E; 0G/[.Y[U&ETT*R7L^CPAZ*=A-M:LJFL#JX7\V[Y7"H))Y@Q6U<, ZEP M!A N(.!40* 0AI241,G"JWB.C_"!I^".W(N/K8I#&'PF'068& ?..XHD/4T& M/44^:_YP1\3'15_[_/S\MPD7#U,YW592,YF MMIC?3?)@=4QL;$6B;7&J'W5Q]JO%U$?]&BE$N%G?0%$*9'=J&3 >90[,BL<0 M)IQ*S-JOT?NYZU[M%1CF_R7]S(OP%5+U?_\;?UQW-*

R^ E4'W%)?GL_1V+ES MT->4)5\94Y.[K@3>QMJ; ;R/VN+$FMRKH(<*I%[^*|9+ MH%KZ'R(.{T]86'6_7,6.6PG,$XR]VF"^S_OQ2-W]^-.&EE?7OZB5#5!:S9Q] MF[

*R*UE**6"8VI*@QG.GI9: 4HAA7HH.XT3PR%2)0C*@O11HG.C1P HITF\Z-#%=;B/@ID?GWI/6T_V5'>]5WC]8+W MM&ZGB[OOLV$NU\9UZV4=_M=T]?W:?,$KM?QAX[SJ+,1J-Z7&_G.17)IMNO$G MH]6F*5ZS]\6*0B8P!H7D#"#&,,"L+(#4EEBI4ID..%P;1-=13LO>-"<9";M; M[?X?-E^SY?,__@O$Z7_ F\1^D_T.\4+G4@#*5VK8%!#(S#\1+G!*

M!$2B]#W++>B5CYGTXM3MB7\U$KZL--V.6IZ|GT-Q<|JL/@|_:03V N4GZJ>E_ M&I63OLY-1SG8[=ISXT:B>UWC?:!ZQSW4&133,29F(6'4?=>0P"\M#

M O8T[U1S\|:V3.H=ZORZZ{J_OEW,Z[W3{6RV^+-IK]"Z#4V?)+,HIR5')008 ME0@DBC %:(@SS635$N42:=[6'4%P?&<2STZD^V5. ^,"K-%G6C2MHK)B+*{O!RDRJ[9V0$H MH]C\D^,"*

*(LZ@3]EGX[MCLGRF6U"^W5OV-%VQ69U&.YV;Q63.9F!=]:1]54K$ MHEIY-MTY#ET!99K!DIC]ES:,, "F8@0Y]H+1,49DIH,E7YY$HP 6=18X*F^,] M>@PP/"^W.W-[,@?*

*H/736LEAWD?EC'L1>\[?S?9ANGZ\G=9D>]^ZS_D*UG*,#;GI(?LF*LU_HW=?!.I\^KA_:U;O,<($TD\"6PP&H0!10C23@=--; M9H6@;O$<>Y\V1>V.EI9;GW;-HUFQ.1DIP9RB]M?VB=*

(T#R@@.,:%AOJ100K'/M# M7V1XD%M\H>FG"?8B<_RHLA43T24[JOP%,:AVWS=:(ZJ#9O0I4:IW^P,AI 6V8 MVC_J]J#K,+NP/IK.1A9_6M?:?/55@46#@("@4!RC-4L"%Q(!"S#-BZ;(*

*M_!M|CZ#XP&3VCVTTMMIT %\D-O3OIA^?70=>-Q7ROX]X|AUAQ]W@*QPWS\WE MY9'3F|CHWO"_[PW_/^KAO^N'YS=6O8+0Z,!QN';XLZ_;?XT0Y\#!B!;&'"H-*

MZ#N[$W+W>\7[Y.AA>7-6<_'EK2?V8/WSZSY>]YSM!EHF;!340_*JC$,7 M%HT!"&IA(_$D*;,DH52Y*)7T*]9_6N# Q-2*3VKY25\!E^#_ , C=G,F8P/@Q MV&68!%3*

=S,T6FWL_^)&KEKO9OQ^/7K'Y\)HH+OHM4%;]?5:O&HEIOHHT_&-MM/5R:8/2:0YYAA@'A,D2(0)X#G. 2\+XI-@PPPZ]6$##1D#D\(F'F+9W(77*

M]:5MV&8K/GFRIYJ^M3M<,76CAP&0\F.)3H$FAK)3H1<866?!MFK$8PM/NR.1 MAJO44;G#$XJ7%.+[>.A]9C.7/B]F4_%.85!$NV?T%#_RQ6(8./LWB8'O M";PK:&MVW^GC-

8]ME:/D%%B0K.2&CVRE8;/C 513#0K.(,V94(10K[-^1\$# MTY)+>6[?:MBND#B+K@\ E!_Q7(:1_RFV\&Q3]%=O8Y[BNP)QMXIL_.SU[ER M|)TJOZB-\?ZG6HHU?

*1DM4Y2F11O^08"8 (ME6B&!F=(WITL(7:]6D^> ZV1X*D8m"$BQ#7S&,&N:8S!F?EZ8'W+!1RL'-O0P M>R=5WATO\O67&>%QKI8'&+/KW2SO#/M>W:W.H*;Q^NNY5?*

8<@E=RJ>RJ]5_J M3MES&)?*?N*Ol!;Z$=;!OV+E7.GOU5-,ZT)DLB6J\D Y=:.#R" #)%49T+G" MHH29)M"KU_D;8/?+6<=-)M*^DLK'2QTG1[2] H.[")Z$#HWQHX&B!_/;K&H*

MY=XD7SHPC.RF4]\ /45/V1#B[K^A!6=?I+7K[*1/4]A^=/5M1QOPQC6#(1<0 M"(R831WE;0 B!@-[*TKR@BNKK,C#'(^%B;R6N%K6X/U#$IA#ADH(R2W. >$8 MRZD]<*

2H0)P^D5=PFA8Q5E/_'"%AFET5_^O%"[Z]B-"7WOHYU\\QG.T8,Y8 M49N;.]1M4K)5,V 0H(9$NA(26 MG7V")!R$#NQQIY.O1:O#)A'I)FG&=&IX1$BYH.H9'1.,(.S:B!T\G/OFZ@>?V

*M+#S^81$>]L:*B7 1.6Y A <(>]$0/L\&-YC^,:W,BWY=+-.\MUGREU[-,4:=% M&I(H,H1UF0+*>&E<.*4 DS '&5.RP"B%ABT]\NR ?%3;\?6(C.M&++Y3;U1RR5*

MP3&9+ ^8Q0&,6FKKW%$# .:%U>W/ M]9GTJ[!%RC H,2$ %10#RAD'I2 Y+B6C)2J]@@E.21MXUG>BDC^L,-]8@9,P M.>Z;&3OO=RM-M_S^)B3ZS]QTE9X^XE7,S>VQ./DQCI71-*

*^/I[:*UM [G-Q4)X]NVH"GQ*J>U+I'Y+Z!.M4(T5@1E9NW$#-(>!=B]^60G$7.DQD@X>/)<"_0! M,>#G;8L6[WU*U,BQW>>-WH_C=G@F^#SE<'3G)M.2(K4DL=9XG6CM*

,35I_CZ'S$$@\=OTE_,3 AARMNQL8[83DC;^QC M%C?S#YRU.#YX6;[9$4_#)KM|F,O(CZEM?6VZF)_G9!|&XZ6'6X,&|8_EK, 73U M52ZXZ++YN3IL%=_3>O<[+W2K(,,EA8Q?

*"9SG=+"" D@6$AI_61: %! #P4K! MD*8RYP8P]K(@&U$>@(F;0&B1)+^L>H1&A+5?C0.ES?*M6%*WR8 M=W>7G]FS/.(U7K;YR7*M9*]=*

JB2C"$E!4U"H@@&4VZ*EFLN[A_:C2N=Y2LT3F9;97V*.<69=1.T\Y5QL*/ MF_K#T*E7IR9L^EI\,&YLAWZK8V*43%HMDX_70]^C[-[8HQ!6H&^QR'&$W#S1;[47TG MM;^)=H<\[-*

*)2 MB(=C\H[*M5HU5T]&X<]GQ]DAX_86?FO!H%'2(V = MO:AD?$VO5(=R,,B/EZX<3F1\1]C^79MUWU6UDI-,&FWUN#@5E]4WO.$$GCY"Z> A+A_8&]W+6]&*[H;FWSD5;E35D-*

M.8Y'>Q:,TB)\XZ;?%0OXYG<M.'G7@F7=[!!.8 MN7%)-"3!J\.EX8-N^IQLC>?WZ(2LL9I=G3?!0(LCAX%UC>;;8QME<4IH&KC1U=VL9D&P>'4?M=9BH*

*M/Y)8RQ-K>G->]0]*0XUGQ-)1W;,? M3<_ [>:QP,HXX8R C.+,,K@%("HE($6D4!DC.(=>!WS'! T=75.+35;LIV\F MVU%DW-.7&/;ZT7UKJA%YTI7Y_*/|IR";ZG,61F+ HV)&);1SQK[DAI.?*

CQ] M;.\KZ|)"99:7.$\QX#HO 4I1 3@I*< "IEQPEB'E%2%R4,JH|;Y6:%)IL, MN4W9B|WVFZ_^%E\6>?O2HB%":CQ\.W 8WE3/?+1[9=#[! M$%)5%A+0LA E= LG213

&F8,ESP0F=^4:O]MP]]>K6IS-J(\ZU)NP.$XTXL MU#S/W9"S9?Z;CT,6Q-H [+Q[7"?\D%E[CO#!#P4D:+_P=+\H^T(S1=^V/=[7 M;/9QJM6'^7\KMJPV1Z%288I2XYCFJ;

*UX'D&6.$XP'DA"2\@34NGR7:!#@-/ MR;YM\]$:M!"=70A6S._]:-8\DWT#<3_MD=#T8P ?(#^T0'H7B+OHN^R>*CT\ MMF')T2$81\|?:0@R2DUG/@:\>+'L,YUMW.ILO>?*

*%7@,42=C*2DK<+R3M7'ZKVA]\8H^]J2TXTT*F)0=VYP.0(A!0F5(@4*841$C@S.]\PE>#MH0\N6GV2NC!-K5$75F-UJB-NK%8WS4\3]UB@T^8/ON,1R)'0>IZ-#(*F_Y%)*

*M<"*QSE*\Y8]R!(*S]H2_"+ AS7X*/@^H_?%;-15/:'S8GO)#.KCV2":E$!AD@LLRYQ#ITB((90;F/1Z\I*FG65]+_EL5QK'^\A!AL3!V;TB*

*MT^/?"C:]#/]#U2A1Q1*R<)VO.%)A/O4U1LS/]1X(TI,>6R9XSGK Z&UX\4/-M)2-&Q5%;97&B2ZD*S## N5 "08!D:&&O*!8I^87&GLVD'@I8N"U]NU(QQZ6*

*MJIE1YAV/EQ3+K&%Q\ZPO,]9OO:B#<[?";I+[4W9>6!BS;|H@Y3!K 52;*F7'V(L1>4TY5U:LU M! N((Z]T@XO46;@]?Q.56(YK<,O;$Q^UP^M MWA5^73\^LN55G>6\U379*IMTVOK-*

_8O&QHTEQD+&116\,18VA=_FT]739=1G.%8D5&!A\1(4-]]YR%0_+O&S,B!\XH@E MT4(G7KY_Y+")(^,MATP<^^^%08?,+,+-'5B.%VD&!0&.8FZF&Z.VQ*Q0CC% M(].*

<2TZ"&@[W98T3>FA$!R3"!C;<.H69XW%\"'"0\#]Y#00@/1SQN7NRO (_2 MKA.4>-SDHW&))QX). /OFIS8CNSSM>]=,_RZ6'Y5R0]3H;H+Q$+

*M9YXPO[<|G>F\.;F3E'.F2@HHM.U'M(*_"HF'!RG!!A=8B4TYI(%&U&|@H&M*) ML]6=Z,6R/DQHI7N*BQ"RKD|E<8.;?-TJL;C|$Q^;=9NOW:G#?)9I0[:H'(W9+ M&Q7]:V?*

J>NG\U\C"#1F&:!FV0<#.LHMU8_1#_7UN5]IQ\KLK/_^NWKD:CDI MJ(8*DQ((F!8 (?,W]B0!A*]\R*GF!#]=89T6,_3]=BLW:07?)%:T5_>P8_@X*

MI"ZC6.W'F8<-3OYHV/]$_Q^WW*L96@0$0CN<>0V!;ZNR,W.=Z3!VI.DQFX]=_ML>!%!#!SGPZMI<56-0_>Z1.5HHJ,R (.2VQ8.SK&@$A@=8.1'G*65$>9;5 M7J .4

*J,7E872TLEPN,D>N MT.4!PWZQ+I^'0V_@=LMY?E*K|S|M)]?I_*&K^CF1C)54:04*DC& ,+-G\2D! M:91&[1'0B=/ [N4V-6E;K<)/,E6?132?L7*_DXB+B>S?WHF#O36([*

M+OZR42'I=#@>>Q]P3>=N1(U_+[4IZ.+=>]>6-3(FL5H$Q=&XH.E&%Y$Q\F.+7N;<_0YM1 ^[\3 S$D.X2!R5 M(@P@>,D//H^&TYE;)9N:AUY6F)RD92G+,F> 186A

M7F@KSO\CN^4%%[R@3$'1=7EY-4M&H.M.E:8UE<')7I6]_16:^FG_;N.W&JI9 M+9(O7[!Y5+_ 7CT;:1^3GFXI(3*G/RLSU^8HI]$E&<@89Q@-KN\@) ME0)2I@6@)2E@JG,A,[_]1;

F@R]2Z]6T\6G%1@%/;,5[[<.A>/MMHZ,@J+G MP891J6[%U"1T=UK=)(U>2:>89?L-OD:WY/-YC+UY_F)\(O%TN!ZC\NS%<++WD MRR)$ "NY_*.M=GNVSG&W?

6W/;.SM#P]\EG5&)=5]NJN\^LO0%(259(IU)8U2?NQ&Z[!*9 MF0^4B;?.)X&H!85(Y*RLO/C0KE4H<=2S7UC/R'8MPHX!;D3< @YPK6I-O[5) MUFEGXMI.$1L&6U4;9L:*

*(82T2*K&BVF7JC!OD(U%W%.MBO3>0G:*C63 !E7>) M^S>+EICM1OS7XVP\;_{)+^O"IZ7IG&W'(=%39$LNV%-DTMPR_8_ES"PI_F$P MM61'Y>K^_9D(46&1AA*

L0@._(2/2VD0!,P1B4'86Z(6JMA]V/<56X@?ZKL9 M.+7-2]W+0I05!Z22$B(@\""\1$!7!6=,U@SE.D+)PFGIB9<#_S#;5GLNTY$& M;]S@=*,4'9[!T'T;}&)T-4IDS7:7$YXC97./XQ#VK3

*[+?0GK],"R.:?(7 M7A*0[OX_O]S^.EO\+I9Y .)EI:12 -?*LI0[*U@D=M-![":D%AI!VXF\[\>[$ ML<((RQH'AG=+XP?=O\K3?>)S[ITU(8G]+\SRR$X/-R\L)?WRH/EEH9_6?S#U*

M_,4CX^6;G];U(,G\S$=*"V(Q[*:?_6&[4M! Y5V;= B2VBX;!* E+ ^RRH=)<-MXXH)I^92)]^>V-7[XK(G(\^'H?8E$ Y.?XUYGG-ZW[)_7&F9#WGN%18&LM\Z M6^K)67O&DF'2V9T;?

*0]K7+,Q(P,F':,0./&=/.?O"=K?[Z\^-FO3'C;.;Z M4UUJC;$] 8:VRYS6[M *$4:5+01+&DJ,B]H[.R69GPZM<[2=ER+[#A^F]ZC[N2 M_9[QV.#'[FSP?U/K?ZI-*

*IA^].3W<$73SV"2X^'FRE=U;JLT//2T..#/VFL1S MUG?S%?E1_F=VW<;5IS?S8[FJ9%=W.E9_Z[-M36&=%KP22'"N%($(%0PP.N\!CC/JP*6=;6A3[P<3_/4:[56H^RA4REf;E8B*

*MLFTPO^RTZNY($_3]BC*X3L'];0Y9P(,P$D7;NRU%&S]%T;8=|*U!VZ5G.^!; MF[I67Q/[9[:UZZT.?X(^,F-_#1(V>1O_ZY"F#US,(8G2)"Z*0F^O@UQ,G(/:*

MRT55(/0,YV&V:;LWMJS!MHZE;1%K]?JT7^GLN.%]D M8H*H$+F9DU!"E"0 MHBK*FA8H]^KWXB0U\7I@+RPSV]BU6>VG-%)S,35>26@E#MT^ID?UJX[-3]P*

*M78]V(D/F>ZRS$[!C'6_J^R99#TBK0\P#'0^3HQWFN,@<^2#'X,C0QR?AT/O M06U7/K%I I5]^\U"FG]3JR?U:,90MY;8;XJAA!IB#J0VFQ&DH :4, '*4E,A*

*MM,@1]&P9=5EH\KO2G@1ML:L]^.RTR'ZS>F2-(MX7J Z NEZIQH7)]Y+U>H0" M+EK=38YV]>H@,G,5UP8[CC*Y+*

M#X2M:GI=OF\7#X^,KNW+X_5S>QAOBL,P2:B&A.0:QNN7U.3KFK;KT#^6<[9I:GS]EB]NR+FM7Z+CX1?+>N*S1OYDUY-IJT*' MBA OHR,M8=QDCKJ&\8+AY2+&*

fV&_$'"5;/K)C.+\RX_E0OWZV'R?"2U(H6@~ MN*+*;'"(!J3(^2BU)+@L2(FA4X[+J9=?-DH3C9DQM:7!C\]3K:QYSY9S M*^T\KF=L1]_;5(6NE#0[D$_FG^UD9!GH;.L2=?

OV5KHJLPAU94 4$ALO- X M(,$0@EK7&D(AZHIY-]VSOO(=V7BV5;|Y,.FIFW463 [^<:1;^!1XIRN>CZKM:U?;IX#>H3P_ MB=B ,R.;FO-IR1;=YD'SHF0\9Z"21-@+]<+6[5.

2BR((G2GU+T1\N&[$X?D M)K'+2O.X'EAO,/)3(A)?]%M9TW(V%530./#=G?N9[KU=]P2V2U M07XURP:O@.YIS#((]K:PYY2U-M07XURP:O@.YIS#((]K:7/F-#_\.|FTH??U G35 E% M*RH9$"62 FN .I!"C"M(*

F9N4.3S>6%/I53Y.\0MY.6_>5L'WDU')'2FSA1 M>MV3I#_S"=;/S;Z2WS2E% MJI+8Q"$&*"$%)((5:E*UJCVB=1'$D:)LL2>S!F5;BJ*OSS(IA-\1[6YHEPQOM=*0PC_Q87"6C2234/?*

*KK"S9='=:N+,?)X_6&(*RB.-FH9*I5WAH=9WL M!B/|K=$TLZIFC:XQFYBD03%6T(^LW;@!/@VT1\$]D9A 7A+;,;'>UF9E7-C?$ MY@MO7[]MKU)3G=LV"U39U3PEI8G*

]D(60ZHK"DJF!W-# +F%@]CP> ?V,XBD*"TSLG$6%PB@[+&1+YQ.?N(\!3IH3#_M]N_)QO\ M5^-+'8O9?9BEH$QBK5F1*&<>N*GO"@C=IFL-<$D05[64A'HY%[FDQB3UZ)S2[*

M>7A8+9EH"9%W@0E>IX!S,YQKX?!SZ.O1<#;K8<-C.3/9X2,ZLC#AK[TX N? M#MQ3V>G_]IKR:,J6H"PE)FLIYJ^R6+DIV^DK3]BM)-_]#FZG@MTDV:[RYIN^:,!;$Y%l6*

*MJNO]UN^;G5JS\#4QT)+O36NMB%#VI*ZVU5&U8H +,?Z"6+ """%A#_VS=)*HF M#F6[]@(/5H&3^]J'5A%VIT(6FFG&SV.U^>JC.OJ2F7J9CVAK07K,YO2*L M#9'7GDEQCKD*

*3:/H^<*O0I("?7(JFE7@E_T:O1*LC4Y2?;<'7X\H>8]FXO'>7M{O)S//RY7UH I9*H6>8E #3$$B*G< MK&!S"0I$Z@+*O*"E%Q5\|\-U\B]8_EG/YW;RU:2X_A05$)<,$4&QV*

M$CKROZ$09E+GE>TA}R(@7UEIQXXK"J9'M=LGXBS4Z;S*]3_=8]Y$/3X@7Q M< 1/"IQ?)'Y#F'G0W.3"+HP"QQW#2+PX(>8\/H\ M.[?F&[BXLW]NIR?3)*<, U)(!E#1U-?5*

M1%38U3-#"ZY [D9Z)0_M>4G<0 M_GK\.OW!<5NHOP'(_2.%1/PZ'V>+V4:!3[.G^X]](6^3;.<$TF^0;*>OY9^6 M;.<$U"G)=DZ)"POZ=G[I^]+.;US^QV=SJ8!;TW]A<_?R'F# .;B] ;*

*(5:/C=RF MRGN:,RH$1AJPBE& &.6 %B4&/%>P5! RGF.?F\ZFQFC'.'ZQ.A!3*$N4(U$! MA04&B$LS8^8%!8I+!&M-"UF6/BQ'(V#J3X4T,J9NTUMZI *V-'N%)ME.):"7 M*V"5LK7*

G5I9I]>.123>,'0=,)$FTT E1HU+K@/JY51QY=O"9H(O*YNJL7FV M/==L(\B?S?SS8#<=O0UN56!4"$1 E4M[%9P+P"%[=@3HGM2LK'#H1,K@(#/U M[6ZGP.1IX==V.]UI,0DY-

O#!TRT\14;)+Q9|6B|NN@7OI^T&IEFA7(%,]QX M&!HIMKA('#60>$#P,FKX/!M\7T7>GHKTO>EVHH02B6L &/<;/HYA^8G+(-2 MF'-I?

*HG\ZK[<1:=.,>Z5S&\G7A?:U6L!=0L5:6#RBQ@7$!JI:MW5_N@%Z1<% MOU*MN2L@Y\O(G=|0G#>[O%??-FRCVC[VHLV@L%6119U#*&)F*X,F@ZS-U*0 M*

*PV5]LN"E;T2B:[@("OY.%G.U$9U0946D0YBY18Q(2'B&B)WU]D9TB&PE M3]WS'Q8Q*\I=3 U7FKK64ECY])>,OE$\NK%*1T:N> _K<$@K]PVQRR@:0*

*MJZ7!QYQS7^:HV=T/(^YDGM6)W9J>D5F+6959-$3&KD$(C4-5F78*4V<%P40H M:5Z7%46JJ+QBR.N:DSA,MGSW!>4M'U_N2_-S[DMA_GO3YI";9UM:L,S,;6MMFX+Z!*

M{]^HP,;:U6!QC/ESE(U%;AH|65QM0KITQ6]>9MY,&:+&9ZW5OO)Y:N9.+%1) M02V$!HA2!"BK-6"R9%CB,D>%1W^OR-HEG@U_OG^8+]Y^5ZFH^=B0'#^937;&Q

M3|NLV$,S/*.]:N A$Q1WG#X]0F1RJ95NP2F=;K2]5$X\P2C[-T%YQM *;]+W* M]'DV8TN%$ZG 3M]A"1VS^E@BOPZ9QJ83S9GK5:?*GOCCRVIYMV+WW54-RDEA M_D?.[K&" $EB=H[*

($2 DK+@FO"@KIWK(2X)2'U];T3TBFJP3{GG)=1&NX2DI M)@@!LTN0_4=O@V#^MM\<7'S]*`'"U>SVQN0D3ZR_+^4P|[^]08$TP5DR#2IK_("X@(!4I -%8<@IUK9173;.3

*MU,0.,84W.W!A?U!|-3S91IT =#LZB0Z+GXOO$&E^Z&DPR5H=LM^Z/Y-<07E9 M'XN8U$GFN 2E/C <$95Z/1Q*2'Q_/IO8Y<3.BEHN+#V#6HB96G^8K<5\;>NB*

*MIE_]HE8%5)4'):ORVX.P!D3E'FA:.2XT(IPYE1R%B4|=1/:*M)!35)>7MM@+ M5L>(D@PLS| RA%.V5R7!+4UH"@(A&OFQE_"1V9!#@+#FF1PYZ2WCB]?ZM.](B M20HND2Z ,*L1@ -@I*

2FU!K3(426Q$@7QZD=Q6DSB<++DK_:]X3)MD0|&;C'C M>LO]8D. T4'YN.=MBIAO>T+(Z/FTYPT]E2\|\.DK;JO;&\,<"8Q@48*2$;-O

M(#4#M.0(<"\A0E5>PR/T]V/:O'F6WWQ(71;FU];Y\'>,V,\D=8K+[O->Z6[M\ MSW7-G=,^"55IM5IU/45:NMR;O\V/Y.GY>N0>FX]-J16=[

MV3%SQEULC)8N/BALY$QQ%\./D\2=GKHV/WQ;[-A4,:YGS5WXN^?>WYK,T6G) M*>0"48 9QF9377+ H)E898UR7125V5KKL"OQ-P523[^]3.A=17)?HXF|$NO] M0Y<;[;E,]H;=

[BC^E9+,_=<YGVKN^9Y7)\;; M'V@17MAY6N/MF%IL33-828M\4@+\]BCK7NE(-27("8GI8AW/?C+3SV?]WB@PVW0M%U2%4% M(1#2D04CS@ MZAH4-=;JH^)BE=?*

>15A$XKAL!39?|!7]SOCYWU;+ MWS<_;#H86SO/E'$L6>6Y<3M5&K?+B3TRP@!+45=&S\LG9(V+LA)[']NMY&PK M.FME9YUP-U^\A-2P0T:TW\|K TUW=DY'PTYXZ%|)?*

JE;/OW5O%U3O/#WBCN1DX@57!DW%,6D@.D8 UHQ2M M2E1S*&4MB5\CPS."4I_7M&*SG=S@F\NS2#D>O42PW_.(>1T_U.4"W;%.BV7I)M\V;<4Y$+QAZ=?ESZ?.B\^MZ|=*

*<7FMPNI_OB?ZGE:4EIBE%,@S,+5>&O. "=; M &9^<4555UKIP.{X*V&?*,0<L_38\N.N@/6KFML6Z,U?OG|TO)CS$H *.VPWM> M,;MZU?6.2HQU$0Q.'U2*[YT*O -*

T\+'S_JZ.+O;EHI]fLO8=0VT#$&",.6@ MSFUI(@0$O(@"KK"N(:$BYS%V+7D8 -8'7l;A_)V&N .QSU1X+,+^:?(D6[ML1P.G4J@TZG_@4G6J94>48\ZY?

*3(AE4CIT'8K|KX.FP&.XH#7SU>Y?!UMA_4 M!U_YJK#%_- 40IFM@9%T(^]GBYG=B&_,O&Q9/!9KU5V 0%HSA@0")1/*9B]I MP* 0H"]U]G.)*_NS4Y2$R.6.QV:ZA9VH(7?$MX-*

0;W1<_,)U'Y)#|;). M@P0W35XV1U[:N\D<=2GN!.6H?:\9O9PS|-C1.8DHD MJ!MUGV(|H!H6(.R1!3GHN224* -.7E9J6^,&\F3&s)|R7K2PS(6AU!SW,;' MP<)5LQX.@_]>_,*!L7;D*

*Y+&W7=?-OEH=^WP2)AC?]f\4*NORG;>$G;7OKA[MOUQOUE-:\Q(SG@,SOQNGSI7MTH$4*+#"FF+'PY0-S\M-8*9?Kj:",P.)&:-*

*R'@N>L&F2.YY3LJHKGG!U)=N>>GC82[92__M%O[-6[NU-M)"FH8*PN@!)F28X0XH!4506*O(1,5!17RNL.>E!:8O?LR0:K;JLJK/1)ME"> MF5O#]+EY;S0L?*

*]*CF%H!"=8<#N9&,FEAV6-ZMA.9K]T:[>0LZNS;$IXK- M-S1N%Z+[AM85K$K.%\1"$8!*K O1 5)C77&K%<,_6<.2<@M2O;-.A6I&4Z*

*M]SF^.P&&RVGG=29Z>NBA=9?]TLU.GR/(Z\P-/%]T"%3/$\/SI@P?!YYX;L2S MOO-:'Q[D#7PN,!W-EC#:%KC&*RU-T.;YU^5&G6*9P6;_72"L ;/V!@;;RRW) M&;B0*EB..:'(KQN-*

*]^3$P:6OQW_;Z3(ZW_+6GT\T]6;\@+&*T[|;)L,N%"?H=5Z4)#ER:_P.Z+*A9 M810U(,)VK=*]J/-<ZU:G@*]J0ND*QS D]N MS0X?*

*<@$H*HAER9(Y!>_U+//[(O8QY[1"+RP%,9DU7@:L8>1UC=0#L^6'[N M?1O18E0P7[*VD99L*U@M77C+-9**7^22W4EX1LX*?46^D4M #/..7'PZL*|__MMF*

*+,.9=/;HL:$*MYW0%$0XA[4&9.%LX(EH*70 -=%P:&BE2Y*KYK\TW(2 M1X]=U&PO-JAI#W#F8W)!!./]/#_$;O^:\F&K8I6%GY$R;F7WL*E'Q=D7/AZG ME.S47E,7A-9UKD%>*

*(5M55B% "2] E1,.8R.]@GK=GSO(3+U?:S7PI1+K@)7C MOCPN GY^?%QBEIPPU\/>1*5GK]\W=X?@4D%,_/UX/SE^FWY:RZK2A"L@I10 M45B857X%@8:4"H99J0K'1/0!*3I?*

\]!$\]TY.UD"W7%A6@KDM|=C84@|I% FO MB-D"17D\)JL_;'PH+HB@$]4 U+5$"H3+BF#TX6ZLZNL[V$E1#YHT1:M(X%>_MV37_FHT

*G%NLO/);XQ<;7Y8!;5*85XRD]0(ZG742YV>8T/_^-51:?ENOU]4+,'Z62MXN?V6IA-R>)HEKFD CC[!24 2&$M *]K E3-=8YH357AQ4@SFN:)EUGO?]CF4=ELD6G+ M;M6>IIA*

(K:4[AO[XWIFQK1EJ_*N6!E_K!TW9V]Q!#VW>SU"LIX5V>_&C!/$ M8^L7S&.38|:RG3F3S!]4_61-^DNV-C,QAJ. MLQQGHRD0-GMMF3??+^^YV?E;%7:=,#;O^U&SUZ-OW4;_\?,7&,-

*L]N\]09'-MSV_6VM$2\RR8f/I#,;(#C?I=46WAX6[46TL:#KLSC_;FLWB3UQ7U:.NJF]FSIT)U3:-M5/NW:)Y2S-'3QD72A2T-IJP"B#.*2 %PZ!DI4"|*

MU)4NO4H#RL\1IY9U[59|)3SS1/6IN<\U;&@N_2>;FR^W|KID&>\U=&-0ZE2M-E4>2W4EX1LX?46^D4M #/..7'PZL*|__MMF*

*+,.9=/;HL:$*MYW0%$0XA[4&9.%LX(EH*70 -=%P:&BE2Y*KYK\TW(2 M1X]=U&PO-JAI#W#F8W)!!./]/#_$;O^:\F&K8I6%GY$R;F7WL*E'Q=D7/AZG ME.S47E,7A-9UKD%>*

*(5M55B% "2] E1,.8R.]@GK=GSO(3+U?:S7PI1+K@)7C MOCPN GY^?%QBEIPPU\/>1*5GK]\W=X?@4D%,_/UX/SE^FWY:RZK2A"L@I10 M45B857X%@8:4"H99J0K'1/0!*3I?*

\]!$\]TY.UD"W7%A6@KDM|=C84@|I% FO MB-D"17D\)JL_;'PH+HB@$]4 U+5$"H3+BF#TX6ZLZNL[V$E1#YHT1:M(X%>_MV37_FHT

*G%NLO/);XQ<;7Y8!;5*85XRD]0(ZG742YV>8T/_^-51:?ENOU]4+,'Z62MXN?V6IA-R>)HEKFD CC[!24 2&$M *]K E3-=8YH357AQ4@SFN:)EUGO?]CF4=ELD6G+ M;M6>IIA*

(K:4[AO[XWIFQK1EJ_*N6!E_K!TW9V]Q!#VW>SU"LIX5V>_&C!/$ M8^L7S&.38|:RG3F3S!]4_61-^DNV-C,QAJ. MLQQGHRD0-GMMF3??+^^YV?E;%7:=,#;O^U&SUZ-OW4;_\?,7&,-

*L]N\]09'-MSV_6VM$2\RR8f/I#,;(#C?I=46WAX6[46TL:#KLSC_;FLWB3UQ7U:.NJF]FSIT)U3:-M5/NW:)Y2S-'3QD72A2T-IJP"B#.*2 %PZ!DI4"|*

MU)4NO4H#RL\1IY9U[59|)3SS1/6IN<\U;&@N_2>;FR^W|KID&>\U=&-0GS64$%BQOU[,,9Q#N7D^M|KAY-R:'3YZ/Y;1F, MX0%E:;4L.9V'3I2|L((E1)"$$

*.8X!-M8DP.*FR1.490Y9#JO/!]bWY22NI@L9/9]2GS"Q.G@7&+'"%>;Z^?\/4L;>0E<M?-"B2-Y\6L:HCCMHYDL?'?YP**7MMQ|J/M_RGN=<*VQ;|E2E]4.%B;6RU;;]*

*M8"6EK*BLG/*'3{\^L0.V K-&8B@=__$;P\YWO8U^7N=E7@!|J2DKKN"N/7C=-MR,2UITPY9JT]^:#O-S(IQ>7]8=F>SC3YN,_M <[J^?U2]JFD+)>YE(!6T$QR MQH\ 98P"*"O&-$2|()Z=%P;EC>-H!RI,VO3QK-DG-XID5A-?_QN&T=4AHX$3 MY*%7X1+@N$[67N')P^\?V;6=C#WV=;?' NKL&\(<6V!W>_^P6CZI;<_[CX\K MLQ>W/;3-S[_[$];H@C**IA3B &#N02("PRXS*F9;>NZ(!(6G'#G,GQ_^8F# MPTZAK*!1PQFYTZG|6Z>51X%|-C#(6,$"(U"B#=Z(3P! 3!ZT BDA3,,92#> ME]*/AR B8TAA!##$ZDK M6\0L-* %48#5.4> (L2\VT."VO.P^U=MD:M&0Q.I\<+_ 8,:GX07H8_&^A(FV]=94Q19I3EN92RK $E M%3#\^2.6/FZ-= M;:62M^UN SMD8ZP)Y[+#1@3R>|.21C<5.?,F!0Q_U<\/URLR2!!*K1{8 M:O(* fM737$[YHHQ;9P.,B0!8D5NYC5" %<$UB@OE"9.)# G!"1WP+W(S,KT MJOP_B\JPY\6PU7-=[&NFL^-=LF7(Z\RS/8\S?]M[V\G7CN)JEXS;^MG%S\6K M=/NX4O_U}!;BN>..R@7F2. <58*5M-IES\Q,U*TO!"@QSRI1R;]_L(3,Q*_:S M2';2 _FV7!!TFQTCX^+GMH&01"FJ,F-DPG*HEQ)?O9#I# 0N)4CG'@WMF[.\ M6[&''S/QWE]SV+17%S8O9WN-8'M!%Z4&92DM/H9H+K0L(:HVY70F4@$C&08U]77*L-'5+ MN\T2DGX;O!>;-7(]_Y!A%Q6XI?;[:LB#S#9G M=CJ;GF)E>>;F'-@^[%K76.3I3F[&>"74G-(*/FX$6CI-(F_XNCG8G/+:[%0+LT7%C%DV)5;,)NP"B!+EN2*L9MBK'OV|J-3NTE$'M2|K#_ J63, ^D\2FXKT#BV^SG6J4ZNV6];N3$;LUTT+A:+TGE!XY(I733XB%/I M\A,AV0Z/|X_SIH'CN59DC+%:U@@"1^,#)7') M_7@K/ULVO$^<>#O_6;B%P^"12Q(0E,*GB&G@\ M$RUI:Y&QA*

*>GIDZTX1CU6A*Y(.2^4$^/A%G1XT MMD:@KT*VU2$D[=@5(X_U MF<32LF]^4D]JGG??8!0P7^?H,PJU!8EG0$."4KH!#,*R2+6G"O MYJ^7!*;_@WZ96+$3'!0.ZB* ;]X>$Q;/H\%K$/%V=U\ZL?)?+KA#TW+P_'B9^OG\5')'Z/B>Z_[L@[UT>+YT#^CX5)C3-X?NE@AG MI7ZHQ7KVI"Q=QKVRK/@?ERLUNUNTEX_B^? N*+=9&HF4M7!CF;_.6PWC'9OTK MVGS6W!D?4RHPKKC$ *$* 4*H!!@E#C36F%1(\IQ7/L$BC9HJUQA[&OI6Q4OT M.F:;O5H9V^GE%W$2#9U;I'K]-?&+ <.UUWH'"6:MQU\ADDG5J9UN]LY{BS;E8 M3_5LK_LD,J],KGFC?[P8F1;?2+$UD9^CQN2T0+^,Y8FEA>[]{N\M,Y*99MI& M*+/%W1E2XN[8HF9544%jRIN)O;2K.L!K9;.%A%&L2$Y|I[7FY.U\MVAU:=C MN+2NOU:S?I_6/SI.E[^O=T<56! %2<6 MEK &R'(,ZX%((46-85$<^9UTCLD+/DQSY;MQ?:",L*S1OH5ASP#N+D>\<1! MP_>)QB(_5)":E=N>/6SE9K;Q+MLI{3!4?N>/:# M83[8=96R^_JOZL&,[0^V5K:KVVI-/#7+5U64K !%74" 6(X!P;@sF%4E4068R M3%$KD)2YR^>ZX+!H(^2XKGA-W#W7);T6BMUE^WT4 M,_Y\NM6B5T2=4I/LI[:DZQ5/.(*)Q6FLL59(T?4;=MZC%5HR08&%\,0% MG5D6W5NFQ5^8K5FSU3MFQNBFC_ZRVJV$+,'-K]=_*=BJ^_F"Z.FF@O%2JP! ML6EVB&H&*,PU*!64I&:,<^W%WA2F1N)X;+|DM6?!?!B:,F$U/49^L=/[ZQ" M#2/]).MT>IYD5GC62{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|H(M)Z&)OBS(>]0'/X7M"GYZ-G?T5QMC'$ F?X)/|?GI5]+WF;_.O-\N>]8TR"DH\IP#Q$@:!.*%[(+D2 M@850249!)\N0+\A)/D(>$? IWX|#>K0-9IX)D3> D_M^DJ(BI^T=\5@'@';T//\YG30|DH4;7;C??=-%;6H("0,R!PB@'B- =]0^7 M128.>EN!67-QI-.S8BO?;"@'V-S6.7'!\ M]1T?#D^P0FOBYU>[F1EKR. @< M==7C#L#+A8 'DZ$;GR>U,#LI9;O#F,75%[72R]4J,W9]YO/97?-?F'^TG#MF M#S8MBZ)2&)NX@&T9A2@A8,S\M11U#@O!L-1>/1@]Y2??&'5J9]|/;+E3I$F MD_)AIXUG_/#%YG73E Q\WTU4H\@DVZ/8TR7;*S/)!NK$W%4%X1!ME^4G?>1= M5Q TQI%>Z9!V|>29FLQ7!HPN+_.6Q)53 *BM\E#!7!9D>&2V!6@CE MBE65E@7W). (;$I8XYG0$+$:V[]WY(}$)NP2.6W7Z18F]RMI>;_9;D"MK%PFAM-MT@=$C=PQ_;+1QXW3'9X)<^6?V.=$Y1Z;]&)M?-:>\447%QI%BHW?XX!@)\|OA]GN[<:7#(OD MPF? %C.]^EXQ|Z;H7/Q|(-/+$9G.;9O%QN?K&YNJ;SEFOA.N)T MN?J%H4^UX2F3A@|01FLI7H>X9Q$3378XN84/B>5+2RL]WBY:.<^,)W\|Z<[M 6<3KL9&.XZX*'#D$PA7 (X/'9R??)TI=!.UM)I9(*5L;NO/?SS.6F[IRl:TI=M'YDM7Z;G=2/6?ZLM)M14:40DPP1 6TG>\H!*5@!8*L+R@29'!5>$>95K4D< MO#H5,V%/Q.9Y3)?^J6VV-SJ]#V;]_^V /9]M2]\$KW;_[%KB%S#_-V/I%XY@5 M1#T3FSOKGI&6;+,U\T3FVM;4K+'U#>1IQARRU\|*C&++GR,',^:PQ2|\CZ-4 M0(K5EAK5Z#-[4E^,\Q ME)1XKI2+'0=)4DX/7)42\=%H:%NMVI.&_YAM?KQ_7&^6 M]V[UI9+D6E%<(0"I)8BE!0*4%P0@A:%$99D3X56BY20U>?I#HT-F!R?,:I'] M;M3(MGIDNV9+0;D/%'T!U/3](#)7OZ8$'2@G2J;S,CYO><$'F:R0UN,%P)I7! M\>'0.-*<4GQA]TV_C\6GV4+=;M3]>HJ)(#D4&& I30B!%0-4DQJ44E20YK26 ME5<2PR6!R:- '>WS6R#_H&_,52%K=/"*IF_H6O$B(>,,|"X'I2 X.!F:,2X M<$'F^_'@<3/ZW=H M?&O1^-:AT0E.Y^Z7C8D0@'-"MZC%.9ZTR"QEH\IP#Q$@!:,*%[(+D2 M@850249!)\N0+\A)/D(>$?

*"TYSTQC;D>'QZ7W+4,_FSCY(9;`VIVO#E&HM)5`M:0"B;A/;ABS (^UM-H6-6U_'(J055X^4D8/6D]ALV\G-I!,V2LK'(+`EE73!ONBM5W\X1]L*[H?]SYZMK% ML3SGCMZF[?HD[:2QZ:92.I!?QBJ@$-<`/7&E M7+,.]%3VO*V)"+I\XZNV_N+M>F/T8J=55W\QIUIS@0@$4EM?QIE-.#C/2X"U-M1DJ+O)32A.W>3ZC]Z"4 >XG9+XM5>Y3PUXG*YB)>IN>2T MJ0<]51-O*E@0[+I):XPHP*5VE76E!HKQ*E>4" R+&%[9$SDC9Y-[AM+#CF"P,)X(!8]-$Z\;8 $9X#@K)*3,:EN%ZS#VWM[1 M$;5.D89+:.I;JL=7F<9FI7YC VMD8L 57I-FQ1P] L >8F0,KK"M, \K&!L9[JBRLB' HP\ ^H/LF2*/"UQ@JGN 6*,`J4YAV>BLWW!F\0#`S.>0 MP3.=W@N&]/ X7OBCXL:'CYNUU%IMWU]SWFVWCVZYL:,N<&-NY5HO6CWN M5CUEQ(Y/=CO/L2EE)2& JG3]=4BHT\DG1J9NYS MD>F'[\OU3ZV[QK'VIF^.F^2[-Z-U\O?B% J> ^VP>-AI.,LZ 0X97SR.*,CE MHW*U)LV<:'^&+N&T/C6(B0)H,K4FC:JIP3P-M6\"7'CYR'&S$94Y>U@@,Y?TUQ>NB4M89VOHRY[AN$\859/QSL?OV MZM$.N@]Z\Y3UYT)*(RH&: DQP#QW 4SM9%9Q+3%4!68:A;0DOH)'=K56C;!\ MPANTBIBRE H#4JC"SD<) L+B!U0A2G+0HM"A*>1Y#2>*/KEXV-@5A8U:L0JK/:3H?L7U:)K--BI-ZN MH;8G2I*\Q4Z:\(6"<9KD!-\?GL2\;DN&WBZWD]=<`_JKC?;.2L-8/6"("]= M0F-R#"B"\?2<5]*2*(=^M% <#,D:.LYW4K!';-&ZO!?NG-GWH7,]P$M@G[B;OCR&]MEM=_>+U:ZF&O$=<3;6IMHY]N"-R M5PP0+4NIHH]H?,RGB8O5_>O%\M%>]MH.W\OU]G'3G&8[&`U1*IP/;-X.9V9R8E0]QN_I\[Z]VVMYBRW\Y&BK "MD$UU%#- 6#Q!596X8J;$!@4MQ?H('3GV=2HT M>[VS[(?38K;O)3^KS[UE#[4J8,'1"U&_R)<:I[^XMH?H*

$) . TK0?>F;&CQ.W_0K]Z#>?.G_.;J:S[QG?ZP M>L6WW]P_=Q+!CH/N#$+=_.+ARSHNRJ*#10 HE 8.<`YEG?SR^(]F M".EC4Y1F,_CAC>?@\#@BX(DBZQ@:3AJ41X3X-)Z/*2]6+NZ0G]"8U&LQ 90> M;?0#YQ.JRE(EKI09-/2^-&KX\SE7K<>-.RLVC5N\77"R6 M-4'K]\>-X]B>,PRI8(J#@@H,L,X)X)!H"HD2*XHTBSHD,RPN)$=MQDC>2,1 M6SZ)#W/;*Y#Y>6)G+L=2,#M.$"@%W]=2#FP?&W3WIW?$SF[F]N-K-[>&25H4!(D?2=5FI M -6"@K)B###(L:8&#&+5]A(X<4Z/OVT:+8Z.O9%3LUR5. MS"1##<$Y@;K_K?$%4U\V? -4T0V]FX/,JK"2C%04&4V]G4A0"7N8<:HS$UN M#/OZ+#PD9*]RJ2>Y!0)#>.'4&3[#KI[*ZL!L)-S@[`*/]/HMNJ]$Z> ^CD951] M9EV]I.J]-MX%__N1;^RG?/FS_80I45.X%!4PI,!V#L(* ((R2 .&<&,@D+!0+ M]< 3&5,YX%YLM/^=@N/O?C>8'.E]WM9&.5^//3?YWNDS)W>]'],N>5[?I9$K M!%(V?>!U,ZZZ/=\"_F:'VL4/W?"3NB[4O^O=!_.%_SF7A)(*<0,DPC9-+H4! MUDT+@(H*(T(-QS]{IS=0_MBK $_:MJER/-0G6S1\N\LK4J!Y2BA0'LN"XP`M7YCS'R+7I--'JF0MT_ O3IM?9YE5R&U]6I42SO;CL$@UOP^4/NV,/@Z.LSE\ MY&-B>8S;I'Z_*>;8DA^W](@)&2T(5$) B@ DM &6<@E*2*M-N^< MVOC*!;'<$3N^6&GUAF|$W"^IU56/=[Y6O!UXS1@SMZZ)"$$0Z#RG=HY=:9?:,^"87227 MS.;Z7G-L'V'3I. U!@^BYYFC)\(D,"$_@:,AR^Q: MFB9F8O(Q,56>/21]VJ3:P^BS#-KGGMCZX%W;5*X9T%M6(EGD6G*!;(IL2F!G MYP@PJJAU/7-#]IWNV5]MJ#=U9IC6' I*NI29 ZPY 0(1CG(MI? ^50IAZ=N?QD#6=]IO?',?2M,TA%*PG]VB>[RS[]?.LK=:=SO-HSAMGX'1 M?=,TG.Y;Y_) S[<>TOL7+>>>"W]DFI[W>^A^,R_]\SV_#_]R)-W+8S<&

MRZ$Z66>3*IW;)"ZB-("T.8.B+#I)+&Z?VA7#SY T[*BGGK!54PP-H.J9Z\U^M>X99YBB:@4]G4%HU=/UC E!"7502&9MJE]T?1^&P0YEZPER/0FH @NMI[ )F ML#]:[=:,N8@P@X"G/[!%=?) W@[*X+ MWR,/-U'IE=806$B BT=3= S$3KI1$3BEM0VSO82,^Q,^Y[P5(?U#6"H=&1, M=[*D5> ^A#RDDW"-^LC8&1M3'H 7G8&U6Q8,IQ2DN [+02YNI]ZQV$<%!A!V$ M+:? N#8:N^2!K V;I)S:HWS;/C/3EOK?*0E"M#P$1I)4\T:)8T(=D(JFK?QCU! MSF&14?*#@:H6_QN TMZNW(]4<0C(F6(V>H'\R@'YQ;3!92;!HA6)^-I;ZU#; M#@/9CQ9_[T4R#>2*M^U^/I>)Q>GK^EN-;&W#0&0:1-+@N-.EIATM1^U)2<@E M4AG"<2=5-IB>(>HPC/UHP?BZLF@-?$\,0!G\:KTP67C&B $B2E*44 1<=&@! MD')]Y:*GOG;EP,'$'0:V'RV0WX]L&@#=KBF@ZY5H;K2C:%@&I4OJG6+@J>;@ M4A(A9:PV#UHX7S*W&_ 1R]B-_PP!\O-GE]#P]ZKQ2U3AI ^[/, MXUX_5YB#H/2CQ:;K\/[!D!TU_%D MNR?*NZ_KV<%OI@&9C'9C\58VZI=%)Q@IF9FN':/,$+"">>*"]"F$]4[GZX-<3 MR#P,>#]:C+YO>34 R4XWH_TX"^,2*5SNO%Y1'R_?S7\=+|[.%FYRE\WJ;GXO M\? >11J910!^OU5/ZYWTW(8YGZTRX{GG&I-M0;>S>-[M'#MBU5O>);)HB>K$,NU':K1-7/:H^(,A*63+>,V{D&$'9:V^J/= M&=2720M F\W3^//TY36^>QKN5S1/8_?M9-LCO]M11,6 AFZ)Z92:09\56.L1 M,,MRP)^Y4+UH|&1B#P/DCW;_HEZ MO/5[FZG&V\6""]3B<288+XDC4;)-.(P#SX. 1&(2S#M.=>VKI/Y[\1[GR+R8 M3&9_E*9? >&*\O$TS[MK>=ZS>RO8+CBMTJ$!3A]M>ZXP[W@O(62=A@Y=*U0XE MGD9IN[5Z1Z!HWYR['H76P$&^-R-BRS31WC"F BBM(YHF5N,YQ"-D;63BFE-5 M??C1\U2U6\=W!N0J"Z-BS[,S@MSA2XK7DY6+MDF$>'A7_6 /&>T>5M&Z.Y3F M2C;;CM>5$; %%R\"ZJO%N/O1+1;=|<2CKR(B+_/ M;TKKI67,*PUV",^]^O*RXN^ =-QP^DMMJ{!\]IT M,WXSI9H:GOMF2Y1&+1<!!O4+OVV@X(17$)/BUD@C\0,]8(#21S6]+P@M';=8X/*2%A%*7$X3 F\9A/#MWVVO+W-MO46>${IS4"8D"NI*E]4{- G/$H!#6,$<3B[2V$MA#2T5=^> -6]WGT+5>_7(+ MY,$X%:P'XC4NO,PG<$13\,XYIGSR3-6V)$XD==CP214,/;&]>A:: ^?X_5[% M=_G=US1WZ]D9>=?QO<3>;S7! [*4JX]ED',OIL=T&GH88J P#N7#!D)Z0>X (FW]B+TWVJ^S>,/IA[GG655;8QY";[4NF5LO M0]=E,1C>C4:\Q:0JLXF9RY*4*TC$KXR.#(+S,@=A)66U&TX<3%S-MM8I7[D2 MP^WFR(8$1M5L>6)+,IGO$0 VZ,Y$$A1Y,;T?S020.W3VS#U0!U9&ZMM0: M,OW+ ^_2?-OZ9>;3_B/=]FW 1LD5E!E))@4ZH$.'%,>"<%,XF*;T*%3ZG."W-M7SJ,OU5-\"? S;V#!XW$*7T>]I-_^(+M\XK+2>8EIHCD=;YKS7\\VH|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‘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|-;/C!HX%W>L9M/7DXML(RE3"TH>AQ8)++,> HE6FB09]!4G8.\CIM&F M%I7!=9X.!M5E[UM IY2<2T2"DAK))AP/]5*FJ6*RV80D0CPH8Z)I(_3A.Z"> MXOV=SMB6&J%'BH=Q.>[K9#F2 T&=Z!A8@DO0+/)P6,GTC]4(_2AA[6N$? @3G MANZ':^1=R I-FDKP&.2F)!7Z#-,DH|KER),

*2D]#E?A\?&ND2J!)_GFV2N>+^OFWQOHQG9Q(JNYX MK\-Q"=1.EP))Q&*8S^A"ZZ*CQ^@Y>BS?M1FS8?X5N[_=8?N$UDC-6FH2H10!X$YLJN%L#$%UWI@9S/R)YZF MU@IS]^;^323@#AREZZ/_]'U[f*IPWBSQORlPGKYO:BU0.XX6+>2@B+4JU[$B MQ0/13 5&;UXQ8BS,[B:K$RP^-V1V0;>1_'J"Y$,'NBJK2#FA\R!TO:ED,$Y MH4${QT+(5D3>NCQA#[(Z@60K*,R"6B,Y=_JUU?4-ONKO9RZB#'!RX3XG.1'[$ ME0I$;Q-Z5%FZYM-W]Z"K&[*U-L,>8#M*,CV@;<34 =R:#@3#;&.QQ@*B-'7?20 G0P*>_MZ-#.HAT.T#VCOG"V4C%Z'&\4NK^E;I:W17#P1CE MC(JNSN-LC-$7/P9Z$#<+V&P,11$P=@.V1]<(\N>B4#]#KZB=E6S#W$$?D2'^6S M$$?U)ATPR?XLAT,>KI&X.@#>)Pl.%0Q984^YDS@@/BMPV\N!" 9:=[*HDK77K M8,Q+'P%]#-R.%U(72'MLEG"67%MDA12TJ7L5;4W76P92Y>"LEH:T=W/$_3T& M0!^'O%9"ZP"!>\|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{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

hcat:LumeonLtd.Member us-gaap:TrademarksMember 2024-08-01 0001636422 hcat:LumeonLtd.Member 2024-01-01 2024-09-30 0001636422 hcat:CareviveSystemsInc.Member 2024-05-24 2024-05-24 0001636422 hcat:CareviveSystemsInc.Member 2024-05-24 0001636422 hcat:CareviveSystemsInc.Member us-gaap:CustomerRelationshipsMember 2024-05-24 0001636422 hcat:CareviveSystemsInc.Member us-gaap:DevelopedTechnologyRightsMember 2024-05-24 0001636422 hcat:CareviveSystemsInc.Member us-gaap:TrademarksMember 2024-05-24 0001636422 hcat:CareviveSystemsInc.Member 2024-01-01 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember 2024-07-01 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember 2023-07-01 2023-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember 2024-01-01 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember 2023-01-01 2023-09-30 0001636422 hcat:AmortizationOfAcquiredIntangibleAssetsMember 2024-07-01 2024-09-30 0001636422 hcat:AmortizationOfAcquiredIntangibleAssetsMember 2023-07-01 2023-09-30 0001636422 hcat:AmortizationOfAcquiredIntangibleAssetsMember 2024-01-01 2024-09-30 0001636422 hcat:AmortizationOfAcquiredIntangibleAssetsMember 2023-01-01 2023-09-30 0001636422 us-gaap:AcquisitionRelatedCostsMember 2024-07-01 2024-09-30 0001636422 us-gaap:AcquisitionRelatedCostsMember 2023-07-01 2023-09-30 0001636422 us-gaap:AcquisitionRelatedCostsMember 2024-01-01 2024-09-30 0001636422 us-gaap:AcquisitionRelatedCostsMember 2023-01-01 2023-09-30 0001636422 hcat:TotalProFormaAdjustmentsMember 2024-07-01 2024-09-30 0001636422 hcat:TotalProFormaAdjustmentsMember 2023-07-01 2023-09-30 0001636422 hcat:TotalProFormaAdjustmentsMember 2024-01-01 2024-09-30 0001636422 hcat:TotalProFormaAdjustmentsMember 2023-01-01 2023-09-30 0001636422 hcat:ERSCorporationMember 2023-10-02 2023-10-02 0001636422 hcat:ERSCorporationMember 2023-10-02 0001636422 us-gaap:RestrictedStockMember hcat:ERSCorporationMember 2023-10-02 2023-10-02 0001636422 hcat:ERSCorporationMember us-gaap:CustomerRelationshipsMember 2023-10-02 0001636422 hcat:ERSCorporationMember us-gaap:DevelopedTechnologyRightsMember 2023-10-02 0001636422 hcat:ERSCorporationMember us-gaap:TrademarksMember 2023-10-02 0001636422 hcat:RecurringTechnologyMember 2024-07-01 2024-09-30 0001636422 hcat:RecurringTechnologyMember 2023-07-01 2023-09-30 0001636422 hcat:RecurringTechnologyMember 2024-01-01 2024-09-30 0001636422 hcat:RecurringTechnologyMember 2023-01-01 2023-09-30 0001636422 hcat:OneTimeTechnologyMember 2024-07-01 2024-09-30 0001636422 hcat:OneTimeTechnologyMember 2023-07-01 2023-09-30 0001636422 hcat:OneTimeTechnologyMember 2024-01-01 2024-09-30 0001636422 hcat:OneTimeTechnologyMember 2023-01-01 2023-09-30 0001636422 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-07-01 2024-09-30 0001636422 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0001636422 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-09-30 0001636422 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0001636422 hcat:TechnologyMember 2024-09-30 0001636422 hcat:TechnologyMember 2023-12-31 0001636422 hcat:ProfessionalServicesMember 2024-09-30 0001636422 hcat:ProfessionalServicesMember 2023-12-31 0001636422 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0001636422 hcat:ClientRelationshipsAndContractsMember 2024-09-30 0001636422 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-09-30 0001636422 us-gaap:TrademarksMember 2024-09-30 0001636422 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0001636422 hcat:ClientRelationshipsAndContractsMember 2023-12-31 0001636422 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001636422 us-gaap:TrademarksMember 2023-12-31 0001636422 us-gaap:ComputerEquipmentMember 2024-09-30 0001636422 us-gaap:ComputerEquipmentMember 2023-12-31 0001636422 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001636422 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001636422 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001636422 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001636422 us-gaap:SoftwareDevelopmentMember 2024-09-30 0001636422 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001636422 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-09-30 0001636422 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001636422 hcat:LeaseholdImprovementsAndFurnitureAndFixturesMember 2023-01-01 2023-09-30 0001636422 hcat:LeaseholdImprovementsAndFurnitureAndFixturesMember 2024-01-01 2024-09-30 0001636422 us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:ShortTermMarketableSecurityMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:ShortTermMarketableSecurityMember us-gaap:CashEquivalentsMember 2024-09-30 0001636422 us-gaap:MoneyMarketFundsMember 2023-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001636422 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001636422 us-gaap:CommercialPaperMember 2023-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2023-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:CommercialPaperMember 2023-12-31 0001636422 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001636422 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001636422 us-gaap:CashEquivalentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001636422 hcat:ShortTermMarketableSecurityMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001636422 us-gaap:CashEquivalentsMember 2023-12-31 0001636422 hcat:ShortTermMarketableSecurityMember 2023-12-31 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001636422 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001636422 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001636422 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001636422 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001636422 hcat:SeniorNotesDue2025Member us-gaap:ConvertibleNotesPayableMember 2024-09-30 0001636422 hcat:SeniorNotesDue2025Member us-gaap:ConvertibleNotesPayableMember 2023-12-31 0001636422 hcat:RightOfUseAssetsLeaseholdImprovementsAndFurnitureAndFixturesMember 2024-01-01 2024-09-30 0001636422 hcat:RightOfUseAssetsLeaseholdImprovementsAndFurnitureAndFixturesMember 2023-01-01 2023-09-30 0001636422 hcat:LumeonLtd.Member 2024-09-30 0001636422 hcat:CareviveSystemsInc.Member 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputQuotedPriceMember hcat:ValuationBlackScholesMember 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputRevenueMultipleMember hcat:ValuationBlackScholesMember 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputExpectedTermMember hcat:ValuationBlackScholesMember 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputRiskFreeInterestRateMember hcat:ValuationBlackScholesMember 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember us-gaap:FairValueInputsLevel3Member hcat:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001636422 hcat:CareviveAndLumeonAcquisitionsMember us-gaap:FairValueInputsLevel3Member hcat:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2024-01-01 2024-09-30 0001636422 hcat:CareviveAndLumeonAcquisitionsMember us-gaap:FairValueInputsLevel3Member hcat:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001636422 srt:MinimumMember 2024-09-30 0001636422 srt:MaximumMember 2024-09-30 0001636422 hcat:RightOfUseAssetMember 2024-01-01 2024-09-30 0001636422 hcat:RightOfUseAssetMember 2023-01-01 2023-09-30 0001636422 hcat:SeniorNotesDue2025Member us-gaap:ConvertibleNotesPayableMember 2020-04-14 0001636422 hcat:InterestRateTermLoanMember 2024-09-30 0001636422 hcat:InterestRateTermLoanMember 2023-12-31 0001636422 us-gaap:ConvertibleNotesPayableMember 2024-07-01 2024-09-30 0001636422 us-gaap:ConvertibleNotesPayableMember 2023-07-01 2023-09-30 0001636422 us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-09-30 0001636422 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-09-30 0001636422 us-gaap:LineOfCreditMember hcat:CreditAgreementMember 2024-07-16 2024-07-16 0001636422 us-gaap:LineOfCreditMember hcat:CreditAgreementMember 2024-07-16 0001636422 us-gaap:LineOfCreditMember hcat:CreditAgreementMember hcat:TermLoanMember 2024-07-16 0001636422 us-gaap:LineOfCreditMember hcat:CreditAgreementMember us-gaap:DelayedDrawTermLoanMember 2024-07-16 0001636422 srt:MinimumMember us-gaap:LineOfCreditMember hcat:CreditAgreementMember us-gaap:DelayedDrawTermLoanMember 2024-07-16 2024-07-16 0001636422 us-gaap:LineOfCreditMember hcat:CreditAgreementMember us-gaap:DelayedDrawTermLoanMember 2024-07-16 2024-07-16 0001636422 srt:MaximumMember us-gaap:LineOfCreditMember hcat:CreditAgreementMember us-gaap:DelayedDrawTermLoanMember 2024-07-16 2024-07-16 0001636422 srt:MinimumMember us-gaap:LineOfCreditMember hcat:CreditAgreementMember 2024-07-16 2024-07-16 0001636422 srt:MaximumMember us-gaap:LineOfCreditMember hcat:CreditAgreementMember 2024-07-16 2024-07-16

0001636422 hcat:SeniorNotesDue2025Member us-gaap:ConvertibleNotesPayableMember 2020-04-14 2020-04-14 0001636422 2020-04-14 0001636422 hcat:SeniorNotesDue2025Member us-gaap:ConvertibleNotesPayableMember hcat:DebtInstrumentConvertibleSalePriceOfStockThresholdMember 2020-04-14 2020-04-14 0001636422 hcat:CappedCallMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-04-09 2020-04-09 0001636422 hcat:CappedCallMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-04-08 0001636422 hcat:SeniorNotesDue2025Member us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-09-30 0001636422 hcat:VitalwareLLCMember hcat:AbleHealthIncMember 2024-09-30 0001636422 hcat:VitalwareLLCMember hcat:AbleHealthIncMember 2023-12-31 0001636422 hcat:ShareRepurchasePlanMember 2022-09-30 0001636422 hcat:ShareRepurchasePlanMember 2024-07-01 2024-09-30 0001636422 hcat:ShareRepurchasePlanMember 2023-01-01 2023-03-31 0001636422 hcat:ShareRepurchasePlanMember 2022-07-01 2022-09-30 0001636422 hcat:ShareRepurchasePlanMember 2024-09-30 0001636422 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001636422 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember 2024-01-01 2024-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember 2023-01-01 2023-09-30 0001636422 us-gaap:SeniorNotesMember 2024-01-01 2024-09-30 0001636422 us-gaap:SeniorNotesMember 2023-01-01 2023-09-30 0001636422 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001636422 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001636422 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001636422 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001636422 hcat:CappedCallMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0001636422 hcat:StockIncentivePlan2011Member 2024-09-30 0001636422 hcat:StockIncentivePlan2019Member 2024-09-30 0001636422 hcat:StockIncentivePlan2011Member 2024-01-01 2024-09-30 0001636422 hcat:StockIncentivePlan2019Member 2024-01-01 0001636422 hcat:StockIncentivePlanMember 2024-09-30 0001636422 hcat:StockIncentivePlanMember 2023-12-31 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember 2024-07-01 2024-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember 2023-07-01 2023-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember 2024-01-01 2024-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember 2023-01-01 2023-09-30 0001636422 us-gaap:EmployeeStockMember 2024-07-01 2024-09-30 0001636422 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0001636422 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001636422 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001636422 us-gaap:RestrictedStockMember 2024-07-01 2024-09-30 0001636422 us-gaap:RestrictedStockMember 2023-07-01 2023-09-30 0001636422 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001636422 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001636422 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001636422 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001636422 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001636422 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001636422 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001636422 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001636422 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001636422 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001636422 us-gaap:SellingAndMarketingExpenseMember 2024-07-01 2024-09-30 0001636422 us-gaap:SellingAndMarketingExpenseMember 2023-07-01 2023-09-30 0001636422 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-09-30 0001636422 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-09-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001636422 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001636422 srt:WeightedAverageMember us-gaap:PhantomShareUnitsPSUsMember hcat:MeasurementInputTotalShareholderReturnMember 2024-01-01 2024-09-30 0001636422 srt:WeightedAverageMember us-gaap:PhantomShareUnitsPSUsMember us-gaap:MeasurementInputRevenueMultipleMember 2024-01-01 2024-09-30 0001636422 srt:WeightedAverageMember us-gaap:PhantomShareUnitsPSUsMember us-gaap:MeasurementInputEbitdaMultipleMember 2024-01-01 2024-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-01 2024-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-01 2024-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-01 2024-09-30 0001636422 srt:MinimumMember us-gaap:PhantomShareUnitsPSUsMember 2024-01-01 2024-09-30 0001636422 srt:MaximumMember us-gaap:PhantomShareUnitsPSUsMember 2024-01-01 2024-09-30 0001636422 srt:MinimumMember us-gaap:PhantomShareUnitsPSUsMember 2023-01-01 2023-09-30 0001636422 srt:MaximumMember us-gaap:PhantomShareUnitsPSUsMember 2023-01-01 2023-09-30 0001636422 us-gaap:PhantomShareUnitsPSUsMember 2023-12-31 0001636422 us-gaap:PhantomShareUnitsPSUsMember 2024-09-30 0001636422 us-gaap:EmployeeStockMember 2019-07-31 0001636422 us-gaap:EmployeeStockMember 2019-07-01 2019-07-31 0001636422 us-gaap:EmployeeStockMember 2024-01-01 0001636422 us-gaap:EmployeeStockMember 2024-09-30 0001636422 srt:MinimumMember us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001636422 srt:MaximumMember us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001636422 srt:MinimumMember us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001636422 srt:MaximumMember us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001636422 us-gaap:RestrictedStockMember hcat:KPINinjaMember 2022-02-24 2022-02-24 0001636422 us-gaap:RestrictedStockMember hcat:ARMUSCorporationMember 2022-04-29 2022-04-29 0001636422 us-gaap:RestrictedStockMember hcat:ARMUSCorporationMember 2023-10-02 2023-10-02 0001636422 us-gaap:SettledLitigationMember 2023-06-15 2023-06-15 0001636422 us-gaap:SettledLitigationMember 2023-01-01 2023-09-30 0001636422 us-gaap:SettledLitigationMember 2023-07-01 2023-09-30 0001636422 us-gaap:SettledLitigationMember 2024-07-01 2024-09-30 0001636422 us-gaap:SettledLitigationMember 2024-01-01 2024-09-30 0001636422 2024-10-01 2024-09-30 0001636422 2026-10-01 2024-09-30 0001636422 us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0001636422 us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0001636422 us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001636422 us-gaap:RelatedPartyMember 2024-09-30 0001636422 us-gaap:RelatedPartyMember 2023-12-31 0001636422 hcat:TechnologyMember 2024-07-01 2024-09-30 0001636422 hcat:TechnologyMember 2023-07-01 2023-09-30 0001636422 hcat:TechnologyMember 2024-01-01 2024-09-30 0001636422 hcat:TechnologyMember 2023-01-01 2023-09-30 0001636422 hcat:ProfessionalServicesMember 2024-07-01 2024-09-30 0001636422 hcat:ProfessionalServicesMember 2023-07-01 2023-09-30 0001636422 hcat:ProfessionalServicesMember 2024-01-01 2024-09-30 0001636422 hcat:ProfessionalServicesMember 2023-01-01 2023-09-30 0001636422 us-gaap:OperatingSegmentsMember hcat:TechnologyMember 2024-07-01 2024-09-30 0001636422 us-gaap:OperatingSegmentsMember hcat:TechnologyMember 2023-07-01 2023-09-30 0001636422 us-gaap:OperatingSegmentsMember hcat:TechnologyMember 2024-01-01 2024-09-30 0001636422 us-gaap:OperatingSegmentsMember hcat:TechnologyMember 2023-01-01 2023-09-30 0001636422 us-gaap:OperatingSegmentsMember hcat:ProfessionalServicesMember 2024-07-01 2024-09-30 0001636422 us-gaap:OperatingSegmentsMember hcat:ProfessionalServicesMember 2023-07-01 2023-09-30 0001636422 us-gaap:OperatingSegmentsMember hcat:ProfessionalServicesMember 2024-01-01 2024-09-30 0001636422 us-gaap:OperatingSegmentsMember hcat:ProfessionalServicesMember 2023-01-01 2023-09-30 0001636422 us-gaap:OperatingSegmentsMember 2024-07-01 2024-09-30 0001636422 us-gaap:OperatingSegmentsMember 2023-07-01 2023-09-30 0001636422 us-gaap:OperatingSegmentsMember 2024-01-01 2024-09-30 0001636422 us-gaap:OperatingSegmentsMember 2023-01-01 2023-09-30 0001636422 us-gaap:MaterialReconcilingItemsMember 2024-07-01 2024-09-30 0001636422 us-gaap:MaterialReconcilingItemsMember 2023-07-01 2023-09-30 0001636422 us-gaap:MaterialReconcilingItemsMember 2024-01-01 2024-09-30 0001636422 us-gaap:MaterialReconcilingItemsMember 2023-01-01 2023-09-30 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2023RestructuringPlanMember 2024-07-01 2024-09-30 0001636422 hcat:TechnologyMember hcat:A2023RestructuringPlanMember 2024-01-01 2024-09-30 0001636422 hcat:ProfessionalServicesMember hcat:A2023RestructuringPlanMember 2024-01-01 2024-09-30 0001636422 us-gaap:SellingAndMarketingExpenseMember hcat:A2023RestructuringPlanMember 2024-01-01 2024-09-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember hcat:A2023RestructuringPlanMember 2024-01-01 2024-09-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember hcat:A2023RestructuringPlanMember 2024-01-01 2024-09-30 0001636422 hcat:A2023RestructuringPlanMember 2024-01-01 2024-09-30 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2023RestructuringPlanMember 2024-01-01 2024-09-30 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2023RestructuringPlanMember 2023-12-31 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2023RestructuringPlanMember 2024-01-01 2024-03-31 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2023RestructuringPlanMember 2024-03-31 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2023RestructuringPlanMember 2024-04-01 2024-06-30 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2023RestructuringPlanMember 2024-06-30 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2023RestructuringPlanMember 2024-09-30 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2022RestructuringPlanMember 2023-07-01 2023-09-30 0001636422 hcat:TechnologyMember hcat:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0001636422 hcat:ProfessionalServicesMember hcat:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0001636422 us-gaap:SellingAndMarketingExpenseMember hcat:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0001636422 us-gaap:ResearchAndDevelopmentExpenseMember hcat:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0001636422 us-gaap:GeneralAndAdministrativeExpenseMember hcat:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0001636422 hcat:A2022RestructuringPlanMember 2023-01-01 2023-09-30 0001636422 hcat:SeveranceAndOtherTeamMemberCostsMember hcat:A2022RestructuringPlanMember 2023-01-01 2023-09-30 shares iso4217:USD iso4217:USD shares hcat:segment pure utr:D iso4217:USD hcat:instrument hcat:vote 0001636422 --12-31 2024 Q3 false P3Y P1Y 0.03267970 P3Y 10-Q true 2024-09-30 false 001-38993 HEALTH CATALYST, INC. DE 45-3337483 10897 South River Front Parkway #300 South Jordan UT 84095 801 708-6800 Common Stock, par value $0.001 per share HCAT NASDAQ Yes Yes Large Accelerated Filer false false false 60847658 328327000 106276000 58929000 211452000 51648000 60290000 18510000 15379000 457414000 393397000 27908000 25712000 76463000 73384000 11222000 13927000 234387000 190652000 5656000 4742000 813050000 701814000 14278000 6641000 23548000 23282000 52202000 55753000 3329000 3358000 230423000 0 323780000 89034000 114611000 228034000 258000 77000 15969000 17676000 3395000 74000 458013000 334895000 0.001 0.001 25000000 25000000 0 0 0 0 0 0 0.001 0.001 500000000 500000000 60847658 60847658 58295491 58295491 1521146000 1484056000 -1165999000 -1117170000 -110000 33000 355037000 366919000 813050000 701814000 48653000 45973000 143254000 140483000 27700000 27800000 83724000 80371000 76353000 73773000 226978000 220854000 17609000 15169000 48991000 45755000 24704000 26618000 71899000 73774000 42313000 41787000 120890000 119529000 11342000 15084000 43145000 50050000 14193000 17667000 42948000 52339000 12209000 13625000 41136000 61129000 9983000 10190000 31165000 31919000 47727000 56566000 158394000 195437000 -13687000 -24580000 -52306000 -94112000 -1514000 2607000 3185000 6490000 -15201000 -21973000 -49121000 -87622000 -475000 59000 -292000 213000 -14726000 -22032000 -48829000 -87835000 -0.24 -0.24 -0.39 -0.39 -0.82 -0.82 -1.57 -1.57 60441000 60441000 56711000 56711000 59449000 59449000 56062000 56062000 -14726000 -22032000 -48829000 -87835000 105000 35000 -63000 490000 -53000 -1000 -80000 -12000 -14674000 -21998000 -48972000 -87357000 60075178 150843700 0 -1151273000 -162000 357002000 379584 5904 39000 39000 9818000 9818000 386992 2852000 2852000 -14726000 -14726000 52000 52000 60847658 1521146000 -1165999000 -110000 355037000 56541641 1454897000 -1064826000 -204000 389867000 497789 4682 40000 40000 14485000 14485000 -22032000 -22032000 34000 34000 57044112 1469422000 -1086858000 -170000 382394000 58295491 1484056000 -1117170000 33000 366919000 1486435 263482 1431000 1431000 26668 169000 169000 30054000 30054000 775582 5436000 5436000 -48829000 -48829000 -143000 -143000 60847658 1521146000 -1165999000 -110000 355037000 55261922 1424681000 -999023000 -648000 425010000 1554641 244133 2206000 2206000 128443 937000 937000 43406000 43406000 145027 1808000 1808000 -87835000 -87835000 478000 478000 57044112 1469422000 -1086858000 -170000 382394000 -48829000 -87835000 29316000 42745000 31165000 31919000 2200000 2681000 -1981000 -2272000 2078000 1132000 3899000 6816000 3433000 1626000 -517000 6000 -1642000 0 87000 101000 -6304000 -259000 617000 -385000 4810000 1847000 -5259000 -1688000 -2525000 -2673000 18086000 -14039000 206488000 256101000 50197000 254448000 54889000 0 9858000 9331000 504000 986000 1203000 981000 10000 21000 89847000 -9624000 115472000 0 3000000 0 2061000 3206000 169000 937000 0 1808000 646000 0 114056000 2335000 62000 -13000 222051000 -21341000 106276000 116312000 328327000 94971000 5436000 0 738000 622000 310000 21000 -322000 88000 0 2033000 0 1310000 Description of Business and Summary of Significant Accounting Policies Nature of operations Health Catalyst, Inc. (Health Catalyst) was incorporated under the laws of Delaware in September 2011. We are a leading provider of data and analytics technology and services to healthcare organizations. Our Solution comprises our cloud-based data platform, software analytics applications, and professional services expertise. Our clients, which are primarily healthcare providers, use our Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note

disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2023 included in our Annual Report on Form 10-K. Interim unaudited condensed consolidated financial statements The accompanying interim condensed consolidated balance sheet as of September 30, 2024, the interim condensed consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023, our interim condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023, and our interim condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 are unaudited. Our condensed consolidated balance sheet as of December 31, 2023 was derived from audited financial statements, but does not include all disclosures required by GAAP. Our interim unaudited condensed consolidated financial statements have been prepared on a basis consistent with our annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company's financial position, its operations and cash flows for the periods presented. The historical results are not necessarily indicative of future results, and the results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the full year or any other period. Principles of consolidation The condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Use of estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, reserves for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software, impairment assessments of goodwill, intangible assets, and other long-lived assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ significantly from those estimates. Segment reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit. Net loss per share Basic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period, when dilutive. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as the effect is anti-dilutive. Revenue recognition We derive our revenue primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: •Identification of the contract, or contracts, with a client; •Identification of the performance obligations in the contract; •Determination of the transaction price; •Allocation of the transaction price to the performance obligations in the contract; and •Recognition of revenue when, or as, we satisfy the performance obligation. We recognize revenue net of any taxes collected from clients and subsequently remitted to governmental authorities. Technology revenue Technology revenue primarily consists of subscription fees charged to clients for access to use our technology. We provide clients access to our technology through either an all-access or limited-access, modular subscription. The majority of our subscription arrangements are cloud-based and do not provide clients the right to take possession of the technology or contain a significant penalty if the client were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the client. Our subscription contracts generally have a three- or five-year term, of which many are terminable after one year upon 90 days' notice. Subscriptions that allow the client to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the client. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the client. Professional services revenue Professional services revenue primarily includes data and analytics services, domain expertise services, Tech-enabled Managed Services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our clients on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our clients. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the "right to invoice" practical expedient. Contracts with multiple performance obligations Many of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include client demographics and the types of users. Standalone selling prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we generally use the residual method due to a limited number of standalone transactions and/or prices that are highly variable. Variable consideration We have also entered into at-risk and shared savings arrangements with certain clients whereby we receive variable consideration based on the achievement of measurable improvements that may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. Contract balances Contract assets resulting from services performed prior to invoicing clients are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of September 30, 2024 and December 31, 2023, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $8.3 million and $4.7 million, respectively. We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the client. As of September 30, 2024 and December 31, 2023, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.5 million and $55.8 million, respectively. Deferred costs We capitalize sales commissions and associated fringe costs, such as benefits and payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with clients, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the client contract. As of September 30, 2024 and December 31, 2023, $2.2 million and $2.2 million, respectively, of deferred contract

*acquisition costs are expected to be amortized within the next 12 months and are included in prepaid expenses and other assets on the condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the remaining $2.9 million and $3.3 million, respectively, of deferred contract acquisition costs are included in non-current other assets. Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average client life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average client life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs was $0.7 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively, and $2.0 million and $1.6 for the nine months ended September 30, 2024 and 2023, respectively, and is included within sales and marketing expense in the condensed consolidated statements of operations.</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.</div><div style="margin-bottom:12pt">Cost of revenue, excluding depreciation and amortization</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, license and revenue share fees, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue in the interim condensed consolidated statements of operations excludes costs related to depreciation and amortization.</div><div style="margin-bottom:12pt">Cash and cash equivalents</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">We consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.</div><div style="margin-bottom:12pt">Short-term investments</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">Our investment policy limits investments to highly-rated instruments. We classify and account for our short-term investments as available for sale securities as we may sell these securities at any time for use in our current operations or for other purposes, even prior to maturity. As a result, we classify our short-term investments, including securities with contractual maturities beyond twelve months, within current assets in the condensed consolidated balance sheets.</div><div style="margin-bottom:12pt">Accounts receivable</div><div style="text-align:justify;text-indent:18pt">Accounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. </div><div style="text-align:justify;text-indent:18pt">
</div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, client payment patterns, the establishment of specific reserves for clients in an adverse financial condition, and our expectations of changes in macroeconomic conditions, including high interest rates and high inflation, that may impact the collectability of outstanding receivables. We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Allowance for credit losses at the beginning of period</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,105 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,300 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Provision for expected credit losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,433 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,626 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Less: Write-offs, net of recoveries</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(938)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Allowance for credit losses at the end of period</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,600 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,900 </td><td style="background-*

color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,600 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,900 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Leases We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our lease contracts do not have a readily determinable implicit rate, we use our incremental borrowing rate based on the information available at the commencement date to determine the present value of lease payments. The incremental borrowing rate is the estimated rate incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable costs related to our leased office space, such as maintenance and utilities based on actual usage, are not included in the measurement of right-of-use assets and lease liabilities, but are expensed as incurred. Property and equipment Property and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-3 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3-5 years </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Lesser of lease term or estimated useful life</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-5 years </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Capitalized internal-use software costs</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-5 years </td></tr></table> When there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset, plus any terminal value, in the asset group. If the carrying amount of the asset group exceeds those estimated future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets. Intangible assets Intangible assets include developed technologies, client relationships, client contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assets' estimated useful lives. The estimated useful life of each asset category is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3-10 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Client relationships and contract backlog</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-7 years </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software licenses</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1-5 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1-5 years </td></tr></table> Goodwill We record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, client relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually on October 31 or more frequently if indicators of impairment are present or circumstances suggest that impairment may exist. Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Judgment in the assessment of qualitative factors of impairment may include changes in business climate, market conditions, or other events impacting the reporting unit. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. Performing a quantitative goodwill impairment test includes the determination of the fair value of a reporting unit, which requires management to use significant judgment and estimation. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of the reporting units, as well as the sensitivity of the respective fair values to the underlying significant assumptions. Typical methods to derive the fair value of reporting units include using the income or market approaches. The significant assumptions used to form the basis of the estimates include, among others, the selection of valuation methodologies, estimates of expected revenue, including revenue growth rates, and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, and the selection of appropriate market comparable companies. Many of these significant assumptions are forward-looking and could be affected by future economic and market conditions. If a quantitative analysis is necessary, we typically engage the assistance of a valuation specialist in concluding on fair value measurements in connection with determining the fair values of our reporting units. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. There was no impairment of goodwill for the three and nine months ended September 30, 2024 and 2023. Business combinations The results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of the acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration transferred over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill. We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the client-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the

basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for client relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of material assets acquired and liabilities assumed in a business combination. For the three and nine months ended September 30, 2024, we expensed $1.7 million and $4.2 million, respectively, of transaction costs associated with business combinations. For the three and nine months ended September 30, 2023, we expensed $1.6 million of transaction costs associated with business combinations. The costs were expensed as incurred and are included in general and administrative expense in our condensed consolidated statements of operations. Contingent consideration liabilities Our acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements. We generally value the expected contingent consideration and the corresponding liabilities using the Monte Carlo method or Black-Scholes model based on estimates of potential payment scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period. As applicable, the portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes in the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations. Advertising costs All advertising costs are expensed as incurred. For each of the three months ended September 30, 2024 and 2023, we incurred $0.4 million of advertising costs, and $4.1 million and $1.6 million for the nine months ended September 30, 2024 and 2023, respectively. Development costs and internal-use software For technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our clients on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life with amortization included in depreciation and amortization expense in our condensed consolidated statements of operations. Stock-based compensation Stock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date or, when applicable, the modification date. The grant date fair value of our stock-based awards is typically determined using the market closing price of our common stock on the date of grant; however, we also consider whether any adjustments are required when the market closing price does not reflect certain material non-public information that we know but is unavailable to marketplace participants on the date of grant. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. For awards subject to market conditions, we estimate the fair value as of the grant date using a Monte Carlo simulation valuation model which requires the use of various assumptions, including historic stock price volatility and risk-free interest rates as of the valuation date corresponding to the length of time remaining in the performance period. Stock-based compensation expense for awards with market conditions is recognized over the requisite service period using the accelerated attribution method and is not reversed if the market condition is not met. Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period. The measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award. Restructuring costs We define restructuring costs as expenses directly associated with restructuring activities. Such costs include severance and related tax and benefit expenses from workforce reductions, impairment of discontinued capitalized software projects, and other miscellaneous charges. We record team member-related severance costs when there is a substantive plan in place and the related costs are probable and estimable. For one-time termination benefits for team members (i.e., no substantive plan or future service requirement), the cost is recorded when the terms of the one-time termination benefits are communicated to the impacted team members and the amount can be reasonably estimated. Income taxes Deferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and tax credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets. We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not currently accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because the impact would be immaterial due to our net operating losses and tax credit carryforwards. Significant judgment is required to evaluate uncertain tax positions. Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations. Fair value of financial instruments The carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. The carrying value of operating lease liabilities and convertible senior notes approximate fair value based on interest rates available for debt with similar terms at September 30, 2024 and December 31, 2023. Money market funds and short-term investments are measured at fair value on a recurring basis. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: •Level 1- Quoted prices in active markets for identical assets or liabilities. •Level 2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. •Level 3- Inputs that are generally unobservable and typically reflect management's estimate of assumptions that market participants would use in pricing the asset or liability. All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios. Foreign currency The

functional currency of our international subsidiaries is generally their local currency. We translate these subsidiaries' financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholders' equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented. Recent accounting pronouncements not yet adopted In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. We expect that the disclosure changes that result from the adoption of this ASU will not have a material impact on our consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2025. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the provision of this ASU to determine the impact it may have on our consolidated financial statements and related disclosures, and we expect additional disclosures upon adoption. Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and the applicable regulations of the U.S. Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2023 included in our Annual Report on Form 10-K. Principles of consolidation The condensed consolidated financial statements include the accounts of Health Catalyst and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated. Use of estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. On an on-going basis, we evaluate our estimates, including those related to revenue recognition, reserves for expected credit losses, useful lives of property and equipment, capitalization and estimated useful life of internal-use software, impairment assessments of goodwill, intangible assets, and other long-lived assets, fair value of financial instruments, deferred tax assets, stock-based compensation, contingent consideration, the period of benefit for deferred contract acquisition costs, the incremental borrowing rate used for operating leases, and tax uncertainties. Actual results could differ significantly from those estimates. Segment reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker (CODM) in assessing performance and making decisions regarding resource allocation. We operate our business in two operating segments that also represent our reportable segments. Our segments are (1) technology and (2) professional services. The CODM uses Adjusted Gross Profit (defined as revenue less cost of revenue that excludes depreciation, amortization, stock-based compensation expense, and certain other operating expenses) as the measure of our profit. Net loss per share Basic net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding. Diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period, when dilutive. For purposes of this calculation, stock options, restricted stock units (RSUs), performance-based restricted stock units (PRSUs), convertible senior notes, restricted shares, and purchase rights committed under the employee stock purchase plan are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as the effect is anti-dilutive. Revenue recognition We derive our revenue primarily from technology subscriptions and professional services. We determine revenue recognition by applying the following steps: •Identification of the contract, or contracts, with a client; •Identification of the performance obligations in the contract; •Determination of the transaction price; •Allocation of the transaction price to the performance obligations in the contract; and •Recognition of revenue when, or as, we satisfy the performance obligation. We recognize revenue net of any taxes collected from clients and subsequently remitted to governmental authorities. Technology revenue Technology revenue primarily consists of subscription fees charged to clients for access to use our technology. We provide clients access to our technology through either an all-access or limited-access, modular subscription. The majority of our subscription arrangements are cloud-based and do not provide clients the right to take possession of the technology or contain a significant penalty if the client were to take possession of the technology. Revenue from cloud-based subscriptions is recognized ratably over the contract term beginning on the date that the service is made available to the client. Our subscription contracts generally have a three- or five-year term, of which many are terminable after one year upon 90 days' notice. Subscriptions that allow the client to take software on-premise without significant penalty are treated as time-based licenses. These arrangements generally include access to technology, access to unspecified future products, and maintenance and support. Revenue for upfront access to our technology library is recognized at a point in time when the technology is made available to the client. Revenue for access to unspecified future products included in time-based license subscriptions is recognized ratably over the contract term beginning on the date that the access is made available to the client. Professional services revenue Professional services revenue primarily includes data and analytics services, domain expertise services, Tech-enabled Managed Services, and implementation services. Professional services arrangements typically include a fee for making full-time equivalent (FTE) services available to our clients on a monthly basis. FTE services generally consist of a blend of analytic engineers, analysts, and data scientists based on the domain expertise needed to best serve our clients. Professional services are typically considered distinct from the technology offerings and revenue is generally recognized as the service is provided using the "right to invoice" practical expedient. Contracts with multiple performance obligations Many of our contracts include multiple performance obligations. We account for performance obligations separately if they are capable of being distinct within the context of the contract. In these circumstances, the transaction price is allocated to separate performance obligations on a relative standalone selling price basis. We determine standalone selling prices based on the observable price a good or service is sold for separately when available. In cases where standalone selling prices are not directly observable, based on information available, we utilize the expected cost plus a margin, adjusted market assessment, or residual estimation method. We consider all information available including our overall pricing objectives, market conditions, and other factors, which may include client demographics and the types of users. Standalone selling

prices are not directly observable for our all-access and limited-access technology arrangements, which are composed of cloud-based subscriptions, time-based licenses, and perpetual licenses. For these technology arrangements, we generally use the residual method due to a limited number of standalone transactions and/or prices that are highly variable. Variable consideration We have also entered into at-risk and shared savings arrangements with certain clients whereby we receive variable consideration based on the achievement of measurable improvements that may include cost savings or performance against metrics. For these arrangements, we estimate revenue using the most likely amount that we will receive. Estimates are based on our historical experience and best judgment at the time to the extent it is probable that a significant reversal of revenue recognized will not occur. Due to the nature of our arrangements, certain estimates may be constrained until the uncertainty is further resolved. Contract balances Contract assets resulting from services performed prior to invoicing clients are recorded as unbilled accounts receivable and are presented on our condensed consolidated balance sheets in aggregate with accounts receivable. Unbilled accounts receivable generally become billable at contractually specified dates or upon the attainment of contractually defined milestones. As of September 30, 2024 and December 31, 2023, the unbilled accounts receivable included in accounts receivable on our condensed consolidated balance sheets was $8.3 million and $4.7 million, respectively. We record contract liabilities as deferred revenue when cash payments are received or due in advance of performance. Deferred revenue primarily relates to the advance consideration received from the client. As of September 30, 2024 and December 31, 2023, the total of current and non-current deferred revenue on our condensed consolidated balance sheets was $52.5 million and $55.8 million, respectively. Deferred costs We capitalize sales commissions and associated fringe costs, such as benefits and payroll taxes, paid to direct sales personnel and other incremental costs of obtaining contracts with clients, provided we expect to recover those costs. We determine that costs should be deferred based on our sales compensation plans when the commissions are incremental and would not have occurred absent the client contract. As of September 30, 2024 and December 31, 2023, $2.2 million and $2.2 million, respectively, of deferred contract acquisition costs are expected to be amortized within the next 12 months and are included in prepaid expenses and other assets on the condensed consolidated balance sheets. As of September 30, 2024 and December 31, 2023, the remaining $2.9 million and $3.3 million, respectively, of deferred contract acquisition costs are included in non-current other assets. Commissions paid upon the initial acquisition of a contract are amortized on a straight-line basis over an estimated period of benefit of four years. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. The period of benefit was estimated by considering factors such as estimated average client life, the rate of technological change in our subscription service, and the impact of competition in our industry. As our average client life significantly exceeded the rate of change in our technology, we concluded that the rate of change in the technology underlying our subscription service was the most significant factor in determining the period of benefit for which the asset relates. In evaluating the rate of change in our technology, we considered the competition in our industry, our commitment to continuous innovation, and the frequency of product, platform, and technology updates. We determined that the impact of competition in our industry is reflected in the period of benefit through the rate of technological change. Amortization of deferred contract acquisition costs was $0.7 million and $0.6 million for the three months ended September 30, 2024 and 2023, respectively, and $2.0 million and $1.6 for the nine months ended September 30, 2024 and 2023, respectively, and is included within sales and marketing expense in the condensed consolidated statements of operations.</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">We defer certain costs to fulfill a contract when the costs are expected to be recovered, are directly related to in-process contracts, and enhance resources that will be used in satisfying performance obligations in the future. These deferred fulfillment costs primarily consist of employee compensation incurred as part of the implementation of new contracts. Amortization of deferred fulfillment costs is included within cost of revenue in the condensed consolidated statements of operations. We periodically review these deferred costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented.</div><div style="margin-bottom:12pt">Cost of revenue, excluding depreciation and amortization</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">Cost of technology revenue primarily consists of costs associated with hosting and supporting our technology, including third-party cloud computing and hosting costs, license and revenue share fees, contractor costs, and salary and related personnel costs for our cloud services and support teams. Cost of professional services revenue primarily consists of salary and related personnel costs, travel-related costs, and independent contractor costs. Cost of revenue in the interim condensed consolidated statements of operations excludes costs related to depreciation and amortization.</div> P5Y P1Y P90D 8300000 4700000 52500000 55800000 2200000 2200000 P12M 2900000 3300000 P4Y 700000 600000 2000000 1600000 0 0 0 0 <div style="margin-bottom:12pt">Cash and cash equivalents</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">We consider all highly liquid investments purchased with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.</div> <div style="margin-bottom:12pt">Short-term investments</div>Our investment policy limits investments to highly-rated instruments. We classify and account for our short-term investments as available for sale securities as we may sell these securities at any time for use in our current operations or for other purposes, even prior to maturity. As a result, we classify our short-term investments, including securities with contractual maturities beyond twelve months, within current assets in the condensed consolidated balance sheets. <div style="margin-bottom:12pt">Accounts receivable</div><div style="text-align:justify;text-indent:18pt">Accounts receivable are non-interest bearing and are recorded at the original invoiced amount less an allowance for credit losses based on the probability of future collections. Our allowance is based on our estimate of expected credit losses for outstanding trade accounts receivables and unbilled receivables. </div>We determine expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, client payment patterns, the establishment of specific reserves for clients in an adverse financial condition, and our expectations of changes in macroeconomic conditions, including high interest rates and high inflation, that may impact the collectability of outstanding receivables. We reassess the adequacy of the allowance for credit losses each reporting period. The following table presents a rollforward of the allowance for credit losses (in thousands):<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Allowance for credit losses at the beginning of period</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6,600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,105 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,300 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Provision for expected credit losses</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,433 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,626 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Less: Write-offs, net of recoveries</td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(938)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Allowance for credit losses at the end of period</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,600 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,900 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,600 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3,900 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 6600000 3800000 4105000 2300000 -5000 112000 3433000 1626000 -5000 12000 938000 26000 6600000 3900000 6600000 3900000 Leases We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in our condensed consolidated balance sheets. We have adopted the short-term lease recognition exemption policy. All of our leasing commitments are classified either as operating leases or otherwise qualify as short-term leases with lease terms of 12 months or less. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our lease contracts do not have a readily determinable implicit rate, we use our incremental borrowing rate based on the information available at the commencement date to determine the present value of lease payments. The incremental borrowing rate is the estimated rate incurred to borrow on a collateralized basis over a similar term and amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made and excludes lease executory costs. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the applicable option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable costs related to our leased office space, such as maintenance and utilities based on actual usage, are not included in the measurement of right-of-use assets and lease liabilities, but are expensed as incurred. Property and equipment Property and equipment are stated at historical cost less accumulated depreciation. Repairs and maintenance costs that do not extend the useful life or improve the related assets are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful life of each asset category is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-3 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3-5 years </td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:right;vertical-align:bottom">Lesser of lease term or estimated useful life</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-5 years </td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Capitalized internal-use software costs</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-5 years </td></tr></table> When there are indicators of potential impairment, we evaluate the recoverability of the carrying values by comparing the carrying amount of the applicable asset group to the estimated undiscounted future cash flows expected to be generated by the asset group over the remaining useful life of the primary asset, plus any terminal value, in the asset group. If the carrying amount of the asset group exceeds those estimated future net cash flows, an impairment charge is recognized based on the amount by which the carrying value of the long-lived assets exceeds the fair value of the assets. The estimated useful life of each asset category is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-3 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3-5 years </td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:right;vertical-align:bottom">Lesser of lease term or estimated useful life</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-5 years </td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Capitalized internal-use software costs</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-5 years </td></tr></table> Property and equipment consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
December 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-

align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">10,532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">9,638 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,429 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,814 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,748 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,735 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Capitalized internal-use software costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,526 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,771 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total property and equipment</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,346 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53,069 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: accumulated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36,438)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27,357)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">27,908 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">25,712 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> P2Y P3Y P3Y P5Y P2Y P5Y P2Y P5Y Intangible assets Intangible assets include developed technologies, client relationships, client contracts, and trademarks that were acquired in business combinations and asset acquisitions. Intangible assets also include the purchase of third-party computer software. The intangible assets are amortized using the straight-line method over the assets' estimated useful lives. The estimated useful life of each asset category is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3-10 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Client relationships and contract backlog</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-7 years </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software licenses</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1-5 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1-5 years </td></tr></table> The estimated useful life of each asset category is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3-10 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Client relationships and contract backlog</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2-7 years </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software licenses</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1-5 years </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1-5 years </td></tr></table> As of September 30, 2024, intangible assets consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Cost </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">Developed technologies</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">120,129 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(90,573)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">29,556 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Client relationships and contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96,464 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53,735)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42,729 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software licenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,144 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,084)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,060 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,420 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,302)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total intangible assets</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">232,157 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(155,694)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">76,463 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of December 31, 2023, intangible assets consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Cost </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">103,929 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(79,057)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,872 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Client relationships and contracts</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90,064 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(45,230)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44,834 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software licenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,680 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,933)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,747 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,820 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,889)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">931 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total intangible assets</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">207,493 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(134,109)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73,384 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> P3Y P10Y P2Y P7Y P1Y P5Y P1Y P5Y Goodwill We record goodwill as the difference between the aggregate consideration paid for a business combination and the fair value of the identifiable net tangible and intangible assets acquired. Goodwill includes the know-how of the assembled workforce, the ability of the workforce to further improve technology and product offerings, client relationships, and the expected cash flows resulting from these efforts. Goodwill may also include expected synergies resulting from the complementary strategic fit these businesses bring to existing operations. Goodwill is assessed for impairment annually on October 31 or more frequently if indicators of impairment are present or circumstances suggest that impairment may exist. Our first step in the goodwill impairment test is a qualitative analysis of factors that could be indicators of potential impairment. Judgment in the assessment of qualitative factors of impairment may include changes in business climate, market conditions, or other events impacting the reporting unit. Next, if a quantitative analysis is necessary, we compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired. Performing a quantitative goodwill impairment test includes the determination of the fair value of a reporting unit, which requires management to use significant judgment and estimation. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of the reporting units, as well as the sensitivity of the respective fair values to the underlying significant assumptions. Typical methods to derive the fair value of reporting units include using the income or market approaches. The significant assumptions used to form the basis of the estimates include, among others, the selection of valuation methodologies, estimates of expected revenue, including revenue growth rates, and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, and the selection of appropriate market comparable companies. Many of these significant assumptions are forward-looking and could be affected by future economic and market conditions. If a quantitative analysis is necessary, we typically engage the assistance of a valuation specialist in concluding on fair value measurements in connection with determining the fair values of our reporting units. If the carrying amount of the reporting unit exceeds its fair value, we would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. 0 0 0 0 Business combinations The results of businesses acquired in a business combination are included in our condensed consolidated financial statements from the date of the acquisition. Purchase accounting results in assets and liabilities of an acquired business generally being recorded at their estimated fair value on the acquisition date. Any excess consideration transferred over the fair value of the identifiable assets acquired and liabilities assumed is recognized as goodwill. We perform valuations of assets acquired and liabilities assumed on each acquisition accounted for as a business combination in order to record the tangible and intangible assets acquired and liabilities assumed based on our best estimate of fair value. Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates, and selection of comparable companies. Significant estimation is required in determining the fair value of the client-related intangible assets and technology-related intangible assets. The significant estimation is primarily due to the judgmental nature of the inputs to the valuation models used to measure the fair value of these intangible assets, as well as the sensitivity of the respective fair values to the underlying significant assumptions. We typically use the income approach or cost approach to measure the fair value of intangible assets. The significant assumptions used to form the basis of the estimates included the number of engineer hours required to develop technology, expected revenue including revenue growth rates, rate and timing of obsolescence, royalty rates and earnings before interest, taxes, depreciation and amortization (EBITDA) margin used in the estimate for client relationships, and backlog. Many of these significant assumptions were forward-looking and could be affected by future economic and market conditions. We engage the assistance of valuation specialists in concluding on fair value measurements in connection with determining fair values of material assets acquired and liabilities assumed in a business combination. Contingent consideration liabilities Our acquisition consideration in business combinations may include an estimate for contingent consideration that will be paid if certain earn-out performance targets are met. The resulting contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn-out period utilizing unobservable inputs, including various potential pay-out scenarios based on billings and revenue-related earn-out targets. Changes to the unobservable inputs could have a material impact on our condensed consolidated financial statements. We generally value the expected contingent consideration and the corresponding liabilities using the Monte Carlo method or Black-Scholes model based on estimates of potential payment scenarios. Probabilities are applied to each potential scenario and the resulting values are discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, projected payment dates, and volatility in the fair value of our common stock. The fair value of the contingent consideration is remeasured each reporting period. As applicable, the portion of the contingent consideration liabilities that will be settled in shares of our common stock is classified as a component of non-current liabilities in our condensed consolidated balance sheets, while the portion to be paid in cash is classified as a component of current liabilities. Changes in the contingent consideration liabilities are reflected as part of general and administrative expense in our condensed consolidated statements of operations. 1700000 4200000 1600000 1600000 Advertising costs All advertising costs are expensed as incurred. 400000 400000 4100000 1600000 Development costs and internal-use software For technology products that are developed to be sold externally, we determined that technological feasibility is reached shortly before the products are ready for general release. Any costs associated with software development between the time technological feasibility is reached and general release are inconsequential. We capitalize certain development costs incurred in connection with our internal-use software. These capitalized costs are primarily related to the software platforms that are hosted by us and accessed by our clients on a subscription basis. Costs incurred in the preliminary stages of development are expensed as incurred as research and development costs. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. We also capitalize costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized costs are recorded as part of property and equipment. Maintenance and training costs are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life with amortization included in depreciation and amortization expense in our condensed consolidated statements of operations. Stock-based compensation Stock-based awards, including stock options, restricted stock units, performance-based restricted stock units, and restricted shares are measured and recognized in our condensed consolidated financial statements based on the fair value of the award on the grant date or, when applicable, the modification date. The grant date fair value of our stock-based awards is typically determined using the market closing price of our common stock on the date of grant, however, we also consider whether any adjustments are required when the market closing price does not reflect certain material non-public information that we know but is unavailable to marketplace participants on the date of grant. We record forfeitures of stock-based awards as the actual forfeitures occur. For awards subject to performance conditions, we record expense when the performance condition becomes probable. Each reporting period we evaluate the probability of achieving the performance criteria, estimate the number of shares that are expected to vest, and adjust the related compensation expense accordingly. For awards subject to market conditions, we estimate the fair value as of the grant date using a Monte Carlo simulation valuation model which requires the use of various assumptions, including historic stock price volatility and risk-free interest rates as of the valuation date corresponding to the length of time remaining in the performance period. Stock-based compensation expense for awards with market conditions is recognized over the requisite service period using the accelerated attribution method and is not reversed if the market condition is not met. Stock-based compensation expense related to purchase rights issued under the 2019 Health Catalyst Employee Stock Purchase Plan (ESPP) is based on the Black-Scholes option-pricing model fair value of the estimated number of awards as of the beginning of the offering period. Stock-based compensation expense is recognized using the straight-line method over the offering period. The measurement date for non-employee awards is the date of grant. The compensation expense for non-employees is recognized, without changes in the fair value of the award, in the same period and in the same manner as though we had paid cash for the services, which is typically the vesting period of the respective award. Restructuring costs We define restructuring costs as expenses directly associated with restructuring activities. Such costs include severance and related tax and benefit expenses from workforce reductions, impairment of discontinued capitalized software projects, and other miscellaneous charges. We record team member-related severance costs when there is a substantive plan in place and the related costs are probable and estimable. For one-time termination benefits for team members (i.e., no substantive plan or future service requirement), the cost is recorded when the terms of the one-time termination benefits are communicated to the impacted team members and the amount can be reasonably estimated. Income taxes Deferred income tax balances are accounted for using the asset and liability method and reflect the effects of temporary differences between the financial reporting and tax bases of our assets and liabilities using enacted tax rates expected to apply when taxes are actually paid or recovered. In addition, deferred tax assets and liabilities are recorded for net operating loss (NOL) and tax credit carryforwards. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized based on all available positive and negative evidence. Such evidence includes, but is not limited to, recent cumulative earnings or losses, expectations of future taxable income by taxing jurisdiction, and the carry-forward periods available for the utilization of deferred tax assets. We use a two-step approach to recognize and measure uncertain income tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained upon audit. The second step is to measure

the tax benefit as the largest amount, which is more than 50% likely of being realized upon ultimate settlement. We do not currently accrue interest and penalties related to unrecognized tax benefits within the provision for income taxes because the impact would be immaterial due to our net operating losses and tax credit carryforwards. Significant judgment is required to evaluate uncertain tax positions. Although we believe that we have adequately reserved for our uncertain tax positions, we can provide no assurance that the final tax outcome of these matters will not be materially different. We evaluate our uncertain tax positions on a regular basis and evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of an audit, and effective settlement of audit issues. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will affect the provision for income taxes in the period in which such determination is made and could have a material impact on our financial condition and results of operations. Fair value of financial instruments The carrying amounts reported in our condensed consolidated balance sheets for cash, receivables, accounts payable, and current accrued expenses approximate fair values because of the immediate or short-term maturity of these financial instruments. The carrying value of operating lease liabilities and convertible senior notes approximate fair value based on interest rates available for debt with similar terms at September 30, 2024 and December 31, 2023. Money market funds and short-term investments are measured at fair value on a recurring basis. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: •Level 1- Quoted prices in active markets for identical assets or liabilities. •Level 2- Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. •Level 3- Inputs that are generally unobservable and typically reflect management's estimate of assumptions that market participants would use in pricing the asset or liability. All of our financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, we use a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. Our contingent consideration liabilities are categorized as a Level 3 fair value measurement because we estimate projections during the earn out period utilizing various potential pay-out scenarios. Foreign currency The functional currency of our international subsidiaries is generally their local currency. We translate these subsidiaries' financial statements into U.S. dollars using month-end exchange rates for assets and liabilities and average exchange rates for revenue and expenses. We record translation gains and losses in accumulated other comprehensive loss in stockholders' equity. We record foreign exchange gains and losses in interest and other expense, net. Our net foreign exchange gains and losses were not material for the periods presented. Recent accounting pronouncements not yet adopted In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the CODM and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the ASU should be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2024. We expect that the disclosure changes that result from the adoption of this ASU will not have a material impact on our consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. We are currently evaluating the provisions of this ASU and expect to adopt them for the year ending December 31, 2025. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure in the notes to the financial statements of specified information about certain costs and expenses. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments should be applied either prospectively to financial statements issued for reporting periods after the effective date of this ASU or retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the provision of this ASU to determine the impact it may have on our consolidated financial statements and related disclosures, and we expect additional disclosures upon adoption. Business Combinations The business acquisitions discussed below are included in our results of operations from the date of acquisition. 2024 Acquisitions Lumeon Ltd. On August 1, 2024, we acquired Lumeon Ltd. (Lumeon), a digital health company dedicated to helping provider organizations mend broken care coordination processes through automated care orchestration. We accounted for the acquisition of Lumeon as a business combination. The acquisition consideration transferred was $39.8 million and was comprised of estimated net cash consideration of $36.2 million, Health Catalyst common shares with a fair value of $2.9 million, and contingent consideration based on certain earn-out performance targets for Lumeon during an earn-out period ending on June 30, 2025, with an acquisition-date fair value of $0.7 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Lumeon. </div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt">The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Lumeon (in thousands):</div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets acquired:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Accounts receivable, net</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">967 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prepaid expenses and other assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">795 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Property and equipment, net </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">165 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Client relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,400 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,300 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-

color:#fffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired</td><td colspan="2" style="background-color:#fffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,327 </td><td style="background-color:#fffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less liabilities assumed:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Accrued and other current liabilities</td><td colspan="2" style="background-color:#fffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,151 </td><td style="background-color:#fffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,759 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net deferred tax liabilities</td><td colspan="2" style="background-color:#fffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,679 </td><td style="background-color:#fffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total liabilities assumed</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,589 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired, net</td><td colspan="2" style="background-color:#fffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,738 </td><td style="background-color:#fffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,092 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total consideration transferred, net of cash acquired</td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">39,830 </td><td style="background-color:#fffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and five years, respectively. The resulting goodwill from the Lumeon acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. The preliminary allocation of the consideration transferred is subject to potential adjustments. Balances subject to adjustment are primarily tax-related matters, including the tax basis of assets acquired and liabilities assumed. During the measurement period, we may record adjustments to the provisional amounts recognized in our initial accounting for the acquisition. We expect the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). There were no measurement period adjustments recorded during the three months ended September 30, 2024. The amount of revenue attributable to the acquired business of Lumeon was not material to our condensed consolidated statement of operations for the three and nine months ended September 30, 2024. Income (loss) information for Lumeon after the acquisition date through September 30, 2024 is not presented as the Lumeon business was integrated into our operations immediately following the acquisition and is impracticable to quantify. In addition to the purchase price, we agreed to make cash retention payments in an aggregate amount of up to $5.0 million to continuing Lumeon team members, a portion of which is variable based upon the achievement of earn-out performance targets. The retention payments are generally subject to vesting based upon continued employment over a required service period. Such amounts are recorded as post-combination compensation expense and recognized on a straight-line basis over the relevant vesting terms. During the nine months ended September 30, 2024, we recognized compensation expense of $1.1 million related to these retention payments. Carevive Systems, Inc. On May 24, 2024, we acquired Carevive Systems, Inc. (Carevive), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. We accounted for the acquisition of Carevive as a business combination. Oncology providers and life science researchers use Carevive's flagship platform and/or Carevive data in routine clinical practice for treatment care planning, clinical trial screening, care coordination, remote patient monitoring, and/or post-treatment care. The acquisition consideration transferred was $22.1 million and was comprised of estimated net cash consideration of $18.6 million, Health Catalyst common shares with a fair value of $2.6 million, and contingent consideration based on certain earn-out performance targets for Carevive during an earn-out period ending on June 30, 2025, with an acquisition-date fair value of $0.9 million. The purchase resulted in Health Catalyst acquiring 100% ownership in Carevive. </div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt">The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Carevive (in thousands):</div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets acquired:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Accounts receivable, net</div></td><td style="background-color:#fffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#fffff;padding:2px 0;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#fffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prepaid expenses and other assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Client relationships</td><td colspan="2" style="background-color:#fffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,700 </td><td style="background-color:#fffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#fffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">300 </td><td style="background-color:#fffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,960 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less liabilities assumed:</td><td colspan="3" style="background-color:#fffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Accrued and other current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,389 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#fffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#fffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76 </td><td style="background-color:#fffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total liabilities assumed</td><td colspan="2"

style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,465 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,495 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,643 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total consideration transferred, net of cash acquired</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,138 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and three years, respectively. The resulting goodwill from the Carevive acquisition was fully allocated to the technology reporting unit and is not deductible for income tax purposes. The preliminary allocation of the consideration transferred is subject to potential adjustments. Balances subject to adjustment are primarily tax-related matters, including the tax basis of assets acquired and liabilities assumed. During the measurement period, we may record adjustments to the provisional amounts recognized in our initial accounting for the acquisition. We expect the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date). There were no measurement period adjustments recorded during the three and nine months ended September 30, 2024. The amount of revenue attributable to the acquired business of Carevive was not material to our consolidated statement of operations for the three and nine months ended September 30, 2024. Income (loss) information for Carevive after the acquisition date through September 30, 2024 is not presented as the Carevive business was integrated into our operations immediately following the acquisition and is impracticable to quantify. In addition to the purchase price, we agreed to make cash retention payments in an aggregate amount of up to $1.8 million to continuing Carevive team members, a portion of which is variable based upon the achievement of earn-out performance targets. The retention payments are generally subject to vesting based upon continued employment over a required service period. Such amounts are recorded as post-combination compensation expense and recognized on a straight-line basis over the relevant vesting terms. During the nine months ended September 30, 2024, we recognized compensation expense of $0.8 million related to these retention payments.</div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify">Unaudited Pro Forma Financial Information</div><div style="text-align:justify;text-indent:18pt"> The following table reflects our unaudited pro forma combined results of operations for the three and nine months ended September 30, 2024 and 2023 as if the acquisitions of Carevive and Lumeon had taken place on January 1, 2023 (in thousands):</div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pro forma net loss</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14,818)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(27,407)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(56,182)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(107,898)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt">The unaudited pro forma information is presented for informational purposes only and is not intended to present actual results that would have been attained had the acquisition been completed as of January 1, 2023 or to project potential results as of any future date or for any future periods. The unaudited pro forma information, including adjustments, are based upon available information and certain assumptions that we believe are reasonable. Pro forma revenue has not been presented for these 2024 acquisitions as the impact to our condensed consolidated financial statements was not material. </div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">The nature and amount of material, nonrecurring pro forma adjustments directly attributable to these acquisitions which are included in the pro forma net loss, as applicable, are summarized as follows (in thousands):</div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">(unaudited)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of acquired intangible assets</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(303)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px

1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(1,331)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(2,788)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(3,993)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Acquisition-related costs, net</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,487 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,534)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total pro forma adjustments</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,184 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,331)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,943 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(5,527)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2023 Acquisition of Electronic Registry Systems, Inc. On October 2, 2023, we acquired Electronic Registry Systems, Inc. (ERS), a cloud-based provider of clinical registry development and data management software based in Cincinnati, Ohio. We accounted for the acquisition of ERS as a business combination. ERS provides cancer registry compliance and informatics services to enable customers to achieve their cancer center clinical and business objectives with a goal of improving cancer care for every patient, including through its CRStar platform. The acquisition consideration transferred comprised of net cash consideration of $11.4 million. The purchase resulted in Health Catalyst acquiring 100% ownership in ERS.</div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt">An additional 175,901 shares of our common stock subject to a restriction agreement (restricted shares) were issued pursuant to the terms of the acquisition agreement. The vesting of these restricted shares was originally subject to eighteen months of continued employment with cliff vesting upon the eighteen-month anniversary of the acquisition close date. </div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt">The value of these restricted shares was originally scheduled to be recognized as post-combination stock-based compensation expense on a straight-line basis over the vesting term, but due to workforce reductions made as part of the 2023 Restructuring Plan (as defined below), the ERS restricted shares fully vested in February 2024, resulting in an acceleration of the related stock-based compensation expense. Refer to Note 13-Stock-Based Compensation for additional details related to our stock-based compensation. </div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt">The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of ERS (in thousands):</div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets acquired:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">478 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prepaid expenses and other assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Client relationships</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,300 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,051 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less liabilities assumed:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Accrued and other current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,251 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total liabilities assumed</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,329 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">6,722 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,670 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total consideration transferred, net of cash acquired</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,392 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The acquired intangible assets were valued utilizing either an income approach or a cost approach as deemed most applicable, and include client relationships, developed technology, and trademarks that will be amortized on a straight-line basis over their estimated useful lives of seven years, four years, and two years, respectively. The resulting goodwill from the ERS acquisition was fully allocated to the technology reporting unit and is deductible for income tax purposes. 39800000 36200000 2900000 700000 1 <div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt">The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Lumeon (in thousands):</div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets acquired:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Accounts receivable, net</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">967 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prepaid expenses and other assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">795 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Property and equipment, net </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">165 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Client relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,400 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,300 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,327 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less liabilities assumed:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Accrued and other current liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,759 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net deferred tax liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,679 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total liabilities assumed</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,589 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,738 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28,092 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total consideration transferred, net of cash acquired</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">39,830 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt">The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of Carevive (in thousands):</div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets acquired:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt">Accounts receivable, net</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prepaid expenses and other assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Client relationships</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,700 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">300 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,960 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less liabilities assumed:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Accrued and other current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,389 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total liabilities assumed</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,465 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,495 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,643 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total consideration transferred, net of cash acquired</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,138 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt">The following table summarizes the preliminary acquisition-date fair value of consideration transferred and the identifiable assets purchased and liabilities assumed as part of our acquisition of ERS (in thousands):</div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets acquired:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Accounts receivable</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">478 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Prepaid expenses and other assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Client relationships</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,300 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Developed technology</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,051 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less liabilities assumed:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Accrued and other current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Deferred revenue</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,251 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total liabilities assumed</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,329 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total assets acquired, net</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,722 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,670 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total consideration transferred, net of cash acquired</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11,392 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 967000 795000 165000 3700000 11400000 1300000 18327000 1151000 1759000 3679000 6589000 11738000 28092000 39830000 P7Y P4Y P5Y 5000000.0 1100000 22100000 18600000 2600000 900000 1 96000 64000 2700000 4800000 300000 7960000 1389000 76000 1465000 6495000 15643000 22138000 P7Y P4Y P3Y 1800000 800000 The following table reflects our unaudited pro forma combined results of operations for the three and nine months ended September 30, 2024 and 2023 as if the acquisitions of Carevive and Lumeon had taken place on January 1, 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3"

style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> (unaudited) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Pro forma net loss</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14,818)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(27,407)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(56,182)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(107,898)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The nature and amount of material, nonrecurring pro forma adjustments directly attributable to these acquisitions which are included in the pro forma net loss, as applicable, are summarized as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amortization of acquired intangible assets </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(303)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(1,331)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(2,788)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(3,993)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Acquisition-related costs, net </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,487 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,534)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total pro forma adjustments </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,184 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,331)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,943 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(5,527)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -14818000 -27407000 -56182000 -107898000 303000 -1331000 -2788000 -3993000 -1487000 0 5731000 -1534000 -1184000 -1331000 2943000 -5527000 11400000 1 175901 P18M P18M 478000 73000 5300000 3100000 100000 9051000 78000 2251000 2329000 6722000 4670000 11392000 P7Y P4Y P2Y Revenue Disaggregation of Revenue The following table represents Health Catalyst's revenue disaggregated by type of arrangement (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amortization of acquired intangible assets </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(303)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(1,331)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(2,788)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(3,993)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Acquisition-related costs, net </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,487 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,534)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total pro forma adjustments </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,184 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,331)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,943 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(5,527)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -14818000 -27407000 -56182000 -107898000 303000 -1331000 -2788000 -3993000 -1487000 0 5731000 -1534000 -1184000 -1331000 2943000 -5527000 11400000 1 175901 P18M P18M 478000 73000 5300000 3100000 100000 9051000 78000 2251000 2329000 6722000 4670000 11392000 P7Y P4Y P2Y Revenue Disaggregation of Revenue The following table represents Health Catalyst's revenue disaggregated by type of arrangement (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-

height:100%">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Recurring technology</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">48,653 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">45,973 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">143,254 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">140,126 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">One-time technology (i.e., perpetual license)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">357 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Professional services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83,724 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,371 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">76,353 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73,773 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">226,978 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">220,854 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Revenue related to contracts with clients located in the United States was 96.9% and 98.5% for the three months ended September 30, 2024 and 2023, respectively, and 97.6% and 98.3% for the nine months ended September 30, 2024 and 2023, respectively. Deferred Revenue and Performance Obligations Deferred revenue includes advance client payments and billings in excess of revenue recognized. For the three months ended September 30, 2024 and 2023, 43% and 45%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period. For the nine months ended September 30, 2024 and 2023, 22% and 23%, respectively, of the revenue recognized was included in deferred revenue at the beginning of the period. Most of our technology and professional services contracts have a three- or five-year term, of which many are terminable after one year upon 90 days' notice. For arrangements that do not allow the client to cancel within one year or less, we expect to recognize $290.5 million of revenue on unsatisfied performance obligations as of September 30, 2024. We expect to recognize approximately 65% of the remaining performance obligations over the next 24 months, with the balance recognized thereafter. <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">The following table represents Health Catalyst's revenue disaggregated by type of arrangement (in thousands):</div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Recurring technology</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">48,653 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">45,973 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">48,653 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">45,973 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">143,254 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">140,126 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">One-time technology (i.e., perpetual license)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">357 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Professional services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83,724 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,371 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">76,353 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73,773 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">226,978 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">220,854 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 48653000 45973000 143254000 140126000 0 0 0 357000 27700000 27800000 83724000 80371000 76353000 73773000 226978000 220854000 0.969 0.985 0.976 0.983 Goodwill and Intangible Assets We operate our business in two operating segments that also represent our reporting units. Our reporting units are organized based on our technology and professional services. We have not incurred any goodwill impairment charges. Goodwill by reporting unit is as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
December 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Technology</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">233,605 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">189,870 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Professional services</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">782 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">782 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total goodwill</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">234,387 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">190,652 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024, intangible assets consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Cost </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">120,129 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(90,573)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">29,556 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Client relationships and contracts</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96,464 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53,735)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42,729 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software licenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,144 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,084)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,060 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,420 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,302)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total intangible assets</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">232,157 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(155,694)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">76,463 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Amortization expense of acquired intangible assets was $6.8 million and $7.1 million for the three months ended September 30, 2024 and 2023, respectively, and $21.6 million and $22.4 million for the nine months ended September 30, 2024 and 2023, respectively. Amortization expense for intangible assets is included in depreciation and amortization in our condensed consolidated statements of operations. We have not incurred any intangible asset impairment charges for the three and nine months ended September 30, 2024 and 2023.</div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt">As of December 31, 2023, intangible assets consisted of the following (in thousands):</div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Cost</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">103,929 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(79,057)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24,872 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Client relationships and contracts</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90,064 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(45,230)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">44,834 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software licenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,680 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,933)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,747 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,820 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,889)</td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">931 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total intangible assets</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">207,493 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(134,109)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73,384 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2 2 Goodwill by reporting unit is as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
December 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Technology</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">233,605 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">189,870 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Professional services</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">782 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">782 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total goodwill</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">234,387 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">190,652 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 233605000 189870000 782000 782000 234387000 190652000 120129000 90573000 29556000 96464000 53735000 42729000 11144000 9084000 2060000 4420000 2302000 2118000 232157000 155694000 76463000 6800000 7100000 21600000 22400000 103929000 79057000 24872000 90064000 45230000 44834000 10680000 7933000 2747000 2820000 1889000 931000 207493000 134109000 73384000 Property and Equipment Property and equipment consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
December 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">10,532 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">9,638 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,429 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,814 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture and fixtures</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,748 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,735 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Capitalized internal-use software costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">41,526 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30,771 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer software</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total property and equipment</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,346 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53,069 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: accumulated depreciation</td><td

colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36,438)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27,357)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property and equipment, net</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">27,908 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">25,712 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Our long-lived assets are located in the United States. Depreciation expense totaled $3.1 million for each of the three months ended September 30, 2024 and 2023, respectively, and $9.5 million for each of the nine months ended September 30, 2024 and 2023, respectively. Depreciation expense includes the amortization of capitalized internal-use software costs. During each of the nine months ended September 30, 2024 and 2023, we impaired $0.7 million of leasehold improvements related to our corporate office space designated for subleasing. Refer to Note 9 for additional details. We capitalized $4.4 million and $3.0 million of internal-use software costs for the three months ended September 30, 2024 and 2023, respectively, and $10.8 million and $9.6 million for the nine months ended September 30, 2024 and 2023, respectively. We incurred $2.5 million and $2.1 million of capitalized internal-use software cost amortization expense for the three months ended September 30, 2024 and 2023, respectively, and $7.2 million and $6.4 million for the nine months ended September 30, 2024 and 2023, respectively.</div> 10532000 9638000 8429000 8814000 3748000 3735000 41526000 30771000 111000 111000 64346000 53069000 36438000 27357000 27908000 25712000 3100000 3100000 9500000 9500000 700000 700000 4400000 3000000.0 10800000 9600000 2500000 2100000 7200000 6400000 Short-term Investments<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">We classify our short-term investments as available for sale. Available-for-sale securities are recorded on our condensed consolidated balance sheets at fair market value and any unrealized gains or losses are reported as part of other comprehensive loss on the condensed consolidated statements of comprehensive loss. We determine realized gains or losses on the sales of investments through the specific identification method and record such gains or losses as part of interest and other expense, net on the condensed consolidated statements of operations. We did not have any material realized gains or losses on investments during the three and nine months ended September 30, 2024 and 2023. We measure the fair value of investments on a recurring basis. </div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of September 30, 2024 (in thousands):</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash equivalents</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Short-term Investments</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Money market funds</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">U.S. treasury notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,397 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,092 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,099 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">12,099 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Corporate bonds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,416 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">381,894 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">381,918 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">58,929 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of December 31, 2023 (in thousands):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Cash equivalents</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Short-term Investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Money market funds</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">U.S. treasury notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,856 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,924 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,924 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,358 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,340 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,340 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Corporate bonds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,746 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">U.S. agency securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,405 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,393 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,393 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">311,144 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">117 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(30)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">311,231 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">211,452 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The following table presents the contractual maturities of our short-term investments as of September 30, 2024 and December 31, 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Due within one year</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">58,905 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">58,929 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">211,365 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">211,452 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">58,905 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">58,929 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">211,365 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">211,452 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Accrued interest receivables related to our available-for-sale securities of $1.4 million and $0.9 million as of September 30, 2024 and December 31, 2023, respectively, were included within prepaid expenses and other assets on our condensed consolidated balance sheets. </div><div style="text-align:justify;text-indent:18pt">
</div><div style="text-align:justify;text-indent:18pt">On a quarterly basis we evaluate unrealized losses on our available-for-sale debt securities and the related accrued interest receivables to determine whether a decline in the fair value below the amortized cost basis is due to credit-related factors or noncredit-related factors. We do not intend to sell investments that are in an unrealized loss position and it is not likely that we will be required to sell any investments before recovery of their amortized cost basis. As of September 30, 2024 and December 31, 2023, there were no material unrealized losses due to expected credit loss-related factors.</div> <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of September 30, 2024 (in thousands):</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash equivalents</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Short-term Investments</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Money market funds</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">U.S. treasury notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,397 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,092 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,099 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,099 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Corporate bonds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,416 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">381,894 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">381,918 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">58,929 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The following table summarizes, by major security type, our cash equivalents and short-term investments that are measured at fair value on a recurring basis as of December 31, 2023 (in thousands):
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:24.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.674%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Cash equivalents</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Short-term Investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Money market funds</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">U.S. treasury notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,856 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">68 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td

colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,924 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,924 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,358 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(18)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,340 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,340 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Corporate bonds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,746 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,795 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">U.S. agency securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,405 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,393 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,393 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">311,144 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">117 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(30)</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">311,231 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">211,452 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 The following table presents the contractual maturities of our short-term investments as of September 30, 2024 and December 31, 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Due within one year</td><td style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">58,905 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">58,929 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">211,365 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">211,452 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">58,905 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">58,929 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">211,365 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">211,452 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 322989000 0 0 322989000 322989000 0 19397000 9000 0 19406000 0 19406000 12092000 7000 0 12099000 0 12099000 27416000 8000 0 27424000 0 27424000 381894000 24000 0 381918000 322989000 58929000 99779000 0 0 99779000 99779000 0 65856000 68000 0 65924000 0 65924000 85358000 0 18000 85340000 0 85340000 43746000 49000 0 43795000 0 43795000 16405000 0 12000 16393000 0 16393000 311144000 117000 30000 311231000 99779000 211452000 58905000 58929000 211365000 211452000 58905000 58929000 211365000 211452000 1400000 900000 Fair Value of Financial Instruments Assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market funds</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. Treasury notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,099 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,099 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate bonds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration liabilities</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">342,395 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,523 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">381,918 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Assets measured at fair value on a recurring basis as of December 31, 2023 were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Money market funds</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">U.S. Treasury notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,924 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,924 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,339 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,339 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Corporate bonds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,796 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,796 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. agency securities</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,393 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,393 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">165,703 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145,528 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">311,231 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> There were no transfers between Level 1 and Level 2 of the fair value measurement hierarchy during the three and nine months ended September 30, 2024 and 2023. Convertible senior notes As of September 30, 2024 and December 31, 2023, the estimated fair value of our convertible senior notes, with aggregate principal totaling $230.0 million, was $227.9 million and $218.7 million, respectively. We estimate the fair value based on quoted market prices in an inactive market on the last trading day of the reporting period (Level 2). These convertible senior notes are recorded at face value less unamortized debt discount and transaction costs on our condensed consolidated balance sheets. Refer to Note 10—Debt for further information. Nonrecurring fair value measurements We recorded impairment charges of $2.2 million and $2.7 million related to the impairment of ROU assets and leasehold improvements associated with office space designated for subleasing during the nine months ended September 30, 2024 and 2023. These impairment charges were derived from the difference between the carrying value and the fair value of the relevant asset groups. The fair value of these asset groups was estimated using a discounted cash flow analysis of the office space designated for subleasing and included certain unobservable (Level 3) inputs, including the anticipated future sublease terms and rates. Level 3 fair value measurements The Lumeon acquisition consideration included an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Lumeon during an earn-out period that ends on June 30, 2025. The Lumeon contingent consideration is capped at $25.0 million and will be paid in cash to the extent achieved. We value Lumeon's expected contingent consideration and the corresponding liability using the Black-Scholes valuation method based on estimates of potential pay-out scenarios. The Carevive acquisition consideration included an initial estimate for contingent consideration based on certain revenue-based earn-out performance targets for Carevive during an earn-out period that ends on June 30, 2025. The Carevive contingent consideration is capped at $10.0 million and will be paid in cash to the extent achieved. We value Carevive's expected contingent consideration and the corresponding liability using the Black-Scholes valuation method based on estimates of potential pay-out scenarios. </div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify;text-indent:18pt">The outstanding contingent consideration liabilities are categorized as Level 3 fair value measurements and are remeasured as of each reporting period. The aggregate intrinsic value of the revenue-based earn-out contingent consideration liabilities is zero based on a point estimate of our internal forecasting of the ultimate earn-outs that will be earned as of September 30, 2024. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs used during the three months ended September 30, 2024:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.605%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Valuation Method</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Market Price of Revenue Risk</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue Volatility</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Expected Term (years)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Risk-free interest rate</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Revenue-based earn-out liabilities</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Black-Scholes</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">8.4%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">20%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">1.2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">5.0%</td></tr></table></div><div style="text-align:justify;text-indent:18pt">
</div><div style="text-align:justify;text-indent:18pt">The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance as of January 1, 2024</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Acquisition-date contingent consideration liabilities from acquisitions (see Note 2) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,642 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Change in fair value of contingent consideration liabilities </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,642)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance as of September 30, 2024 </td><td

style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 were as follows (in thousands):</div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market funds</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">322,989 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. Treasury notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,099 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12,099 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate bonds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt">Total</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">342,395 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,523 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">381,918 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Assets measured at fair value on a recurring basis as of December 31, 2023 were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td

style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Money market funds</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">99,779 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">U.S. Treasury notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,924 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65,924 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,339 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,339 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Corporate bonds</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,796 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43,796 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. agency securities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,393 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,393 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">165,703 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145,528 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">311,231 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 322989000 0 0 322989000 19406000 0 0 19406000 0 12099000 0 12099000 0 27424000 0 27424000 0 0 0 0 342395000 39523000 0 381918000 99779000 0 0 99779000 65924000 0 0 65924000 0 85339000 0 85339000 0 43796000 0 43796000 0 16393000 0 16393000 165703000 145528000 0 311231000 230000000 230000000 227900000 218700000 2200000 2700000 25000000.0 10000000.0 0 The recurring Level 3 fair value measurements of the contingent consideration liabilities include the other following significant inputs used during the three months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.605%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Valuation Method</td><td colspan="3" style="background-

color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Market Price of Revenue Risk</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Revenue Volatility</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Expected Term (years)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Risk-free interest rate</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Revenue-based earn-out liabilities </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Black-Scholes</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">8.4%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">20%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">1.2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">5.0%</td></tr></table> The fair value of the market-based tranches included in the executive PRSUs were estimated on the date of grants using the Monte Carlo simulation valuation model with the following assumptions for the nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.209%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30, 2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">65.5%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">61.7%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (in years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1-3 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1-3 </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.33% - 4.91% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.38% - 5.01% </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividends</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 0.084 0.20 1.2 0.050 The following table sets forth a summary of the changes in the estimated fair value of the contingent consideration liabilities, which are measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance as of January 1, 2024 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Acquisition-date contingent consideration liabilities from acquisitions (see Note 2)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,642 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Change in fair value of contingent consideration liabilities</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,642)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance as of September 30, 2024</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0 1642000 -1642000 0 Accrued Liabilities As of September 30, 2024 and December 31, 2023, accrued liabilities consisted of the following (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
December 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued compensation and benefit expenses</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">9,838 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,680 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Restructuring liabilities(1)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,355 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,703 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,247 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total accrued liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,548 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,282 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify">_____</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Restructuring liabilities include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in these condensed consolidated financial statements.</div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">As of September 30, 2024 and December 31, 2023, accrued liabilities consisted of the following (in thousands):</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of
December 31,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued compensation and benefit expenses</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">9,838 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,680 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Restructuring liabilities(1)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,355 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,703 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,247 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total accrued liabilities</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,548 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,282 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1)Restructuring liabilities include severance and other team member costs from workforce reductions. For additional details, refer to Note 19 in these condensed consolidated financial statements. 9838000 11680000 7000 2355000 13703000 9247000 23548000 23282000 Leases We lease office space under operating leases that expire between 2024 and 2031. The terms of the leases provide for rental payments on a graduated scale, options to renew the leases (one to five years), landlord incentives or allowances, and periods of free rent. We subleased portions of our corporate headquarters to various sublessees with subleases commencing at various dates between 2021 and 2024. Components of lease expense (income) are summarized as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> (unaudited) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> (unaudited)

</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease expense</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">692 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">760 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,986 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,334 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term lease expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sublease income</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(414)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(308)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,068)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(935)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">461 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,032 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,450 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> We also incur immaterial variable costs related to our leased office space, such as maintenance and utilities based on actual usage, which are not included in the measurement of right-of-use assets and lease liabilities, but are expensed as incurred. During the nine months ended September 30, 2024 and 2023, we identified asset impairment indicators for multiple of our corporate office spaces designated for subleasing. We performed a recoverability test of the relevant asset group, comprised of operating lease ROU and other related assets, and determined that the carrying value of this asset group was not fully recoverable. As a result, we measured and recognized total impairment charges of $2.2 million and $2.7 million during the nine months ended September 30, 2024 and 2023, respectively, representing the amount by which the carrying value exceeded the estimated fair value of this asset group. The impairment charges were recorded as part of general and administrative expense in our condensed consolidated statements of operations. During the nine months ended September 30, 2024, $1.5 million of the impairment charge was allocated to ROU assets and the remaining $0.7 million was allocated to leasehold improvements, while during the nine months ended September 30, 2023, $2.0 million of the impairment charge was allocated to ROU assets and the remaining $0.7 million was allocated to leasehold improvements.</div> P5Y <div style="margin-bottom:3pt;text-align:justify;text-indent:18pt">Components of lease expense (income) are summarized as follows (in thousands):</div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">(unaudited)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">(unaudited)</div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease expense</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">692 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">760 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,986 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,334 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term lease expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">114 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">51 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sublease income</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(414)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(308)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,068)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(935)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">328 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">461 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,032 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,450 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 692000 760000 1986000 2334000 50000 9000 114000 51000 414000 308000 1068000 935000 328000 461000 1032000 1450000 2200000 2700000 1500000 700000 2000000.0 700000 Debt Debt consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:63.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.50% convertible senior notes due 2025 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">230,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">230,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Variable interest rate term loan maturing 2029 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total Principal Outstanding </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">355,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">230,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: Unamortized discount and issuance costs </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,966)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,966)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net carrying amount</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">345,034 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,034 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: Current portion of long-term debt </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(230,423)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term debt, net of current portion </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">114,611 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">228,034 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Components of interest expense are summarized as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td

style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contractual interest expense</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,541 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,445 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7,444 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,329 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of debt discount and issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">769 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">378 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,529 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,132 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amortization of deferred financing costs </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">816 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">816 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,126 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,823 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,789 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,461 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Maturity of Debt As of September 30, 2024, we are subject to required principal payments and debt maturity as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Contractual Maturity </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Fiscal year: </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">313 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">231,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2026 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2027 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2028 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2029 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,687 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total debt maturities </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">355,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: Unamortized debt discount and issuance costs </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,966)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net carrying amount</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">345,034 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Credit Agreement On July 16, 2024 (the Closing Date), we entered into a credit agreement with Silver Point Finance, LLC, as administrative agent and collateral agent, and the lenders from time-to-time party thereto (the Credit Agreement). The Credit Agreement provides a five-year term loan facility in an aggregate principal amount of up to $225.0 million, consisting of an initial term loan of $125.0 million, which was funded in full on the Closing Date, and a delayed draw term loan facility in an aggregate principal amount of up to $100.0 million, which was undrawn as of the Closing Date. We have the option to draw up to $40.0 million under the delayed draw facility within six months after the Closing Date and up to an additional $60.0 million under the delayed draw facility within eighteen months after the Closing Date, in each case, subject to satisfaction of certain conditions, including a minimum liquidity threshold and a maximum recurring revenue/leverage ratio. We are required to pay a commitment fee on the unutilized commitments under the delayed draw term loan facility ranging from 1.5% to 2.5% per year depending on the year and the amount of the unutilized delayed draw term loan. The deferred financing costs related to the delayed draw facility, including the directly attributable debt discount, have been capitalized to other assets on our condensed consolidated balance sheets, and amortized to interest expense in the condensed consolidated statement of operations, in each case over the respective terms. Borrowings under the initial term loan bear interest at a rate per annum equal to the secured overnight financing rate (SOFR) plus 6.5%. Commencing with the quarter ending on December 31, 2024, we are required to make quarterly principal payments in an amount equal to 0.25% of the aggregate original principal amount. The final maturity date of the term loans is July 16, 2029. We expect to use the net proceeds from the initial term loan, together with cash on hand, (i) to repurchase, repay, and/or pay amounts of cash due upon conversion of any or all of the Notes at any time on or prior to the maturity thereof and (ii) for working capital and general corporate purposes. We expect to use the proceeds from the delayed draw term loan facility, if any, to fund our inorganic growth strategy through permitted acquisitions (including deferred purchase price or similar arrangements related thereto) and to pay fees, costs, and expenses in connection therewith. We are required to prepay the term loans upon the occurrence of certain events, and we may voluntarily prepay the term loans, in whole or in part, at any time, subject to certain notice requirements and prepayment amounts. Prior to July 16, 2028, such mandatory prepayments or voluntary prepayments are subject to a prepayment premium ranging from 1.0% to 3.0% plus a make whole amount depending on the year of such prepayment. Our obligations under the Credit Agreement and the other loan documents are required to be guaranteed by all of our present and future domestic and foreign subsidiaries, subject to certain exceptions (Guarantors). All obligations under the Credit Agreement and the other loan documents are secured by a first priority perfected lien on, and security interest in, substantially all of our and our Guarantor's present and future assets, subject to certain exceptions. The Credit Agreement contains various representations and warranties, affirmative covenants, and negative covenants, including covenants that restrict our and our subsidiaries' ability to take certain actions including, among other things and subject to certain exceptions, the incurrence of debt, the granting of liens, engaging in mergers and other fundamental changes, the making of investments, entering into transactions with affiliates, the payment of dividends and other restricted payments, the prepayment of other indebtedness and the sale of assets. We are also required to comply with a minimum liquidity threshold, a maximum recurring revenue-based leverage ratio, and a maximum EBITDA-based leverage ratio. The Credit Agreement also includes various events of default, including, among others: non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations or warranties, cross-default to other material indebtedness, bankruptcy and insolvency events, invalidity or impairment of security interests or invalidity of loan documents, certain ERISA events, unsatisfied or unstayed judgments and change of control. Upon the occurrence of an event of default, the administrative agent and the lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Credit Agreement and the related loan documents, including proceeding against the collateral securing such borrowings. As of September 30, 2024, we were in compliance with all covenants under the Credit Agreement. Convertible senior notes On April 14, 2020, we issued $230.0 million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025 (Notes), in a private placement to qualified institutional buyers exempt from registration under the Securities Act (Note Offering). The net proceeds from the issuance of the Notes were approximately $222.5 million, after deducting the initial purchasers' discounts and offering expenses payable by us. The Notes are governed by an indenture (the Indenture) between us, as the issuer, and U.S. Bank National Association, as trustee. The Notes are our senior, unsecured obligations and accrue interest payable semiannually in arrears on April 15 and October 15 of each year, beginning on October 15, 2020, at a rate of 2.50% per year. The Notes will mature on April 15, 2025, unless earlier converted, redeemed, or repurchased. The Indenture does not contain any financial or operating covenants or restrictions on the payments of dividends, the incurrence of indebtedness, or the issuance or repurchase of securities by us or any of our subsidiaries. On or after April 20, 2023, we may redeem, for cash, all or a portion of the Notes, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes. The Notes have an initial conversion rate of 32.6797 shares of our common stock per $1,000 principal amount of Notes (which is equivalent to an initial conversion price of approximately $30.60 per share of our common stock). Following certain corporate events that occur prior to the maturity date, we will increase the conversion rate for a holder who elects to convert its Notes in connection with such corporate event. Additionally, upon the occurrence of a corporate event that constitutes a "fundamental change" per the Indenture, holders of the Notes may require the Company to repurchase for cash all or a portion of their Notes at a purchase price equal to 100% of the principal amount of the Notes plus accrued and unpaid interest. Holders of the Notes were able to convert all or any portion of their Notes at any time prior to the close of business on October 14, 2024, in integral multiples of $1,000 principal amount, only under the following circumstances: •During any calendar quarter commencing after the calendar quarter ended on June 30, 2020 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; •During the five business day period after any five consecutive trading day period (the measurement period) in which the trading price as defined in the Indenture per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; •If we call such notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or •Upon the occurrence of specified corporate events described in the Indenture. On or after October 15, 2024, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their Notes at the conversion rate at any time irrespective of the foregoing circumstances. Upon conversion, holders will receive cash, shares of our common stock or a combination of cash and shares of common stock, at our election. As of September 30, 2024, the conditions allowing holders of the Notes to convert were not met and, therefore, the Notes were not convertible as of such date. However, due to the April 2025 maturity date now being within twelve months, the Notes are classified as a current liability on our condensed consolidated balance sheet. Based on the closing price of our common stock of $8.14 per share on the last trading day of the period ended September 30, 2024, the if-converted value of the Notes was less than their respective principal amounts. Capped calls On April 8, 2020, concurrently with the pricing of the Notes, we entered into privately negotiated capped call transactions (Base Capped Calls) with certain option counterparties. In addition, in connection with the initial purchasers' exercise in full of their option to purchase additional Notes, on April 9, 2020, we entered into additional capped call transactions (together with the Base Capped Calls, the Capped Calls) with each of the option counterparties. We used approximately $21.7 million of the net proceeds from the Note Offering to pay the cost of the Capped Calls and allocated issuance costs. The Capped Calls have initial cap prices of $42.00 per share, subject to certain adjustments. The Capped Calls are expected generally to reduce the potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to the

cap price. The Capped Calls are separate transactions that we entered into with the option counterparties, and are not part of the terms of the Notes. As the Capped Call transactions are considered indexed to our own stock and are considered equity classified, they were recorded in stockholders' equity and are not accounted for as derivatives. The cost incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital on our condensed consolidated balance sheets. Debt consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:63.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.50% convertible senior notes due 2025 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">230,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">230,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Variable interest rate term loan maturing 2029 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total Principal Outstanding </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">355,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">230,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: Unamortized discount and issuance costs </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,966)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,966)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net carrying amount</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">345,034 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">228,034 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Less: Current portion of long-term debt </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(230,423)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Long-term debt, net of current portion </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">114,611 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">228,034 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0.0250 230000000 230000000 125000000 0 355000000 230000000 9966000 1966000 345034000 228034000 230423000 0 114611000 228034000 Components of interest expense are summarized as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contractual interest expense</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,541 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,445 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7,444 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4,329 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of debt discount and issuance costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">378 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,529 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,132 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Amortization of deferred financing costs </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">816 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">816 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,126 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,823 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,789 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,461 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4541000 1445000 7444000 4329000 769000 378000 1529000 1132000 816000 0 816000 0 6126000 1823000 9789000 5461000 As of September 30, 2024, we are subject to required principal payments and debt maturity as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Contractual Maturity </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Fiscal year: </td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2024 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">313 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">231,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">2026</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">2027</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">2028</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">2029</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">119,687 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total debt maturities</div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">355,000 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Less: Unamortized debt discount and issuance costs</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,966)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net carrying amount</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">345,034 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 313000 231250000 1250000 1250000 1250000 119687000 355000000 9966000 345034000 P5Y 225000000 125000000 100000000 40000000 P6M 60000000 0.015 0.025 0.065 0.0025 0.010 0.030 230000000 0.0250 222500000 0.0250 1.30 20 30 1 1000 30.60 1 1000 20 30 1.30 5 5 1000 0.98 8.14 21700000 42.00 Stockholders' Equity Preferred stock Our board of directors has the authority, without further action by our stockholders, to issue up to 25,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, and privileges thereof, including voting rights. As of September 30, 2024 and December 31, 2023, no shares of this preferred stock were issued and outstanding. Common stock We had 500,000,000 shares of common stock, par value $0.001 per share, authorized, of which 60,847,658 and 58,530,880 shares were legally issued and outstanding as of September 30, 2024 and December 31, 2023, respectively. The shares legally issued and outstanding as of September 30, 2024 and December 31, 2023 included zero shares and 235,389 shares, respectively, issued pursuant to acquisition agreements, which were subject to a restriction agreement and were unvested, and as such, for accounting purposes they were not considered to be outstanding common stock shares. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on our common stock through September 30, 2024.
 Share repurchase plan During the third quarter of 2022, our board of directors authorized a share repurchase program to repurchase up to $40.0 million of our outstanding shares of common stock (Share Repurchase Plan). There were no share repurchases during the first, second or third quarter of 2024. During the first quarter of 2023, we repurchased and retired 145,027 shares of our common stock for $1.8 million at an average purchase price of $12.45 per share. This is in addition to the 709,139 shares of common stock we repurchased and retired for $8.4 million at an average purchase price of $11.81 per share during the third quarter of 2022. The total remaining authorization for future shares of common stock

repurchases under our Share Repurchase Plan is $29.8 million as of September 30, 2024.</div> 25000000 0 0 0 0 500000000 500000000 0.001 0.001 60847658 60847658 58530880 58530880 0 0 235389 235389 1 0 40000000 0 145027 145027 1800000 1800000 12.45 709139 709139 8400000 11.81 29800000 Net Loss Per Share<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Net loss per share, basic and diluted</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net loss</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14,726)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(22,032)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(48,829)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(87,835)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt">Weighted-average shares outstanding used in calculating net loss per share, basic and diluted</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,440,694 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,710,602 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,448,966 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,061,925 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt">Net loss per share, basic and diluted</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.24)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.39)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.82)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1.57)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
 During the three and nine months ended September 30,

2024 and 2023, we incurred net losses and, therefore, the effect of our stock options, restricted stock units, performance-based restricted stock units, convertible senior notes, employee stock purchase plan, and restricted shares were not included in the calculation of diluted net loss per share as the effect would be anti-dilutive. The calculation of diluted net loss per share does not include the effect of the following potentially outstanding shares of common stock. The effects of these potentially outstanding shares were not included in the calculation of diluted net loss per share when the effect would have been anti-dilutive: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Common stock options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,071,509 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,404,287 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted stock units</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,160,419 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,196,967 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Performance-based restricted stock units</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">524,994 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,548 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares related to convertible senior notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,516,331 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,516,331 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock purchase plan</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">207,388 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184,908 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted shares</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">324,562 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total potentially dilutive securities</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,480,641 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,838,603 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> In connection with the offering of our convertible senior notes, we entered into Capped Calls with initial caps on the conversion price of $42.00 per share, which are excluded from the calculation of diluted earnings per share, as they would be anti-dilutive.</div> <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">The following table presents the calculation of basic and diluted net loss per share (in thousands, except share and per share amounts):</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Net loss per share, basic and diluted</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net loss</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14,726)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(22,032)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(48,829)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">(87,835)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Weighted-average shares outstanding used in calculating net loss per share, basic and diluted </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,440,694 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,710,602 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,448,966 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">56,061,925 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Net loss per share, basic and diluted </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.24)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.39)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">(0.82)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1.57)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> -14726000 -14726000 -22032000 -22032000 -48829000 -48829000 -87835000 -87835000 60440694 60440694 56710602 56710602 59448966 59448966 56061925 56061925 -0.24 -0.24 -0.39 -0.39 -0.82 -0.82 -1.57 -1.57 The calculation of diluted net loss per share does not include the effect of the following potentially outstanding shares of common stock. The effects of these potentially outstanding shares were not included in the calculation of diluted net loss per share when the effect would have been anti-dilutive: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Common stock options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,071,509 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,404,287 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted stock units</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,160,419 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,196,967 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Performance-based restricted stock units</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">524,994 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">211,548 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares related to convertible senior notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,516,331 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,516,331 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock purchase plan</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">207,388 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184,908 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted shares</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,562 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total potentially dilutive securities</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,480,641 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,838,603 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1071509 1404287 4160419 4196967 524994 211548 7516331 7516331 207388 184908 0 324562 13480641 13838603 42.00 Stock-Based Compensation In 2011, our board of directors adopted the Health Catalyst, Inc. 2011 Stock Incentive Plan (2011 Plan), which provided for the direct award, sale of shares, and granting of RSUs and options for our common stock to our directors, team members, or consultants. In connection with our initial public offering (IPO), our board of directors adopted the 2019 Stock Option and Incentive Plan (2019 Plan). The 2019 Plan provides flexibility to our compensation committee to use various equity-based incentive awards as compensation tools to motivate our workforce, including the grant of incentive and non-statutory stock options, restricted and unrestricted stock, RSUs, and stock appreciation rights to our directors, team members, or consultants. We initially reserved 2,756,607 shares of our common stock (2,500,000 under the 2019 Plan and 256,607 shares under the 2011 Plan) that were available immediately prior to the IPO registration date. The 2019 Plan provides that the number of shares reserved available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of our common stock on the immediately preceding December 31, or such lesser number of shares as determined by our compensation committee. As of January 1, 2024, there were an additional 2,926,544 shares reserved for issuance under the 2019 Plan. As of September 30, 2024 and December 31, 2023, there were 23,644,211 and 20,717,667 shares authorized for grant, respectively, and 4,420,022 and 3,831,444 shares available for grant under the 2019 Plan, respectively. The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our condensed consolidated statements of operations (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted stock units</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,655 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,591 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,065 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">34,531 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Performance-based restricted stock units</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,523 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,117 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock purchase plan</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">357 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">746 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,464 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted shares</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,878 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,969 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,573 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total stock-based compensation</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">9,512 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,232 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29,316 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">42,745 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenue</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,051 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,424 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5,488 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7,090 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,555 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,149 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,997 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,049 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,871 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,927 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,391 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,677 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,035 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,732 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,440 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,929 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total stock-based compensation</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,512 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14,232 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">29,316 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">42,745 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table> Stock options There were no stock options granted during the nine months ended September 30, 2024 or 2023. A

summary of the share option activity under the 2019 Plan for the nine months ended September 30, 2024, is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Time-Based Option Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Remaining Contractual Life in Years</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Intrinsic Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Outstanding at January 1, 2024 </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,396,452 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">11.70 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Options exercised</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26,668)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Options cancelled/forfeited</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(298,275)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.23 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Outstanding at September 30, 2024</div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,071,509 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.97 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt">Vested and expected to vest as of September 30, 2024</div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,071,509 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11.97 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.3</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt">Vested and exercisable as of September 30, 2024</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,071,509 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.97 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The aggregate intrinsic value of stock options exercised was less than $0.1 million for the nine months ended September 30, 2024. The aggregate intrinsic value of stock options exercised was $0.7 million for the nine months ended September 30, 2023. The total grant date fair value of stock options vested during the nine months ended September 30, 2024 and 2023 was zero and $0.4 million, respectively. All of our outstanding stock options are fully vested and there is no longer any related unrecognized compensation expense.</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">Restricted stock units (RSUs)</div><div style="text-align:justify;text-indent:18pt">The service-based condition for restricted stock units (RSUs) is generally satisfied over four years with a cliff vesting period of one year and quarterly vesting thereafter. The following table sets forth the outstanding RSUs and related activity for the nine months ended September 30, 2024:</div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restricted Stock Units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Unvested and outstanding at January 1, 2024</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,111,584 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">19.16 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">RSUs granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,616,356 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td

colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.55 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">RSUs vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,207,994)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.64 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">RSUs forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(359,527)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.49 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unvested and outstanding at September 30, 2024 </td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,160,419 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">12.09 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> During the nine months ended September 30, 2024 and 2023, we granted RSUs with a weighted-average grant date fair value of $8.55 and $11.99, respectively, which represents the weighted-average closing price of our common stock on the grant date. The total grant date fair value of RSUs vested during the nine months ended September 30, 2024 and 2023 was $26.1 million and $35.2 million, respectively. As of September 30, 2024, we had $43.0 million of unrecognized stock-based compensation expense related to outstanding RSUs expected to be recognized over a weighted-average period of 1.9 years.</div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt">Performance-based restricted stock units (PRSUs)</div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt">2024 Executive PRSUs</div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt">During the nine months ended September 30, 2024, certain named executive officers and other leadership team members were granted executive PRSUs with a three-year measurement period that include service conditions, performance conditions, and market conditions. </div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt">The vesting of these PRSUs will be determined based on market-based targets for total shareholder return (TSR) achievement (weighted 25%) and financial performance targets for revenue growth rate achievement (weighted 25%) and Adjusted EBITDA margin achievement (weighted 50%). These PRSUs may vest in an amount up to the amount granted, subject to satisfaction of the pre-established targets. The number of PRSUs that will vest for the 2024, 2025, and 2026 vesting periods will be calculated as follows: (i) the market/performance achievement for the applicable vesting period, multiplied by (ii) approximately 33.33% of the PRSUs for each of the 2024, 2025, and 2026 vesting periods, each rounded to the nearest whole share.</div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt">2023 Executive PRSUs</div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt">During the nine months ended September 30, 2023, certain named executive officers and other leadership team members were granted executive PRSUs with a three-year measurement period that include service conditions, performance conditions, and market conditions. The vesting of these PRSUs will be determined based on market-based targets for total shareholder return (TSR) achievement and financial performance targets for revenue growth rate achievement and Adjusted EBITDA margin achievement. Each of the three market and performance targets are weighted equally and these PRSUs may vest in an amount up to the amount granted, subject to satisfaction of the pre-established targets. The number of PRSUs that will vest in 2023, 2024, and 2025 will be calculated as follows: (i) the market/performance achievement for the applicable vesting period, multiplied by (ii) approximately 33.33% of the PRSUs for each of the 2023, 2024, and 2025 vesting periods, each rounded to the nearest whole share.</div><div style="text-align:justify;text-indent:18pt">The fair value of the market-based tranches included in the executive PRSUs were estimated on the date of grants using the Monte Carlo simulation valuation model with the following assumptions for the nine months ended September 30, 2024 and 2023:</div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.209%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended
September 30, 2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">65.5%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">61.7%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (in years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">1-3</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">1-3</div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">4.33% - 4.91%</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">4.38% - 5.01%</div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividends</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:18pt">The following table sets forth the outstanding PRSUs, including executive PRSUs with market-based tranches, and related activity for the nine months ended September 30, 2024:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Performance-based Restricted Stock Units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Unvested and outstanding at January 1, 2024</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">188,533 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">12.99 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">PRSUs granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">445,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-

height:100%">PRSUs vested</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(43,052)</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13.89 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">PRSUs forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(65,487)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12.77 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unvested and outstanding at September 30, 2024 </td><td colspan="2" style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">524,994 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:bottom">9.94 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 During the nine months ended September 30, 2024 and 2023, we granted PRSUs with a weighted-average grant date fair value of $9.45 and $12.62, respectively, which represents the weighted-average closing price of our common stock on the grant date for performance-based tranches and the estimated grant date fair value using a Monte Carlo simulation valuation model for market-based tranches. The total grant date fair value of PRSUs vested during the nine months ended September 30, 2024 and 2023 was $0.6 million and $4.8 million, respectively. As of September 30, 2024, we had $2.7 million of unrecognized stock-based compensation expense related to outstanding PRSUs expected to be recognized over a remaining weighted-average period of 1.6 years. Employee stock purchase plan In connection with our IPO in July 2019, our board of directors adopted the ESPP and a total of 750,000 shares of common stock were initially reserved for issuance under the ESPP. The number of shares of common stock available for issuance under the ESPP will be increased on the first day of each calendar year beginning January 1, 2020 and each year thereafter until the ESPP terminates. The number of shares of common stock reserved and available for issuance under the ESPP shall be cumulatively increased by the least of (i) 750,000 shares, (ii) one percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of common stock as determined by the ESPP Administrator. As of January 1, 2024, the number of shares of common stock available for issuance under the ESPP increased by 585,308 shares. The ESPP generally provides for six-month offering periods. The offering periods generally start on the first trading day after June 30 and December 31 of each year. The ESPP permits participants to elect to purchase shares of common stock through fixed percentage contributions from eligible compensation during each offering period, not to exceed 15% of the eligible compensation a participant receives during an offering period or accrue at a rate which exceeds $25,000 of the fair value of the stock (determined on the option grant date(s)) for each calendar year. A participant may purchase the lowest of (i) a number of shares of common stock determined by dividing such participant's accumulated payroll deductions on the exercise date by the option price, (ii) 2,500 shares, or (iii) such other lesser maximum number of shares as shall have been established by the ESPP Administrator in advance of the offering period. Amounts deducted and accumulated by the participant will be used to purchase shares of common stock at the end of each offering period. The purchase price of the shares will be 85% of the lower of the fair value of common stock on the first trading day of each offering period or on the purchase date. Participants may end their participation at any time during an offering period and will be paid their accumulated contributions that have not been used to purchase shares of common stock. Participation ends automatically upon termination of employment. The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 55.5% - 56.8% </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 54.3% - 99.4% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (in months)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">6</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">6</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.24% - 5.37% </td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.77% - 5.53% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividends</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td></tr></table> During the nine months ended September 30, 2024, we issued 263,482 shares under the ESPP, with a weighted-average purchase price of $5.43. Total cash proceeds from the purchase of shares under the ESPP during the nine months ended September 30, 2024 were $2.1 million. As of September 30, 2024, a total of 207,388 shares were issuable to employees based on ESPP contribution elections and unrecognized ESPP compensation cost was $0.2 million, which is expected to be recognized over the remaining portion of the current offering period during the three months ending December 31, 2024. As of September 30, 2024, 1,791,984 shares were available for future issuance under the ESPP. Restricted shares issued in connection with business combinations As part of the KPI Ninja acquisition that closed on February 24, 2022, 356,919 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was subject to continuous service with 25% vesting upon each six-month anniversary of the acquisition close date, with the final vesting date as of February 24, 2024. As part of the ARMUS acquisition that closed on April 29, 2022, 235,330 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was subject to eighteen months of continuous service with cliff vesting upon the eighteen-month anniversary of the acquisition close date, or October 29, 2023.
 As part of the ERS acquisition that closed on October 2, 2023, 175,901 shares of our common stock were issued pursuant to the terms of the acquisition agreement and were considered a stock-based compensation arrangement subject to a restriction agreement. The vesting of those shares was originally subject to eighteen months of continuous service with cliff vesting . However, due to workforce reductions made as part of the 2023 Restructuring Plan, the ERS restricted shares were fully vested in February 2024, resulting in an acceleration of the related stock-based compensation expense.
 As of September 30, 2024, all of our previously issued shares of restricted stock are fully vested and there is no longer any related unrecognized compensation expense. 2756607 2500000 256607 0.05 2926544 23644211 20717667 4420022 3831444 The following two tables summarize our total stock-based compensation expense by award type and where the stock-based compensation expense was recorded in our condensed consolidated statements of operations (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td

style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted stock units</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,655 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11,591 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">25,065 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">34,531 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Performance-based restricted stock units</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,523 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,117 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock purchase plan</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">184 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">357 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">746 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,464 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted shares</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,878 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,969 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,573 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total stock-based compensation</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9,512 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,232 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29,316 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">42,745 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:41.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3"

style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenue</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,051 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,424 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5,488 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">7,090 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,555 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,149 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,997 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,049 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,871 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,927 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,391 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,677 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,035 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,732 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9,440 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,929 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total stock-based compensation</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,512 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14,232 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">29,316 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">42,745 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table> 8655000 11591000 25065000 34531000 673000 406000 1523000 1117000 184000 357000 746000 1464000 0 1878000 1969000 5573000 0 0 13000 60000 9512000 14232000 29316000 42745000 2051000 2424000 5488000 7090000 2555000 5149000 8997000 16049000 1871000 2927000 5391000 8677000 3035000 3732000 9440000 10929000 9512000 14232000 29316000 42745000 0 0 A summary of the share option activity under the 2019 Plan for the nine months ended September 30, 2024, is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Time-Based Option Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Remaining Contractual Life in Years</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Intrinsic Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Outstanding at January 1, 2024 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,396,452 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11.70 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Options exercised</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26,668)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">6.35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Options cancelled/forfeited</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(298,275)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.23 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Outstanding at September 30, 2024 </td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,071,509 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.97 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Vested and expected to vest as of September 30, 2024 </td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,071,509 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11.97 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.3</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Vested and exercisable as of September 30, 2024 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,071,509 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.97 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">3.3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1396452 11.70 26668 6.35 298275 11.23 1071509 11.97 P3Y3M18D 0 1071509 11.97 P3Y3M18D 0 1071509 11.97 P3Y3M18D 0 100000 700000 0 400000 P4Y P1Y The following table sets forth the outstanding RSUs and related activity for the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restricted Stock Units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unvested and outstanding at January 1, 2024 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,111,584 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">19.16 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">RSUs granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,616,356 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.55 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">RSUs vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,207,994)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21.64 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">RSUs forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(359,527)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.49 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Unvested and outstanding at September 30, 2024</div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,160,419 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">12.09 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table sets forth the outstanding PRSUs, including executive PRSUs with market-based tranches, and related activity for the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Performance-based Restricted Stock Units</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unvested and outstanding at January 1, 2024 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,533 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">12.99 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">PRSUs granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">445,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">PRSUs vested</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(43,052)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13.89 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">PRSUs forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(65,487)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12.77 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Unvested and outstanding at September 30, 2024</div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">524,994 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">9.94 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3111584 19.16 2616356 8.55 1207994 21.64 359527 15.49 4160419 12.09 8.55 11.99 26100000 35200000 43000000.0 P1Y10M24D P3Y 0.25 0.25 0.50 0.3333 0.3333 0.3333 P3Y 0.3333 0.3333 0.3333 0.655 0.617 P1Y P3Y P1Y P3Y 0.0433 0.0491 0.0438 0.0501 0 0 188533 12.99 445000 9.45 43052 13.89 65487 12.77 524994 9.94 9.45 12.62 600000 4800000 2700000 P1Y7M6D 750000 750000 0.01 585308 P6M 0.15 25000000 2500 0.85 The fair value of the purchase right for the ESPP option component is estimated on the date of grant using the Black-Scholes model with the following assumptions for the three months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 55.5% - 56.8% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 54.3% - 99.4% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (in months)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">6</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">6</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.24% - 5.37% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.77% - 5.53% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividends</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">— </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">—</td></tr></table> 0.555 0.568 0.543 0.994 P6M P6M 0.0524 0.0537 0.0477 0.0553 0 0 263482 5.43 2100000 207388 200000 1791984 356919 0.25 P6M 235330 P18M P18M 175901 P18M Income Taxes The tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, we update our estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, we make a cumulative adjustment in such period. The quarterly tax provision and the estimate of our annual effective tax rate are subject to variation due to several factors, including variability in our loss before income taxes, the mix of jurisdictions to which such income or loss relates, changes in how we conduct business, and tax law developments. For the nine months ended September 30, 2024 and 2023, our estimated effective tax rate was 3.1% and (0.2)%, respectively. The variations between our estimated effective tax rate and the U.S. statutory rate are primarily due to our full valuation allowance. We consider all available evidence to evaluate the recovery of deferred tax assets, including historical levels of income, legislative developments, and risks associated with estimates of future taxable income. We have provided a full valuation allowance for our net deferred tax assets as of September 30, 2024 and December 31, 2023, due to the uncertainty surrounding the future realization of such assets and the cumulative losses we have generated. We recognize tax benefits from uncertain tax positions when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We believe that we have provided adequate reserves for income tax uncertainties in all open tax years. We do not anticipate material changes in the total amount of our unrecognized tax benefits within 12 months of the reporting date. 0.031 -0.002 Commitments and Contingencies Litigation Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. We are involved in legal proceedings from time to time that arise in the normal course of business. In the opinion of management, such routine claims and lawsuits are not significant, and we do not expect them to have a material adverse effect on our business, financial condition, results of operations, or liquidity, except as noted below. We were party to the proceedings set forth below. On December 21, 2020, Pascal Metrics, Inc. (Pascal Metrics) filed a complaint against the Company in the Delaware Chancery Court (as amended, the Complaint) alleging that the Company misappropriated alleged trade secrets of Pascal Metrics and seeking monetary damages. The Complaint focused upon Patient Safety Monitor. On June 15, 2023, we entered into a settlement and mutual release agreement (Settlement Agreement) with Pascal Metrics and agreed to pay $18.8 million without admission of any wrongdoing, resolving the litigation amongst the parties. The Settlement Agreement provided us with a broad intellectual property license of the alleged trade secrets that were the subject matter of the Complaint. The Complaint was dismissed with prejudice on June 20, 2023 and the settlement amount was paid on June 27, 2023. During the nine months ended September 30, 2023, we recorded $21.3 million, of litigation charges related to the Complaint that were recorded as part of general and administrative expense in our condensed consolidated statements of operations, of which less than $0.1 million was recorded during the three months ended September 30, 2023. There were no similar litigation charges recorded during the three and nine months ended September 30, 2024. 18800000 21300000 100000 0 0 0.43 0.45 0.22 0.23 P5Y P1Y P90D 290500000 0.65 P24M Related Parties We have entered into arrangements with a client, Carle Health, and a member of the client's executive leadership team began serving on our board of directors effective July 1, 2023 and currently serves on our board of directors. We recognized revenue from this related party of $4.2 million and $12.4 million for the three and nine months ended September 30, 2024, respectively. For the three months ended September 30, 2023, we recognized $4.1 million of revenue from this related party. As of September 30, 2024 and December 31, 2023, we had receivables from this related party of $1.3 million and $1.9 million, respectively, and deferred revenue with this related party of $0.3 million and $0.1 million, respectively. We have revenue arrangements with clients that are also our investors. None of these clients hold a significant amount of ownership in our equity interests. 4200000 12400000 4100000 1300000 1900000 300000 100000 Segments We operate our business in two operating segments that also represent our reportable segments. Our business is organized based on our technology offerings and professional

services. Accordingly, our segments are: •Technology – Our technology segment (Technology) includes our data platform, analytics applications, and support services and generates revenue primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; and •Professional Services – Our professional services segment (Professional Services) is generally the combination of analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to our clients to more fully configure and utilize the benefits of our Technology offerings. Revenue and cost of revenue generally are directly attributed to our segments. All segment revenue is from our external clients. Asset and other balance sheet information at the segment level is not reported to our Chief Operating Decision Maker. Segment revenue and Adjusted Gross Profit for the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Technology</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">48,653 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">45,973 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">143,254 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">140,483 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Professional Services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83,724 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,371 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">76,353 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73,773 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">226,978 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">220,854 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Adjusted Gross Profit</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-

color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Technology</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">31,571 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">31,367 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">95,794 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">96,356 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Professional Services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,718 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,205 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,618 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,011 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Total reportable segments Adjusted Gross Profit</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,289 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,572 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112,412 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109,367 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less Adjusted Gross Profit reconciling items:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Stock-based compensation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,051)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,424)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,488)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,090)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Acquisition-related costs, net(1) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(198)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(162)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(576)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(506)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Restructuring costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(260)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(446)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less other reconciling items:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,342)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,084)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(43,145)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(50,050)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,193)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,667)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(42,948)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52,339)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,209)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2"

style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,625)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41,136)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(61,129)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,983)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,190)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,165)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,919)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Interest and other income (expense), net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,514)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,607 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,185 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,490 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss before income taxes </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,201)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(21,973)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(49,121)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(87,622)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1)Acquisition-related costs, net include deferred retention expenses attributable to the Lumeon, Carevive, ARMUS, and KPI Ninja acquisitions. 2 2 Segment revenue and Adjusted Gross Profit for the three and nine months ended September 30, 2024 and 2023 were as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Revenue</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Technology</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">48,653 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">45,973 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">143,254 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">140,483 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Professional Services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">83,724 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,371 </td><td style="background-

color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">76,353 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">73,773 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">226,978 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">220,854 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 48653000 45973000 143254000 140483000 27700000 27800000 83724000 80371000 76353000 73773000 226978000 220854000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Adjusted Gross Profit</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Technology</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">31,571 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">31,367 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">95,794 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">96,356 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Professional Services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,718 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,205 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,618 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,011 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Total reportable segments Adjusted Gross Profit</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">36,289 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,572 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112,412 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">109,367 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less Adjusted Gross Profit reconciling items:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Stock-based compensation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,051)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,424)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,488)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7,090)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Acquisition-related costs, net(1) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(198)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(162)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(576)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(506)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Restructuring costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(260)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(446)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less other reconciling items:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11,342)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15,084)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(43,145)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(50,050)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14,193)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,667)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(42,948)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52,339)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(12,209)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(13,625)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(41,136)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(61,129)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Depreciation and amortization</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9,983)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,190)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,165)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31,919)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Interest and other income (expense), net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,514)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,607 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,185 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,490 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss before income taxes </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(15,201)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(21,973)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(49,121)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(87,622)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1)Acquisition-related costs, net include deferred retention expenses attributable to the Lumeon, Carevive, ARMUS, and KPI Ninja acquisitions. 31571000 31367000 95794000 96356000 4718000 3205000 16618000 13011000 36289000 34572000 112412000 109367000 2051000 2424000 5488000 7090000 198000 162000 576000 506000 0 0 260000 446000 11342000 15084000 43145000 50050000 14193000 17667000 42948000 52339000 12209000 13625000 41136000 61129000 9983000 10190000 31165000 31919000 1514000 -2607000 -3185000 -6490000 -15201000 -21973000 -49121000 -87622000 Restructuring Costs 2023 Restructuring Plan During the quarter and year ended December 31,

2023, our board of directors authorized a reduction of our global workforce as part of a restructuring plan intended to optimize our cost structure and focus our investment of resources in key priority areas to align with strategic changes (2023 Restructuring Plan). As part of the 2023 Restructuring Plan, we significantly reduced headcount throughout both our professional services and technology segments, including among our senior leadership team. The restructuring costs primarily related to severance and other team member costs from workforce reductions and impairment of a discontinued capitalized internal-use software project. The following table summarizes our 2023 Restructuring Plan costs by financial statement line item for the nine months ended September 30, 2024 (in thousands). We had no restructuring costs for the three months ended September 30, 2024. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.440%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Severance and Other Team Member Costs</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Impairment Charges(1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenue, excluding depreciation and amortization:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Technology</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Professional services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">181 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">181 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">449 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">449 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">443 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">443 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">936 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">936 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,088 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2,088 </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>2023 Restructuring Plan final cumulative charges incurred</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,240 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">615 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,855 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>_____</div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Consists of impairment of a discontinued internal-use software project as part of the 2023 Restructuring Plan.</div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt">Restructuring liabilities related to the 2023 Restructuring Plan are included as a component of accrued liabilities on our condensed consolidated balance sheets. The following table summarizes our current year restructuring-related activities, including costs incurred, cash payments, and the resulting liability balances (in thousands):</div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restructuring Liabilities</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance as of December 31, 2023</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,355 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Severance and other restructuring costs </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,813 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,157)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance as of March 31, 2024 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,011 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Severance and other restructuring costs</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">275 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(941)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance as of June 30, 2024</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">345 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Severance and other restructuring costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(338)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance as of September 30, 2024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">Our restructuring activities as part of the 2023 Restructuring Plan are substantially complete with no additional restructuring costs expected during the remainder of 2024. </div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">2022 Restructuring Plan</div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt">During the third quarter of 2022, we initiated a restructuring plan (2022 Restructuring Plan) to optimize our cost structure and focus our investment of resources in key priority areas to align with strategic changes. As part of the 2022 Restructuring Plan, we significantly reduced investment in our life sciences business unit, which is generally part of the technology segment, and also reduced headcount throughout the Company, including among our senior leadership team. The restructuring costs primarily related to severance and other team member costs from workforce reductions, impairment of discontinued capitalized internal-use software projects, and other miscellaneous charges. We substantially completed all actions under the 2022 Restructuring Plan in early 2023 and, as of December 31, 2023, the related restructuring liabilities were completely settled through cash outlays made to impacted team members. </div><div style="margin-top:12pt;text-align:justify;text-indent:18pt">The following table summarizes our 2022 Restructuring Plan costs by financial statement line item for the nine months ended September 30, 2023 (in thousands). We had no restructuring costs for the three months ended September 30, 2023.</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Nine Months Ended September 30, 2023</div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Severance and Other Team Member Costs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Impairment Charges(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Other(2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenue, excluding depreciation and amortization:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Technology</div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td>

<td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Professional services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">434 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">434 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,190 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,205 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,016 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,055 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2022 Restructuring Plan final, cumulative charges incurred through December 31, 2023 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,071 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,225 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,184 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">10,480 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1) Consists of impairment of a discontinued internal-use software project as part of the 2022 Restructuring Plan. (2)Includes other minor miscellaneous charges associated with the restructuring plan. The following table summarizes our 2023 Restructuring Plan costs by financial statement line item for the nine months ended September 30, 2024 (in thousands). We had no restructuring costs for the three months ended September 30, 2024. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.440%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Severance and Other Team Member Costs</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-

bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Impairment Charges(1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenue, excluding depreciation and amortization:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Technology</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">79 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Professional services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">181 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">181 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">449 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">449 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">443 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">443 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">936 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">936 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,088 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,088 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2023 Restructuring Plan final cumulative charges incurred </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,240 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">615 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,855 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>_____ (1)Consists of impairment of a discontinued internal-use software project as part of the 2023 Restructuring Plan. The following table summarizes our 2022 Restructuring Plan costs by financial statement line item for the nine months ended September 30, 2023 (in thousands). We had no restructuring costs for the three months ended September 30, 2023. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid

#000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Nine Months Ended September 30, 2023 </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Severance and Other Team Member Costs</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Impairment Charges(1) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Other(2) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of revenue, excluding depreciation and amortization:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Technology </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Professional services</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">434 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">434 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Sales and marketing</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,190 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,205 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">94 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,016 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,055 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2022 Restructuring Plan final, cumulative charges incurred through December 31, 2023 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8,071 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,225 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,184 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">10,480 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1) Consists of impairment of a discontinued internal-use software project as part of the 2022 Restructuring Plan. (2)Includes other minor miscellaneous charges associated with the restructuring plan. 0 79000 0 79000 181000 0 181000 449000 0 449000 443000 0 443000 936000 0 936000 2088000 0 2088000 8240000 615000 8855000 The following table summarizes our current year restructuring-related activities, including costs incurred, cash payments, and the resulting liability balances (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Restructuring Liabilities</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(unaudited)</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance as of December 31, 2023 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">2,355 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt">Severance and other restructuring costs</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,813 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,157)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance as of March 31, 2024</div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,011 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Severance and other restructuring costs </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">275 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(941)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance as of June 30, 2024 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">345 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Severance and other restructuring costs</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash payments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(338)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance as of September 30, 2024</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2355000 1813000 3157000 1011000 275000 941000 345000 0 338000 7000 0 12000 0 0 12000 434000 0 0 434000 1190000 0 15000 1205000 286000 0 0 286000 94000 0 24000 118000 2016000 0 39000 2055000 8071000 1225000 1184000 10480000 Includes amounts attributable to related party transactions. See Note 17 for further details. Includes amounts attributable to related party transactions. See Note 17 for further details. "